FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Snider, AJ
Gandy, KAO
Obeid, LM
AF Snider, Ashley J.
Gandy, K. Alexa Orr
Obeid, Lina M.
TI Sphingosine kinase: Role in regulation of bioactive sphingolipid
mediators in inflammation
SO BIOCHIMIE
LA English
DT Review
DE Sphingosine-1-phosphate; Sphingosine kinase; Inflammation; Ceramide;
Tumor necrosis factor-alpha
ID NECROSIS-FACTOR-ALPHA; COLLAGEN-INDUCED ARTHRITIS; CIRCULATING MATURE
LYMPHOCYTES; PROTEIN-COUPLED RECEPTORS; CELL-PROLIFERATION; TNF-ALPHA;
SPHINGOSINE-1-PHOSPHATE RECEPTORS; PLASMA-MEMBRANE; IN-VIVO; DEPENDENT
TRANSLOCATION
AB Sphingolipids and their synthetic enzymes are emerging as important mediators in inflammatory responses and as regulators of immune cell functions. In particular, sphingosine kinase (SK) and its product sphingosine-1-phosphate (S1P) have been extensively implicated in these processes. SK catalyzes the phosphorylation of sphingosine to SIP and exists as two isoforms, SK1 and SK2. SK1 has been shown to be activated by cytokines including tumor necrosis factor-alpha (TNF-alpha) and interleukin 1-beta (IL1-beta). The activation of SK1 in this pathway has been shown to be, at least in part, required for mediating TNF-alpha and IL1-beta inflammatory responses in cells, including induction of cyclo-oxygenase 2 (COX2). In addition to their role in inflammatory signaling, SK and SIP have also been implicated in various immune cell functions including, mast cell degranulation, migration of neutrophils, and migration and maturation of lymphocytes. The involvement of sphingolipids and sphingolipid metabolizing enzymes in inflammatory signaling and immune cell functions has implicated these mediators in numerous inflammatory disease states as well. The contribution of these mediators, specifically SK1 and S1P, to inflammation and disease are discussed in this review. Published by Elsevier Masson SAS.
C1 [Snider, Ashley J.; Gandy, K. Alexa Orr; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA.
[Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA.
[Obeid, Lina M.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St,MSC 779, Charleston, SC 29425 USA.
EM obeidl@musc.edu
OI obeid, lina/0000-0002-0734-0847
FU National Institutes of Health [1F32KD084604-01, GM062887]; GAANN
fellowship [P200A070596]; Institutional Training Grant [HL007260]; VA
Merit Award; VAMC Research Excellence Award
FX This work was supported by National Institutes of Health Grants
1F32KD084604-01 (AJS), GM062887 (LMO), and GAANN fellowship P200A070596
and Institutional Training Grant, HL007260 (KAOG). As well as, VA Merit
Award (LMO) and by the VAMC Research Excellence Award Program (REAP)
(LMO and AJS). We would like to thank Kathy Wiita-Fisk for her
administrative assistance.
NR 124
TC 66
Z9 68
U1 0
U2 10
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0300-9084
J9 BIOCHIMIE
JI Biochimie
PD JUN
PY 2010
VL 92
IS 6
SI SI
BP 707
EP 715
DI 10.1016/j.biochi.2010.02.008
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 614YF
UT WOS:000279095000019
PM 20156522
ER
PT J
AU Schroeck, FR
Kattan, MW
Moul, JW
Aronson, WJ
Presti, JC
Terris, MK
Kane, CJ
Amling, CL
Sun, L
Freedland, SJ
AF Schroeck, Florian R.
Kattan, Michael W.
Moul, Judd W.
Aronson, William J.
Presti, Joseph C., Jr.
Terris, Martha K.
Kane, Christopher J.
Amling, Christopher L.
Sun, Leon
Freedland, Stephen J.
TI Re-calibration and external validation of an existing nomogram to
predict aggressive recurrences after radical prostatectomy
SO BJU INTERNATIONAL
LA English
DT Article
DE prostate cancer; biochemical recurrence; PSA doubling time; aggressive
recurrence; nomogram
ID BIOCHEMICAL RECURRENCE; DOUBLING TIME; CANCER; RADIOTHERAPY;
PROGRESSION; MORTALITY; FAILURE; TRIAL; RACE
AB OBJECTIVE
To re-calibrate the previously published Duke Prostate Center (DPC) nomogram for the prediction of biochemical recurrence (BCR) after radical prostatectomy (RP) to not only predict overall BCR but also the clinically more relevant endpoint of an aggressive recurrence (i.e. a BCR with a postoperative PSA doubling time (PSADT) of < 9 months).
PATIENTS AND METHODS
Using the established point-scale system based upon the previously published DPC nomogram, we re-calibrated this point system to predict not just BCR, but also aggressive BCR within 2599 men treated with RP from the DPC database. PSADT was computed on all patients meeting the recurrence definition who had a minimum of two PSA values, separated by at least 3 months, and < 2 years after recurrence. External validation was performed using data from 1695 men treated with RP within the Shared Equal Access Regional Cancer Hospital (SEARCH) database by calculating the concordance index c and by plotting calibration curves.
RESULTS
The median follow-up for patients with no BCR was 56 and 47 months for DPC and SEARCH, respectively. In the DPC modelling cohort and the SEARCH validation cohort, 645 (25%) and 557 (33%) men had BCR, while 83 (3.2%) and 71 (4.2%) patients had an aggressive recurrence. In external validation, predictive accuracy for an aggressive BCR was high (c = 0.83) and the nomogram showed good calibration.
CONCLUSIONS
We re-calibrated an existing nomogram to not only predict overall BCR after RP but also aggressive recurrence after RP. Our new tool can provide valuable information for patient counselling and patient selection for adjuvant therapy trials.
C1 [Freedland, Stephen J.] Duke Univ, Sch Med, Div Urol, Dept Pathol, Durham, NC 27710 USA.
[Schroeck, Florian R.; Moul, Judd W.; Sun, Leon; Freedland, Stephen J.] Duke Univ, Sch Med, Dept Surg, Div Urol Surg, Durham, NC 27710 USA.
[Schroeck, Florian R.; Moul, Judd W.; Sun, Leon; Freedland, Stephen J.] Duke Univ, Sch Med, Duke Prostate Ctr, Durham, NC 27710 USA.
[Schroeck, Florian R.; Sun, Leon; Freedland, Stephen J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA.
[Kattan, Michael W.] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA.
[Aronson, William J.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA.
[Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
[Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA.
[Presti, Joseph C., Jr.] VA Med Ctr, Urol Sect, Palo Alto, CA USA.
[Terris, Martha K.] VA Med Ctr, Urol Sect, Augusta, GA USA.
[Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA.
[Kane, Christopher J.] Univ Calif San Diego, Med Ctr, Dept Surg, Div Urol, San Diego, CA 92103 USA.
[Amling, Christopher L.] Oregon Hlth & Sci Univ, Dept Surg, Div Urol, Portland, OR USA.
RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Div Urol, Dept Pathol, Box 2626 DUMC, Durham, NC 27710 USA.
EM steve.freedland@duke.edu
OI Terris, Martha/0000-0002-3843-7270; Schroeck,
Florian/0000-0002-1860-2611
FU Department of Defense; Department of Veterans Affairs, National
Institute of Health [R01CA100938]; NIH [P50 CA92131-01A1]; Georgia
Cancer Coalition; American Urological Association Foundation/Astellas;
Committee for Urologic Research, Education, and Development (CURED) at
Duke University
FX Research support: Department of Defense, Prostate Cancer Research
Program (S.J.F.); Department of Veterans Affairs, National Institute of
Health R01CA100938 (W.J.A.), NIH Specialized Programs of Research
Excellence Grant P50 CA92131-01A1 (W.J.A.), the Georgia Cancer Coalition
(M.K.T.), the American Urological Association Foundation/Astellas Rising
Star in Urology Award (S.J.F.), and Committee for Urologic Research,
Education, and Development (CURED) at Duke University (F.R.S., J.W.M.,
L.S., S.J.F.).
NR 18
TC 6
Z9 6
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1464-4096
J9 BJU INT
JI BJU Int.
PD JUN
PY 2010
VL 105
IS 12
BP 1654
EP 1659
DI 10.1111/j.1464-410X.2009.09060.x
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 601BT
UT WOS:000278033700007
PM 19912203
ER
PT J
AU Karila, L
Weinstein, A
Aubin, HJ
Benyamina, A
Reynaud, M
Batki, SL
AF Karila, Laurent
Weinstein, Aviv
Aubin, Henri-Jean
Benyamina, Amine
Reynaud, Michel
Batki, Steven L.
TI Pharmacological approaches to methamphetamine dependence: a focused
review
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Review
DE addiction; amphetamine; clinical trials; dependence; medication;
methamphetamine; treatment
ID PLACEBO-CONTROLLED TRIAL; VESICULAR MONOAMINE TRANSPORTERS; INDUCED
BEHAVIORAL SENSITIZATION; MODAFINIL IMPROVES COGNITION; DOUBLE-BLIND;
AMPHETAMINE DEPENDENCE; COCAINE-DEPENDENCE; DRUG-ADDICTION;
MONOCLONAL-ANTIBODIES; POTENTIAL PHARMACOTHERAPY
AB Methamphetamine dependence is a serious worldwide public health problem with major medical, psychiatric, socioeconomic and legal consequences. Various neuronal mechanisms implicated in methamphetamine dependence have suggested several pharmacological approaches. A literature search from a range of electronic databases (PubMed, EMBASE, PsycInfo, the NIDA research monograph index and the reference list of clinicaltrials.gov) was conducted for the period from January 1985 to October 2009. There were no restrictions on the identification or inclusion of studies in terms of publication status, language and design type. A variety of medications have failed to show efficacy in clinical trials, including a dopamine partial agonist (aripiprazole), GABAergic agents (gabapentin) and serotonergic agents (SSRI, ondansetron, mirtazapine). Three double-blind placebo-controlled trials using modafinil, bupropion and naltrexone have shown positive results in reducing amphetamine or methamphetamine use. Two studies employing agonist replacement medications, one with d-amphetamine and the other with methylphenidate, have also shown promise. Despite the lack of success in most studies to date, increasing efforts are being made to develop medications for the treatment of methamphetamine dependence and several promising agents are targets of further research.
C1 [Karila, Laurent] Univ Paris 11, Hop Paul Brousse, INSERM, Addict Res & Treatment Ctr,AP HP,CEA,U1000, Villejuif, France.
[Weinstein, Aviv] Hadassah Hosp Ein Kerem, Dept Med Biophys & Nucl Med, Jerusalem, Israel.
[Aubin, Henri-Jean; Benyamina, Amine; Reynaud, Michel] Univ Paris 11, Hop Paul Brousse, INSERM, Addict Res & Treatment Ctr,AP HP,U669, Villejuif, France.
[Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Karila, L (reprint author), Univ Paul Brousse, CERTA, 12 Ave Paul Vaillant Couturier, F-94800 Villejuif, France.
EM laurent.karila@pbr.aphp.fr
FU MILDT (Mission Interministrielle de Lutte contre les Drogues et la
Toxicomanie) INSERM; Assistance Publique- H pitaux de Paris. Dr
Weinstein (Israel); National Institute for Psychobiology (Israel);
National Institute of Health, National Institute on Drug Abuse (NIDA)
[5R01 DA016764- 05, U10 DA015815]; National Institute on Alcohol Abuse
and Alcoholism and a Department of Veterans Affairs
FX Dr Karila (France) received support from the MILDT (Mission
Interministerielle de Lutte contre les Drogues et la Toxicomanie) INSERM
and Assistance Publique- Hopitaux de Paris. Dr Weinstein (Israel) is
supported by the National Institute for Psychobiology (Israel). Dr Batki
(USA) received support from National Institute of Health, National
Institute on Drug Abuse (NIDA) Grants N. 5R01 DA016764- 05 and U10
DA015815, National Institute on Alcohol Abuse and Alcoholism and a
Department of Veterans Affairs Grant for the VISN 2 Center for
Integrated Healthcare.
NR 139
TC 81
Z9 84
U1 3
U2 22
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0306-5251
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
PD JUN
PY 2010
VL 69
IS 6
BP 578
EP 592
DI 10.1111/j.1365-2125.2010.03639.x
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 594FT
UT WOS:000277522100003
PM 20565449
ER
PT J
AU Corcoran, AM
Casarett, DJ
AF Corcoran, Amy M.
Casarett, David J.
TI Improving Communication and Rethinking Hospice Care
SO CHEST
LA English
DT Editorial Material
ID SERIOUSLY ILL; CANCER; LIFE; DISCUSSIONS; END
C1 [Corcoran, Amy M.] Univ Penn, Dept Clin Med, Div Geriatr, Philadelphia, PA 19104 USA.
[Casarett, David J.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Corcoran, AM (reprint author), Penn Ralston Ctr, 3615 Chestnut St, Philadelphia, PA 19104 USA.
EM amym.corcoran@uphs.upenn.edu
NR 11
TC 0
Z9 0
U1 0
U2 2
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JUN
PY 2010
VL 137
IS 6
BP 1262
EP 1263
DI 10.1378/chest.10-0040
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 608DB
UT WOS:000278561400005
PM 20525649
ER
PT J
AU Ortiz, G
Frutos-Vivar, F
Ferguson, ND
Esteban, A
Raymondos, K
Apezteguia, C
Hurtado, J
Gonzalez, M
Tomicic, V
Elizalde, J
Abroug, F
Arabi, Y
Pelosi, P
Anzueto, A
AF Ortiz, Guillermo
Frutos-Vivar, Fernando
Ferguson, Niall D.
Esteban, Andres
Raymondos, Konstantinos
Apezteguia, Carlos
Hurtado, Javier
Gonzalez, Marco
Tomicic, Vinko
Elizalde, Jose
Abroug, Fekri
Arabi, Yaseen
Pelosi, Paolo
Anzueto, Antonio
CA Ventila Grp
TI Outcomes of Patients Ventilated With Synchronized Intermittent Mandatory
Ventilation With Pressure Support A Comparative Propensity Score Study
SO CHEST
LA English
DT Article
ID MECHANICAL VENTILATION; WEANING PATIENTS; CARDIAC-SURGERY; IMV; OUTPUT
AB Background: Few data are available regarding the benefits of one mode over another for ventilatory support. We set out to compare clinical outcomes of patients receiving synchronized intermittent mandatory ventilation with pressure support (SIMV-PS) compared with assist-control (A/C) ventilation as their primary mode of ventilatory support.
Methods: This was a secondary analysis of an observational study conducted in 349 ICUs from 23 countries. A propensity score stratified analysis was used to compare 350 patients ventilated with SIMV-PS with 1,228 patients ventilated with A/C ventilation. The primary outcome was in-hospital mortality.
Results: in a logistic regression model, patients were more likely to receive SIMV-PS if they were from North America, had lower severity of illness, or were ventilated postoperatively or for trauma. SIMV-PS was less likely to be selected if patients were ventilated because of asthma or coma, or if they developed complications such as sepsis or cardiovascular failure during mechanical ventilation. In the stratified analysis according to propensity score, we did not find significant differences in the in-hospital mortality. After adjustment for propensity score, overall effect of SIMV-PS on in-hospital mortality was not significant (odds ratio, 1.04; 95% CI, 0.77-1.42; P = .78).
Conclusions: In our cohort of ventilated patients, ventilation with SIMV-PS compared with A/C did not offer any advantage in terms of clinical outcomes, despite treatment-allocation bias that would have favored SIMV-PS. CHEST 2010; 137(6):1265-1277
C1 [Esteban, Andres] Hosp Univ Getafe, Intens Care Unit, Madrid 28905, Spain.
[Ortiz, Guillermo] Hosp Santa Clara, Bogota, Colombia.
[Frutos-Vivar, Fernando; Esteban, Andres] CIBER Enfermedades Resp, Madrid, Spain.
[Ferguson, Niall D.] Univ Toronto, Interdept Div Crit Care Med, Univ Hlth Network, Div Respirol, Toronto, ON, Canada.
[Ferguson, Niall D.] Univ Toronto, Dept Med, Univ Hlth Network, Div Respirol, Toronto, ON, Canada.
Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Raymondos, Konstantinos] Hannover Med Sch, D-30623 Hannover, Germany.
[Apezteguia, Carlos] Hosp Profesor A Posadas, Buenos Aires, DF, Argentina.
[Hurtado, Javier] Hosp Clin Montevideo, Montevideo, Uruguay.
[Gonzalez, Marco] Clin Medellin & Univ Pontificia Bolivariana, Medellin, Colombia.
[Tomicic, Vinko] Clin Alemana Santiago, Santiago, Chile.
[Elizalde, Jose] Hosp ABC, Mexico City, DF, Mexico.
[Abroug, Fekri] Fattouma Bourguiba Monastir, Monastir, Tunisia.
[Arabi, Yaseen] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia.
[Pelosi, Paolo] Univ Insubria, Osped Circolo, Varese, Italy.
[Anzueto, Antonio] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
RP Esteban, A (reprint author), Hosp Univ Getafe, Intens Care Unit, Carretera Toledo Km 12,500, Madrid 28905, Spain.
EM aesteban@ucigetafe.com
OI Frutos-Vivar, Fernando/0000-0002-4648-9636; Ferguson,
Niall/0000-0002-6213-5264
FU Instituto de Salud Carlos III, Spain; Canadian Institutes of Health
(Ottawa, ON, Canada)
FX Funding/Support: This study was funded by CIBER Enfermedades
Respiratorias from Instituto de Salud Carlos III, Spain. Dr Ferguson is
supported by a Canadian Institutes of Health Research New Investigator
Award (Ottawa, ON, Canada).
NR 22
TC 16
Z9 16
U1 0
U2 1
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JUN
PY 2010
VL 137
IS 6
BP 1265
EP 1277
DI 10.1378/chest.09-2131
PG 13
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 608DB
UT WOS:000278561400006
PM 20022967
ER
PT J
AU Peralta, CA
Li, YM
Wassel, C
Choudhry, S
Palmas, W
Seldin, MF
Risch, N
Siscovick, D
Arnett, D
Psaty, B
Shlipak, MG
AF Peralta, Carmen A.
Li, Yongmei
Wassel, Christina
Choudhry, Shweta
Palmas, Walter
Seldin, Michael F.
Risch, Neil
Siscovick, David
Arnett, Donna
Psaty, Bruce
Shlipak, Michael G.
TI Differences in Albuminuria Between Hispanics and Whites: An Evaluation
by Genetic Ancestry and Country of Origin The Multi-Ethnic Study of
Atherosclerosis
SO CIRCULATION-CARDIOVASCULAR GENETICS
LA English
DT Article
DE genetics; kidney; albuminuria; ancestry
ID CHRONIC KIDNEY-DISEASE; NUTRITION EXAMINATION SURVEY; 3RD
NATIONAL-HEALTH; MULTILOCUS GENOTYPE DATA; STAGE RENAL-DISEASE; SURVEY
NHANES-III; POPULATION-STRUCTURE; ADMIXED POPULATIONS;
MEXICAN-AMERICANS; LATINO POPULATIONS
AB Background-Reports show higher prevalence of albuminuria among Hispanics compared with whites. Differences by country of origin or genetic background are unknown.
Methods and Results-In Multi-Ethnic Study of Atherosclerosis, we studied the associations of both genetic ancestry and country of origin with albumin to creatinine ratio among 1417 Hispanic versus white participants using multivariable linear regression and back transforming beta coefficients into relative difference (%RD, 95% CI). Percentage European, Native American, and African ancestry components for Hispanics were estimated using genetic admixture analysis. The proportions of European, Native American, and African genetic ancestry differed significantly by country of origin (P<0.0001); Mexican/Central Americans had the highest Native American (41 +/- 13%), Puerto Ricans had the highest European (61 +/- 15%), and Dominicans had the highest African (39 +/- 21%) ancestry. Hispanic ethnicity was associated with higher albumin/creatinine ratio compared with whites, but the association varied with the country of origin (adjusted P interaction=0.04). Mexican/Central Americans and Dominicans had higher albumin/creatinine ratio compared with whites after adjustment (RD 19%, 2% to 40% and RD 27%, 1% to 61%), but not Puerto Ricans (RD 8%, -12% to 34%). Higher Native American ancestry was associated with higher albuminuria after age and sex adjustment among all Hispanics (RD 11%, 1% to 21%) but was attenuated after further adjustment. Higher European ancestry was independently associated with lower albumin/creatinine ratio among Puerto Ricans (-21%, -34% to -6%) but not among Mexican/Central Americans and Dominicans.
Conclusions-Hispanics are a heterogeneous group with varying genetic ancestry. Risks of albuminuria differ across the country of origin groups. These differences may be due, in part, to differences in genetic ancestral components. (Circ Cardiovasc Genet. 2010;3:240-247.)
C1 [Peralta, Carmen A.; Choudhry, Shweta; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Peralta, Carmen A.; Li, Yongmei; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Wassel, Christina] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
[Palmas, Walter] Columbia Univ, Dept Med, New York, NY USA.
[Seldin, Michael F.] Univ Calif Davis, Dept Biochem, Davis, CA 95616 USA.
[Seldin, Michael F.] Univ Calif Davis, Dept Mol Med & Med, Davis, CA 95616 USA.
[Risch, Neil] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
[Risch, Neil] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Arnett, Donna] Univ Alabama, Dept Epidemiol, Birmingham, AL USA.
[Psaty, Bruce] Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, Seattle, WA 98195 USA.
[Psaty, Bruce] Univ Washington, Cardiovasc Hlth Res Unit, Dept Epidemiol, Seattle, WA 98195 USA.
[Psaty, Bruce] Univ Washington, Cardiovasc Hlth Res Unit, Dept Hlth Serv, Seattle, WA 98195 USA.
[Psaty, Bruce] Grp Hlth, Ctr Hlth Studies, Seattle, WA USA.
RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA.
EM CarmenAlicia.Peralta@ucsf.edu
FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95165,
N01-HC-95169]; National Institute of Diabetes and Digestive and Kidney
Diseases [1K23DK082793-01]
FX This work was supported by contracts (N01-HC-95159 through N01-HC-95165)
and (N01-HC-95169) from the National Heart, Lung, and Blood Institute.
This work was also funded by the National Institute of Diabetes and
Digestive and Kidney Diseases (1K23DK082793-01 to C.A.P.).
NR 45
TC 22
Z9 23
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1942-325X
J9 CIRC-CARDIOVASC GENE
JI Circ.-Cardiovasc. Genet.
PD JUN
PY 2010
VL 3
IS 3
BP 240
EP 247
DI 10.1161/CIRCGENETICS.109.914499
PG 8
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA 611GH
UT WOS:000278799900005
PM 20445135
ER
PT J
AU Tsai, TT
Ho, PM
Xu, S
Powers, JD
Carroll, NM
Shetterly, SM
Maddox, TM
Rumsfeld, JS
Margolis, K
Go, AS
Magid, DJ
AF Tsai, Thomas T.
Ho, P. Michael
Xu, Stanley
Powers, J. David
Carroll, Nikki M.
Shetterly, Susan M.
Maddox, Thomas M.
Rumsfeld, John S.
Margolis, Karen
Go, Alan S.
Magid, David J.
TI Increased Risk of Bleeding in Patients on Clopidogrel Therapy After
Drug-Eluting Stents Implantation Insights From the HMO Research
Network-Stent Registry (HMORN-Stent)
SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE angioplasty; revascularization; myocardial infarction; hemorrhage
ID PERCUTANEOUS CORONARY INTERVENTION; MARGINAL STRUCTURAL MODELS;
CONTROLLED TRIAL; ASPIRIN; OUTCOMES; STROKE
AB Background-Studies suggest that extended clopidogrel use after drug-eluting stent (DES) implantation may decrease the risk of myocardial infarction (MI) and death. Little is known about the competing risk of bleeding from clopidogrel in "real world" clinical practice.
Methods and Results-We studied 7689 patients undergoing drug-eluting stent implantation enrolled in the HMO Research Network-Stent Registry between 2004 and 2007. Patients were analyzed in 6-month intervals for the occurrence of major bleeding, MI, and death. Clopidogrel use was determined by pharmacy dispensing data. Regression models assessed the association between clopidogrel use and outcomes. Overall, 3603 patients (49.1%) received clopidogrel for >6 months. During a mean follow-up of 418 days (SD, +/- 168 days), 217 (2.9%) patients died, 279 (3.7%) had a MI, and 271 (3.6%) had major bleeding. After adjustment, patients on clopidogrel therapy were associated with increased major bleeding in all time intervals (0 to 6 months: relative risk (RR)=2.70, 95% CI=1.41 to 5.19; 7 to 12 months: RR=1.71, 95% CI=1.05 to 2.79; 13 to 18 months: RR=2.34, 95% CI=1.26 to 4.34), compared with patients off clopidogrel. Clopidogrel use was also associated with decreased risk of MI for all time intervals (0 to 6 months: RR=0.52, 95% CI=0.36 to 0.77; 7 to 12 months: RR=0.46, 95% CI=0.30 to 0.70; 13 to 18 months: RR=0.53, 95% CI=0.29 to 0.99) and decreased death in the 7 to 12 month interval (RR=0.50, 95% CI=0.30 to 0.83).
Conclusions-Clopidogrel use was associated with increased major bleeding and decreased MI persisting to 18 months. Bleeding risks on clopidogrel therapy deserve consideration in the ongoing debate regarding optimal clopidogrel duration after PCI. (Circ Cardiovasc Interv. 2010;3:230-235.)
C1 [Tsai, Thomas T.; Maddox, Thomas M.; Rumsfeld, John S.] Denver VA Med Ctr, Cardiol Sect 111B, Denver, CO 80220 USA.
[Tsai, Thomas T.; Xu, Stanley; Powers, J. David; Carroll, Nikki M.; Shetterly, Susan M.; Maddox, Thomas M.; Rumsfeld, John S.; Magid, David J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA.
[Tsai, Thomas T.; Powers, J. David; Maddox, Thomas M.; Rumsfeld, John S.; Magid, David J.] Univ Colorado, Denver, CO 80202 USA.
[Tsai, Thomas T.; Xu, Stanley; Powers, J. David; Carroll, Nikki M.; Shetterly, Susan M.; Maddox, Thomas M.; Rumsfeld, John S.; Magid, David J.] Colorado Cardiovasc Outcomes Res Grp, Denver, CO USA.
[Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Margolis, Karen] HealthPartners Res Fdn, Minneapolis, MN USA.
RP Tsai, TT (reprint author), Denver VA Med Ctr, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA.
EM thomas.tsai@coloradooutcomes.org
FU Agency for Healthcare Research and Quality, US Department of Health and
Human Services [290-05-0033I]; National Heart, Lung, and Blood Institute
[U19 HL091179]; VA Research and Development Career Development Award
[05-026-2]; [0875162N]
FX This project was funded under contract No. 290-05-0033I, task order No.
5 from the Agency for Healthcare Research and Quality, US Department of
Health and Human Services as part of the Developing Evidence to Inform
Decisions about Effectiveness (DEcIDE) program.; Drs Magid and Go are
supported by the National Heart, Lung, and Blood Institute funded
Cardiovascular Research Network (U19 HL091179). Dr Go receives funding
for the AHA Pharmaceutical Roundtable Outcomes Research Center (AHA
#0875162N) for relevant work. Dr Ho is supported by a VA Research and
Development Career Development Award (05-026-2).
NR 21
TC 26
Z9 27
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7640
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD JUN
PY 2010
VL 3
IS 3
BP 230
EP 235
DI 10.1161/CIRCINTERVENTIONS.109.919001
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 623CC
UT WOS:000279714200006
PM 20442361
ER
PT J
AU Hage, FG
de Mattos, AM
Khamash, H
Mehta, S
Warnock, D
Iskandrian, AE
AF Hage, Fadi G.
de Mattos, Angelo M.
Khamash, Hasan
Mehta, Shikha
Warnock, David
Iskandrian, Ami E.
TI QT Prolongation Is an Independent Predictor of Mortality in End-Stage
Renal Disease
SO CLINICAL CARDIOLOGY
LA English
DT Article
ID HEART-ASSOCIATION ELECTROCARDIOGRAPHY;
FOR-COMPUTERIZED-ELECTROCARDIOLOGY; OF-CARDIOLOGY FOUNDATION;
AHA/ACCF/HRS RECOMMENDATIONS; ARRHYTHMIAS COMMITTEE; SCIENTIFIC
STATEMENT; CLINICAL CARDIOLOGY; MAINTENANCE HEMODIALYSIS; INTERVAL
PROLONGATION; CARDIAC-ARREST
AB Background: Coronary artery disease (CAD) is the predominant cause of sudden cardiac death in the general population, and sudden cardiac death is the leading cause of mortality in end-stage renal disease (ESRD).
Hypothesis: QT-interval prolongation is an independent prognosticator in ESRD.
Methods: We reviewed clinical, electrocardiographic, stress test, and coronary angiography data on ESRD patients evaluated for transplantation at our institution between 2000 and 2004 who underwent coronary angiography. The QT interval was corrected for heart rate and QRS duration (QTc). All-cause mortality data were prospectively collected and verified against the Social Security Death Index database.
Results: During 40 +/- 28 months of follow-up, 132 of the 280(47%) patients died prior to renal transplantation. Patients with a prolonged QTc (39%) had 1-, 3-, and 5-year death-rates of 12%, 36%, and 47%, respectively, vs 8%, 24%, and 36% for those with normal QTc (log-rank P = 0.03). In a multivariate Cox regression model that adjusted for age, gender, diabetes mellitus, myocardial infarction, presence and severity of CAD on angiography, left ventricular (LV) hypertrophy, LV ejection fraction (EF), and multiple other variables, QTc remained to be an independent predictor of survival (hazard ratio pin 1.008, 95% confidence interval [CI]: 1.001-1.014, P = 0.016). Female gender, decreasing LVEF, and decreasing severity of CAD on angiography were independent predictors of prolonged QTc.
Conclusions: QTc prolongation is an independent predictor of mortality in ESRD patients being evaluated for renal transplantation. The prognostic information gained from the QTc is additive to that provided by the LVEF and the severity of CAD.
C1 [Hage, Fadi G.; Iskandrian, Ami E.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL USA.
[Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA.
[de Mattos, Angelo M.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA.
[Khamash, Hasan; Mehta, Shikha; Warnock, David] Univ Alabama, Div Nephrol, Birmingham, AL USA.
RP Hage, FG (reprint author), Zeigler Res Bldg 1024 1530 3rd Ave S, Birmingham, AL 35294 USA.
EM fadihage@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
NR 33
TC 22
Z9 23
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0160-9289
J9 CLIN CARDIOL
JI Clin. Cardiol.
PD JUN
PY 2010
VL 33
IS 6
BP 361
EP 366
DI 10.1002/clc.20768
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 621PW
UT WOS:000279594600007
PM 20556806
ER
PT J
AU Singh, H
Schiesser, R
Anand, G
Richardson, PA
El-Serag, HB
AF Singh, Hardeep
Schiesser, Rachel
Anand, Gobind
Richardson, Peter A.
El-Serag, Hashem B.
TI Underdiagnosis of Lynch Syndrome Involves More Than Family History
Criteria
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Lynch Syndrome; Health Outcomes; Familial Colorectal Cancer; Practice
Patterns; Missed Diagnosis; Guideline Non-adherence; Genetic Evaluation;
Delayed Cancer Diagnosis
ID NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; BETHESDA
GUIDELINES; CLINICAL-CRITERIA; GENOMIC MEDICINE; MUTATIONS; ERRORS;
MLH1; MSH2; CARRIERS
AB BACKGROUND & AIMS: Physicians' cancer-related family history assessment for Lynch syndrome is often Inadequate Furthermore, the extent to which clinicians recognize non-family history-related clues for Lynch syndrome is unclear We reviewed an integrated electronic health record (EHR) to determine diagnostic evaluation for Lynch syndrome in patients diagnosed with colorectal cancer (CRC) METHODS: We conducted a retrospective cohort study of consecutive patients with CRC, newly diagnosed at a ternary care Veterans Affairs facility, between 1999 and 2007 A detailed review of the EHR was conducted to evaluate the presence of family history-related and non-family history-related criteria of the Bethesda guidelines Patient outcomes (identification in clinical practice and referral for genetic testing) were also determined RESULTS: We identified a total of 499 patients (mean age, 65 4 years, 98 6% male, 51 1% non-Hispanic white) At least 1 of the Bethesda criteria was met for 57 patients (11 4%), none was met for 198 (39 7%), and there was uncertainty for 244 (48 9%) because of inadequate family history documentation and/or the patient was unsure about their family history Forty-nine patients met criteria unrelated to family history Only 4 of 57 patients (7%) who met the Bethesda guidelines had documentation of counseling. Among 244 patients with uncertainty, a suspicion for Lynch syndrome was documented in the EH R of 6 patients (2.5%), 3 received counseling CONCLUSIONS: Lynch syndrome is under-recognized, even when patients have clear criteria unrelated to family history. Multifaceted strategies focused on reducing providers' cognitive errors and harnessing EHR capabilities to improve recognition of Lynch syndrome are needed.
C1 [Singh, Hardeep; Richardson, Peter A.; El-Serag, Hashem B.] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA.
[Singh, Hardeep] Baylor Coll Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Singh, Hardeep; Richardson, Peter A.; El-Serag, Hashem B.] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA.
[Anand, Gobind] Johns Hopkins Sch Med, Baltimore, MD USA.
[El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.edu
FU NIH [K23CA125585]; Houston VA HSR&D Center of Excellence [HFP90-020]
FX The study was supported by an NIH K23 career development award
(K23CA125585) to Dr Singh and in part by the Houston VA HSR&D Center of
Excellence (HFP90-020)
NR 26
TC 24
Z9 25
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD JUN
PY 2010
VL 8
IS 6
BP 523
EP 529
DI 10.1016/j.cgh.2010.03.010
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 610PV
UT WOS:000278747200014
PM 20303416
ER
PT J
AU Singh, N
Sun, HY
AF Singh, Nina
Sun, Hsin-Yun
TI Lipid Formulations of Amphotericin B and Solid Organ Transplant
Recipients with Central Nervous System Cryptococcosis Reply
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
C1 [Singh, Nina; Sun, Hsin-Yun] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
[Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA.
[Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
[Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan.
RP Singh, N (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C, Pittsburgh, PA 15240 USA.
EM nis5@pitt.edu
NR 3
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 1
PY 2010
VL 50
IS 11
BP 1544
EP 1545
DI 10.1086/652715
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 590AF
UT WOS:000277194800020
ER
PT J
AU Jun, M
Lambers Heerspink, HJ
Ninomiya, T
Gallagher, M
Bellomo, R
Myburgh, J
Finfer, S
Palevsky, PM
Kellum, JA
Perkovic, V
Cass, A
AF Jun, Min
Lambers Heerspink, Hiddo J.
Ninomiya, Toshiharu
Gallagher, Martin
Bellomo, Rinaldo
Myburgh, John
Finfer, Simon
Palevsky, Paul M.
Kellum, John A.
Perkovic, Vlado
Cass, Alan
TI Intensities of Renal Replacement Therapy in Acute Kidney Injury: A
Systematic Review and Meta-Analysis
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Review
ID CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMOFILTRATION;
RANDOMIZED CLINICAL-TRIALS; FAILURE; SURVIVAL; DIALYSIS; QUALITY;
RECOVERY; STANDARD; OUTCOMES
AB Background and objectives: Clinical trials of the intensity of renal replacement therapy (RRT) for people with acute kidney injury (AKI) have produced conflicting results. A systematic review and meta-analysis was undertaken to assess the effect of different intensities of RRT on all-cause mortality and renal recovery in AKI patients.
Design, setting, participants, & measurements: MEDLINE, EMBASE, and the Cochrane Library database were systematically searched for trials published between 1950 and 2009. Inclusion criteria were completed, prospective, adult-population, randomized controlled studies. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated. Summary estimates of RR were obtained using a random effects model. Heterogeneity, metaregression, publication bias, and subgroup analyses were conducted.
Results: Eight trials were identified that provided data on 3841 patients and 1808 deaths. More intense RRT (35 to 48 ml/kg per h or equivalent) had no overall effect on the risk of death (RR 0.89, 95% CI 0.76 to 1.04, P = 0.143) or recovery of renal function (RR 1.12, 95% CI 0.95 to 1.31, P = 0.181) compared with less-intensive regimens (20 to 25 ml/kg per h or equivalent). Significant heterogeneity was identified with contributing factors including publication year (P = 0.004) and Jadad score (P = 0.048).
Conclusions: Within the intensity ranges studied, higher intensity RRT does not reduce mortality rates or improve renal recovery among patients with AKI. The results do not negate the importance of RRT intensity in the treatment of AKI patients but rather reinforce the need to better understand the effects of treatment modalities, doses, and timing in this varied, high-risk population. Clin J Am Soc Nephrol 5: 956-963, 2010. doi: 10.2215/CJN.09111209
C1 [Jun, Min; Lambers Heerspink, Hiddo J.; Ninomiya, Toshiharu; Gallagher, Martin; Myburgh, John; Finfer, Simon; Perkovic, Vlado; Cass, Alan] Univ Sydney, George Inst Int Hlth, Sydney, NSW 2050, Australia.
[Lambers Heerspink, Hiddo J.] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharmacol, Groningen, Netherlands.
[Bellomo, Rinaldo] Austin Hlth, Dept Intens Care & Med, Melbourne, Vic, Australia.
[Myburgh, John] St George Hosp, Dept Intens Care Med, Sydney, NSW, Australia.
[Finfer, Simon] Royal N Shore Hosp, Intens Care Unit, Sydney, NSW, Australia.
[Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA.
[Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA.
[Kellum, John A.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA.
RP Cass, A (reprint author), Univ Sydney, George Inst Int Hlth, POB M201,Missenden Rd, Sydney, NSW 2050, Australia.
EM acass@george.org.au
RI Lambers Heerspink, Hiddo/K-3358-2014
OI Lambers Heerspink, Hiddo/0000-0002-3126-3730; Perkovic,
Vlado/0000-0002-4257-7620; Palevsky, Paul/0000-0002-7334-5400
FU Australasian Kidney Trials Network (AKTN); Dutch Kidney Foundation;
Foundation of High Blood Pressure Research Council of Australia;
Australian National Health and Medical Research Council
FX M.J. was supported by a postgraduate scholarship from the Australasian
Kidney Trials Network (AKTN). H.J.L.H. was supported by a fellowship
from the Dutch Kidney Foundation and International Society of
Hypertension Visiting Postdoctoral Fellowship awarded by the Foundation
of High Blood Pressure Research Council of Australia. A.C. was supported
by a Senior Research Fellowship from the Australian National Health and
Medical Research Council. M.J., H.J.L.H., T.N., M.G., V.P., and A.C.
were responsible for data collection, analysis, interpretation, and
manuscript preparation. R.B. and J.M. contributed to data
interpretation. A.C., V.P., H.J.L.H., M.G., R.B., J.M., S.F., J.A.K.,
and P.M.P. contributed to critical revision of the publication. The
corresponding author had full access to all data in the study and takes
responsibility for the integrity of the data and accuracy of the
analysis.
NR 22
TC 38
Z9 40
U1 0
U2 2
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JUN
PY 2010
VL 5
IS 6
BP 956
EP 963
DI 10.2215/CJN.09111209
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 608OY
UT WOS:000278596200003
PM 20395356
ER
PT J
AU Sunwoo, B
Kuna, ST
AF Sunwoo, Bernie
Kuna, Samuel T.
TI Ambulatory Management of Patients with Sleep Apnea: Is There a Place for
Portable Monitor Testing?
SO CLINICS IN CHEST MEDICINE
LA English
DT Article
DE Polysomnogram; Apnea-hypopnea index; Continuous positive airway
pressure; Cost-effectiveness; Comparative effectiveness
ID POSITIVE AIRWAY PRESSURE; PRACTICE PARAMETERS; CARDIOVASCULAR-DISEASE;
HOME DIAGNOSIS; ADULT PATIENTS; POLYSOMNOGRAPHY; ASSOCIATION; DEVICES;
HEALTH; EPIDEMIOLOGY
AB Portable monitor testing is being increasingly used as an alternative strategy for the diagnosis and treatment of patients with obstructive sleep apnea. Portable monitors have become progressively sophisticated but lack standardization. Recent studies comparing clinical outcomes of ambulatory management pathways using portable monitor testing support their use in patients with a high pretest probability for obstructive sleep apnea. Whether ambulatory management is cost-effective and will improve patient access to diagnosis and treatment requires further investigation.
C1 [Sunwoo, Bernie] Univ Penn, Hosp Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA.
[Kuna, Samuel T.] Philadelphia VA Med Ctr, Dept Med, Pulm Crit Care & Sleep Med Sect, Philadelphia, PA 19104 USA.
[Kuna, Samuel T.] Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA.
RP Sunwoo, B (reprint author), Univ Penn, Hosp Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, 844 W Gates, Philadelphia, PA 19104 USA.
EM Bernie.Sunwoo@uphs.upenn.edu
FU [HSRD 04-021-2]
FX This work was supported by Grant No. HSR&D 04-021-2.
NR 49
TC 2
Z9 2
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-5231
J9 CLIN CHEST MED
JI Clin. Chest Med.
PD JUN
PY 2010
VL 31
IS 2
BP 299
EP +
DI 10.1016/j.ccm.2010.02.003
PG 11
WC Respiratory System
SC Respiratory System
GA 612AQ
UT WOS:000278868900010
PM 20488288
ER
PT J
AU Kremen, SA
Solis, OE
Shapira, JS
Vinters, HV
Mendez, MF
AF Kremen, Sarah A.
Solis, Orestes E.
Shapira, Jill S.
Vinters, Harry V.
Mendez, Mario F.
TI "Fantastic Thinking'' in Pathologically Proven Pick Disease
SO COGNITIVE AND BEHAVIORAL NEUROLOGY
LA English
DT Article
DE frontotemporal dementia; Pick disease; confabulations; delusions;
fantasy
ID FRONTOTEMPORAL DEMENTIA; ALZHEIMERS-DISEASE; CONFABULATION; DELUSIONS;
SYMPTOMS
AB Background: Reports of false beliefs may be a unique feature of behavioral variant frontotemporal dementia (bvFTD) but the nature of these experiences is unclear.
Objective: To report a case of pathologically verified Pick disease in a patient presenting with prominent and recurrent fantasies.
Methods: We describe the clinical, neuroradiologic, and neuropathologic findings of a 53-year-old woman presenting with fantasies and meeting Clinical Consensus Criteria for bvFTD.
Results: Early in her course, she reported interactions with different actors, having torrid affairs with them, and other related fantasies. When confronted with her false beliefs, she admitted that these relationships were imaginary. Autopsy revealed Pick disease with t-immunoreactive Pick bodies in the frontal and temporal cortices, and in the hippocampi.
Conclusions: Fantastic thinking, or vividly experienced imagination, may be a manifestation of bvFTD that is distinct from delusions and confabulations and could be the source of previously reported delusions and confabulations in bvFTD.
C1 [Kremen, Sarah A.; Mendez, Mario F.] VA Greater Angeles Healthcare Syst, Neurobehav Unit, Dept Neurol, Los Angeles, CA 90073 USA.
[Kremen, Sarah A.; Shapira, Jill S.; Vinters, Harry V.; Mendez, Mario F.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Solis, Orestes E.; Vinters, Harry V.] Univ Calif Los Angeles, Div Neuropathol, Dept Pathol, David Geffen Sch Med, Los Angeles, CA 90024 USA.
RP Kremen, SA (reprint author), VA Greater Angeles Healthcare Syst, Neurobehav Unit, Dept Neurol, Bldg 500 3S 116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM skremen@ucla.edu
FU UCLA Alzheimer Disease Research Center [P50AG16570]; Daljit S. & Elaine
Sarkaria Chair in Diagnostic Medicine
FX Harry V. Vinters, MD is supported in part by the UCLA Alzheimer Disease
Research Center grant P50AG16570 and the Daljit S. & Elaine Sarkaria
Chair in Diagnostic Medicine.
NR 17
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1543-3633
J9 COGN BEHAV NEUROL
JI Cogn. Behav. Neurol.
PD JUN
PY 2010
VL 23
IS 2
BP 130
EP 134
DI 10.1097/WNN.0b013e3181df3007
PG 5
WC Behavioral Sciences; Clinical Neurology
SC Behavioral Sciences; Neurosciences & Neurology
GA 608GD
UT WOS:000278570500010
PM 20535063
ER
PT J
AU Sox, HC
Helfand, M
Grimshaw, J
Dickersin, K
Tovey, D
Knottnerus, JA
Tugwell, P
AF Sox, Harold C.
Helfand, Mark
Grimshaw, Jeremy
Dickersin, Kay
Tovey, David
Knottnerus, J. Andre
Tugwell, Peter
CA PLoS Med Editors
TI Comparative Effectiveness Research: Challenges for Medical Journals
SO CROATIAN MEDICAL JOURNAL
LA English
DT Editorial Material
C1 [Sox, Harold C.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dartmouth Inst, Hanover, NH 03756 USA.
[Helfand, Mark] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
[Helfand, Mark] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Grimshaw, Jeremy] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
[Dickersin, Kay] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Tovey, David] Cochrane Lib, London, England.
[Knottnerus, J. Andre] Univ Maastricht, Dept Gen Practice, Maastricht, Netherlands.
[Tugwell, Peter] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
[Tugwell, Peter] Univ Ottawa, Dept Epidemiol, Ottawa, ON, Canada.
[Tugwell, Peter] Univ Ottawa, Dept Community Med, Ottawa, ON, Canada.
RP Sox, HC (reprint author), Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dartmouth Inst, Hanover, NH 03756 USA.
EM helfand@ohsu.edu
RI Knottnerus, Johannes/A-3829-2009
OI Grimshaw, Jeremy/0000-0001-8015-8243; Tugwell, Peter/0000-0001-5062-0556
NR 7
TC 1
Z9 1
U1 0
U2 1
PU MEDICINSKA NAKLADA
PI ZAGREB
PA VLASKA 69, HR-10000 ZAGREB, CROATIA
SN 0353-9504
J9 CROAT MED J
JI Croat. Med. J.
PD JUN
PY 2010
VL 51
IS 3
BP 191
EP 194
DI 10.3325/cmj.2010.51.191
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 656RM
UT WOS:000282354300002
PM 20578332
ER
PT J
AU Zhong, WW
Zhang, ZL
Hinrichs, D
Wu, XM
Hall, M
Xia, ZW
Rosenbaum, JT
AF Zhong, Wenwei
Zhang, Zili
Hinrichs, David
Wu, Xiumei
Hall, Mark
Xia, Zhenwei
Rosenbaum, James T.
TI OX40 induces CCL20 expression in the context of antigen stimulation: An
expanding role of co-stimulatory molecules in chemotaxis
SO CYTOKINE
LA English
DT Article
DE CCL20; CD4+T cells; Co-stimulatory molecule; OX40; T cell co-stimulation
ID T-CELL TRAFFICKING; INFLAMMATORY PROTEIN-3-ALPHA; CYTOKINE
DIFFERENTIATION; CHEMOKINE RECEPTOR; TH17 CELLS; ACTIVATION; DISEASE;
INTERLEUKIN-8; MIGRATION; MEMORY
AB OX40 is an inducible co-stimulatory molecule expressed by activated T cells. It plays an important role in the activation and proliferation of T lymphocytes. Recently, some co-stimulatory molecules have been shown to direct leukocyte trafficking. Chemotaxis is essential for achieving an effective immune response. CCL20 is an important chemoattractant produced by activated T cells. In this study, using DO11.10 mice whose transgenic T cell receptor specifically recognizes ovalbumin, we demonstrate that ovalbumin induces OX40 expression in CD4+ lymphocytes. Further stimulation of OX40 by OX40 activating antibody up-regulates CCL20 production. Both NF-kappa B dependent and independent signaling pathways are implicated in the induction of CCL20 by OX40. Finally, we primed the DO11.10 splenocytes with or without OX40 activating antibody in the presence of ovalbumin. Intranasal administration of the cell lysates derived from the cells with OX40 stimulation results in more severe leukocyte infiltration in the lung of DO11.10 mice, which is substantially attenuated by CCL20 blocking antibody. Taken together, this study has shown that activation of OX40 induces CCL20 expression in the presence of antigen stimulation. Thus, our results broaden the role of OX40 in chemotaxis, and reveal a novel effect of costimulatory molecules in orchestrating both T cell up-regulation and migration. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
[Hinrichs, David] Portland VA Med Ctr, Portland, OR 97239 USA.
[Zhong, Wenwei; Zhang, Zili; Wu, Xiumei; Hall, Mark] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA.
[Zhong, Wenwei; Xia, Zhenwei] RuiJin Hosp, Dept Pediat, Shanghai 200025, Peoples R China.
RP Zhang, ZL (reprint author), CDRCP, 707 Gaines St, Portland, OR 97239 USA.
EM zhangzi@ohsu.edu
FU National Institutes of Health [EY016788, EY013093, EY006484]; Child
Digestive Health and Nutrition Foundation/CCFA; Stan and Madelle
Rosenfeld Family Trust; Research to Prevent Blindness; William and Mary
Bauman Foundation; Fund for Arthritis and Infectious Disease Research
FX We thank Judie McDonald for help in preparing the manuscript. This study
was supported by National Institutes of Health Grants EY016788 (ZZ),
EY013093 (JTR), EY006484 (JTR), and Child Digestive Health and Nutrition
Foundation/CCFA Young Investigator Award (ZZ). JTR Funds from the Stan
and Madelle Rosenfeld Family Trust, Research to Prevent Blindness, the
William and Mary Bauman Foundation, and the Fund for Arthritis and
Infectious Disease Research also contributed to this work.
NR 47
TC 5
Z9 5
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
J9 CYTOKINE
JI Cytokine
PD JUN
PY 2010
VL 50
IS 3
BP 253
EP 259
DI 10.1016/j.cyto.2010.03.021
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 606GU
UT WOS:000278411600006
PM 20400327
ER
PT J
AU Redmon, JB
Bertoni, AG
Connelly, S
Feeney, PA
Glasser, SP
Glick, H
Greenway, F
Hesson, LA
Lawlor, MS
Montez, M
Montgomery, B
AF Redmon, J. Bruce
Bertoni, Alain G.
Connelly, Stephanie
Feeney, Patricia A.
Glasser, Stephen P.
Glick, Henry
Greenway, Frank
Hesson, Louise A.
Lawlor, Michael S.
Montez, Maria
Montgomery, Brenda
CA Look AHEAD Res Grp
TI Effect of the Look AHEAD Study Intervention on Medication Use and
Related Cost to Treat Cardiovascular Disease Risk Factors in Individuals
With Type 2 Diabetes
SO DIABETES CARE
LA English
DT Article
ID LIFE EXPECTANCY; WEIGHT-LOSS; MELLITUS; INSULIN; PREVENTION; THERAPY;
TRIAL
AB OBJECTIVE-To examine the effect of a lifestyle intervention to produce weight loss and increased physical fitness on use and cost of medications to treat cardiovascular disease (CVD) risk factors in people with type 2 diabetes.
RESEARCH DESIGN AND METHODS-Look AHEAD is a multicenter randomized controlled trial of 5,145 overweight or obese individuals with type 2 diabetes, aged 45-76 years. An intensive lifestyle intervention (ILI) involving group and individual meetings to achieve and maintain weight loss through decreased caloric intake and increased physical activity was compared with a diabetes support and education (DSE) condition. Medications prescribed to treat diabetes, hypertension, and hyperlipidemia were compared at baseline and 1 year. Medication costs were conservatively estimated using prices from a national online pharmacy.
RESULTS-Participants randomized to an ILI had significantly greater improvements in CVD risk parameters and reduced medication use and cost compared with those assigned to DSE. At 1 year, average number of medications prescribed to treat CVD risk factors was 3.1 +/- 1.8 for the ILI group and 3.6 +/- 1.8 for the DSE group (P < 0.0001), with estimated total monthly medication costs of $143 and $173, respectively (P < 0.0001). DSE participants meeting optimal care goals at 1 year were taking an average of 3.8 +/- 1.6 medications at an estimated cost of $194/month. ILL participants at optimal care required fewer medications (3.2 +/- 1.7) at lower cost ($1.54/month) (P < 0.001).
CONCLUSIONS-At 1 year, ILI significantly improved CVD risk factors, while at the same time reduced medication use and cost. Continued intervention and follow-up will determine whether these changes are maintained and reduce cardiovascular risk.
C1 [Redmon, J. Bruce] Univ Minnesota, Sch Med, Dept Med, Div Endocrinol, Minneapolis, MN 55455 USA.
[Bertoni, Alain G.] Wake Forest Univ, Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA.
[Connelly, Stephanie] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA.
[Feeney, Patricia A.] Wake Forest Univ, Dept Biostat, Winston Salem, NC 27109 USA.
[Glasser, Stephen P.] Univ Alabama, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA.
[Glick, Henry] Univ Penn, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Greenway, Frank] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA USA.
[Hesson, Louise A.] Univ Penn, Weight & Eating Disorders Program, Philadelphia, PA 19104 USA.
[Lawlor, Michael S.] Wake Forest Univ, Dept Econ, Winston Salem, NC 27109 USA.
[Montez, Maria] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA.
[Montgomery, Brenda] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Montgomery, Brenda] Univ Washington, Seattle, WA 98195 USA.
RP Redmon, JB (reprint author), Univ Minnesota, Sch Med, Dept Med, Div Endocrinol, Minneapolis, MN 55455 USA.
EM redmo001@umn.edu
OI Redmon, J. Bruce/0000-0002-1883-9467; Glasser,
Stephen/0000-0001-9620-6406
FU National Institutes of Health (NIH) [DK57136, DK57149, DK56990, DK57177,
DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178,
DK57219, DK57008, DK57135, DK56992, DK046204]; National Institute of
Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and
Blood Institute; National Institute of Nursing Research; National Center
on Minority Health and Health Disparities; Office of Research on Women's
Health; Centers for Disease Control and Prevention; Johns Hopkins
Medical Institution Bayview General Clinical Research Center
[M01RR02719]; Massachusetts General Hospital Mallinckrodt General
Clinical Research Center [M01RR01066]; University of Colorado Health
Sciences Center General Clinical Research Center [M01RR00051]; Clinical
Nutrition Research Unit [P30 DK48520]; University of Tennessee
[M01RR0021140]; University of Pittsburgh [M01RR000056 44]; VA Puget
Sound HealthCare Sysrem Medical Research Service, Department of Veterans
Affairs; Frederic C. Banter General Clinical Research Center
[M01RR01346]
FX This study is supported by the Department of Health and Human Services
through the following cooperative agreements from the National
Institutes of Health (NIH): DK57136, DK57149, DK56990, DK57177, DK57171,
DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219,
DK57008, DK57135, and DK56992. The following federal agencies have
contributed support: the National Institute of Diabetes and Digestive
and Kidney Diseases; the National Heart, Lung, and Blood Institute; the
National Institute of Nursing Research; the National Center on Minority
Health and Health Disparities; the Office of Research on Women's Health;
and the Centers for Disease Control and Prevention. This research was
supported in part by the Intramural Research Program of the National
Institute of Diabetes and Digestive and Kidney Diseases. The Indian
Health Service (IHS) provided personnel, medical oversight, and use of
facilities. Additional support was received from the Johns Hopkins
Medical Institution Bayview General Clinical Research Center
(M01RR02719); the Massachusetts General Hospital Mallinckrodt General
Clinical Research Center (M01RR01066); the University of Colorado Health
Sciences Center General Clinical Research Center (M01RR00051) and
Clinical Nutrition Research Unit (P30 DK48520); the University of
Tennessee at Memphis General Clinical Research Center (M01RR0021140);
the University of Pittsburgh General Clinical Research Center
(M01RR000056 44); NIH Grant DK046204; the VA Puget Sound HealthCare
Sysrem Medical Research Service, Department of Veterans Affairs; and the
Frederic C. Banter General Clinical Research Center (M01RR01346). The
following organizations have committed to make major contributions to
the Look AHEAD study: Federal Express; Health Management Resources; Life
Scan, a Johnson & Johnson Company; Optifast of Nestle Health Care
Nutrition; Hoffmann-La Roche; Abbott Nutrition; and Slim-Fast Brand of
Unilever North America.
NR 24
TC 37
Z9 38
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD JUN
PY 2010
VL 33
IS 6
BP 1153
EP 1158
DI 10.2337/dc09-2090
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 617TI
UT WOS:000279304300001
PM 20332353
ER
PT J
AU Ausk, KJ
Boyko, EJ
Ioannou, GN
AF Ausk, Karlee J.
Boyko, Edward J.
Ioannou, George N.
TI Insulin Resistance Predicts Mortality in Nondiabetic Individuals in the
US
SO DIABETES CARE
LA English
DT Article
ID HOMEOSTASIS MODEL ASSESSMENT; TYPE-2 DIABETES-MELLITUS; CARDIOVASCULAR
EVENTS; HEART-FAILURE; DISEASE; RISK; INFLAMMATION; ASSOCIATION;
GLUCOSE; OBESITY
AB OBJECTIVE - Insulin resistance is a suspected causative factor in a wide variety of diseases. We aimed to determine whether insulin resistance, estimated by the homeostasis model assessment for insulin resistance (HOMA-IR), is associated with all-cause or disease-specific mortality among nondiabetic persons in the U.S.
RESEARCH DESIGN AND METHODS - We determined the association between HOMA-IR and death certificate based mortality among 5,511 nondiabetic, adult participants of the third U.S. National Health and Nutrition Examination Survey (1988-1994) during up to 12 years of follow-up, after adjustment for potential confounders (age, sex, BM!, waist-to-hip ratio, alcohol consumption, race/ethnicity, educational attainment, smoking status, physical activity, C-reactive protein, systolic and diastolic blood pressure, plasma total and HDL cholesterol, and triglycerides).
RESULTS - HOMA-IR was significantly associated with all-cause mortality (adjusted hazard ratio 1.16[95% CI 1.01-1.3], comparing successive quartiles of HOMA-IR in a linear model and 1.64 [1.1-2.5], comparing the top [HOMA-IR >2.8] to the bottom [HOMA-IR 1.4] quartile). HOMA-IR was significantly associated with all-cause mortality only in subjects with BMI <25.2 kg/m(2) (the median value) but not in subjects with BMI 25.2 kg/m(2). Subjects in the second, third, and fourth quartile of HOMA-IR appeared to have higher cardiovascular mortality than subjects in the lowest quartile of HOMA-IR. HOMA-IR was not associated with cancer-related mortality.
CONCLUSIONS - HOMA-IR is associated with all-cause mortality in the nondiabetic U.S. population but only among persons with normal BMI HOMA-IR is a readily available measure that can be used in the future to predict mortality in clinical or epidemiological settings.
C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA USA.
[Ausk, Karlee J.; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA.
[Ausk, Karlee J.; Boyko, Edward J.; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA.
[Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Internal Med, Seattle, WA USA.
RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA USA.
EM georgei@medicine.washington.edu
OI Boyko, Edward/0000-0002-3695-192X
FU American Liver Foundation; American Association for the Study of Liver
Diseases Jan Albrecht Award; Veterans Affairs Research Enhancement Award
Program
FX This work is supported by the American Liver Foundation and the American
Association for the Study of Liver Diseases Jan Albrecht Award and
Veterans Affairs Research Enhancement Award Program.
NR 25
TC 32
Z9 35
U1 0
U2 0
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD JUN
PY 2010
VL 33
IS 6
BP 1179
EP 1185
DI 10.2337/dc09-2110
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 617TI
UT WOS:000279304300007
PM 20200308
ER
PT J
AU Alish, CJ
Garvey, WT
Maki, KC
Sacks, GS
Hustead, DS
Hegazi, RA
Mustad, VA
AF Alish, Carolyn J.
Garvey, W. Timothy
Maki, Kevin C.
Sacks, Gordon S.
Hustead, Deborah S.
Hegazi, Refaat A.
Mustad, Vikkie A.
TI A Diabetes-Specific Enteral Formula Improves Glycemic Variability in
Patients with Type 2 Diabetes
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID CRITICALLY-ILL PATIENTS; BLOOD-GLUCOSE; HOSPITAL MORTALITY;
HYPERGLYCEMIA; CARBOHYDRATE; PALATINOSE; INSULIN; TRIAL; ASSOCIATION;
FAT
AB Background: Well-controlled studies have demonstrated that inpatient hyperglycemia is an indicator of poor clinical outcomes, but the use of diabetes-specific enteral formulas in hospitalized patients remains a topic of great debate.
Methods: In two different protocols, postprandial glycemia and insulinemia were measured in 22 subjects with diabetes fed a diabetes-specific or standard formula (protocol 1). Continuous glucose monitoring was used to assess glucose levels in 12 enterally fed patients with diabetes receiving the standard formula followed by the diabetes-specific formula continuously for 5 days each (protocol 2). End points included postprandial glycemia and insulinemia, glycemic variability (mean amplitude of glycemic excursions [MAGE]), mean glucose, and insulin use.
Results: In the postprandial response protocol, the diabetes-specific formula resulted in lower positive areas under the postprandial curve (P < 0.001) and peak glucose (P < 0.001) and insulin (P = 0.017) levels. In the protocol using continuous glucose monitoring, glycemic variability (as measured by MAGE) was lower with continuous administration of the diabetes-specific than the standard formula (64.6 +/- 6.8mg/dL vs. 110.6 +/- 15.3mg/dL, P = 0.003). Also, administration of the diabetes-specific formula resulted in lower mean glucose concentrations during feeding (171.1 +/- 16.1 vs. 202.1 +/- 17.4mg/dL, P = 0.024) and insulin requirements (7.8 +/- 2.3 vs. 10.9 +/- 3.3 units/day, P = 0.039) than the standard formula.
Conclusions: Relative to the standard formula, the diabetes-specific formula reduced postprandial glycemia, mean glucose, glycemic variability, and short-acting insulin requirements. These results suggest potential clinical usefulness of a diabetes-specific enteral formula for minimizing glycemic excursions in hospitalized patients.
C1 [Alish, Carolyn J.; Hustead, Deborah S.; Hegazi, Refaat A.; Mustad, Vikkie A.] Abbott Labs, Columbus, OH 43215 USA.
[Garvey, W. Timothy] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA.
[Maki, Kevin C.] Provident Clin Res, Glen Ellyn, IL USA.
[Sacks, Gordon S.] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA.
RP Alish, CJ (reprint author), Abbott Labs, 625 Cleveland Ave, Columbus, OH 43215 USA.
EM carolyn.alish@abbott.com
NR 26
TC 21
Z9 22
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD JUN
PY 2010
VL 12
IS 6
BP 419
EP 425
DI 10.1089/dia.2009.0185
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 597EB
UT WOS:000277738000001
PM 20470226
ER
PT J
AU Lynch, CP
Strom, JL
Egede, LE
AF Lynch, Cheryl P.
Strom, Joni L.
Egede, Leonard E.
TI Effect of Veterans Administration Use on Indicators of Diabetes Care in
a National Sample of Veterans
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID AFFAIRS HEALTH-CARE; QUALITY-OF-CARE; ADULTS; SYSTEM
AB Background: Diabetes poses a serious health burden, of which veterans have a disproportionate share. Few data exist regarding differences in self-care behaviors and provider-based quality of care indicators among a large sample of veterans. The objective of this study was to determine the effect of Veterans Affairs (VA) use on diabetes quality of care indicators among veterans.
Methods: A cross-sectional analysis was done on data from 36,525 veterans in the 2003 Behavioral Risk Factor Surveillance Survey. VA use was defined as receiving some or all health care from a VA facility in the previous 12 months. Diabetes quality indicators such as two or more provider visits, two or more hemoglobin A1c tests, and flu and pneumonia shots were compared between VA users and non-VA users. The independent effect of VA use on each quality indicator was analyzed with multiple regression using STATA version 10 (Stata Press, College Station, TX) to account for the complex survey design and yield population estimates.
Results: Among veterans with diabetes, 26.8% were VA users. The only significant difference between VA users and non-VA users was that VA users were significantly more likely to check their feet one or more times daily (75.7% vs. 68.5%, P = 0.015). In final adjusted models, VA users were at least twice as likely as non-VA users to have foot exams by a provider (odds ratio 2.59) and receive flu and pneumonia shots (odds ratio 2.30 and 2.05, respectively). VA users were also more likely to have two or more provider visits, dilated eye exams, and two or more hemoglobin A1c tests than non-VA users.
Conclusions: Key quality indicators for diabetes care were better among veterans getting some or all of their care from VA facilities, suggesting more effective care strategies. However, interventions should identify and perpetuate excellent self-care behaviors to more substantially impact adverse diabetes-related outcomes.
C1 [Lynch, Cheryl P.] Med Univ S Carolina, Ctr Hlth Dispar Res, Ralph H Johnson VA Med Ctr, Charleston VA Res Enhancement Award Program, Charleston, SC 29456 USA.
RP Lynch, CP (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Ralph H Johnson VA Med Ctr, Charleston VA Res Enhancement Award Program, 135 Rutledge Ave,MSC 250593, Charleston, SC 29456 USA.
EM lynchcp@musc.edu
FU NIDDK NIH HHS [R01 DK081121]
NR 22
TC 4
Z9 4
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD JUN
PY 2010
VL 12
IS 6
BP 427
EP 433
DI 10.1089/dia.2009.0171
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 597EB
UT WOS:000277738000002
PM 20470227
ER
PT J
AU Zraika, S
Hull, RL
Verchere, CB
Clark, A
Potter, KJ
Fraser, PE
Raleigh, DP
Kahn, SE
AF Zraika, S.
Hull, R. L.
Verchere, C. B.
Clark, A.
Potter, K. J.
Fraser, P. E.
Raleigh, D. P.
Kahn, S. E.
TI Toxic oligomers and islet beta cell death: guilty by association or
convicted by circumstantial evidence?
SO DIABETOLOGIA
LA English
DT Article
ID AMYLOID FIBRIL FORMATION; ALZHEIMERS-DISEASE BRAIN; HUMAN AMYLIN;
DIABETES-MELLITUS; TRANSGENIC MICE; APOLIPOPROTEIN-E; NONDIABETIC
INDIVIDUALS; PROTEIN AGGREGATION; PEPTIDE DEPOSITION; MOUSE MODEL
AB Type 2 diabetes is a progressive disease characterised by islet amyloid deposits in the majority of patients. Amyloid formation is considered a significant factor in deterioration of islet function and reduction in beta cell mass, and involves aggregation of monomers of the normally soluble beta cell peptide, human islet amyloid polypeptide (hIAPP) into oligomers, fibrils and, ultimately, mature amyloid deposits. Despite extensive in vitro studies, the process of hIAPP aggregation in vivo is poorly understood, though it is widely reported to promote cytotoxicity. Recently, studies have suggested that only the early stages of fibril assembly, and in particular small hIAPP oligomers, are responsible for beta cell cytotoxicity. This challenges the prior concept that newly formed fibrils and/or mature fibrillar amyloid are cytotoxic. Herein, evidence both for and against the toxic hIAPP oligomer hypothesis is presented; from this, it is apparent that what exactly causes beta cell death when hIAPP aggregates remains debatable. Moreover, substantially more work with more specific reagents and techniques than are currently available will be required to identify conclusively the toxic species resulting from hIAPP aggregation. Keeping an open mind on the nature of the cytotoxic insult has implications for therapeutic developments and clinical care in type 2 diabetes.
C1 [Zraika, S.; Hull, R. L.; Kahn, S. E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA.
[Zraika, S.; Hull, R. L.; Kahn, S. E.] Univ Washington, Seattle, WA 98108 USA.
[Verchere, C. B.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.
[Verchere, C. B.] Univ British Columbia, Dept Surg, Child & Family Res Inst, Vancouver, BC V6T 1W5, Canada.
[Clark, A.] Churchill Hosp, Diabet Res Labs, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England.
[Potter, K. J.] Univ British Columbia, Child & Family Res Inst, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.
[Fraser, P. E.] Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON, Canada.
[Fraser, P. E.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
[Raleigh, D. P.] SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.
RP Zraika, S (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way 151, Seattle, WA 98108 USA.
EM zraikas@u.washington.edu
OI Verchere, Bruce/0000-0002-9262-0586; Kahn, Steven/0000-0001-7307-9002;
Hull, Rebecca/0000-0001-9690-4087; raleigh, daniel/0000-0003-3248-7493
FU Department of Veterans Affairs; Canadian Diabetes Association; Canadian
Institutes of Health Research; Alzheimer Society of Ontario; NIH
[DK-075998, DK-074404, DK-080945, GM-078114]; Canadian Institutes of
Health Research [MOP-14682]; Juvenile Diabetes Research Foundation;
Canadian Institutes of Health Research RD Studentship; Michael Smith
Foundation for Health Research
FX The authors are supported by the Medical Research Service of the
Department of Veterans Affairs (S. Zraika, R. L. Hull, S. E. Kahn), the
Canadian Diabetes Association (C. B. Verchere), the Canadian Institutes
of Health Research (P. E. Fraser) and the Alzheimer Society of Ontario
(P. E. Fraser). They are also in receipt of the following grants: NIH
grants DK-075998 to S. E. Kahn, DK-074404 to R. L. Hull, DK-080945 to S.
Zraika and GM-078114 to D. P. Raleigh; a Canadian Institutes of Health
Research grant MOP-14682 to C. B. Verchere; a Juvenile Diabetes Research
Foundation Postdoctoral Fellowship grant to S. Zraika; and a Canadian
Institutes of Health Research R&D Studentship to K. J. Potter. C. B.
Verchere is a Senior Scholar of the Michael Smith Foundation for Health
Research.
NR 83
TC 80
Z9 80
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD JUN
PY 2010
VL 53
IS 6
BP 1046
EP 1056
DI 10.1007/s00125-010-1671-6
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 589HP
UT WOS:000277138100005
PM 20182863
ER
PT J
AU Hawkins, EJ
Lapham, GT
Kivlahan, DR
Bradley, KA
AF Hawkins, Eric J.
Lapham, Gwendolyn T.
Kivlahan, Daniel R.
Bradley, Katharine A.
TI Recognition and management of alcohol misuse in OEF/OIF and other
veterans in the VA: A cross-sectional study
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Alcohol misuse; OEF/OIF; Brief alcohol interventions; Referral to
treatment; Alcohol screening
ID IDENTIFICATION TEST AUDIT; SUBSTANCE USE DISORDERS; MENTAL-HEALTH
PROBLEMS; BRIEF PHYSICIAN ADVICE; BENEFIT-COST-ANALYSIS; PRIMARY-CARE
PATIENTS; PROBLEM DRINKING; US-VETERANS; BRIEF INTERVENTIONS; PROBLEM
DRINKERS
AB Background: Mental health problems have been identified among soldiers serving in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF), but little is known about the prevalence and management of alcohol misuse in OEF/OIF veterans seen in the Veterans Administration health care system (VA).
Methods: We identified 12,092 veterans (n = 2009 women) 55 and younger and screened for alcohol misuse in FY2007 from a cross-sectional national sample of VA outpatients randomly selected for standardized medical record review for quality monitoring. Alcohol misuse was assessed with the Alcohol Use Disorders Identification Test Consumption questions (AUDIT-C >= 5). Based on medical record reviews, brief alcohol interventions (BI) were defined as documented (1) advice to abstain or drink within recommended limits or (2) feedback about health risks associated with drinking.
Results: Adjusted prevalence of alcohol misuse was higher in OEF/OIF men than non-OEF/OIF men [21.8% vs. 10.5%, adjusted odds ratio (AOR) = 2.37(95% CI: 1.88-2.99)], but did not differ reliably between OEF/OIF and non-OEF/OIF women [4.7% vs. 2.9%, AOR = 1.68 (0.74-3.79)]. Adjusted rates of documented advice or feedback [31.6% vs. 34.6%, AOR =0.87 (0.58-1.21)] and referral [24.1% vs. 28.9%, AOR = 0.78 (0.47-1.30)] were not significantly different between OEF/OIF and non-OEF/OIF men who screened positive for alcohol misuse.
Conclusion: OEF/OIF men were more likely to screen positive for alcohol misuse than non-OEF/OIF men. Overall, approximately half of those with alcohol misuse had documented BI and/or referral to alcohol treatment suggesting a need for improvement in addressing alcohol misuse in OEF/OIF and other veterans. Published by Elsevier Ireland Ltd.
C1 [Hawkins, Eric J.] VA Puget Sound Hlth Care Syst, Seattle Div S116ATC, Hlth Serv Res & Dev, Seattle, WA 98108 USA.
[Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care, Seattle, WA 98108 USA.
[Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
RP Hawkins, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div S116ATC, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM Eric.Hawkins@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development Service; Veteran Affairs' Substance
Use Disorders Quality Enhancement Research Initiative [SUB 98-000]
FX The research reported here was supported by Department of Veterans
Affairs, Veterans Health Administration, Health Services Research and
Development Service. The manuscript was specifically produced with
support from the Veteran Affairs' Substance Use Disorders Quality
Enhancement Research Initiative (SUB 98-000). Dr. Kivlahan and Dr.
Bradley presently serve as the Clinical Coordinator and Co-Clinical
Coordinator of the Substance Use Disorders Quality Enhancement Research
Initiative. Supporting organizations had no further role in study
design; in the collection, analysis and interpretation of data; in the
writing of the report; or in the decision to submit the paper for
publication. The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the University of Washington.
NR 42
TC 50
Z9 50
U1 3
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD JUN 1
PY 2010
VL 109
IS 1-3
BP 147
EP 153
DI 10.1016/j.drugalcdep.2009.12.025
PG 7
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 609MF
UT WOS:000278660000023
PM 20167440
ER
PT J
AU Ahn, J
Ko, S
Kim, S
Knapczyk-Stwora, K
Song, CS
Chatterjee, B
AF Ahn, J.
Ko, S.
Kim, S.
Knapczyk-Stwora, K.
Song, C. S.
Chatterjee, B.
TI Methylation of Androgen Receptor by Set9 Histone Methyltransferase and
Its Functional Impact
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Ahn, J.; Ko, S.; Kim, S.; Knapczyk-Stwora, K.; Song, C. S.; Chatterjee, B.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Song, C. S.; Chatterjee, B.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
BP S4
EP S4
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989400005
ER
PT J
AU Hirano, LA
Page, ST
Dighe, M
Marck, BT
Matsumoto, AM
AF Hirano, L. A.
Page, S. T.
Dighe, M.
Marck, B. T.
Matsumoto, A. M.
TI Dutasteride Reduces Prostate Size and Prostate Specific Antigen in
Hypogonadal Men with Benign Prostatic Hyperplasia Undergoing
Testosterone Replacement Therapy.
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Hirano, L. A.; Page, S. T.; Dighe, M.; Matsumoto, A. M.] Univ Washington, Seattle, WA 98195 USA.
[Hirano, L. A.; Marck, B. T.; Matsumoto, A. M.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
BP S861
EP S861
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989400101
ER
PT J
AU Rao, RH
Cunningham, CA
Perreiah, PL
AF Rao, R. H.
Cunningham, C. A.
Perreiah, P. L.
TI Achieving Tight Glycemic Control in Critical Care without Precipitating
Life-Threatening Hypoglycemia: The VA Pittsburgh Experience
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Rao, R. H.; Cunningham, C. A.; Perreiah, P. L.] VA Pittsburgh Healthcare Syst, Univ Dr Div, Pittsburgh, PA USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
BP S1685
EP S1685
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989400140
ER
PT J
AU Xu, J
Jiang, J
Lobie, PE
Fuchs, SY
Frank, SJ
AF Xu, Jie
Jiang, Jing
Lobie, Peter E.
Fuchs, Serge Y.
Frank, Stuart J.
TI Role of Prolactin Receptor in Growth Hormone Signaling in Human Breast
Cancer Cells.
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Xu, Jie; Jiang, Jing; Frank, Stuart J.] Univ Alabama, Birmingham, AL USA.
[Lobie, Peter E.] Univ Auckland, Auckland 1, New Zealand.
[Fuchs, Serge Y.] Univ Penn, Philadelphia, PA 19104 USA.
[Frank, Stuart J.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
BP S2492
EP S2492
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989400199
ER
PT J
AU Anawalt, BD
Hirano, L
Hotaling, JM
Walsh, TJ
Shields, A
Matsumoto, AM
AF Anawalt, B. D.
Hirano, L.
Hotaling, J. M.
Walsh, T. J.
Shields, A.
Matsumoto, A. M.
TI Total Testosterone (TT) Measurement Is a Good Screening Test for Male
Hypogonadism, but Should Not Be Used To Make a Definitive Biochemical
Diagnosis.
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Soc
C1 [Anawalt, B. D.; Hirano, L.; Hotaling, J. M.; Walsh, T. J.; Shields, A.; Matsumoto, A. M.] Univ Washington, Seattle, WA 98195 USA.
[Hirano, L.; Walsh, T. J.; Matsumoto, A. M.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989402458
ER
PT J
AU Brar, M
Knaub, L
Watson, PA
Reusch, JEB
AF Brar, M.
Knaub, L.
Watson, P. A.
Reusch, J. E. B.
TI Oxidized LDL-Induced CREB Down-Regulation and Protein Oxidation in
Vascular Smooth Muscle Cells.
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Brar, M.; Knaub, L.; Watson, P. A.; Reusch, J. E. B.] Univ Colorado Denver, Aurora, CO USA.
[Brar, M.; Watson, P. A.; Reusch, J. E. B.] Denver VA Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989403137
ER
PT J
AU Cardozo, CP
Pan, J
Wu, Y
Bauman, WA
Qin, W
AF Cardozo, C. P.
Pan, J.
Wu, Y.
Bauman, W. A.
Qin, W.
TI Anabolic Steroids Activate Calcineurin- NFAT Signaling in Denervated
Muscle, and by This Mechanism Reduce Denervation Atrophy.
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Cardozo, C. P.; Pan, J.; Wu, Y.; Bauman, W. A.; Qin, W.] James J Peters VA Med Ctr, Bronx, NY USA.
[Cardozo, C. P.; Bauman, W. A.; Qin, W.] Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989402005
ER
PT J
AU Deng, LQ
Jiang, J
Yang, N
Waters, MJ
Hwa, V
Frank, SJ
AF Deng, Luqin
Jiang, Jing
Yang, Ning
Waters, Michael J.
Hwa, Vivian
Frank, Stuart J.
TI Evaluation of GH Receptor Dimerization Interface Mutants.
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Deng, Luqin; Jiang, Jing; Frank, Stuart J.] Univ Alabama, Birmingham, AL USA.
[Yang, Ning] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
[Waters, Michael J.] Univ Queensland, Brisbane, Qld, Australia.
[Hwa, Vivian] Oregon Hlth & Scis Univ, Portland, OR USA.
[Frank, Stuart J.] Birmingham VA Med Ctr, Birmingham, AL USA.
RI waters, michael/C-9582-2014
NR 3
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989403230
ER
PT J
AU Echchgadda, I
Chang, TH
Sabbah, A
Bakri, I
Chatterjee, B
Bose, S
AF Echchgadda, Ibtissam
Chang, Te-Hung
Sabbah, Ahmed
Bakri, Imad
Chatterjee, Bandana
Bose, Santanu
TI Growth Inhibition of Androgen-Dependent and Androgen-Refractive Prostate
Tumor by the Oncolytic Respiratory Syncytial Virus.
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Echchgadda, Ibtissam; Chang, Te-Hung; Sabbah, Ahmed; Bakri, Imad; Chatterjee, Bandana; Bose, Santanu] UTHSCSA, San Antonio, TX USA.
[Chatterjee, Bandana] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989402035
ER
PT J
AU Liu, XH
Pan, JP
Wu, Y
Qin, WP
Bauman, WA
Cardozo, C
AF Liu, Xin-Hua
Pan, Jiangping
Wu, Yong
Qin, Weiping
Bauman, William A.
Cardozo, Christopher
TI Nandrolone-Induced Nuclear Translocation of Myo-D in Denervated Rat
Skeletal Muscle Associated with Induction of Wnt- and Inhibition of
Notch-Signaling Pathways
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Liu, Xin-Hua; Pan, Jiangping; Wu, Yong; Qin, Weiping; Bauman, William A.; Cardozo, Christopher] James J Peter VA Med Ctr, Bronx, NY USA.
[Liu, Xin-Hua; Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989401040
ER
PT J
AU Mediwala, SN
Sun, H
Marcelli, M
AF Mediwala, S. N.
Sun, H.
Marcelli, M.
TI Truncated Androgen Receptor Gene Expression Is Regulated by Androgen.
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Mediwala, S. N.; Sun, H.; Marcelli, M.] Baylor Coll Med, Houston, TX 77030 USA.
Michael DeBakey Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989402009
ER
PT J
AU Mody, K
Kogai, T
Brent, G
AF Mody, K.
Kogai, T.
Brent, G.
TI Retinoic Acid Regulation of the Thyroid Hormone Transporter,
Monocarboxylate Transporter 8 (Mct8), in Neural Differentiation.
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Mody, K.; Kogai, T.; Brent, G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Mody, K.; Kogai, T.; Brent, G.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989402581
ER
PT J
AU Page, ST
Lin, DW
Mostaghel, EA
Marck, B
Wright, JL
Amory, JK
Matsumoto, AM
AF Page, S. T.
Lin, D. W.
Mostaghel, E. A.
Marck, B.
Wright, J. L.
Amory, J. K.
Matsumoto, A. M.
TI Exogenous Dihydrotestosterone Does Not Increase Intraprostatic
Dihydrotestosterone Concentrations in Healthy Men.
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Page, S. T.; Lin, D. W.; Mostaghel, E. A.; Wright, J. L.; Amory, J. K.; Matsumoto, A. M.] Univ Washington, Sch Med, Seattle, WA USA.
[Marck, B.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989401387
ER
PT J
AU Pham, AN
Datta, SK
Weber, TJ
Walter, LC
Colon-Emeric, CS
AF Pham, A. N.
Datta, S. K.
Weber, T. J.
Walter, L. C.
Colon-Emeric, C. S.
TI Cost-Effectiveness of Oral Bisphosphonates for Osteoporosis at Different
Ages and Levels of Life Expectancy.
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Pham, A. N.; Weber, T. J.] Duke Univ, Med Ctr, Durham, NC USA.
[Datta, S. K.; Colon-Emeric, C. S.] Durham VA Med Ctr, Durham, NC USA.
[Walter, L. C.] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989403170
ER
PT J
AU Qin, WP
Peng, YZ
Sun, L
Pan, JP
Liu, XA
Wu, Y
Zaidi, M
Bauman, WA
Cardozo, C
AF Qin, Weiping
Peng, Yuanzhen
Sun, Li
Pan, Jiangping
Liu, Xuan
Wu, Yong
Zaidi, Mone
Bauman, William A.
Cardozo, Christopher
TI Anabolic Steroids Slow Hindlimb Bone Loss in a Rat Model of Osteoporosis
Due to Spinal Cord Injury: The Role of Wnt Signaling Pathway.
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Qin, Weiping; Pan, Jiangping; Wu, Yong; Bauman, William A.; Cardozo, Christopher] James J Peters VA Med Ctr, Bronx, NY USA.
[Qin, Weiping; Peng, Yuanzhen; Sun, Li; Liu, Xuan; Zaidi, Mone; Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, New York, NY USA.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989402196
ER
PT J
AU Wu, Y
Bauman, WA
Blitzer, R
Cardozo, C
AF Wu, Y.
Bauman, W. A.
Blitzer, R.
Cardozo, C.
TI Testosterone-Induced Hypertrophy of L6 Myoblasts Is Dependent upon mTOR
and Erk 1/2
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Wu, Y.; Bauman, W. A.; Cardozo, C.] James J Peters VA Med Ctr, Bronx, NY USA.
[Bauman, W. A.; Blitzer, R.; Cardozo, C.] Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989401039
ER
PT J
AU Zhang, Y
Gan, YJ
Huang, Y
Jiang, J
Frank, SJ
AF Zhang, Yue
Gan, Yujun
Huang, Yao
Jiang, Jing
Frank, Stuart J.
TI Deletion of IGF-1 Receptor in a Human Prostate Cancer Cell Line Reduces
GH-Induced JAK2 and STAT5 Phosphorylation.
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
CT 92nd Meeting and Expo of the Endocrine Society (ENDO 2010)
CY JUN 19-22, 2010
CL San Diego, CA
SP Endocrine Society
C1 [Zhang, Yue; Gan, Yujun; Huang, Yao; Jiang, Jing; Frank, Stuart J.] Univ Alabama, Birmingham, AL USA.
St Josephs Hosp, Phoenix, AZ USA.
Med Ctr, Phoenix, AZ USA.
Birmingham VA Med Ctr, Birmingham, AL USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0163-769X
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2010
VL 31
IS 3
SU 1
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 652FV
UT WOS:000281989403233
ER
PT J
AU Pomerantz, AS
Sayers, SL
AF Pomerantz, Andrew S.
Sayers, Steven L.
TI Primary Care-Mental Health Integration in Healthcare in the Department
of Veterans Affairs
SO FAMILIES SYSTEMS & HEALTH
LA English
DT Article
DE primary care-mental health integration; primary care; mental health
services; military veterans
ID COLLABORATIVE CARE; MEDICAL HOME; MODEL
AB The U.S. Department of Veterans Affairs (VA) has been undergoing tremendous transformation in the past 15 years with regard to the delivery of health care. This special issue describes one aspect of this transformation of the largest health system in the U.S.; the system-wide efforts to integrate mental health treatment into the primary care setting in VA. This primary care-mental health integration (PC-MHI) is being accomplished through the central VA system support and implementation of three primary models developed in the field: the White River Colocated models, the Behavioral Health Laboratory, and TIDES (Translating Initiatives in Depression into Effective Solutions). The papers in this special issue describe the development of these models, local and regional efforts to prepare medical centers to adapt and implement PC-MHI, and the impact of the integration on mental health care in these settings. These efforts could represent a national model of PC-MHI implementation for health care systems throughout the U.S.
C1 [Pomerantz, Andrew S.] White River Junction VA Med Ctr, VA Med Ctr, White River Jct, VT 05009 USA.
[Pomerantz, Andrew S.] Dartmouth Med Sch, Dept Psychiat, Hanover, NH USA.
[Sayers, Steven L.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Sayers, Steven L.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
RP Pomerantz, AS (reprint author), White River Junction VA Med Ctr, VA Med Ctr, 215 N Main St,116-D, White River Jct, VT 05009 USA.
EM Andrew.Pomerantz@va.gov
FU VA Medical Center of White River Junction; Mental Illness, Research,
Education and Clinical Center; VISN 4; Philadelphia VA Medical Center
FX This paper does not necessarily represent the position or opinions of
the Department of Veterans Affairs, and those expressed are the sole
responsibility of the authors. The preparation of this paper was in part
supported by the VA Medical Center of White River Junction, the Mental
Illness, Research, Education and Clinical Center, VISN 4, and the
Philadelphia VA Medical Center.
NR 16
TC 25
Z9 25
U1 1
U2 6
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1091-7527
J9 FAM SYST HEALTH
JI Fam. Syst. Health
PD JUN
PY 2010
VL 28
IS 2
SI SI
BP 78
EP 82
DI 10.1037/a0020341
PG 5
WC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
SC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
GA 829AP
UT WOS:000295547200002
PM 20695667
ER
PT J
AU Rubenstein, LV
Chaney, EF
Ober, S
Felker, B
Sherman, SE
Lanto, A
Vivell, S
AF Rubenstein, Lisa V.
Chaney, Edmund F.
Ober, Scott
Felker, Bradford
Sherman, Scott E.
Lanto, Andy
Vivell, Susan
TI Using Evidence-Based Quality Improvement Methods for Translating
Depression Collaborative Care Research Into Practice
SO FAMILIES SYSTEMS & HEALTH
LA English
DT Article
DE depression; quality improvement; evaluation; implementation;
collaborative care
ID AFFAIRS PRIMARY-CARE; MANAGED PRIMARY-CARE; DIABETES-MELLITUS; CHRONIC
ILLNESS; QUERI SERIES; HEALTH; IMPACT; VETERANS; INTERVENTIONS; LESSONS
AB Objective: Translating Initiatives in Depression into Effective Solution (TIDES) aimed to translate research-based collaborative care for depression into an approach for the Veterans Health Administration (VA). Sites: Three multistate administrative regions and seven of their medium-sized primary care practices. Intervention: Researchers assisted regional leaders in adapting research-based depression care models using evidence-based quality improvement (EBQI) methods. Evaluation: We evaluated model fidelity and impacts on patients. Trained nurse depression care managers collected data on patient adherence and outcomes. Results: Among 72% (128) of the 178 patients followed in primary care with depression care manager assistance during the 3-year study period, mean PHQ-9 scores dropped from 15.1 to 4.7 (p < .001). A total of 87% of patients achieved a PHQ-9 score lower than 10 (no major depression). 62% achieved a score lower than six (symptom resolution). Care managers referred 28% (50) TIDES patients to mental health specialty (MHS). In the MHS-referred group, mean PHQ-9 scores dropped from 16.4 to 9.0 (p < .001). A total of 58% of MHS-referred patients achieved a PHQ-9 score lower than 10, and 40%, a score less than 6. Over the 2 years following the initial development phase reported here, national policymakers endorsed TIDES through national directives and financial support. Conclusions: TIDES developed an evidence-based depression collaborative care prototype for a large health care organization (VA) using EBQI methods. As expected, care managers referred sicker patients to mental health specialists; these patients also improved. Overall, TIDES achieved excellent overall patient outcomes, and the program is undergoing national spread.
C1 [Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA.
[Rubenstein, Lisa V.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Rubenstein, Lisa V.] RAND Hlth Program, Santa Monica, CA USA.
[Chaney, Edmund F.; Felker, Bradford] VA Puget Sound Healthcare Syst, Mental Hlth Serv, Seattle, WA USA.
[Chaney, Edmund F.; Felker, Bradford] VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA.
[Chaney, Edmund F.; Felker, Bradford] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Ober, Scott] Cleveland VA Med Ctr, Dept Med, Cleveland, OH USA.
[Sherman, Scott E.] VA New York Harbor Healthcare Syst, Dept Med, New York, NY USA.
[Sherman, Scott E.] NYU, Dept Med, Sch Med, New York, NY 10003 USA.
[Rubenstein, Lisa V.; Lanto, Andy; Vivell, Susan] VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Ctr Excellence, Los Angeles, CA USA.
[Ober, Scott] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA.
RP Rubenstein, LV (reprint author), VA Greater Los Angeles Sepulveda, 16111 Plummer St,152, North Hills, CA 91343 USA.
EM lisa.rubenstein@va.gov
OI Sherman, Scott/0000-0003-1752-7303
NR 49
TC 46
Z9 47
U1 5
U2 8
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1091-7527
J9 FAM SYST HEALTH
JI Fam. Syst. Health
PD JUN
PY 2010
VL 28
IS 2
SI SI
BP 91
EP 113
DI 10.1037/a0020302
PG 23
WC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
SC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
GA 829AP
UT WOS:000295547200004
PM 20695669
ER
PT J
AU Tew, J
Klaus, J
Oslin, DW
AF Tew, James
Klaus, Johanna
Oslin, David W.
TI The Behavioral Health Laboratory: Building a Stronger Foundation for the
Patient-Centered Medical Home
SO FAMILIES SYSTEMS & HEALTH
LA English
DT Article
DE care management; collaborative care; primary care-mental health
integration; patient-centered medical home
ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; TREATMENT ENGAGEMENT;
COLLABORATIVE CARE; FAMILY PHYSICIANS; ALCOHOL-PROBLEMS; REFERRAL CARE;
MENTAL-HEALTH; LATE-LIFE; DEPRESSION
AB The Veterans Health Affairs is in the process of implementing a new model for the delivery of primary care: The Patient-Centered Medical Home (PCMH). One critical challenge of any PCMH model will be the integration of basic mental health treatment into primary care. Such a mental health integration program must be flexible enough to incorporate new evidence-based treatments as patient demographics and health care needs evolve over time. This paper summarizes the Behavioral Health Laboratory (BHL) care management model, a program already in place in more than 20 Veterans Affairs facilities along with private sector insurance providers, as ideally suited to fill this role in the PCMH. The BHL uses a platform of standardized, software-aided mental health assessments and clinical care managers to deliver evidence-based treatments for depression, anxiety, and substance abuse in primary care settings. The authors review this comprehensive program of screening, assessment, treatment, and referral to specialty care when needed. The BHL program is consistent with the guiding principles of the Patient-Centered Medical Home: applying chronic illness disease management principles to provide more continuous, coordinated, and efficient primary care services to patients with diverse needs. Just as importantly, the authors review how this standardized platform for delivering integrated mental health services provides the flexibility to incorporate novel interventions for a changing population.
C1 [Tew, James; Klaus, Johanna; Oslin, David W.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA 19104 USA.
[Tew, James; Klaus, Johanna; Oslin, David W.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA.
RP Klaus, J (reprint author), Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM Johanna.Klaus@va.gov
NR 30
TC 29
Z9 29
U1 1
U2 3
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1091-7527
J9 FAM SYST HEALTH
JI Fam. Syst. Health
PD JUN
PY 2010
VL 28
IS 2
SI SI
BP 130
EP 145
DI 10.1037/a0020249
PG 16
WC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
SC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
GA 829AP
UT WOS:000295547200006
PM 20695671
ER
PT J
AU Sweet, RA
Fish, KN
Lewis, DA
AF Sweet, Robert A.
Fish, Kenneth N.
Lewis, David A.
TI Mapping synaptic pathology within cerebral cortical circuits in subjects
with schizophrenia
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Article
DE schizophrenia; synapse; cerebral cortex; postmortem; immunofluorescence
ID PRIMARY AUDITORY-CORTEX; MISMATCH NEGATIVITY GENERATION; DENDRITIC SPINE
DENSITY; DORSOLATERAL PREFRONTAL CORTEX; MESSENGER-RNA EXPRESSION;
FLUORESCENCE MICROSCOPY; PYRAMIDAL NEURONS; BIPOLAR DISORDER; ARBITRARY
PARTICLES; GENE-EXPRESSION
AB Converging lines of evidence indicate that schizophrenia is characterized by impairments of synaptic machinery within cerebral cortical circuits. Efforts to localize these alterations in brain tissue from subjects with schizophrenia have frequently been limited to the quantification of structures that are non-selectively identified (e. g., dendritic spines labeled in Golgi preparations, axon boutons labeled with synaptophysin), or to quantification of proteins using methods unable to resolve relevant cellular compartments. Multiple label fluorescence confocal microscopy represents a means to circumvent many of these limitations, by concurrently extracting information regarding the number, morphology, and relative protein content of synaptic structures. An important adaptation required for studies of human disease is coupling this approach to stereologic methods for systematic random sampling of relevant brain regions. In this review article we consider the application of multiple label fluorescence confocal microscopy to the mapping of synaptic alterations in subjects with schizophrenia and describe the application of a novel, readily automated, iterative intensity/morphological segmentation algorithm for the extraction of information regarding synaptic structure number, size, and relative protein level from tissue sections obtained using unbiased stereological principles of sampling. In this context, we provide examples of the examination of pre- and post-synaptic structures within excitatory and inhibitory circuits of the cerebral cortex.
C1 [Sweet, Robert A.; Fish, Kenneth N.; Lewis, David A.] Univ Pittsburgh, Translat Neurosci Program, Dept Psychiat, Pittsburgh, PA USA.
[Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA.
[Lewis, David A.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA.
RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA.
EM sweetra@upmc.edu
RI Lewis, David/G-4053-2014
OI Lewis, David/0000-0002-3225-6778
FU USPHS [MH 071533, MH 084053]
FX This work was supported by USPHS grants MH 071533 and MH 084053. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute of
Mental Health or the National Institutes of Health. The authors would
like to thank Mrs. Mary Brady and Caitlin Moyer for assistance with the
figures, and Dr. Karl-Anton Dorph-Petersen for his comments on the
manuscript. The authors gratefully acknowledge the efforts of the
research staff of the Translational Neuroscience Program and the Conte
Center for Neuroscience of Mental Disorders at the University of
Pittsburgh.
NR 85
TC 16
Z9 16
U1 3
U2 6
PU FRONTIERS RES FOUND
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD JUN
PY 2010
VL 4
AR 44
DI 10.3389/fnhum.2010.00044
PG 14
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA 662QU
UT WOS:000282827200001
PM 20631852
ER
PT J
AU Nguyen, DM
Richardson, P
El-Serag, HB
AF Nguyen, Dang M.
Richardson, Peter
El-Serag, Hashem B.
TI Medications (NSAIDs, Statins, Proton Pump Inhibitors) and the Risk of
Esophageal Adenocarcinoma in Patients With Barrett's Esophagus
SO GASTROENTEROLOGY
LA English
DT Article
DE Epidemiology; Chemoprevention; Gastroesophageal Reflux Disease; VA
ID CANCER; DYSPLASIA; METAPLASIA; PREVALENCE; HISTORY
AB BACKGROUND & AIMS: Limited evidence suggests that proton pump inhibitors (PPI), nonsteroidal anti-inflammatory drugs (NSAID)/aspirin, and statins may be associated with a low risk of esophageal neoplasia. However, the possible effect these medications may have on the risk of esophageal adenocarcinoma (EAC) in patients with existing Barrett's esophagus (BE) is unclear. METHODS: We conducted a nested case-control study in a cohort of patients with BE identified in the national Department of Veterans' Affairs computerized databases. Cases with incident EAC were matched by incidence density sampling to controls with BE who remained without EAC at the date of the EAC diagnosis for the corresponding case. We identified prescriptions for PPI, NSAIDs/aspirin, and statins that were filled between BE diagnosis and EAC diagnosis. Incidence density ratios were calculated using conditional logistic regression models that adjusted for race, outpatient encounters, a disease comorbidity index, and socioeconomic status. RESULTS: In a cohort of 11,823 patients with first-time BE diagnosis, we examined 116 EAC cases and 696 matched controls. Most cases and controls had at least one filled PPI prescription (95% vs 94%; P = .5). In this setting of almost universal PPI use, filled NSAID/aspirin prescriptions were associated with a reduced risk of EAC (adjusted incidence density ratio, 0.64; 95% confidence interval, 0.42-0.97). Filled statin prescriptions also were associated with a reduction in EAC risk (0.55; 95% confidence interval, 0.36 - 0.86), with a significant trend toward greater risk reduction with longer duration of statin use. However, the strong inverse associations with even short periods of use raise concerns of uncontrolled confounding. CONCLUSIONS: This observational study indicates that in patients with BE using PPI, NSAID/aspirin, or statin therapy might reduce the risk of developing EAC.
C1 Houston Dept Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA.
Houston Dept Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA.
Baylor Coll Med, Houston, TX 77030 USA.
RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hasheme@bcm.tmc.edu
FU National Institutes of Health [K24DK07815403]; Texas Gulf Coast
Digestive Diseases Center, National Institutes of Health [P50 DK56338];
Houston VA HSR&D Center of Excellence [HFP90-020]
FX Supported by National Institutes of Health grant K24DK07815403 and The
Texas Gulf Coast Digestive Diseases Center (National Institutes of
Health grant P50 DK56338) (H.B.E.-S.). Partly funded by Houston VA HSR&D
Center of Excellence (HFP90-020).
NR 22
TC 91
Z9 92
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUN
PY 2010
VL 138
IS 7
BP 2260
EP 2266
DI 10.1053/j.gastro.2010.02.045
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 602KB
UT WOS:000278136900016
PM 20188100
ER
PT J
AU Horiuchi, A
Nakayama, Y
Kajiyama, M
Kato, N
Kamijima, T
Graham, DY
Tanaka, N
AF Horiuchi, Akira
Nakayama, Yoshiko
Kajiyama, Masashi
Kato, Naoyuki
Kamijima, Tetsuya
Graham, David Y.
Tanaka, Naoki
TI Biliary stenting in the management of large or multiple common bile duct
stones
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID SHOCK-WAVE LITHOTRIPSY; ELECTROHYDRAULIC LITHOTRIPSY; ENDOSCOPIC
SPHINCTEROTOMY; URSODEOXYCHOLIC ACID; DIFFICULT; MULTICENTER; CLEARANCE
AB Background: Endoscopic biliary stenting with a plastic stent is often performed to prevent impaction of common bile duct (CBD) stones. The therapeutic effect of a plastic stent placement in terms of reduction in stone size and number has not been established.
Objective: The aim of this study was to study the effect of biliary stenting as therapy for CBD stones.
Design: Retrospective study.
Setting: Municipal hospital outpatients.
Interventions: Patients with large (>= 20 mm) and/or multiple (>= 3) stones had placement of a 7F double-pigtail plastic stent without stone extraction at the initial ERCP. Approximately 2 months later, stone removal was attempted. The number and size of CBD stones before and after stent placement, stone clearance, complications, and 180-day mortality were evaluated.
Results: Forty patients were studied. Stent placement averaged 65 days (range, 50-82 days). The median number (interquartile range) of stones per patient fell after stent placement (4.0 [3.0] before vs. 2.0 [1.0] after; P < .0001). Characteristically, larger stones became smaller and small stones disappeared (ie, the median stone index decreased from 4.6 [3.0] to 2.0 [1.5]; P < .0001). Stone clearance at the second ERCP was achieved in 37 out of 40 patients (93%). Complications included cholangitis (13%) and pancreatitis (5%) after the second ERCP. No 180-day mortality occurred.
Limitations: A retrospective, single-center study.
Conclusions: Stent placement for 2 months was associated with large and/or multiple CBI) stones becoming smaller and/or disappearing without any complications. Stenting followed by a wait period may assist in difficult CBD stone removal. (Gastrointest Endosc 2010;71:1200-3.)
C1 [Horiuchi, Akira; Nakayama, Yoshiko; Kajiyama, Masashi; Kato, Naoyuki; Kamijima, Tetsuya; Tanaka, Naoki] Showa Inan Gen Hosp, Ctr Digest Dis, Komagane 3994191, Japan.
[Nakayama, Yoshiko] Shinshu Univ, Sch Med, Dept Pediat, Matsumoto, Nagano 390, Japan.
[Tanaka, Naoki] Shinshu Univ, Grad Sch Med, Dept Metab Regulat, Matsumoto, Nagano 390, Japan.
[Graham, David Y.] Michael E Debakey Vet Adm Med Ctr, Houston, TX USA.
RP Horiuchi, A (reprint author), Showa Inan Gen Hosp, Ctr Digest Dis, Komagane 3994191, Japan.
NR 18
TC 30
Z9 31
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD JUN
PY 2010
VL 71
IS 7
BP 1200
EP 1203
DI 10.1016/j.gie.2009.12.055
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 608KL
UT WOS:000278582700016
PM 20400079
ER
PT J
AU Shergill, AK
McQuaid, KR
Rempel, D
AF Shergill, Amandeep K.
McQuaid, Kenneth R.
Rempel, David
TI Call for guidelines on ergonomics in GI endoscopy Response
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Letter
C1 [Shergill, Amandeep K.; McQuaid, Kenneth R.] San Francisco VA Med Ctr, Div Gastroenterol, San Francisco, CA USA.
[Rempel, David] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.
[Rempel, David] Univ Calif San Francisco, Div Occupat Med, San Francisco, CA 94143 USA.
RP Shergill, AK (reprint author), San Francisco VA Med Ctr, Div Gastroenterol, San Francisco, CA USA.
RI Rempel, David/E-8424-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD JUN
PY 2010
VL 71
IS 7
BP 1333
EP 1333
DI 10.1016/j.gie.2009.11.039
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 608KL
UT WOS:000278582700046
ER
PT J
AU Shay, K
Yoshikawa, TT
AF Shay, Kenneth
Yoshikawa, Thomas T.
TI Overview of VA Healthcare for Older Veterans: Lessons Learned and Policy
Implications
SO GENERATIONS-JOURNAL OF THE AMERICAN SOCIETY ON AGING
LA English
DT Article
ID LONG-TERM-CARE; GERIATRICS
C1 [Yoshikawa, Thomas T.] VA Greater Los Angeles Healthcare Syst, Staff Geriatr & Extended Care & Special Projects, Los Angeles, CA USA.
NR 14
TC 2
Z9 2
U1 0
U2 4
PU AMER SOC AGING
PI SAN FRANCISCO
PA 833 MARKET ST, STE 511, SAN FRANCISCO, CA 94103-1824 USA
SN 0738-7806
J9 GENERATIONS
JI Generations-J. Am. Soc. Aging
PD SUM
PY 2010
VL 34
IS 2
BP 20
EP 28
PG 9
WC Gerontology
SC Geriatrics & Gerontology
GA 685VJ
UT WOS:000284655900004
ER
PT J
AU Cooley, SG
Asthana, S
AF Cooley, Susan G.
Asthana, Sanjay
TI Dementia Care for Veterans: Enhancing Comprehensive, Coordinated
Services
SO GENERATIONS-JOURNAL OF THE AMERICAN SOCIETY ON AGING
LA English
DT Article
ID CONTROLLED-TRIAL; HEALTH-CARE; DISEASE; INTERVENTION; PREVALENCE;
CAREGIVERS; OUTCOMES; QUALITY; SYSTEM; COSTS
C1 [Cooley, Susan G.] US Dept Vet Affairs, Off Geriatr & Extended Care, Washington, DC USA.
[Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA.
RP Cooley, SG (reprint author), US Dept Vet Affairs, Off Geriatr & Extended Care, Washington, DC USA.
NR 14
TC 5
Z9 5
U1 0
U2 2
PU AMER SOC AGING
PI SAN FRANCISCO
PA 833 MARKET ST, STE 511, SAN FRANCISCO, CA 94103-1824 USA
SN 0738-7806
J9 GENERATIONS
JI Generations-J. Am. Soc. Aging
PD SUM
PY 2010
VL 34
IS 2
BP 57
EP 63
PG 7
WC Gerontology
SC Geriatrics & Gerontology
GA 685VJ
UT WOS:000284655900009
ER
PT J
AU Jabbar, U
Leischner, J
Kasper, D
Gerber, R
Sambol, SP
Parada, JP
Johnson, S
Gerding, DN
AF Jabbar, Umair
Leischner, Julie
Kasper, Douglas
Gerber, Robert
Sambol, Susan P.
Parada, Jorge P.
Johnson, Stuart
Gerding, Dale N.
TI Effectiveness of Alcohol-Based Hand Rubs for Removal of Clostridium
difficile Spores from Hands
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID DISEASE; INFECTION; HOSPITALS; HYGIENE; AGENTS
AB BACKGROUND. Alcohol-based hand rubs (ABHRs) are an effective means of decreasing the transmission of bacterial pathogens. Alcohol is not effective against Clostridium difficile spores. We examined the retention of C. difficile spores on the hands of volunteers after ABHR use and the subsequent transfer of these spores through physical contact.
METHODS. Nontoxigenic C. difficile spores were spread on the bare palms of 10 volunteers. Use of 3 ABHRs and chlorhexidine soap-and-water washing were compared with plain water rubbing alone for removal of C. difficile spores. Palmar cultures were performed before and after hand decontamination by means of a plate stamping method. Transferability of C. difficile after application of ABHR was tested by having each volunteer shake hands with an uninoculated volunteer.
RESULTS. Plain water rubbing reduced palmar culture counts by a mean (+/- standard deviation [SD]) of 1.57 +/- 0.11 log(10) colony-forming units (CFU) per cm(2), and this value was set as the zero point for the other products. Compared with water washing, chlorhexidine soap washing reduced spore counts by a mean (+/- SD) of 0.89 +/- 0.34 log(10) CFU per cm2; among the ABHRs, Isagel accounted for a reduction of 0.11 +/- 0.20 log(10) CFU per cm(2) (P = .005), Endure for a reduction of 0.37 +/- 0.42 log(10) CFU per cm(2) (P = .010), and Purell for a reduction of 0.14 +/- 0.33 log(10) CFU per cm(2) (P = .005). There were no statistically significant differences between the reductions achieved by the ABHRs; only Endure had a reduction statistically different from that for water control rubbing (P = .040). After ABHR use, handshaking transferred a mean of 30% of the residual C. difficile spores to the hands of recipients.
CONCLUSIONS. Hand washing with soap and water is significantly more effective at removing C. difficile spores from the hands of volunteers than are ABHRs. Residual spores are readily transferred by a handshake after use of ABHR. Infect Control Hosp Epidemiol 2010; 31(6): 565-570
C1 [Jabbar, Umair; Leischner, Julie; Kasper, Douglas; Gerber, Robert; Sambol, Susan P.; Parada, Jorge P.; Johnson, Stuart; Gerding, Dale N.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA.
[Parada, Jorge P.; Johnson, Stuart; Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
RP Gerding, DN (reprint author), Hines VA Hosp, Res Serv 151, 5000 S 5th Ave,Bldg 1,Rm C344, Hines, IL 60141 USA.
EM dale.gerding2@va.gov
FU US Department of Veterans Affairs Research Service [1I01BX000515-01];
Loyola Stritch School of Medicine; Massachusetts Biological
Laboratories; ViroPharma; Gojo; Cepheid; Optimer; Merck
FX Financial support. The US Department of Veterans Affairs Research
Service (to J.P.P. and S.J. and grant 1I01BX000515-01 to D.N.G.); and
the Loyola Stritch School of Medicine (Student Approaches to Research
grant to U.J.).; Potential conflicts of interest. D.N.G. holds patents
for the prevention and treatment of C. difficile-associated disease
licensed to ViroPharma; has received research funding from Massachusetts
Biological Laboratories, ViroPharma, Gojo, Cepheid, Optimer, and Merck;
and is a consultant for Optimer, Actelion, Gojo, Schering-Plough,
Cepheid, BD GeneOhm, Cubist, and ViroPharma. S.J. is a consultant for
Genzyme, Salix, Optimer, ViroPharma, and BD GeneOhm. J.P.P. has received
honoraria for services as a consultant and/or as a member of the
speakers bureau for ViroPharma, Merck, Cepheid, and Pfizer. All other
authors report no potential conflicts of interest relevant to this
article.
NR 21
TC 48
Z9 48
U1 5
U2 45
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD JUN
PY 2010
VL 31
IS 6
BP 565
EP 570
DI 10.1086/652772
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 590EX
UT WOS:000277208400001
PM 20429659
ER
PT J
AU Lee, BY
Bailey, RR
Smith, KJ
Muder, RR
Strotmeyer, ES
Lewis, GJ
Ufberg, PJ
Song, YH
Harrison, LH
AF Lee, Bruce Y.
Bailey, Rachel R.
Smith, Kenneth J.
Muder, Robert R.
Strotmeyer, Elsa S.
Lewis, G. Jonathan
Ufberg, Paul J.
Song, Yeohan
Harrison, Lee H.
TI Universal Methicillin-Resistant Staphylococcus aureus (MRSA)
Surveillance for Adults at Hospital Admission: An Economic Model and
Analysis
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID COST-EFFECTIVENESS; ACQUIRED INFECTION; CARE; ENTEROCOCCUS; VANCOMYCIN;
CARRIAGE; BURDEN
AB BACKGROUND. Methicillin-resistant Staphylococcus aureus (MRSA) transmission and infections are a continuing problem in hospitals. Although some have recommended universal surveillance for MRSA at hospital admission to identify and to isolate MRSA-colonized patients, there is a need for formal economic studies to determine the cost-effectiveness of such a strategy.
METHODS. We developed a stochastic computer simulation model to determine the potential economic impact of performing MRSA surveillance (ie, single culture of an anterior nares specimen) for all hospital admissions at different MRSA prevalences and basic reproductive rate thresholds from the societal and third party-payor perspectives. Patients with positive surveillance culture results were placed under isolation precautions to prevent transmission by way of respiratory droplets. MRSA-colonized patients who were not isolated could transmit MRSA to other hospital patients.
RESULTS. The performance of universal MRSA surveillance was cost-effective (defined as an incremental cost-effectiveness ratio of less than $50,000 per quality-adjusted life-year) when the basic reproductive rate was 0.25 or greater and the prevalence was 1% or greater. In fact, surveillance was the dominant strategy when the basic reproductive rate was 1.5 or greater and the prevalence was 15% or greater, the basic reproductive rate was 2.0 or greater and the prevalence was 10% or greater, and the basic reproductive rate was 2.5 or greater and the prevalence was 5% or greater.
CONCLUSIONS. Universal MRSA surveillance of adults at hospital admission appears to be cost-effective at a wide range of prevalence and basic reproductive rate values. Individual hospitals and healthcare systems could compare their prevailing conditions (eg, the prevalence of MRSA colonization and MRSA transmission dynamics) with the benchmarks in our model to help determine their optimal local strategies. Infect Control Hosp Epidemiol 2010; 31(6): 598-606
C1 [Lee, Bruce Y.; Harrison, Lee H.] Univ Pittsburgh, Infect Dis Epidemiol Res Unit, Sch Med, Pittsburgh, PA 15213 USA.
[Harrison, Lee H.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Lee, Bruce Y.; Bailey, Rachel R.; Smith, Kenneth J.; Lewis, G. Jonathan; Ufberg, Paul J.; Song, Yeohan] Vet Affairs Pittsburgh Hlth Care Syst, Sect Decis Sci & Clin Syst Modeling, Pittsburgh, PA USA.
[Bailey, Rachel R.; Lewis, G. Jonathan; Ufberg, Paul J.; Song, Yeohan] Vet Affairs Pittsburgh Hlth Care Syst, Dept Biomed Informat, Pittsburgh, PA USA.
[Bailey, Rachel R.; Strotmeyer, Elsa S.; Lewis, G. Jonathan; Ufberg, Paul J.; Song, Yeohan] Vet Affairs Pittsburgh Hlth Care Syst, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Muder, Robert R.] Vet Affairs Pittsburgh Hlth Care Syst, Div Infect Dis, Pittsburgh, PA USA.
RP Lee, BY (reprint author), Univ Pittsburgh, Infect Dis Epidemiol Res Unit, Sch Med, 200 Meyran Ave,Rm 217, Pittsburgh, PA 15213 USA.
EM BYL1@pitt.edu
RI Strotmeyer, Elsa/F-3015-2014
OI Smith, Kenneth J/0000-0001-8088-566X; Strotmeyer,
Elsa/0000-0002-4093-6036; Slayton, Rachel/0000-0003-4699-8040
FU National Institute of General Medical Sciences Models of Infectious
Disease Agent Study (MIDAS) [5U01GM070708-05]
FX Financial support. National Institute of General Medical Sciences Models
of Infectious Disease Agent Study (MIDAS) (grant 5U01GM070708-05).
NR 30
TC 34
Z9 35
U1 0
U2 10
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD JUN
PY 2010
VL 31
IS 6
BP 598
EP 606
DI 10.1086/652524
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 590EX
UT WOS:000277208400007
PM 20402588
ER
PT J
AU Pena, A
Virk, SS
Shewchuk, RM
Allison, JJ
Williams, OD
Kiefe, CI
AF Pena, Adolfo
Virk, Sandeep S.
Shewchuk, Richard M.
Allison, Jeroan J.
Williams, O. Dale
Kiefe, Catarina I.
TI Validity versus feasibility for quality of care indicators: expert panel
results from the MI-Plus study
SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE
LA English
DT Article
DE clinical guidelines; feasibility; myocardial infarction; quality
indicators; quality of health care; validity
ID MYOCARDIAL-INFARCTION; HEALTH; MANAGEMENT
AB In the choice and definition of quality of care indicators, there may be an inherent tension between feasibility, generally enhanced by simplicity, and validity, generally enhanced by accounting for clinical complexity.
To study the process of developing quality indicators using an expert panel and analyze the tension between feasibility and validity.
A multidisciplinary panel of 12 expert physicians was engaged in two rounds of modified Delphi process to refine and choose a smaller subset from 36 indicators; these were developed by a research team studying the quality of care in ambulatory post-myocardial infarction patients with co-morbidities. We studied the correlation between validity/feasibility ranks provided by the expert panel. The correlation between the quality indicators ranks on validity and feasibility scale and variance of experts' responses was also individually studied.
Ten of 36 indicators were ranked in both the highest validity and feasibility groups. The strength of association between validity and feasibility of indicators measured by Kendall tau-b was 0.65. In terms of validity, a strong negative correlation was observed between the ranks of indicators and the variability in expert panel responses (Spearman's rho, r = -0.85). A weak correlation was found between the ranks of feasibility and the variability of expert panel responses (Spearman's rho, r = 0.23).
There was an unexpectedly strong association between the validity and feasibility of quality indicators, with a high level of consensus among experts regarding both feasibility and validity for indicators rated highly on each of these attributes.
C1 [Pena, Adolfo] Birmingham VA Med Ctr, C SMART Ctr Surg Med Acute Care Res & Transit, Birmingham, AL 35233 USA.
[Pena, Adolfo] Univ Alabama, Vet Affairs Natl Qual Scholars Fellowship Program, Birmingham VA Med Ctr, Birmingham, AL USA.
[Virk, Sandeep S.] Univ Alabama, Montgomery Internal Med Residency Program, Birmingham, AL USA.
[Shewchuk, Richard M.] Univ Alabama, Sch Hlth Related Profess, Dept Hlth Serv Adm, Birmingham, AL USA.
[Shewchuk, Richard M.; Williams, O. Dale] Univ Alabama, Ctr Outcomes & Effectiveness Res & Educ, Birmingham, AL USA.
[Allison, Jeroan J.; Kiefe, Catarina I.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Williams, O. Dale] Univ Alabama, Sch Med, Dept Med, Birmingham, AL USA.
RP Pena, A (reprint author), Birmingham VA Med Ctr, C SMART Ctr Surg Med Acute Care Res & Transit, 151 REAP,700 S 19th St, Birmingham, AL 35233 USA.
EM adolfope@uab.edu
OI Allison, Jeroan/0000-0003-4472-2112
FU National Heart, Lung and Blood Institute [R01 HL70786]
FX This project was funded in part by grant number R01 HL70786 from the
National Heart, Lung and Blood Institute. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Heart, Lung and Blood Institute or the
National Institutes of Health.
NR 22
TC 8
Z9 8
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1353-4505
J9 INT J QUAL HEALTH C
JI Int. J. Qual. Health Care
PD JUN
PY 2010
VL 22
IS 3
BP 201
EP 209
DI 10.1093/intqhc/mzq018
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 597CR
UT WOS:000277734100007
PM 20382663
ER
PT J
AU Karp, JF
Weiner, DK
Dew, MA
Begley, A
Miller, MD
Reynolds, CF
AF Karp, Jordan F.
Weiner, Debra K.
Dew, Mary A.
Begley, Amy
Miller, Mark D.
Reynolds, Charles F., III
TI Duloxetine and care management treatment of older adults with comorbid
major depressive disorder and chronic low back pain: results of an
open-label pilot study
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE depression; pain; geriatric; back pain; clinical trial
ID LATE-LIFE DEPRESSION; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED
TRIAL; MEDICAL ILLNESS BURDEN; SELF-RATED HEALTH; TREATMENT RESPONSE;
DOUBLE-BLIND; EFFICACY; SYMPTOMS; QUESTIONNAIRE
AB Objective: In older adults, major depressive disorder (MDD) and chronic low back pain (CLEW) are common and mutually exacerbating. We predicted that duloxetine pharmacotherapy and Depression and Pain Care Management (DPCM) would result in (1) significant improvement in NI DD and CLBP and (2) significant improvements in health-related quality of life, anxiety, disability, self-efficacy, and sleep quality.
Design and Intervention: Twelve week open-label study using duloxetine up to 120 mg/day + DPCM.
Setting: Outpatient late-life depression research clinic.
Patients: Thirty community-dwelling adults >60 years old.
Outcome Measures: Montgomery Asberg Depression Rating Scale (MADRS) and McGill Pain Questionnaire-Short Form (MPQ-SF).
Results: 46.7% (n = 14) of the sample had a depression remission. All subjects who met criteria for the depression remission also had a pain response. 93.3% (n = 28) had a significant pain response. Of the subjects who met criteria for a low back pain response, 50% (n = 14) also met criteria for the depression remission. The mean time to depression remission was 7.6 (SE = 0.6) weeks. The mean time to pain response was 2.8 (SE = 0.5) weeks. There were significant improvements in mental health-related quality of life, anxiety, sleep quality, somatic complaints, and both self-efficacy for pain management and for coping with symptoms. Physical health-related quality of life, back pain-related disability, and self-efficacy for physical functioning did not improve.
Conclusions: Serotonin and norepinephrine reuptake inhibitors like duloxetine delivered with DPCM may be a good choice to treat these linked conditions in older adults. Treatments that target low self-efficacy for physical function and improving disability may further increase response rates. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Karp, Jordan F.; Dew, Mary A.; Begley, Amy; Miller, Mark D.; Reynolds, Charles F., III] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Adv Ctr Intervent & Serv Res Late Life Mood Disor, Pittsburgh, PA 15261 USA.
[Karp, Jordan F.; Reynolds, Charles F., III] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, John A Hartford Ctr Excellence Geriatr Psychiat, Pittsburgh, PA 15261 USA.
[Karp, Jordan F.; Weiner, Debra K.; Dew, Mary A.; Begley, Amy; Miller, Mark D.; Reynolds, Charles F., III] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA.
[Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA.
[Dew, Mary A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Karp, Jordan F.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA.
[Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Karp, JF (reprint author), Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Adv Ctr Intervent & Serv Res Late Life Mood Disor, Pittsburgh, PA 15261 USA.
EM karpjf@upmc.edu
FU John A. Hartford Center of Excellence in Geriatric Psychiatry [P30
MH71944]; UPMC Endowment in Geriatric Psychiatry; National Center for
Research Resources (NCRR), a component of the National Institutes of
Health (NIH) [KL2 RR-024154-03]; NIH Roadmap for Medical Research
FX Supported in part by: P30 MH71944 and The John A. Hartford Center of
Excellence in Geriatric Psychiatry, and the UPMC Endowment in Geriatric
Psychiatry. This publication was also made possible by grant number KL2
RR-024154-03 from the National Center for Research Resources (NCRR), a
component of the National Institutes of Health (NIH), and NIH Roadmap
for Medical Research. Eli Lilly and Company provided medication supplies
for this investigator-initiated trial.
NR 70
TC 14
Z9 15
U1 4
U2 14
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0885-6230
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD JUN
PY 2010
VL 25
IS 6
BP 633
EP 642
DI 10.1002/gps.2386
PG 10
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 605KP
UT WOS:000278346800011
PM 19750557
ER
PT J
AU Lewinsohn, D
AF Lewinsohn, David
TI Rethinking the natural history of infection with M. tuberculosis
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article; Proceedings Paper
CT 2nd Global Symposium on Interferon-Gamma Release Assays
CY MAY 30-JUN 01, 2009
CL Dubrovnik, CROATIA
SP Fdn Innovat New Diagnost, Cellestis Ltd
AB The tuberculin skin test is associated with exposure to TB, and conversion of a TST is associated with the risk of disease. A consistent number of TB cases occur over the years in persons with positive TSTs. The question is: How much of this is reactivation vs. re-exposure in an endemic setting? The actual case rate is really quite low, even among those with positive TSTs, so either only a minority of those infected with M. tuberculosis develop disease, i.e., the M. tuberculosis organism really does a poor job, or it is possible that there are exposures that do not reflect infection. In either case, we need to do a better job of identifying those at risk for developing TB. IFN-gamma is associated with TB exposure, and it is quantitative, with natural variations over time. Dr Lewinsohn offered some food for thought. He expects to see rising amounts of IFN-gamma with exposure, and this rise will indicate either a recent exposure to M. tuberculosis or a reactivation. Another prediction is that a negative IFN-gamma may not distinguish remote exposure from no exposure. Some will be transiently exposed, and will develop TEM/TDC (like tetanus). The duration of these responses will depend upon the environment. T-cells reflect immunologic history, and his prediction is that some will vet a memory response just like tetanus, but he would predict these would be at low risk. What about understanding T-cell memory and persistent infection? In guinea pigs, conversion of the TST is associated with exposure to M. tuberculosis, but many of the animals will have skin test reversions in which no bacteria can be detected either pathologically or microbiologically. These data challenge the notion of 'once infected, always infected'. In humans, we do not yet have reliable tools to distinguish exposure from infection. However, post-mortem series of those with a positive TST often fail to reveal mycobacteria, and if present it is often found in areas of normal lung. CD8 T-cells are present at high frequency in both active and latent TB infection. CD8 T-cells preferentially recognize heavily infected cells, and may be a surrogate for bacterial burden and/or disease progression. D8 cells recognize MHCII-negative cells and may play a unique role in chronic/persistent phases of infection. They may be a good surrogate for intercellular infection. CD8 T-cell responses to ESAT-6 and CFP-10 were measured in young children with pulmonary TB, or in the setting of household exposure. Here, CD8 responses were associated with pulmonary TB, but not residence in a household. In contrast, the CD4 response was present in both groups. These data were consistent with the hypothesis that exposure to M. tuberculosis and infection could be immunologically differentiated. Dr Lewinsohn's prediction is that a CD8 response will identify those at risk for progression but additional antigens will be needed to improve sensitivity. We know what we do not know, and what we need is a way to find out who are at greatest risk. Who are the acutely infected? We need to think next about what kind of studies need to be done and where, and whom we study.
C1 [Lewinsohn, David] Portland VA Med Ctr, Portland, OR USA.
[Lewinsohn, David] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Lewinsohn, D (reprint author), Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD JUN
PY 2010
VL 14
IS 6
SU 1
BP S7
EP S10
PG 4
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 602BS
UT WOS:000278113700003
ER
PT J
AU Li, HK
Hubbard, LD
Danis, RP
Esquivel, A
Florez-Arango, JF
Krupinski, EA
AF Li, Helen K.
Hubbard, Larry D.
Danis, Ronald P.
Esquivel, Adol
Florez-Arango, Jose F.
Krupinski, Elizabeth A.
TI Monoscopic versus Stereoscopic Retinal Photography for Grading Diabetic
Retinopathy Severity
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID DIGITAL PHOTOGRAPHY; COMPLICATIONS; METHODOLOGY; DIAGNOSIS; COHORT
AB PURPOSE. To assess agreement between monoscopic and stereoscopic photography for research classification of the severity of diabetic retinopathy (DR).
METHODS. Monoscopic digital (MD) images were compared with stereo digital (SD) and film (SF) photographs from a 152-eye cohort with full-spectrum Early Treatment Diabetic Retinopathy Study (ETDRS) severity levels for agreement on severity level, DR presence with ascending severity threshold, presence of DR index lesions, and repeatability of grading.
RESULTS. There was substantial agreement classifying ETDRS DR severity levels between MD and SF (kappa = 0.65, kappa(w) [linear weighted] = 0.87), MD and SD (kappa = 0.66, kappa(w) = 0.87), and SD and SF (kappa = 0.62, kappa(w) = 0.86) images. Marginal homogeneity analyses found no significant difference between MD and SF images (P = 0.53, Bhapkar test). The kappa agreement between MD and SF ranged from 0.80 to 0.94 for the presence or absence of eight ascending DR severity thresholds. Repeatability between the readers of the MD images was equal to or better than that of the readers of SD or SF images. Severity threshold grading repeatability between readers was similar with the MD and SF images. The kappa agreement between MD and SF for identifying diabetic retinopathy lesions ranged from moderate to almost perfect. The kappa comparisons showed that performance of grading new vessels on the disc in MD images was slightly lower than that with the SF images.
CONCLUSIONS. Monoscopic photography can equal the reliability of stereo photography for full ETDRS DR severity scale grading. (Invest Ophthalmol Vis Sci. 2010;51:3184-3192) DOI: 10.1167/iovs.09-4886
C1 [Li, Helen K.] Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.
[Li, Helen K.; Florez-Arango, Jose F.] Univ Texas Hlth Sci Ctr, Sch Hlth Informat Sci, Houston, TX USA.
[Hubbard, Larry D.; Danis, Ronald P.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
[Esquivel, Adol] Houston Vet Affairs Med Ctr, Houston, TX USA.
[Esquivel, Adol] Baylor Coll Med, Houston, TX 77030 USA.
[Florez-Arango, Jose F.] Univ De Antioquia, Medellin, Colombia.
[Krupinski, Elizabeth A.] Univ Arizona, Dept Radiol, Tucson, AZ 85724 USA.
RP Li, HK (reprint author), Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, 301 Univ Blvd, Galveston, TX 77555 USA.
EM hlimed@mac.com
OI Florez-Arango, Jose F/0000-0001-9083-0195
FU Juvenile Diabetes Foundation Research International, New York, NY;
Research to Prevent Blindness (Department of Ophthalmology and Visual
Sciences, The University of Texas Medical Branch); Department of
Ophthalmology and Visual Sciences, University of Wisconsin School of
Medicine and Public Health
FX Supported by a grant from Juvenile Diabetes Foundation Research
International, New York, NY (HKL), and by unrestricted grants from
Research to Prevent Blindness (Department of Ophthalmology and Visual
Sciences, The University of Texas Medical Branch, and the Department of
Ophthalmology and Visual Sciences, University of Wisconsin School of
Medicine and Public Health).
NR 31
TC 7
Z9 7
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2010
VL 51
IS 6
BP 3184
EP 3192
DI 10.1167/iovs.09-4886
PG 9
WC Ophthalmology
SC Ophthalmology
GA 598OC
UT WOS:000277846500049
PM 20053978
ER
PT J
AU Lopes, RD
Peterson, ED
Chen, AY
Roe, MT
Wang, TY
Ohman, EM
Magid, DJ
Ho, PM
Wiviott, SD
Scirica, BM
Alexander, KP
AF Lopes, Renato D.
Peterson, Eric D.
Chen, Anita Y.
Roe, Matthew T.
Wang, Tracy Y.
Ohman, E. Magnus
Magid, David J.
Ho, P. Michael
Wiviott, Stephen D.
Scirica, Benjamin M.
Alexander, Karen P.
TI Antithrombotic Strategy in Non-ST-Segment Elevation Myocardial
Infarction Patients Undergoing Percutaneous Coronary Intervention
Insights From the ACTION (Acute Coronary Treatment and Intervention
Outcomes Network) Registry
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE antithrombotic therapy; in-hospital major bleeding; mortality;
non-ST-segment elevation myocardial infarction; percutaneous coronary
intervention
ID POSTINFARCTION ANGINA; BIVALIRUDIN; HEPARIN; TRIAL; ANGIOPLASTY; CRUSADE
AB Objectives The aim of this study was to examine the use of and outcomes associated with antithrombotic strategies in patients with non-ST-segment elevation myocardial infarction (NSTEMI) who undergo percutaneous coronary intervention (PCI).
Background A variety of antithrombotic strategies have been tested in clinical trials for NSTEMI patients treated with PCI.
Methods Antithrombotic strategies for NSTEMI patients undergoing PCI at 217 ACTION (Acute Coronary Treatment and Intervention Outcomes Network) hospitals from January 1, 2007, to December 31, 2007, (n = 11,085) were classified into commonly observed antithrombotic groups: heparin alone (Hep alone; low-molecular-weight heparin or unfractionated heparin), bivalirudin alone (Bival alone), heparin with glycoprotein IIb/IIIa inhibitors (Hep/GPI), and bivalirudin with GPI (Bival/GPI). Baseline characteristics are shown across treatment groups. In addition, unadjusted and adjusted rates of in-hospital major bleeding and death are shown.
Results The standard strategy used was Hep/GPI (64%), followed by Hep or Bival alone (28%), and Bival/GPI (8%). Patients who received Hep or Bival alone were older with more comorbidities, higher baseline bleeding and mortality risk, and lower peak troponin. Compared with patients who received Hep/GPI, those who received Hep alone and Bival alone had lower rates of major bleeding (adjusted odds ratio [OR] 0.52; 95% confidence interval [CI]: 0.42 to 0.65; adjusted OR: 0.48; 95% CI: 039 to 0.60; respectively), yet only patients who received Bival alone had lower mortality (adjusted OR: 0.39; 95% CI: 021 to 0.71).
Conclusions NSTEMI patients undergoing PCI are more likely to receive Bival or Hep alone when at higher baseline bleeding risk than when at lower baseline bleeding risk. Despite higher baseline risk, those receiving Bival or Hep alone had less bleeding. (J Am Coll Cardiol Intv 2010;3:669-77) (C) 2010 by the American College of Cardiology Foundation
C1 [Lopes, Renato D.; Peterson, Eric D.; Chen, Anita Y.; Roe, Matthew T.; Wang, Tracy Y.; Ohman, E. Magnus; Alexander, Karen P.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA.
[Magid, David J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA.
[Magid, David J.] Univ Colorado, Hlth Sci Ctr, Dept Emergency Med, Denver, CO USA.
[Magid, David J.] Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA.
[Ho, P. Michael] Denver VA Med Ctr, Cardiol Sect, Denver, CO USA.
[Wiviott, Stephen D.; Scirica, Benjamin M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Lopes, RD (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, Box 3850,2400 Pratt St,Room 0311, Durham, NC 27705 USA.
EM renato.lopes@duke.edu
FU Bristol-Myers Squibb/Sanofi Pharmaceuticals; Genentech
FX The National Cardiovascular Dam Registry ACTION Registry is administered
by the American College of Cardiology Foundation (ACCF) and sponsored by
Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Genentech, and
Schering-Plough Corporation, who provide material support for the
operation of the dam collection and infrastructure. The sponsors had no
additional role in this project, including the selection of topic,
analysis of data, decision to publish, or approval of the manuscript
before publication. Data analysis was performed independently by a
statistician (Dr. Chen) from the Duke Clinical Research Institute.
NR 19
TC 17
Z9 17
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-8798
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD JUN
PY 2010
VL 3
IS 6
BP 669
EP 677
DI 10.1016/j.jcin.2010.03.015
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 621QC
UT WOS:000279595700012
PM 20630461
ER
PT J
AU Howard, AA
Hoover, DR
Anastos, K
Wu, X
Shi, QH
Strickler, HD
Cole, SR
Cohen, MH
Kovacs, A
Augenbraun, M
Latham, PS
Tien, PC
AF Howard, Andrea A.
Hoover, Donald R.
Anastos, Kathryn
Wu, Xi
Shi, Qiuhu
Strickler, Howard D.
Cole, Stephen R.
Cohen, Mardge H.
Kovacs, Andrea
Augenbraun, Michael
Latham, Patricia S.
Tien, Phyllis C.
TI The Effects of Opiate Use and Hepatitis C Virus Infection on Risk of
Diabetes Mellitus in the Women's Interagency HIV Study
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE diabetes mellitus; fasting glucose; Hepatitis C virus; HIV; opiate use;
women
ID ACTIVE ANTIRETROVIRAL THERAPY; ACQUIRED-IMMUNODEFICIENCY-SYNDROME;
MULTICENTER AIDS COHORT; GLUCOSE-METABOLISM; INSULIN-RESISTANCE;
PREVALENCE; HCV; HEROIN; LOPINAVIR/RITONAVIR; COINFECTION
AB Background: Opiate use is common in HIV-infected and hepatitis C virus (HCV)-infected individuals, however, its contribution to the risk of diabetes mellitus is not well understood.
Methods: Prospective study of 1713 HIV-infected and 652 HIV-uninfected participants from the Women's Interagency HIV Study between October 2000 and March 2006. Diabetes defined as fasting glucose >= 126 mg/dL, self report of diabetes medication use, or confirmed diabetes diagnosis. Opiate use determined using an interviewer-administered questionnaire. Detectable plasma HCV RNA confirmed HCV infection.
Results: Current opiate users had a higher prevalence of diabetes (15%) than nonusers (10%, P = 0.03), and a higher risk of incident diabetes (adjusted relative hazard: 1.58, 95% confidence interval: 1.01 to 2.46), after controlling for HCV infection, HIV/antiretroviral therapy status, and diabetes risk factors including age, race/ethnicity, family history of diabetes, and body mass index. HCV infection was also an independent risk factor for diabetes (adjusted relative hazard: 1.61, 95% confidence interval: 1.02 to 2.52). HCV-infected women reporting current opiate use had the highest diabetes incidence (4.83 cases per 100 person-years).
Conclusions: Among women with or at-risk for HIV, opiate use is associated with increased diabetes risk independently of HCV infection. Diabetic screening should be part of care for opiate users and those infected with HCV.
C1 [Howard, Andrea A.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA.
[Hoover, Donald R.] Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ USA.
[Hoover, Donald R.] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, Piscataway, NJ USA.
[Anastos, Kathryn] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA.
[Anastos, Kathryn; Strickler, Howard D.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Wu, Xi] Data Solut LLC, Bronx, NY USA.
[Shi, Qiuhu] New York Med Coll, Sch Hlth Sci & Practice, Dept Epidemiol & Community Hlth, Valhalla, NY 10595 USA.
[Cole, Stephen R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Cole, Stephen R.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[Cohen, Mardge H.] John H Stroger Jr Hosp Cook Cty, CORE Ctr, Chicago, IL USA.
[Kovacs, Andrea] Univ So Calif, Keck Sch Med, Dept Pediat & Pathol, Los Angeles, CA 90033 USA.
[Kovacs, Andrea] Univ So Calif, Keck Sch Med, Maternal Child & Adolescent Ctr Infect Dis & Viro, Los Angeles, CA 90033 USA.
[Augenbraun, Michael] SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA.
[Latham, Patricia S.] George Washington Univ, Med Ctr, Dept Pathol & Med, Washington, DC 20037 USA.
[Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Howard, AA (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, 722 W 168th St,Room 709, New York, NY 10032 USA.
EM aah2138@columbia.edu
OI Latham, Patricia/0000-0003-2782-9444
FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590,
R01-AI-052065, R01-AI-057006, P30-AI-51519, K23-AI-66943]; National
Institute of Child Health and Human Development [UO1-HD-32632]; National
Cancer Institute; National Institute on Deafness and Other Communication
Disorders; National Center for Research Resources [UL1 RR024131];
National Institute on Drug Abuse [K23-DA-15003]
FX The Women's Interagency HIV Study is funded by the National Institute of
Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834,
UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the
National Institute of Child Health and Human Development (UO1-HD-32632).
The study is cofunded by the National Cancer Institute, the National
Institute on Drug Abuse, and the National Institute on Deafness and
Other Communication Disorders. Funding is also provided by the National
Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131).
Hepatitis C virus testing was supported by grants from the National
Institute of Allergy and Infectious Diseases (R01-AI-052065 and
R01-AI-057006). This work was also supported in part by the Center for
AIDS Research at the Albert Einstein College of Medicine and Montefiore
Medical Center funded by the National Institutes of Allergy and
Infectious Diseases (P30-AI-51519). Dr. A. A. H. received support from
the National Institute on Drug Abuse (K23-DA-15003). Dr. P. C. T.
received support from the National Institute of Allergy and Infectious
Diseases (K23-AI-66943).
NR 38
TC 12
Z9 12
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN
PY 2010
VL 54
IS 2
BP 152
EP 159
DI 10.1097/QAI.0b013e3181d0c911
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 601XK
UT WOS:000278100600007
PM 20190642
ER
PT J
AU Dau, B
Ayers, D
Singer, J
Harrigan, PR
Brown, S
Kyriakides, T
Cameron, DW
Angus, B
Holodniy, M
AF Dau, Birgitt
Ayers, Dieter
Singer, Joel
Harrigan, P. Richard
Brown, Sheldon
Kyriakides, Tassos
Cameron, D. William
Angus, Brian
Holodniy, Mark
TI Connection Domain Mutations in Treatment-Experienced Patients in the
OPTIMA Trial
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE antiretroviral; clinical trial; HIV; resistance; veterans
ID HIV-1 REVERSE-TRANSCRIPTASE; RNASE-H ACTIVITY; CONFERS ZIDOVUDINE;
CLINICAL-TRIAL; RESISTANCE; 3'-AZIDO-3'-DEOXYTHYMIDINE; MECHANISM;
INHIBITOR; EXCISION; THERAPY
AB Objectives: To determine the frequency of mutations in the connection domain (CD) of HIV reverse transcriptase in treatment-experienced patients in the Options in Management with Antiretrovirals trial, their impact on susceptibility to antiretroviral (ARV) drugs, and their impact on virologic outcomes.
Methods: Baseline plasma ARV genotypes and inferred resistance phenotypes were obtained. Frequencies of E312Q, Y318F, G333D, G333E, G335C, G335D, N348I, A360I, A360V, V365I, A371V, A376S, and E399G were compared with a treatment-naive population. The association of CD mutations with inferred IC(50) fold changes to nucleos(t)ide reverse transcriptase inhibitors was evaluated. Univariate and multivariate analyses examined the association of CD mutations with a>1 log(10) per milliliter decrease in HIV viral load after 24 weeks on a new ARV regimen.
Results: Higher CD mutation rates were seen in Options in Management with Antiretrovirals patients (n = 345) compared with a treatment-naive population. CD mutations were associated with increased inferred IC50 fold changes to abacavir, stavudine, tenofovir, and zidovudine. On univariate analysis, A371V was associated with lack of virologic response, as was having any CD mutation on multivariate analysis.
Conclusions: CD mutations are frequent in treatment-experienced populations. They are associated with reduced susceptibility to some nucleos(t)ide reverse transcriptase inhibitors and with a diminished response to ARV therapy.
C1 [Dau, Birgitt] VA Palo Alto Hlth Care Syst, AIDS Res Ctr, Palo Alto, CA 94304 USA.
[Ayers, Dieter; Singer, Joel] Canadian HIV Trials Network, Canadian Inst Hlth Res, Vancouver, BC, Canada.
[Harrigan, P. Richard] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
[Brown, Sheldon] Bronx Vet Affairs Med Ctr, Div Infect Dis, New York, NY USA.
[Kyriakides, Tassos] Cooperat Studies Program Coordinating Ctr, West Haven, CT USA.
[Cameron, D. William] Ottawa Gen Hosp, Dept Med, Div Infect Dis, Ottawa, ON K1H 8L6, Canada.
[Angus, Brian] Univ Oxford, Dept Med, Oxford, England.
[Holodniy, Mark] Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA.
RP Dau, B (reprint author), VA Palo Alto Hlth Care Syst, AIDS Res Ctr, 3801 Miranda Ave 132, Palo Alto, CA 94304 USA.
EM birgitt.dau@gmail.com
OI Angus, Brian/0000-0003-3598-7784; Cameron, Bill/0000-0002-0090-3539
FU US Department of Veterans Affairs Office of Research and Development;
Canadian Institutes for Health Research; Canadian HIV Trials Network; UK
Medical Research Council; Veterans Affairs
FX The Options in Management with Antiretrovirals study was funded in part
by the Cooperative Studies Program of the US Department of Veterans
Affairs Office of Research and Development, the Canadian Institutes for
Health Research, the Canadian HIV Trials Network, and the UK Medical
Research Council. This substudy was funded in part by a Veterans Affairs
grant to M. H. and by the Canadian HIV Trials Network.
NR 28
TC 10
Z9 10
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN
PY 2010
VL 54
IS 2
BP 160
EP 166
DI 10.1097/QAI.0b013e3181cbd235
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 601XK
UT WOS:000278100600008
PM 20130473
ER
PT J
AU Suryakumar, G
Kasiganesan, H
Balasubramanian, S
Kuppuswamy, D
AF Suryakumar, Geetha
Kasiganesan, Harinath
Balasubramanian, Sundaravadivel
Kuppuswamy, Dhandapani
TI Lack of beta 3 Integrin Signaling Contributes to Calpain-Mediated
Myocardial Cell Loss in Pressure-Overloaded Myocardium
SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
LA English
DT Article
DE cardiac hypertrophy; beta 3 integrin knockout mice; pressure-overload;
programmed cell death
ID ENDOPLASMIC-RETICULUM STRESS; CARDIAC MYOCYTE APOPTOSIS;
SMOOTH-MUSCLE-CELLS; FACTOR-KAPPA-B; HEART-FAILURE; DEGRADED COLLAGEN;
CARDIOMYOCYTE APOPTOSIS; CROSS-TALK; ACTIVATION; HYPERTROPHY
AB Although cardiac hypertrophy initially ensues as a compensatory mechanism, it often culminates in congestive heart failure. Based on our earlier studies that calpain and beta 3 integrin play cell death and survival roles, respectively, during pressure-overload (PO) hypertrophy, we investigated if the loss of beta 3 integrin signaling is a potential mechanism for calpain-mediated cardiomyocyte death during PO. beta 3 Integrin knockout (beta 3(-/-)) and wild-type mice were used to induce either moderate or severe PO in vivo for short-term (72-hour) and long-term (4-week) transverse aortic constriction. Whereas wild-type mice showed no changes during moderate PO at both time points, beta 3(-/-) mice exhibited both enrichment of the m-calpain isoform and programmed cell death of cardiomyocytes after 4-week PO. However, with severe PO that caused increased mortality in both mice groups, cell death was observed in wild-type mice also. To study calpain's role, calpeptin, a specific inhibitor of calpain, was administered through an osmotic mini-pump at 2.5 mg/kg per day beginning 3 days before moderate transverse aortic constriction or sham surgery. Calpeptin administration blocked both calpain enrichment and myocardial cell death in the 4-week PO beta 3(-/-) mice. Because beta 3 integrin contributes to cardioprotective signaling, these studies indicate that the loss of specific integrin function could be a key mechanism for calpain-mediated programmed cell death of cardiomyocytes in PO myocardium.
C1 [Suryakumar, Geetha; Kasiganesan, Harinath; Balasubramanian, Sundaravadivel; Kuppuswamy, Dhandapani] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA.
[Kuppuswamy, Dhandapani] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA.
RP Kuppuswamy, D (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, 114 Doughty St, Charleston, SC 29425 USA.
EM kuppusd@musc.edu
FU National Institutes of Health (NIH) [HL-48788, RHL092124A]; Research
Service of the Department of Veterans Affairs; Department of Science and
Technology, India
FX This study was supported by National Institutes of Health (NIH) grant
PPG HL-48788, by NIH grant RHL092124A (to D. K), by a Merit award from
the Research Service of the Department of Veterans Affairs, and by a
BOYSCAST fellowship from the Department of Science and Technology, India
(to G. S.).
NR 36
TC 15
Z9 16
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0160-2446
J9 J CARDIOVASC PHARM
JI J. Cardiovasc. Pharmacol.
PD JUN
PY 2010
VL 55
IS 6
BP 567
EP 573
DI 10.1097/FJC.0b013e3181d9f5d4
PG 7
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA 612EQ
UT WOS:000278880000006
PM 20224428
ER
PT J
AU Bhasin, S
Cunningham, GR
Hayes, FJ
Matsumoto, AM
Snyder, PJ
Swerdloff, RS
Montori, VM
AF Bhasin, Shalender
Cunningham, Glenn R.
Hayes, Frances J.
Matsumoto, Alvin M.
Snyder, Peter J.
Swerdloff, Ronald S.
Montori, Victor M.
TI Testosterone Therapy in Men with Androgen Deficiency Syndromes: An
Endocrine Society Clinical Practice Guideline
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID PROSTATE-SPECIFIC ANTIGEN; PLACEBO-CONTROLLED TRIALS; LOW SERUM
TESTOSTERONE; BONE-MINERAL DENSITY; NOCTURNAL PENILE TUMESCENCE;
RANDOMIZED CONTROLLED-TRIAL; DIGITAL RECTAL EXAMINATION; VISUAL EROTIC
STIMULI; MIDDLE-AGED MEN; VIRUS-INFECTED MEN
AB Objective: Our objective was to update the guidelines for the evaluation and treatment of androgen deficiency syndromes in adult men published previously in 2006.
Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration.
Conclusions: We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels. We suggest the measurement of morning total testosterone level by a reliable assay as the initial diagnostic test. We recommend confirmation of the diagnosis by repeating the measurement of morning total testosterone and, in some men in whom total testosterone is near the lower limit of normal or in whom SHBG abnormality is suspected by measurement of free or bioavailable testosterone level, using validated assays. We recommend testosterone therapy for men with symptomatic androgen deficiency to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density. We recommend against starting testosterone therapy in patients with breast or prostate cancer, a palpable prostate nodule or induration or prostate-specific antigen greater than 4 ng/ml or greater than 3 ng/ml in men at high risk for prostate cancer such as African-Americans or men with first-degree relatives with prostate cancer without further urological evaluation, hematocrit greater than 50%, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms with International Prostate Symptom Score above 19, or uncontrolled or poorly controlled heart failure. When testosterone therapy is instituted, we suggest aiming at achieving testosterone levels during treatment in the mid-normal range with any of the approved formulations, chosen on the basis of the patient's preference, consideration of pharmacokinetics, treatment burden, and cost. Men receiving testosterone therapy should be monitored using a standardized plan. (J Clin Endocrinol Metab 95: 2536-2559, 2010)
C1 [Bhasin, Shalender] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Cunningham, Glenn R.] Baylor Coll Med, Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Hayes, Frances J.] St Vincents Univ Hosp, Dublin 4, Ireland.
[Matsumoto, Alvin M.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Snyder, Peter J.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Swerdloff, Ronald S.] Harbor Univ Calif, Los Angeles Med Ctr, Torrance, CA 90502 USA.
[Montori, Victor M.] Mayo Clin, Rochester, MN 55905 USA.
RP Bhasin, S (reprint author), Endocrine Soc, 8401 Connecticut Ave,Suite 900, Chevy Chase, MD 20815 USA.
EM govt-prof@endo-society.org
RI Perez , Claudio Alejandro/F-8310-2010
OI Perez , Claudio Alejandro/0000-0001-9688-184X; Montori,
Victor/0000-0003-0595-2898
NR 152
TC 805
Z9 829
U1 11
U2 56
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN
PY 2010
VL 95
IS 6
BP 2536
EP 2559
DI 10.1210/jc.2009-2354
PG 24
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 606RD
UT WOS:000278444000004
PM 20525905
ER
PT J
AU Valdiserri, RO
Nazi, K
McInnes, DK
Ross, D
Kinsinger, L
AF Valdiserri, Ronald O.
Nazi, Kim
McInnes, D. Keith
Ross, David
Kinsinger, Linda
TI Need to Improve Routine HIV Testing of US Veterans in Care: Results of
an Internet Survey
SO JOURNAL OF COMMUNITY HEALTH
LA English
DT Article
ID UNITED-STATES; ANTIRETROVIRAL THERAPY; COST-EFFECTIVENESS; INFECTION;
PREVALENCE; DIAGNOSIS; CENTERS; LESSONS; VIRUS; ERA
AB Late diagnosis of HIV infection contributes to poor medical outcomes and helps sustain continued transmission of virus. Published evidence suggests that despite current public health recommendations, patients receiving care in the Veterans Health Administration (VHA) system are not being routinely tested for HIV infection. Using a sample of computer-literate veterans, we conducted a survey of recent testing experiences. My HealtheVet (MHV) is a secure website allowing registered Veterans to access limited personal VHA health information. Using the American Customer Satisfaction Index (ACSI) Survey, an electronic questionnaire on "health screening" was conducted in late Fall/early winter 2008-2009. A random sample (4%) of MHV users were surveyed; approximately 17% completed the survey and responses ranged from 31,237 to 33,074. Only 9% of the respondents indicated that they had been offered a test for HIV in the last 12 months compared to 83% who had been offered cholesterol screening, 65% blood sugar screening and 19% who had been offered testing for Hepatitis C virus (HCV). Of those who had been offered HIV testing, 91% indicated that they'd had the test performed. Of note, the percentage of respondents who indicated that they would "very likely" accept a test, if offered, was similar for HIV (73%), HCV (79%), cholesterol (75%), and blood sugar (75%). Although these results cannot be generalized to all Veterans in care, they suggest that routine testing for HIV has not been taking place and support recent VHA policy changes to remove barriers to HIV testing.
C1 [Valdiserri, Ronald O.; Ross, David] US Dept Vet Affairs, Publ Hlth Strateg Hlth Care Grp 13B, Off Publ Hlth & Environm Hazards, Washington, DC 20420 USA.
[Nazi, Kim] US Dept Vet Affairs, Vet & Consumers Hlth Informat Off, Washington, DC 20420 USA.
[McInnes, D. Keith] US Dept Vet Affairs, Ctr Hlth Qual Outcomes & Econ Res, Washington, DC 20420 USA.
[Kinsinger, Linda] US Dept Vet Affairs, Natl Ctr Hlth Promot & Dis Prevent, Washington, DC 20420 USA.
RP Valdiserri, RO (reprint author), US Dept Vet Affairs, Publ Hlth Strateg Hlth Care Grp 13B, Off Publ Hlth & Environm Hazards, 810 Vermont Ave NW, Washington, DC 20420 USA.
EM R.Valdiserri@va.gov
NR 31
TC 8
Z9 8
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0094-5145
J9 J COMMUN HEALTH
JI J. Community Health
PD JUN
PY 2010
VL 35
IS 3
BP 215
EP 219
DI 10.1007/s10900-010-9233-x
PG 5
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 586DA
UT WOS:000276880600001
PM 20146092
ER
PT J
AU Kullgren, JT
McLaughlin, CG
AF Kullgren, Jeffrey T.
McLaughlin, Catherine G.
TI Beyond Affordability: The Impact of Nonfinancial Barriers on Access for
Uninsured Adults in Three Diverse Communities
SO JOURNAL OF COMMUNITY HEALTH
LA English
DT Article
DE Uninsured; Access to care; Nonfinancial barriers; Health reform
ID HEALTH-INSURANCE; MEDICAL-CARE; UNITED-STATES; SERVICES; SATISFACTION;
DEFINITION
AB Most proposals to improve access for uninsured adults focus on removing financial barriers to health care. Health services researchers have long recognized, however, that access to care is a multidimensional concept consisting of both financial and nonfinancial dimensions. While financial barriers faced by those without health insurance have been well-documented, it is not known to what degree nonfinancial barriers limit access for those without coverage. In this study we sought to identify the types and frequencies of nonfinancial access barriers faced by low-income uninsured adults, as well as determine how frequently nonfinancial barriers coexist with financial access barriers in this population. We conducted a telephone survey of 1,118 low-income uninsured adults in Alameda, California, Austin, Texas, and Southern Maine who had enrolled in local access programs funded through the Robert Wood Johnson Foundation's Communities in Charge initiative. Financial barriers were the most often cited barrier to access in each of the three groups, though nonfinancial barriers were often cited as well. Across all three populations, one-third to one-half of respondents with financial access barriers also cited one or more nonfinancial barriers as contributing to their problems accessing health care. Our results suggest that many uninsured adults face nonfinancial health care barriers in addition to their well-documented financial challenges. Health reform efforts must address both types of barriers in order to maximally improve access for the uninsured population.
C1 [Kullgren, Jeffrey T.] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA.
[Kullgren, Jeffrey T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Kullgren, Jeffrey T.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[McLaughlin, Catherine G.] Math Policy Res Inc, Ann Arbor, MI USA.
[McLaughlin, Catherine G.] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI 48104 USA.
[Kullgren, Jeffrey T.] Brigham & Womens Hosp, Residency Program Primary Care & Populat Hlth Har, Boston, MA 02115 USA.
[Kullgren, Jeffrey T.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA.
RP Kullgren, JT (reprint author), Univ Penn, Robert Wood Johnson Clin Scholars Program, 1303A Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM kullgren@mail.med.upenn.edu
NR 30
TC 10
Z9 11
U1 2
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0094-5145
J9 J COMMUN HEALTH
JI J. Community Health
PD JUN
PY 2010
VL 35
IS 3
BP 240
EP 248
DI 10.1007/s10900-010-9230-0
PG 9
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 586DA
UT WOS:000276880600005
PM 20127505
ER
PT J
AU Salanitro, A
Safford, M
Ovalle, F
Curry, W
Williams, JH
Kim, Y
Estrada, C
Foster, PP
Houston, T
Allison, J
AF Salanitro, Amanda
Safford, Monika
Ovalle, Fernando
Curry, William
Williams, Jessica Hillman
Kim, Yongin
Estrada, Carlos
Foster, Pamela Payne
Houston, Thomas
Allison, Jeroan
TI A CLUSTER-RANDOMIZED TRIAL OF A WEB-BASED PHYSICIAN INTERVENTION TO
IMPROVE DIABETES CARE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Salanitro, Amanda] Birmingham VA Med Ctr, Birmingham, AL USA.
[Safford, Monika; Ovalle, Fernando; Curry, William; Williams, Jessica Hillman; Kim, Yongin; Estrada, Carlos] Univ Alabama, Birmingham, AL USA.
[Foster, Pamela Payne] Univ Alabama, Tuscaloosa, AL USA.
[Houston, Thomas; Allison, Jeroan] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA.
RI Houston, Thomas/F-2469-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 206
EP 206
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300005
ER
PT J
AU Steinman, M
Goldstein, M
AF Steinman, Michael
Goldstein, Mary
TI A NEW APPROACH TO PERFORMANCE MEASUREMENT FOR HYPERTENSION: PRELIMINARY
RESULTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Steinman, Michael] UCSF, San Francisco VAMC, San Francisco, CA USA.
[Goldstein, Mary] CHCE, VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 211
EP 211
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300015
ER
PT J
AU Moskowitz, D
Smith, CS
Zia, J
Wipf, J
AF Moskowitz, David
Smith, C. Scott
Zia, Jasmine
Wipf, Joyce
TI A STRUCTURED MENTORSHIP PROGRAM INCREASES RESIDENTS' SATISFACTION WITH
MENTORING: A TWO-YEAR COHORT STUDY AT A MULTI-HOSPITAL INTERNAL MEDICINE
RESIDENCY PROGRAM
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Moskowitz, David] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Smith, C. Scott] Boise VA Med Ctr, Boise, ID USA.
[Wipf, Joyce] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 214
EP 215
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300024
ER
PT J
AU Chen, GQ
Moran, W
Egede, L
Jia, HG
Yu, HJ
AF Chen, Guoqing
Moran, William
Egede, Leonard
Jia, Huanguang
Yu, Hong-Jen
TI ADHERENCE TO GUIDELINE-RECOMMENDED CARE FOR VETERANS WITH CHRONIC KIDNEY
DISEASE IN VA
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Chen, Guoqing] Baylor Coll Med, Houston, TX 77030 USA.
[Chen, Guoqing; Yu, Hong-Jen] VA Houston HSR&D Ctr Excellence, Houston, TX USA.
[Moran, William; Egede, Leonard] Med Univ S Carolina, Charleston, SC 29425 USA.
[Egede, Leonard] Ralph H Johnson VAMC, Charleston, SC USA.
[Jia, Huanguang] RORC, Gainesville, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 219
EP 220
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300034
ER
PT J
AU Salanitro, A
Agee, B
Burczyk-Brown, J
Funkhouser, E
Muntner, P
Crenshaw, K
Horton, T
Halanych, J
Richman, J
Kaffka, J
Safford, M
AF Salanitro, Amanda
Agee, Bonita
Burczyk-Brown, Jennifer
Funkhouser, Ellen
Muntner, Paul
Crenshaw, Katie
Horton, Trudi
Halanych, Jewell
Richman, Joshua
Kaffka, Jaimee
Safford, Monika
TI APPROPRIATE INACTION AND CLINICAL INERTIA
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Salanitro, Amanda] Birmingham VA Med Ctr, Birmingham, AL USA.
[Agee, Bonita; Burczyk-Brown, Jennifer; Funkhouser, Ellen] C SMART, Birmingham VA Med Ctr, Birmingham, AL USA.
[Muntner, Paul] Univ Alabama, Dept Epidemiol, Birmingham, AL USA.
[Crenshaw, Katie; Horton, Trudi] Univ Alabama, Div Continuing Med Educ, Birmingham, AL USA.
[Halanych, Jewell; Richman, Joshua; Kaffka, Jaimee] Univ Alabama, Div Prevent Med, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 223
EP 224
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300043
ER
PT J
AU Seal, K
McCaslin, S
McCamish, N
Ren, L
Abadjian, L
Burt, M
Daley, A
AF Seal, Karen
McCaslin, Shannon
McCamish, Nicole
Ren, Li
Abadjian, Linda
Burt, Michelle
Daley, Aaron
TI CAN MOTIVATIONAL INTERVIEWING ENHANCE MENTAL HEALTH TREATMENT ENGAGEMENT
IN IRAQ AND AFGHANISTAN VETERANS: PRELIMINARY RESULTS FROM A RANDOMIZED
CONTROLLED TRIAL
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Seal, Karen] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[McCaslin, Shannon; McCamish, Nicole; Ren, Li; Abadjian, Linda; Burt, Michelle; Daley, Aaron] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 235
EP 236
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300070
ER
PT J
AU Laiteerapong, N
Karter, A
Liu, J
Moffet, H
Sudore, R
Schillinger, D
John, P
Huang, E
AF Laiteerapong, Neda
Karter, Andrew
Liu, Jennifer
Moffet, Howard
Sudore, Rebecca
Schillinger, Dean
John, Priya
Huang, Elbert
TI DETERMINANTS OF QUALITY OF LIFE IN OLDER ADULTS WITH DIABETES: THE
DIABETES & AGING STUDY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Laiteerapong, Neda; John, Priya; Huang, Elbert] Univ Chicago, Chicago, IL 60637 USA.
[Karter, Andrew; Liu, Jennifer; Moffet, Howard] Kaiser Permanente No Calif, Oakland, CA USA.
[Sudore, Rebecca; Schillinger, Dean] Univ Calif San Francisco, San Francisco, CA USA.
[Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 251
EP 251
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300103
ER
PT J
AU Yano, E
Washington, D
Bean-Mayberry, B
Canelo, I
Rose, D
AF Yano, Elizabeth
Washington, Donna
Bean-Mayberry, Bevanne
Canelo, Ismelda
Rose, Danielle
TI EROSION OF WOMEN'S HEALTH SERVICES IN THE VA: VHA SURVEY OF WOMEN
VETERANS HEALTH PROGRAMS AND PRACTICES, 2001-2006
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Yano, Elizabeth; Canelo, Ismelda] VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA.
[Washington, Donna] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Rose, Danielle] VA HSR&D Ctr Study Healthcare Provider Behav, Sepulveda, CA USA.
[Bean-Mayberry, Bevanne] VA Greater Los Angeles HSR&D Ctr, Sherman Oaks, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 270
EP 270
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300145
ER
PT J
AU True, G
Crowley-Matoka, M
Bayliss, N
AF True, Gala
Crowley-Matoka, Megan
Bayliss, Nichole
TI EXPLORING VARIABILITY IN PRIMARY CARE PROVIDERS' APPROACHES TO
NON-CANCER PAIN
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [True, Gala] Ctr Hlth Equity Res & Promot, Philadelphia, PA USA.
[Crowley-Matoka, Megan; Bayliss, Nichole] Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 274
EP 274
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300156
ER
PT J
AU John, L
Loewenstein, G
Volpp, K
Norton, L
Troxel, A
Fassbender, J
AF John, Leslie
Loewenstein, George
Volpp, Kevin
Norton, Laurie
Troxel, Andrea
Fassbender, Jennifer
TI FINANCIAL INCENTIVES FOR LONGER-TERM WEIGHT LOSS: A RANDOMIZED
CONTROLLED TRIAL
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [John, Leslie; Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
[Volpp, Kevin] Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Wharton Sch,Philadelpia VA Med Ctr, Philadelphia, PA 19104 USA.
[Norton, Laurie] Philadelphia Vet Adm, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 278
EP 279
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300167
ER
PT J
AU Steinman, M
Sloane, R
Schmader, K
Hanlon, J
AF Steinman, Michael
Sloane, Richard
Schmader, Kenneth
Hanlon, Joseph
TI FRAILTY AND RISK OF ADVERSE DRUG REACTIONS IN AMBULATORY ELDERS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Steinman, Michael] UCSF, San Francisco VAMC, San Francisco, CA USA.
[Sloane, Richard; Schmader, Kenneth] Duke Univ, Durham, NC USA.
[Hanlon, Joseph] Univ Pittsburgh, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 281
EP 282
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300174
ER
PT J
AU Zeliadt, S
Cresswell, D
Etzioni, R
Lin, D
Ginger, VA
AF Zeliadt, Steven
Cresswell, Darlene
Etzioni, Ruth
Lin, Daniel
Ginger, Van Anh
TI GAPS IN FOLLOW-UP CARE AFTER AN ELEVATED PSA TEST
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Zeliadt, Steven] VA Puget Sound Healthcare Syst, HSR& COE, Seattle, WA USA.
[Etzioni, Ruth] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Ginger, Van Anh] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 282
EP 283
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300177
ER
PT J
AU Korthuis, P
Bass, M
Berkenblit, G
Cofrancesco, J
Cook, R
Edison, M
Bashook, P
Sosman, J
Asch, S
Sullivan, L
AF Korthuis, Philip
Bass, Michael
Berkenblit, Gail
Cofrancesco, Joseph, Jr.
Cook, Robert
Edison, Marcia
Bashook, Philip
Sosman, James
Asch, Steven
Sullivan, Lynn
TI GENERAL INTERNISTS' BELIEFS AND BEHAVIORS REGARDING ROUTINE HIV
SCREENING IN PRIMARY CARE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Korthuis, Philip] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Bass, Michael] Univ Illinois, Jane Addams Coll Social Work, Chicago, IL USA.
[Berkenblit, Gail] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
[Cofrancesco, Joseph, Jr.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Cook, Robert] Univ Florida, Gainesville, FL USA.
[Edison, Marcia] Univ Illinois, Chicago Sch Med, Chicago, IL USA.
[Bashook, Philip] Univ Illinois, Dept Med Educ, Chicago, IL 60612 USA.
[Sosman, James] Univ Wisconsin, Madison Sch Med & Publ Hlth, Madison, WI USA.
[Asch, Steven] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Sullivan, Lynn] Yale Sch Med, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 284
EP 285
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300180
ER
PT J
AU Bains, S
Egede, L
Osborn, C
AF Bains, Sujeev
Egede, Leonard
Osborn, Chandra
TI HEALTH LITERACY, DEMOGRAPHIC PROXIES, AND DIABETES SELF-CARE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Egede, Leonard] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
[Osborn, Chandra] Vanderbilt Univ, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 292
EP 292
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300191
ER
PT J
AU Tetrault, J
McGinnis, K
Sullivan, L
Fiellin, D
Justice, A
AF Tetrault, Jeanette
McGinnis, Kathleen
Sullivan, Lynn
Fiellin, David
Justice, Amy
TI HEPATIC SAFETY AND ANTIRETROVIRAL EFFECTIVENESS IN HIV-INFECTED PATIENTS
RECEIVING NALTREXONE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Tetrault, Jeanette; Fiellin, David] Yale Univ, Sch Med, New Haven, CT USA.
[McGinnis, Kathleen] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Sullivan, Lynn] Yale Sch Med, New Haven, CT USA.
[Justice, Amy] Yale Univ, Sch Med, West Haven, CT 06516 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 293
EP 293
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300193
ER
PT J
AU Caton, C
Strom, J
Moran, W
Lynch, C
AF Caton, Cathryn
Strom, Joni
Moran, William
Lynch, Cheryl
TI IDENTIFYING FALL RISK FACTORS AMONG NURSING HOME PATIENTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Lynch, Cheryl] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 300
EP 300
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300209
ER
PT J
AU Beach, MC
Roter, D
Moore, RD
Korthuis, PT
Saha, S
Sharp, V
Wilson, IB
Cohn, J
Eggly, S
Sankar, A
AF Beach, Mary Catherine
Roter, Debra
Moore, Richard D.
Korthuis, P. Todd
Saha, Somnath
Sharp, Victoria
Wilson, Ira B.
Cohn, Jonathon
Eggly, Susan
Sankar, Andrea
TI IMPACT OF A PATIENT AND PROVIDER INTERVENTION TO IMPROVE THE QUALITY OF
COMMUNICATION ABOUT MEDICATION ADHERENCE AMONG HIV PATIENTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Beach, Mary Catherine; Roter, Debra; Moore, Richard D.] Johns Hopkins Univ, Baltimore, MD USA.
[Korthuis, P. Todd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Saha, Somnath] Portland VA Med Ctr, Portland, OR USA.
[Sharp, Victoria] St Lukes Roosevelt, New York, NY USA.
[Wilson, Ira B.] Tufts Med Ctr, Boston, MA USA.
[Cohn, Jonathon; Eggly, Susan; Sankar, Andrea] Wayne State, Detroit, MI USA.
RI Roter, Debra/N-8830-2014; Wilson, Ira/F-9190-2016
OI Wilson, Ira/0000-0002-0246-738X
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 301
EP 302
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300213
ER
PT J
AU Cohen, A
Young, A
Niv, N
Reist, C
Hamilton, A
AF Cohen, Amy
Young, Alexander
Niv, Noosha
Reist, Christopher
Hamilton, Alison
TI IMPLEMENTATION OF A PSYCHOSOCIAL WEIGHT MANAGEMENT PROGRAM AT MENTAL
HEALTH CLINICS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Cohen, Amy; Young, Alexander] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
[Niv, Noosha; Reist, Christopher] Long Beach VA Healthcare Ctr, Long Beach, CA USA.
[Hamilton, Alison] MIRECC, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 305
EP 305
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300219
ER
PT J
AU Cohen, A
Glynn, S
Young, A
Hamilton, A
AF Cohen, Amy
Glynn, Shirley
Young, Alexander
Hamilton, Alison
TI IMPLEMENTING FAMILY SERVICES AT MENTAL HEALTH CLINICS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Cohen, Amy; Glynn, Shirley; Young, Alexander] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
[Hamilton, Alison] MIRECC, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 305
EP 306
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300220
ER
PT J
AU Mortensen, E
Pugh, MJ
Copeland, L
Restrepo, M
Nakashima, B
Perry, T
Anzueto, A
AF Mortensen, Eric
Pugh, Mary Jo
Copeland, Laurel
Restrepo, Marcos
Nakashima, Brandy
Perry, Theodore
Anzueto, Antonio
TI INCIDENCE OF CARDIAC ARRHYTHMIA AFTER HOSPITALIZATION FOR PNEUMONIA
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Copeland, Laurel] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Nakashima, Brandy; Perry, Theodore; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 312
EP 312
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300231
ER
PT J
AU Bishop, T
Ross, J
Federman, A
AF Bishop, Tara
Ross, Joseph
Federman, Alex
TI LABORATORY TEST ORDERING AT PHYSICIAN OFFICES WITH AND WITHOUT ON-SITE
LABORATORIES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Bishop, Tara] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY USA.
[Ross, Joseph] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, HSR&D Res Enhancement Award Program, New York, NY USA.
[Ross, Joseph] James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Federman, Alex] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 322
EP 323
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300255
ER
PT J
AU Lynch, C
Egede, L
Gebregziabher, M
Mueller, M
Zhao, YM
Echols, C
Gilbert, G
AF Lynch, Cheryl
Egede, Leonard
Gebregziabher, Mulugeta
Mueller, Martina
Zhao, Yumin
Echols, Carrae
Gilbert, Gregory
TI LONGITUDINAL EFFECTS OF MEDICATION NON-ADHERENCE ON GLYCEMIC CONTROL
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Lynch, Cheryl] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 324
EP 324
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300259
ER
PT J
AU Saha, S
Perrin, N
Gerrity, M
Gatchell, M
AF Saha, Somnath
Perrin, Nancy
Gerrity, Martha
Gatchell, Melissa
TI MEASURING PHYSICIAN CULTURAL COMPETENCE: RESULTS FROM A NATIONAL SURVEY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Saha, Somnath; Gatchell, Melissa] Portland VA Med Ctr, Portland, OR USA.
[Perrin, Nancy] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA.
[Gerrity, Martha] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 329
EP 329
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300269
ER
PT J
AU Hamilton, A
Cohen, A
Young, A
AF Hamilton, Alison
Cohen, Amy
Young, Alexander
TI ORGANIZATIONAL READINESS IN MENTAL HEALTH CLINICS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Hamilton, Alison] MIRECC, Los Angeles, CA USA.
[Cohen, Amy; Young, Alexander] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 339
EP 340
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300291
ER
PT J
AU Bryson, C
Jackson, G
Maciejewski, M
Au, D
Fihn, S
Perkins, M
Sharp, N
Liu, CF
Blough, D
Piette, J
AF Bryson, Christopher
Jackson, George
Maciejewski, Matthew
Au, David
Fihn, Stephan
Perkins, Mark
Sharp, Nancy
Liu, Chuan-Fen
Blough, David
Piette, John
TI PATIENT FACTORS DO NOT EXPLAIN LARGE FACILITY VARIATION IN MEDICATION
ADHERENCE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Bryson, Christopher; Au, David; Fihn, Stephan; Perkins, Mark; Sharp, Nancy; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Jackson, George; Maciejewski, Matthew] Durham VA Med Ctr, Hlth Serv Res & Dev, Durham, NC USA.
[Blough, David] Univ Washington, Sch Pharm, Seattle, WA 98195 USA.
[Piette, John] Univ Michigan, Ann Arbor, MI 48109 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 342
EP 342
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300298
ER
PT J
AU McTigue, K
Zickmund, S
Simkin-Silverman, L
Bryce, C
Bhargava, T
Conroy, M
Fischer, G
Meiksin, R
AF McTigue, Kathleen
Zickmund, Susan
Simkin-Silverman, Laurey
Bryce, Cindy
Bhargava, Tina
Conroy, Molly
Fischer, Gary
Meiksin, Rebecca
TI PATIENT PREFERENCES FOR FEATURES OF AN ONLINE INTERACTIVE BEHAVIORAL
WEIGHT LOSS PROGRAM
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Zickmund, Susan] Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
[Simkin-Silverman, Laurey] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Bryce, Cindy] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Bhargava, Tina] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Bhargava, Tina] Univ Pittsburgh, Dept Behav Sci & Community Hlth, Pittsburgh, PA USA.
[Meiksin, Rebecca] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 342
EP 343
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300299
ER
PT J
AU Copeland, L
Zeber, J
MacCarthy, D
Lawrence, V
AF Copeland, Laurel
Zeber, John
MacCarthy, Dan
Lawrence, Valerie
TI PERIOPERATIVE OUTCOMES OF NON-CARDIAC SURGERY FOR SERIOUSLY MENTALLY ILL
ELDERLY (POSSE)
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Copeland, Laurel; MacCarthy, Dan; Lawrence, Valerie] South Texas Vet Hlth Care Syst, VERDICT Res, San Antonio, TX USA.
[Zeber, John] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Lawrence, Valerie] UTHSCSA, Dept Med, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 348
EP 348
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300312
ER
PT J
AU Saha, S
Moore, R
Beach, MC
Korthuis, T
Sharp, V
Cohn, J
AF Saha, Somnath
Moore, Richard
Beach, Mary Catherine
Korthuis, Todd
Sharp, Victoria
Cohn, Jonathan
TI PHYSICIAN INTERRACIAL ANXIETY, COMMUNICATION, AND SATISFACTION AMONG
PATIENTS WITH HIV
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA.
[Moore, Richard; Beach, Mary Catherine] Johns Hopkins Univ, Baltimore, MD USA.
[Korthuis, Todd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Cohn, Jonathan] Wayne State Univ, Detroit, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 350
EP 350
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300317
ER
PT J
AU Saha, S
Beach, MC
AF Saha, Somnath
Beach, Mary Catherine
TI PHYSICIAN PATIENT-CENTEREDNESS AND PATIENT DECISION-MAKING: A RANDOMIZED
STUDY USING VIDEO VIGNETTES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA.
[Beach, Mary Catherine] Johns Hopkins Univ, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 351
EP 352
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300321
ER
PT J
AU Bishop, T
Keyhani, S
Federman, A
AF Bishop, Tara
Keyhani, Salomeh
Federman, Alex
TI PHYSICIAN VIEWS ON DEFENSIVE MEDICINE: A NATIONAL SURVEY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Bishop, Tara; Federman, Alex] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY USA.
[Keyhani, Salomeh] James J Peters Vet Adm Med Ctr, Mt Sinai Sch Med, Dept Hlth Policy, Div Gen Internal Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 352
EP 353
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300323
ER
PT J
AU Federman, A
Keyhani, S
Woodward, M
AF Federman, Alex
Keyhani, Salomeh
Woodward, Mark
TI PHYSICIANS OPINIONS ABOUT REFORMING REIMBURSEMENT: RESULTS OF A NATIONAL
SURVEY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Federman, Alex] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY USA.
[Keyhani, Salomeh] James J Peters Vet Adm Med Ctr, Mt Sinai Sch Med, Dept Hlth Policy, Div Gen Internal Med, New York, NY USA.
[Woodward, Mark] George Inst Int Hlth, Sydney, NSW, Australia.
RI Woodward, Mark/D-8492-2015
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 353
EP 353
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300324
ER
PT J
AU Finley, E
Pugh, MJ
Parchman, M
Noel, P
Zeber, J
Copeland, L
Cantu, G
AF Finley, Erin
Pugh, Mary Jo
Parchman, Michael
Noel, Polly
Zeber, John
Copeland, Laurel
Cantu, Gabriel
TI POST-DEPLOYMENT HEALTHCARE FOR RETURNING OEF/OIF MILITARY PERSONNEL AND
THEIR SOCIAL NETWORKS: A QUALITATIVE APPROACH
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Parchman, Michael] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Family & Community Med, San Antonio, TX 78229 USA.
[Noel, Polly] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78229 USA.
[Zeber, John; Copeland, Laurel] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Psychiat, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 354
EP 354
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300327
ER
PT J
AU Castiglioni, A
Kertesz, S
Kim, Y
Schumacher, J
Snyder, E
AF Castiglioni, Analia
Kertesz, Stefan
Kim, Young
Schumacher, Joseph
Snyder, Erin
TI PRESCRIBING OPIATES FOR CHRONIC PAIN IN RESIDENT CONTINUITY CLINICS-
EXPERIENCE MAY NOT ASSURE ADEQUATE KNOWLEDGE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Kertesz, Stefan] Birmingham VA Med Ctr, Birmingham, AL USA.
[Kim, Young; Schumacher, Joseph] Univ Alabama, Sch Med, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 360
EP 361
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300338
ER
PT J
AU Korthuis, P
Fleishman, J
Gebo, K
Cameron, B
Hickam, D
Hellinger, J
Mathews, W
AF Korthuis, Philip
Fleishman, John
Gebo, Kelly
Cameron, Bonnie
Hickam, David
Hellinger, James
Mathews, William
TI PREVALENCE AND CORRELATES OF NON-RECOMMENDED ANTIRETROVIRAL THERAPY IN A
MULTICENTER HIV COHORT
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Fleishman, John] Agcy Healthcare Res & Qual, Rockville, MD USA.
[Gebo, Kelly] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Cameron, Bonnie] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Hickam, David] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
[Hellinger, James] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Mathews, William] UCSD, Dept Med, San Diego, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 361
EP 362
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300340
ER
PT J
AU Lynch, C
Gebregziabher, M
Zhao, YM
Echols, C
Gilbert, G
Egede, L
AF Lynch, Cheryl
Gebregziabher, Mulugeta
Zhao, Yumin
Echols, Carrae
Gilbert, Gregory
Egede, Leonard
TI RACIAL DISPARITIES IN ALL-CAUSE MORTALITY AMONG VETERANS WITH TYPE 2
DIABETES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Lynch, Cheryl; Egede, Leonard] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 376
EP 376
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300370
ER
PT J
AU Borrero, S
Dehlendorf, C
Abebe, K
Schwarz, E
Creinin, M
Nikolajski, C
Ibrahim, S
AF Borrero, Sonya
Dehlendorf, Christine
Abebe, Kaleab
Schwarz, Eleanor
Creinin, Mitchell
Nikolajski, Cara
Ibrahim, Said
TI RACIAL VARIATION IN TUBAL STERILIZATION RATES: THE ROLE OF PATIENT-LEVEL
FACTORS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Borrero, Sonya; Ibrahim, Said] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Borrero, Sonya] UPMC, Pittsburgh, PA USA.
[Dehlendorf, Christine] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Abebe, Kaleab; Schwarz, Eleanor; Creinin, Mitchell; Nikolajski, Cara] Univ Pittsburgh, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 377
EP 377
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300372
ER
PT J
AU Brooks, G
Prochazka, A
Gopal, R
Huang, J
Smart, A
Bowles, D
Yamashita, T
Jamieson, D
Heist, K
AF Brooks, Gabriel
Prochazka, Allan
Gopal, Ravi
Huang, Janice
Smart, Alexandra
Bowles, Daniel
Yamashita, Traci
Jamieson, Daniel
Heist, Kathleen
TI REPORTING OF NEGATIVE RANDOMIZED CONTROLLED TRIALS IN THREE MAJOR
MEDICAL JOURNALS: EFFECT OF TRIAL REGISTRATION
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Brooks, Gabriel; Huang, Janice; Smart, Alexandra; Bowles, Daniel; Yamashita, Traci; Jamieson, Daniel] Univ Colorado Denver, Aurora, CO USA.
[Prochazka, Allan; Gopal, Ravi] Denver VA Med Ctr, Denver, CO USA.
[Heist, Kathleen] Univ Colorado, Denver, CO 80202 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 384
EP 385
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300391
ER
PT J
AU Cordasco, K
Schneider, DC
Franco, I
Sarkisian, C
AF Cordasco, Kristina
Schneider, Diana C.
Franco, Idalid
Sarkisian, Catherine
TI SENSITIVITIES OF THREE SINGLE-ITEM LITERACY SCREENER (SILS) QUESTIONS IN
GERIATRIC MONOLINGUAL SPANISH-SPEAKING PATIENTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Cordasco, Kristina; Franco, Idalid] RAND Corp, Santa Monica, CA USA.
[Schneider, Diana C.] LAC, USC Med Ctr, Los Angeles, CA USA.
[Sarkisian, Catherine] Univ Calif Los Angeles, VA Greater Los Angeles, GRECC, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 389
EP 389
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300404
ER
PT J
AU Sudore, R
Williams, B
Castillo, L
AF Sudore, Rebecca
Williams, Brie
Castillo, Leslie
TI THE CLASH BETWEEN ADVANCE DIRECTIVE LAW AND CLINICAL CARE: RAMIFICATIONS
FOR VULNERABLE POPULATIONS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Sudore, Rebecca; Williams, Brie; Castillo, Leslie] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 399
EP 399
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300423
ER
PT J
AU Ahluwalia, S
Fried, T
Gross, C
Chaudhry, S
AF Ahluwalia, Sangeeta
Fried, Terri
Gross, Cary
Chaudhry, Sarwat
TI THE IMPACT OF COMORBIDITY ON MORTALITY AMONG OLDER PERSONS WITH ADVANCED
HEART FAILURE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Ahluwalia, Sangeeta] Vet Adm Greater Los Angeles, Los Angeles, CA USA.
[Fried, Terri] VA CT Healthcare Syst, West Haven, CT USA.
[Gross, Cary] Yale Univ, Sch Med, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 406
EP 406
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300439
ER
PT J
AU Morone, N
Rollman, B
Belnap, BH
Houck, P
Karp, J
Mazumdar, S
He, F
Weiner, D
AF Morone, Natalia
Rollman, Bruce
Belnap, Bea Herbeck
Houck, Patricia
Karp, Jordan
Mazumdar, Sati
He, Fanyin
Weiner, Debra
TI THE IMPACT OF PAIN AND DEPRESSION ON POST-CABG RECOVERY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Morone, Natalia; Rollman, Bruce] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Belnap, Bea Herbeck; Houck, Patricia] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Weiner, Debra] Ctr Geriatr Res Educ & Clin, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 406
EP 406
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300440
ER
PT J
AU Beach, MC
Brown, R
Hughes, M
Saha, S
Haywood, C
Lanzkron, S
Massa, M
AF Beach, Mary Catherine
Brown, Rochelle
Hughes, Mark
Saha, Somnath
Haywood, Carlton, Jr.
Lanzkron, Sophie
Massa, Michele
TI THE INFLUENCE OF CLINICIAN RACE ON ATTITUDES TOWARD PATIENTS WITH SICKLE
CELL DISEASE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Beach, Mary Catherine; Brown, Rochelle; Haywood, Carlton, Jr.; Lanzkron, Sophie; Massa, Michele] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Hughes, Mark] Johns Hopkins Univ, Towson, MD USA.
[Saha, Somnath] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 409
EP 410
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300448
ER
PT J
AU Englander, H
Kansagara, D
AF Englander, Honora
Kansagara, Devan
TI UNDERSTANDING AND IMPROVING CARE TRANSITIONS FOR THE UNDERSERVED
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Englander, Honora] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Kansagara, Devan] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 419
EP 419
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300469
ER
PT J
AU Borrero, S
McCall-Hosenfeld, J
Brandt, C
Mattocks, K
Nikolajski, C
Haskell, S
AF Borrero, Sonya
McCall-Hosenfeld, Jennifer
Brandt, Cynthia
Mattocks, Kristin
Nikolajski, Cara
Haskell, Sally
TI UNDERSTANDING WOMEN VETERAN'S PERCEPTIONS OF REPRODUCTIVE HEALTH CARE
SERVICES IN THE VETERANS ADMINISTRATION
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Borrero, Sonya] UPMC, Pittsburgh, PA USA.
[McCall-Hosenfeld, Jennifer] Penn State Milton S Hershey Med Ctr, Hershey, PA USA.
[Brandt, Cynthia; Mattocks, Kristin] VA Connecticut Healtcare Syst, West Haven, CT USA.
[Nikolajski, Cara] Univ Pittsburgh, Pittsburgh, PA USA.
[Haskell, Sally] Yale Univ, Sch Med, West Haven, CT 06516 USA.
[Borrero, Sonya] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Nikolajski, Cara] VAPHS, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 420
EP 420
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300471
ER
PT J
AU Chen, G
Egede, L
Jia, H
Yu, HJ
AF Chen, Guoqing
Egede, Leonard
Jia, Huanguang
Yu, Hong-Jen
TI UNDERUTILIZATION OF NEPHROLOGISTS SERVICES FOR VETERANS WITH CHRONIC
KIDNEY DISEASE IN VA
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Chen, Guoqing] Baylor Coll Med, Houston, TX 77030 USA.
[Chen, Guoqing; Yu, Hong-Jen] VA Houston HSR&D Ctr Excellence, Houston, TX USA.
[Egede, Leonard] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA.
[Jia, Huanguang] RORC, Gainesville, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 420
EP 420
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300472
ER
PT J
AU Gellad, W
Donohue, J
Good, CB
Lowe, J
AF Gellad, Walid
Donohue, Julie
Good, C. Bernie
Lowe, John
TI USE OF ANGIOTENSIN RECEPTOR BLOCKERS IN THE VA, 2000-2009: WHY SO MUCH
VARIATION?
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Gellad, Walid] VA Pittsburgh, RAND Hlth, Pittsburgh, PA USA.
[Donohue, Julie] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
[Good, C. Bernie] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Lowe, John] VHA Pharm Benefits Management Serv, Washington, DC USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 421
EP 422
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300475
ER
PT J
AU Liu, CF
Maciejewski, M
Bryson, C
Perkins, M
Sharp, N
AF Liu, Chuan-Fen
Maciejewski, Matthew
Bryson, Christopher
Perkins, Mark
Sharp, Nancy
TI USE OF OUTPATIENT CARE IN VA AND MEDICARE AMONG DISABILITY-ELIGIBLE AND
AGE-ELIGIBLE VETERANS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Liu, Chuan-Fen; Bryson, Christopher; Perkins, Mark; Sharp, Nancy] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Maciejewski, Matthew] Durham VA Med Ctr, Hlth Serv Res & Dev, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 423
EP 423
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300478
ER
PT J
AU Roy, B
Salanitro, A
Willett, L
Qu, H
Shewchuk, R
Centor, R
Castiglioni, A
AF Roy, Brita
Salanitro, Amanda
Willett, Lisa
Qu, Haiyan
Shewchuk, Richard
Centor, Robert
Castiglioni, Analia
TI USING COGNITIVE MAPPING TO IDENTIFY ATTRIBUTES CONTRIBUTING TO
SUCCESSFUL WARD-ATTENDING ROUNDS - A RESIDENT AND STUDENT PERSPECTIVE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Roy, Brita; Willett, Lisa; Qu, Haiyan; Shewchuk, Richard; Centor, Robert; Castiglioni, Analia] Univ Alabama, Birmingham, AL USA.
[Salanitro, Amanda] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 424
EP 425
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300481
ER
PT J
AU Korenstein, D
Ross, J
Keyhani, S
Mendelson, A
AF Korenstein, Deborah
Ross, Joseph
Keyhani, Salomeh
Mendelson, Ali
TI WHEN THE CAT LOOKS AWAY, WILL THE MICE PLAY? ADHERENCE OF PHARMACEUTICAL
ADS IN MEDICAL JOURNALS TO FDA STANDARDS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Ross, Joseph] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, HSR&D Res Enhancement Award Program & Geriatr Res, New York, NY USA.
[Ross, Joseph] James J Peters Vet Adm Med Ctr, Ctr Clin, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 432
EP 432
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300496
ER
PT J
AU Conde, M
Lawrence, V
Wathen, P
AF Conde, Michelle
Lawrence, Val
Wathen, Patricia
TI USING STANDARDIZED PATIENTS TO TEACH ALCOHOL SCREENING
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 18-MAY 01, 2010
CL Minneapolis, MN
SP Soc Gen Internal Med
C1 [Conde, Michelle; Lawrence, Val] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA.
[Wathen, Patricia] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
SU 3
BP 454
EP 454
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591EO
UT WOS:000277282300546
ER
PT J
AU Noel, PH
Copeland, LA
Pugh, MJ
Kahwati, L
Tsevat, J
Nelson, K
Wang, CP
Bollinger, MJ
Hazuda, HP
AF Noel, Polly Hitchcock
Copeland, Laurel A.
Pugh, Mary Jo
Kahwati, Leila
Tsevat, Joel
Nelson, Karin
Wang, Chen-Pin
Bollinger, Mary J.
Hazuda, Helen P.
TI Obesity Diagnosis and Care Practices in the Veterans Health
Administration
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE obesity; diagnosis; patient education; health services research;
veterans
ID WEIGHT MANAGEMENT; NATIONAL TRENDS; ADULTS; OVERWEIGHT
AB In response to dramatic increases in obesity prevalence, clinical guidelines urge health care providers to prevent and treat obesity more aggressively.
To describe the proportion of obese primary care patients receiving obesity care over a 5-year period and identify factors predicting receipt of care.
Retrospective cohort study utilizing VHA administrative data from 6 of 21 VA administrative regions.
Veterans seen in primary care in FY2002 with a body mass index (BMI) a parts per thousand yen30 kg/m(2) based on heights and weights recorded in the electronic medical record (EMR), survival through FY2006, and active care (1 or more visits in at least 3 follow-up years FY2003-2006).
Receipt of outpatient visits for individual or group education or instruction in nutrition, exercise, or weight management; receipt of prescriptions for any FDA-approved medications for weight reduction; and receipt of bariatric surgery.
Of 933,084 (88.6%) of 1,053,228 primary care patients who had recorded heights and weights allowing calculation of BMI, 330,802 (35.5%) met criteria for obesity. Among obese patients who survived and received active care (N = 264,667), 53.5% had a recorded obesity diagnosis, 34.1% received at least one outpatient visit for obesity-related education or counseling, 0.4% received weight-loss medications, and 0.2% had bariatric surgery between FY2002-FY2006. In multivariable analysis, patients older than 65 years (OR = 0.62; 95% CI: 0.60-0.64) were less likely to receive obesity-related education, whereas those prescribed 5-7 or 8 or more medication classes (OR = 1.41; 1.38-1.45; OR = 1.94; 1.88-2.00, respectively) or diagnosed with obesity (OR = 4.0; 3.92-4.08) or diabetes (OR = 2.23; 2.18-2.27) were more likely to receive obesity-related education.
Substantial numbers of VHA primary care patients did not have sufficient height or weight data recorded to calculate BMI or have recorded obesity diagnoses when warranted. Receipt of obesity education varied by sociodemographic and clinical factors; providers may need to be cognizant of these when engaging patients in treatment.
C1 [Noel, Polly Hitchcock; Copeland, Laurel A.; Pugh, Mary Jo; Wang, Chen-Pin; Bollinger, Mary J.] VERDICT S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Noel, Polly Hitchcock; Copeland, Laurel A.; Pugh, Mary Jo; Wang, Chen-Pin; Hazuda, Helen P.] UT Hlth Sci Ctr San Antonio, San Antonio, TX USA.
[Kahwati, Leila] VHA Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA.
[Tsevat, Joel] Cincinnati VAMC, Cincinnati, OH USA.
[Tsevat, Joel] Univ Cincinnati, Cincinnati, OH USA.
[Nelson, Karin] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Nelson, Karin] Univ Washington, Dept Med, Seattle, WA USA.
RP Noel, PH (reprint author), VERDICT S Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78229 USA.
EM noelp@uthscsa.edu
OI Pugh, Mary Jo/0000-0003-4196-7763; Copeland, Laurel/0000-0002-9478-0209
FU Department of Veteran Affairs, Veterans Health Administration, Health
Services Research and Development Service [IIR 05-121]
FX The research reported here was supported by the Department of Veteran
Affairs, Veterans Health Administration, Health Services Research and
Development Service (project no. IIR 05-121). Dr. Noel is a Research
Psychologist at the South Texas Veterans Health Care System. The views
expressed in this article are those of the author(s) and do not
necessarily represent the views of the Department of Veterans Affairs.
NR 32
TC 23
Z9 23
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2010
VL 25
IS 6
BP 510
EP 516
DI 10.1007/s11606-010-1279-z
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 596UY
UT WOS:000277712200008
PM 20180155
ER
PT J
AU Basile, J
Babazadeh, S
Lillestol, M
Wright, M
Laflamme, AK
Weitzman, R
AF Basile, J.
Babazadeh, S.
Lillestol, M.
Wright, M.
Laflamme, A. K.
Weitzman, R.
TI FIRST-LINE ALISKIREN/HYDROCHLOROTHIAZIDE COMBINATION THERAPY LOWERS
BLOOD PRESSURE MORE EFFECTIVELY THAN HYDROCHLOROTHIAZIDE ALONE IN OBESE
OLDER PATIENTS WITH STAGE 2 HYPERTENSION
SO JOURNAL OF HYPERTENSION
LA English
DT Meeting Abstract
CT 20th Annual Meeting of the European-Society-of-Hypertension
CY JUN 18-21, 2010
CL Oslo, NORWAY
SP European Soc Hypertens
C1 [Basile, J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Babazadeh, S.] Crest Clin Trials Inc, Santa Ana, CA USA.
[Lillestol, M.] Lillestol Res LLC, Fargo, ND USA.
[Wright, M.; Laflamme, A. K.] Novartis Pharma AG, Basel, Switzerland.
[Weitzman, R.] Novartis Pharmaceut, E Hanover, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0263-6352
J9 J HYPERTENS
JI J. Hypertens.
PD JUN
PY 2010
VL 28
SU A
BP E563
EP E563
PG 1
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 665GM
UT WOS:000283023405151
ER
PT J
AU Sullivan, LV
Hicks, P
Salazar, G
Robinson, CK
AF Sullivan, Loretta V.
Hicks, Paul
Salazar, Gilda
Robinson, C. Kelet
TI Patient Beliefs and Sense of Control Among Spanish-Speaking Patients
with Diabetes in Northeast Colorado
SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH
LA English
DT Article
DE Diabetes; Self-management; Health disparities; Latino
ID AMERICANS EXPLANATORY MODEL; NON-HISPANIC WHITES; MEXICAN-AMERICANS;
HEALTH-CARE; ETHNIC-DIFFERENCES; UNITED-STATES; ADULTS; DISEASE
AB Purpose Latinos have higher diabetes prevalence and complication rates with lower use of self-management compared to other populations. This study evaluated perceived barriers to diabetes control among Spanish-speaking only patients in rural Colorado. Methods Thirty-five Spanish-speaking patients with diabetes were randomly sampled and interviewed about their attitudes and beliefs concerning diabetes, self-management activities, and the care they received. Results Patients perceived a high level of control over their diabetes. A minority of patients were adherent to recommended dietary changes or levels of exercise. Use of herbal home remedies to maintain glycemic control was common. Almost half of respondents felt that susto played a role in the development of their diabetes. Three fourths of those testing their glucose felt their physician was not interested in reviewing their blood sugar log. Conclusions Diabetes management programs should recognize the barriers patients may have to self-management and help patients incorporate traditional beliefs into a workable treatment regimen.
C1 [Hicks, Paul] Univ Arizona, Dept Family & Community Med, Tucson, AZ 85719 USA.
[Sullivan, Loretta V.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Sullivan, Loretta V.] Univ Calif Los Angeles, David Geffen Sch Med, Westwood, CA USA.
[Salazar, Gilda; Robinson, C. Kelet] Salud Family Hlth Ctr, Ft Lupton, CO 80621 USA.
RP Hicks, P (reprint author), Univ Arizona, Dept Family & Community Med, 1450 N Cherry Ave, Tucson, AZ 85719 USA.
EM phicks@uph.org
NR 20
TC 6
Z9 6
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1912
J9 J IMMIGR MINOR HEALT
JI J. Immigr. Minor. Health
PD JUN
PY 2010
VL 12
IS 3
BP 384
EP 389
DI 10.1007/s10903-008-9184-9
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 645ZW
UT WOS:000281505700013
PM 19266283
ER
PT J
AU Vanderwerf, S
David, L
Buck, D
Romanelli, R
Neve, K
AF Vanderwerf, S.
David, L.
Buck, D.
Romanelli, R.
Neve, K.
TI Methamphetamine-induced alterations in the proteome of striatal lipid
rafts
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
CT 4th ISN Special Conference on Membrane Domains in CNS Physiology and
Pathology
CY MAY 22-26, 2010
CL Erice, ITALY
SP ISN
C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD JUN
PY 2010
VL 113
SU 1
MA 101
BP 30
EP 30
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 603SV
UT WOS:000278229300102
ER
PT J
AU Sinha, S
Subramanian, S
Emerson-Webber, A
Lindner, M
Burrows, GG
Grafe, M
Linington, C
Vandenbark, AA
Bernard, CCA
Offner, H
AF Sinha, Sushmita
Subramanian, Sandhya
Emerson-Webber, Ashley
Lindner, Maren
Burrows, Gregory G.
Grafe, Marjorie
Linington, Christopher
Vandenbark, Arthur A.
Bernard, Claude C. A.
Offner, Halina
TI Recombinant TCR Ligand Reverses Clinical Signs and CNS Damage of EAE
Induced by Recombinant Human MOG
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Article
DE EAE; MS; recombinant human MOG; CNS damage
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN OLIGODENDROCYTE
GLYCOPROTEIN; MULTIPLE-SCLEROSIS; CYTOKINE SWITCH; MICE; PEPTIDE; CELLS;
PATTERN; PROTEIN; RAT
AB Increasing evidence suggests that in addition to T cell-dependent effector mechanisms, autoantibodies are also involved in the pathogenesis of MS, including demyelinating antibodies specific for myelin oligodendrocyte glycoprotein (MOG). Our previous studies have demonstrated that recombinant T cell receptor ligands (RTLs) are very effective for treating T cell-mediated experimental autoimmune encephalomyelitis (EAE). In order to expand the scope of RTL therapy in MS patients, it was of interest to study RTL treatment of EAE involving a demyelinating antibody component. Therefore, we evaluated the therapeutic effects of RTL551, specific for T cells reactive to mouse (m)MOG-35-55 peptide, on EAE induced with recombinant human (rh)MOG in C57BL/6 mice. We report that RTL551 therapy can reverse disease progression and reduce demyelination and axonal damage induced by rhMOG without suppressing the anti-MOG antibody response. This result suggests that T cell-mediated inflammation and associated blood-brain barrier dysfunction are the central contributors to EAE pathogenesis and that successful regulation of these key players restricts potential damage by demyelinating antibodies. The results of our study lend support for the use of RTL therapy for treatment of MS subjects whose disease includes inflammatory T cells as well as those with an additional antibody component.
C1 [Sinha, Sushmita; Subramanian, Sandhya; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, Portland, OR 97239 USA.
[Sinha, Sushmita; Burrows, Gregory G.; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Emerson-Webber, Ashley; Bernard, Claude C. A.] Monash Univ, Immunol & Stem Cell Labs, Multiple Sclerosis Res Grp, Clayton, Vic 3800, Australia.
[Lindner, Maren; Linington, Christopher] Univ Glasgow, Div Clin Neurosci, Glasgow G12 9PP, Lanark, Scotland.
[Burrows, Gregory G.] Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.
[Burrows, Gregory G.; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Tykeson Multiple Sclerosis Res Lab, Portland, OR 97239 USA.
[Grafe, Marjorie] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA.
[Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
[Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA.
RP Offner, H (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM offnerva@ohsu.edu
OI Linington, Christopher/0000-0002-0937-9526
FU National Multiple Sclerosis Society [FG1749-A-1, RG3794-A-4, RG3468,
RG3844A2/1]; Multiple Sclerosis Society [874/07]; National Institutes of
Health [NS47661, AI43960, NS46877]; Nancy Davis Center Without Walls;
Biomedical Laboratory R&D Service, Department of Veterans Affairs;
National Health and Medical Research Council of Australia; Baker
Foundation; Bellberry Ltd Fund
FX The authors wish to thank Ms. Eva K. Niehaus for assistance in
manuscript preparation. Dr. Sinha is a Postdoctoral Fellow of the
National Multiple Sclerosis Society, and this work was supported in part
by National Multiple Sclerosis Society Postdoctoral Fellowship
FG1749-A-1 and National Multiple Sclerosis Society grants RG3794-A-4,
RG3468, and RG3844A2/1; Multiple Sclerosis Society grant 874/07;
National Institutes of Health grants NS47661, AI43960, and NS46877; The
Nancy Davis Center Without Walls; The Biomedical Laboratory R&D Service,
Department of Veterans Affairs; The National Health and Medical Research
Council of Australia, The Baker Foundation; and the Bellberry Ltd Fund.
NR 22
TC 11
Z9 11
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD JUN
PY 2010
VL 5
IS 2
BP 231
EP 239
DI 10.1007/s11481-009-9175-1
PG 9
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 593CR
UT WOS:000277430100008
PM 19789980
ER
PT J
AU Zhao, SP
Aviles, ER
Fujikawa, DG
AF Zhao, Shuangping
Aviles, Ernesto R., Jr.
Fujikawa, Denson G.
TI Nuclear Translocation of Mitochondrial Cytochrome c, Lysosomal
Cathepsins B and D, and Three Other Death-Promoting Proteins Within the
First 60 Minutes of Generalized Seizures
SO JOURNAL OF NEUROSCIENCE RESEARCH
LA English
DT Article
DE epilepsy; necrosis; programmed cell death
ID PROGRAMMED CELL-DEATH; INDUCED STATUS EPILEPTICUS; INTERNUCLEOSOMAL DNA
CLEAVAGE; APOPTOSIS-INDUCING FACTOR; INDUCED NEURONAL NECROSIS; KAINIC
ACID; FRAGMENTATION; ACTIVATION; MECHANISMS; CASPASE-3
AB We have shown that generalized seizures produce necrotic neurons with caspase-independent nuclear pyknosis and DNA fragmentation. In this study, we determined the time course of translocation of mitochondrial cytochrome c, apoptosis-inducing factor, endonuclease G, lysosomal cathepsins B and D, and DNase II with respect to signs of irreversible neuronal damage. Adult male Wistar rats underwent lithium-pilocarpine-induced seizures lasting for 60 min, 3 hr, and 3 hr with 6- or 24-hr survival periods, after which the brains were prepared for immunofluorescence microscopic examination of piriform cortex. Contrary to expectation, cytochrome c and cathepsins B and D translocated to neuronal nuclei with DNase II, endonuclease G, and apoptosis-inducing factor within 60 min of seizure onset and persisted for 24 hr after 3-hr seizures. After 60-min seizures, some neurons showed translocation of the death-promoting proteins in normal-appearing neurons, prior to their appearance in irreversibly damaged neurons. Western blots of subcellular fractions of cytochrome c and cathepsins B and D confirmed their nuclear translocation. This is the first evidence of nuclear translocation of cathepsins B and D and the first in vivo evidence of nuclear translocation of cytochrome c. The appearance of these mitochondrial proteins and lysosomal enzymes before signs of irreversible neuronal death suggests that they could contribute to seizure-induced nuclear pyknosis and DNA fragmentation. (C) 2010 Wiley-Liss, Inc.dagger
C1 [Zhao, Shuangping; Aviles, Ernesto R., Jr.; Fujikawa, Denson G.] VA Greater Los Angeles Healthcare Syst, Expt Neurol Lab, North Hills, CA 91343 USA.
[Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA.
RP Fujikawa, DG (reprint author), VA Greater Los Angeles Healthcare Syst, Expt Neurol Lab 151B4, 16111 Plummer St, North Hills, CA 91343 USA.
EM dfujikawa@ucla.edu
FU Medical Research Service, Office of Research and Development, Department
of Veterans Affairs
FX Contract grant sponsor: Medical Research Service, Office of Research and
Development, Department of Veterans Affairs.
NR 47
TC 15
Z9 16
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0360-4012
J9 J NEUROSCI RES
JI J. Neurosci. Res.
PD JUN
PY 2010
VL 88
IS 8
BP 1727
EP 1737
DI 10.1002/jnr.22338
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 590RQ
UT WOS:000277245500011
PM 20077427
ER
PT J
AU Hage, FG
Venkataraman, R
Aljaroudi, W
Bravo, PE
McLarry, J
Faulkner, M
Heo, J
Iskandrian, AE
AF Hage, Fadi G.
Venkataraman, Rajesh
Aljaroudi, Wael
Bravo, Paco E.
McLarry, Joel
Faulkner, Michael
Heo, Jaekyeong
Iskandrian, Ami E.
TI The impact of viability assessment using myocardial perfusion imaging on
patient management and outcome
SO JOURNAL OF NUCLEAR CARDIOLOGY
LA English
DT Article
DE Viability; coronary revascularization; myocardial perfusion imaging;
mortality
ID LEFT-VENTRICULAR DYSFUNCTION; CORONARY-ARTERY-BYPASS; ISCHEMIC
CARDIOMYOPATHY; HEART-FAILURE; NONVIABLE MYOCARDIUM; EJECTION FRACTION;
CONTROLLED-TRIAL; TL-201; REVASCULARIZATION; INFARCTION
AB Prior studies show that ischemic cardiomyopathy (ICM) patients with substantial viable myocardium have better survival with coronary revascularization (CR) than medical therapy (MT). When myocardial perfusion imaging (MPI) is used, the analysis is often based on visual scoring. We sought to determine the value of automated quantitative viability analysis in guiding management and predicting outcome.
We identified 246 consecutive ICM patients who had rest-redistribution gated SPECT thallium-201 MPI. Size and severity of perfusion defects were assessed by automated method. Regions with < 50% activity vs normal were considered nonviable. Mortality was verified against the social security death index database.
Of the 246 patients, 37% underwent CR within 3 months of MPI. The initial images showed a total perfusion defect size of 32 +/- A 17%, redistribution of 3.5 +/- A 4.6% and nonviable myocardium of 13 +/- A 14%LV. Using multivariate logistic regression analysis, independent predictors of CR included chest pains (OR 2.74) and rest-delayed transient ischemic dilatation (OR 4.49), while a prior history of CR or ventricular arrhythmias favored MT. The cohort was followed-up for 41 +/- A 30 m during which 111 patients (45%) died. Survival was better with CR than MT (P < .0001). For CR, survival was better for those with a smaller area of nonviable myocardium (risk of death increased by 5%/1% increase in size of nonviable myocardium, P = .009) but this was not seen in MT. CR had a mortality advantage over MT when the area of nonviable myocardium was a parts per thousand currency sign20%LV but not larger.
Automated quantitative analysis of MPI is useful in predicting survival in ICM, but the decision for or against CR is a complex one as it depends on multiple other factors and "viability testing" is just one variable that needs to be incorporated in the decision-making process.
C1 [Hage, Fadi G.; Venkataraman, Rajesh; Aljaroudi, Wael; Heo, Jaekyeong; Iskandrian, Ami E.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA.
[Bravo, Paco E.] Johns Hopkins Univ, Div Nucl Med, Baltimore, MD USA.
[McLarry, Joel; Faulkner, Michael] Univ Alabama, Dept Med, Birmingham, AL 35294 USA.
RP Hage, FG (reprint author), Univ Alabama, Div Cardiovasc Dis, Zeigler Res Bldg 1024,1530 3rd AVE S, Birmingham, AL 35294 USA.
EM fadihage@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
NR 35
TC 15
Z9 15
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-3581
J9 J NUCL CARDIOL
JI J. Nucl. Cardiol.
PD JUN
PY 2010
VL 17
IS 3
BP 378
EP 389
DI 10.1007/s12350-010-9199-1
PG 12
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 594PW
UT WOS:000277550700008
PM 20186583
ER
PT J
AU Reinke, LF
Shannon, SE
Engelberg, R
Dotolo, D
Silvestri, GA
Curtis, JR
AF Reinke, Lynn F.
Shannon, Sarah E.
Engelberg, Ruth
Dotolo, Danae
Silvestri, Gerard A.
Curtis, J. Randall
TI Nurses' Identification of Important yet Under-Utilized End-of-Life Care
Skills for Patients with Life-Limiting or Terminal Illnesses
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID PALLIATIVE CARE; NURSING-EDUCATION; COMMUNICATION; PERSPECTIVES; ILL
AB Rationale: This study was designed to identify nurses' perspectives on nursing skills that are important yet under-utilized in end-of-life care.
Methods: A 45-item survey was administered to nurses (n = 717) in four U. S. states with a response rate of 79%. We identified skills that were endorsed by more than 60% of nurses as extremely important and also endorsed as not currently practiced by more than 25% of nurses. We used Chi square statistics to examine professional characteristics associated with ratings of end-of-life care skills including practice settings, years of experience, and end-of-life care education. Content analysis was used to examine nurses' responses to open-ended questions.
Results: Nineteen items were endorsed as extremely important and also ranked as under-utilized. These end-of-life care skills included communication skills, symptom management competencies especially those concerning anxiety and depression, and issues related to patient-centered care systems. Four complementary themes emerged from qualitative analysis of nurses' comments, which supported the quantitative findings.
Conclusions: This study provides a summary of skills nurses feel are important and under-utilized in their care of patients with life-limiting illnesses. The findings support the need to target both nursing education and healthcare system interventions to improve the use of practical end-of-life care skills by nurses with a focus on communication and symptom management skills.
C1 [Reinke, Lynn F.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA.
[Engelberg, Ruth; Dotolo, Danae; Curtis, J. Randall] Univ Washington, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
[Reinke, Lynn F.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev, Seattle, WA USA.
[Silvestri, Gerard A.] Med Univ S Carolina, Dept Med, Div Pulm & Crit Care Med, Charleston, SC 29425 USA.
RP Reinke, LF (reprint author), Univ Washington, Dept Biobehav Nursing & Hlth Syst, 1959 NE Pacific St, Seattle, WA 98195 USA.
EM reinkl@u.washington.edu
FU Agency for Health Research and Quality [R01 HS11425-02]; National
Institute of Nursing Research [1F31NR010055]; VA Health Services R D
[TPP-61-021]; VA Puget Sound Health Care System, Seattle, Washington
FX Funding was provided by Agency for Health Research and Quality (R01
HS11425-02) and an NRSA from the National Institute of Nursing Research
(1F31NR010055) and Post-Doctoral Fellowship, VA Health Services R & D
(TPP-61-021).; This material is the result of work supported with
resources at the VA Puget Sound Health Care System, Seattle, Washington.
NR 29
TC 20
Z9 21
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD JUN
PY 2010
VL 13
IS 6
BP 753
EP 759
DI 10.1089/jpm.2009.0423
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 619UM
UT WOS:000279455800025
PM 20597709
ER
PT J
AU Horan, WP
Rassovsky, Y
Kern, RS
Lee, J
Wynn, JK
Green, MF
AF Horan, William P.
Rassovsky, Yuri
Kern, Robert S.
Lee, Junghee
Wynn, Jonathan K.
Green, Michael F.
TI Further support for the role of dysfunctional attitudes in models of
real-world functioning in schizophrenia
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Schizophrenia; Negative symptoms; Dysfunctional attitudes; Outcome;
Structural equation modeling; Recovery
ID PSYCHIATRIC RATING-SCALE; NEGATIVE SYMPTOMS; NEUROCOGNITIVE DEFICITS;
COGNITIVE IMPAIRMENT; QUALITY-ASSURANCE; SKILLS; PERFORMANCE; MEDIATOR;
PEOPLE; PERSPECTIVE
AB According to A.T. Beck and colleagues' cognitive formulation of poor functioning in schizophrenia, maladaptive cognitive appraisals play a key role in the expression and persistence of negative symptoms and associated real-world functioning deficits. They provided initial support for this model by showing that dysfunctional attitudes are elevated in schizophrenia and account for significant variance in negative symptoms and subjective quality of life. The current study used structural equation modeling to further evaluate the contribution of dysfunctional attitudes to outcome in schizophrenia. One hundred eleven outpatients and 67 healthy controls completed a Dysfunctional Attitudes Scale, and patients completed a competence measure of functional capacity, clinical ratings of negative symptoms, and interview-based ratings of real-world functioning. Patients reported higher defeatist performance beliefs than controls and these were significantly related to lower functional capacity, higher negative symptoms, and worse community functioning. Consistent with Beck and colleagues' formulation, modeling analyses indicated a significant indirect pathway from functional capacity -> dysfunctional attitudes -> negative symptoms -> real-world functioning. These findings support the value of dysfunctional attitudes for understanding the determinants of outcome in schizophrenia and suggest that therapeutic interventions targeting these attitudes may facilitate functional recovery. Published by Elsevier Ltd.
C1 [Horan, William P.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Horan, WP (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 210A, Los Angeles, CA 90073 USA.
EM horan@ucla.edu
RI Lee, Junghee/C-5226-2014; Wynn, Jonathan/H-3749-2014
OI Lee, Junghee/0000-0001-9567-8700; Wynn, Jonathan/0000-0002-1763-8540
FU National Institute of Mental Health [MH077141, MH43292, MH65707];
Department of Veterans Affairs, Veterans Integrated Service Network 22,
Mental Illness Research Education and Clinical Center
FX This research was supported by Research Grants MH077141 (to W.P.H.),
MH43292 and MH65707 (to M.F.G.) from the National Institute of Mental
Health, and by the Department of Veterans Affairs, Veterans Integrated
Service Network 22, Mental Illness Research Education and Clinical
Center.
NR 38
TC 41
Z9 41
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD JUN
PY 2010
VL 44
IS 8
BP 499
EP 505
DI 10.1016/j.jpsychires.2009.11.001
PG 7
WC Psychiatry
SC Psychiatry
GA 609JW
UT WOS:000278653500003
PM 20006849
ER
PT J
AU Muehlenkamp, JJ
Cowles, ML
Gutierrez, PM
AF Muehlenkamp, Jennifer J.
Cowles, Margaret L.
Gutierrez, Peter M.
TI Validity of the Self-Harm Behavior Questionnaire with Diverse
Adolescents
SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT
LA English
DT Article
DE Self-harm; Adolescents; Assessment; Suicide; Self-injury
ID SUICIDAL-BEHAVIOR; INJURIOUS-BEHAVIOR; LIVING INVENTORY; COMMUNITY
SAMPLE; RISK; INSTRUMENTS; POPULATION; VALIDATION; IDEATION; REASONS
AB Suicide and non-suicidal self-injurious behavior (NSSI) continue to be significant health problems for adolescents. Although there are many instruments available to assess self-harm behaviors, few have been validated for use with adolescents, and even fewer have been validated for use with different racial/ethnic groups. The Self-Harm Behavior Questionnaire (SHBQ) assesses NSSI, suicidal ideation, suicide threats, and past suicide attempts. Data from 1,386 racially/ethnically diverse adolescents (57.5% minority) were collected to examine the validity of the SHBQ in this age group. Analyses supported the four-factor structure, revealed the SHBQ is internally consistent, and provided evidence for convergent validity within Caucasian, African American, and Hispanic adolescents. However, slight differences were noted. Overall, the findings suggest the SHBQ is a useful assessment tool appropriate for use with Caucasian, African American, and Hispanic adolescents.
C1 [Muehlenkamp, Jennifer J.; Cowles, Margaret L.] Univ N Dakota, Dept Psychol, Grand Forks, ND 58282 USA.
[Gutierrez, Peter M.] Denver VA Med Ctr, Denver, CO USA.
RP Muehlenkamp, JJ (reprint author), Univ N Dakota, Dept Psychol, 319 Harvard St,Stop 8380, Grand Forks, ND 58282 USA.
EM jennifer.muehlenkamp@und.edu
OI Gutierrez, Peter/0000-0001-8981-8404
NR 49
TC 12
Z9 12
U1 0
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0882-2689
J9 J PSYCHOPATHOL BEHAV
JI J. Psychopathol. Behav. Assess.
PD JUN
PY 2010
VL 32
IS 2
BP 236
EP 245
DI 10.1007/s10862-009-9131-7
PG 10
WC Psychology, Clinical
SC Psychology
GA 584AO
UT WOS:000276722600009
ER
PT J
AU Ellis, C
Zhao, YM
Egede, LE
AF Ellis, Charles
Zhao, Yumin
Egede, Leonard E.
TI Depression and increased risk of death in adults with stroke
SO JOURNAL OF PSYCHOSOMATIC RESEARCH
LA English
DT Article
DE Depression; Mortality; Stroke
ID POSTSTROKE DEPRESSION; FOLLOW-UP; MAJOR DEPRESSION; MOOD DISORDERS;
ALL-CAUSE; MORTALITY; SYMPTOMS; IMPAIRMENT; COMMUNITY; HEALTH
AB Objective: Depression is a common condition among individuals with stroke and believed to influence post-stroke mortality. The objective of this study was to evaluate the effect of depression on all-cause mortality among adults with and without a history of stroke. Methods: We studied 10,025 participants in the population-based National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study who were alive and interviewed in 1982 and had complete data for the Center for Epidemiologic Studies Depression Scale. Four groups were created based on history of stroke and depression status in 1982: (1) no stroke, no depression (reference group); (2) no stroke, depression present; (3) history of stroke, no depression; and (4) history of stroke present, depression present. Cox proportional hazards regression models were used to calculate multivariate-adjusted hazard ratios (HRs) of death for each group compared with the reference group. Results: Over 8 years (83,624 person-years of follow-up), 1,925 deaths were documented. Mortality rate per 1,000 person-years of follow-up was highest in the group with both a history of stroke and depression. Compared with the reference group, HRs for all-cause mortality were: no stroke, depression present, 1.23 (95% Cl 1.08-1.40); stroke present, no depression 1.74 (1.06-2.85); and stroke present, depression present, 1.88 (1.27-2.79). Conclusions: The coexistence of stroke and depression increases the risk of death; however, the combined effect is less than additive. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Ellis, Charles; Zhao, Yumin; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA.
[Ellis, Charles; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
[Ellis, Charles] Med Univ S Carolina, Dept Hlth Profess, Charleston, SC 29425 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU NIDDK NIH HHS [R01 DK081121, R01 DK081121-02]
NR 35
TC 36
Z9 41
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3999
J9 J PSYCHOSOM RES
JI J. Psychosomat. Res.
PD JUN
PY 2010
VL 68
IS 6
BP 545
EP 551
DI 10.1016/j.jpsychores.2009.11.006
PG 7
WC Psychiatry
SC Psychiatry
GA 606ZO
UT WOS:000278468200006
PM 20488271
ER
PT J
AU Hall, DE
Koenig, HG
Meador, KG
AF Hall, Daniel E.
Koenig, Harold G.
Meador, Keith G.
TI Episcopal Measure of Faith Tradition: A Context-Specific Approach to
Measuring Religiousness
SO JOURNAL OF RELIGION & HEALTH
LA English
DT Article
ID HEALTH RESEARCH; SCALE; SPIRITUALITY; BELIEFS; ORIENTATION; RELIABILITY;
DIMENSIONS; INVENTORY; VALIDITY; ILLNESS
AB Precise measurement of religiousness remains a vexing problem. In addition to relying almost exclusively on self-report, existing measures of religiousness pay little attention to the specific context of religious belief, and this may override distinctive norms of particular faith traditions and potentially confound the conclusions drawn from such research. To address these limitations, the authors describe a modified form of narrative content analysis that could eventually sort respondents into distinct theological traditions. A pilot test among Episcopalians demonstrates encouraging reliability (kappa 0.74, 95% LCI 0.47, P < 0.0002), and tests for convergent and discriminate validity suggest that the context of religious belief is both relevant and insufficiently assessed by the existing paradigm of religious measurements. If validated in a religiously diverse sample, this approach could be combined with existing, context-free measures of religiousness to generate more meaningful findings.
C1 [Hall, Daniel E.] Univ Pittsburgh, Pittsburgh, PA 15213 USA.
[Hall, Daniel E.; Koenig, Harold G.; Meador, Keith G.] Duke Univ, Med Ctr, Durham, NC 27710 USA.
[Meador, Keith G.] Duke Divin Sch, Durham, NC 27708 USA.
[Hall, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Hall, DE (reprint author), Univ Pittsburgh, Suite F-1264 Presbyterian,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM hallde@upmc.edu
RI Koenig, Harold/F-7379-2011; Hall, Daniel/H-4843-2013
OI Hall, Daniel/0000-0001-6382-0522
NR 40
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0022-4197
J9 J RELIG HEALTH
JI J. Relig. Health
PD JUN
PY 2010
VL 49
IS 2
BP 164
EP 178
DI 10.1007/s10943-009-9240-3
PG 15
WC Public, Environmental & Occupational Health; Religion
SC Public, Environmental & Occupational Health; Religion
GA 590CY
UT WOS:000277202800003
PM 19288198
ER
PT J
AU Singh, JA
Noorbaloochi, S
Singh, G
AF Singh, Jasvinder A.
Noorbaloochi, Shahrzad
Singh, Gurkirpal
TI Golimumab for Rheumatoid Arthritis: A Systematic Review
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Review
DE GOLIMUMAB; RHEUMATOID ARTHRITIS; EFFICACY; SAFETY; SYSTEMATIC REVIEW
ID COLLEGE-OF-RHEUMATOLOGY; PATIENT-REPORTED OUTCOMES;
NECROSIS-FACTOR-ALPHA; MONOCLONAL-ANTIBODY; RESPONSE CRITERIA; WORK
DISABILITY; CLINICAL-TRIALS; METHOTREXATE; DISEASE; PROGRESSION
AB Objective. To perform a Cochrane systematic review of benefit (American College of Rheumatology 50% improvement criteria; ACR50) and safety (adverse events and withdrawals) of golimumab in patients with rheumatoid arthritis (RA).
Methods. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), OVID Medline, CINAHL, Embase, Science Citation Index (Web of Science), and Current Controlled Trials databases for randomized or controlled clinical trials of golimumab compared to placebo or disease-modifying antirheumatic drug in adults with RA. Two authors independently selected appropriate studies and abstracted study characteristics and safety and efficacy data and performed risk-of-bias assessment. We calculated mean differences for continuous measures, and relative risks for categorical measures.
Results. Four randomized controlled trials with 1231 golimumab-treated and 483 placebo-treated patients were included. Of these, 436 were treated with golimumab at 50 ma every 4 weeks [a dosage approved by the US Food and Drug Administration (FDA)]. At an average of 4-6 months, compared to patients treated with placebo and methotrexate (MTX), patients treated with the FDA-approved dosage of golimumab and MTX were 2.6 times more likely to reach ACR50 (p = 0.005, 95% CI 1.3, 4.9; absolute percentage, 38% vs 15%) and 0.5 times as likely to have overall withdrawals (p = 0.005, 95% CI 0.3, 0.8; absolute percentage, 5% vs 10%). Golimumab-treated patients were significantly more likely than those taking placebo to achieve remission (22% vs 4%; p<0.00001), and to have improvement in functional ability on the Health Assessment questionnaire 10.2 points lower (p<0.00001, 95% CI 0.25, 0.15); absolute risk difference, 20% (95% CI 25% to 15%); relative percentage difference, 11% (95% CI 14% to 8.3%)]. The studies were too small and short to be powered sufficiently for safety outcomes, but no substantive statistically significant differences were noted between golimumab and placebo regarding adverse events, serious adverse events, infections, serious infections, lung infections, tuberculosis, cancer, withdrawals due to adverse events, and withdrawals due to inefficacy and deaths.
Conclusion. At the approved dosage, in patients with active RA taking background MTX, golimumab is significantly more beneficial than placebo. The short-term safety profile is reasonable. Longterm surveillance studies are needed for safety assessment. (First Release May 1 2010; J Rheumatol 2010;37:1096-104: doi: 10.3899/jrheum.091466)
C1 [Singh, Jasvinder A.] Univ Alabama, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Singh, Jasvinder A.; Noorbaloochi, Shahrzad] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN USA.
[Singh, Jasvinder A.; Noorbaloochi, Shahrzad] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
[Singh, Gurkirpal] Stanford Univ, Sch Med, Div Gastroenterol & Hepatol, Palo Alto, CA 94304 USA.
RP Singh, JA (reprint author), Univ Alabama, 820 Fac Off Tower,Room 805B, Birmingham, AL 35294 USA.
EM jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Abbott; Takeda; Savient; Wyeth; Amgen; Savietu; URL Pharmaceuticals;
Centocor; Johnson Johnson
FX Dr. J.A. Singh has received speaker honoraria from Abbott, research and
travel grants from Takeda, Savient, Wyeth and Amgen, and consultant fees
from Savietu and URL Pharmaceuticals. Dr. G. Singh has received
honoraria/consultant/research grants from Centocor, Abbott, Amgen, and
Johnson & Johnson.
NR 48
TC 11
Z9 11
U1 1
U2 2
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD JUN
PY 2010
VL 37
IS 6
BP 1096
EP 1104
DI 10.3899/jrheum.091466
PG 9
WC Rheumatology
SC Rheumatology
GA 616FO
UT WOS:000279194600005
PM 20436075
ER
PT J
AU Ogdie, A
Schumacher, HR
Dai, L
Chen, LX
Einhorn, E
Pessler, F
AF Ogdie, Alexis
Schumacher, H. Ralph, Jr.
Dai, Lie
Chen, Lan X.
Einhorn, Eugene
Pessler, Frank
TI Synovial Biopsy Findings in Arthritis Associated with Hepatitis C Virus
Infection
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Letter
ID WAR-VETERANS-ILLNESS; RHEUMATOID-ARTHRITIS; JOINT PAIN; OSTEOARTHRITIS;
ARTHROPATHIES; ANGIOGENESIS
C1 [Pessler, Frank] Tech Univ Dresden, Univ Childrens Hosp, Dresden, Germany.
[Pessler, Frank] Helmholtz Ctr Infect Res, Braunschweig, Germany.
[Ogdie, Alexis] Univ Penn, Sch Med, Dept Internal Med, Philadelphia, PA 19104 USA.
[Schumacher, H. Ralph, Jr.; Dai, Lie; Chen, Lan X.] Philadelphia VA Med Ctr, Div Rheumatol, Philadelphia, PA USA.
[Schumacher, H. Ralph, Jr.; Dai, Lie] Sun Yat Sen Univ, Affiliated Hosp 2, Guangzhou 510275, Guangdong, Peoples R China.
[Chen, Lan X.] Univ Penn, Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA.
[Einhorn, Eugene] Philadelphia VA Med Ctr, Dept Pathol, Philadelphia, PA USA.
RP Pessler, F (reprint author), Tech Univ Dresden, Univ Childrens Hosp, Dresden, Germany.
EM frank.pessler@helmholtz-hzi.de
OI Ogdie, Alexis/0000-0002-4639-0775
FU NCI NIH HHS [T32-CA 09140]; NIAMS NIH HHS [T32-AR 007442]
NR 14
TC 2
Z9 2
U1 0
U2 1
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD JUN
PY 2010
VL 37
IS 6
BP 1361
EP 1363
DI 10.3899/jrheum.091309
PG 3
WC Rheumatology
SC Rheumatology
GA 616FO
UT WOS:000279194600283
PM 20516045
ER
PT J
AU Mohamed, OA
Hamed, HA
Roaiah, MF
Helmy, T
Mahran, A
Bennett, CJ
AF Mohamed, Osama A.
Hamed, Hamed A.
Roaiah, Mohamed Farid
Helmy, Tarek
Mahran, Ali
Bennett, Carol J.
TI Correlation Between the European System for Cardiac Operative Risk
Evaluation and Sexual Function After Coronary Artery Bypass Graft
Surgery
SO JOURNAL OF SEXUAL MEDICINE
LA English
DT Article
DE Erectile Dysfunction; Vascular Risk Factors; Coronary Artery Bypass
Grafting; EuroSCORE
ID VASCULOGENIC ERECTILE DYSFUNCTION; OBSTRUCTIVE PULMONARY-DISEASE;
EUROSCORE ADDITIVE-MODEL; STRATIFICATION ANALYSIS; SILDENAFIL CITRATE;
HEART-SURGERY; PREVALENCE; PREDICTOR; MORTALITY; IMPOTENCE
AB Introduction.
The published studies discussing the prognostic factors for expected sexual function after coronary artery bypass graft (CABG) are still limited.
Aim.
Examining the correlation between the European System for Cardiac Operative Risk Evaluation (EuroSCORE) and the abridged form of International Index of Erectile Function questionnaire (IIEF-5), as a quick and inexpensive tool for the cardiologist to predict the sexual function after CABG.
Main Outcome Measures.
Validated standardized questionnaire commonly used by cardiologists in identifying appropriate weight to various risk factors related to adult cardiac operations.
Methods.
Preoperatively patients were evaluated as regards to the sexual function by (IIEF-5) and pharmaco-penile duplex ultrasound. Moreover all patients were evaluated bu EuroSCORE. Six months after surgery, the erectile function of all patients was revaluated according to the same preoperative procedures. The patients were categorized with EuroSCORE as follows: The low-risk group (EuroSCORE 0-2), the medium-risk group (EuroSCORE 3-5), and the high-risk group (EuroSCORE 6 plus).
Results.
The EuroSCORE was negatively correlated with the IIEF-5 score (r = -0.224, P = 0.025 or rs = -0.259, P = 0.009). Moreover, low-risk patients had significantly higher IIEF-5 scores compared with medium-risk patients (mean +/- standard deviation = 15.27 +/- 6.03 vs. 12.18 +/- 6.07, P < 0.05).
Conclusions.
There is an inverse correlation between the components of EuroSCORE and the IIEF-5 score. Patients with higher EuroSCORE had lower IIEF-5 scores and vice versa.The EuroSCORE is a useful, quick, and inexpensive tool that allows prediction of ED in those patients with coronary artery disease patients who are undergoing CABG. Mohamed OA, Hamed HA, Roaiah MF, Helmy T, Mahran A, and Bennett CJ. Correlation between the European System for Cardiac Operative Risk Evaluation and sexual function after coronary artery bypass graft surgery. J Sex Med 2010;7:2158-2165.
C1 [Mohamed, Osama A.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.
[Mohamed, Osama A.; Hamed, Hamed A.; Roaiah, Mohamed Farid] Cairo Univ, Fac Med, Androl & STDS Dept, Cairo, Egypt.
[Helmy, Tarek] Cairo Univ, Fac Med, Cardiothorac Dept, Cairo, Egypt.
[Mahran, Ali] Asyut Univ, Fac Med, Androl Dept, Asyut, Egypt.
[Bennett, Carol J.] Greater Los Angeles VA Med Syst, Urol, Los Angeles, CA USA.
[Bennett, Carol J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Mohamed, OA (reprint author), Baylor Coll Med, Scott Dept Urol, 6560 Fannin St, Houston, TX 77030 USA.
EM azimusama@gmail.com
NR 50
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1743-6095
J9 J SEX MED
JI J. Sex. Med.
PD JUN
PY 2010
VL 7
IS 6
BP 2158
EP 2165
DI 10.1111/j.1743-6109.2010.01727.x
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 604XF
UT WOS:000278311100019
PM 20954293
ER
PT J
AU Bauman, WA
Kirshblum, S
Cirnigliaro, C
Forrest, GF
Spungen, AM
AF Bauman, William A.
Kirshblum, Steven
Cirnigliaro, Christopher
Forrest, Gail F.
Spungen, Ann M.
TI Underestimation of Bone Loss of the Spine With Posterior-Anterior
Dual-Energy X-Ray Absorptiometry in Patients With Spinal Cord Injury
SO JOURNAL OF SPINAL CORD MEDICINE
LA English
DT Article
DE Spinal cord injuries; Paraplegia; Tetraplegia; Bone mineral density;
Vertebral body; Dual-energy X-ray absorptiometry; Osteoporosis
ID QUANTITATIVE COMPUTED-TOMOGRAPHY; LOWER-EXTREMITY FRACTURES; MINERAL
DENSITY; LUMBAR SPINE; OSTEOPOROSIS; DENSITOMETRY; DEMINERALIZATION;
DISEASE; WOMEN
AB Background: Bone mineral density (BMD) of the lumbar spine (L-spine) has been reported to be normal by routine posterior-anterior (PA) bone density imaging in patients with chronic spinal cord injury (SCI).
Objective: To determine BMD of the L-spine by PA and lateral (LAT) dual-energy radiographic absorptiometry (DXA) in patients with chronic SCI.
Design: Prospective study.
Setting: Veterans Affairs Medical Center and a private rehabilitation facility.
Methods: Measurements of the PA and LAT L-spine and hip were performed in 15 patients with SCI: 9 with tetraplegia and 6 with paraplegia. The DXA (GE Lunar Advance DXA) images were obtained using standard software. Results are reported as mean +/- SD.
Results: The mean age was 35 +/- 15 years (range = 20-62 years), and the duration of injury was 57 +/- 74 months (range = 3-240 months). T- and Z-scores were lower for the LAT L-spine than those for PA L-spine (T-scores L2: -0.7 +/- 1.2 vs 0.0 +/- 1.4, P < 0.01; L3: -0.9 +/- 1.6 vs 0.3 +/- 1.3, P < 0.002; L2-L3: -0.8 +/- 1.3 vs 0.2 +/- 1.3, P < 0.001; Z-scores L2: -0.3 +/- 1.1 vs 0.2 +/- 1.2, P < 0.05; L3: -0.6 +/- 1.3 vs 0.5 +/- 1.3, P < 0.01; L2-L3: -0.4 +/- 1.1 vs 0.4 +/- 1.2, P < 0.005). The T- and Z-scores for the total hip (-1.1 +/- 1.0 and -1.0 +/- 1.0, respectively) and L2-L3 LAT L-spine demonstrated remarkable similarity, whereas the L2-L3 PA L-spine scores were not reduced. Bone mineral density of the LAT L-spine, but not the PA L-spine, was significantly reduced with increasing duration of injury.
Conclusions: Individuals with SCI may have bone loss of the L-spine that is evident on LAT DXA that may be misdiagnosed by PA DXA, underestimating the potential risk of fracture.
C1 [Bauman, William A.] James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Med Serv, Bronx, NY 10468 USA.
[Bauman, William A.; Cirnigliaro, Christopher; Spungen, Ann M.] Vet Affairs Rehabil Res & Dev Ctr Excellence Med, Bronx, NY USA.
[Bauman, William A.; Cirnigliaro, Christopher; Spungen, Ann M.] James J Peters Vet Affairs Med Ctr, Spinal Cord Injury Serv, Bronx, NY 10468 USA.
[Bauman, William A.; Cirnigliaro, Christopher; Spungen, Ann M.] James J Peters Vet Affairs Med Ctr, Res Serv, Bronx, NY 10468 USA.
[Bauman, William A.; Spungen, Ann M.] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA.
[Bauman, William A.; Spungen, Ann M.] Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA.
[Kirshblum, Steven] Kessler Inst Rehabil, W Orange, NJ USA.
[Kirshblum, Steven; Forrest, Gail F.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA.
[Kirshblum, Steven; Forrest, Gail F.] Kessler Fdn Res Ctr, W Orange, NJ USA.
RP Bauman, WA (reprint author), James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Med Serv, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM william.bauman@va.gov
FU VA Rehabilitation Research and Development Service Center of Excellence
for the Medical Consequences of Spinal Cord Injury [B4162C]; James J.
Peters VA Medical Center; Department of Veterans Affairs Rehabilitation
Research and Development Service; Kessler Institute for Rehabilitation;
Kessler Foundation Research Center; Centers for Disease Control and
Prevention; Christopher and Dana Reeve Foundation
FX This work was funded by a VA Rehabilitation Research and Development
Service Center of Excellence for the Medical Consequences of Spinal Cord
Injury grant (B4162C).; We thank the James J. Peters VA Medical Center,
Department of Veterans Affairs Rehabilitation Research and Development
Service, Kessler Institute for Rehabilitation, Kessler Foundation
Research Center, Centers for Disease Control and Prevention, and the
Christopher and Dana Reeve Foundation for their support.
NR 20
TC 7
Z9 8
U1 0
U2 1
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 1079-0268
EI 2045-7723
J9 J SPINAL CORD MED
JI J. Spinal Cord. Med.
PD JUN
PY 2010
VL 33
IS 3
BP 214
EP 220
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 639WQ
UT WOS:000281007700003
PM 20737794
ER
PT J
AU Ling, W
Jacobs, P
Hillhouse, M
Hasson, A
Thomas, C
Freese, T
Sparenborg, S
McCarty, D
Weiss, R
Saxon, A
Cohen, A
Straus, M
Brigham, G
Liu, D
McLaughlin, P
Tai, B
AF Ling, Walter
Jacobs, Petra
Hillhouse, Maureen
Hasson, Albert
Thomas, Christie
Freese, Thomas
Sparenborg, Steven
McCarty, Dennis
Weiss, Roger
Saxon, Andrew
Cohen, Allan
Straus, Michele
Brigham, Gregory
Liu, David
McLaughlin, Paul
Tai, Betty
TI From research to the real world: Buprenorphine in the decade of the
Clinical Trials Network
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Buprenorphine; CTN; Clinical Trials Network; Opioids; Opiate dependence;
Pharmacotherapy
ID SUBSTANCE-ABUSE TREATMENT; OPIOID DEPENDENCE; RANDOMIZED-TRIAL;
ADOPTION; DETOXIFICATION; NALOXONE; ADDICTION
AB The National Institute on Drug Abuse (NIDA) established the National Drug Abuse Treatment Clinical Trials Network (CTN) in 1999 to bring researchers and treatment providers together to develop a clinically relevant research agenda. Initial CTN efforts addressed the use of buprenorphine, a mu-opioid partial agonist, as treatment for opioid dependence. Strong evidence of buprenorphine's therapeutic efficacy was demonstrated in clinical trials involving several thousand opioid-dependent participants, and in 2002, the Food and Drug Administration approved buprenorphine for the treatment of opioid dependence. With the advent of a sublingual tablet containing both buprenorphine and naloxone to mitigate abuse and diversion (Suboxone), buprenorphine appeared poised to be the first-line treatment for opioid addiction. Notwithstanding its many attributes, certain implementation barriers remained to be addressed in CTN studies, and these efforts have brought a body of knowledge on buprenorphine to frontline clinicians. The purpose of this article is to review CTN-based buprenorphine research and related efforts to overcome challenges to the implementation of buprenorphine therapy in mainstream practice. Furthermore, this article explores current issues and future challenges that may require additional CTN efforts. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Ling, Walter; Hillhouse, Maureen; Hasson, Albert; Thomas, Christie; Freese, Thomas] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
[Jacobs, Petra; Sparenborg, Steven; Straus, Michele; Liu, David; Tai, Betty] Natl Inst Drug Abuse, NIDA CCTN, Ctr Clin Trials Network, Lexington, KY USA.
[McCarty, Dennis] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Weiss, Roger] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Saxon, Andrew] Vet Affairs Puget Sound Hlth Care Syst, Washington Reg Node, Washington, DC USA.
RP Hillhouse, M (reprint author), Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
EM hillhous@ucla.edu
OI Brigham, Gregory/0000-0003-1150-4493
FU NIDA NIH HHS [U10 DA015831, K24 DA022288, K24DA022288, U10 DA 13036, U10
DA 13045, U10 DA013045, U10 DA013045-09, U10 DA013045-10, U10 DA13732,
U10 DA15831]
NR 30
TC 22
Z9 22
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD JUN
PY 2010
VL 38
IS 4
SU 1
BP S53
EP S60
DI 10.1016/j.jsat.2010.01.009
PG 8
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 595AG
UT WOS:000277582500006
PM 20307796
ER
PT J
AU Wells, EA
Saxon, AJ
Calsyn, DA
Jackson, TR
Donovan, DM
AF Wells, Elizabeth A.
Saxon, Andrew J.
Calsyn, Donald A.
Jackson, Thomas R.
Donovan, Dennis M.
TI Study results from the Clinical Trials Network's first 10 years: Where
do they lead?
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Clinical trials; Substance abuse treatment; Effectiveness research
ID SUBSTANCE-ABUSE TREATMENT; MOTIVATIONAL ENHANCEMENT THERAPY; ADAPTIVE
TREATMENT STRATEGIES; MULTISITE RANDOMIZED-TRIAL; RISK REDUCTION GROUPS;
DRUG-ABUSE; TREATMENT PROGRAMS; BUPRENORPHINE-NALOXONE; BEHAVIORAL
THERAPIES; SMOKING-CESSATION
AB The National Drug Abuse Treatment Clinical Trials Network (CTN) began in 2000 with the goal of "improv[ing] the quality of drug abuse treatment throughout the country using science as the vehicle." Since then, 24 discrete clinical trials were launched, 20 are completed, and 15 have published main outcome papers. Of the latter, 4 tested pharmacological treatment, 8 psychosocial/behavioral treatment, 1 a combination of medication and counseling, and 2 targeted HIV/hepatitis C virus risk behavior. We review main study findings for these trials, including treatment retention, substance use or risk behavior outcomes, and secondary outcomes when analyzed. The purpose of this review is to identify the incremental progress toward improving drug treatment made by these trials and to propose next steps for the CTN and for the field arising from these studies. The CTN provides a unique opportunity to systematically design trials that incorporate treatment improvements from previous trials and to direct efforts toward innovations most likely to be incorporated into practice. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Wells, Elizabeth A.; Jackson, Thomas R.] Univ Washington, Sch Social Work, Seattle, WA 98105 USA.
[Saxon, Andrew J.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA.
[Calsyn, Donald A.; Donovan, Dennis M.] Inst Alcohol & Drug Abuse, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA.
[Jackson, Thomas R.] Evergreen Treatment Serv, Seattle, WA 98134 USA.
RP Wells, EA (reprint author), Univ Washington, Sch Social Work, 4101 15th Ave NE, Seattle, WA 98105 USA.
EM bwells@u.washington.edu
FU NIDA NIH HHS [5U10 DA013714, U10 DA013714, U10 DA013714-08]
NR 52
TC 17
Z9 17
U1 3
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD JUN
PY 2010
VL 38
IS 4
SU 1
BP S14
EP S30
DI 10.1016/j.jsat.2009.12.009
PG 17
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 595AG
UT WOS:000277582500003
PM 20307792
ER
PT J
AU Dille, MF
Konrad-Martin, D
Gallun, F
Helt, WJ
Gordon, JS
Reavis, KM
Bratt, GW
Fausti, SA
AF Dille, Marilyn F.
Konrad-Martin, Dawn
Gallun, Frederick
Helt, Wendy J.
Gordon, Jane S.
Reavis, Kelly M.
Bratt, Gene W.
Fausti, Stephen A.
TI Tinnitus Onset Rates from Chemotherapeutic Agents and Ototoxic
Antibiotics: Results of a Large Prospective Study
SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY
LA English
DT Article
DE Ototoxicity; ototoxicity monitoring; tinnitus; veterans
ID CISPLATIN-INDUCED OTOTOXICITY; INDUCED HEARING-LOSS; QUALITY-OF-LIFE;
TESTICULAR CANCER; RISK-FACTORS; RANGE
AB Background and Purpose: To report on the incidence and relative risk of tinnitus onset from a variety of drug therapies known to be ototoxic. Two main questions were asked: (1) What is the prevalence and incidence of tinnitus among patients treated with cisplatin, carboplatin, or-ototoxic antibiotic therapies? (2) Do commonly reported treatment or subject factors confound or modify the incidence of tinnitus onset?
Data Collection and Analysis: A prospective observational study design was used to evaluate occurrence of significant otologic changes in 488 veterans (962 ears) receiving chemotherapeutic agents (cisplatin, carboplatin), ototoxic antibiotics (primarily aminoglycoside), or nonototoxic drugs (control medications). A subset of 260 veterans lacking tinnitus prior to drug exposure was used to compare rates of tinnitus onset. Subjects were tested prior to, during, and following their treatment. Planned comparisons using logistic regression, analysis of variance (ANOVA), and chi(2) statistics were made among groups by the type of medication taken, age, presence of preexisting hearing loss, days on drug, and cumulative dose of drug.
Results: Baseline tinnitus rates were high (nearly 47%) relative to the general population of a similar age. Subjects with exposure to ototoxic medications had significantly increased risk for developing tinnitus. Those on chemotherapeutic agents were found to have the greatest risk. Cisplatin elevated the risk by 5.53 times while carboplatin increased the risk by 3.75 over nonototoxic control medications. Ototoxic antibiotics resulted in borderline risk (2.81) for new tinnitus. Contrary to other reports, we did not find that subject factors (increased age or pre-existing hearing loss) or treatment factors (days on drug or cumulative dose) contributed to rates of tinnitus onset during treatment.
Conclusions: This large prospective study confirms that new tinnitus during treatment is associated with chemotherapy and with certain ototoxic antibiotic treatment. Cisplatin and carboplatin were found to be the most potent ototoxic agents causing tinnitus at much greater numbers than the other drugs studied. Implications for counseling and audiological resource allocation are discussed.
C1 [Dille, Marilyn F.; Konrad-Martin, Dawn; Gallun, Frederick; Helt, Wendy J.; Gordon, Jane S.; Fausti, Stephen A.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res, Portland, OR USA.
[Dille, Marilyn F.; Konrad-Martin, Dawn; Gallun, Frederick; Fausti, Stephen A.] Oregon Hlth & Sci Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA.
[Reavis, Kelly M.] Univ Calif Irvine, Dept Otolaryngol, Irvine, CA 92717 USA.
[Bratt, Gene W.] Vanderbilt Univ, Dept Otolaryngol, Sch Med, Nashville, TN USA.
RP Dille, MF (reprint author), 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM marilyn.dille@va.gov
RI Gallun, Frederick/G-3792-2012
OI Gallun, Frederick/0000-0002-4145-2199; Reavis, Kelly/0000-0002-4906-1010
FU Rehabilitation Research and Development Service (RR&D), Department of
Veterans Affairs [C4183R, C3213R, C2346R, C4447K]
FX This work was supported by grants from the Rehabilitation Research and
Development Service (RR&D), Department of Veterans Affairs (C4183R,
C3213R, C2346R, and C4447K).
NR 24
TC 19
Z9 20
U1 0
U2 4
PU AMER ACAD AUDIOLOGY
PI RESTON
PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA
SN 1050-0545
J9 J AM ACAD AUDIOL
JI J. Am. Acad. Audiol.
PD JUN
PY 2010
VL 21
IS 6
BP 409
EP 417
DI 10.3766/jaaa.21.6.6
PG 9
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 637DP
UT WOS:000280796300006
PM 20701838
ER
PT J
AU Fink, AS
Prochazka, AV
Henderson, WG
Bartenfeld, D
Nyirenda, C
Webb, A
Berger, DH
Itani, K
Whitehill, T
Edwards, J
Wilson, M
Karsonovich, C
Parmelee, P
AF Fink, Aaron S.
Prochazka, Allan V.
Henderson, William G.
Bartenfeld, Debra
Nyirenda, Carsie
Webb, Alexandra
Berger, David H.
Itani, Kamal
Whitehill, Thomas
Edwards, James
Wilson, Mark
Karsonovich, Cynthia
Parmelee, Patricia
TI Predictors of Comprehension during Surgical Informed Consent
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article; Proceedings Paper
CT 95th Annual Clinical Congress of the American-College-of-Surgeons/64th
Annual Sessions of the Owen H Wangensteen Forum on Fundamental Surgical
Problems
CY OCT 11-15, 2009
CL Chicago, IL
SP Amer Coll Surg
ID LITERACY SKILLS; HEALTH LITERACY; PATIENT RECALL; SHORT-FORM;
INFORMATION; ANXIETY; TRIALS; INTERVENTIONS; COMMUNICATION; VOLUNTEERS
AB BACKGROUND: Patient comprehension during surgical informed consent remains problematic. Using data from our randomized trial of methods to improve informed consent comprehension, we performed an additional analysis to define independent factors associated with improved patient understanding.
STUDY DESIGN: Patients scheduled for 1 of 4 elective operations (total hip arthroplasty [n = 137], carotid endarterectomy [n = 178], laparoscopic cholecystectomy [n = 179], or radical prostatectomy [n = 81]) at 7 Department of Veterans Affairs (VA) medical centers were enrolled. All informed consent discussions were performed using iMedConsent (Dialog Medical), the VA's computerized informed consent platform. Using a unique module within iMedConsent, we randomized patients to repeat back (RB), requiring correct reiteration of procedure-specific facts, or standard (STD) iMedConsent. Patient comprehension was tested after the informed consent discussion using procedure-specific questionnaires. Time spent completing the informed consent process was measured using time stamps within iMedConsent. Multiple linear regression identified factors independently associated with improved comprehension.
RESULTS: We enrolled 575 patients (276 RB, 299 standard); 93% were male, 74% were Caucasian, and 89% had at least a high school education. Independent factors associated with improved comprehension included race (p < 0.01), ethnicity (p < 0.05), age (p < 0.02), operation type (p < 0.01), group assignment (+/- RB; p < 0.05), and total consent time (p < 0.0001). Patient comprehension was maximized when informed consent took between 15 and 30 minutes. RB's positive impact on patient comprehension was weaker in the analysis including consent time.
CONCLUSIONS: Comprehension during informed consent discussions may be limited in individuals with potential language difficulty due to ethnicity or education. Total consent time was the strongest predictor of patient comprehension. Affording adequate time for informed consent discussions and using informed consent adjuncts such as RB may enhance comprehension in such individuals. (J Am Coll Surg 2010;210:919-926. (C) 2010 by the American College of Surgeons)
C1 [Fink, Aaron S.; Bartenfeld, Debra; Webb, Alexandra] VAMC Atlanta, Decatur, GA 30033 USA.
[Fink, Aaron S.; Webb, Alexandra] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA.
[Prochazka, Allan V.] Denver VAMC, Denver, CO USA.
[Prochazka, Allan V.; Henderson, William G.; Nyirenda, Carsie] Univ Colorado, Hlth Outcomes Program, Denver, CO 80202 USA.
[Berger, David H.] Baylor Coll Med, Michael DeBakey VAMC, Houston, TX 77030 USA.
[Berger, David H.] Baylor Coll Med, Michael DeBakey Dept Surg, Houston, TX 77030 USA.
[Itani, Kamal] Boston Univ, Boston VAMC, Boston, MA 02215 USA.
[Itani, Kamal] Boston Univ, Dept Surg, Boston, MA 02215 USA.
[Itani, Kamal] Harvard Univ, Sch Med, Boston, MA USA.
[Whitehill, Thomas] Univ Colorado, Denver VAMC, Denver, CO 80202 USA.
[Whitehill, Thomas] Univ Colorado, Dept Surg, Denver, CO 80202 USA.
[Edwards, James] Oregon Hlth & Sci Univ, Portland VAMC, Portland, OR 97201 USA.
[Edwards, James] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA.
[Wilson, Mark] Univ Pittsburgh, Med Ctr, Pittsburgh VAMC, Pittsburgh, PA USA.
[Wilson, Mark] Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA USA.
[Karsonovich, Cynthia] Univ S Florida, Tampa VAMC, Tampa, FL USA.
[Karsonovich, Cynthia] Univ S Florida, Dept Surg, Tampa, FL USA.
[Parmelee, Patricia] Univ Alabama, Dept Psychol, Tuscaloosa, AL 35487 USA.
RP Fink, AS (reprint author), VAMC Atlanta, 112,1670 Clairmont Rd, Decatur, GA 30033 USA.
EM aaron.fink@va.gov
NR 48
TC 36
Z9 37
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2010
VL 210
IS 6
BP 919
EP 926
DI 10.1016/j.jamcollsurg.2010.02.049
PG 8
WC Surgery
SC Surgery
GA 609IH
UT WOS:000278649100005
PM 20510800
ER
PT J
AU Kelley, AS
Wenger, NS
Sarkisian, CA
AF Kelley, Amy S.
Wenger, Neil S.
Sarkisian, Catherine A.
TI Opiniones: End-of-Life Care Preferences and Planning of Older Latinos
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE advance care planning; Latino; Hispanic; medical decision-making
ID ETHNIC-DIFFERENCES; DECISION-MAKING; HEALTH-CARE; ATTITUDES;
ACCULTURATION; COMPLETION; PHYSICIANS; AMERICANS; AUTONOMY; TRIAL
AB OBJECTIVES: To measure end-of-life (EOL) care preferences and advance care planning (ACP) in older Latinos and to examine the relationship between culture-based attitudes and extent of ACP.
DESIGN: Cross-sectional interview.
SETTING: Twenty-two senior centers in greater Los Angeles.
PARTICIPANTS: One hundred forty-seven Latinos aged 60 and older.
MEASUREMENTS: EOL care preferences, extent of ACP, attitudes regarding patient autonomy, family-centered decision-making, trust in healthcare providers, and health and sociodemographic characteristics.
RESULTS: If seriously ill, 84% of participants would prefer medical care focused on comfort rather than care focused on extending life, yet 47% had never discussed such preferences with their family or doctor, and 77% had no advance directive. Most participants favored family-centered decision making (64%) and limited patient autonomy (63%). Greater acculturation, education, and desire for autonomy were associated with having an advance directive (P-values < .03). Controlling for sociodemographic characteristics, greater acculturation (adjusted odds ratio (AOR) 51.6, 95% confidence interval (CI) = 1.1-2.4) and preferring greater autonomy (AOR = 1.6, 95% CI = 1.1-2.3) were independently associated with having an advance directive.
CONCLUSIONS: The majority of older Latinos studied preferred less-aggressive, comfort-focused EOL care, yet few had documented or communicated this preference. This discrepancy places older Latinos at risk of receiving high-intensity care inconsistent with their preferences. J Am Geriatr Soc 58: 1109-1116, 2010.
C1 [Kelley, Amy S.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA.
[Wenger, Neil S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Wenger, Neil S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
[Sarkisian, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA.
[Sarkisian, Catherine A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
RP Kelley, AS (reprint author), 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA.
EM amy.kelley@mssm.edu
FU University of California at Los Angeles John A. Hartford Center of
Excellence in Geriatric Medicine; HRSA Institutional National Research
Service Award [T32HP19001]; National Institute on Aging [RO1-AG02446005]
FX Funding support for this project was provided by the University of
California at Los Angeles John A. Hartford Center of Excellence in
Geriatric Medicine, the HRSA Institutional National Research Service
Award T32HP19001, and a grant from the National Institute on Aging
(RO1-AG02446005). This research was presented as a poster at the
national meeting of the American Geriatrics Society on April 30, 2009,
and an oral presentation at the national meeting of the Society for
General Internal Medicine on May 15, 2009.
NR 30
TC 33
Z9 33
U1 3
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2010
VL 58
IS 6
BP 1109
EP 1116
DI 10.1111/j.1532-5415.2010.02853.x
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 604WO
UT WOS:000278309400013
PM 20487080
ER
PT J
AU Smith, AL
Wang, PC
Anger, JT
Mangione, CM
Trejo, L
Rodriguez, LV
Sarkisian, CA
AF Smith, Ariana L.
Wang, Pin-Chieh
Anger, Jennifer T.
Mangione, Carol M.
Trejo, Laura
Rodriguez, Larissa V.
Sarkisian, Catherine A.
TI Correlates of Urinary Incontinence in Community-Dwelling Older Latinos
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE urinary incontinence; epidemiology; Latino; prevalence; aging
ID NURSING-HOME RESIDENTS; RISK-FACTORS; CLINICAL RESEARCH; UNITED-STATES;
SHORT-FORM; US WOMEN; PREVALENCE; QUESTIONNAIRE; POPULATION; ADULTS
AB The prevalence of urinary incontinence (UI) has varied in the literature and is reflective of the definition and sampling methodologies used, as well as the age, ethnicity, and sex being studied. The aim of the current study was to measure the prevalence and correlates of UI in a sample of 572 older Latinos participating in Caminemos, a trial of a behavioral intervention to increase walking. Participants completed an in-person survey and physical performance measures. UI was measured using the International Consultation on Incontinence item: "How often do you leak urine?" Potential correlates of UI included sociodemographic variables, body mass index, smoking, physical activity, medical comorbidity, physical performance, activity of daily living (ADL) impairment, use of assistive ambulatory devices, health-related quality of life (HRQoL), and depressive symptoms. The prevalence of UI in this sample was 26.9%. Women were more likely to report UI, as were those who were less physically active; used assistive ambulatory devices; and had depressive symptoms, greater medical comorbidity, worse physical performance, greater ADL impairment, worse cognitive function, and lower HRQoL. Multivariate logistic regression revealed that medical comorbidity was independently associated with higher rates of UI (odds ratio (OR) = 1.66, 95% confidence interval (CI) = 1.30-2.12), whereas better cognitive function (OR = 0.73, 95% CI = 0.57-0.93) and higher weighted physical activity scores (OR= 0.77, 95% CI = 0.60-0.98) were independently associated with lower rates of UI. UI is highly prevalent but not ubiquitous among community-residing older Latinos, suggesting that UI is not an inevitable consequence of aging. Future studies should examine whether interventions that decrease comorbidity and cognitive decline and increase physical activity improve continence status. J Am Geriatr Soc 58: 1170-1176, 2010.
C1 [Smith, Ariana L.] Univ Penn, Div Urol, Sch Med, Philadelphia, PA 19106 USA.
[Wang, Pin-Chieh] Univ Calif Los Angeles, David Geffen Sch Med, Dept Epidemiol, Los Angeles, CA 90095 USA.
[Anger, Jennifer T.; Rodriguez, Larissa V.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.
[Mangione, Carol M.; Sarkisian, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Trejo, Laura] Dept Aging, Los Angeles, CA USA.
[Sarkisian, Catherine A.] Geriatr Res Educ Clin Ctr, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Smith, AL (reprint author), Univ Penn, Div Urol, Sch Med, 299 S 8th St, Philadelphia, PA 19106 USA.
EM ariana.smith@uphs.upenn.edu
FU National Institute on Aging (NIA) [RO1-AG02446005]; Resource Centers for
Minority Aging Research/Center for Health Improvement of Minority
Elderly (RCMAR/CHIME) [P30 AG021684]; University of California at Los
Angeles Older Americans Independence Center [5 P30 AG028748]; Trial to
Increase Walking among Sedentary Older Latinos [RO1 AG024460]; National
Institutes of Health/NIA
FX Drs. Sarkisian and Mangione were supported by the National Institute on
Aging (NIA) (RO1-AG02446005). Dr. Mangione received support from the
Resource Centers for Minority Aging Research/Center for Health
Improvement of Minority Elderly (RCMAR/CHIME) (P30 AG021684), from the
University of California at Los Angeles Older Americans Independence
Center (5 P30 AG028748), and from the Trial to Increase Walking among
Sedentary Older Latinos (RO1 AG024460), all funded by the National
Institutes of Health/NIA.
NR 39
TC 14
Z9 18
U1 8
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2010
VL 58
IS 6
BP 1170
EP 1176
DI 10.1111/j.1532-5415.2010.02814.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 604WO
UT WOS:000278309400022
PM 20406311
ER
PT J
AU Hutt, E
Radcliff, TA
Oman, KS
Fink, R
Ruscin, JM
Linnebur, S
Fish, D
Liebrecht, D
Fish, R
McNulty, M
AF Hutt, Evelyn
Radcliff, Tiffany A.
Oman, Kathleen S.
Fink, Regina
Ruscin, J. Mark
Linnebur, Sunny
Fish, Doug
Liebrecht, Debra
Fish, Ron
McNulty, Monica
TI Impact of NHAP Guideline Implementation Intervention on Staff and
Resident Vaccination Rates
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Influenza vaccination; nursing home staff vaccination; pneumococcal
vaccination
ID LONG-TERM-CARE; HOME-ACQUIRED PNEUMONIA; MINIMUM DATA SET; NURSING-HOME;
PNEUMOCOCCAL PNEUMONIA; INFLUENZA IMMUNIZATION; INCREASING INFLUENZA;
FACILITIES; MORTALITY; ADHERENCE
AB Objectives: Determine whether a comprehensive approach to implementing national consensus guidelines for nursing home acquired pneumonia (NHAP), including influenza and pneumococcal vaccination, improves resident subject and staff vaccination rates.
Methods: Quasi-experimental, mixed-methods multifaceted intervention trial conducted at 16 nursing homes (NHs) from 1 corporation (8 in metropolitan Denver, Colorado; 8 in Kansas and Missouri) during 3 influenza seasons, October to April 2004 to 2007. Residents with 2 or more signs and symptoms of systemic lower respiratory tract infection (LRTI) and NH staff and physicians were eligible. Subjects' NH records were reviewed for vaccination. Each director of nursing (DON) completed a questionnaire assessing staffing and the number of direct care staff vaccinated against influenza. DONs and study liaison nurses were interviewed after the intervention. Bivariate analysis compared vaccination outcomes and covariates between intervention and control homes, and risk-adjusted models were fit. Qualitative interview transcripts were analyzed using content coding.
Results: No statistically significant relationship between the intervention and improved resident vaccination rates was found, so other factors associated with improved rates were explored. Estimated direct patient care staff vaccination rates were better during the baseline and improved more in the intervention NHs. Qualitative results suggested that facility-specific factors and national policy changes impacted vaccination rates.
Conclusions: External factors influence staff and resident vaccination rates, diluting the potential impact of a comprehensive program to improve care for NHAP on vaccination. (J Am Med Dir Assoc 2010; 11: 365-370)
C1 [Hutt, Evelyn; Radcliff, Tiffany A.] Denver VA Med Ctr, Denver, CO USA.
[Hutt, Evelyn; Radcliff, Tiffany A.; Oman, Kathleen S.; Fink, Regina; Ruscin, J. Mark; Linnebur, Sunny; Fish, Doug; Liebrecht, Debra; Fish, Ron; McNulty, Monica] Univ Colorado, Denver, CO 80202 USA.
RP Hutt, E (reprint author), Denver VAMC 151, 1055 Clermont St, Denver, CO 80220 USA.
EM evelyn.hutt@ucdenver.edu
FU Agency for Health Care Research and Quality [RO1-HS13608]; National
Institutes of Health [AHRQ R01 HS013618]
FX Supported by a grant from the Agency for Health Care Research and
Quality, RO1-HS13608.; We thank the residents who graciously
participated in the study, and our data collectors: Margie Ahring, RN,
Cathleen Brethauer, RN, Karen Cotter-Hoffman, RN, Susan Lucas, RN, Nancy
Robertson, RN, Sara Schultz, RN, and Evelyn Shinn, RN for their hard
work. The study would not have been possible without the active support
of Clarence Acklam, RN, Divisional Director of Nursing, Mountain States
Division, Life Care Corporation of America, and the directors of nursing
and their staff at the 16 study nursing homes. This work was supported
by AHRQ R01 HS013618 from the National Institutes of Health. The views
expressed herein are those of the authors and do not necessarily reflect
the position or policy of the University of Colorado Denver or the
Department of Veterans Affairs.
NR 27
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD JUN
PY 2010
VL 11
IS 5
BP 365
EP 370
DI 10.1016/j.jamda.2009.09.017
PG 6
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 614AU
UT WOS:000279028200012
PM 20511104
ER
PT J
AU Miller, YE
AF Miller, York E.
TI Does Unilateral DIPNECH Provide Clues to Pathogenesis?
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Editorial Material
ID NEUROENDOCRINE CELL HYPERPLASIA; IDIOPATHIC DIFFUSE HYPERPLASIA;
CARCINOID-TUMORS; RESPIRATORY EPITHELIUM; LUNG; MUTATIONS; DISEASE
C1 Denver Vet Affairs Med Ctr, Denver, CO 80220 USA.
RP Miller, YE (reprint author), Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO 80220 USA.
EM york.miller@uchsc.edu
NR 12
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2010
VL 5
IS 6
BP 761
EP 762
DI 10.1097/JTO.0b013e3181dd0ba7
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 601XJ
UT WOS:000278100500002
PM 20502267
ER
PT J
AU Yeomans, PD
Forman, EM
Herbert, JD
Yuen, E
AF Yeomans, Peter D.
Forman, Evan M.
Herbert, James D.
Yuen, Erica
TI A Randomized Trial of a Reconciliation Workshop With and Without PTSD
Psychoeducation in Burundian Sample
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; HOPKINS SYMPTOM CHECKLIST-25; HARVARD
TRAUMA QUESTIONNAIRE; EXPOSURE THERAPY; SRI-LANKA; REFUGEES; GENOCIDE;
INTERVENTION; ASSESSMENTS; INSTRUMENT
AB Posttraumatic stress disorder (PTSD) psychoeducation is increasingly offered in diverse cultural settings. As the literature offers theoretical arguments for why such information might be normalizing and distress-reducing, or might risk morbid suggestion of greater vulnerability, a two-sided hypothesis was proposed to examine the specific effect of PTSD psychoeducation. Participants of a trauma healing and reconciliation intervention in Burundi were randomized to conditions with and without PTSD psychoeducation, or to a waitlist control. Both interventions reduced symptoms more than the waitlist. Participants in the condition without psychoeducation experienced a greater reduction in PTSD symptoms relative to other conditions. Findings are discussed in relationship to intervention development for traumatic stress in nonindustrialized and culturally diverse settings.
C1 [Yeomans, Peter D.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Forman, Evan M.; Herbert, James D.; Yuen, Erica] Drexel Univ, Dept Psychol, Philadelphia, PA USA.
RP Yeomans, PD (reprint author), Philadelphia Vet Affairs Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM peter.yeomans@va.gov
RI Forman, Evan/I-1042-2012
NR 37
TC 20
Z9 20
U1 4
U2 14
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2010
VL 23
IS 3
BP 305
EP 312
DI 10.1002/jts.20531
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 619HG
UT WOS:000279419300001
PM 20564362
ER
PT J
AU Anger, JT
Weinberg, A
Suttorp, MJ
Litwin, MS
Shekelle, PG
AF Anger, Jennifer T.
Weinberg, Aviva
Suttorp, Marika J.
Litwin, Mark S.
Shekelle, Paul G.
TI Outcomes of Intravesical Botulinum Toxin for Idiopathic Overactive
Bladder Symptoms: A Systematic Review of the Literature
SO JOURNAL OF UROLOGY
LA English
DT Article
DE urinary bladder, overactive; urinary incontinence, urge; treatment
outcome
ID DETRUSOR OVERACTIVITY; CLINICAL-TRIALS; A TOXIN; METAANALYSES; BIAS
AB Purpose: We systematically reviewed the evidence for the efficacy and safety of botulinum toxin in the management of overactive bladder.
Materials and Methods: We performed a systematic review of the literature to identify articles published between 1985 and March 2009 on intravesical botulinum toxin-A injections for the treatment of refractory idiopathic overactive bladder in men and women. Databases searched included MEDLINE (R), CENTRAL and Embase (R). Data were tabulated from case series and from randomized controlled trials, and data were pooled where appropriate.
Results: Our literature search identified 432 titles and 23 full articles were included in the final review. Three randomized placebo controlled trials addressing the use of botulinum toxin-A were identified (99 patients total). The pooled random effects estimate of effect across all 3 studies was 3.88 (95% CI -6.15, -1.62), meaning that patients treated with botulinum toxin-A had 3.88 fewer incontinence episodes per day. Urogenital Distress Inventory data revealed significant improvements in quality of life compared with placebo with a standardized mean difference of -0.62 (CI -1.04, -0.21). Data from case series demonstrated significant improvements in overactive bladder symptoms and quality of life, despite heterogeneity in methodology and case mix. However, based on the randomized controlled trials there was a 9-fold increased odds of increased post-void residual after botulinum toxin-A compared with placebo (8.55; 95% CI 3.22, 22.71).
Conclusions: Intravesical injection of botulinum toxin resulted in improvement in medication refractory overactive bladder symptoms. However, the risk of increased post-void residual and symptomatic urinary retention was significant. Several questions remain concerning the optimal administration of botulinum toxin-A for the patient with overactive bladder.
C1 [Anger, Jennifer T.; Weinberg, Aviva; Litwin, Mark S.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA.
[Litwin, Mark S.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA.
[Suttorp, Marika J.; Shekelle, Paul G.] RAND Corp, Los Angeles, CA USA.
[Shekelle, Paul G.] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
RP Anger, JT (reprint author), Dept Urol, 1260 15th St,Suite 1200, Santa Monica, CA 90404 USA.
EM janger@mednet.ucla.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases [1 K23
DK080227-01]
FX Supported by National Institute of Diabetes and Digestive and Kidney
Diseases Grant 1 K23 DK080227-01.
NR 17
TC 44
Z9 45
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD JUN
PY 2010
VL 183
IS 6
BP 2258
EP 2264
DI 10.1016/j.juro.2010.02.009
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 595QZ
UT WOS:000277628700051
PM 20400142
ER
PT J
AU Wang, GP
Sherrill-Mix, SA
Chang, KM
Quince, C
Bushman, FD
AF Wang, Gary P.
Sherrill-Mix, Scott A.
Chang, Kyong-Mi
Quince, Chris
Bushman, Frederic D.
TI Hepatitis C Virus Transmission Bottlenecks Analyzed by Deep Sequencing
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; RESISTANCE
MUTATIONS; MICROBIAL DIVERSITY; GENETIC DIVERSITY; GUT MICROBIOME;
INFECTION; EVOLUTION; IMMUNOSUPPRESSION; DETERMINANTS
AB Hepatitis C virus (HCV) replication in infected patients produces large and diverse viral populations, which give rise to drug-resistant and immune escape variants. Here, we analyzed HCV populations during transmission and diversification in longitudinal and cross-sectional samples using 454/Roche pyrosequencing, in total analyzing 174,185 sequence reads. To sample diversity, four locations in the HCV genome were analyzed, ranging from high diversity (the envelope hypervariable region 1 [HVR1]) to almost no diversity (the 5' untranslated region [UTR]). For three longitudinal samples for which early time points were available, we found that only 1 to 4 viral variants were present, suggesting that productive infection was initiated by a very small number of HCV particles. Sequence diversity accumulated subsequently, with the 5' UTR showing almost no diversification while the envelope HVR1 showed >100 variants in some subjects. Calculation of the transmission probability for only a single variant, taking into account the measured population structure within patients, confirmed initial infection by one or a few viral particles. These findings provide the most detailed sequence-based analysis of HCV transmission bottlenecks to date. The analytical methods described here are broadly applicable to studies of viral diversity using deep sequencing.
C1 [Wang, Gary P.; Sherrill-Mix, Scott A.; Bushman, Frederic D.] Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
[Wang, Gary P.] Univ Florida, Dept Med, Coll Med, Gainesville, FL 32610 USA.
[Chang, Kyong-Mi] Philadelphia VA Med Ctr, Dept Med, Philadelphia, PA 19104 USA.
[Quince, Chris] Univ Glasgow, Dept Civil Engn, Glasgow G12 8LT, Lanark, Scotland.
RP Bushman, FD (reprint author), Univ Penn, Sch Med, Dept Microbiol, 3610 Hamilton Walk, Philadelphia, PA 19104 USA.
EM bushman@mail.med.upenn.edu
OI Bushman, Frederic/0000-0003-4740-4056
FU Human Microbiome Demonstration Project [UH2DK083981]; NIH [K08
AI077713]; University of Pennsylvania Department of Medicine Measey
Basic Science
FX This work was supported by a Human Microbiome Demonstration Project
Grant to F. D. B., James Lewis, and Gary Wu (UH2DK083981). G.P.W. was
supported by NIH K08 AI077713 and a University of Pennsylvania
Department of Medicine Measey Basic Science Fellowship Award.
NR 47
TC 87
Z9 89
U1 1
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUN
PY 2010
VL 84
IS 12
BP 6218
EP 6228
DI 10.1128/JVI.02271-09
PG 11
WC Virology
SC Virology
GA 597CQ
UT WOS:000277733900034
PM 20375170
ER
PT J
AU Barone, P
Poewe, W
Albrecht, S
Debieuvre, C
Massey, D
Rascol, O
Tolosa, E
Weintraub, D
AF Barone, Paolo
Poewe, Werner
Albrecht, Stefan
Debieuvre, Catherine
Massey, Dan
Rascol, Olivier
Tolosa, Eduardo
Weintraub, Daniel
TI Pramipexole for the treatment of depressive symptoms in patients with
Parkinson's disease: a randomised, double-blind, placebo-controlled
trial
SO LANCET NEUROLOGY
LA English
DT Article
ID DOPAMINE-RECEPTOR AGONIST; RATING-SCALE; ANTIDEPRESSANT; METAANALYSIS;
INVENTORY; VALIDITY
AB Background Depression is common in patients with Parkinson's disease, but evidence on the efficacy of antidepressants in this population is lacking. Because depression in patients with Parkinson's disease might be related to dopaminergic dysfunction, we aimed to assess the efficacy of the dopamine agonist pramipexole for treatment of depressive symptoms in patients with Parkinson's disease.
Methods We did a 12-week randomised, double-blind, placebo-controlled (1:1 ratio) trial of pramipexole (0.125-1.0 mg three times per day) compared with placebo in patients with mild-to-moderate Parkinson's disease. Patients from 76 centres in 12 European countries and South Africa were included if they were on stable antiparkinsonian therapy without motor fluctuations and had depressive symptoms (15-item geriatric depression scale score >= 5 and unified Parkinson's disease rating scale [UPDRS] part 1 depression item score a 2). Patients were randomly assigned by centre in blocks of four by use of a randomisation number generating system. Clinical monitors, the principal investigator, and patients were masked to treatment allocation. The primary endpoint was change in Beck depression inventory (BDI) score and all treated patients who had at least one post-baseline efficacy assessment were included in the primary analysis. We also did a pre-specified path analysis with regression models to assess the relation between BDI and UPDRS part 3 (motor score) changes. This trial is registered with ClinicalTrials.gov, number NCT00297778, and EudraCT, number 2005-003788-22.
Findings Between March, 2006, and February, 2008, we enrolled 323 patients. Of 296 patients randomly assigned to pramipexole or placebo, 287 were induded in the primary analysis: 139 in the pramipexole group and 148 in the placebo group. BDI scores decreased by an adjusted mean 5.9 (SE 0.5) points in the pramipexole group and 4.0 (0.5) points in the placebo group (difference 1.9, 95% CI 0.5-3.4; p=0.01, ANCOVA). The UPDRS motor score decreased by an adjusted mean 4.4 (0.6) points in the pramipexole group and 2.2 (0.5) points in the placebo group (difference 2.2, 95% CI 0-7-3-7; p=0.003, ANCOVA). Path analysis showed the direct effect of pramipexole on depressive symptoms accounted for 80% of total treatment effect (p=0.04). Adverse events were reported in 105 of 144 patients in the pramipexole group and 101 of 152 in the placebo group. Adverse events in the pramipexole group were consistent with the known safety profile of the drug.
Interpretation Pramipexole improved depressive symptoms in patients with Parkinson's disease, mainly through a direct antidepressant effect. This effect should be considered in the clinical management of patients with Parkinson's disease.
C1 [Barone, Paolo] Univ Naples Federico 2, Dept Neurol Sci, I-80131 Naples, Italy.
[Barone, Paolo] IDC Hermitage Capodimonte, Naples, Italy.
[Poewe, Werner] Innsbruck Med Univ, Dept Neurol, Innsbruck, Austria.
[Albrecht, Stefan] Boehringer Ingelheim GmbH & Co KG, Corp Dept Med Affairs, Ingelheim, Germany.
[Debieuvre, Catherine] Boehringer Ingelheim France SAS, Dept Clin Res, Reims, France.
[Massey, Dan] Boehringer Ingelheim UK, Bracknell, Berks, England.
[Rascol, Olivier] Toulouse Univ Hosp, UMR 825, Toulouse, France.
[Rascol, Olivier] Toulouse Univ Hosp, INSERM 9302, Clin Invest Ctr, Dept Clin Pharmacol & Neurosci, Toulouse, France.
[Tolosa, Eduardo] Univ Barcelona, Hosp Clin, IDIBAPS, Neurol Serv,CIBERNED, E-08007 Barcelona, Spain.
[Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis & Mental Illness Res Educ & Clin C, Philadelphia, PA USA.
RP Barone, P (reprint author), Univ Naples Federico 2, Dept Neurol Sci, Via Pansini 5, I-80131 Naples, Italy.
EM barone@unina.it
RI TM, Inct/J-8630-2013
FU Boehringer Ingelheim
FX This study was funded by Boehringer Ingelheim. E Jay Bienen and Linnea
Elliott provided editing assistance. Funding for editing assistance was
provided by Boehringer Ingelheim.
NR 41
TC 165
Z9 177
U1 2
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1474-4422
J9 LANCET NEUROL
JI Lancet Neurol.
PD JUN
PY 2010
VL 9
IS 6
BP 573
EP 580
DI 10.1016/S1474-4422(10)70106-X
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 607NY
UT WOS:000278512000010
PM 20452823
ER
PT J
AU Radulovic, M
Schilero, GJ
Wecht, JM
La Fountaine, M
Rosado-Rivera, D
Bauman, WA
AF Radulovic, Miroslav
Schilero, Gregory J.
Wecht, Jill M.
La Fountaine, Michael
Rosado-Rivera, Dwindally
Bauman, William A.
TI Exhaled Nitric Oxide Levels Are Elevated in Persons with Tetraplegia and
Comparable to that in Mild Asthmatics
SO LUNG
LA English
DT Article
DE Spinal cord injury; Tetraplegia; Fraction exhaled nitric oxide; Nitric
oxide; Asthma
ID SPINAL-CORD-INJURY; AIRWAY HYPERRESPONSIVENESS; LUNG; SYNTHASE
AB The role of airway inflammation in mediating airflow obstruction in persons with chronic traumatic tetraplegia is unknown. Measurement of the fraction of exhaled nitric oxide (FeNO) affords a validated noninvasive technique for gauging the airway inflammatory response in asthma, although it has never been assessed in persons with tetraplegia. This study was designed to determine the FeNO in individuals with chronic tetraplegia compared with that in patients with mild asthma and healthy able-bodied individuals. Nine subjects with chronic tetraplegia, seven subjects with mild asthma, and seven matched healthy able-bodied controls were included in this prospective, observational, pilot study. All subjects were nonsmokers and clinically stable at the time of study. Spirometry was performed on all participants at baseline. FENO was determined online by a commercially available closed circuit, chemiluminescence method, using a single-breath technique. Subjects with tetraplegia had significantly higher values of FeNO than controls (17.72 +/- A 3.9 ppb vs. 10.37 +/- A 4.9 ppb; P a parts per thousand currency sign 0.01), as did subjects with asthma (20.23 +/- A 4.64 ppb vs. 10.37 +/- A 4.9 ppb, P a parts per thousand currency sign 0.001). There was no significant difference in FeNO between subjects with tetraplegia and those with asthma (17.72 +/- A 3.9 ppb vs. 20.23 +/- A 4.64 ppb, P a parts per thousand currency sign 0.27). Individuals with chronic tetraplegia have FeNO levels that are comparable to that seen in mild asthmatics and higher than that in healthy able-bodied controls. The clinical relevance of this observation has yet to be determined.
C1 [Radulovic, Miroslav; Schilero, Gregory J.; Wecht, Jill M.; La Fountaine, Michael; Rosado-Rivera, Dwindally; Bauman, William A.] James J Peters VA Med Ctr, Rehabil Res & Dev Ctr Excellence Med Consequences, Bronx, NY 10468 USA.
[Radulovic, Miroslav; Schilero, Gregory J.; Wecht, Jill M.; Bauman, William A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA.
[Radulovic, Miroslav; Schilero, Gregory J.; Wecht, Jill M.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Wecht, Jill M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.
RP Radulovic, M (reprint author), James J Peters VA Med Ctr, Rehabil Res & Dev Ctr Excellence Med Consequences, Rm 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Miroslav.Radulovic@va.gov
FU Rehabilitation Research and Development (RR&D) Service Career
Development award [B4335 V]; RR&D Center of Excellence for the Medical
Consequences of Spinal Cord Injury [B4162C]; Department of Veterans
Affairs Rehabilitation Research and Development
FX This work was funded by a Rehabilitation Research and Development (RR&D)
Service Career Development award (B4335 V) & RR&D Center of Excellence
for the Medical Consequences of Spinal Cord Injury (B4162C). The authors
thank The James J. Peters Medical Center, Bronx, NY, and Department of
Veterans Affairs Rehabilitation Research and Development service for
their support.
NR 17
TC 3
Z9 4
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341-2040
J9 LUNG
JI Lung
PD JUN
PY 2010
VL 188
IS 3
BP 259
EP 262
DI 10.1007/s00408-009-9207-x
PG 4
WC Respiratory System
SC Respiratory System
GA 586LM
UT WOS:000276910400011
PM 20012982
ER
PT J
AU Egede, LE
Mueller, M
Echols, CL
Gebregziabher, M
AF Egede, Leonard E.
Mueller, Martina
Echols, Carrae L.
Gebregziabher, Mulugeta
TI Longitudinal Differences in Glycemic Control by Race/Ethnicity Among
Veterans With Type 2 Diabetes
SO MEDICAL CARE
LA English
DT Article
DE diabetes; ethnicity; veterans; glycemic control
ID AFFAIRS HEALTH-CARE; RACIAL DISPARITIES; UNITED-STATES; RACIAL/ETHNIC
DIFFERENCES; INTERMEDIATE OUTCOMES; MEDICATION ADHERENCE;
ETHNIC-DIFFERENCES; GLUCOSE CONTROL; ADULTS; QUALITY
AB Objective: To examine longitudinal differences in glycemic control between non-Hispanic white and non-Hispanic black veterans with type 2 diabetes.
Design: Retrospective cohort study.
Setting: VA facility in the Southeastern United States.
Participants: A 3-month person-period dataset was created for 8813 veterans with type 2 diabetes between June 1997 and May 2006.
Main Outcome Measures: Primary outcome was mean change in hemoglobin A1c (HbA1c) over time. Secondary outcome was the odds of poor glycemic control over time (HbA1c >8%). For the primary outcome, a linear mixed model (LMM) approach was used to model the relationship of HbA1c levels and race/ethnicity over time. For the secondary outcome, generalized LMMs were used to assess whether glycemic control changed over time and whether change in glycemic control varied by racial/ethnic group.
Results: Mean age was 66.3 years, 36% were non-Hispanic black (NHB), 98% were male, 65% were married, and 50% were unemployed. Mean follow-up time was 4.4 years. Least square mean HbA1c levels from LMM adjusted for time and relevant confounders showed that NHBs had higher HbA1c values over time (mean difference of 0.54% [P < 0.001]). The final model with poor versus good glycemic control as the dependent variable, race/ethnicity as primary independent variable adjusted for time, and relevant confounders showed that NHBs were likely to have poor control compared with NHWs (OR: 1.8, 95% CI, 1.7; 2.0, P < 0.0001).
Conclusions: NHB veterans were more likely to have higher mean HbA1c values and less likely to have good glycemic control over time compared with NHW veterans.
C1 [Egede, Leonard E.; Echols, Carrae L.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Egede, Leonard E.; Mueller, Martina; Echols, Carrae L.; Gebregziabher, Mulugeta] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
[Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA.
[Mueller, Martina] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA.
[Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Biostat, Charleston, SC 29425 USA.
[Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Bioinformat, Charleston, SC 29425 USA.
[Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Epidemiol, Charleston, SC 29425 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA.
EM egedel@musc.edu
OI Gebregziabher, Mulugeta/0000-0002-4826-481X
FU Veterans Health Administration [REA 08-261]
FX Supported by the Veterans Health Administration Health Services Research
Development program (VA HSRD) grant REA 08-261. All authors had full
access to all the data in the study and take responsibility for the
integrity of the data and the accuracy of the data analysis.
NR 40
TC 12
Z9 12
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD JUN
PY 2010
VL 48
IS 6
BP 527
EP 533
DI 10.1097/MLR.0b013e3181d558dc
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 603ER
UT WOS:000278191900006
PM 20473215
ER
PT J
AU Kozak, L
Boynton, L
Bentley, J
Bezy, E
AF Kozak, Leila
Boynton, Lorin
Bentley, Jacob
Bezy, Emma
TI Introducing spirituality, religion and culture curricula in the
psychiatry residency programme
SO MEDICAL HUMANITIES
LA English
DT Article
ID MENTAL-HEALTH; MEDICINE; CARE; EDUCATION
AB A growing body of research suggests that religion and spirituality may have a positive effect on mental and physical health. Medical schools have been increasingly offering courses in spirituality and health, particularly about the multi-cultural dimensions of religion and spirituality. There is a trend towards integrating the teaching of cross-cultural issues related to spirituality and religion into medical education. This trend is particularly evident in the field of psychiatry, where an increasing number of residency programmes are developing curriculum in this area. This article describes a specific curriculum in spirituality, religion and culture that was introduced in 2003 at the University of Washington Psychiatry Residency Program in Seattle, Washington. Reflections about the present and future of subject areas such as spirituality and religion in medical education and psychiatry residency are discussed.
C1 [Kozak, Leila] Dept Vet Affairs Med Ctr, Hlth Serv R&D Serv, Dept Vet Affairs, VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA.
[Kozak, Leila] Univ Washington, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98195 USA.
[Boynton, Lorin] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Bentley, Jacob] Seattle Pacific Univ, Dept Psychol, Seattle, WA 98119 USA.
[Bezy, Emma] Ctr Spirit & Hlth Seattle, Seattle, WA USA.
RP Kozak, L (reprint author), Dept Vet Affairs Med Ctr, Hlth Serv R&D Serv, Dept Vet Affairs, VA Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM leila.kozak@va.gov
NR 28
TC 4
Z9 4
U1 1
U2 5
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1468-215X
J9 MED HUMANIT
JI Med. Humanit.
PD JUN
PY 2010
VL 36
IS 1
BP 48
EP 51
DI 10.1136/jmh.2010.004267
PG 4
WC Humanities, Multidisciplinary
SC Arts & Humanities - Other Topics
GA 701TE
UT WOS:000285845500016
PM 21393277
ER
PT J
AU Yamamura, S
Kawakami, K
Hirata, H
Ueno, K
Saini, S
Majid, S
Dahiya, R
AF Yamamura, Soichiro
Kawakami, Kazumori
Hirata, Hiroshi
Ueno, Koji
Saini, Sharanjot
Majid, Shahana
Dahiya, Rajvir
TI Oncogenic Functions of Secreted Frizzled-Related Protein 2 in Human
Renal Cancer
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID FREQUENT EPIGENETIC INACTIVATION; COLORECTAL-CANCER; BETA-CATENIN;
BREAST-CANCER; WNT PROTEINS; BCL2 FAMILY; SFRP2 GENE; FECAL DNA;
CYCLIN-E; APOPTOSIS
AB The secreted Frizzled-related proteins (sFRP) are modulators of the Wnt signaling pathway, which is involved in embryonic development and tumor progression. The functions of sFRP2 have not been studied in renal cancer. Transient transfection of sFRP2 promoted cell growth in renal carcinoma cells, whereby the largest effect was observed in A498 cells. To further study the functions of sFRP2 gene in renal carcinoma cells, we established A498 renal cancer cell lines, which stably expressed sFRP2. Stably expressed sFRP2 significantly promoted cell proliferation in vitro and in vivo tumor growth. The stably expressed sFRP2 cells were also found to have reduced UV-induced apoptosis and increased G(2) phase of the cell cycle. The phosphorylation level at Ser(33/37)/Thr(41) of beta-catenin was lower in the stable sFRP2 cell lines compared with the control cell line. sFRP2 significantly activated T-cell factor/lymphoid enhancer factor transcriptional activity. In the stable sFRP2 cell line, expression of c-Fos, Bcl2, Bcl-w, cyclin B2, and cyclin E2 genes was significantly increased and p53 expression was decreased. This is the first report documenting that sFRP2 activates the canonical Wnt pathway and promotes cell growth by evoking diverse signaling cascades in renal cancer cells. This study may provide better strategies for the management of renal cancer through regulation of sFRP2 pathways. Mol Cancer Ther; 9(6); 1680-7. (C)2010 AACR.
C1 San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU NIH [RO1CA130860, T32DK007790]; Veterans Affairs Research Enhancement
Award Program; Veterans Affairs Merit Review
FX Grant Support; NIH grants RO1CA130860 (S. Yamamura, K. Kawakami, H.
Hirata, K. Ueno, and R. Dahiya) and T32DK007790 (S. Saini, S. Majid, and
R. Dahiya), Veterans Affairs Research Enhancement Award Program (R.
Dahiya), and Veterans Affairs Merit Review (R. Dahiya).
NR 37
TC 20
Z9 20
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUN
PY 2010
VL 9
IS 6
BP 1680
EP 1687
DI 10.1158/1535-7163.MCT-10-0012
PG 8
WC Oncology
SC Oncology
GA 608FS
UT WOS:000278569200020
PM 20501806
ER
PT J
AU Lovera, JF
Frohman, E
Brown, TR
Bandari, D
Nguyen, L
Yadav, V
Stuve, O
Karman, J
Bogardus, K
Heimburger, G
Cua, L
Remingon, G
Fowler, J
Monahan, T
Kilcup, S
Courtney, Y
McAleenan, J
Butler, K
Wild, K
Whitham, R
Bourdette, D
AF Lovera, J. F.
Frohman, E.
Brown, T. R.
Bandari, D.
Nguyen, L.
Yadav, V.
Stuve, O.
Karman, J.
Bogardus, K.
Heimburger, G.
Cua, L.
Remingon, G.
Fowler, J.
Monahan, T.
Kilcup, S.
Courtney, Y.
McAleenan, J.
Butler, K.
Wild, K.
Whitham, R.
Bourdette, D.
TI Memantine for cognitive impairment in multiple sclerosis: a randomized
placebo-controlled trial
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE attention; cognition disorders; memantine; memory; multiple sclerosis;
neuropsychological tests; placebo; randomized controlled trial
ID NEUROPSYCHIATRIC INVENTORY; MS PATIENTS; GLUTAMATE; DONEPEZIL; MODERATE;
DISEASE; MEMORY; SCALE
AB Background: Memantine, an NMDA antagonist, is effective for moderate to severe Alzheimer's disease.
Objective: Determine whether memantine improves cognitive performance (CP) among subjects with multiple sclerosis (MS) and cognitive impairment (CI).
Methods: This double-blind, randomized, placebo-controlled trial (Clinicaltrials.gov NCT00300716) compared memantine 10 mg twice a day (4 week titration followed by 12 weeks on the highest tolerated dose) with placebo. The primary outcome was the change from baseline to exit on the Paced Auditory Serial Addition Test (PASAT) and the California Verbal Learning Test-II (CVLT-II) Long Delay Free Recall (LDFR). Secondary outcomes included additional neuropsychological tests; self-report measures of quality of life, fatigue, and depression; and family/caregiver reports of subjects' CI and neuropsychiatric symptoms.
Results: The differences between the groups on the change on the PASAT (placebo-memantine = 0.0 correct responses, 95% CI 3.4, 3.4; p = 0.9) and on CVLT-II LDFR (placebo-memantine = -0.6 words, 95% CI - 2.1, 0.8; p = 0.4) as well as on the other cognitive tests were not significant. Subjects on memantine had no serious adverse events (AEs) but had more fatigue and neurological AEs as well as, per family members' reports, less cognitive improvement and greater neuropsychiatric symptoms than subjects on placebo.
Conclusion: Memantine 10 mg twice a day does not improve CP in subjects with MS, ages 18-65, without major depression, who have subjective cognitive complaints and perform worse than one SD below the mean on the PASAT or on the California Verbal Learning Test-II (total recall or delayed free recall).
C1 [Lovera, J. F.] Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA 70003 USA.
[Frohman, E.; Stuve, O.; Remingon, G.; Fowler, J.] UT SW, Dallas, TX USA.
[Brown, T. R.; Monahan, T.; Kilcup, S.; Courtney, Y.; McAleenan, J.; Butler, K.] Evergreen Neurosci Inst & Med Ctr, Kirkland, WA USA.
[Bandari, D.; Cua, L.] Univ So Calif, Los Angeles, CA USA.
[Nguyen, L.; Yadav, V.; Karman, J.; Bogardus, K.; Heimburger, G.; Wild, K.; Whitham, R.; Bourdette, D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Whitham, R.; Bourdette, D.] Portland VA Med Ctr, Portland, OR USA.
RP Lovera, JF (reprint author), Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, RM 718,1542 Tulane Ave, New Orleans, LA 70003 USA.
EM jlover@lsuhsc.edu
FU Forest Laboratories
FX Special thanks to: Cynthia Morris, PhD for performing the randomization
and Debbie Griffith, RN, Stacey Moultrie, RN, Lynn Tylkalsky, John
Phillips for entering the data into the database. This study was
supported by an investigator-initiated grant from Forest Laboratories.
NR 27
TC 37
Z9 37
U1 1
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
J9 MULT SCLER J
JI Mult. Scler. J.
PD JUN
PY 2010
VL 16
IS 6
BP 715
EP 723
DI 10.1177/1352458510367662
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 611OY
UT WOS:000278829800010
PM 20483885
ER
PT J
AU Hugos, CL
Copperman, LF
Fuller, BE
Yadav, V
Lovera, J
Bourdette, DN
AF Hugos, C. L.
Copperman, L. F.
Fuller, B. E.
Yadav, V.
Lovera, J.
Bourdette, D. N.
TI Clinical trial of a formal group fatigue program in multiple sclerosis
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE energy conservation; exercise; fatigue; guideline; multiple sclerosis;
quality of life; rehabilitation; self-efficacy; symptom management
ID RANDOMIZED CONTROLLED-TRIAL; ENERGY-CONSERVATION COURSE; SELF-EFFICACY;
IMPACT SCALE; VALIDATION; DISABILITY; THERAPY; MS
AB Fatigue: Take Control is a novel program to teach fatigue management to people with multiple sclerosis (MS) following recommendations in the Fatigue and Multiple Sclerosis guideline. Fatigue: Take Control includes six 2-hour group sessions with DVD viewing, discussion and homework and accompanying participant and leader workbooks. While many people have participated in Fatigue: Take Control programs, its efficacy has not been determined. The objective of this study was to determine whether participation in Fatigue: Take Control reduces fatigue and increases self-efficacy in people with MS. Thirty participants were randomly assigned to a group who immediately participated in the program (FTC) or a wait-list group (WL). The primary outcome was the Modified Fatigue Impact Scale (MFIS) and secondary outcomes were the Multiple Sclerosis Self-Efficacy Scale (MSSE) and the Fatigue Severity Scale (FSS). The MFIS was administered on 10 occasions. Other measures were administered on four occasions. A mixed model tested the effects using all observations. Compared with the WL, the FTC group had significantly more improvement on the MFIS [F(1, 269) = 7.079, p = 0.008] and the MSSE [F(1, 111) = 5.636, p = 0.019]. No significant effect was found for the FSS. Across all visits, fatigue was significantly lower and self-efficacy was significantly higher for the FTC group compared with the WL group. This pilot study demonstrated significant effects in fatigue and self-efficacy among subjects taking the Fatigue: Take Control program, suggesting that this comprehensive program based on the Fatigue and Multiple Sclerosis guideline may be beneficial in MS.
C1 [Hugos, C. L.] Oregon Hlth & Sci Univ, Dept Rehabil Serv, Dept Neurol, Portland, OR 97239 USA.
[Fuller, B. E.] Portland VA Med Ctr, Div Mental Hlth, Portland, OR USA.
[Lovera, J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Neurol, Portland, OR 97239 USA.
[Lovera, J.] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA.
[Fuller, B. E.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
RP Hugos, CL (reprint author), Oregon Hlth & Sci Univ, Dept Rehabil Serv, Dept Neurol, 3303 SW Bond Ave,CH3T, Portland, OR 97239 USA.
EM hugosc@ohsu.edu
FU National MS Society Pilot [1327]; NIH [K23 AT003258, UL1 RR024140];
Department of Veterans Affairs
FX The PI would like to acknowledge Laura Mitchell, OTR, for her
contribution as the 'trained substitute' leading two of the Fatigue:
Take Control classes. This study was funded by National MS Society Pilot
Grant 1327 (CLH), NIH K23 AT003258 (VY), the Department of Veterans
Affairs (JL and DNB), Nancy Davis Center Without Walls, and Oregon
Clinical and Translational Research Institute (OCTRI) NIH UL1 RR024140.
NR 27
TC 23
Z9 23
U1 2
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
J9 MULT SCLER J
JI Mult. Scler. J.
PD JUN
PY 2010
VL 16
IS 6
BP 724
EP 732
DI 10.1177/1352458510364536
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 611OY
UT WOS:000278829800011
PM 20375125
ER
PT J
AU Chi, LY
Yu, J
Zhu, H
Li, XG
Zhu, SG
Li, ZZ
Pettigrew, LC
Grass, D
Hickman, JJ
Kindy, MS
AF Chi, Lingyi
Yu, Jin
Zhu, Hong
Li, Xingang
Zhu, Shugan
Li, Zhenzhong
Pettigrew, L. Creed
Grass, David
Hickman, James J.
Kindy, Mark S.
TI Dual neuronal response to tumor necrosis factor-alpha following spinal
cord injury
SO NEURAL REGENERATION RESEARCH
LA English
DT Article
DE spinal cord injury; tumor necrosis factor-alpha; rats; inflammation;
motor function; astrocytes; microglia; nerve growth factor;
brain-derived neurotrophic factors
ID NERVE GROWTH-FACTOR; BRAIN-INJURY; TRANSGENIC MICE; GENE-EXPRESSION;
WORKING-MEMORY; CYTOKINES; RATS; APOPTOSIS; SYSTEM; INFLAMMATION
AB BACKGROUND: Numerous studies have shown that tumor necrosis factor a (TNF-alpha) is closely correlated with spinal cord injury (SCI), but the mechanisms of TNF-alpha and therapeutic treatments for SCI are still poorly understood.
OBJECTIVE: To determine the role of TNF-alpha in the pathogenesis of SCI.
DESIGN, TIME AND SETTING: An in vivo experiment based on genetically engineered animals was performed at the Medical University of South Carolina, Charleston, South Carolina, USA, between June 2007 and October 2008.
MATERIALS: TNF-alpha transgenic rats (Xenogen Biosciences in Cranbury, New Jersey, USA) were utilized in this study.
METHODS: TNF-alpha transgenic (tg) and wild-type (WT) rats underwent a complete single-level laminectomy at the 10(th) thoracic vertebra (T(10)).
MAIN OUTCOME MEASURES: Motor function of rat hindlimb was assessed using the Basso, Beattie, and Bresnahan hindlimb locomotor rating scale. Histological evaluation of spinal cord tissue loss was conducted. Immunohistochemistry for astrocytes, microglia/macrophages, and TNF receptors (TNFRs) was performed on spinal cord tissue sections. TNF-alpha mRNA expression was detected by real-time polymerase chain reaction. The concentrations of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in the supernatant were determined using an enzyme-linked immunosorbent assay kit for rat NGF or BDNF, respectively. The rats were injected subcutaneously with etanercept to verify that TNF-alpha was the direct effect of the modulation of behavioral and neurodegenerative outcomes in the TNF-alpha tg rats.
RESULTS: TNF-alpha tg rats showed higher expression of TNF-alpha mRNA in the spinal cord prior to SCI. TNF-alpha tg rats showed worse motor deficits than WT rats in the acute period (<3 days) after SCI (P < 0.01), while in the chronic period, TNF-alpha tg rats exhibited persistent elevated baseline levels of TNF-alpha mRNA and improved recovery in motor function and tissue healing compared to WT rats (P < 0.01). Following SCI, the number of microglia/macrophages in TNF-alpha tg rat was always greater than in WT rat (P < 0.01). There were no significant differences in NGF and BDNF levels in the supernatant of spinal cord homogenates. TNFR1 expression was significantly greater in the TNF-alpha tg rats compared to the WT rats (P < 0.01). However, TNFR2 expression did not reveal a significant increase in the TNF-alpha tg rats compared to the WT rats. Finally, treatment with etanercept reduced injury acutely, but exacerbated the injury chronically.
CONCLUSION: Overexpression of TNF-alpha is deleterious in the acute phase, but beneficial in the chronic phase in the response to SCI. The role of TNF-alpha post-injury may depend on TNF-alpha expression in the spinal cord and its differential binding to TNFR1. Our observations may have clinical relevance that antagonists or inhibitors of TNF-alpha could be administered within the early time window post-injury, and appropriate amounts of TNF-alpha could be administered during the chronic stage, in order to improve the final neurological recovery in patients with SCI.
C1 [Chi, Lingyi; Yu, Jin; Zhu, Hong; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Chi, Lingyi; Li, Xingang; Zhu, Shugan] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan 250012, Shandong, Peoples R China.
[Chi, Lingyi; Li, Xingang] Shandong Univ, Qilu Hosp, Lab Neurosurg, Jinan 250012, Shandong, Peoples R China.
[Li, Zhenzhong; Kindy, Mark S.] Shandong Univ, Sch Med, Dept Anat, Jinan 250012, Shandong, Peoples R China.
[Pettigrew, L. Creed] Univ Kentucky, Sanders Brown Ctr Aging, Stroke Program, Coll Med, Lexington, KY 40536 USA.
[Pettigrew, L. Creed] Dept Vet Affairs Med Ctr, Lexington, KY 40536 USA.
[Grass, David] Xenogen Corp, Cranbury, NJ 08512 USA.
[Hickman, James J.] Univ Cent Florida, NanoSci Technol Ctr, Orlando, FL 32826 USA.
[Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
EM drlixingangneurosurgery@yahoo.com.cn; kindyms@musc.edu
FU VA [ES016774-01A1]; National Science Foundation [EPS-0132573,
EPS-0447660, NS050452-05]
FX Supported by: the ES016774-01A1*, VA Merit Award and National Science
Foundation EPSCoR grant, No. EPS-0132573* and EPS-0447660 (MSK)* and
NS050452-05 (JJH)*
NR 56
TC 2
Z9 2
U1 0
U2 7
PU SHENYANG EDITORIAL DEPT NEURAL REGENERATION RES
PI SHENYANG
PA PO BOX 1234, SHENYANG, LIAONING 110004, PEOPLES R CHINA
SN 1673-5374
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD JUN
PY 2010
VL 5
IS 12
BP 917
EP 926
DI 10.3969/j.issn.1673-5374.2010.12.007
PG 10
WC Cell Biology; Neurosciences
SC Cell Biology; Neurosciences & Neurology
GA 625LC
UT WOS:000279895700007
ER
PT J
AU Filley, CM
AF Filley, Christopher M.
TI White Matter: Organization and Functional Relevance
SO NEUROPSYCHOLOGY REVIEW
LA English
DT Review
DE White matter; Geschwind; Disconnection; Distributed neural networks;
White matter dementia
ID CENTRAL-NERVOUS-SYSTEM; AIDS DEMENTIA COMPLEX; NORMAL-PRESSURE
HYDROCEPHALUS; CHRONIC TOLUENE ABUSE; MULTIPLE-SCLEROSIS; COGNITIVE
IMPAIRMENT; BINSWANGERS-DISEASE; VASCULAR DEMENTIA; DISCONNECTION
SYNDROMES; LUPUS-ERYTHEMATOSUS
AB Norman Geschwind's landmark paper in 1965, "Disconnexion Syndromes in Animals and Man," inspired a generation of investigators to consider the effects of focal brain lesions disrupting higher brain functions. Although Geschwind viewed disconnection as resulting from either white or gray matter lesions, his signature article drew upon the insights of 19th century neurologists and firmly established white matter within the vocabulary of behavioral neurology, neuropsychology, and cognitive neuroscience. This influence, and the advent of sensitive neuroimaging techniques later in the 20th century, led to white matter gradually gaining more attention as an essential component of distributed neural networks subserving cognition and emotion. Today, whereas focal white matter lesions remain central to the pathogenesis of classic neurobehavioral syndromes, diffuse white matter involvement is regarded as increasingly relevant to a wide variety of dementia syndromes and a host of neuropsychiatric disorders as well. In parallel, better understanding of the neurobiology of brain white matter at all ages has been achieved. While much remains to be explored, a general conceptual formulation is that white matter supports information transfer to complement the information processing carried out by gray matter. As knowledge of the organization and functional relevance of white matter continues to advance, improved understanding of the role of myelinated tracts in higher function can be anticipated, and with it many clinical benefits.
C1 [Filley, Christopher M.] Behav Neurol Sect, Aurora, CO 80045 USA.
[Filley, Christopher M.] Univ Colorado, Sch Med, Behav Neurol Sect, Denver, CO USA.
[Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Filley, CM (reprint author), Behav Neurol Sect, 12631 E 17th Ave,MS B185,POB 6511, Aurora, CO 80045 USA.
EM christopher.filley@ucdenver.edu
FU National Institutes of Health [R01 AR049152-02S1, R01 AR049152-01A2]
FX Preparation of this article was supported by National Institutes of
Health research grants R01 AR049152-02S1 and R01 AR049152-01A2.
NR 119
TC 29
Z9 30
U1 1
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1040-7308
J9 NEUROPSYCHOL REV
JI Neuropsychol. Rev.
PD JUN
PY 2010
VL 20
IS 2
SI SI
BP 158
EP 173
DI 10.1007/s11065-010-9127-9
PG 16
WC Psychology, Clinical; Neurosciences
SC Psychology; Neurosciences & Neurology
GA 607AK
UT WOS:000278470400005
PM 20352350
ER
PT J
AU Rane, S
Nair, G
Duong, TQ
AF Rane, Swati
Nair, Govind
Duong, Timothy Q.
TI DTI at long diffusion time improves fiber tracking
SO NMR IN BIOMEDICINE
LA English
DT Article
DE diffusion tensor imaging; STEAM sequence; rhesus macaques; cross-terms;
formalin fixation; fractional anisotropy; white matter tracking
ID HUMAN BRAIN; SPIN-ECHO; SELF-DIFFUSION; TENSOR; MRI; TISSUE; WATER; NMR;
COEFFICIENT; PRINCIPLES
AB While diffusion-tensor-imaging tractography provides remarkable in vivo anatomical connectivity of the central nervous system, the majority of DTI studies to date are predominantly limited to tracking large white-matter fibers. This study investigated DTI tractography using long diffusion time (t(diff)) to improve tracking of thinner fibers in fixed rhesus monkey brains. Stimulated Echo Acquisition Mode (STEAM) sequence on a 3T Siemens TRIO was modified to include a diffusion module. DTI was acquired using STEAM with t(diff) of 48 and 192 ms with matched signal-to-noise ratios (SNR). Comparisons were also made with the conventional double-spin echo (DSE) at a short t(diff) of 45 ms. Not only did the fractional anisotropy increase significantly with the use of long diffusion time, but directional entropy measures indicated that there was an increased coherence amongst neighboring tensors. Further, the magnitude of the major eigenvector was larger at the t(diff) = 192 ms as compared to the short t(diff). Probabilistic connectivity maps at long t(diff) showed larger areas of connectivity with the use of long diffusion time, which traversed deeper into areas of low anisotropy. With tractography, it was found that the length of the fibers, increased by almost 10% in the callosal fibers that branch into the paracentral gyrus, the precentral gyrus and the post central gyrus. A similar increase of about 20% was observed in the fibers of the internal capsule. These findings offer encouraging data that DTI at long diffusion time could improve tract tracing of small fibers in areas of low fractional anisotropy (FA), such as at the interfaces of white matter and grey matter. Copyright (C) 2010 John Wiley & Sons, Ltd.
C1 [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Physiol, San Antonio, TX 78229 USA.
[Rane, Swati] Georgia Inst Technol, Atlanta, GA 30332 USA.
[Rane, Swati; Nair, Govind] Emory Univ, Atlanta, GA 30322 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Duong, Timothy Q.] SW Natl Primate Res Ctr, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008
FU NIH [R01NS45879]; Center for Behavioral Neuroscience, NSF [IBN-9876754]
FX Contract/grant sponsor: NIH; contract/grant number: R01NS45879.;
Contract/grant sponsor: The Center for Behavioral Neuroscience;
contract/grant number: NSF, IBN-9876754.
NR 38
TC 8
Z9 8
U1 0
U2 7
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0952-3480
J9 NMR BIOMED
JI NMR Biomed.
PD JUN
PY 2010
VL 23
IS 5
BP 459
EP 465
DI 10.1002/nbm.1482
PG 7
WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
GA 620UQ
UT WOS:000279526300003
PM 20175137
ER
PT J
AU Eckstein, F
Wirth, W
Hunter, DJ
Guermazi, A
Kwoh, CK
Nelson, DR
Benichou, O
AF Eckstein, F.
Wirth, W.
Hunter, D. J.
Guermazi, A.
Kwoh, C. K.
Nelson, D. R.
Benichou, O.
CA OAI Investigators
TI Magnitude and regional distribution of cartilage loss associated with
grades of joint space narrowing in radiographic osteoarthritis - data
from the Osteoarthritis Initiative (OAI)
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Joint space narrowing; Radiographic osteoarthritis; Cartilage loss;
Magnetic resonance imaging; Side comparison
ID KNEE-JOINT; ARTICULAR-CARTILAGE; SURFACE-AREA; STANDING ANTEROPOSTERIOR;
TIBIOFEMORAL COMPARTMENT; 3 TESLA; RESONANCE; BONE; MORPHOLOGY;
PRECISION
AB Objective Clinically, radiographic joint space narrowing (JSN) is regarded a surrogate of cartilage loss in osteoarthritis (OA) Using magnetic resonance imaging (MRI), we explored the magnitude and regional distribution of differences in cartilage thickness and subchondral bone area associated with specific Osteoarthritis Research Society International (OARSI) JSN grades
Method Seventy-three participants with unilateral medial JSN were selected from the first half (2678 cases) of the OA Initiative cohort (45, 21, and 7 with OARSI JSN grades 1, 2, and 3, respectively, no medial JSN in the contra-lateral knee) Bilateral sagittal baseline DESSwe MRIs were segmented by experienced operators Intra-person between-knee differences in cartilage thickness and subchondral bone areas were determined in medial femorotibial subregions
Results Knees with medial OARSI JSN grades 1, 2, and 3 displayed a 190 mu m (5 2%), 630 mu m (18%), and 1560 mu m (44%) smaller cartilage thickness in weight-bearing medial femorotibial compartments compared to knees without JSN, respectively. The weight-bearing femoral condyle displayed relatively greater differences than the posterior femoral condyle or the medial tibia (MT) The central subregion within the weight-bearing medial femur (cMF) of the femoral condyle (30-75 degrees), and the external and central subregions within the tibia displayed relatively greater JSN-associated differences compared to other medial femorotibial subregions Knees with higher JSN grades also displayed larger than contralateral femorotibial subchondral bone areas
Conclusions This study provides quantitative estimates of JSN-related cartilage loss, with the central part of the weight-bearing femoral condyle being most strongly affected Knees with higher JSN grades displayed larger subchondral bone areas, suggesting that an increase in subchondral bone area occurs in advanced OA (C) 2010 Osteoarthritis Research Society International Published by Elsevier Ltd All rights reserved
C1 [Eckstein, F.; Wirth, W.] PMU, Inst Anat, A-5020 Salzburg, Austria.
[Eckstein, F.; Wirth, W.] Chondrometrics GmbH, Ainring, Germany.
[Hunter, D. J.] New England Baptist Hosp, Div Res, Boston, MA USA.
[Guermazi, A.] Boston Univ, Med Ctr, Dept Radiol, Boston, MA 02118 USA.
[Kwoh, C. K.] Univ Pittsburgh, Div Clin Immunol & Rheumatol, Pittsburgh, PA USA.
[Kwoh, C. K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Nelson, D. R.; Benichou, O.] Eli Lilly & Co, Indianapolis, IN 46285 USA.
RP Eckstein, F (reprint author), PMU, Inst Anat & Musculoskeletal Res, Strubergasse 21, A-5020 Salzburg, Austria.
RI Eckstein, Felix/E-1585-2011; Hunter, David/A-4622-2010; Wirth,
Wolfgang/C-8724-2011
OI Hunter, David/0000-0003-3197-752X; Wirth, Wolfgang/0000-0002-2297-8283
FU Eli Lilly Co, IN; National Institute of Health, Department of Health and
Human Services [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260,
N01-AR-2-2261, N01-AR-22262]; OAI include Merck Research Laboratories;
Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Pfizer, Inc.
FX Funding sources The image analysis of this study was funded by Eli Lilly
& Co, IN. The images were acquired by the OAI, a public private
partnership comprised five contracts (N01-AR-2-2258, N01-AR-2-2259;
N01-AR-2-2260, N01-AR-2-2261; N01-AR-22262) funded by the National
Institute of Health, a branch of the Department of Health and Human
Services, and conducted by the OAI Study Investigators. Private funding
partners of the OAI include Merck Research Laboratories; Novartis
Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer, Inc. Private
sector funding for the OAI is managed by the Foundation for the National
Institute of Health This manuscript has received the approval of the OAI
Publications Committee based on a review of its scientific content and
data interpretation
NR 43
TC 31
Z9 31
U1 0
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD JUN
PY 2010
VL 18
IS 6
BP 760
EP 768
DI 10.1016/j.joca.2009.12.009
PG 9
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 609FX
UT WOS:000278642400005
PM 20171298
ER
PT J
AU Goebel, JR
Sherbourne, CD
Asch, SM
Meredith, L
Cohen, AB
Hagenmaier, E
Lanto, AB
Simon, B
Rubenstein, LV
Shugarman, LR
Lorenz, KA
AF Goebel, Joy R.
Sherbourne, Cathy D.
Asch, Steven M.
Meredith, Lisa
Cohen, Angela B.
Hagenmaier, Emily
Lanto, Andy B.
Simon, Barbara
Rubenstein, Lisa V.
Shugarman, Lisa R.
Lorenz, Karl A.
TI Addressing Patients' Concerns about Pain Management and Addiction Risks
SO PAIN MANAGEMENT NURSING
LA English
DT Article
ID NURSES; QUALITY; KNOWLEDGE; VIGNETTES; BARRIERS
AB Fear of engendering addiction is frequently reported as both a provider and a patient barrier to effective pain management. In this study, a clinical scenario ascertained nursing staff members' usual practice in addressing addiction fears for patients with concerns about the addictive potential of pain medication. One hundred forty-five Veterans Health Administration nursing staff members from eight ambulatory care sites were queried to identify variables associated with proclivity to address patient fears about addiction risks in a population where pain is prevalent and the risk for substance abuse is high. Regarding addressing addiction concerns, 66% of nursing staff were very likely, 16% somewhat likely, 9% unsure, 6% somewhat unlikely, and 2% very unlikely to take action. Health technicians were less likely to address addiction concerns than registered or licensed vocational nurses (odds ratio [OR] 0.116; p=.004). Nursing staff with more years' experience (OR 1.070; p=.005) and higher levels of self-efficacy/confidence (OR 1.380; p=.001) were more likely to engage in discussions related to addiction risks. Targeted efforts to improve pain management activities should focus on retaining experienced nursing staff in initial assessment positions and improving the skills and confidence of less experienced and less skilled staff. (C) 2010 by the American Society for Pain Management Nursing
C1 [Goebel, Joy R.] Calif State Univ Long Beach, Dept Nursing, Long Beach, CA 90840 USA.
[Sherbourne, Cathy D.; Asch, Steven M.; Meredith, Lisa; Rubenstein, Lisa V.; Shugarman, Lisa R.; Lorenz, Karl A.] RAND Corp, Santa Monica, CA USA.
[Asch, Steven M.; Meredith, Lisa; Rubenstein, Lisa V.; Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Asch, Steven M.; Cohen, Angela B.; Hagenmaier, Emily; Lanto, Andy B.; Simon, Barbara; Rubenstein, Lisa V.; Lorenz, Karl A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Goebel, JR (reprint author), Calif State Univ Long Beach, Dept Nursing, 1250 Bellflower Blvd, Long Beach, CA 90840 USA.
NR 36
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1524-9042
EI 1532-8635
J9 PAIN MANAG NURS
JI Pain Manag. Nurs.
PD JUN
PY 2010
VL 11
IS 2
BP 92
EP 98
DI 10.1016/j.pmn.2009.03.009
PG 7
WC Nursing
SC Nursing
GA 610QH
UT WOS:000278748700005
PM 20510839
ER
PT J
AU Rodriguez, KL
Bayliss, NK
Jaffe, E
Zickmund, S
Sevick, MA
AF Rodriguez, Keri L.
Bayliss, Nichole K.
Jaffe, Emily
Zickmund, Susan
Sevick, Mary Ann
TI Factor analysis and internal consistency evaluation of the FAMCARE Scale
for use in the long-term care setting
SO PALLIATIVE & SUPPORTIVE CARE
LA English
DT Article
DE Long-term care; Nursing homes; Consumer satisfaction; Family;
Psychometrics
AB Objective: The FAMCARE Scale was originally designed to measure family satisfaction with advanced cancer care. The current study evaluated the instrument's psychometric qualities when used in the long-term care (LTC) setting.
Method: In a prospective cohort study in 2004, the 20-item instrument was administered via telephone to family members of 51 patients receiving LTC in Veterans Affairs facilities. Satisfaction scores on a 5-point Likert scale were used for factor analysis and internal consistency evaluation.
Results: Although 16 patients were in geriatric palliative care and 35 were in nursing home care, scores of their family members did not vary based on care unit. The total satisfaction score was high, with a mean (SD) of 44.7 (11.9) and a Cronbach alpha of 0.94. Inter-item correlations were low for care availability items (range, 0.01-0.59). Two items-availability of a hospital bed and availability of nurses to the family-had low eigenvalues (0.26 and 0.18, respectively) and weak correlations with the total score (0.23 and 0.16, respectively).
Significance of results: In the LTC setting, FAMCARE appears to have good internal consistency, but it may be preferable to exclude the two items with weak correlations and to use a 10-point visual analog scale.
C1 [Rodriguez, Keri L.; Bayliss, Nichole K.; Zickmund, Susan; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Rodriguez, Keri L.; Zickmund, Susan; Sevick, Mary Ann] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Rodriguez, Keri L.; Jaffe, Emily; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA.
[Bayliss, Nichole K.] Univ Pittsburgh, Sociol Dept, Pittsburgh, PA USA.
[Jaffe, Emily] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA USA.
[Sevick, Mary Ann] Univ Pittsbsburg, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA.
RP Rodriguez, KL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,Bldg 2,Room 4083E,151C-H, Pittsburgh, PA 15206 USA.
EM keri.rodriguez@va.gov
NR 25
TC 10
Z9 10
U1 1
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1478-9515
J9 PALLIAT SUPPORT CARE
JI Palliat. Support Care
PD JUN
PY 2010
VL 8
IS 2
BP 169
EP 176
DI 10.1017/S1478951509990927
PG 8
WC Health Policy & Services
SC Health Care Sciences & Services
GA V25ON
UT WOS:000208487400009
PM 20331914
ER
PT J
AU Pekary, AE
Stevens, SA
Blood, JD
Sattin, A
AF Pekary, Albert Eugene
Stevens, Schetema A.
Blood, James D.
Sattin, Albert
TI Rapid modulation of TRH and TRH-like peptide release in rat brain,
pancreas, and testis by a GSK-3 beta inhibitor
SO PEPTIDES
LA English
DT Article
DE GSK-3 beta; Thyrotropin-releasing hormone; Limbic system; Testis; HPLC;
Radioimmunoassay
ID GLYCOGEN-SYNTHASE KINASE-3-BETA; PGLU-GLU-PRO-NH2 EEP;
TAU-PHOSPHORYLATION; PERIPHERAL-TISSUES; INSULIN-SECRETION; LIGHT-CHAIN;
HORMONE TRH; IN-VITRO; KINESIN; GSK3
AB Antidepressants have been shown to be neuroprotective and able to reverse damage to glia and neurons. Thyrotropin-releasing hormone (TRH) is an endogenous antidepressant-like neuropeptide that reduces the expression of glycogen synthase kinase-3 beta (GSK-3 beta), an enzyme that hyperphosphorylates tau and is implicated in bipolar disorder, diabetes and Alzheimer's disease. In order to understand the potential role of GSK-3 beta in the modulation of depression by TRH and TRH-like peptides and the therapeutic potential of GSK-3 beta inhibitors for neuropsychiatric and metabolic diseases, young adult male Sprague-Dawley (SD) rats were (a) injected ip with 1.8 mg/kg of GSK-3 beta inhibitor VIII (GSKI) and sacrificed 0, 2, 4, 6, and 8 h later or (b) injected with 0, 0.018, 0.18 or 1.8 mg/kg GSKI and bled 4 h later. Levels of TRH and TRH-like peptides were measured in various brain regions involved in mood regulation, pancreas and reproductive tissues. Large, 3-15-fold, increases of TRH and TRH-like peptide levels in cerebellum, for example, as well as other brain regions were noted at 2 and 4 h. In contrast, a nearly complete loss of TRH and TRH-like peptides from testis within 2 h and pancreas by 4 h following GSKI injection was observed. We have previously reported similar acute effects of corticosterone in brain and peripheral tissues. Incubation of a decapsulated rat testis with either GSKI or corticosterone accelerated release of TRH, and TRH-like peptides. Glucocorticoids, via inhibition of GSK3-beta activity, may thus be involved in the inhibition of TRH and TRH-like peptide release in brain, thereby contributing to the depressogenic effect of this class of steroids. Corticosterone-induced acceleration of release of these peptides from testis may contribute to the decline in reproductive function and redirection of energy needed during life-threatening emergencies. These contrasting effects of glucocorticoid on peptide release appear to be mediated by GSK-3 beta. Published by Elsevier Inc.
C1 [Pekary, Albert Eugene; Stevens, Schetema A.; Blood, James D.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
[Sattin, Albert] VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA.
[Pekary, Albert Eugene] VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA.
[Pekary, Albert Eugene] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA.
[Sattin, Albert] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA.
[Sattin, Albert] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA.
RP Pekary, AE (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM Eugene.Pekary@va.gov
FU Veterans Administration Medical Research Funds; Pekary Family Trust
FX This work was supported by Veterans Administration Medical Research
Funds (AEP and AS) and the Pekary Family Trust.
NR 63
TC 6
Z9 8
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
J9 PEPTIDES
JI Peptides
PD JUN
PY 2010
VL 31
IS 6
BP 1083
EP 1093
DI 10.1016/j.peptides.2010.03.020
PG 11
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
GA 676SN
UT WOS:000283939000013
PM 20338209
ER
PT J
AU Peter, L
Stengel, A
Noetzel, S
Inhoff, T
Goebel, M
Tache, Y
Veh, RW
Bannert, N
Grotzinger, C
Wiedenmann, B
Klapp, BF
Monnikes, H
Kobelt, P
AF Peter, Lisa
Stengel, Andreas
Noetzel, Steffen
Inhoff, Tobias
Goebel, Miriam
Tache, Yvette
Veh, Ruediger W.
Bannert, Norbert
Groetzinger, Carsten
Wiedenmann, Bertram
Klapp, Burghard F.
Moennikes, Hubert
Kobelt, Peter
TI Peripherally injected CCK-8S activates CART positive neurons of the
paraventricular nucleus in rats
SO PEPTIDES
LA English
DT Article
DE CCK; CART; c-Fos; Food intake; PVN
ID C-FOS EXPRESSION; CORTICOTROPIN-RELEASING HORMONE; DORSAL VAGAL COMPLEX;
FOOD-INTAKE; SOLITARY TRACT; HYPOTHALAMIC NEUROENDOCRINE;
CHOLECYSTOKININ-OCTAPEPTIDE; GENE-EXPRESSION; BRAIN-STEM; PEPTIDE
AB Cholecystokinin (CCK) plays a role in the short-term inhibition of food intake. Cocaine-and amphetamine-regulated transcript (CART) peptide has been observed in neurons of the paraventricular nucleus (PVN). It has been reported that intracerebroventricular injection of CART peptide inhibits food intake in rodents. The aim of the study was to determine whether intraperitoneally (ip) injected CCK-8S affects neuronal activity of PVN-CART neurons. Ad libitum fed male Sprague-Dawley rats received 6 or 10 mu g/kg CCK-8S or 0.15M NaCl ip (n = 4/group). The number of c-Fos-immunoreactive neurons was determined in the PVN, arcuate nucleus (ARC), and the nucleus of the solitary tract (NTS). CCK-8S dose-dependently increased the number of c-Fos-immunoreactive neurons in the PVN (mean +/- SEM: 102 +/- 6 vs. 150 +/- 5 neurons/section, p < 0.05) and compared to vehicle treated rats (18 +/- 7, p < 0.05 vs. 6 and 10 mu g/kg CCK-8S). CCK-8S at both doses induced an increase in the number of c-Fos-immunoreactive neurons in the NTS (65 +/- 13, p < 0.05, and 182 +/- 16, p < 0.05). No effect on the number of c-Fos neurons was observed in the ARC. Immunostaining for CART and c-Fos revealed a dose-dependent increase of activated CART neurons (19 +/- 3 vs. 29 +/- 7; p < 0.05), only few activated CART neuron were observed in the vehicle group (1 +/- 0). The present observation shows that CCK-8S injected ip induces an increase in neuronal activity in PVN-CART neurons and suggests that CART neurons in the PVN may play a role in the mediation of peripheral CCK-8S's anorexigenic effects. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Klapp, Burghard F.; Kobelt, Peter] Charite, Dept Med, Div Psychosomat Med & Psychotherapy, D-10117 Berlin, Germany.
[Peter, Lisa; Noetzel, Steffen; Inhoff, Tobias; Groetzinger, Carsten; Wiedenmann, Bertram; Kobelt, Peter] Charite, Dept Med, Div Hepatol Gastroenterol & Endocrinol, D-10117 Berlin, Germany.
[Stengel, Andreas; Goebel, Miriam; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Div Digest Dis, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA.
[Stengel, Andreas; Goebel, Miriam; Tache, Yvette] Univ Calif Los Angeles, Ctr Neurobiol Stress, Los Angeles, CA USA.
[Stengel, Andreas; Goebel, Miriam; Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Veh, Ruediger W.] Charite, Inst Integrat Neuroanat, D-10117 Berlin, Germany.
[Bannert, Norbert] Robert Koch Inst, D-1000 Berlin, Germany.
[Moennikes, Hubert] Martin Luther Hosp, Dept Med, Berlin, Germany.
[Moennikes, Hubert] Martin Luther Hosp, Inst Neurogastroenterol, Berlin, Germany.
RP Kobelt, P (reprint author), Charite, Dept Med, Div Psychosomat Med & Psychotherapy, Campus Mitte,Luisenstr 13 A, D-10117 Berlin, Germany.
EM peter.kobelt@charite.de
OI Grotzinger, Carsten/0000-0001-9872-3087
FU German Research Foundation [DFG KO 3864/2-1];
Charite-Universitatsmedizin Berlin [UFF 09/41730, 09/42458]; Veterans
Administration; NIHDK [33061]; [DK-41301]
FX This work was supported by grants from the German Research Foundation to
P.K (DFG KO 3864/2-1), and from Charite-Universitatsmedizin Berlin to
P.K (UFF 09/41730 and 09/42458) as well as Veterans Administration
Research Career Scientist Award (Y.T), Veterans Administration Merit
Award (Y.T), NIHDK 33061 (Y.T), Center Grant DK-41301 (Animal Core)
(Y.T.).
NR 44
TC 10
Z9 11
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
J9 PEPTIDES
JI Peptides
PD JUN
PY 2010
VL 31
IS 6
BP 1118
EP 1123
DI 10.1016/j.peptides.2010.03.013
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
GA 676SN
UT WOS:000283939000018
PM 20307613
ER
PT J
AU Sharma, SD
Katiyar, SK
AF Sharma, Som D.
Katiyar, Santosh K.
TI Dietary Grape Seed Proanthocyanidins Inhibit UVB-Induced
Cyclooxygenase-2 Expression and Other Inflammatory Mediators in
UVB-Exposed Skin and Skin Tumors of SKH-1 Hairless Mice
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE chemoprevention; COX-2; grape seed proanthocyanidins; skin cancer;
ultraviolet radiation
ID INDUCED OXIDATIVE STRESS; NF-KAPPA-B; MOUSE SKIN; GREEN TEA; DNA-REPAIR;
PREVENTS PHOTOCARCINOGENESIS; ULTRAVIOLET-LIGHT; COX-2 EXPRESSION;
CARCINOMA-CELLS; IN-VIVO
AB The purpose of this study was to determine the chemopreventive mechanism of dietary grape seed proanthocyanidins (GSPs) against ultraviolet (UV) radiation-induced skin tumor development in mice.
Six-to-seven-week-old SKH-1 hairless mice were subjected to photocarcinogenesis protocol, and exposed to UVB radiation (180 mJ/cm(2)) three times/week for 24 weeks. Mice were fed a standard AIN76A control diet with or without supplementation with grape seed proanthocyanidins (GSPs; 0.2% or 0.5%, w/w). At the termination of the experiment, mice were sacrificed, and skin and skin tumor samples were harvested and subjected to the analysis of biomarkers related to inflammation using immunostaining, western blot analysis, ELISA and real-time PCR.
Dietary GSPs inhibited UVB-induced infiltration of proinflammatory leukocytes and the levels of myeloperoxidase, cyclooxygenase-2 (COX-2), prostaglandin (PG) E-2, cyclin D1 and proliferating cell nuclear antigen (PCNA) in the skin and skin tumors compared to non-GSPs-treated UVB irradiated mouse skin and skin tumors. GSPs also significantly inhibited the levels of proinflammatory cytokines, tumor necrosis factor-alpha (P < 0.01), IL-1 beta (P < 0.001) and IL-6 (P < 0.001), in UVB-exposed skin and skin tumors.
The results from this study clearly suggest that dietary GSPs inhibit photocarcinogenesis in mice through the inhibition of UVB-induced inflammation and mediators of inflammation in mouse skin.
C1 [Sharma, Som D.; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU Veterans Administration Merit Review Award
FX This work was financially supported by the Veterans Administration Merit
Review Award (S.K.K.).
NR 42
TC 40
Z9 43
U1 1
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JUN
PY 2010
VL 27
IS 6
BP 1092
EP 1102
DI 10.1007/s11095-010-0050-9
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 597VW
UT WOS:000277791300016
PM 20143255
ER
PT J
AU Luttrell, LM
Gesty-Palmer, D
AF Luttrell, Louis M.
Gesty-Palmer, Diane
TI Beyond Desensitization: Physiological Relevance of Arrestin-Dependent
Signaling
SO PHARMACOLOGICAL REVIEWS
LA English
DT Review
ID PROTEIN-COUPLED RECEPTOR; BETA-ADRENERGIC-RECEPTOR; PARATHYROID-HORMONE
PTH; CLATHRIN-MEDIATED ENDOCYTOSIS; ANGIOTENSIN-II RECEPTOR;
GROWTH-FACTOR RECEPTOR; TERNARY COMPLEX MODEL; CHRONIC HEART-FAILURE;
FAILING HUMAN HEART; BETA(2)-ADRENERGIC RECEPTOR
AB Heptahelical G protein-coupled receptors are the most diverse and therapeutically important family of receptors in the human genome. Ligand binding activates heterotrimeric G proteins that transmit intracellular signals by regulating effector enzymes or ion channels. G protein signaling is terminated, in large part, by arrestin binding, which uncouples the receptor and G protein and targets the receptor for internalization. It is clear, however, that heptahelical receptor signaling does not end with desensitization. Arrestins bind a host of catalytically active proteins and serve as ligand-regulated scaffolds that recruit protein and lipid kinase, phosphatase, phosphodiesterase, and ubiquitin ligase activity into the receptor-arrestin complex. Although many of these arrestin-bound effectors serve to modulate G protein signaling, degrading second messengers and regulating endocytosis and trafficking, other signals seem to extend beyond the receptor-arrestin complex to regulate such processes as protein translation and gene transcription. Although these findings have led to a re-envisioning of heptahelical receptor signaling, little is known about the physiological roles of arrestin-dependent signaling. In vivo, the duality of arrestin function makes it difficult to dissociate the consequences of arrestin-dependent desensitization from those that might be ascribed to arrestin-mediated signaling. Nonetheless, recent evidence generated using arrestin knockouts, G protein-uncoupled receptor mutants, and arrestin pathway-selective "biased agonists" is beginning to reveal that arrestin signaling plays important roles in the retina, central nervous system, cardiovascular system, bone remodeling, immune system, and cancer. Understanding the signaling roles of arrestins may foster the development of pathway-selective drugs that exploit these pathways for therapeutic benefit.
C1 [Gesty-Palmer, Diane] Duke Univ, Med Ctr, Div Endocrinol & Metab, Dept Med, Durham, NC 27710 USA.
[Gesty-Palmer, Diane] Durham Vet Affairs Med Ctr, Durham, NC USA.
[Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Gesty-Palmer, D (reprint author), Duke Univ, Med Ctr, Div Endocrinol & Metab, Dept Med, Box 103015, Durham, NC 27710 USA.
EM gesty001@mc.duke.edu
FU National Institutes of Health National Institute of Diabetes and
Digestive and Kidney Diseases [DK64353, DK55524]; National Institutes of
Health National Institute of Child Health & Human Development
[HD043446]; Arthritis Foundation; Research Services of the Charleston,
SC, and Durham, NC, Veterans Affairs Medical Centers
FX This work was supported by the National Institutes of Health National
Institute of Diabetes and Digestive and Kidney Diseases [Grants DK64353,
DK55524 (to L. M. L.)]; the National Institutes of Health National
Institute of Child Health & Human Development [Grant HD043446 (to
D.G.-P.)]; the Arthritis Foundation (to D.G.-P.); and the Research
Services of the Charleston, SC, and Durham, NC, Veterans Affairs Medical
Centers. We offer our sincere apologies to the many outstanding
researchers whose work has been omitted because of space and topic
constraints. There is no intent to diminish or downplay the significance
of their contributions to this rapidly expanding field.
NR 224
TC 187
Z9 194
U1 1
U2 12
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0031-6997
J9 PHARMACOL REV
JI Pharmacol. Rev.
PD JUN
PY 2010
VL 62
IS 2
BP 305
EP 330
DI 10.1124/pr.109.002436
PG 26
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 596QB
UT WOS:000277698900005
PM 20427692
ER
PT J
AU Pedersen, ME
Baldwin, RA
Niquet, J
Stafford, GI
van Staden, J
Wasterlain, CG
Jager, AK
AF Pedersen, Mikael E.
Baldwin, Roger A.
Niquet, Jerome
Stafford, Gary I.
van Staden, Johannes
Wasterlain, Claude G.
Jager, Anna K.
TI Anticonvulsant Effects of Searsia dentata (Anacardiaceae) Leaf Extract
in Rats
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE traditional medicine; epilepsy; NMDA receptor antagonists
AB Searsia species are used in South Africa to treat epilepsy. Previous studies have demonstrated an in vitro N-methyl-D-aspartic acid (NMDA) receptor antagonistic effect of the ethanolic leaf extract. The aim of this study was to evaluate the potential anticonvulsant properties of the ethanolic extract of S. dentata in various animal models of epilepsy. The extract was submitted to a screening in anticonvulsant assays including NMDA-, kainic acid (KA)-, pentylenetetrazol (PTZ)- and bicuculline (BIC)-induced seizures in rats. The extract protected 47% of the PN 18 Wistar pups (postnatal day 18, date of birth PN 0) (p < 0.05, n > 10) against NMDA-induced seizures and significantly delayed the onset of PTZ-induced seizures (p < 0.05, n > 8) at a dose of 250 mg/kg. A dose optimum was detected at 500 mg/kg for protection against KA-(63% protection, p < 0.05, n > 8) and BIC-induced seizures (50% protection, p < 0.05, n > 8) in young adult and PN 18 rats, respectively. The ethanolic extract of S. dentata showed anticonvulsive properties in several models of epilepsy. These results are compatible with previous findings of NMDA receptor antagonism. Due to the complex composition of the extract, the effect might be caused by more than one compound. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Pedersen, Mikael E.; Jager, Anna K.] Univ Copenhagen, Fac Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen O, Denmark.
[Pedersen, Mikael E.; Stafford, Gary I.; van Staden, Johannes] Univ KwaZulu Natal Pietermaritzburg, Sch Biol & Conservat Sci, Res Ctr Plant Growth & Dev, ZA-3209 Scottsville, South Africa.
[Pedersen, Mikael E.; Baldwin, Roger A.; Niquet, Jerome; Wasterlain, Claude G.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Jager, AK (reprint author), Univ Copenhagen, Fac Pharmaceut Sci, Dept Med Chem, 2 Univ Pk, DK-2100 Copenhagen O, Denmark.
EM ankj@farma.ku.dk
RI Stafford, Gary/E-8668-2011; Pedersen, Mikael/F-9158-2011
OI Stafford, Gary/0000-0003-0198-0955;
FU National Research Foundation (South Africa)
FX The National Research Foundation (South Africa) is thanked for financial
assistance.
NR 11
TC 5
Z9 5
U1 2
U2 4
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0951-418X
J9 PHYTOTHER RES
JI Phytother. Res.
PD JUN
PY 2010
VL 24
IS 6
BP 924
EP 927
DI 10.1002/ptr.3016
PG 4
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 614OS
UT WOS:000279070200021
PM 19953526
ER
PT J
AU Gold, MC
Cerri, S
Smyk-Pearson, S
Cansler, ME
Vogt, TM
Delepine, J
Winata, E
Swarbrick, GM
Chua, WJ
Yu, YYL
Lantz, O
Cook, MS
Null, MD
Jacoby, DB
Harriff, MJ
Lewinsohn, DA
Hansen, TH
Lewinsohn, DM
AF Gold, Marielle C.
Cerri, Stefania
Smyk-Pearson, Susan
Cansler, Meghan E.
Vogt, Todd M.
Delepine, Jacob
Winata, Ervina
Swarbrick, Gwendolyn M.
Chua, Wei-Jen
Yu, Yik Y. L.
Lantz, Olivier
Cook, Matthew S.
Null, Megan D.
Jacoby, David B.
Harriff, Melanie J.
Lewinsohn, Deborah A.
Hansen, Ted H.
Lewinsohn, David M.
TI Human Mucosal Associated Invariant T Cells Detect Bacterially Infected
Cells
SO PLOS BIOLOGY
LA English
DT Article
ID MYCOBACTERIUM-TUBERCULOSIS INFECTION; MR1 ANTIGEN PRESENTATION;
ALPHA-CHAIN; MAIT CELLS; RECOGNITION; LYMPHOCYTES; RESPONSES; RECEPTOR;
PROTEIN; INNATE
AB Control of infection with Mycobacterium tuberculosis (Mtb) requires Th1-type immunity, of which CD8(+) T cells play a unique role. High frequency Mtb-reactive CD8(+) T cells are present in both Mtb-infected and uninfected humans. We show by limiting dilution analysis that nonclassically restricted CD8(+) T cells are universally present, but predominate in Mtb-uninfected individuals. Interestingly, these Mtb-reactive cells expressed the V alpha 7.2 T-cell receptor (TCR), were restricted by the nonclassical MHC (HLA-Ib) molecule MR1, and were activated in a transporter associated with antigen processing and presentation (TAP) independent manner. These properties are all characteristics of mucosal associated invariant T cells (MAIT), an "innate'' T-cell population of previously unknown function. These MAIT cells also detect cells infected with other bacteria. Direct ex vivo analysis demonstrates that Mtb-reactive MAIT cells are decreased in peripheral blood mononuclear cells (PBMCs) from individuals with active tuberculosis, are enriched in human lung, and respond to Mtb-infected MR1-expressing lung epithelial cells. Overall, these findings suggest a generalized role for MAIT cells in the detection of bacterially infected cells, and potentially in the control of bacterial infection.
C1 [Gold, Marielle C.; Cerri, Stefania; Smyk-Pearson, Susan; Delepine, Jacob; Winata, Ervina; Swarbrick, Gwendolyn M.; Cook, Matthew S.; Jacoby, David B.; Harriff, Melanie J.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
[Gold, Marielle C.; Delepine, Jacob; Swarbrick, Gwendolyn M.; Harriff, Melanie J.; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR USA.
[Smyk-Pearson, Susan; Cansler, Meghan E.; Vogt, Todd M.; Swarbrick, Gwendolyn M.; Cook, Matthew S.; Null, Megan D.; Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA.
[Chua, Wei-Jen; Yu, Yik Y. L.; Hansen, Ted H.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
[Lantz, Olivier] Inst Curie Paris, Inserm 932, Lab Immunol & Unite, Paris, France.
[Lewinsohn, Deborah A.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
RP Gold, MC (reprint author), Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
EM goldm@ohsu.edu; lewinsod@ohsu.edu
RI Lantz, Olivier/J-4960-2012; Cerri, Stefania/N-9701-2016; Lewinsohn,
David/I-4936-2013
OI Lantz, Olivier/0000-0003-3161-7719; Cerri, Stefania/0000-0003-4612-1580;
Jacoby, David/0000-0003-2195-9512; Lewinsohn, David/0000-0001-9906-9494;
Gold, Marielle/0000-0003-2505-3291
FU Department of Veterans Affairs; National Institutes of Health (NIH)
[AI48090, HHSN266200400081C]
FX Funding was provided in part by the Department of Veterans Affairs and
with resources and the use of facilities at the Portland VA Medical
Center, National Institutes of Health (NIH) grant AI48090, and NIH
contract HHSN266200400081C. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 52
TC 193
Z9 193
U1 3
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1544-9173
J9 PLOS BIOL
JI PLoS. Biol.
PD JUN
PY 2010
VL 8
IS 6
AR e1000407
DI 10.1371/journal.pbio.1000407
PG 14
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics
GA 618LK
UT WOS:000279355600019
PM 20613858
ER
PT J
AU Figoni, SF
Kunkel, CF
Scremin, AME
Scremin, OU
Cohen, B
AF Figoni, Stephen F.
Kunkel, Charles F.
Scremin, A. M. Erika
Scremin, Oscar U.
Cohen, Babak
TI Ergometric Performance During Exercise Training in Men With Intermittent
Claudication
SO PM&R
LA English
DT Article
AB Objective: To determine and describe changes in weekly work, power, exercise times, and recovery times during an exercise training intervention in men with peripheral arterial disease (PAD) and intermittent calf claudication.
Design: Tracking of weekly exercise training parameters involved repeated measures over time in one group of participants. Other outcomes of this pilot study used a one-group, pretest-posttest design.
Setting: Tertiary-care medical center.
Participants: Fifteen male veterans (mean age, 69 years) with Fontaine stage ha PAD and classic intermittent calf claudication.
Main Outcome Measurements: Participants completed graded treadmill exercise tests before and after intervention from which maximal walking power was calculated. Work, power, and exercise and recovery times for each exercise training session were computed and averaged for each week.
Intervention: The intervention consisted of an intensive 3-month exercise training program involving walking and calf muscle exercises: 3 sessions per week at the clinic (treadmill walking and calf ergometry) and 2 sessions per week at home (free walking and standing heel raises).
Results: After training, participants increased treadmill maximal walking power from 220 to 414 W (by 87%). Treadmill and calf exercise work, power, and exercise time per session increased linearly during 13 weeks of training, whereas recovery time per session of treadmill exercise decreased. During the same period, treadmill and calf exercise training power outputs increased by averages of 227% and 92%, respectively.
Conclusion: Calculation of work and power during exercise training can be used to track progress quantitatively at short intervals. Weekly linear increases in training work and power per exercise session suggest that optimal intervention duration may be longer than 3 months for men with PAD and intermittent calf claudication. PM R 2010;2:528-536
C1 [Figoni, Stephen F.; Kunkel, Charles F.; Scremin, A. M. Erika; Cohen, Babak] VA Greater Los Angeles Healthcare Syst, Phys Med & Rehabil Serv, Los Angeles, CA 90073 USA.
[Kunkel, Charles F.; Scremin, A. M. Erika] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Scremin, Oscar U.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
[Scremin, Oscar U.; Cohen, Babak] VA Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA 90073 USA.
RP Figoni, SF (reprint author), VA Greater Los Angeles Healthcare Syst, Phys Med & Rehabil Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM sfigoni@gmail.com
FU Rehabilitation Research and Development Service, Department of Veterans
Affairs [B3644P]
FX Disclosure: 8, Rehabilitation Research and Development Service,
Department of Veterans Affairs grant #B3644P
NR 18
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD JUN
PY 2010
VL 2
IS 6
BP 528
EP 536
DI 10.1016/j.pmrj.2010.03.009
PG 9
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA V24LQ
UT WOS:000208412300008
PM 20630439
ER
PT J
AU Banez, LL
Loftis, RM
Freedland, SJ
Presti, JC
Aronson, WJ
Amling, CL
Kane, CJ
Terris, MK
AF Banez, L. L.
Loftis, R. M.
Freedland, S. J.
Presti, J. C., Jr.
Aronson, W. J.
Amling, C. L.
Kane, C. J.
Terris, M. K.
TI The influence of hepatic function on prostate cancer outcomes after
radical prostatectomy
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Article
DE prostate neoplasm; staging; pathology; PSA recurrence; radical
prostatectomy; liver function tests
ID HORMONE-BINDING GLOBULIN; LIVER-CIRRHOSIS; ALCOHOL-CONSUMPTION; RISK;
ANTIGEN; FINASTERIDE; OBESITY; COHORT; MALES; MEN
AB Prostate growth is dependent on circulating androgens, which can be influenced by hepatic function. Liver disease has been suggested to influence prostate cancer (CaP) incidence. However, the effect of hepatic function on CaP outcomes has not been investigated. A total of 1181 patients who underwent radical prostatectomy (RP) between 1988 and 2008 at four Veterans Affairs hospitals that comprise the Shared Equal Access Regional Cancer Hospital database and had available liver function test (LFT) data were included in the study. Independent associations of LFTs with unfavorable pathological features and biochemical recurrence were determined using logistic and Cox regression analyses. Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) levels were elevated in 8.2 and 4.4% of patients, respectively. After controlling for CaP features, logistic regression revealed a significant association between SGOT levels and pathological Gleason sum >= 7(4 + 3) cancer (odds ratio = 2.12; 95% confidence interval = 1.11-4.05; P = 0.02). Mild hepatic dysfunction was significantly associated with adverse CaP grade, but was not significantly associated with other adverse pathological features or biochemical recurrence in a cohort of men undergoing RP. The effect of moderate-to-severe liver disease on disease outcomes in CaP patients managed non-surgically remains to be investigated. Prostate Cancer and Prostatic Diseases (2010) 13, 173-177; doi:10.1038/pcan.2010.3; published online 2 March 2010
C1 [Banez, L. L.; Freedland, S. J.] Duke Univ, Div Urol Surg, Dept Surg, Med Ctr, Durham, NC 27710 USA.
[Banez, L. L.; Freedland, S. J.] Duke Univ, Duke Prostate Ctr, Dept Surg, Med Ctr, Durham, NC 27710 USA.
[Banez, L. L.; Freedland, S. J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA.
[Loftis, R. M.; Terris, M. K.] Med Coll Georgia, Dept Surg, Urol Sect, Augusta, GA 30912 USA.
[Loftis, R. M.; Terris, M. K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA.
[Freedland, S. J.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
[Presti, J. C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA.
[Presti, J. C., Jr.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA.
[Aronson, W. J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
[Aronson, W. J.] Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA.
[Amling, C. L.] Oregon Hlth & Sci Univ, Dept Surg, Div Urol, Portland, OR 97201 USA.
[Kane, C. J.] Univ Calif San Diego, Dept Urol, San Diego, CA 92103 USA.
[Kane, C. J.] Vet Affairs Med Ctr, Urol Sect, San Diego, CA 92161 USA.
RP Banez, LL (reprint author), Duke Univ, Div Urol Surg, Dept Surg, Med Ctr, Box 2626,571 Res Dr, Durham, NC 27710 USA.
EM lionel.banez@duke.edu
OI Terris, Martha/0000-0002-3843-7270
FU Department of Veterans Affairs; Department of Defense; Georgia Cancer
Coalition; American Urological Association Foundation; National
Institutes of Health [R01 CA100938, P50 CA921310-1A1]
FX This study was supported by the Department of Veterans Affairs,
Department of Defense Prostate Cancer Research Program, the Georgia
Cancer Coalition, the American Urological Association
Foundation/Astellas Rising Star in Urology Award, National Institutes of
Health R01 CA100938, and National Institutes of Health Specialized
Programs of Research Excellence Grant P50 CA921310-1A1.
NR 24
TC 9
Z9 9
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1365-7852
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD JUN
PY 2010
VL 13
IS 2
BP 173
EP 177
DI 10.1038/pcan.2010.3
PG 5
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 595QC
UT WOS:000277626300011
PM 20195294
ER
PT J
AU Pratchett, LC
Pelcovitz, MR
Yehuda, R
AF Pratchett, Laura C.
Pelcovitz, Michelle R.
Yehuda, Rachel
TI Trauma and Violence: Are Women the Weaker Sex?
SO PSYCHIATRIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Trauma; Gender; Risk; Prevalence
ID POSTTRAUMATIC-STRESS-DISORDER; BORDERLINE PERSONALITY-DISORDER;
NATIONAL-COMORBIDITY-SURVEY; PSYCHOLOGICAL RISK-FACTORS;
GENDER-DIFFERENCES; CHILDHOOD EXPERIENCES; GENERAL-POPULATION;
FEMALE-PATIENTS; MENTAL-HEALTH; LIFE EVENTS
AB Posttraumatic stress disorder (PTSD) as a response to trauma is repeatedly found to be more common among women than men. This article explores prevalence rates and gender differences. Explanations for this gender bias and examined and the literature on trauma types and resulting PTSD is reviewed. Other disorders that may result from trauma that also have gender biases are considered as a potential way to understand this difference. Risk and resilience can perhaps more appropriately be considered specific to symptom picture rather than merely development of pathology.
C1 [Pratchett, Laura C.; Pelcovitz, Michelle R.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
[Pratchett, Laura C.; Pelcovitz, Michelle R.; Yehuda, Rachel] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
RP Pratchett, LC (reprint author), James J Peters Vet Affairs Med Ctr, 526 OOMH 116-A,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM laura.pratchett@va.gov
NR 62
TC 30
Z9 31
U1 2
U2 14
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0193-953X
J9 PSYCHIAT CLIN N AM
JI Psychiatr. Clin. North Amer.
PD JUN
PY 2010
VL 33
IS 2
BP 465
EP +
DI 10.1016/j.psc.2010.01.010
PG 12
WC Psychiatry
SC Psychiatry
GA 591FN
UT WOS:000277285300013
PM 20385347
ER
PT J
AU Kettl, P
AF Kettl, Paul
TI State Hospitals and Getting Stuck in a Train
SO PSYCHIATRIC SERVICES
LA English
DT Editorial Material
C1 Philadelphia Dept Vet Affairs Med Ctr, Behav Hlth Serv, Philadelphia, PA 19104 USA.
RP Kettl, P (reprint author), Philadelphia Dept Vet Affairs Med Ctr, Behav Hlth Serv, Univ & Woodland Ave, Philadelphia, PA 19104 USA.
EM paul.kettl@va.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD JUN
PY 2010
VL 61
IS 6
BP 552
EP 553
PG 2
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 602UT
UT WOS:000278165100004
PM 20513676
ER
PT J
AU Perron, BE
Grahovac, ID
Parrish, D
AF Perron, Brian E.
Grahovac, Ivana D.
Parrish, Diana
TI Students for Recovery: A Novel Way to Support Students on Campus
SO PSYCHIATRIC SERVICES
LA English
DT Editorial Material
C1 [Perron, Brian E.] Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA.
[Grahovac, Ivana D.] Univ Texas Austin, Ctr Students Recovery, Austin, TX 78712 USA.
[Parrish, Diana] US Dept Vet Affairs, Ann Arbor, MI USA.
RP Perron, BE (reprint author), Univ Michigan, Sch Social Work, 1080 S Univ Ave, Ann Arbor, MI 48109 USA.
EM beperron@umich.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD JUN
PY 2010
VL 61
IS 6
BP 633
EP 633
PG 1
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 602UT
UT WOS:000278165100019
PM 20513691
ER
PT J
AU Moore, SA
Varra, AA
Michael, ST
Simpson, TL
AF Moore, Sally A.
Varra, Alethea A.
Michael, Scott T.
Simpson, Tracy L.
TI Stress-Related Growth, Positive Reframing, and Emotional Processing in
the Prediction of Post-Trauma Functioning Among Veterans in Mental
Health Treatment
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE stress-related growth; emotional processing; reappraisal; positive
reframing; posttraumatic stress disorder
ID BREAST-CANCER; TRAUMA; ADJUSTMENT; DEPRESSION; VALIDATION
AB The role of stress related growth (SRG) in posttrauma functioning is currently uncertain and may be obscured by the overlap between SRG and key coping strategies. Utilizing a veteran sample in mental health treatment, the current study examined whether SRG accounts for unique variance in the severity of posttraumatic stress disorder (PTSD), depression, and Disorders of Extreme Stress Not Otherwise Specified (DESNOS) beyond the effects of two general coping strategies, emotional processing and positive reframing. Curvilinear relationships were evident between SRG and outcome measures, such that individuals with moderate SRG reported the greatest distress, and individuals with the lowest and highest SRG scores reported lower distress. In regression analyses. SRG accounted for significant variance in lower PTSD, depression, and DESNOS while accounting for demographics, trauma type, emotional processing, and positive reframing. The results suggest that SRG captures variance in posttrauma functioning that may be distinct from general emotional processing and positive refraining coping and provides further evidence for a curvilinear relationship between SRG and measures of psychological distress.
C1 [Moore, Sally A.] Dept Vet Affairs Med Ctr, MIRECC, Seattle, WA USA.
[Moore, Sally A.; Varra, Alethea A.; Michael, Scott T.; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Varra, Alethea A.; Michael, Scott T.; Simpson, Tracy L.] Dept Vet Affairs Med Ctr, Mental Hlth Serv, Seattle, WA USA.
RP Moore, SA (reprint author), VA Puget Sound Hlth Care Syst, Mail Stop S116-WTRC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM sally.moore2@va.gov
NR 15
TC 6
Z9 6
U1 1
U2 2
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD JUN
PY 2010
VL 2
IS 2
BP 93
EP 96
DI 10.1037/a0018975
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 742CD
UT WOS:000288914800004
ER
PT J
AU Boscarino, JA
Forsberg, CW
Goldberg, J
AF Boscarino, Joseph A.
Forsberg, Christopher W.
Goldberg, Jack
TI A Twin Study of the Association Between PTSD Symptoms and Rheumatoid
Arthritis
SO PSYCHOSOMATIC MEDICINE
LA English
DT Article
DE posttratimatic stress disorder; rheumatoid arthritis; autoimmune
disease; inflammation; zygosity; co-twin study
ID POSTTRAUMATIC-STRESS-DISORDER; CORONARY-HEART-DISEASE; TRADE-CENTER
DISASTER; VIETNAM VETERANS; CLINICAL-RESEARCH; COMBAT EXPOSURE;
CHILDHOOD ABUSE; PHYSICAL HEALTH; MORTALITY; TRAUMA
AB Objectives: To assess the association between posttraumatic stress disorder (PTSD) and rheumatoid arthritis (RA) and to determine if this was due to PTSD or confounding by environmental and genetic factors. Methods: Data were obtained from 3143 twin pairs in the Vietnam Era Twin Registry, which included male twin pairs who served during the Vietnam War era (mean age, 40.6 years; standard deviation, 2.9). Measurements included a PTSD symptom scale, history of physician-diagnosed RA, sociodemographics, and health confounding factors. Co-twin control analytic methods used generalized estimating equation logistic regression to account for the paired twin data and to examine the association between PTSD symptoms and RA in all twins. Separate analyses were conducted within twin pairs. Results: The prevalence of RA among this population was 1.9% (95% confidence interval, 1.6-2.3) and the mean PTSD symptom level was 25.5 (standard deviation, 9.6). PTSD symptoms were associated with an increased likelihood of adult RA even after adjustment for confounding (p(trend) < .001). Among all twins, those in the highest PTSD symptom quartile were 3.8 times more likely (95% confidence interval, 2.1-6.1) to have RA compared with those in the lowest. These findings also persist when examined within twin pairs (p(trend) < .022). Conclusions: PTSD symptoms were associated with adult RA onset. Even after adjustment for familial/genetic factors and other confounders, an association between PTSD symptoms and RA remained. This is one of the first studies to demonstrate a link between PTSD and RA onset among a community-based population sample, independent of familial and genetic factors.
C1 [Boscarino, Joseph A.] Geisinger Med Clin, Ctr Hlth Res, Danville, PA 17822 USA.
[Boscarino, Joseph A.] Mt Sinai Sch Med, Dept Internal Med, New York, NY USA.
[Boscarino, Joseph A.] Mt Sinai Sch Med, Dept Pediat, New York, NY USA.
[Forsberg, Christopher W.; Goldberg, Jack] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Goldberg, Jack] Univ Washington, Dept Epidemiol, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA.
RP Boscarino, JA (reprint author), Geisinger Med Clin, Ctr Hlth Res, 100 N Acad Ave, Danville, PA 17822 USA.
EM jaboscarino@geisinger.edu
FU VA Puget Sound Health Care System, Seattle, Washington; U.S. Department
of Veterans Affairs
FX This study was supported, in part, by the VA Puget Sound Health Care
System, Seattle, Washington. The U.S. Department of Veterans Affairs
provided financial support for the development and maintenance of the
VET Registry.
NR 49
TC 40
Z9 40
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0033-3174
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD JUN
PY 2010
VL 72
IS 5
BP 481
EP 486
DI 10.1097/PSY.0b013e3181d9a80c
PG 6
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 613UB
UT WOS:000279005800007
PM 20410244
ER
PT J
AU Grudzen, CR
Hoffman, JR
Koenig, WJ
Boscardin, J
Lorenz, KA
Asch, SM
AF Grudzen, Corita R.
Hoffman, Jerome R.
Koenig, William J.
Boscardin, John
Lorenz, Karl A.
Asch, Steven M.
TI The LA story: What happened after a new policy allowing paramedics to
forgo resuscitation attempts in prehospital cardiac arrest
SO RESUSCITATION
LA English
DT Article
DE Prehospital care; Cardiopulmonary resuscitation; Ethics
ID EMERGENCY MEDICAL-SERVICES; OF-LIFE CARE; PATIENT PREFERENCES; DEATH;
SURVIVAL; PLACE; FATES; WORSE
AB Background: Despite potential harm to patients, families, and emergency personnel, a low survival rate, and high costs and intensity of care, attempting resuscitation after prehospital cardiac arrest is the norm, unless there are signs of irreversible death or the presence of a valid, state-issued DNR.
Objective: To determine whether there was a change in the rate of forgoing resuscitation attempts in prehospital cardiac arrest after implementation of a new policy allowing paramedics to forgo resuscitation based on a verbal family request or the presence of certain arrest characteristics.
Methods and results: All prehospital run sheets for cardiac arrest in Los Angeles County were reviewed for the first seven days of each month August 2006-January 2007 (pre-policy) and January-June 2008 (post-policy). Paramedics were more likely to forgo resuscitation attempts after the policy change (13.3% vs. 8.5%, p < 0.01). In addition, the percentage of patients with documented signs of irreversible death decreased post-policy, from 50.4% to 35.8%, p < 0.01. After adjustment for potential confounders (patient demographics, clinical characteristics and EMS factors), as well as exclusion of patients with signs of irreversible death, paramedics are significantly more likely to forgo a resuscitation, and less likely to attempt resuscitation, after the policy change (OR 1.67 [95% CI 1.07, 2.61], p = 0.024).
Conclusions: Paramedics are more likely to forgo, and less likely to attempt, resuscitation in victims of cardiac arrest after implementation of a new policy. There was also an associated decrease in the percentage of patients who had signs of irreversible death, which might reflect a change in paramedic behavior. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Grudzen, Corita R.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA.
[Grudzen, Corita R.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Hoffman, Jerome R.] Univ Calif Los Angeles, Dept Emergency Med, Los Angeles, CA USA.
[Koenig, William J.] Los Angeles Cty Emergency Med Serv Agcy, Los Angeles, CA USA.
[Boscardin, John] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Boscardin, John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Lorenz, Karl A.; Asch, Steven M.] VA Greater Los Angeles, Los Angeles, CA USA.
RP Grudzen, CR (reprint author), Mt Sinai Sch Med, Dept Emergency Med, 1 Gustave L Levy Pl,Box 1620, New York, NY 10029 USA.
EM corita.grudzen@mssm.edu
OI Grudzen, Corita/0000-0003-3039-8497
FU California HealthCare Foundation; Los Angeles County EMS
FX We would like to thank Nui Brown and Jacqueline Torres for their help
collecting the data as well as Susan Mori, Richard Taddeo, Maureen
Hasbrouck, and Robin Smilor at Los Angeles County EMS for support of the
project and help in acquiring the run sheets.; Funding sources: This
project was supported by the California HealthCare Foundation.
NR 17
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0300-9572
J9 RESUSCITATION
JI Resuscitation
PD JUN
PY 2010
VL 81
IS 6
BP 685
EP 690
DI 10.1016/j.resuscitation.2010.02.011
PG 6
WC Critical Care Medicine; Emergency Medicine
SC General & Internal Medicine; Emergency Medicine
GA 614VM
UT WOS:000279087900012
PM 20236748
ER
PT J
AU Olincy, A
Braff, DL
Adler, LE
Cadenhead, KS
Calkins, ME
Dobie, DJ
Green, MF
Greenwood, TA
Gur, RE
Gur, RC
Light, GA
Mintz, J
Nuechterlein, KH
Radant, AD
Schork, NJ
Seidman, LJ
Siever, LJ
Silverman, JM
Stone, WS
Swerdlow, NR
Tsuang, DW
Tsuang, MT
Turetsky, BI
Wagner, BD
Freedman, R
AF Olincy, Ann
Braff, David L.
Adler, Lawrence E.
Cadenhead, Kristin S.
Calkins, Monica E.
Dobie, Dorcas J.
Green, Michael F.
Greenwood, Tiffany A.
Gur, Raquel E.
Gur, Reuben C.
Light, Gregory A.
Mintz, James
Nuechterlein, Keith H.
Radant, Allen D.
Schork, Nicholas J.
Seidman, Larry J.
Siever, Larry J.
Silverman, Jeremy M.
Stone, William S.
Swerdlow, Neal R.
Tsuang, Debby W.
Tsuang, Ming T.
Turetsky, Bruce I.
Wagner, Brandie D.
Freedman, Robert
TI Inhibition of the P50 cerebral evoked response to repeated auditory
stimuli: Results from the Consortium on Genetics of Schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Evoked potentials auditory; Inhibition; Genetics
ID SENSORY-GATING DEFICIT; REM-SLEEP; HIPPOCAMPUS; SUPPRESSION;
ABNORMALITIES; HERITABILITY; POLYMORPHISM; RELATIVES; P300
AB Inhibitiion of the P50 evoked electroencephalographic response to the second of paired auditory stimuli has been frequently examined as a neurophysiological deficit in schizophrenia. The Consoritum on the Genetics of Schizophrenia (COGS), a 7-site study funded by the National Institute of Mental Health, examined this endophenotype in recording from 181 probands with schizophrenia, 429 of their first degree relatives, and 333 community comparison control subjects. Most probands were treated with second generation antipsychotic medications. Highly significant differnces in P50 inhibtion, measured as either the ratio of amplitudes or their difference in response to the two stimuli, were found between the probands and the community comparison sample. There were no differences between the COGS sites for these findings. For the ratio parameter, an admixture analysis found that nearly 40% of the relatives demonstrated deficiencies in P50 inhibition that are comparable to the deficit found in the probands. These results indicate that P50 auditory evoked potentials can be recorded across multiple sites and reliably demonstrate a physiological abnormality in schizophrenia. The appearance of the physicological abnormality in a substantial proporition of clinically unaffected first degree relatives is consisten with the hypothesis that deficits in cerebral inhibition are a familial neurobiological risk factor for the illness. Published by Elsevier B.V.
C1 [Olincy, Ann] Univ Colorado Denver, Dept Psychiat, Aurora, CO 80045 USA.
[Olincy, Ann; Adler, Lawrence E.; Freedman, Robert] Vet Affairs Denver Med Ctr VISN 19 MIRECC, Dept Psychiat, Denver, CO USA.
[Braff, David L.; Cadenhead, Kristin S.; Greenwood, Tiffany A.; Light, Gregory A.; Swerdlow, Neal R.; Tsuang, Ming T.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Calkins, Monica E.; Gur, Raquel E.; Gur, Reuben C.; Turetsky, Bruce I.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Dobie, Dorcas J.; Radant, Allen D.; Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Green, Michael F.; Mintz, James; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA.
[Green, Michael F.; Mintz, James] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Schork, Nicholas J.] Scripps Genome Med, La Jolla, CA USA.
[Schork, Nicholas J.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.
[Seidman, Larry J.; Stone, William S.] Harvard Univ, Sch Med,Publ Psychiat Div,Beth Israel Deaconess M, Dept Psychiat,Massachusetts Mental Hlth Ctr, Harvard Inst Psychiat Epidemiol & Genet, Boston, MA 02115 USA.
[Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Siever, Larry J.; Silverman, Jeremy M.] James J Peters VA Med Ctr, Bronx, NY USA.
[Siever, Larry J.; Silverman, Jeremy M.] VISN 3 MIRECC, Bronx, NY USA.
[Wagner, Brandie D.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO 80045 USA.
RP Olincy, A (reprint author), Univ Colorado Denver, Dept Psychiat, Mail Stop F546,13001 E 17th Pl, Aurora, CO 80045 USA.
EM Ann.olincy@ucdenver.edu
RI Greenwood, Tiffany/F-6356-2012; Tsuang, Debby/L-7234-2016
OI Greenwood, Tiffany/0000-0002-6080-6503; Tsuang,
Debby/0000-0002-4716-1894
FU NIMH [R01]
FX Funding for this study was provided by the NIMH Collaborative R01 Grants
to each of the 7 sites; the NIMH had no further role in study design; in
the collection, analysis and interpretation of data; in the writing of
the report; and in the decisiion to submit the paper for publication.
NR 37
TC 48
Z9 50
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD JUN
PY 2010
VL 119
IS 1-3
BP 175
EP 182
DI 10.1016/j.schres.2010.03.004
PG 8
WC Psychiatry
SC Psychiatry
GA 631JC
UT WOS:000280341700026
PM 20382002
ER
PT J
AU Li, Y
Xiang, M
Wilson, M
Fan, J
AF Li, Y.
Xiang, M.
Wilson, M.
Fan, J.
TI TLR4-IL-1RI CROSS-TALK MEDIATES HEMORRHAGIC SHOCK-PRIMED CASPASE-1
ACTIVATION IN LUNG ENDOTHELIAL CELLS
SO SHOCK
LA English
DT Meeting Abstract
CT 33rd Annual Conference on Shock
CY JUN 12-15, 2010
CL Portland, OR
SP Shock Soc
C1 [Li, Y.; Xiang, M.; Wilson, M.; Fan, J.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15240 USA.
[Li, Y.; Xiang, M.; Wilson, M.; Fan, J.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
NR 0
TC 0
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD JUN
PY 2010
VL 33
SU 1
BP 36
EP 37
PG 2
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
& Cardiology
GA 598IC
UT WOS:000277828000122
ER
PT J
AU Kilzieh, N
Rastam, S
Ward, KD
Maziak, W
AF Kilzieh, Nael
Rastam, Samer
Ward, Kenneth D.
Maziak, Wasim
TI Gender, depression and physical impairment: an epidemiologic perspective
from Aleppo, Syria
SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
LA English
DT Article
DE Physical impairment; Gender; Depression; Epidemiologic studies; Syria
ID GENERAL-POPULATION; MENTAL-DISORDERS; MAJOR DEPRESSION; PRIMARY-CARE;
HEALTH; DISABILITY; ILLNESS; DETERMINANTS; OUTCOMES; ADHERENCE
AB Examine the association of physical impairment with gender, depression, and socio-demographics in the community in Aleppo, Syria.
We conducted a cross-sectional, population-based study in Aleppo on adults aged 18-65 (N = 2,038). We used a computerized interviewer-administered structured questionnaire. Physical impairment was measured via an adapted 12-item World Health Organization, Health State Description Individual Questionnaire which includes both physical and emotional items. We used physical impairment items score to classify individuals into low, middle, and high physical impairment category. Self-report of physician-diagnosed depression and chronic diseases active in the past year and their current treatment status were obtained.
Sample mean age (SD) was 35.3 (12.1) years, 55% were female, and 4.5% had depression. Female gender, low socioeconomic status (SES), and depression were associated with high physical impairment. Women had more impairment (OR = 3.35, 95% CI: 2.15-5.21) with little change after controlling for depression and chronic diseases, but significantly decreased after controlling for socio-demographics (OR = 1.51, 95% CI: 0.84-2.73). The association with low (vs. high) SES was prominent (OR = 2.48, 95% CI: 1.32-4.67) after controlling for all variables. Depression's association (OR = 4.85, 95% CI: 1.93-12.15) lost significance after controlling for chronic diseases (OR = 2.81, 95% CI: 0.96-8.25), but further adjustment for socio-demographics had little effect.
Women and individuals of low SES appear more vulnerable to physical impairment in the community in Aleppo. Depression's association with physical impairment may be mediated through co-existing chronic diseases. Public health planning regarding physical impairment in Syria should encompass these as putative risk factors.
C1 [Kilzieh, Nael] VA Puget Sound Hlth Care Syst, Amer Lake Div, Tacoma, WA 98493 USA.
[Kilzieh, Nael] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Rastam, Samer; Maziak, Wasim] Syrian Ctr Tobacco Studies, Aleppo, Syria.
[Ward, Kenneth D.; Maziak, Wasim] Univ Memphis, Dept Hlth & Sport Sci, Memphis, TN 38152 USA.
[Ward, Kenneth D.; Maziak, Wasim] Univ Memphis, Ctr Community Hlth, Memphis, TN 38152 USA.
RP Kilzieh, N (reprint author), VA Puget Sound Hlth Care Syst, Amer Lake Div, 9600 Vet Dr,A-116, Tacoma, WA 98493 USA.
EM nael.kilzieh@va.gov
OI Rastam, Samer/0000-0002-4004-7773
FU US Public Health Service [R01 TW05962, R21 TW006545]; NIDA
[R01DA024876-01]; Fulbright Scholar Grant, Bureau of Cultural and
Educational Affairs, US Department of State; Veterans Affairs Mental
Illness Research, Education, and Clinical Center (MIRECC); VISN 20
FX This work is supported by US Public Health Service grants R01 TW05962
and R21 TW006545; and NIDA grant R01DA024876-01. Nael Kilzieh is
supported by The Fulbright Scholar Grant, Bureau of Cultural and
Educational Affairs, US Department of State and the Veterans Affairs
Mental Illness Research, Education, and Clinical Center (MIRECC), VISN
20.
NR 32
TC 3
Z9 3
U1 1
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0933-7954
J9 SOC PSYCH PSYCH EPID
JI Soc. Psychiatry Psychiatr. Epidemiol.
PD JUN
PY 2010
VL 45
IS 6
BP 595
EP 602
DI 10.1007/s00127-009-0076-7
PG 8
WC Psychiatry
SC Psychiatry
GA 599VS
UT WOS:000277942500001
PM 20195569
ER
PT J
AU Krause, JS
Terza, JV
Saunders, LL
Dismuke, CE
AF Krause, J. S.
Terza, J. V.
Saunders, L. L.
Dismuke, C. E.
TI Delayed entry into employment after spinal cord injury: factors related
to time to first job
SO SPINAL CORD
LA English
DT Article
DE spinal cord injury; employment; vocational rehabilitation;
participation; psychosocial
ID LIFE; ADJUSTMENT; EARNINGS; RETURN; GENDER; WORK
AB Study design: Data were cross-sectional and were collected by survey methodology.
Objectives: To investigate factors predictive of length of time between spinal cord injury (SCI) onset and start of first post-injury employment and full-time employment.
Setting: A large specialty hospital in the Southeastern United States, with additional participant samples from two hospitals in the Midwestern United States.
Methods: Participants were identified from patient records at the participating hospitals. They met the following three exclusion/inclusion criteria: traumatic SCI, at least 18 years of age at time of survey, and a minimum of 1-year after SCI. Outcome measures were years from injury onset to beginning first post-injury job and years to first full-time post-injury job. Two separate models were developed for each outcome using a regression analysis. All those 10 years and more post-injury were censored (that is eliminated) in the analysis.
Results: Having a higher level of education, less severe injury, being Caucasian, and returning to the pre-injury employer were associated with a shorter interval to initiation of employment with 10-year censoring. In addition to these variables, gender was associated with time to return to first full-time job.
Conclusion: The findings underscore the importance of using pre-injury education and opportunities to return to the pre-injury employer to minimize the length of time until initiation of employment after SCI. Spinal Cord (2010) 48, 487-491; doi: 10.1038/sc.2009.157; published online 24 November 2009
C1 [Krause, J. S.; Saunders, L. L.; Dismuke, C. E.] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA.
[Terza, J. V.] Univ N Carolina, Bryan Sch Business & Econ, Greensboro, NC 27412 USA.
[Dismuke, C. E.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
RP Krause, JS (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, 77 President St,Suite 117,MSC 700, Charleston, SC 29425 USA.
EM krause@musc.edu
FU National Institute for Disability and Rehabilitation Research (NIDRR) of
the Office of Special Education and Rehabilitative Services (OSERS)
[H133G020239, H133G060126]; United States Department of Education
FX This research was supported by field initiated grants (H133G020239,
H133G060126) from the National Institute for Disability and
Rehabilitation Research (NIDRR) of the Office of Special Education and
Rehabilitative Services (OSERS), the United States Department of
Education. The opinions expressed here are those of the grantee and not
the funding agency. We thank the following people whose contributions
made completion of this article possible: Richard Aust, Dr Rickey E
Carter Jennifer Coker, Karla Reed, and Yusheng Zhai, and Sarah Lottes
and Christina McCleery of the Shepherd Center.
NR 18
TC 18
Z9 18
U1 1
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
J9 SPINAL CORD
JI Spinal Cord
PD JUN
PY 2010
VL 48
IS 6
BP 487
EP 491
DI 10.1038/sc.2009.157
PG 5
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 605BI
UT WOS:000278321900009
PM 19935754
ER
PT J
AU Zhao, XH
Zhao, Q
Chu, BC
Yang, Y
Li, FY
Zhou, XH
Cai, JM
Cai, ZL
Yuan, C
AF Zhao, Xihai
Zhao, Qian
Chu, Baocheng
Yang, Yin
Li, Feiyu
Zhou, Xiao-Hua
Cai, Jianming
Cai, Zulong
Yuan, Chun
TI Prevalence of Compositional Features in Subclinical Carotid
Atherosclerosis Determined by High-Resolution Magnetic Resonance Imaging
in Chinese Patients With Coronary Artery Disease
SO STROKE
LA English
DT Article
DE carotid artery; coronary artery disease; magnetic resonance imaging;
plaque composition; subclinical atherosclerosis
ID TRANSIENT ISCHEMIC ATTACK; INTIMA-MEDIA THICKNESS; MYOCARDIAL-ISCHEMIA;
PLAQUE COMPOSITION; MRI; CALCIFICATION; ASSOCIATION; TOMOGRAPHY; STROKE;
STENOSIS
AB Background and Purpose-Previous studies have reported that carotid atherosclerosis frequently can be seen in coronary artery disease (CAD) patients. This study sought to determine the prevalence of compositional features in subclinical carotid atherosclerosis by MRI in CAD patients.
Methods-Ninety-six subjects with suspected CAD but free of neurological symptoms underwent coronary CT angiography and carotid MRI including 3-dimensional time-of-flight, T1-weighted, T2-weighted, and proton density-weighted sequences at 3 T within a 2-week interval. The coronary artery calcium score (CACS) and degree of stenosis were measured. Areas for carotid lumen, wall, total vessel, and percent wall volume (wall volume/total vessel volume) were measured. The prevalence of carotid calcification, lipid-rich necrotic core, intraplaque hemorrhage, and surface disruption in coronary stenosis and CACS categories were determined.
Results-Carotid percent wall volume was correlated with CACS (P = 0.001). Both coronary stenosis and CACS were significantly associated with presence of carotid calcification (OR = 5.79 for 1%-49% vs 0% stenosis; OR = 10.23 for >50% vs 0% stenosis; OR = 10.65 for CACS 1-399 vs CACS 0; and OR = 20.28 for CACS >400 vs CACS 0; all P<0.05) and lipid-rich necrotic core (OR = 10.29 for 1%-49% vs 0% stenosis; OR = 4.66 for >50% vs 0% stenosis; OR = 8.23 for CACS 1-399 vs CACS 0; and OR = 11.87 for CACS >400 vs CACS 0; all P < 0.05) High prevalence of lipid-rich necrotic core was found in low-grade coronary stenosis (75.6% in 1%-49% stenosis) and CACS (73.5% in CACS 1-399).
Conclusions-Carotid plaque burden and compositional features are significantly associated with CAD severity. The finding of high prevalence of lipid-rich necrotic core in patients with low-grade coronary stenosis and CACS suggests the need for early monitoring of carotid atherosclerosis in CAD patients. (Stroke. 2010; 41: 1157-1162.)
C1 [Zhao, Xihai; Chu, Baocheng; Li, Feiyu; Yuan, Chun] Univ Washington, Dept Radiol, Seattle, WA 98109 USA.
[Yang, Yin; Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Zhao, Qian; Cai, Jianming; Cai, Zulong] Peoples Liberat Army Gen Hosp, Dept Radiol, Beijing, Peoples R China.
[Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA USA.
RP Yuan, C (reprint author), Univ Washington, Dept Radiol, 815 Mercer St,Box 358050, Seattle, WA 98109 USA.
EM cyuan@u.washington.edu
FU National Institutes of Health [RO1 HL 56874]
FX This study is supported in part by a grant from the National Institutes
of Health (RO1 HL 56874).
NR 30
TC 10
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUN
PY 2010
VL 41
IS 6
BP 1157
EP 1162
DI 10.1161/STROKEAHA.110.580027
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 600WK
UT WOS:000278019400016
PM 20395607
ER
PT J
AU Bagley, SC
Munjas, B
Shekelle, P
AF Bagley, Steven C.
Munjas, Brett
Shekelle, Paul
TI A Systematic Review of Suicide Prevention Programs for Military or
Veterans
SO SUICIDE AND LIFE-THREATENING BEHAVIOR
LA English
DT Article
ID HEALTH; QUALITY; RISK; POPULATION; FORCE; ARMY; IRAQ; WAR
AB Military personnel and veterans have important suicide risk factors. After a systematic review of the literature on suicide prevention, seven (five in the U.S.) studies of military personnel were identified containing interventions that may reduce the risk of suicide. The effectiveness of the individual components was not assessed, and problems in methodology or reporting of data were common. Overall, multifaceted interventions for active duty military personnel are supported by consistent evidence, although of very mixed quality, and in some cases during intervals of declines in suicide rates in the general population. There were insufficient studies of U.S. Veterans to reach conclusions.
C1 [Bagley, Steven C.; Munjas, Brett; Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Bagley, Steven C.; Munjas, Brett; Shekelle, Paul] So Calif RAND Evidence Based Practice Ctr, Los Angeles, CA USA.
RP Bagley, SC (reprint author), Dept Vet Affairs, 3801 Miranda Ave, Palo Alto, CA 94304 USA.
EM steven.bagley2@va.gov
NR 27
TC 19
Z9 19
U1 1
U2 5
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0363-0234
J9 SUICIDE LIFE-THREAT
JI Suicide Life-Threat. Behav.
PD JUN
PY 2010
VL 40
IS 3
BP 257
EP 265
PG 9
WC Psychiatry; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 610NQ
UT WOS:000278740200005
PM 20560747
ER
PT J
AU Cho, AH
Arar, NH
Edelman, DE
Hartwell, PH
Oddone, EZ
Yancy, WS
AF Cho, Alex H.
Arar, Nedal H.
Edelman, David E.
Hartwell, Patricia H.
Oddone, Eugene Z.
Yancy, William S., Jr.
TI Do Diabetic Veterans Use the Internet? Self-Reported Usage, Skills, and
Interest in Using My HealtheVet Web Portal
SO TELEMEDICINE JOURNAL AND E-HEALTH
LA English
DT Article
DE veterans; medical informatics; patient preferences; diabetes; self-care;
Internet
ID GLUCOSE MONITORING-SYSTEM; CARE; MANAGEMENT
AB Objective: The Veterans Health Administration has developed My HealtheVet (MHV), a Web-based portal that links veterans to their care in the veteran affairs (VA) system. The objective of this study was to measure diabetic veterans' access to and use of the Internet, and their interest in using MHV to help manage their diabetes. Materials and Methods: Cross-sectional mailed survey of 201 patients with type 2 diabetes and hemoglobin A(1c) > 8.0% receiving primary care at any of five primary care clinic sites affiliated with a VA tertiary care facility. Main measures included Internet usage, access, and attitudes; computer skills; interest in using the Internet; awareness of and attitudes toward MHV; demographics; and socioeconomic status. Results: A majority of respondents reported having access to the Internet at home. Nearly half of all respondents had searched online for information about diabetes, including some who did not have home Internet access. More than a third obtained "some'' or "a lot'' of their health-related information online. Forty-one percent reported being "very interested'' in using MHV to help track their home blood glucose readings, a third of whom did not have home Internet access. Factors associated with being "very interested'' were as follows: having access to the Internet at home (p < 0.001), "a lot/some'' trust in the Internet as a source of health information (p = 0.002), lower age (p = 0.03), and some college (p = 0.04). Neither race (p = 0.44) nor income (p = 0.25) was significantly associated with interest in MHV. Conclusions: This study found that a diverse sample of older VA patients with sub-optimally controlled diabetes had a level of familiarity with and access to the Internet comparable to an age-matched national sample. In addition, there was a high degree of interest in using the Internet to help manage their diabetes.
C1 [Cho, Alex H.; Edelman, David E.; Oddone, Eugene Z.; Yancy, William S., Jr.] Duke Univ, Div Gen Internal Med, Durham, NC 27710 USA.
[Arar, Nedal H.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA.
[Edelman, David E.; Hartwell, Patricia H.; Oddone, Eugene Z.; Yancy, William S., Jr.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
RP Cho, AH (reprint author), Duke Univ, Div Gen Internal Med, 106 Davison Bldg,DUMC Box 3701, Durham, NC 27710 USA.
EM alex.cho@duke.edu
OI Edelman, David/0000-0001-7112-6151
FU Agency for Healthcare Research and Quality [5T32HS00079]
FX This work was supported by Grant 5T32HS00079 from Agency for Healthcare
Research and Quality.
NR 15
TC 20
Z9 20
U1 2
U2 6
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
J9 TELEMED J E-HEALTH
JI Telemed. J. e-Health
PD JUN
PY 2010
VL 16
IS 5
BP 595
EP 602
DI 10.1089/tmj.2009.0164
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 615ZW
UT WOS:000279178400011
PM 20575727
ER
PT J
AU Wang, J
Pfleger, CM
Friedman, L
Vittorino, R
Zhao, W
Qian, XJ
Conley, L
Ho, L
Pasinetti, GM
AF Wang, Jun
Pfleger, Cathie M.
Friedman, Lauren
Vittorino, Roselle
Zhao, Wei
Qian, Xianjuan
Conley, Lindsay
Ho, Lap
Pasinetti, Giulio M.
TI POTENTIAL APPLICATION OF GRAPE DERIVED POLYPHENOLS IN HUNTINGTON'S
DISEASE
SO TRANSLATIONAL NEUROSCIENCE
LA English
DT Article
DE Neurological disorders; Motor function; Abnormal protein aggregation
Huntingtin protein; Drosophila; PC-12 cell; R6/2 mouse
AB Huntington's disease (HD) is a progressive neurodegenerative disorder associated with selective neuronal cell death. Abnormal aggregation of huntingtin protein with polyQ expansion has been shown to be causally linked to HD. Grape seed polyphenolic extract (GSPE) is a natural compound that has previously been shown to interfere with aggregations of proteins involved in neurological disorders, such as amyloid beta peptides (A beta) and Tau protein. In this study we found that GSPE treatment significantly inhibits polyQ aggregation in phaeochromocytoma (PC)-12 cell line containing an ecdysone-inducible protein comprising the first 17 amino acid of huntingtin plus 103 glutamines fused with enhanced GFP. In vivo feasibility studies using the Q93httexon1 drosophila model of HD, we extended our in vitro evidence and found that flies fed with GSPE had a significantly improved lifespan compared to the control flies. Using the R6/2 rodent model of HD, we found that oral administration of 100 mg/kg/day GSPE (equivalent to 500mg per day in human) significantly attenuated the motor skill decay as well as extended the lifespan in the R6/2 mice relative to vehicle-control mice. Collectively, our studies strongly suggest that GSPE might be able to modulate the onset and/or progression of HD.
C1 [Wang, Jun; Friedman, Lauren; Vittorino, Roselle; Zhao, Wei; Qian, Xianjuan; Conley, Lindsay; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Wang, Jun; Zhao, Wei; Qian, Xianjuan; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Pfleger, Cathie M.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.
[Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA.
[Ho, Lap; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY 10468 USA.
RP Wang, J (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
FU Polyphenolics, Inc.
FX This work was supported by Polyphenolics, Inc. We thank Hayley Fivecoat
for assistance in the preparation of the manuscript.
NR 38
TC 7
Z9 7
U1 0
U2 2
PU VERSITA
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 2081-3856
J9 TRANSL NEUROSCI
JI Transl. Neurosci.
PD JUN
PY 2010
VL 1
IS 2
BP 95
EP 100
DI 10.2478/v10134-010-0022-y
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA V20PY
UT WOS:000208153100001
PM 21331299
ER
PT J
AU Arrieta-Cruz, I
Pavlides, C
Pasinetti, GM
AF Arrieta-Cruz, Isabel
Pavlides, Constantine
Pasinetti, Giulio Maria
TI DEEP BRAIN STIMULATION FACILITATES MEMORY IN A MODEL OF ALZHEIMER'S
DISEASE
SO TRANSLATIONAL NEUROSCIENCE
LA English
DT Article
DE Alzheimer's disease; Deep brain stimulation; Hippocampus; LTP; Neuronal
transmission Synaptic plasticity; Memory; TgCRND8 mice; Thalamus
AB Based on evidence suggesting that deep brain stimulation (DBS) may promote certain cognitive processes, we have been interested in developing DBS as a means of mitigating memory and learning impairments in Alzheimer's disease (AD). In this study we used an animal model of AD (TgCRND8 mice) to determine the effects of high-frequency stimulation (HFS) on non-amyloidogenic a-secretase activity and DBS in short-term memory. We tested our hypothesis using hippocampal slices (in vitro studies) from TgCRND8 mice to evaluate whether HFS increases a-secretase activity (non-amyloidogenic pathway) in the CA1 region. In a second set of experiments, we performed in vivo studies to evaluate whether DBS in midline thalamic region re-establishes hippocampal dependent short-term memory in TgCRND8 mice. The results showed that application of HFS to isolated hippocampal slices significantly increased synaptic plasticity in the CA1 region and promoted a 2-fold increase of non-amyloidogenic a-secretase activity, in comparison to low frequency stimulated controls from TgCRND8 mice. In the in vivo studies, DBS treatment facilitated acquisition memory in TgCRND8 mice, in comparison to their own baseline before treatment. These results provide evidence that DBS could enhance short-term memory in a mouse model of AD by increasing synaptic transmission and a-secretase activity in the C A1 region of hippocampus.
C1 [Arrieta-Cruz, Isabel; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Pavlides, Constantine] Rockefeller Univ, Neuroendocrinol Lab, New York, NY 10065 USA.
[Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY 10468 USA.
RP Arrieta-Cruz, I (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
NR 14
TC 0
Z9 0
U1 1
U2 7
PU VERSITA
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 2081-3856
J9 TRANSL NEUROSCI
JI Transl. Neurosci.
PD JUN
PY 2010
VL 1
IS 2
BP 170
EP 176
DI 10.2478/v10134-010-0026-7
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA V20PY
UT WOS:000208153100010
ER
PT J
AU Ahmad, M
Graham, SH
AF Ahmad, Muzamil
Graham, Steven H.
TI Inflammation After Stroke: Mechanisms and Therapeutic Approaches
SO TRANSLATIONAL STROKE RESEARCH
LA English
DT Review
DE Stroke; Ischemia; Inflammation; Inflammatory cells; Cytokines; Cell
adhesion molecules; Eicosanoids
AB Reperfusion of ischemic brain can reduce injury and improve outcome, but secondary injury due to inflammatory mechanisms limits the efficacy and time window of such treatments for stroke. This review summarizes the cellular and molecular basis of inflammation in ischemic injury as well as possible therapeutic strategies.
C1 [Ahmad, Muzamil; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr 00 GR H, Pittsburgh, PA 15206 USA.
[Ahmad, Muzamil; Graham, Steven H.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
RP Graham, SH (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr 00 GR H, 7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM sgra@pitt.edu
FU NCATS NIH HHS [UL1 TR000005]; NINDS NIH HHS [R01 NS037459, R01
NS037459-04, R01 NS037459-11]
NR 178
TC 33
Z9 41
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1868-4483
EI 1868-601X
J9 TRANSL STROKE RES
JI Transl. Stroke Res.
PD JUN
PY 2010
VL 1
IS 2
BP 74
EP 84
DI 10.1007/s12975-010-0023-7
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA V23ER
UT WOS:000208326600002
PM 20976117
ER
PT J
AU Zhang, F
Xing, J
Liou, AKF
Wang, S
Gan, Y
Luo, YM
Ji, XM
Stetler, RA
Chen, J
Cao, GD
AF Zhang, Feng
Xing, Juan
Liou, Anthony Kian-Fong
Wang, Suping
Gan, Yu
Luo, Yumin
Ji, Xuming
Stetler, R. Anne
Chen, Jun
Cao, Guodong
TI Enhanced Delivery of Erythropoietin Across the Blood-Brain Barrier for
Neuroprotection Against Ischemic Neuronal Injury
SO TRANSLATIONAL STROKE RESEARCH
LA English
DT Article
DE Erythropoietin; Drug delivery system; HIV TAT protein; Blood-brain
barrier; Neuroprotection; Ischemia/brain
AB Due to limited penetration of the blood-brain barrier (BBB), many therapeutic agents in clinical use require higher doses in order to reach effective concentrations in brain. In some instances, these high doses elicit severe side effects. In the case of erythropoietin (EPO), an established neuroprotectant against ischemic brain injury, its low BBB permeability requires such a high therapeutic dose that it can induce dangerous complications such as polycythemia and secondary stroke. The purpose of this study is to generate a modified EPO that has increased facility crossing the BBB without losing its neuroprotective element. We have engineered a fusion protein (EPO-TAT) by tagging a protein transduction domain derived from HIV trans-acting activator of transcription (TAT) to the EPO protein. This sequence enhanced the capacity of EPO to cross the BBB in animals at least twofold when intraperitoneally administered and up to fivefold when intravenously administered. In vitro experiments showed that this EPO fusion protein retained all its protective properties against neuronal death elicited by oxygen-glucose deprivation and N-methyl-D-aspartate insults. The needed therapeutic dose of the EPO-TAT was decreased by similar to tenfold compared to that of regular EPO to achieve equivalent neuroprotection in terms of reducing volume of infarction induced by middle cerebral artery occlusion in mice. Our results support the approach of using a protein transduction domain coupled to therapeutic agents. In this way, not only can the therapeutic doses be lowered but also agents without BBB permeability may now be available for clinical applications.
C1 [Cao, Guodong] Univ Pittsburgh, Sch Med, Dept Neurol, BST S505, Pittsburgh, PA 15261 USA.
[Zhang, Feng; Xing, Juan; Wang, Suping; Stetler, R. Anne; Chen, Jun; Cao, Guodong] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15260 USA.
[Luo, Yumin; Ji, Xuming] Capital Univ Med Sci, Xuanwu Hosp, Cerebrovasc Dis Res Inst, Beijing 100053, Peoples R China.
[Zhang, Feng; Xing, Juan; Liou, Anthony Kian-Fong; Wang, Suping; Gan, Yu; Stetler, R. Anne; Chen, Jun; Cao, Guodong] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Zhang, Feng; Xing, Juan; Liou, Anthony Kian-Fong; Wang, Suping; Gan, Yu; Stetler, R. Anne; Chen, Jun; Cao, Guodong] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA.
RP Cao, GD (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, BST S505, 200 Lothrop St, Pittsburgh, PA 15261 USA.
EM caog@upmc.edu
OI Zhang, Feng/0000-0001-7275-9989
FU National Institutes of Health [NS053473, NS43802, NS45048, NS36736, NS
56118]; American Heart Association Scientist Development [06300064N];
Chinese Natural Science Foundation [30670725]
FX The project was supported by National Institutes of Health Grants
NS053473 (to G. C.), NS43802, NS45048, NS36736, and NS 56118 (to J.C.),
and the American Heart Association Scientist Development Grant 06300064N
(to G. C.). Y.L. is a recipient of the Chinese Natural Science
Foundation Grant 30670725.
NR 28
TC 19
Z9 22
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1868-4483
EI 1868-601X
J9 TRANSL STROKE RES
JI Transl. Stroke Res.
PD JUN
PY 2010
VL 1
IS 2
BP 113
EP 121
DI 10.1007/s12975-010-0019-3
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA V23ER
UT WOS:000208326600006
PM 20577577
ER
PT J
AU Liu, H
Wang, C
Chen, PH
Zhang, BS
Zheng, YL
Zhang, CX
Meng, HQ
Wang, Y
Chen, DC
Xiu, MH
Kosten, TR
Zhang, XY
AF Liu, Hong
Wang, Cui
Chen, Pin Hong
Zhang, Ben Shu
Zheng, You Lan
Zhang, Chong Xi
Meng, Hua Qing
Wang, Yu
Chen, Da Chun
Xiu, Mei Hong
Kosten, Thomas R.
Zhang, Xiang Yang
TI Association of the manganese superoxide dismutase gene Ala-9Val
polymorphism with clinical phenotypes and tardive dyskinesia in
schizophrenic patients
SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
LA English
DT Review
DE Association; Manganese superoxide dismutase; Polymorphism;
Schizophrenia; Tardive dyskinesia
ID ABNORMAL INVOLUNTARY MOVEMENTS; FREE-RADICAL PATHOLOGY;
PARKINSONS-DISEASE; OXIDATIVE STRESS; MNSOD GENES; RISK;
PHARMACOGENOMICS; METAANALYSIS; POPULATION; SOD2
AB Objective: Several recent studies that have investigated the genetic association between the manganese superoxide dismutase (MnSOD) gene Ala-9Val single-nucleotide polymorphism (SNP) and tardive dyskinesia (TD) have produced conflicting results. This study was to investigate whether this SNP was associated with clinical phenotypes and antipsychotic-induced tardive dyskinesia (TD) in schizophrenia in a genetically homogeneous Han Chinese inpatient population.
Methods: Genotyping was performed for the MnSOD gene Ala-9Val SNP in Chinese schizophrenia patients with (n = 176) and without TD (n = 346). The severity of TD was assessed using the abnormal involuntary movement scale (AIMS), and psychopathology using the Positive and Negative Syndrome Scale (PANSS).
Results: The frequencies of genotypes and alleles did not differ significantly between schizophrenic patients with and without TO (both p>0.05). Also, there was no significant difference in the AIMS total score between the Val/Val and Ala allele carrier groups (p>0.05). However, the PANSS negative symptom subscore was significantly higher in patients with Val/Val genotype (21.8 +/- 7.3) than those with Ala alleles (20.1 +/- 7.7) (t = 2.32, p = 0.03).
Conclusion: While the MnSOD gene Ala-9Val polymorphism did not play a major role in the susceptibility to TD in schizophrenic patients, it might be associated with negative symptoms of schizophrenia. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Liu, Hong; Zhang, Ben Shu; Wang, Yu] Tianjin Med Univ, Gen Hosp, Dept Neurol, Tianjin 300052, Peoples R China.
[Liu, Hong] Heping Hosp Affiliated, Changzhi Med Coll, Dept Neurol, Changzhi 046000, Shanxi Province, Peoples R China.
[Wang, Cui; Zheng, You Lan] Jilin Agr Univ, Coll Chinese Med Mat, Changchun, Peoples R China.
[Chen, Pin Hong; Meng, Hua Qing] Chongqing Med Univ, Affiliated Hosp 1, Dept Mental Hlth, Chongqing 400016, Peoples R China.
[Zhang, Chong Xi] Shandong Univ Weihai, Marine Coll, Weihai, Shandong, Peoples R China.
[Chen, Da Chun; Xiu, Mei Hong; Zhang, Xiang Yang] Beijing Huilongguan Hosp, Ctr Biol Psychiat, Beijing, Peoples R China.
[Kosten, Thomas R.; Zhang, Xiang Yang] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
RP Kosten, TR (reprint author), VA Med Ctr, Res Bldg 110,Room 229,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM kosten@bcm.edu; xyzhang@bcm.edu
FU Stanley Medical Research Institute [03T-459, 05T-726]; Beijing Municipal
Natural Science Foundation [ID: 7072035]; Department of Veterans Affairs
FX This study was funded by the Stanley Medical Research Institute (03T-459
and 05T-726), the Beijing Municipal Natural Science Foundation (ID:
7072035), and the Department of Veterans Affairs, VISN 16, Mental
Illness Research, Education and Clinical Center (MIRECC), United States
National Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639.
NR 35
TC 10
Z9 10
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-5846
J9 PROG NEURO-PSYCHOPH
JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry
PD MAY 30
PY 2010
VL 34
IS 4
BP 692
EP 696
DI 10.1016/j.pnpbp.2010.03.026
PG 5
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 612GV
UT WOS:000278885700021
PM 20346996
ER
PT J
AU Saito, A
Wakao, M
Deguchi, H
Mawatari, A
Sobel, M
Suda, Y
AF Saito, Akihiro
Wakao, Masahiro
Deguchi, Hiroshi
Mawatari, Aya
Sobel, Michael
Suda, Yasuo
TI Toward the assembly of heparin and heparan sulfate oligosaccharide
libraries: efficient synthesis of uronic acid and disaccharide building
blocks
SO TETRAHEDRON
LA English
DT Article
DE Synthesis; Uronic acid; Glucuronic acid; Iduronic acid; Glucosamine;
Heparin; Heparan sulfate
ID L-IDURONIC ACID; BIOLOGICAL-ACTIVITY; PROTEIN INTERACTIONS; MODULAR
SYNTHESIS; SUGAR CHIPS; GLYCOSAMINOGLYCANS; BINDING; STRATEGY; ROUTE;
PENTASACCHARIDE
AB The monosaccharide moieties found in heparin (HP) and heparan sulfate (HS), glucosamine and two kinds of uronic acids, glucuronic and iduronic acids, were efficiently synthesized by use of glucosamine hydrochloride and glucurono-6,3-lactone as starting compounds. In the synthesis of the disaccharide building block, the key issues of preparation of uronic acids (glucuronic acid and iduronic acid moieties) were achieved in 12 steps and 15 steps, respectively, without cumbersome C-6 oxidation. The resulting monosaccharide moieties were utilized to the syntheses of HP/HS disaccharide building blocks possessing glucosamine-glucuronic acid (GlcN-GlcA) or iduronic acid (GlcN-IdoA) sequences. The disaccharide building blocks were also suitable for further modification such as glycosylation, selective deprotection, and sulfation. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Saito, Akihiro; Wakao, Masahiro; Deguchi, Hiroshi; Mawatari, Aya; Suda, Yasuo] Kagoshima Univ, Grad Sch Sci & Engn, Dept Chem Biotechnol & Chem Engn, Kagoshima 8900065, Japan.
[Sobel, Michael] VA Puget Sound Hlth Care Syst, Div Vasc Surg, Seattle, WA USA.
[Sobel, Michael] Univ Washington, Sch Med, Seattle, WA USA.
[Suda, Yasuo] SUDx Biotec Corp, Kagoshima 8900013, Japan.
RP Wakao, M (reprint author), Kagoshima Univ, Grad Sch Sci & Engn, Dept Chem Biotechnol & Chem Engn, 1-21-40 Kohrimoto, Kagoshima 8900065, Japan.
EM wakao@eng.kagoshima-u.ac.jp; ysuda@eng.kagoshima-u.ac.jp
FU Japan Science and Technology Agency [V07-05]; Japan Ministry of Health,
Labour and Welfare (MHLW); National Institutes of Health, USA [RO1
HL079182]
FX The present work was financially supported in part by grants from Japan
Science and Technology Agency (Evolutionally-venture program V07-05 to
Y.S., CREST to Y.S.), and the Japan Ministry of Health, Labour and
Welfare (MHLW) (Nanomedicine program to Y.S.), and the National
Institutes of Health, USA (RO1 HL079182 to M.S.).
NR 55
TC 10
Z9 11
U1 2
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4020
J9 TETRAHEDRON
JI Tetrahedron
PD MAY 29
PY 2010
VL 66
IS 22
BP 3951
EP 3962
DI 10.1016/j.tet.2010.03.077
PG 12
WC Chemistry, Organic
SC Chemistry
GA 603GK
UT WOS:000278196500009
PM 20473366
ER
PT J
AU Liu, XH
Manzano, G
Lovett, DH
Kim, HT
AF Liu, Xuhui
Manzano, Givenchy
Lovett, David H.
Kim, Hubert T.
TI Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2
transcriptional regulation in skeletal muscle atrophy
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Matrix metalloproteinase-2; Muscle atrophy; Extracellular matrix; Gene
expression regulation; Transcription; AP-1
ID HINDLIMB IMMOBILIZATION; EXPRESSION; RECOVERY; ISCHEMIA; CELLS; MMP-2;
JUNB; YB-1; RATS; FOSB
AB Previous work has suggested that an extracellular matrix degrading enzyme matrix metalloproteinase-2 (MMP-2) plays an important role in the development of muscle atrophy. However, the transcriptional regulation mechanism of MMP-2 in skeletal muscle atrophy remains largely unknown. Using transgenic MMP-2 promoter reporter mice, we have demonstrated that AP-1 and RE-1 binding sites in the MMP-2 promoter region, coupled with increased binding of Fra-1, Fra-2 and AP-2, play a critical role in MMP-2 transcriptional regulation in muscle atrophy. Novel information gained from this study has improved our understanding of in vivo transcriptional regulation of MMP-2 in skeletal muscle atrophy. Published by Elsevier Inc.
C1 [Liu, Xuhui; Manzano, Givenchy; Lovett, David H.; Kim, Hubert T.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA 94121 USA.
[Liu, Xuhui; Manzano, Givenchy; Kim, Hubert T.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94122 USA.
[Lovett, David H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94122 USA.
RP Kim, HT (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs, 4150 Clement St 112, San Francisco, CA 94121 USA.
EM Kimh@orthosurg.ucsf.edu
FU Orthopedic Research & Education Foundation; Illinois Bone and Joint
Institute
FX This work was supported by Orthopedic Research & Education Foundation
and Illinois Bone and Joint Institute.
NR 19
TC 5
Z9 5
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 28
PY 2010
VL 396
IS 2
BP 219
EP 223
DI 10.1016/j.bbrc.2010.04.067
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 609LL
UT WOS:000278658000008
PM 20398633
ER
PT J
AU Cavusoglu, E
Chopra, V
Gupta, A
Battala, VR
Poludasu, S
Eng, C
Marmur, JD
AF Cavusoglu, Erdal
Chopra, Vineet
Gupta, Amit
Battala, Venkata R.
Poludasu, Shyam
Eng, Calvin
Marmur, Jonathan D.
TI Relation between red blood cell distribution width (RDW) and all-cause
mortality at two years in an unselected population referred for coronary
angiography
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE RDW; Anemia; Coronary angiography; Prognosis
ID INDEPENDENT PREDICTOR; CHARM PROGRAM; HEART-FAILURE; CHEST-PAIN; ANEMIA;
OUTCOMES
AB Background: Red blood cell distribution width (RDW), a numerical measure of the variability in size of circulating erythrocytes, has recently been shown to be a strong predictor of adverse outcomes in patients with heart failure and in patients with prior myocardial infarction but no symptomatic heart failure at baseline, even after adjustment for hematocrit. However, there are no data in other cardiac populations, including patients with acute coronary syndromes (ACS).
Methods: The present study investigated the long-term prognostic significance of baseline RDW in a well-characterized cohort of 389 male patients who were referred to coronary angiography for a variety of indications. All patients were followed prospectively for all-cause mortality, and data regarding this endpoint was available for 97% of the population at 24 months.
Results: After controlling for a variety of baseline variables (including hemoglobin and the presence of heart failure), RDW (analyzed as a categorical variable comparing the upper tertile of baseline values to the lower two levels combined) was a strong and independent predictor of all-cause mortality using a Cox proportional hazards model [ hazard ratio (HR) 2.69, 95% confidence interval (CI) 1.50-4.84, p=0.0008]. In addition, baseline RDW was also an independent predictor of all-cause mortality in the non-anemic (HR 4.73, 95% CI 2.06-10.86, p=0.0003) and ACS (HR 2.90, 95% CI 1.32-6.38, p=0.0082) subpopulations of patients.
Conclusions: These data demonstrate that elevated RDW is a strong and independent predictor of all-cause mortality in an unselected population of male patients across a broad spectrum of risk (including ACS) referred for coronary angiography. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Cavusoglu, Erdal; Gupta, Amit; Battala, Venkata R.; Poludasu, Shyam; Marmur, Jonathan D.] Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA.
[Cavusoglu, Erdal; Chopra, Vineet; Eng, Calvin] Bronx Vet Affairs Med Ctr, Dept Med, Div Cardiol, Bronx, NY USA.
RP Cavusoglu, E (reprint author), Suny Downstate Med Ctr, Dept Med, Div Cardiol, 450 Clarkson Ave,Box 1257, Brooklyn, NY 11203 USA.
EM ECavusoglu@aol.com
NR 12
TC 91
Z9 101
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD MAY 28
PY 2010
VL 141
IS 2
BP 141
EP 146
DI 10.1016/j.ijcard.2008.11.187
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 597AI
UT WOS:000277727200004
PM 19144426
ER
PT J
AU Frei, CR
Mortensen, EM
Copeland, LA
Attridge, RT
Pugh, MJV
Restrepo, MI
Anzueto, A
Nakashima, B
Fine, MJ
AF Frei, Christopher R.
Mortensen, Eric M.
Copeland, Laurel A.
Attridge, Russell T.
Pugh, Mary Jo V.
Restrepo, Marcos I.
Anzueto, Antonio
Nakashima, Brandy
Fine, Michael J.
TI Disparities of Care for African-Americans and Caucasians with
Community-Acquired Pneumonia: A Retrospective Cohort Study
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
ID OF-VETERANS-AFFAIRS; EMPIRIC ANTIBIOTIC-THERAPY; UNITED-STATES;
ANTIMICROBIAL THERAPY; ADMINISTRATIVE DATA; RACIAL-DIFFERENCES;
ELDERLY-PATIENTS; HOSPITAL MORTALITY; PULMONARY-DISEASE; IMPACT
AB Background: African-Americans admitted to U.S. hospitals with community-acquired pneumonia (CAP) are more likely than Caucasians to experience prolonged hospital length of stay (LOS), possibly due to either differential treatment decisions or patient characteristics.
Methods: We assessed associations between race and outcomes (Intensive Care Unit [ICU] variables, LOS, 30-day mortality) for African-American or Caucasian patients over 65 years hospitalized in the Veterans Health Administration (VHA) with CAP (2002-2007). Patients admitted to the ICU were analyzed separately from those not admitted to the ICU. VHA patients who died within 30 days of discharge were excluded from all LOS analyses. We used chi-square and Fisher's exact statistics to compare dichotomous variables, the Wilcoxon Rank Sum test to compare age by race, and Cox Proportional Hazards Regression to analyze hospital LOS. We used separate generalized linear mixed-effect models, with admitting hospital as a random effect, to examine associations between patient race and the receipt of guideline-concordant antibiotics, ICU admission, use of mechanical ventilation, use of vasopressors, LOS, and 30-day mortality. We defined statistical significance as a two-tailed p <= 0.0001.
Results: Of 40,878 patients, African-Americans (n = 4,936) were less likely to be married and more likely to have a substance use disorder, neoplastic disease, renal disease, or diabetes compared to Caucasians. African-Americans and Caucasians were equally likely to receive guideline-concordant antibiotics (92% versus 93%, adjusted OR = 0.99; 95% CI = 0.81 to 1.20) and experienced similar 30-day mortality when treated in medical wards (adjusted OR = 0.98; 95% CI = 0.87 to 1.10). African-Americans had a shorter adjusted hospital LOS (adjusted HR = 0.95; 95% CI = 0.92 to 0.98). When admitted to the ICU, African Americans were as likely as Caucasians to receive guideline-concordant antibiotics (76% versus 78%, adjusted OR = 0.99; 95% CI = 0.81 to 1.20), but experienced lower 30-day mortality (adjusted OR = 0.82; 95% CI = 0.68 to 0.99) and shorter hospital LOS (adjusted HR = 0.84; 95% CI = 0.76 to 0.93).
Conclusions: Elderly African-American CAP patients experienced a survival advantage (i.e., lower 30-day mortality) in the ICU compared to Caucasians and shorter hospital LOS in both medical wards and ICUs, after adjusting for numerous baseline differences in patient characteristics. There were no racial differences in receipt of guideline-concordant antibiotic therapies.
C1 [Frei, Christopher R.; Mortensen, Eric M.; Copeland, Laurel A.; Attridge, Russell T.; Pugh, Mary Jo V.; Restrepo, Marcos I.; Anzueto, Antonio; Nakashima, Brandy] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Frei, Christopher R.; Attridge, Russell T.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA.
[Mortensen, Eric M.; Copeland, Laurel A.; Pugh, Mary Jo V.; Restrepo, Marcos I.; Anzueto, Antonio; Nakashima, Brandy] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA.
[Mortensen, Eric M.; Copeland, Laurel A.; Pugh, Mary Jo V.; Restrepo, Marcos I.; Nakashima, Brandy] S Texas Vet Hlth Care Syst, VERDICT Res Program, San Antonio, TX 78229 USA.
[Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA.
RP Mortensen, EM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM mortensene@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563;
Copeland, Laurel/0000-0002-9478-0209
FU National Institute of Nursing Research [R01NR010828]
FX The authors would like to thank Christine Oramasionwu and Warunee
Srisupha-Olarn for their editorial review of this manuscript. The
project described herein was supported by Grant Number R01NR010828 from
the National Institute of Nursing Research. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institute of Nursing Research or the
National Institutes of Health. This material is the result of work
supported with resources and the use of facilities at the South Texas
Veterans Health Care System and The University of Texas at Austin. Dr.
Frei is supported by a Loan Repayment award from the National Institute
of Allergy and Infectious Diseases of the National Institutes of Health,
salary support from The University of Texas at Austin College of
Pharmacy, and research support from AstraZeneca, Elan, and Ortho-McNeil
Janssen. Dr Copeland is funded by Merit Review Entry Program grant
MRP-05-145 from the VA Health Services Research and Development program.
Dr. Restrepo is supported by a National Institutes of Health Grant KL2
RR025766, salary support by the South Texas Veterans Health Care System
Audie L. Murphy Division and The University of Texas Health Science
Center at San Antonio. The funding agencies had no role in conducting
the study, or role in the preparation, review, or approval of the
manuscript. The views expressed in this article are those of the authors
and do not necessarily represent the views of the Department of Veterans
Affairs. This manuscript was presented, in part, at the American
Thoracic Society International Conference, May 15-20, 2009, San Diego,
CA.
NR 60
TC 10
Z9 10
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD MAY 27
PY 2010
VL 10
AR 143
DI 10.1186/1472-6963-10-143
PG 11
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 625FB
UT WOS:000279878900005
PM 20507628
ER
PT J
AU Han, LH
Wu, SM
Condit, JC
Kemp, NJ
Milner, TE
Feldman, MD
Chen, SC
AF Han, Li-Hsin
Wu, Shaomin
Condit, J. Christopher
Kemp, Nate J.
Milner, Thomas E.
Feldman, Marc D.
Chen, Shaochen
TI Light-powered micromotor driven by geometry-assisted, asymmetric
photon-heating and subsequent gas convection
SO APPLIED PHYSICS LETTERS
LA English
DT Article
DE convection; gold; micromotors; molecular dynamics method; nanoparticles;
nanoporous materials; polymers
AB We report on the design, fabrication, and analysis of a light-driven micromotor. The micromotor was created from a nanoporous polymer with close-packed gold nanoparticles which generate heat by absorbing light. The blades of the micromotor were curved, forming convex and concave sides. Upon lateral irradiation, by geometric effect the convex side transfers more photon-generated heat to the surrounding gas molecules, causing a convective motion of gas and leading to the rotation of the micromotor. The light-driven motions of gas molecules were analyzed using molecular dynamics modeling. (C) 2010 American Institute of Physics. [doi:10.1063/1.3431741]
C1 [Han, Li-Hsin; Wu, Shaomin; Chen, Shaochen] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA.
[Condit, J. Christopher; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA.
[Kemp, Nate J.] Volcano Corp, Billerica, MA 01821 USA.
[Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Feldman, Marc D.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Chen, SC (reprint author), Univ Texas Austin, Dept Mech Engn, C2200, Austin, TX 78712 USA.
EM scchen@mail.utexas.edu
RI Han, Li-Hsin/C-5440-2015
OI Han, Li-Hsin/0000-0002-0135-2863
FU Office of Naval Research [N00014-07-1-0609]; National Science Foundation
[CMMI 0555275]
FX This work is supported by grants from the Office of Naval Research
N00014-07-1-0609 and the National Science Foundation CMMI 0555275 to
S.C. We appreciate the donation of the DMD tool kit from Texas
Instruments. We also thank the computer support from Intel's High
Education Program.
NR 20
TC 7
Z9 7
U1 2
U2 11
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
MELVILLE, NY 11747-4501 USA
SN 0003-6951
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD MAY 24
PY 2010
VL 96
IS 21
AR 213509
DI 10.1063/1.3431741
PG 3
WC Physics, Applied
SC Physics
GA 603BP
UT WOS:000278183200085
ER
PT J
AU Ho, PM
Zeng, C
Tavel, HM
Selby, JV
O'Connor, PJ
Margolis, KL
Magid, DJ
AF Ho, P. Michael
Zeng, Chan
Tavel, Heather M.
Selby, Joe V.
O'Connor, Patrick J.
Margolis, Karen L.
Magid, David J.
TI Trends in First-line Therapy for Hypertension in the Cardiovascular
Research Network Hypertension Registry, 2002-2007
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Letter
ID JOINT NATIONAL COMMITTEE; LIPID-LOWERING TREATMENT; HIGH BLOOD-PRESSURE;
7TH REPORT; PREVENTION
C1 [Ho, P. Michael; Zeng, Chan; Tavel, Heather M.; Magid, David J.] Inst Hlth Res, Denver, CO USA.
[Ho, P. Michael] Vet Affairs Med Ctr, Denver Dept, Denver, CO USA.
[Ho, P. Michael] Univ Colorado, Dept Med, Denver, CO USA.
[Magid, David J.] Univ Colorado, Dept Emergency Med, Denver, CO 80202 USA.
[Selby, Joe V.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[O'Connor, Patrick J.; Margolis, Karen L.] HealthPartners Res Fdn, Minneapolis, MN USA.
RP Ho, PM (reprint author), Denver VA Med Ctr, 1055 Clermont St 111B, Denver, CO 80220 USA.
FU NHLBI NIH HHS [U19HL091179]
NR 6
TC 10
Z9 10
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAY 24
PY 2010
VL 170
IS 10
BP 912
EP 913
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 599LO
UT WOS:000277914400012
PM 20498420
ER
PT J
AU Jespersen, S
Sogaard, OS
Schonheyder, HC
Fine, MJ
Ostergaard, L
AF Jespersen, Sanne
Sogaard, Ole S.
Schonheyder, Henrik C.
Fine, Michael J.
Ostergaard, Lars
TI Clinical features and predictors of mortality in admitted patients with
community- and hospital-acquired legionellosis: A Danish historical
cohort study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID LEGIONNAIRES-DISEASE; PROGNOSTIC-FACTORS; PNEUMONIA; VALIDATION;
MORBIDITY; THERAPY; TRENDS
AB Background: Legionella is a common cause of bacterial pneumonia. Community-acquired [CAL] and hospital-acquired legionellosis [HAL] may have different presentations and outcome. We aimed to compare clinical characteristics and examine predictors of mortality for CAL and HAL.
Methods: We identified hospitalized cases of legionellosis in 4 Danish counties from January 1995 to December 2005 using the Danish national surveillance system and databases at departments of clinical microbiology. Clinical and laboratory data were retrieved from medical records; vital status was obtained from the Danish Civil Registration System. We calculated 30- and 90-day case fatality rates and identified independent predictors of mortality using logistic regression analyses.
Results: We included 272 cases of CAL and 60 cases of HAL. Signs and symptoms of HAL were less pronounced than for CAL and time from in-hospital symptoms to legionellosis diagnosis was shorter for CAL than for HAL (5.5 days vs. 12 days p < 0.001). Thirty-day case fatality was 12.9% for CAL and 33.3% for HAL; similarly 90-day case fatalities in the two groups were 15.8% and 55.0%, respectively. In a logistic regression analysis (excluding symptoms and laboratory tests) age > 65 years (OR = 2.6, 95% CI: 1.1-5.9) and Charlson comorbidty index = 2 (OR = 2.7, 95% CI: 1.1-6.5) were associated with an increased risk of death in CAL. We identified no statistically significant predictors of 30-day mortality in HAL.
Conclusions: Signs and symptoms were less pronounced in HAL compared to CAL. Conversely, 30-day case fatality was almost 3 times higher. Clinical awareness is important for the timely diagnosis and treatment especially of HAL. There is a need for further studies of prognostic factors in order to improve the therapeutic approach to legionellosis and potentially reduce mortality.
C1 [Jespersen, Sanne; Sogaard, Ole S.; Ostergaard, Lars] Aarhus Univ Hosp, Dept Infect Dis, DK-8200 Aarhus N, Denmark.
[Schonheyder, Henrik C.] Aarhus Univ Hosp, Dept Clin Microbiol, DK-9000 Aalborg, Denmark.
[Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Med, UPMC Montefiore Hosp, Pittsburgh, PA 15213 USA.
RP Jespersen, S (reprint author), Aarhus Univ Hosp, Dept Infect Dis, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark.
EM sanne.jespersen@ki.au.dk
RI Sogaard, Ole/P-6058-2016
FU Beckett-fonden
FX We would like to acknowledge Statens Serum Institut for making the
microbiological data available to us and Beckett-fonden for financial
support.
NR 20
TC 12
Z9 14
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAY 21
PY 2010
VL 10
AR 124
DI 10.1186/1471-2334-10-124
PG 12
WC Infectious Diseases
SC Infectious Diseases
GA 605XP
UT WOS:000278382100001
PM 20492639
ER
PT J
AU Smith, KJ
Twal, WO
Soodavar, F
Virella, G
Lopes-Virella, MF
Hammad, SM
AF Smith, Kent J.
Twal, Waleed O.
Soodavar, Farzan
Virella, Gabriel
Lopes-Virella, Maria F.
Hammad, Samar M.
TI Heat Shock Protein 70B ' (HSP70B ') Expression and Release in Response
to Human Oxidized Low Density Lipoprotein Immune Complexes in
Macrophages
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID U937 MONOCYTIC CELLS; SPHINGOSINE KINASE; CYTOKINE PRODUCTION;
PLASMA-MEMBRANE; STRESS-PROTEINS; LDL; HEAT-SHOCK-PROTEIN-70; SURVIVAL;
PATHWAY; ATHEROSCLEROSIS
AB Heat shock proteins (HSPs) have been implicated in the activation and survival of macrophages. This study examined the role of HSP70B', a poorly characterized member of the HSP70 family, in response to oxidatively modified LDL (oxLDL) and immune complexes prepared with human oxLDL and purified human antibodies to oxLDL (oxLDL-IC) in monocytic and macrophage cell lines. Immunoblot analysis of cell lysates and conditioned medium from U937 cells treated with oxLDL alone revealed an increase in intracellular HSP70B' protein levels accompanied by a concomitant increase in HSP70B' extracellular levels. Fluorescence immunohistochemistry and confocal microscopy, however, demonstrated that oxLDL-IC stimulated the release of HSP70B', which co-localized with cell-associated oxLDL-IC. In HSP70B'-green fluorescent protein-transfected mouse RAW 264.7 cells, oxLDL-IC-induced HSP70B' co-localized with membrane-associated oxLDL-IC as well as the lipid moiety of internalized oxLDL-IC. Furthermore, the data demonstrated that HSP70B' is involved in cell survival, and this effect could be mediated by sphingosine kinase 1 (SK1) activation. An examination of regularly implicated cytokines revealed a significant relationship between HSP70B' and the release of the anti-inflammatory cytokine interleukin-10 (IL-10). Small interfering RNA knockdown of HSP70B' resulted in a corresponding decrease in SK1 mRNA levels and SK1 phosphorylation as well as increased release of IL-10. In conclusion, these findings suggest that oxLDL-IC induce the synthesis and release of HSP70B', and once stimulated, HSP70B' binds to the cell-associated and internalized lipid moiety of oxLDL-IC. The data also implicate HSP70B' in key cellular functions, such as regulation of SK1 activity and release of IL-10, which influence macrophage activation and survival.
C1 [Smith, Kent J.; Twal, Waleed O.; Soodavar, Farzan; Hammad, Samar M.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
[Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
[Lopes-Virella, Maria F.] Med Univ S Carolina, Div Endocrinol, Dept Med, Charleston, SC 29425 USA.
[Lopes-Virella, Maria F.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
RP Hammad, SM (reprint author), Med Univ S Carolina, Dept Regenerat Med & Cell Biol, 114 Doughty St,630B,POB 250776, Charleston, SC 29425 USA.
EM hammadsm@musc.edu
FU National Institutes of Health (NIH) [HL079274]; NIH (American Recovery
and Investment Act (ARRA)) [R01 HL079274-04S1]; NIH (National Center for
Research Resources) [P20 RR17677]; NIH [P01 HL55782, R01 DK081352, R01
DK081352-02S1]; Department of Veterans Affairs
FX This work was supported, in whole or in part, by National Institutes of
Health (NIH) Grant HL079274 and NIH (American Recovery and Investment
Act (ARRA)) Grant R01 HL079274-04S1 (to S. M. H.); NIH (National Center
for Research Resources) Grant P20 RR17677 (South Carolina Center of
Biomedical Research Excellence in Lipidomics and Pathobiology) (to S. M.
H.); and NIH Grants P01 HL55782, R01 DK081352, and R01 DK081352-02S1
(ARRA) (to M. F. L.-V.). This work was also supported by funding from
the Department of Veterans Affairs (to M. F. L.-V.).
NR 58
TC 14
Z9 14
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 21
PY 2010
VL 285
IS 21
BP 15985
EP 15993
DI 10.1074/jbc.M110.113605
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 596WJ
UT WOS:000277715900036
PM 20348092
ER
PT J
AU Anaya, DA
Richardson, PA
Albo, D
Artinyan, A
Petersen, NJ
Awad, SS
Berger, DH
Cormier, JN
AF Anaya, D. A.
Richardson, P. A.
Albo, D.
Artinyan, A.
Petersen, N. J.
Awad, S. S.
Berger, D. H.
Cormier, J. N.
TI Treatment patterns in patients with colorectal liver metastasis: A
cohort study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 3628
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003440
ER
PT J
AU Beadling, C
Heinrich, MC
Schuff, K
Druker, BJ
Corless, CL
AF Beadling, C.
Heinrich, M. C.
Schuff, K.
Druker, B. J.
Corless, C. L.
TI Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a
personalized cancer medicine registry
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10503
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005611
ER
PT J
AU Beer, TM
Rademacher, BL
Geng, H
Pittsenbarger, J
Garzotto, M
Nelson, P
Higano, CS
Qian, DZ
AF Beer, T. M.
Rademacher, B. L.
Geng, H.
Pittsenbarger, J.
Garzotto, M.
Nelson, P.
Higano, C. S.
Qian, D. Z.
TI Effect of ID1 expression change following chemotherapy on chemotherapy
sensitivity.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Portland VA Med Ctr, Portland, OR USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Univ Washington, Sch Med, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 4548
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852003671
ER
PT J
AU Da Grace, DI
Yellapragada, S
Yasin, Z
Arce-Lara, CE
AF Da Grace, D. I.
Yellapragada, S.
Yasin, Z.
Arce-Lara, C. E.
TI Retrospective analysis of multiple myeloma survival outcomes in
veterans: Focus on racial differences, age, and novel therapies
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Da Grace, D. I.; Yellapragada, S.; Yasin, Z.; Arce-Lara, C. E.] Baylor Coll Med, Dan L Duncan Canc Ctr, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8127
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005147
ER
PT J
AU Dumont, AG
Rink, L
Miettinen, M
Joensuu, H
Strosberg, JR
Gronchi, A
Corless, CL
Lazar, AJ
Lev, D
von Mehren, M
AF Dumont, A. G.
Rink, L.
Miettinen, M.
Joensuu, H.
Strosberg, J. R.
Gronchi, A.
Corless, C. L.
Lazar, A. J.
Lev, D.
von Mehren, M.
TI Coexistence of gastrointestinal stromal tumor (GIST) with desmoid tumor
(DT): Case series of 22 patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Armed Forces Inst Pathol, Washington, DC 20306 USA.
Helsinki Univ Cent Hosp, Helsinki, Finland.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Ist Nazl Tumori, I-20133 Milan, Italy.
Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10052
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005561
ER
PT J
AU Garzotto, M
Hung, A
Beer, TM
Farris, PE
AF Garzotto, M.
Hung, A.
Beer, T. M.
Farris, P. E.
TI Phase I/II study of preoperative intensity-modulated radiation therapy
(IMRT) and docetaxel for high-risk prostate cancer: A platform for
radiosensitizer development
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS250
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002250
ER
PT J
AU Gramza, AW
Patterson, J
Peters, J
Kaufman, M
Wise, S
Flynn, D
AF Gramza, A. W.
Patterson, J.
Peters, J.
Kaufman, M.
Wise, S.
Flynn, D.
TI Activity of novel RET inhibitors against RET genotypes associated with
medullary thyroid cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Deciphera Pharmaceut, Lawrence, KS USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 5559
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004236
ER
PT J
AU Heinrich, MC
Wise, S
Hood, M
Smith, B
Kaufman, M
Lu, W
Wang, Y
Griffith, D
Flynn, D
Fletcher, JA
AF Heinrich, M. C.
Wise, S.
Hood, M.
Smith, B.
Kaufman, M.
Lu, W.
Wang, Y.
Griffith, D.
Flynn, D.
Fletcher, J. A.
TI In vitro activity of novel KIT/PDGFRA switch pocket kinase inhibitors
against mutations associated with drug-resistant GI stromal tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Deciphera Pharmaceut, Lawrence, KS USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10007
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005516
ER
PT J
AU Nannini, M
Pantaleo, MA
Astolfi, A
Maleddu, A
Heinrich, MC
Corless, CL
di Battista, M
Catena, F
Santini, D
Biasco, G
AF Nannini, M.
Pantaleo, M. A.
Astolfi, A.
Maleddu, A.
Heinrich, M. C.
Corless, C. L.
di Battista, M.
Catena, F.
Santini, D.
Biasco, G.
TI Identification of oncogenic events in gastrointestinal stromal tumors
(GISTs) by combined gene expression and copy number analysis.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Bologna, Bologna, Italy.
Univ Bologna, Seragnoli Dept, Bologna, Italy.
Univ Bologna, GIST Study Grp, Bologna, Italy.
Interdept Ctr Canc Res, Bologna, Italy.
Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Univ Bologna, S Orsola Malpighi Hosp, Emergency Surg & Transplant Dept, Bologna, Italy.
St Orsola Marcello Malpighi Hosp, Pathol Unit, Bologna, Italy.
RI nannini, margherita/J-9866-2016
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10039
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005548
ER
PT J
AU Peled, N
Hakim, M
Haick, H
Bunn, PA
Miller, YE
Kennedy, TC
Mitchell, JD
Weyant, MJ
Hirsch, FR
AF Peled, N.
Hakim, M.
Haick, H.
Bunn, P. A.
Miller, Y. E.
Kennedy, T. C.
Mitchell, J. D.
Weyant, M. J.
Hirsch, F. R.
TI Use of a nanoparticle-based artificial olfactory system, NaNose, to
distinguish malignant from benign pulmonary nodules
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Colorado Denver Canc Ctr, Aurora, CO USA.
Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel.
Russell Berrie Nanotechnol Inst, Haifa, Israel.
Denver Vet Affairs Med Ctr, Denver, CO USA.
Univ Colorado Denver, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 10521
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005629
ER
PT J
AU Pindyck, T
Spurgeon, SE
Okada, CY
Epner, EE
AF Pindyck, T.
Spurgeon, S. E.
Okada, C. Y.
Epner, E. E.
TI Cladribine plus rituximab for the initial treatment of mantle cell
lymphoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA.
Penn State Hershey Canc Inst, Hershey, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 8099
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852005119
ER
PT J
AU Shannon, J
Lieberman, S
Maxcy, C
Thuillier, P
Peters, L
Garzotto, M
AF Shannon, J.
Lieberman, S.
Maxcy, C.
Thuillier, P.
Peters, L.
Garzotto, M.
TI Fish oil, green tea, and prostate cancer prevention
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Kaiser Permanente Northwest, Portland, OR USA.
Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS140
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002143
ER
PT J
AU Spurgeon, SE
Okada, CY
Huang, J
Phillips, J
Epner, EE
AF Spurgeon, S. E.
Okada, C. Y.
Huang, J.
Phillips, J.
Epner, E. E.
TI Targeting the epigenome: A phase I/II study of vorinostat (SAHA),
cladribine (2-CdA), and rituximab in relapsed B-cell malignancies
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA.
Univ Utah, Salt Lake City, UT USA.
Penn State Hershey Canc Inst, Hershey, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA TPS301
PG 1
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852002301
ER
PT J
AU Zeliadt, SB
Sekaran, NK
Slatore, CG
Au, DH
Wu, DY
Crawford, J
Lyman, GH
Dale, DC
AF Zeliadt, S. B.
Sekaran, N. K.
Slatore, C. G.
Au, D. H.
Wu, D. Y.
Crawford, J.
Lyman, G. H.
Dale, D. C.
TI Comparison of the Veterans Affairs Oncology Registry and the SEER Cancer
Registry among patients with lung cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 VA Puget Sound Healthcare Syst, HSR&D Northwest Ctr Excellence, Seattle, WA USA.
VA Puget Sound, Seattle, WA USA.
Univ Washington, Sch Med, Seattle, WA USA.
Portland VAMC Hlth Serv Res & Dev, Portland, OR USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
VA Puget Sound Healthcare Syst, Seattle, WA USA.
Duke Univ, Med Ctr, Durham, NC USA.
Duke Univ, Durham, NC USA.
Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2010
VL 28
IS 15
SU S
MA 6056
PG 2
WC Oncology
SC Oncology
GA V30YT
UT WOS:000208852004335
ER
PT J
AU Guiguemde, WA
Shelat, AA
Bouck, D
Duffy, S
Crowther, GJ
Davis, PH
Smithson, DC
Connelly, M
Clark, J
Zhu, FY
Jimenez-Diaz, MB
Martinez, MS
Wilson, EB
Tripathi, AK
Gut, J
Sharlow, ER
Bathurst, I
El Mazouni, F
Fowble, JW
Forquer, I
McGinley, PL
Castro, S
Angulo-Barturen, I
Ferrer, S
Rosenthal, PJ
DeRisi, JL
Sullivan, DJ
Lazo, JS
Roos, DS
Riscoe, MK
Phillips, MA
Rathod, PK
Van Voorhis, WC
Avery, VM
Guy, RK
AF Guiguemde, W. Armand
Shelat, Anang A.
Bouck, David
Duffy, Sandra
Crowther, Gregory J.
Davis, Paul H.
Smithson, David C.
Connelly, Michele
Clark, Julie
Zhu, Fangyi
Jimenez-Diaz, Maria B.
Martinez, Maria S.
Wilson, Emily B.
Tripathi, Abhai K.
Gut, Jiri
Sharlow, Elizabeth R.
Bathurst, Ian
El Mazouni, Farah
Fowble, Joseph W.
Forquer, Isaac
McGinley, Paula L.
Castro, Steve
Angulo-Barturen, Inigo
Ferrer, Santiago
Rosenthal, Philip J.
DeRisi, Joseph L.
Sullivan, David J., Jr.
Lazo, John S.
Roos, David S.
Riscoe, Michael K.
Phillips, Margaret A.
Rathod, Pradipsinh K.
Van Voorhis, Wesley C.
Avery, Vicky M.
Guy, R. Kiplin
TI Chemical genetics of Plasmodium falciparum
SO NATURE
LA English
DT Article
ID DIHYDROOROTATE DEHYDROGENASE; SCREENING LIBRARIES; DRUG DISCOVERY;
MALARIA; IDENTIFICATION; DISRUPTION; RESISTANCE; SURVIVAL; GROWTH
AB Malaria caused by Plasmodium falciparum is a disease that is responsible for 880,000 deaths per year worldwide. Vaccine development has proved difficult and resistance has emerged for most antimalarial drugs. To discover new antimalarial chemotypes, we have used a phenotypic forward chemical genetic approach to assay 309,474 chemicals. Here we disclose structures and biological activity of the entire library-many of which showed potent in vitro activity against drug-resistant P. falciparum strains-and detailed profiling of 172 representative candidates. A reverse chemical genetic study identified 19 new inhibitors of 4 validated drug targets and 15 novel binders among 61 malarial proteins. Phylochemogenetic profiling in several organisms revealed similarities between Toxoplasma gondii and mammalian cell lines and dissimilarities between P. falciparum and related protozoans. One exemplar compound displayed efficacy in a murine model. Our findings provide the scientific community with new starting points for malaria drug discovery.
C1 [Guiguemde, W. Armand; Shelat, Anang A.; Bouck, David; Smithson, David C.; Connelly, Michele; Clark, Julie; Zhu, Fangyi; Guy, R. Kiplin] St Jude Childrens Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA.
[Duffy, Sandra; Avery, Vicky M.] Griffith Univ, Eskitis Inst Cell & Mol Therapies, Brisbane, Qld 4111, Australia.
[Crowther, Gregory J.; Van Voorhis, Wesley C.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Davis, Paul H.; Roos, David S.] Univ Penn, Penn Genome Frontiers Inst, Philadelphia, PA 19104 USA.
[Davis, Paul H.; Roos, David S.] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.
[Jimenez-Diaz, Maria B.; Martinez, Maria S.; Angulo-Barturen, Inigo; Ferrer, Santiago] GlaxoSmithKline Inc, Dis Developing World, Tres Cantos 28760, Spain.
[Wilson, Emily B.; DeRisi, Joseph L.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA.
[Tripathi, Abhai K.; Sullivan, David J., Jr.] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
[Gut, Jiri; Rosenthal, Philip J.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA.
[Sharlow, Elizabeth R.; Lazo, John S.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA.
[Bathurst, Ian] Med Malaria Venture, CH-1215 Geneva, Switzerland.
[El Mazouni, Farah; Phillips, Margaret A.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
[Fowble, Joseph W.; Rathod, Pradipsinh K.] Univ Washington, Dept Chem, Seattle, WA 98195 USA.
[Forquer, Isaac; Riscoe, Michael K.] Portland VA Med Ctr, Expt Chemotherapy Lab, Portland, OR 97239 USA.
[McGinley, Paula L.; Castro, Steve] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA.
RP Guy, RK (reprint author), St Jude Childrens Hosp, Dept Chem Biol & Therapeut, 332 N Lauderdale St, Memphis, TN 38105 USA.
EM kip.guy@stjude.org
RI Avery, Vicky/A-5449-2010; Davis, Paul/J-6141-2012; Shelat, Anang
/J-4995-2013; Guy, Rodney/J-7107-2013; duffy, sandra/B-8479-2017
OI Davis, Paul/0000-0002-0526-3841; Guy, Rodney/0000-0002-9638-2060; duffy,
sandra/0000-0002-2814-1193; Crowther, Gregory/0000-0003-0530-9130
FU American Lebanese Syrian Associated Charities (ALSAC); St Jude
Children's Research Hospital (SJCRH); Medicines for Malaria Venture;
National Institute of Allergy and Infectious Diseases [AI772682,
AI075517, AI067921, AI080625, AI28724, AI53862, AI35707, AI053680,
AI075594, AI082617, AI045774]; National Cancer Institute [CA78039];
Welch Foundation [I-1257]; Doris Duke Charitable Foundation; Ellison
Medical Foundation
FX This work was supported by the American Lebanese Syrian Associated
Charities (ALSAC) and St Jude Children's Research Hospital (SJCRH, R. K.
G.), the Medicines for Malaria Venture (W. C. V. V. and V. M. A.),
National Institute of Allergy and Infectious Diseases (AI772682 (P. H.
D.), AI075517 (R. K. G.), AI067921 (W. C. V. V.) and AI080625 (W. C. V.
V.), AI28724 (D. S. R.), AI53862 (J.L.D.), AI35707 (P.J.R.), AI053680
(M. A. P. and P. K. R.), AI075594 (M. A. P., P. K. R. and I. B.),
AI082617 (P. K. R.) and AI045774 (D.J.S.)), the National Cancer
Institute (CA78039 (J.S.L.)), the Welch Foundation (I-1257 (M. A. P.)),
the Doris Duke Charitable Foundation (P.J.R.), and the Ellison Medical
Foundation (D. S. R.). We acknowledge A. B. Vaidya for providing the
parasite strain D10_yDHOD. We acknowledge M. Sigal for assistance in the
early leads project coordination, the SJCRH High Throughput Screening
Center, particularly J. Cui; the SJCRH Lead Discovery Informatics
Center, and the SJCRH High Throughput Analytical Chemistry Center,
particularly C. Nelson and A. Lemoff; at UW, F. Buckner, W. Hol and A.
Napuli (AI067921, W. Hol); S. Wei and W. Hao in the UT Southwestern HTS
Center; and the Australian Red Cross Blood Service for the provision of
O+ erythrocytes to Griffith University.
NR 27
TC 289
Z9 292
U1 5
U2 58
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 20
PY 2010
VL 465
IS 7296
BP 311
EP 315
DI 10.1038/nature09099
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 598IO
UT WOS:000277829200032
PM 20485428
ER
PT J
AU Parker, BD
Schurgers, LJ
Brandenburg, VM
Christenson, RH
Vermeer, C
Ketteler, M
Shlipak, MG
Whooley, MA
Ix, JH
AF Parker, Benjamin D.
Schurgers, Leon J.
Brandenburg, Vincent M.
Christenson, Robert H.
Vermeer, Cees
Ketteler, Markus
Shlipak, Michael G.
Whooley, Mary A.
Ix, Joachim H.
TI The Associations of Fibroblast Growth Factor 23 and Uncarboxylated
Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart
and Soul Study
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; FETUIN-A LEVELS; CARDIOVASCULAR MORTALITY; SERUM
PHOSPHORUS; MYOCARDIAL-INFARCTION; DIALYSIS PATIENTS; VASCULAR
CALCIFICATION; GLYCOPROTEIN/FETUIN-A; PHOSPHATE LEVELS; RISK
AB Background: Fibroblast growth factor 23 (FGF23), uncarboxylated matrix Gla protein (ucMGP), and fetuin-A are regulators of mineral metabolism and inhibitors of vascular calcification. Whether circulating levels of each are associated with cardiovascular disease (CVD) events or mortality in populations without end-stage renal disease is unknown.
Objective: To evaluate the associations of FGF23, ucMGP, and fetuin-A with mortality and CVD events.
Design: Observational study.
Setting: 12 outpatient clinics in the San Francisco Bay area.
Patients: 833 outpatients with stable coronary artery disease (CAD), recruited from 11 September 2000 to 20 December 2002.
Measurements: Fibroblast growth factor 23, ucMGP, and fetuin-A concentrations were measured at baseline. Participants were followed until 1 December 2008 for mortality and CVD events.
Results: During a median follow-up of 6.0 years, 220 participants died and 182 had CVD events. Compared with participants with FGF-23 levels in the lowest tertile, those in the highest tertile had 2-fold greater risk for mortality (hazard ratio [HR], 2.15 [95% CI, 1.43 to 3.24]) and CVD events (HR, 1.83 [CI, 1.15 to 2.91]) after adjustment for traditional CVD risk factors, C-reactive protein levels, and kidney function. The highest ucMGP tertile was associated with lower mortality risk (HR, 0.48 [CI, 0.31 to 0.75]) and showed a nonsignificant trend toward lower CVD event risk by tertile analysis (HR, 0.65 [CI, 0.40 to 1.05])-an association that was significant when modeled continuously (P = 0.029). No significant association of fetuin-A with mortality (HR, 0.84 [CI, 0.55 to 1.27]) or CVD events (HR, 0.99 [CI, 0.64 to 1.55]) was observed.
Limitation: Participants had prevalent CAD.
Conclusion: In outpatients with stable CAD, higher FGF23 and lower ucMGP levels are independently associated with mortality and CVD events.
C1 [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92161 USA.
Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
Maastricht Univ, Cardiovasc Res Inst, Maastricht, Netherlands.
VitaK, Maastricht, Netherlands.
Rhein Westfal TH Aachen, Univ Hosp, Aachen, Germany.
Klinikum Coburg, Coburg, Germany.
Univ Maryland, Baltimore, MD 21201 USA.
RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA.
EM joeix@ucsd.edu
OI Vermeer, Cees/0000-0002-2300-8561
FU National Heart, Lung, and Blood Institute (NHLBI) [T32 HL007261,
R01HL096851, R01 HL079235]; American Heart Association; Department of
Veterans Epidemiology Merit Review Program; Department of Veterans
Affairs Health Services Research and Development service; American
Federation for Aging Research; Robert Wood Johnson Foundation; Ischemia
Research and Education Foundation
FX Grant Support: By a Hypertension Training Grant (T32 HL007261) through
the National Heart, Lung, and Blood Institute (NHLBI) (Dr. Parker), an
American Heart Association Fellow-to-Faculty transition grant, and the
NHLBI (grant R01HL096851, Dr. Ix). The Heart and Soul Study was
supported by the Department of Veterans Epidemiology Merit Review
Program; the Department of Veterans Affairs Health Services Research and
Development service; the NHLBI (grant R01 HL079235); the American
Federation for Aging Research (Paul Beeson Scholars Program); the Robert
Wood Johnson Foundation (Generalist Physician Faculty Scholars Program);
and the Ischemia Research and Education Foundation. Dr. Ix had full
access to all of the data in the study and takes responsibility for the
integrity of the data and the accuracy of the data analysis.
NR 56
TC 235
Z9 243
U1 1
U2 15
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAY 18
PY 2010
VL 152
IS 10
BP 640
EP +
DI 10.1059/0003-4819-152-10-201005180-00004
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 598RJ
UT WOS:000277855500003
PM 20479029
ER
PT J
AU Rugge, M
de Boni, M
Pennelli, G
de Bona, M
Giacomelli, L
Fassan, M
Basso, D
Plebani, M
Graham, DY
AF Rugge, M.
de Boni, M.
Pennelli, G.
de Bona, M.
Giacomelli, L.
Fassan, M.
Basso, D.
Plebani, M.
Graham, D. Y.
TI Gastritis OLGA-staging and gastric cancer risk: a twelve-year
clinico-pathological follow-up study
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID HELICOBACTER-PYLORI ERADICATION; RANDOMIZED CONTROLLED-TRIAL; ATROPHIC
GASTRITIS; INTESTINAL METAPLASIA; SERUM PEPSINOGEN; CLASSIFICATION;
SYSTEM; PATHOGENESIS; METAANALYSIS; POPULATION
AB P>Background
Intestinal-type gastric cancer (GC) still ranks among the high-incidence, highly lethal malignancies. Atrophic gastritis is the cancerization field in which GC develops. The current histological reporting formats for gastritis do not include any (atrophy-based) ranking of GC risk.
Aim
To test the gastritis OLGA-staging (Operative Link for Gastritis Assessment) in prognosticating neoplastic progression.
Methods
Ninety-three Italian patients were followed up for more than 12 years (range: 144-204 months). Clinical examinations, pepsinogen serology, endoscopy and histology (also assessing Helicobacter pylori status) were performed both at enrolment (T1) and at the end of the follow-up (T2).
Results
All invasive or intra-epithelial gastric neoplasia were consistently associated with high-risk (III/IV) OLGA stages. There was a significant inverse correlation between the mean pepsinogen ratio and the OLGA stage (test for trend; P < 0.001). OLGA-staging at T1 predicted both the OLGA stage (Kaplan-Maier log-rank test, P = 0.001) and the neoplasia at T2 (Kaplan-Maier log-rank test, P = 0.001).
Conclusions
This long-term follow-up study provides the first evidence that gastritis OLGA-staging conveys relevant information on the clinico-pathological outcome of gastritis and therefore for patient management. According to OLGA-staging and H. pylori-status, gastritis patients could be confidently stratified and managed according to their different cancer risks.
C1 [Rugge, M.] Univ Padua, Cattedra Anat Patol, Ist Oncol Veneto IOV IRCCS, I-35121 Padua, Italy.
[Rugge, M.; Pennelli, G.; Fassan, M.] Univ Padua, Dept Diagnost Med Sci & Special Therapies, Pathol Unit, I-35121 Padua, Italy.
[de Boni, M.; de Bona, M.] Feltre Hosp, Dept Gastroenterol, Feltre, Italy.
[Giacomelli, L.] Azienda Osped Padova, Dept Pathol, Padua, Italy.
[Basso, D.; Plebani, M.] Univ Padua, Dept Diagnost Med Sci & Special Therapies, Clin Biochem Unit, I-35121 Padua, Italy.
[Graham, D. Y.] Baylor Coll Med, Vet Adm Hosp, Div Digest Dis, Houston, TX 77030 USA.
RP Rugge, M (reprint author), Univ Padua, Cattedra Anat Patol, Ist Oncol Veneto IOV IRCCS, Via Aristide Gabelli 61, I-35121 Padua, Italy.
EM massimo.rugge@unipd.it
RI Fassan, Matteo/F-5152-2012; Basso, Daniela/J-7855-2016; Rugge,
Massimo/K-7525-2016
OI Fassan, Matteo/0000-0001-6515-5482; Basso, Daniela/0000-0001-8745-6171;
PENNELLI, GIANMARIA/0000-0003-0210-165X
FU Office of Research and Development Medical Research Service, Department
of Veterans Affairs; Public Health Service [DK56338]; Texas Medical
Center Digestive Diseases Center [R01 CA116845]; 'Arianna' Association
ONLUS (Feltre); AIRC; 'Guido Berlucchi' Foundation; 'Morgagni'
Association for Oncological Research (Padova)
FX Declaration of personal interests: Guarantor of the article: Dr Rugge
had full access to all the data in the study and takes responsibility
for the integrity of the data and the accuracy of the data analysis.
Specific author contributions: Massimo Rugge - Pathological assessment
and clinico-pathological correlations. Michele de Boni - Patient
recruitment, clinical examination and endoscopy assessment. Gianmaria
Pennelli and Matteo Fassan - Pathological assessment. Manuela de Bona -
patient recruitment. Luciano Giacomelli - Biostatistician. Daniela Basso
and Mario Plebani - Serology study. David Y Graham -
Clinico-pathological correlations. All authors have read and approved
the final manuscript draft submitted. The authors would like to thank G.
Bonet, MD, general practitioner of the Vanoi valley residents: without
his enthusiastic, highly professional and dedicated co-operation, the
present study would not have been possible. Special thanks to the Head
of the Department of Pathology at Feltre Hospital, Dr. R. Barbazza, who
kindly provided the histological material for this study. The authors
are indebted to A. Bellumat, MD and F. Valiante, MD (of the
Gastroenterology Department at Feltre Hospital), who were involved in
the endoscopic procedures, to M. Tollardo, MD, who helped in preliminary
data collection, and to Dr. M. Guido, MD, for her critical review of the
manuscript. Dr. Graham is supported in part by the Office of Research
and Development Medical Research Service, Department of Veterans
Affairs, and by a Public Health Service grant (DK56338), which funds the
Texas Medical Center Digestive Diseases Center, and R01 CA116845. The
contents are solely the responsibility of the authors and do not
necessarily represent the official views of the VA or NIH. In the last 2
years, Dr. Graham has received small sums as grants from Meretek and
BioHit for investigator-initiated and completely investigator-controlled
research. Dr. Graham is also a paid consultant for Otsuka
Pharmaceuticals (a manufacturer of the 13C-urea breath test). None of
the other authors have any potential conflicts of interest. Declaration
of funding interests: This research was supported in part by the
'Arianna' Association ONLUS (Feltre); the AIRC grant Veneto Region,
2009; the 'Guido Berlucchi' Foundation and the 'Morgagni' Association
for Oncological Research (Padova). The funding agencies had no role in
the design and conduct of the study.
NR 37
TC 89
Z9 93
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD MAY 15
PY 2010
VL 31
IS 10
BP 1104
EP 1111
DI 10.1111/j.1365-2036.2010.04277.x
PG 8
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 586NL
UT WOS:000276917100006
PM 20180784
ER
PT J
AU Gebregziabher, M
Egede, LE
Lynch, CP
Echols, C
Zhao, YM
AF Gebregziabher, Mulugeta
Egede, Leonard E.
Lynch, Cheryl P.
Echols, Carrae
Zhao, Yumin
TI Effect of Trajectories of Glycemic Control on Mortality in Type 2
Diabetes: A Semiparametric Joint Modeling Approach
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE cohort studies; diabetes mellitus; type 2; hemoglobin A; glycosylated;
mortality; retrospective studies; veterans
ID OF-VETERANS-AFFAIRS; EVENT TIME DATA; CARDIOVASCULAR MORTALITY;
MEDICATION ADHERENCE; HEMOGLOBIN A(1C); GLUCOSE CONTROL; ALL-CAUSE;
ASSOCIATION; DISEASE; POPULATION
AB Data on the effect of trajectories in long-term glycemia and all-cause mortality are lacking. The authors studied the effect of trajectories in long-term glycemic control on all-cause mortality in patients with type 2 diabetes. A cohort of 8,812 veterans with type 2 diabetes was assembled retrospectively using Veterans Affairs registry data. For each veteran in the cohort, a 3-month person-period data set was created from April 1997 to May 2006. The average duration of follow-up was 4.5 years. The overall mortality rate was 15.3%. Using a novel approach for joint modeling of time to death and longitudinal measurements of hemoglobin A1c (HbA1c) level, after adjustment for all significant baseline covariates, baseline HbA1c was found to be significantly associated with mortality (hazard ratio = 2.1, 95% confidence interval: 1.3, 3.6) (i.e., a 1% increase in baseline HbA1c level was associated with an average 2-fold increase in mortality risk). Similarly, the slope of the HbA1c trajectory was marginally significantly associated with mortality (hazard ratio = 7.3, 95% confidence interval: 0.9, 57.1) after adjustment for baseline covariates (i.e., a 1% increase in HbA1c level over 3 months was associated with a 22% increase in mortality risk). The authors conclude that a positive trajectory of long-term hyperglycemia is associated with increased mortality.
C1 [Egede, Leonard E.; Lynch, Cheryl P.; Zhao, Yumin] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA.
[Gebregziabher, Mulugeta; Egede, Leonard E.; Lynch, Cheryl P.; Echols, Carrae] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
[Egede, Leonard E.; Lynch, Cheryl P.; Zhao, Yumin] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA.
EM egedel@musc.edu
OI Gebregziabher, Mulugeta/0000-0002-4826-481X
FU Center for Disease Prevention and Health Interventions for Diverse
Populations [REA 08-261]; Department of Veterans Affairs Health Services
Research and Development Service
FX This study was supported by grant REA 08-261 from the Center for Disease
Prevention and Health Interventions for Diverse Populations, which is
funded by the Department of Veterans Affairs Health Services Research
and Development Service (Principal Investigator, Leonard E. Egede).
NR 38
TC 9
Z9 9
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD MAY 15
PY 2010
VL 171
IS 10
BP 1090
EP 1098
DI 10.1093/aje/kwq070
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 597AU
UT WOS:000277728400005
PM 20427326
ER
PT J
AU Wynn, JK
Sugar, C
Horan, WP
Kern, R
Green, MF
AF Wynn, Jonathan K.
Sugar, Catherine
Horan, William P.
Kern, Robert
Green, Michael F.
TI Mismatch Negativity, Social Cognition, and Functioning in Schizophrenia
Patients
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Functioning; mismatch negativity; schizophrenia; social cognition
ID EVENT-RELATED POTENTIALS; NEUROCOGNITIVE DEFICITS; PERCEPTION;
REDUCTION; MATRICS; MEMORY; ERP
AB Background: Cognition and social cognition have been found to influence functional outcome in schizophrenia patients. However, little is known about the underlying neural substrates that are associated with social cognition or daily functioning. Prior studies found associations between mismatch negativity (MMN), an event-related potential response indexing early auditory processing, and functioning in schizophrenia patients.
Methods: In this study, we examined MMN, social cognition (social perception and theory of mind), and four domains of functioning (work, independent living, social networks, and family networks) in 33 schizophrenia patients and 42 demographically comparable healthy control subjects.
Results: Schizophrenia patients exhibited reduced MMN activity at frontocentral electrode sites compared with healthy control subjects. Within the schizophrenia sample, greater MMN activity at frontocentral sites correlated with better work and independent living (but not social or family networks) and with better social perception.
Conclusions: These results suggest that MMN activity is more closely tied to some outcome domains (work and independent living) than others. Mismatch negativity has been previously shown to be associated with basic cognition and functional outcome in schizophrenia, but these findings are the first, to our knowledge, to show MMN associations with social cognition. These results are consistent with cascade models of information processing in which deficits in early perceptual processing have a downstream impact on higher order social cognition and community functioning.
C1 [Wynn, Jonathan K.] Univ Calif Los Angeles, Los Angeles & VA Greater Los Angeles Healthcare S, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA.
[Sugar, Catherine] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90073 USA.
[Wynn, Jonathan K.; Horan, William P.; Kern, Robert; Green, Michael F.] Vet Affairs Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA.
RP Wynn, JK (reprint author), Univ Calif Los Angeles, Los Angeles & VA Greater Los Angeles Healthcare S, Dept Psychiat & Biobehav Sci, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jkwynn@ucla.edu
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
FU National Institutes of Mental Health [MH-43292]; Veterans Affairs Career
Development Award
FX This work was supported by a National Alliance fir Research on
Schizophrenia and Depression Young Investigator Award to JKW and Grant
MH-43292 from the National Institutes of Mental Health to MFG. JKW was
supported by a Veterans Affairs Career Development Award while preparing
the manuscript for publication.
NR 45
TC 58
Z9 58
U1 3
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 15
PY 2010
VL 67
IS 10
BP 940
EP 947
DI 10.1016/j.biopsych.2009.11.024
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 595RK
UT WOS:000277629900007
PM 20074704
ER
PT J
AU Chi, RC
Rock, MT
Neuzil, KM
AF Chi, Ru-Chien
Rock, Michael T.
Neuzil, Kathleen M.
TI Immunogenicity and Safety of Intradermal Influenza Vaccination in
Healthy Older Adults
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID CELLULAR IMMUNE-RESPONSES; RANDOMIZED CONTROLLED-TRIAL;
ANTIBODY-RESPONSES; ELDERLY-PEOPLE; MORTALITY BENEFITS; SEASONAL
INFLUENZA; T-CELLS; EFFICACY; IMMUNIZATION; PROTECTION
AB Background. Influenza vaccine immunogenicity is suboptimal in older persons. Intradermal (ID) vaccination may be a promising alternative to intramuscular (IM) vaccination.
Methods. This randomized trial compared the immunogenicity of 60% dose ID influenza vaccination to standard IM vaccination of full-dose or 60% dose vaccine. Pre- and postvaccination measurements in the hemagglutination inhibition antibody titer were compared. Participants who received reduced-dose vaccine were revaccinated with full-dose IM vaccine.
Results. 257 healthy adults aged >= 65 years received 1 of the following trivalent inactivated influenza vaccines: standard-dose (15 mu g each of 3 hemagglutinin vaccine antigens in 0.5 mL) IM injection, reduced-dose (9 mu g, 0.3 mL) IM injection, reduced-dose ( 9 mu g, 0.3 mL) ID injection, or 2 reduced-dose (4.5 mu g, 0.15 mL) ID injections. Respective seroprotection rates were 65.6%, 57.8%, 68.9%, and 67.2% against A/H1N1; 76.6%, 75.0%, 75.4%, and 75.0% against A/H3N2; and 26.6%, 17.2%, 16.4%, and 25.0% against influenza B. Subsequent full-dose IM vaccination of participants randomized to reduced-dose vaccine by either IM or ID routes did not improve seroprotection rates. Local reactions of redness, swelling, and itching were significantly more frequent among recipients of ID injections.
Conclusion. Influenza vaccine at 60% dose by either IM or ID route elicited antibody responses generally similar to full-dose IM vaccination among healthy elderly persons (ClinicalTrials. gov identifier: NCT00504231).
C1 [Chi, Ru-Chien] Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Neuzil, Kathleen M.] Univ Washington, Dept Global Hlth, Seattle, WA 98108 USA.
[Chi, Ru-Chien] Univ Washington, Dept Med, Seattle, WA 98108 USA.
[Neuzil, Kathleen M.] PATH, Seattle, WA USA.
[Rock, Michael T.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
RP Chi, RC (reprint author), Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-182, Seattle, WA 98108 USA.
EM rchi@u.washington.edu
FU Research and Development Medical Research Service, Department of
Veterans Affairs; World Health Organization; Fondation Merieux entitled
"Intradermal Immunization: An Alternative Route for Vaccine
Administration" in Annecy, France
FX This material is based on work supported by the Research and Development
Medical Research Service, Department of Veterans Affairs. The views in
this article do not necessarily represent the views of the Department of
Veterans Affairs.; Presented in part: a conference sponsored by the
World Health Organization and Fondation Merieux entitled "Intradermal
Immunization: An Alternative Route for Vaccine Administration" in
Annecy, France, 8 April 2008, and 2 American Geriatrics Society annual
meetings, 2 May 2008 and 30 April 2009.
NR 43
TC 24
Z9 24
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2010
VL 50
IS 10
BP 1331
EP 1338
DI 10.1086/652144
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 584PO
UT WOS:000276764900001
PM 20377407
ER
PT J
AU Guo, CY
Hirano, AA
Stella, SL
Bitzer, M
Brecha, NC
AF Guo, Chenying
Hirano, Arlene A.
Stella, Salvatore L., Jr.
Bitzer, Michaela
Brecha, Nicholas C.
TI Guinea Pig Horizontal Cells Express GABA, the GABA-Synthesizing Enzyme
GAD(65), and the GABA Vesicular Transporter
SO JOURNAL OF COMPARATIVE NEUROLOGY
LA English
DT Article
DE GABA; GAD; GAT; VGAT; VIAAT; horizontal cells; retina; visual system
ID GAMMA-AMINOBUTYRIC-ACID; PLASMA-MEMBRANE TRANSPORTER; OUTER PLEXIFORM
LAYER; INTRACELLULAR CHLORIDE CONCENTRATION; MAMMALIAN CONE
PHOTORECEPTORS; DECARBOXYLASE MESSENGER-RNA; CALCIUM-BINDING PROTEINS;
CARRIER-MEDIATED RELEASE; IN-SITU HYBRIDIZATION; RAT RETINA
AB gamma-Aminobutyric acid (GABA) is likely expressed in horizontal cells of all species, although conflicting physiological findings have led to considerable controversy regarding its role as a transmitter in the outer retina. This study has evaluated key components of the GABA system in the outer retina of guinea pig, an emerging retinal model system. The presence of GABA, its rate-limiting synthetic enzyme glutamic acid decarboxylase (GAD(65) and GAD(67) isoforms), the plasma membrane GABA transporters (GAT-1 and GAT-3), and the vesicular GABA transporter (VGAT) was evaluated by using immunohistochemistry with well-characterized antibodies. The presence of GAD(65) mRNA was also evaluated by using laser capture microdissection and reverse transcriptase-polymerase chain reaction. Specific GABA, GAD(65), and VGAT immunostaining was localized to horizontal cell bodies, as well as to their processes and tips in the outer plexiform layer. Furthermore, immunostaining of retinal whole mounts and acutely dissociated retinas showed GAD(65) and VGAT immunoreactivity. in both A-type and B-type horizontal cells. However, these cells did not contain GAD(67), GAT-1, or GAT-3 immunoreactivity. GAD(65) mRNA was detected in horizontal cells, and sequencing of the amplified GAD(65) fragment showed approximately 85% identity with other mammalian GAD(65) mRNAs. These studies demonstrate the presence of GABA, GAD(65), and VGAT in horizontal cells of the guinea pig retina, and support the idea that GABA is synthesized from GAD(65), taken up into synaptic vesicles by VGAT, and likely released by a vesicular mechanism from horizontal cells. J. Comp. Neurol. 518:1647-1669, 2010. (C) 2009 Wiley-Liss, Inc.
C1 [Guo, Chenying; Hirano, Arlene A.; Stella, Salvatore L., Jr.; Bitzer, Michaela; Brecha, Nicholas C.] Univ Calif Los Angeles, Dept Neurobiol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Vet Adm Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Brecha, NC (reprint author), Univ Calif Los Angeles, Dept Neurobiol, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM nbrecha@ucla.edu
OI Stella Jr., Salvatore/0000-0003-1971-2537
FU National Institutes of Health [EY 15573]; Veterans Administration
FX Grant sponsor: National Institutes of Health; Grant number: EY 15573;
Grant sponsor: Veterans Administration (Senior Career Research
Scientist: N.C.B.).
NR 161
TC 25
Z9 25
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9967
EI 1096-9861
J9 J COMP NEUROL
JI J. Comp. Neurol.
PD MAY 15
PY 2010
VL 518
IS 10
BP 1647
EP 1669
DI 10.1002/cne.22294
PG 23
WC Neurosciences; Zoology
SC Neurosciences & Neurology; Zoology
GA 581CX
UT WOS:000276499800003
PM 20235161
ER
PT J
AU Jimenez, F
Quinones, MP
Martinez, HG
Estrada, CA
Clark, K
Garavito, E
Ibarra, J
Melby, PC
Ahuja, SS
AF Jimenez, Fabio
Quinones, Marlon P.
Martinez, Hernan G.
Estrada, Carlos A.
Clark, Kassandra
Garavito, Edgar
Ibarra, Jessica
Melby, Peter C.
Ahuja, Seema S.
TI CCR2 Plays a Critical Role in Dendritic Cell Maturation: Possible Role
of CCL2 and NF-kappa B
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID LEISHMANIA-MAJOR INFECTION; SECONDARY LYMPHOID ORGANS; REGULATORY
T-CELLS; IN-VIVO; LANGERHANS CELLS; TNF-ALPHA; GENE-EXPRESSION;
TRANSCRIPTION FACTORS; PROTEASOME INHIBITOR; ANTIGEN PRESENTATION
AB We postulated that CCR2-driven activation of the transcription factor NF-kappa B plays a critical role in dendritic cell (DC) maturation (e.g., migration, costimulation, and IL-12p70 production), necessary for the generation of protective immune responses against the intracellular pathogen Leishmania major. Supporting this notion, we found that CCR2, its ligand CCL2, and NF-kappa B were required for CCL19 production and adequate Langerhans cell (LC) migration both ex vivo and in vivo. Furthermore, a role for CCR2 in upregulating costimulatory molecules was indicated by the reduced expression of CD80, CD86, and CD40 in Ccr2(-/-) bone marrow-derived dendritic cells (BMDCs) compared with wild-type (WT) BMDCs. Four lines of evidence suggested that CCR2 plays a critical role in the induction of protective immunity against L. major by regulating IL-12p70 production and migration of DC populations such as LCs. First, compared with WT, Ccr2(-/-) lymph node cells, splenocytes, BMDCs, and LCs produced lower levels of IL-12p70 following stimulation with LPS/IFN-gamma or L. major. Second, a reduced number of LCs carried L. major from the skin to the draining lymph nodes in Ccr2(-/-) mice compared with WT mice. Third, early treatment with exogenous IL-12 reversed the susceptibility to L major infection in Ccr2(-/-) mice. Finally, disruption of IL-12p70 in radioresistant cells, such as LCs, but not in BMDCs resulted in the inability to mount a fully protective immune response in bone marrow chimeric mice. Collectively, our data point to an important role for CCR2-driven activation of NF-kappa B in the regulation of DC/LC maturation processes that regulate protective immunity against intracellular pathogens. The Journal of Immunology, 2010, 184: 5571-5581.
C1 [Jimenez, Fabio; Quinones, Marlon P.; Martinez, Hernan G.; Estrada, Carlos A.; Clark, Kassandra; Garavito, Edgar; Ibarra, Jessica; Melby, Peter C.; Ahuja, Seema S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Jimenez, Fabio; Quinones, Marlon P.; Martinez, Hernan G.; Clark, Kassandra; Melby, Peter C.; Ahuja, Seema S.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, Vet Adm Ctr Res AIDS & HIV Infect 1, San Antonio, TX 78229 USA.
RP Ahuja, SS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, MC 7870,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM ahuja@uthscsa.edu
FU National Institutes of Health [RO1-AR052755, RO1-AI48644]; Veterans
Affairs
FX This work was supported by National Institutes of Health Grants
RO1-AR052755 and RO1-AI48644 and a Veterans Affairs merit grant.
NR 76
TC 45
Z9 47
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 15
PY 2010
VL 184
IS 10
BP 5571
EP 5581
DI 10.4049/jimmunol.0803494
PG 11
WC Immunology
SC Immunology
GA 594IO
UT WOS:000277530700018
PM 20404272
ER
PT J
AU Haug, A
Mahalingam, R
Cohrs, RJ
Schmid, DS
Corboy, JR
Gilden, D
AF Haug, Aaron
Mahalingam, Ravi
Cohrs, Randall J.
Schmid, D. Scott
Corboy, John R.
Gilden, Don
TI Recurrent polymorphonuclear pleocytosis with increased red blood cells
caused by varicella zoster virus infection of the central nervous system
Case report and review of the literature
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE VZV; Recurrent vasculopathy; Myelitis; Polymorphonuclear cells; Red
blood cells
ID IMMUNE-DEFICIENCY-SYNDROME; CEREBROSPINAL-FLUID; TRANSVERSE MYELITIS;
HERPES-ZOSTER; CYTOMEGALOVIRUS; MENINGITIS; PATIENT; ENCEPHALITIS;
VASCULOPATHY; VASCULITIS
AB We describe an immunocompetent 45-year-old woman who had four episodes of neurological disease (meningoencephalitis, multifocal vasculopathy, myelitis and inflammatory brain stem disease) produced by varicella zoster virus (VZV) over an 11-month period, all in the absence of rash. The cerebrospinal fluid (CSF) contained anti-VZV IgG antibody, but not VZV DNA throughout her illness, reaffirming the superiority of detection of anti-VZV IgG in CSF compared to VZV DNA in diagnosing VZV infection of the nervous system. Moreover, 3 of 7 CSF samples examined during the 11 months showed a VZV-induced pleocytosis consisting predominantly of polymorphonuclear cells (PMNs), and 4 of 7 samples also contained increased numbers of red blood cells (RBCs). Because increased PMNs and RBCs in CSF can also occur in patients with central and peripheral nervous system disease produced by cytomegalovirus (CMV), the differential diagnosis of chronic nervous system infection with increased PMNs and RBCs in CSF should include analyses for both VZV and CMV. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Haug, Aaron; Mahalingam, Ravi; Cohrs, Randall J.; Corboy, John R.; Gilden, Don] Univ Colorado Denver, Sch Med, Dept Neurol, Aurora, CO USA.
[Schmid, D. Scott] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA.
[Gilden, Don] Univ Colorado Denver, Sch Med, Dept Microbiol, Aurora, CO USA.
[Corboy, John R.] Denver Vet Affairs Med Ctr, Dept Neurol, Denver, CO USA.
RP Gilden, D (reprint author), 12700 E 19th Ave,Mail Stop B182, Aurora, CO 80045 USA.
EM don.gilden@ucdenver.edu
FU National Institutes of Health [AG006127, NS032623, AG032958]
FX This work was supported in part by the Public Health Service grants
AG006127, and NS032623 and AG032958 from the National Institutes of
Health. The authors thank Marina Hoffman for editorial review and Cathy
Allen for manuscript preparation.
NR 31
TC 19
Z9 19
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAY 15
PY 2010
VL 292
IS 1-2
BP 85
EP 88
DI 10.1016/j.jns.2010.01.019
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 584WJ
UT WOS:000276784100016
PM 20170926
ER
PT J
AU Friedman, JH
Alves, G
Hagell, P
Marinus, J
Marsh, L
Martinez-Martin, P
Goetz, CG
Poewe, W
Rascol, O
Sampaio, C
Stebbins, G
Schrag, A
AF Friedman, Joseph H.
Alves, Guido
Hagell, Peter
Marinus, Johan
Marsh, Laura
Martinez-Martin, Pablo
Goetz, Christopher G.
Poewe, Werner
Rascol, Olivier
Sampaio, Cristina
Stebbins, Glenn
Schrag, Anette
TI Fatigue Rating Scales Critique and Recommendations by the Movement
Disorders Society Task Force on Rating Scales for Parkinson's Disease
SO MOVEMENT DISORDERS
LA English
DT Review
DE fatigue; Parkinson's disease; rating scales-fatigue rating scales
AB Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was "recommended" if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of "recommended" differs from the use of this term in previous MDS task force scale reviews. "Suggested" scales failed to meet all the criteria of a "recommended" scale, usually the criterion of sensitivity to change in a study of PD. Scales were "listed" if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was "recommended" for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is "suggested" for both screening and severity. The Functional Assessment of Chronic Illness Therapy-Fatigue was "recommended" for screening and "suggested" for severity. The Multidimensional Fatigue Inventory was "suggested" for screening and "recommended" for severity. The Parkinson Fatigue Scale was "recommended" for screening and "suggested" for severity rating. The Fatigue Severity Inventory was "listed" for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was "listed" for screening and "suggested" for severity. Visual Analogue and Global Impression Scales are both "listed" for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed. (C) 2010 Movement Disorder Society
C1 [Friedman, Joseph H.] Parkinsons Dis & Movement Disorders Ctr, Warwick, RI USA.
[Friedman, Joseph H.] Brown Univ, Dept Neurol, Warren Alpert Med Sch, Providence, RI 02912 USA.
[Alves, Guido] Stavanger Univ Hosp, Norwegian Ctr Movement Disorders, Stavanger, Norway.
[Alves, Guido] Stavanger Univ Hosp, Dept Neurol, Stavanger, Norway.
[Hagell, Peter] Univ Lund Hosp, Dept Neurol, S-22185 Lund, Sweden.
[Marinus, Johan] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands.
[Marsh, Laura] Johns Hopkins Univ Hosp, Dept Psychiat, Baltimore, MD 21287 USA.
[Marsh, Laura] Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA.
[Marsh, Laura] Baylor Coll Med, Dept Psychiat, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Martinez-Martin, Pablo] Carlos III Inst Hlth, Area Appl Epidemiol, Ctr Epidemiol, Madrid, Spain.
[Martinez-Martin, Pablo] Carlos III Inst Hlth, CIBERNED, Madrid, Spain.
[Goetz, Christopher G.; Stebbins, Glenn] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
[Poewe, Werner] Innsbruck Med Univ, Dept Neurol, Innsbruck, Austria.
[Rascol, Olivier] CHU, Clin Invest Ctr 9302, INSERM, Toulouse, France.
[Rascol, Olivier] CHU, Dept Clin Pharmacol, Toulouse, France.
[Rascol, Olivier] CHU, Dept Neurosci, Toulouse, France.
[Rascol, Olivier] Univ UPS Toulouse, Toulouse, France.
[Sampaio, Cristina] Fac Med Lisbon, Lab Farmacol Clin & Terapeut, Lisbon, Portugal.
[Sampaio, Cristina] Fac Med Lisbon, Inst Mol Med, Lisbon, Portugal.
[Schrag, Anette] UCL, Inst Neurol, Dept Clin Neurosci, London WC1E 6BT, England.
RP Friedman, JH (reprint author), 227 Centerville Rd, Warwick, RI 02886 USA.
EM joseph_friedman@brown.edu
RI Schrag, Anette/B-4181-2011; Marinus, Johan/E-4038-2010; Hagell,
Peter/F-5915-2010; Hagell, Peter/G-9559-2014
OI Schrag, Anette/0000-0002-9872-6680; Hagell, Peter/0000-0003-2174-372X;
Hagell, Peter/0000-0003-2174-372X; Alves, Guido/0000-0003-0630-2870
FU Teva; Novartis; Ingelheim-Boehringer; Cephalon; NIH [R01-MH06966];
Valeant; Epivax; Glaxosmithkline; Norwegian Parkinson's disease
association; Swedish Research Council; Swedish Parkinson Foundation;
Skane County Council Research and Development Foundation; AFA
Forsakringar; Faculty of Medicine at Lund University; Eli Lilly; Forest
Research Institute; Boehringer-Ingelheim; Michael J. Fox Foundation;
Kinetics FoundationParkinson's Disease Foundation; American Cancer
Society; Fragile X Foundation; Employment-Rush University Medical
Center; Eisai; Solvay; Lundbeck; Morris K. Udall Parkinson's Disease
Research Center of Excellence at Johns Hopkins [P50-NS-58377]
FX J.H. Friedman: Consultancies Acadia Pharm, EMD Serono, MJFox Fdn;
Advisory Boards: Lewy body dementia association; Honoraria Astra Zeneca,
Teva, Novartis, Ingelheim-Boehringer, Glaxosmithkline; Grants Teva,
Novartis, Ingelheim-Boehringer, Cephalon, NIH, Valeant, Epivax;
Employment-NeuroHeatlh: Royalties Demos. G. Alves: Honoraria H. Lundbeck
A/S; Orion Pharma; Grants-Glaxosmithkline; Norwegian Parkinson's disease
association; Employment-Stavenger University Hospital. P Hagell:
Consultancies-Glaxo SmithKline; Advisory boards H Lundbeck; Partnerships
H Lundbeck; Honoraria H Lundbeck, the World Federation of Neuroscience
Nurses; Grants-Swedish Research Council, the Swedish Parkinson
Foundation, the Skane County Council Research and Development
Foundation, AFA Forsakringar, and the Faculty of Medicine at Lund
University; Employment-Lund University; J. Marinus: Employment Leiden
University. L. Marsh: Consultancies Merck Serono; Grants-NIH, Eli Lilly;
Forest Research Institute; Boehringer-Ingelheim; Employment-Johns
Hopkins Medical Center; NIH grant R01-MH06966 and the Morris K. Udall
Parkinson's Disease Research Center of Excellence at Johns Hopkins (15)
provided support for Dr. Marsh to participate in preparation of this
manuscript. P. Martinez-Martin: Consultancies Novartis, Solvay,
Glaxosmithkline, and UCB; Honoraria Novartis, Solvay, Glaxosmithkline,
and UCB; Employment National Center for Epidemiology and CIBERNED,
Carlos Ill Institute of Health, Madrid, Spain. W. Poewe: Employment
Innsbruck Medical Center; consultancy and lecture fees from
Astra-Zeneca, Teva, Novartis, GSK, Boehringer Ingelheim, UCB, Orion
Pharma, and ECB Merck Serono in relation to clinical drug development
for Parkinson's disease. C.G. Goetz: Disclosures for the past 12 months:
Consulting and Advisory Board Membership with honoraria-Allergan,
Biogen, Boehringer-Ingelheim, Ceregene, EMD Pharmaceuticals, Embryon,
EMD/Merck KGaA, Impax Pharmaceuticals, 13 Research, Juvantia
Pharmaceuticals, Kiowa Pharmaceuticals, Merck and Co, Neurim
Pharmaceuticals, Novartis Pharmaceuticals, Osmotica Pharmaceuticals,
Ovation Pharmaceuticals, Oxford Biomedica, Schering-Plough, Solstice
Neurosciences, Solvay Pharmaceuticals, Synergy/Intec, and Teva
Pharmaceuticals; Grants/Research-Funding from NIH, Michael J. Fox
Foundation, Kinetics Foundation, and directs the Rush Parkinson's
Disease Research Center that receives support from the Parkinson's
Disease Foundation; Honoraria-Movement Disorder Society, Northwestern
University, American Academy of Neurology, Robert Wood Johnson Medical
School; Royalties-Oxford University Press, Elsevier Publishers;
Salary-Rush University Medical Center. C. Sampaio:
Consultancies/Advisory Boards-In all cases the honoraria due are paid to
department and not received personally: Lundbeck, Abbott, Bial,
Boeringher-LMS GroupSchering-Plough, Solvay. Salary-Instituto de
medicina molecular. G. Stebbins: Honoraria-American Academy of
Neurology; Movement Disorder Society, Grants-NIH, Michael J. Fox
Foundation, American Cancer Society, Fragile X Foundation;
Employment-Rush University Medical Center. O. Rascol:
Consultancies-Boehringer-Ingelheim, Eisai, Glaxosmithkline, Novartis,
Schering, Solvay, Teva, Lundbeck, UCB; Grants-Boehringer-Ingelheim,
Eisai, Glaxosmithkline, Novartis, Solvay, Teva, Lundbeck;
Employment-Centre d'Investigation Clinique. A. Schrag:
Consultancies-Ingelheim-Boehringer, Osmotica Pharm;
Employment-University College.
NR 141
TC 64
Z9 67
U1 4
U2 18
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAY 15
PY 2010
VL 25
IS 7
BP 805
EP 822
DI 10.1002/mds.22989
PG 18
WC Clinical Neurology
SC Neurosciences & Neurology
GA 605IH
UT WOS:000278340700001
PM 20461797
ER
PT J
AU Karlsson, KAE
Windischberger, C
Gerstl, F
Mayr, W
Siegel, JM
Moser, E
AF Karlsson, K. AE.
Windischberger, C.
Gerstl, F.
Mayr, W.
Siegel, J. M.
Moser, E.
TI Modulation of hypothalamus and amygdalar activation levels with stimulus
valence
SO NEUROIMAGE
LA English
DT Article
DE fMRI; Hypothalamus; Amygdala; Emotion
ID FACIAL EXPRESSIONS; HUMAN NARCOLEPSY; EMOTION; HUMOR; FMRI; NEURONS;
HYPOCRETIN/OREXIN; METAANALYSIS; REWARD; EPI
AB In spite of long-standing evidence showing that the hypothalamus is instrumental in generating behaviors associated with positive and negative emotions, little is known about the role of the hypothalamus in normal human emotional processing. Recent findings have suggested that the hypothalamus plays a role beyond mere control of HPA-axis function; this is also supported by the existence of rich anatomical connections between the hypothalamus and the amygdala. a region known for its important role in emotional processing. However, evidence of emotion-induced hypothalamic activity from neuroimaging studies has been inconsistent, possibly due to methodological limitations (e.g., low spatial resolution). Taking advantage of recent improvements in fMRI technology we set out to explore a possible valence-dependent modulation of hypothalamic activity. Using second order parametric analysis of high-resolution BOLD fMRI, we assessed hypothalamic activation patterns during passive viewing of visual stimuli of varying valence, and compared the results with the activity pattern in the amygdalae, i.e. nuclei with known valence-dependent activity profiles. We show that both hypothalamic and amygdalar activation is modulated by the second-order stimulus valence term, i.e., there is increased neural activity following the processing of both positive and negative stimuli. Our results suggest that the hypothalamus may serve a role in generating emotions broader than generally assumed. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Windischberger, C.; Gerstl, F.; Moser, E.] Med Univ Vienna, MR Ctr Excellence, A-1090 Vienna, Austria.
[Karlsson, K. AE.] Reykjavik Univ, Sch Sci & Engn, Dept Biomed Engn, Reykjavik, Iceland.
[Windischberger, C.; Mayr, W.; Moser, E.] Med Univ Vienna, Ctr Biomed Engn & Phys, A-1090 Vienna, Austria.
[Siegel, J. M.] VA GLAHS Sepulveda, Ctr Sleep Res, Neurobiol Res, Los Angeles, CA USA.
[Siegel, J. M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
[Moser, E.] Univ Penn, Med Ctr, Dept Psychiat, Philadelphia, PA 19104 USA.
RP Moser, E (reprint author), Med Univ Vienna, MR Ctr Excellence, Lazarettgasse 14, A-1090 Vienna, Austria.
EM ewald.moser@meduniwien.ac.at
RI Moser, Ewald/B-3666-2013
OI Moser, Ewald/0000-0001-8278-9583; Windischberger,
Christian/0000-0002-9944-0190
FU Icelandic Centre for Research [070431022]; Reykjavik University [14630]
FX Financially supported by Icelandic Centre for Research grant no.
070431022 (to KAEK) and Reykjavik University Development fund no. 14630
(to KAEK). We are grateful to M. Fursatz (Vienna) for his support with
the initial experiments, as well as H. Arnadottir and I. Johannesdottir
(Reykjavik) for collecting and validating the stimulus material.
NR 32
TC 8
Z9 9
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD MAY 15
PY 2010
VL 51
IS 1
BP 324
EP 328
DI 10.1016/j.neuroimage.2010.02.029
PG 5
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 580WC
UT WOS:000276480200033
PM 20156568
ER
PT J
AU DallaPiazza, M
Amorosa, VK
Localio, R
Kostman, JR
Lo Re, V
AF DallaPiazza, Michelle
Amorosa, Valerianna K.
Localio, Russell
Kostman, Jay R.
Lo Re, Vincent, III
TI Prevalence and risk factors for significant liver fibrosis among
HIV-monoinfected patients
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED PATIENTS;
ANTIRETROVIRAL DRUGS; INSULIN-RESISTANCE; NONALCOHOLIC STEATOHEPATITIS;
COINFECTED PATIENTS; DISEASE; PROGRESSION; STEATOSIS
AB Background: HIV-monoinfected patients may be at risk for significant liver fibrosis, but its prevalence and determinants in these patients are unknown. Since HIV-monoinfected patients do not routinely undergo liver biopsy, we evaluated the prevalence and risk factors of significant hepatic fibrosis in this group using the aspartate aminotransferase (AST)-to-platelet ratio index (APRI).
Methods: We conducted a cross-sectional study among HIV-infected patients negative for hepatitis B surface antigen and hepatitis C antibody in the Penn Center for AIDS Research Adult/Adolescent Database. Clinical and laboratory data were collected from the database at enrollment. Hypothesized determinants of significant fibrosis were modifiable risk factors associated with liver disease progression, hepatic fibrosis, or hepatotoxicity, including immune dysfunction (i.e., CD4 T lymphocyte count < 200 cells/mm(3), HIV viremia), diseases associated with hepatic steatosis (e. g., obesity, diabetes mellitus), and use of antiretroviral therapy. The primary outcome was an APRI score > 1.5, which suggests significant hepatic fibrosis. Multivariable logistic regression identified independent risk factors for significant fibrosis by APRI.
Results: Among 432 HIV-monoinfected patients enrolled in the CFAR Database between November 1999 and May 2008, significant fibrosis by APRI was identified in 36 (8.3%; 95% CI, 5.9-11.4%) patients. After controlling for all other hypothesized risk factors as well as active alcohol use and site, detectable HIV viremia (adjusted OR, 2.56; 95% CI, 1.02-8.87) and diabetes mellitus (adjusted OR, 3.15; 95% CI, 1.12-10.10) remained associated with significant fibrosis by APRI.
Conclusions: Significant fibrosis by APRI score was found in 8% of HIV-monoinfected patients. Detectable HIV viremia and diabetes mellitus were associated with significant fibrosis. Future studies should explore mechanisms for fibrosis in HIV-monoinfected patients.
C1 [Amorosa, Valerianna K.; Kostman, Jay R.; Lo Re, Vincent, III] Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA.
[DallaPiazza, Michelle] NYU, Sch Med, Dept Med, Div Infect Dis, New York, NY USA.
[Amorosa, Valerianna K.; Lo Re, Vincent, III] Vet Affairs Med Ctr, Infect Dis Sect, Philadelphia, PA USA.
[Localio, Russell; Lo Re, Vincent, III] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Localio, Russell; Lo Re, Vincent, III] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
RP Lo Re, V (reprint author), Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA.
EM vincentl@mail.med.upenn.edu
RI Lo Re, Vincent/N-7817-2015
FU National Institutes of Health [K01-AI070001]
FX This work was supported by National Institutes of Health research grant
K01-AI070001 (to V. L. R.).
NR 33
TC 42
Z9 43
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD MAY 13
PY 2010
VL 10
AR 116
DI 10.1186/1471-2334-10-116
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 603CU
UT WOS:000278186900001
PM 20465840
ER
PT J
AU Singh, JA
Lewallen, D
AF Singh, Jasvinder A.
Lewallen, David
TI Predictors of pain and use of pain medications following primary Total
Hip Arthroplasty (THA): 5,707 THAs at 2-years and 3,289 THAs at 5-years
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
ID TOTAL KNEE ARTHROPLASTY; QUALITY-OF-LIFE; FUNCTIONAL STATUS;
REPLACEMENT; AGE; QUESTIONNAIRE; HEALTH; IMPACT; OSTEOARTHRITIS;
SATISFACTION
AB Background: Study pain and use of pain medications and their predictors after primary Total Hip Arthroplasty (THA).
Methods: We examined whether gender, age (reference, < = 60 yrs), body mass index (BMI; reference, < 25 kg/m(2))), comorbidity measured by Deyo-Charlson index (5-point increase), anxiety and depression predict moderate-severe hip pain and use of pain medications 2- and 5-years after primary THA. Multivariable logistic regression adjusted for these predictors and distance from medical center, operative diagnosis, American Society of Anesthesiologists (ASA) score and implant type.
Results: Moderate-severe pain was reported by 8.1% at 2-years and 10.8% at 5-years. Significant predictors of moderate-severe pain at 2-year follow-up were [Odds ratio (95% confidence interval)]: BMI 35-39.9, 1.8 (1.2,2.8); BMI > = 40, 1.7 (1.0,2.9); depression, 2.1 (1.4,3.0). Moderate-severe pain at 5-years was more common in patients with higher BMI: 25-29.9, 1.5 (1.1,2.1); 30-34.9, 1.8 (1.2,2.6); 35-39.9, 1.9 (1.2,3.1); and > = 40, 3.1 (1.7,5.7).
Significant predictors of NSAID use were [Odds ratio (95% confidence interval)]: female gender at 2- and 5-years, 1.4 (1.1,1.7) and 1.4 (1.1,1.8); BMI 35-39.9 at 2-years, 1.9 (1.4, 2.6) and 30-34.9 at 2-years, 1.7 (1.2,2.4); and depression at 5-years, 1.8 (1.2,2.8).
Significant predictors of opioid medication use were [Odds ratio (95% confidence interval)]: female gender at 2-and 5-years, 2.0 (1.1,3.0) and 2.4 (1.4,4.0); BMI 30-34.9 at 2-years, 2.0 (1.0,3.9); and depression at 2-years, 2.0 (1.1,3.7).
Conclusions: Higher BMI and depression impacted moderate-severe pain; and female gender, higher BMI and depression predicted use of pain medications at 2-and 5-years post-primary THA.
C1 [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN 55905 USA.
[Singh, Jasvinder A.; Lewallen, David] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN 55905 USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA.
[Singh, Jasvinder A.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA.
RP Singh, JA (reprint author), Mayo Clin, Coll Med, Dept Hlth Sci Res, 200 1st St SW, Rochester, MN 55905 USA.
EM jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU National Institute of Health (NIH) [1 KL2 RR024151-01]
FX This material is the result of work supported with National Institute of
Health (NIH) Clinical Translational Science Award 1 KL2 RR024151-01
(Mayo Clinic Center for Clinical and Translational Research) and the
resources and the use of facilities at the Birmingham VA Medical Center,
Alabama, USA.
NR 38
TC 44
Z9 44
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD MAY 13
PY 2010
VL 11
AR 90
DI 10.1186/1471-2474-11-90
PG 8
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 606AE
UT WOS:000278391600001
PM 20462458
ER
PT J
AU Dao, TK
Youssef, NA
Gopaldas, RR
Chu, D
Bakaeen, F
Wear, E
Menefee, D
AF Dao, Tam K.
Youssef, Nagy A.
Gopaldas, Raja R.
Chu, Danny
Bakaeen, Faisal
Wear, Emily
Menefee, Deleene
TI Autonomic cardiovascular dysregulation as a potential mechanism
underlying depression and coronary artery bypass grafting surgery
outcomes
SO JOURNAL OF CARDIOTHORACIC SURGERY
LA English
DT Article
ID HEART-RATE-VARIABILITY; PHYSICAL-ACTIVITY QUESTIONNAIRE; PLASMA
NOREPINEPHRINE; MAJOR DEPRESSION; ADMINISTRATIVE DATABASES; COMORBIDITY
INDEX; NERVOUS-SYSTEM; RISK-FACTORS; DISEASE; VALIDITY
AB Background: Coronary artery bypass grafting (CABG) is often used to treat patients with significant coronary heart disease (CHD). To date, multiple longitudinal and cross-sectional studies have examined the association between depression and CABG outcomes. Although this relationship is well established, the mechanism underlying this relationship remains unclear. The purpose of this study was twofold. First, we compared three markers of autonomic nervous system (ANS) function in four groups of patients: 1) Patients with coronary heart disease and depression (CHD/Dep), 2) Patients without CHD but with depression (NonCHD/Dep), 3) Patients with CHD but without depression (CHD/NonDep), and 4) Patients without CHD and depression (NonCHD/NonDep). Second, we investigated the impact of depression and autonomic nervous system activity on CABG outcomes.
Methods: Patients were screened to determine whether they met some of the study's inclusion or exclusion criteria. ANS function (i.e., heart rate, heart rate variability, and plasma norepinephrine levels) were measured. Chi-square and one-way analysis of variance were performed to evaluate group differences across demographic, medical variables, and indicators of ANS function. Logistic regression and multiple regression analyses were used to assess impact of depression and autonomic nervous system activity on CABG outcomes.
Results: The results of the study provide some support to suggest that depressed patients with CHD have greater ANS dysregulation compared to those with only CHD or depression. Furthermore, independent predictors of in-hospital length of stay and non-routine discharge included having a diagnosis of depression and CHD, elevated heart rate, and low heart rate variability.
Conclusions: The current study presents evidence to support the hypothesis that ANS dysregulation might be one of the underlying mechanisms that links depression to cardiovascular CABG surgery outcomes. Thus, future studies should focus on developing and testing interventions that targets modifying ANS dysregulation, which may lead to improved patient outcomes.
C1 [Dao, Tam K.; Wear, Emily] Univ Houston, Houston, TX 77004 USA.
[Chu, Danny; Bakaeen, Faisal; Menefee, Deleene] Texas Med Ctr, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77021 USA.
[Dao, Tam K.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Gopaldas, Raja R.; Chu, Danny; Bakaeen, Faisal; Menefee, Deleene] Baylor Coll Med, Div Cardiothorac Surg, Dept Surg, Houston, TX 77030 USA.
[Youssef, Nagy A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA.
[Youssef, Nagy A.] VA Med Ctr, Durham, NC 27705 USA.
[Dao, Tam K.; Youssef, Nagy A.; Gopaldas, Raja R.; Chu, Danny; Bakaeen, Faisal; Wear, Emily; Menefee, Deleene] Univ S Alabama, Coll Med, Mobile, AL 36617 USA.
RP Dao, TK (reprint author), Univ Houston, 4800 Calhoun Rd, Houston, TX 77004 USA.
EM tkdao@uh.edu
OI Youssef, Nagy/0000-0002-1922-9396
NR 45
TC 13
Z9 14
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1749-8090
J9 J CARDIOTHORAC SURG
JI J. Cardiothorac. Surg.
PD MAY 13
PY 2010
VL 5
AR 36
DI 10.1186/1749-8090-5-36
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 616WD
UT WOS:000279241100001
PM 20465820
ER
PT J
AU Lo, AC
Guarino, PD
Richards, LG
Haselkorn, JK
Wittenberg, GF
Federman, DG
Ringer, RJ
Wagner, TH
Krebs, HI
Volpe, BT
Bever, CT
Bravata, DM
Duncan, PW
Corn, BH
Maffucci, AD
Nadeau, SE
Conroy, SS
Powell, JM
Huang, GD
Peduzzi, P
AF Lo, Albert C.
Guarino, Peter D.
Richards, Lorie G.
Haselkorn, Jodie K.
Wittenberg, George F.
Federman, Daniel G.
Ringer, Robert J.
Wagner, Todd H.
Krebs, Hermano I.
Volpe, Bruce T.
Bever, Christopher T., Jr.
Bravata, Dawn M.
Duncan, Pamela W.
Corn, Barbara H.
Maffucci, Alysia D.
Nadeau, Stephen E.
Conroy, Susan S.
Powell, Janet M.
Huang, Grant D.
Peduzzi, Peter
TI Robot-Assisted Therapy for Long-Term Upper-Limb Impairment after Stroke
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID CONSTRAINT-INDUCED MOVEMENT; RANDOMIZED CONTROLLED-TRIAL;
CLINICAL-TRIALS; UPPER EXTREMITY; SINGLE-BLIND; FORCED USE;
REHABILITATION; INFORMATION; RECOVERY; IMPACT
AB BACKGROUND
Effective rehabilitative therapies are needed for patients with long-term deficits after stroke.
METHODS
In this multicenter, randomized, controlled trial involving 127 patients with moderate-to-severe upper-limb impairment 6 months or more after a stroke, we randomly assigned 49 patients to receive intensive robot-assisted therapy, 50 to receive intensive comparison therapy, and 28 to receive usual care. Therapy consisted of 36 1-hour sessions over a period of 12 weeks. The primary outcome was a change in motor function, as measured on the Fugl-Meyer Assessment of Sensorimotor Recovery after Stroke, at 12 weeks. Secondary outcomes were scores on the Wolf Motor Function Test and the Stroke Impact Scale. Secondary analyses assessed the treatment effect at 36 weeks.
RESULTS
At 12 weeks, the mean Fugl-Meyer score for patients receiving robot-assisted therapy was better than that for patients receiving usual care (difference, 2.17 points; 95% confidence interval [CI], -0.23 to 4.58) and worse than that for patients receiving intensive comparison therapy (difference, -0.14 points; 95% CI, -2.94 to 2.65), but the differences were not significant. The results on the Stroke Impact Scale were significantly better for patients receiving robot-assisted therapy than for those receiving usual care (difference, 7.64 points; 95% CI, 2.03 to 13.24). No other treatment comparisons were significant at 12 weeks. Secondary analyses showed that at 36 weeks, robot-assisted therapy significantly improved the Fugl-Meyer score (difference, 2.88 points; 95% CI, 0.57 to 5.18) and the time on the Wolf Motor Function Test (difference, -8.10 seconds; 95% CI, -13.61 to -2.60) as compared with usual care but not with intensive therapy. No serious adverse events were reported.
CONCLUSIONS
In patients with long-term upper-limb deficits after stroke, robot-assisted therapy did not significantly improve motor function at 12 weeks, as compared with usual care or intensive therapy. In secondary analyses, robot-assisted therapy improved outcomes over 36 weeks as compared with usual care but not with intensive therapy. (ClinicalTrials.gov number, NCT00372411.)
C1 [Lo, Albert C.] Brown Univ, Providence Vet Affairs Med Ctr, Providence, RI 02909 USA.
[Lo, Albert C.] Brown Univ, Ctr Restorat & Regenerat Med, VA Res & Dev Ctr Excellence, Providence, RI 02909 USA.
[Guarino, Peter D.; Corn, Barbara H.; Maffucci, Alysia D.; Peduzzi, Peter] VA Cooperat Studies Program Coordinating Ctr, West Haven, CT USA.
[Federman, Daniel G.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Federman, Daniel G.] Yale Univ, New Haven, CT USA.
[Richards, Lorie G.; Nadeau, Stephen E.] N Florida S Georgia Vet Hlth Syst, Gainesville, FL USA.
[Richards, Lorie G.; Nadeau, Stephen E.] Univ Florida, Gainesville, FL USA.
[Haselkorn, Jodie K.; Powell, Janet M.] VA Puget Sound Healthcare Syst, Seattle, WA USA.
[Haselkorn, Jodie K.; Powell, Janet M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Wittenberg, George F.] VAMC Baltimore Geriatr Res Educ & Clin Ctr, Baltimore, MD USA.
[Wittenberg, George F.; Bever, Christopher T., Jr.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA.
[Bever, Christopher T., Jr.] VA Maryland Healthcare Syst, Res Serv, Baltimore, MD USA.
[Conroy, Susan S.] VAMC, Baltimore, MD USA.
[Ringer, Robert J.] Clin Res Pharm Coordinating Ctr, VA Cooperat Studies Program, Albuquerque, NM USA.
[Wagner, Todd H.] VA Palo Alto Healthcare Syst, Hlth Econ Resource Ctr, Menlo Pk, CA USA.
[Krebs, Hermano I.] MIT, Cambridge, MA 02139 USA.
[Volpe, Bruce T.] Cornell Univ, Weill Med Coll, Burke Med Res Inst, White Plains, NY USA.
[Bravata, Dawn M.] Richard L Roudebush VAMC, Indianapolis, IN USA.
[Duncan, Pamela W.] Duke Univ, Doctor Phys Therapy Program, Duke Div, Durham, NC USA.
[Huang, Grant D.] VA Off Res & Dev Serv, Cooperat Studies Program Cent Off, Washington, DC USA.
RP Lo, AC (reprint author), Brown Univ, Providence Vet Affairs Med Ctr, 830 Chalkstone Ave,111N, Providence, RI 02909 USA.
EM albert.lo@va.gov
OI Volpe, Bruce/0000-0002-1098-1848
FU Veterans Affairs Cooperative Studies Program and Rehabilitation Research
and Development Service
FX Supported by the Veterans Affairs Cooperative Studies Program and
Rehabilitation Research and Development Service.
NR 32
TC 406
Z9 427
U1 10
U2 74
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 13
PY 2010
VL 362
IS 19
BP 1772
EP 1783
DI 10.1056/NEJMoa0911341
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 594RQ
UT WOS:000277555500004
PM 20400552
ER
PT J
AU Chafen, JJS
Newberry, SJ
Riedl, MA
Bravata, DM
Maglione, M
Suttorp, MJ
Sundaram, V
Paige, NM
Towfigh, A
Hulley, BJ
Shekelle, PG
AF Chafen, Jennifer J. Schneider
Newberry, Sydne J.
Riedl, Marc A.
Bravata, Dena M.
Maglione, Margaret
Suttorp, Marika J.
Sundaram, Vandana
Paige, Neil M.
Towfigh, Ali
Hulley, Benjamin J.
Shekelle, Paul G.
TI Diagnosing and Managing Common Food Allergies A Systematic Review
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID COWS MILK ALLERGY; PLACEBO-CONTROLLED TRIAL; HIGH-RISK INFANTS; ATOPY
PATCH TEST; BREAST-FED INFANTS; RANDOMIZED CONTROLLED-TRIAL; BRIEF
NEONATAL EXPOSURE; DOUBLE-BLIND TRIAL; SKIN-PRICK TESTS; 1ST 2 YEARS
AB Context There is heightened interest in food allergies but no clear consensus exists regarding the prevalence or most effective diagnostic and management approaches to food allergies.
Objective To perform a systematic review of the available evidence on the prevalence, diagnosis, management, and prevention of food allergies.
Data Sources Electronic searches of PubMed, Cochrane Database of Systematic Reviews, Cochrane Database of Abstracts of Reviews of Effects, and Cochrane Central Register of Controlled Trials. Searches were limited to English-language articles indexed between January 1988 and September 2009.
Study Selection Diagnostic tests were included if they had a prospective, defined study population, used food challenge as a criterion standard, and reported sufficient data to calculate sensitivity and specificity. Systematic reviews and randomized controlled trials (RCTs) for management and prevention outcomes were also used. For foods where anaphylaxis is common, cohort studies with a sample size of more than 100 participants were included.
Data Extraction Two investigators independently reviewed all titles and abstracts to identify potentially relevant articles and resolved discrepancies by repeated review and discussion. Quality of systematic reviews and meta-analyses was assessed using the AMSTAR criteria, the quality of diagnostic studies using the QUADAS criteria most relevant to food allergy, and the quality of RCTs using the Jadad criteria.
Data Synthesis A total of 12 378 citations were identified and 72 citations were included. Food allergy affects more than 1% to 2% but less than 10% of the population. It is unclear if the prevalence of food allergies is increasing. Summary receiver operating characteristic curves comparing skin prick tests (area under the curve [AUC], 0.87; 95% confidence interval [CI], 0.81-0.93) and serum food-specific IgE (AUC, 0.84; 95% CI, 0.78-0.91) to food challenge showed no statistical superiority for either test. Elimination diets are the mainstay of therapy but have been rarely studied. Immunotherapy is promising but data are insufficient to recommend use. In high-risk infants, hydrolyzed formulas may prevent cow's milk allergy but standardized definitions of high risk and hydrolyzed formula do not exist.
Conclusion The evidence for the prevalence and management of food allergy is greatly limited by a lack of uniformity for criteria for making a diagnosis. JAMA. 2010; 303(18): 1848-1856
C1 [Chafen, Jennifer J. Schneider; Bravata, Dena M.; Sundaram, Vandana] Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA.
[Chafen, Jennifer J. Schneider; Sundaram, Vandana] VA Palo Alto Healthcare Syst, Palo Alto, CA USA.
[Newberry, Sydne J.; Maglione, Margaret; Suttorp, Marika J.; Paige, Neil M.; Towfigh, Ali; Hulley, Benjamin J.; Shekelle, Paul G.] Rand Hlth, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA.
[Riedl, Marc A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Paige, Neil M.; Towfigh, Ali; Shekelle, Paul G.] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
RP Chafen, JJS (reprint author), Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, 117 Encina Commons, Stanford, CA 94305 USA.
EM jjschnei@stanford.edu
RI Osborne, Nicholas/N-4915-2015
OI Osborne, Nicholas/0000-0002-6700-2284
FU National Institutes of Health [HHSN272200800065C]; National Institute of
Allergy and Infectious Diseases
FX Funding/Support: This work was funded in part by contract
HHSN272200800065C from the National Institutes of Health. This work was
commissioned by National Institute of Allergy and Infectious Diseases in
support of the development of practice guidelines.
NR 113
TC 174
Z9 182
U1 10
U2 45
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 12
PY 2010
VL 303
IS 18
BP 1848
EP 1856
DI 10.1001/jama.2010.582
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 594DK
UT WOS:000277513900026
PM 20460624
ER
PT J
AU Hayden, KM
Norton, MC
Darcey, D
Ostbye, T
Zandi, PP
Breitner, JCS
Welsh-Bohmer, KA
AF Hayden, K. M.
Norton, M. C.
Darcey, D.
Ostbye, T.
Zandi, P. P.
Breitner, J. C. S.
Welsh-Bohmer, K. A.
CA Cache Cty Study Investigators
TI Occupational exposure to pesticides increases the risk of incident AD
The Cache County Study
SO NEUROLOGY
LA English
DT Article
ID ALZHEIMERS-DISEASE; HEALTH; RELIABILITY; DEMENTIA; FARMERS; CANADA
AB Background: Commonly used organophosphate and organochlorine pesticides inhibit acetylcholinesterase at synapses in the somatic, autonomic, and central nervous systems and may therefore have lasting effects on the nervous system. Few studies have examined the relationship of pesticide exposure and risk of dementia or Alzheimer disease (AD). We sought to examine the association of occupational pesticide exposure and the risk of incident dementia and AD in later life.
Methods: Residents of the agricultural community of Cache County, UT, who were aged 65 years and older as of January 1995, were invited to participate in the study. At baseline, participants completed detailed occupational history questionnaires that included information about exposures to various types of pesticides. Cognitive status was assessed at baseline and after 3, 7, and 10 years. Standardized methods were used for detection and diagnosis of dementia and AD. Cox proportional hazards survival analyses were used to evaluate the risk of incident dementia and AD associated with pesticide exposure.
Results: Among 3,084 enrollees without dementia, more men than women reported pesticide exposure (p < 0.0001). Exposed individuals (n = 572) had more years of education (p < 0.01) but did not differ from others in age. Some 500 individuals developed incident dementia, 344 with AD. After adjustment for baseline age, sex, education, APOE is an element of 4 status, and baseline Modified Mini-Mental State Examination scores, Cox proportional hazards models showed increased risks among pesticide-exposed individuals for all-cause dementia, with hazard ratio (HR) 1.38 and 95% confidence interval (Cl) 1.09-1.76, and for AD (HR 1.42, 95% Cl 1.06-1.91). The risk of AD associated with organophosphate exposure (HR 1.53,95% Cl 1.05-2.23) was slightly higher than the risk associated with organochlorines (HR 1.49, 95% Cl 0.99-2.24), which was nearly significant.
Conclusions: Pesticide exposure may increase the risk of dementia and Alzheimer disease in late life. Neurology (R) 2010;74:1524-1530
C1 [Hayden, K. M.] Duke Univ, Med Ctr, Joseph & Kathleen Bryan ADRC, Dept Psychiat & Behav Sci, Durham, NC 27705 USA.
[Darcey, D.; Ostbye, T.] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27705 USA.
[Norton, M. C.] Utah State Univ, Dept Family Consumer & Human Dev, Logan, UT 84322 USA.
[Norton, M. C.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA.
[Zandi, P. P.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Breitner, J. C. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Breitner, J. C. S.] Univ Washington, Seattle, WA 98195 USA.
RP Hayden, KM (reprint author), Duke Univ, Med Ctr, Joseph & Kathleen Bryan ADRC, Dept Psychiat & Behav Sci, 2200 W Main St,Suite A-200, Durham, NC 27705 USA.
EM khayden@duke.edu
RI Norton, Maria/E-6994-2013; Hayden, Kathleen/B-6442-2012
OI Hayden, Kathleen/0000-0002-7745-3513
FU NIH/NIA [R01-AG1380, P30-AG 028377]
FX Supported by NIH/NIA R01-AG1380 and P30-AG 028377 [APOE genotyping].
NR 32
TC 83
Z9 85
U1 3
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD MAY 11
PY 2010
VL 74
IS 19
BP 1524
EP 1530
DI 10.1212/WNL.0b013e3181dd4423
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 593RE
UT WOS:000277477000008
PM 20458069
ER
PT J
AU Grady, D
Redberg, RF
AF Grady, Deborah
Redberg, Rita F.
TI Less Is More How Less Health Care Can Result in Better Health
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Editorial Material
ID REGIONAL-VARIATIONS; ACQUIRED PNEUMONIA; CONTROLLED TRIAL; RISK;
BENEFITS
C1 [Grady, Deborah] Univ Calif San Francisco, Dept Med, San Francisco, CA 94115 USA.
[Redberg, Rita F.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94115 USA.
[Grady, Deborah] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA.
RP Grady, D (reprint author), Univ Calif San Francisco, Dept Med, 1635 Divisadero St,Ste 600, San Francisco, CA 94115 USA.
EM Deborah.Grady@ucsf.edu
NR 16
TC 67
Z9 67
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAY 10
PY 2010
VL 170
IS 9
BP 749
EP 750
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 592EE
UT WOS:000277357800002
PM 20458080
ER
PT J
AU Kerlikowske, K
Molinaro, AM
Gauthier, ML
Berman, HK
Waldman, F
Bennington, J
Sanchez, H
Jimenez, C
Stewart, K
Chew, K
Ljung, BM
Tlsty, TD
AF Kerlikowske, Karla
Molinaro, Annette M.
Gauthier, Mona L.
Berman, Hal K.
Waldman, Fred
Bennington, James
Sanchez, Henry
Jimenez, Cynthia
Stewart, Kim
Chew, Karen
Ljung, Britt-Marie
Tlsty, Thea D.
TI Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal
Carcinoma In Situ Diagnosis
SO JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID BREAST-CONSERVING SURGERY; SURGICAL ADJUVANT BREAST; BASAL-LIKE;
PROGNOSTIC-SIGNIFICANCE; RADIATION-THERAPY; DEFINITIVE BREAST; CANCER;
RECURRENCE; DCIS; WOMEN
AB Studies have failed to identify characteristics of women who have been diagnosed with ductal carcinoma in situ (DCIS) and have a high or low risk of subsequent invasive cancer.
We conducted a nested case-control study in a population-based cohort of 1162 women who were diagnosed with DCIS and treated by lumpectomy alone from 1983 to 1994. We collected clinical characteristics and information on subsequent tumors, defined as invasive breast cancer or DCIS diagnosed in the ipsilateral breast containing the initial DCIS lesion or at a regional or distant site greater than 6 months after initial treatment of DCIS (N = 324). We also conducted standardized pathology reviews and immunohistochemical staining for the estrogen receptor (ER), progesterone receptor, Ki67 antigen, p53, p16, epidermal growth factor receptor-2 (ERBB2, HER2/neu oncoprotein), and cyclooxygenase-2 (COX-2) on the initial paraffin-embedded DCIS tissue. Competing risk models were used to determine factors associated with risk of subsequent invasive cancer vs DCIS, and cumulative incidence survival functions were used to estimate 8-year risk.
Factors associated with subsequent invasive cancer differed from those associated with subsequent DCIS. Eight-year risk of subsequent invasive cancer was statistically significantly (P = .018) higher for women with initial DCIS lesions that were detected by palpation or that were p16, COX-2, and Ki67 triple positive (p16(+)COX-2(+)Ki67(+)) (19.6%, 95% confidence interval [CI] = 18.0% to 21.3%) than for women with initial lesions that were detected by mammography and were p16, COX-2, and Ki67 triple negative (p16(-)COX-2(-)Ki67(-)) (4.1%, 95% CI = 3.4% to 5.0%). In a multivariable model, DCIS lesions that were p16(+)COX-2(+)Ki67(+) or those detected by palpation were statistically significantly associated with subsequent invasive cancer, but nuclear grade was not. Eight-year risk of subsequent DCIS was highest for women with DCIS lesions that had disease-free margins of 1 mm or greater combined with either ER(-)ERBB2(+)Ki67(+) or p16(+)COX-2(-)Ki67(+) status (23.6%, 95% CI = 18.1% to 34.0%).
Biomarkers can identify which women who were initially diagnosed with DCIS are at high or low risk of subsequent invasive cancer, whereas histopathology information cannot.
C1 [Kerlikowske, Karla] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Gen Internal Med Sect, Dept Vet Affairs, San Francisco, CA 94121 USA.
[Kerlikowske, Karla; Stewart, Kim] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA.
[Kerlikowske, Karla; Waldman, Fred; Sanchez, Henry; Chew, Karen; Ljung, Britt-Marie; Tlsty, Thea D.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94121 USA.
[Waldman, Fred] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94121 USA.
[Waldman, Fred] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94121 USA.
[Waldman, Fred] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94121 USA.
[Sanchez, Henry; Ljung, Britt-Marie; Tlsty, Thea D.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94121 USA.
[Jimenez, Cynthia] Univ Calif San Francisco, Sch Med, San Francisco, CA 94121 USA.
[Molinaro, Annette M.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Div Biostat, New Haven, CT 06510 USA.
[Berman, Hal K.] Univ Toronto, Princess Margaret Hosp, Campbell Family Inst Breast Canc Res, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
[Gauthier, Mona L.] Univ Toronto, Princess Margaret Hosp, Campbell Family Inst Breast Canc Res, Dept Med Biophys, Toronto, ON, Canada.
[Bennington, James] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
RP Kerlikowske, K (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Gen Internal Med Sect, Dept Vet Affairs, 111A1,4150 Clement St, San Francisco, CA 94121 USA.
EM karla.kerlikowkse@ucsf.edu; thea.tlsty@ucsf.edu
FU National Cancer Institute [P50 CA58207]; California Breast Cancer
Research Program [2RB-0197]
FX National Cancer Institute-funded University of California, San Francisco
Breast Cancer SPORE (P50 CA58207); California Breast Cancer Research
Program (2RB-0197). Technical support was received from the UCSF Cancer
Center (P30 CA82103), UCSF Cancer Center Tissue and Immunohistochemistry
Cores, and Northern California Surveillance, Epidemiology, and End
Results Program.
NR 44
TC 164
Z9 172
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 J NATL CANCER I
JI J. Natl. Cancer Inst.
PD MAY 5
PY 2010
VL 102
IS 9
BP 627
EP 637
DI 10.1093/jnci/djq101
PG 11
WC Oncology
SC Oncology
GA 593IZ
UT WOS:000277448700011
PM 20427430
ER
PT J
AU Lin, AL
Fox, PT
Hardies, J
Duong, TQ
Gao, JH
AF Lin, Ai-Ling
Fox, Peter T.
Hardies, Jean
Duong, Timothy Q.
Gao, Jia-Hong
TI Nonlinear coupling between cerebral blood flow, oxygen consumption, and
ATP production in human visual cortex
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE cerebral metabolic rate of oxygen; lactate production
ID POSITRON-EMISSION-TOMOGRAPHY; ACTIVATED HUMAN BRAIN;
OXIDATIVE-METABOLISM; NEURONAL-ACTIVITY; STIMULATION; VOLUME; TIME;
SPECTROSCOPY; DEPENDENCE; DYNAMICS
AB The purpose of this study was to investigate activation-induced hypermetabolism and hyperemia by using a multifrequency (4, 8, and 16 Hz) reversing-checkerboard visual stimulation paradigm. Specifically, we sought to (i) quantify the relative contributions of the oxidative and nonoxidative metabolic pathways in meeting the increased energy demands [i. e., ATP production (J(ATP))] of task-induced neuronal activation and (ii) determine whether task-induced cerebral blood flow(CBF) augmentation was driven by oxidative or nonoxidative metabolic pathways. Focal increases in CBF, cerebral metabolic rate of oxygen (CMRO(2); i.e., index of aerobic metabolism), and lactate production (J(Lac); i.e., index of anaerobic metabolism) were measured by using physiologically quantitative MRI and spectroscopy methods. Task-induced increases in JATP were small (12.2-16.7%) at all stimulation frequencies and were generated by aerobic metabolism (approximately 98%), with %Delta J(ATP) being linearly correlated with the percentage change in CMRO(2) (r = 1.00, P < 0.001). In contrast, task-induced increases in CBF were large (51.7-65.1%) and negatively correlated with the percentage change in CMRO(2) (r=-0.64, P=0.024), but positively correlated with %Delta J(Lac) (r = 0.91, P < 0.001). These results indicate that (i) the energy demand of task-induced brain activation is small (approximately 15%) relative to the hyperemic response (approximately 60%), (ii) this energy demand is met through oxidative metabolism, and (iii) the CBF response is mediated by factors other than oxygen demand.
C1 [Lin, Ai-Ling; Fox, Peter T.; Hardies, Jean; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Lin, Ai-Ling; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Fox, Peter T.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Fox, Peter T.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Fox, Peter T.; Duong, Timothy Q.] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Gao, Jia-Hong] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA.
[Gao, Jia-Hong] Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA.
[Gao, Jia-Hong] Univ Chicago, Dept Behav Neurosci, Chicago, IL 60637 USA.
[Gao, Jia-Hong] Univ Chicago, Brain Res Imaging Ctr, Chicago, IL 60637 USA.
RP Lin, AL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
EM lina3@uthscsa.edu; jgao@uchicago.edu
RI Hardies, Lou /F-2102-2010; Lin, Ai-Ling/F-3972-2010; Duong,
Timothy/B-8525-2008; Fox, Peter/B-4725-2010
OI Fox, Peter/0000-0002-0465-2028
FU National Institutes of Health; University of Texas Health Science Center
at San Antonio General Clinical Research Center [M01 RR01346]
FX We express our appreciation to Drs. Silvia Mangia and Xiao-Hong Zhu at
the University of Minnesota for fruitful discussions and valuable
comments. This work was supported by National Institutes of Health and
University of Texas Health Science Center at San Antonio General
Clinical Research Center Grant M01 RR01346.
NR 47
TC 77
Z9 77
U1 1
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 4
PY 2010
VL 107
IS 18
BP 8446
EP 8451
DI 10.1073/pnas.0909711107
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 591OK
UT WOS:000277310400072
PM 20404151
ER
PT J
AU Hwang, U
Baumlin, K
Berman, J
Chawla, NK
Handel, DA
Heard, K
Livote, E
Pines, JM
Valley, M
Yadav, K
AF Hwang, Ula
Baumlin, Kevin
Berman, Jeremy
Chawla, Neal K.
Handel, Daniel A.
Heard, Kennon
Livote, Elayne
Pines, Jesse M.
Valley, Morgan
Yadav, Kabir
TI Emergency Department Patient Volume and Troponin Laboratory Turnaround
Time
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article; Proceedings Paper
CT Annual Scientific Meeting of the
Canadian-Association-of-Emergency-Physicians
CY JUN 06-10, 2009
CL Calgary, CANADA
SP Canadian Assoc Emergency Phys
DE emergency department; laboratory turnaround time; emergency department
crowding
ID LENGTH-OF-STAY; MYOCARDIAL-INFARCTION; CHEST-PAIN; CARE; IMPACT;
ASSOCIATION; GUIDELINES; IMPLEMENTATION; MANAGEMENT; SOCIETY
AB Objectives: Increases in emergency department (ED) visits may place a substantial burden on both the ED and hospital-based laboratories. Studies have identified laboratory turnaround time (TAT) as a barrier to patient process times and lengths of stay. Prolonged laboratory study results may also result in delayed recognition of critically ill patients and initiation of appropriate therapies. The objective of this study was to determine how ED patient volume itself is associated with laboratory TAT.
Methods: This was a retrospective cohort review of patients at five academic, tertiary care EDs in the United States. Data were collected on all adult patients seen in each ED with troponin laboratory testing during the months of January, April, July, and October 2007. Primary predictor variables were two ED patient volume measures at the time the troponin test was ordered: 1) number of all patients in the ED/number of beds (occupancy) and 2) number of admitted patients waiting for beds/beds (boarder occupancy). The outcome variable was troponin turnaround time (TTAT). Adjusted covariates included patient characteristics, triage severity, season (month of the laboratory test), and site. Multivariable adjusted quantile regression was carried out to assess the association of ED volume measures with TTAT.
Results: At total of 9,492 troponin tests were reviewed. Median TTAT for this cohort was 107 minutes (interquartile range [IQR] = 73-148 minutes). Median occupancy for this cohort was 1.05 patients (IQR = 0.78-1.38 patients) and median boarder occupancy was 0.21 (IQR = 0.11-0.32). Adjusted quantile regression demonstrated a significant association between increased ED patient volume and longer times to TTAT. For every 100% increase in census, or number of boarders over the number of ED beds, respectively, there was a 12 (95% confidence interval [CI] = 9 to 14) or 33 (95% CI = 24 to 42)-minute increase in TTAT.
Conclusions: Increased ED patient volume is associated with longer hospital laboratory processing times. Prolonged laboratory TAT may delay recognition of conditions in the acutely ill, potentially affecting clinician decision-making and the initiation of timely treatment. Use of laboratory TAT as a patient throughput measure and the study of factors associated with its prolonging should be further investigated.
ACADEMIC EMERGENCY MEDICINE 2010; 17:501-507 (C) 2010 by the Society for Academic Emergency Medicine
C1 [Hwang, Ula; Baumlin, Kevin; Chawla, Neal K.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA.
[Hwang, Ula; Livote, Elayne] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Berman, Jeremy; Yadav, Kabir] George Washington Sch Med, Dept Emergency Med, Washington, DC USA.
[Chawla, Neal K.] INOVA Fairfax Hosp, Dept Emergency Med, Falls Church, VA USA.
[Handel, Daniel A.] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA.
[Heard, Kennon; Valley, Morgan] Univ Colorado, Sch Med, Div Emergency Med, Denver, CO USA.
[Pines, Jesse M.] Univ Penn, Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA.
RP Hwang, U (reprint author), Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA.
EM ula.hwang@mountsinai.org
OI Yadav, Kabir/0000-0002-1092-9935
FU NIDA NIH HHS [K08 DA020573, K08 DA020573-03]
NR 29
TC 14
Z9 15
U1 1
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1069-6563
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD MAY
PY 2010
VL 17
IS 5
BP 501
EP 507
DI 10.1111/j.1553-2712.2010.00738.x
PG 7
WC Emergency Medicine
SC Emergency Medicine
GA 587NN
UT WOS:000276999500009
PM 20536804
ER
PT J
AU Landman, AB
Bernstein, SL
Hsiao, AL
Desai, RA
AF Landman, Adam B.
Bernstein, Steven L.
Hsiao, Allen L.
Desai, Rani A.
TI Emergency Department Information System Adoption in the United States
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article; Proceedings Paper
CT Annual Scientific Meeting of the
Canadian-Association-of-Emergency-Physicians
CY JUN 06-10, 2009
CL Calgary, CANADA
SP Canadian Assoc Emergency Phys
DE Financing; government/legislation and jurisprudence; United States;
medical informatics; medical records systems; computerized; emergency
service; hospital
ID ELECTRONIC HEALTH RECORDS; CARE; TECHNOLOGY; PHYSICIANS; OUTCOMES;
QUALITY
AB Objectives: The American Recovery and Reinvestment Act of 2009 incentivizes adoption of health care information technology (HIT) based on support for specific standards, policies, and features. Limited data have been published on national emergency department information systems (EDIS) adoption, and to our knowledge, no prior studies have considered functionality measures. This study determined current national estimates of EDIS adoption using both single-response rates of EDIS adoption and a novel feature-based definition and also identified emergency department (ED) characteristics associated with EDIS use.
Methods: The 2006 National Hospital Ambulatory Medical Care Survey, a nationally representative sample of ED visits that also surveyed participating EDs on EDIS, was used to estimate EDIS adoption. EDIS adoption rates were calculated using two definitions: 1) single-response-response to a single survey question as to whether the EDIS was complete, partial, or none; and 2) feature-based-based on the reported features supported by the EDIS, systems were categorized as fully functional, basic, other, or none. The relationship of EDIS adoption to specific ED characteristics such as facility type and location was also examined.
Results: Using the single-response classification, 16.1% of EDs had a complete EDIS, while 30.4% had a partial EDIS, and 53.5% had none. In contrast, using a feature-based categorization, 1.7% EDs had a fully functional EDIS, 12.3% had basic, 32.1% had other, and 53.9% had none. In multivariable analysis, urban EDs were significantly more likely to have a fully functional or basic EDIS than were rural EDs. Pediatric EDs were significantly more likely than general EDs to have other EDIS.
Conclusions: Despite more optimistic single-response estimates, fewer than 2% of our nation's EDs have a fully functional EDIS. EDs in urban areas and those specializing in the care of pediatric patients are more likely to support EDIS. Accurate and consistent EDIS adoption estimates are dependent on whether there are standardized EDIS definitions and classifications of features. To realize the potential value of EDIS for improved emergency care, we need to better understand the extent and correlates of the diffusion of this technology and increase emergency medicine engagement in national HIT policy-making.
ACADEMIC EMERGENCY MEDICINE 2010; 17:536-544 (C) 2010 by the Society for Academic Emergency Medicine
C1 [Landman, Adam B.; Desai, Rani A.] Yale Univ, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA.
[Landman, Adam B.; Bernstein, Steven L.] Yale Univ, Dept Emergency Med, New Haven, CT USA.
[Hsiao, Allen L.] Yale Univ, Dept Pediat Emergency Med, New Haven, CT USA.
[Desai, Rani A.] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
[Landman, Adam B.; Desai, Rani A.] US Dept Vet Affairs, West Haven, CT USA.
RP Landman, AB (reprint author), Yale Univ, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA.
EM adam.landman@yale.edu
OI Landman, Adam/0000-0002-2166-0521
NR 28
TC 14
Z9 14
U1 1
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1069-6563
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD MAY
PY 2010
VL 17
IS 5
BP 536
EP 544
DI 10.1111/j.1553-2712.2010.00722.x
PG 9
WC Emergency Medicine
SC Emergency Medicine
GA 587NN
UT WOS:000276999500015
PM 20536810
ER
PT J
AU Giordano, TP
Bartsch, G
Zhang, YF
Tedaldi, E
Absalon, J
Mannheimer, S
Thomas, A
MacArthur, RD
AF Giordano, Thomas P.
Bartsch, Glenn
Zhang, Yafeng
Tedaldi, Ellen
Absalon, Judith
Mannheimer, Sharon
Thomas, Avis
MacArthur, Rodger D.
TI Disparities in Outcomes for African American and Latino Subjects in the
Flexible Initial Retrovirus Suppressive Therapies (FIRST) Trial
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED PATIENTS; UNITED-STATES;
VIROLOGICAL FAILURE; RACIAL DISPARITIES; ADHERENCE; CARE; PREVALENCE;
PREDICTORS; SURVIVAL
AB To benefit maximally from antiretroviral therapy, patients with HIV infection must enter care before their disease is advanced and adhere to care. We sought to determine if and where on this continuum of care racial/ethnic disparities were evident. Data from the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial, which evaluated three strategies for initial HIV therapy, were compared for White, African American, and Latino subjects. Outcomes included progression of disease and death, HIV viral suppression, and change in CD4(+) cell count. Multivariate Cox proportional hazard models adjusted for known predictors of survival. There were 1357 subjects, including 368 non-Latino white, 751 non-Latino African American, and 238 Latino subjects. At baseline, the two latter groups were more likely to have had AIDS and had lower CD4(+) cell counts than white subjects. In follow-up, African American subjects had lower self-reported adherence to therapy, lower CD4(+) cell count increases, and lower odds of viral suppression. African American and Latino subjects had unadjusted hazard ratios of progression of disease or death of 1.57 (1.17, 2.10; p - 0.0025) and 1.57 (1.09, 2.26; p - 0.02), respectively. Adjusting for baseline differences and differences in adherence, CD4(+) cell count change, and viral suppression accounted for the disparities in outcomes. Opportunities to reduce disparities in outcomes for African American and Latino patients exist along the continuum of HIV care. Efforts to promote access to HIV testing and care and to improve adherence have the potential to reduce racial/ethnic disparities in outcomes of patients with HIV infection.
C1 [Giordano, Thomas P.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
[Giordano, Thomas P.] Thomas St Hlth Ctr, Houston, TX USA.
[Bartsch, Glenn; Zhang, Yafeng; Thomas, Avis] Univ Minnesota, Minneapolis, MN USA.
[Tedaldi, Ellen] Temple Univ, Sch Med, Philadelphia, PA 19122 USA.
[Absalon, Judith] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
[Mannheimer, Sharon] Columbia Univ Coll Phys & Surg, Harlem Hosp, New York, NY 10032 USA.
[MacArthur, Rodger D.] Wayne State Univ, Detroit, MI USA.
RP Giordano, TP (reprint author), Michael E DeBakey VA Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM tpg@bcm.tmc.edu
FU National Institute of Allergy and Infectious Diseases, National
Institutes of Health [5U01AI042170-10, 5U01 AI046362-03) 058]; National
Institute of Mental Health, National Institutes of Health [K23MH067505];
Houston VA HSR&D Center of Excellence [HFP90-020]
FX The Flexible Initial Retrovirus Suppressive Therapies (FIRST; CPCRA 058)
study was supported by the National Institute of Allergy and Infectious
Diseases, National Institutes of Health (grants 5U01AI042170-10 and 5U01
AI046362-03) 058). TPG received support from the National Institute of
Mental Health, National Institutes of Health, grant K23MH067505 (TPG),
and, in part, from the Houston VA HSR&D Center of Excellence
(HFP90-020). The views expressed in this article are those of the
authors and do not necessarily represent the views of the Department of
Veterans Affairs.
NR 42
TC 24
Z9 24
U1 1
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD MAY
PY 2010
VL 24
IS 5
BP 287
EP 295
DI 10.1089/apc.2009.0332
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 599LS
UT WOS:000277914800003
PM 20438378
ER
PT J
AU Durazzo, TC
Gazdzinski, S
Mon, A
Meyerhoff, DJ
AF Durazzo, Timothy C.
Gazdzinski, Stefan
Mon, Anderson
Meyerhoff, Dieter J.
TI Cortical perfusion in alcohol-dependent individuals during short-term
abstinence: relationships to resumption of hazardous drinking after
treatment
SO ALCOHOL
LA English
DT Article
DE Alcohol dependence; Neuroimaging; Brain perfusion; Relapse; Abstinence;
Treatment outcome
ID DSM-IV ALCOHOL; MAGNETIC-RESONANCE SPECTROSCOPY; CONSUMPTION FOLLOWING
TREATMENT; NATIONAL EPIDEMIOLOGIC SURVEY; CHRONIC CIGARETTE-SMOKING;
ADDICTED HUMAN BRAIN; UNITED-STATES; USE DISORDERS; PREDICT RELAPSE;
DRUG-ADDICTION
AB Relapse to hazardous levels of alcohol consumption after treatment for alcohol use disorders is common. Investigation of the neurobiological correlates of resumption of hazardous drinking is necessary to clarify the mechanisms contributing to relapse. Fifty-seven treatment-seeking alcohol-dependent participants (ALC) completed arterial spin labeling perfusion MRI of the frontal and parietal gray matter (GM) at 7 +/- 3 days of abstinence (baseline). ALC participants were restudied after 35 +/- 11 days of abstinence (assessment point 2: AP2). Twenty-eight nonsmoking, light-drinking control participants (nsLD) from the community were studied with perfusion MRI. ALC participants were followed over 12 months after baseline study and were classified as abstainers (no alcohol consumption; n = 19) and resumers (any alcohol consumption; n = 38) at follow-up. Cross-sectional and longitudinal perfusion was compared in abstainers, resumers, and nsLD. At baseline, resumers demonstrated significantly lower frontal and parietal GM perfusion than nsLD and abstainers. Abstainers and nsLD were not different on frontal or parietal GM perfusion. No significant longitudinal perfusion changes were observed in abstainers and resumers. At AP2, resumers showed significantly lower frontal GM perfusion than nsLD and abstainers, whereas no group differences were observed for parietal GM. Abstainers and nsLD were not different on frontal GM perfusion. The significantly decreased frontal GM perfusion in resumers compared with both abstainers and nsLD across the assessment interval suggests premorbid and/or acquired neurobiological abnormalities of the frontal GM in resumers. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Durazzo, Timothy C.; Gazdzinski, Stefan; Mon, Anderson; Meyerhoff, Dieter J.] San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA.
[Durazzo, Timothy C.; Mon, Anderson; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94121 USA.
RP Durazzo, TC (reprint author), San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St 114M, San Francisco, CA 94121 USA.
EM timothy.durazzo@ucsf.edu
FU NIH [AA10788, DA DA24136]
FX This material is the result of work supported by NIH AA10788 (DJM) and
DA DA24136 (TCD) with resources and the use of facilities at the San
Francisco Veterans Administration Medical Center. We thank Mary Rebecca
Young, Bill Clift, and Jeanna Eichenbaum of the San Francisco Veterans
Administration Substance Abuse Day Hospital and Dr David Pating, Karen
Moise and their colleagues at the San Francisco Kaiser Permanente
Chemical Dependency Recovery Program for their valuable assistance in
recruiting participants. We also wish to extend our gratitude to the
study participants, who made this research possible.
NR 72
TC 11
Z9 11
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-8329
J9 ALCOHOL
JI Alcohol
PD MAY
PY 2010
VL 44
IS 3
BP 201
EP 210
DI 10.1016/j.alcohol.2010.03.003
PG 10
WC Substance Abuse; Pharmacology & Pharmacy; Toxicology
SC Substance Abuse; Pharmacology & Pharmacy; Toxicology
GA 615AF
UT WOS:000279100500001
PM 20682188
ER
PT J
AU Weiner, MW
Aisen, PS
Jack, CR
Jagust, WJ
Trojanowski, JQ
Shaw, L
Saykin, AJ
Morris, JC
Cairns, N
Beckett, LA
Toga, A
Green, R
Walter, S
Soares, H
Snyder, P
Siemers, E
Potter, W
Cole, PE
Schmidt, M
AF Weiner, Michael W.
Aisen, Paul S.
Jack, Clifford R., Jr.
Jagust, William J.
Trojanowski, John Q.
Shaw, Leslie
Saykin, Andrew J.
Morris, John C.
Cairns, Nigel
Beckett, Laurel A.
Toga, Arthur
Green, Robert
Walter, Sarah
Soares, Holly
Snyder, Peter
Siemers, Eric
Potter, William
Cole, Patricia E.
Schmidt, Mark
CA Alzheimer's Dis Neuroimaging Initi
TI The Alzheimer's Disease Neuroimaging Initiative: Progress report and
future plans
SO ALZHEIMERS & DEMENTIA
LA English
DT Review
DE ADNI; Alzheimer's disease; MRI; PET; Amyloid; Memory; Tau
ID MILD COGNITIVE IMPAIRMENT; BIOMARKERS; DEPOSITION
AB The Alzheimer's Disease Neuroimaging, Initiative (ADNI) beg Tilling in October 2004, is a 6-year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls. subjects with mild cognitive impairment. and subjects with Alzheimer's disease (AD) A major goal is to determine and validate MRI. PET images. and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments Structural MRI. FDG PET. C-11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid beta (A beta) and species of tau. with clinical/cognitive measurements were performed on elderly controls. subjects with mild cognitive impairment. and subjects with AD Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects FDG PET, C-11 Pittsburgh compound B PET, and CSF measurements of A beta and tau were significant predictors of cognitive decline and brain atrophy All data are available at UCLA/LONI/ADNI, without embargo ADNI-like projects started in Australia. Europe, Japan. and Korea ADNI provides significant new information concerning the progression of AD (C) 2010 The Alzheimer's Association All rights reserved
C1 [Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA.
[Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Aisen, Paul S.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Jack, Clifford R., Jr.] Mayo Clin, Dept Radiol, Rochester, MN USA.
[Jagust, William J.] Univ Calif Berkeley, Inst Neurosci, Berkeley, CA 94720 USA.
[Trojanowski, John Q.; Shaw, Leslie] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Saykin, Andrew J.] Indiana Univ, Dept Radiol & Imaging Sci, Bloomington, IN USA.
[Morris, John C.; Cairns, Nigel] Washington Univ, Dept Neurol, St Louis, MO USA.
[Beckett, Laurel A.] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA.
[Toga, Arthur] Univ Calif Los Angeles, Dept Neurol LONI, Los Angeles, CA USA.
[Green, Robert] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[Walter, Sarah] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Soares, Holly] Pfizer Global Res & Dev, Translat Med, Groton, CT USA.
[Snyder, Peter] Brown Univ, Dept Bio Med Neurol, Providence, RI 02912 USA.
[Siemers, Eric] Eli Lilly & Co, Alzheimers Dis Res, Indianapolis, IN 46285 USA.
[Potter, William] Merck Res Labs, Rahway, NJ USA.
[Cole, Patricia E.] Imagepace, Cincinnati, OH USA.
[Schmidt, Mark] Johnson & Johnson, Pharmaceut Res & Dev, Antwerp Area, Beerse, Belgium.
RP Weiner, MW (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA.
RI ; Jack, Clifford/F-2508-2010; Morris, John/A-1686-2012; Scharre,
Douglas/E-4030-2011; Saykin, Andrew/A-1318-2007; Schmidt,
Mark/I-5052-2016
OI Beckett, Laurel/0000-0002-2418-9843; Snyder, Peter/0000-0003-0555-4654;
Jack, Clifford/0000-0001-7916-622X; Saykin, Andrew/0000-0002-1376-8532;
Schmidt, Mark/0000-0003-3417-8977
FU NIA NIH HHS [U01 AG024904, U01 AG024904-05, U19 AG010483]
NR 16
TC 173
Z9 176
U1 2
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD MAY
PY 2010
VL 6
IS 3
BP 202
EP 211
DI 10.1016/j.jalz.2010.03.007
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 599RV
UT WOS:000277931700002
PM 20451868
ER
PT J
AU Chirinos, JA
Williams, MM
Bregman, DB
Ashfaq, H
Khayyam, U
Iqbal, N
AF Chirinos, Julio A.
Williams, Monica M.
Bregman, David B.
Ashfaq, Hera
Khayyam, Umar
Iqbal, Nayyar
TI Efficacy of cholesterol uptake inhibition added to statin therapy among
subjects following a low-carbohydrate diet: A randomized controlled
trial
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID LOW-FAT DIET; PRIMARY HYPERCHOLESTEROLEMIA; WEIGHT-LOSS; SEVERE OBESITY;
RISK-FACTORS; EZETIMIBE; SIMVASTATIN; ATKINS; ORNISH; WOMEN
AB Background Low-carbohydrate diets are frequently used as part of weight-loss programs. These are typically associated with increased fat intake. Therefore, cholesterol absorption inhibition is a logical therapeutic strategy to lower low-density lipoprotein cholesterol (LDL-C) in subjects following a low-carbohydrate diet. However, the efficacy of cholesterol absorption inhibition added to statin therapy has not been studied in this common clinical setting.
Methods We performed a randomized controlled trial to compare the effects of ezetimibe on LDL-C when added to simvastatin among subjects following a low-carbohydrate diet. We enrolled 65 subjects who were overweight or obese (body mass index 25-45 kg/m(2)) and had a moderately elevated LDL-C (130-190 mg/dL). During a 4-week diet run-in, subjects were instructed to restrict carbohydrate intake to <30 g/day. Subjects demonstrating adequate adherence to a low-carbohydrate diet (n = 58) were randomized to simvastatin (20 mg) or simvastatin (20 mg) plus ezetimibe (10 mg) for 8 weeks.
Results Body weight decreased by 3.1% (95% CI 2.1%-4.0%, P < .0001), but the magnitude of weight change did not differ between the groups (P = .92). The LDL-C decreased by 32 mg/dL (95% CI 21-42 mg/dL) in the simvastatin arm and 60 mg/dL (95% CI 45-75 mg/dL) in the combined simvastatin-ezetimibe arm (P = .002). This corresponded to a 20.9% reduction (95% CI 14.5%-27.4%) in LDL-C on simvastatin alone, compared with a 37.4% reduction (95% CI 29.3%-45.6%) on simvastatin-ezetimibe (P = .002). A significant 15.8% reduction in triglycerides was observed among enrolled subjects, which did not differ between the groups.
Conclusions Among subjects following a low-carbohydrate diet, combined statin and cholesterol absorption inhibitor therapy is more effective than statin monotherapy for LDL-C lowering. (Am Heart J 2010; 159: 918.e1-918.e6.)
C1 [Chirinos, Julio A.; Williams, Monica M.; Ashfaq, Hera; Khayyam, Umar; Iqbal, Nayyar] Univ Penn, Dept Med, Div Cardiovasc Dis, Philadelphia, PA 19104 USA.
[Chirinos, Julio A.; Williams, Monica M.; Ashfaq, Hera; Khayyam, Umar; Iqbal, Nayyar] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Bregman, David B.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA.
[Iqbal, Nayyar] Bristol Myers Squibb Co, New York, NY 10154 USA.
RP Chirinos, JA (reprint author), 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM julio.chirinos@uphs.upenn.edu
FU Philadelphia VA Medical Center
FX This manuscript is dedicated to the memory of Frederick F. Samaha, MD, a
friend and mentor. Dr Samaha conceived and led the design of this
clinical trial and was the Principal Investigator of this trial until
all subjects were closed out from the study.; The authors would like to
acknowledge the support of the Philadelphia VA Medical Center and its
laboratory staff.
NR 15
TC 0
Z9 0
U1 3
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD MAY
PY 2010
VL 159
IS 5
AR 918.e1
DI 10.1016/j.ahj.2010.02.010
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 590QY
UT WOS:000277243300031
PM 20435205
ER
PT J
AU Burkitt, KH
Sinkowitz-Cochran, RL
Obrosky, DS
Cuerdon, T
Miller, LJ
Jain, R
Jernigan, JA
Fine, MJ
AF Burkitt, Kelly H.
Sinkowitz-Cochran, Ronda L.
Obrosky, D. Scott
Cuerdon, Timothy
Miller, LaToya J.
Jain, Rajiv
Jernigan, John A.
Fine, Michael J.
TI Survey of employee knowledge and attitudes before and after a
multicenter Veterans' Administration quality improvement initiative to
reduce nosocomial methicillin-resistant Staphylococcus aureus infections
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Methicillin-resistant Staphylococcus aureus; quality improvement;
prevention; employee survey; knowledge; attitudes; practices
ID BLOOD-STREAM INFECTIONS; ANTIMICROBIAL RESISTANCE; HAND HYGIENE;
UNITED-STATES; PERCEPTIONS; HOSPITALS; IMPLEMENTATION; PHYSICIANS;
BELIEFS; STAFF
AB Background: Although guidelines currently recommend prevention practices to decrease in-hospital transmission of infections, increasing adherence to the practices remains a challenge. This study assessed the effect of a multicenter methicillin-resistant Staphylococcus aureus (MRSA) prevention initiative on changes in employees' knowledge, attitudes, and practices.
Methods: Two cross-sectional surveys were distributed at baseline (October 2006) and follow-up (July 2007) at 17 medical centers participating in the Veterans' Administration (VA) MRSA initiative.
Results: Surveys were completed by 1362 employees at baseline and 952 employees at follow-up (representing 57% and 56% of eligible respondents, respectively). Respondents included physicians (9%), nurses (38%), allied health professionals (30%), and other support staff (24%). Of the 5 knowledge items, the mean proportion answered correctly increased slightly from baseline to follow-up (from 71% to 73%; P = .07). The percentage of respondents who believed that MRSA was a problem on their unit increased over time (from 56% to 65%; P < .001). Respondents also reported increased comfort with reminding other staff about proper hand hygiene (from 61% to 70%; P < .001) and contact precautions (from 63% to 70%; P < .002). The percentage of respondents reporting at least one barrier to proper hand hygiene decreased over time (from 25% to 20%; P = .003).
Conclusions: In this multicenter study of VA employees, implementation of a MRSA quality improvement initiative was associated with temporal improvements in knowledge and perceptions regarding MRSA prevention.
C1 [Burkitt, Kelly H.; Obrosky, D. Scott; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Sinkowitz-Cochran, Ronda L.; Jernigan, John A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Cuerdon, Timothy] VA Cent Off, Off Qual & Performance, Washington, DC USA.
[Miller, LaToya J.] Atlanta VA Med Ctr, Directors Off, Atlanta, GA USA.
[Miller, LaToya J.; Jain, Rajiv] VA Pittsburgh Healthcare Syst, Chief Staffs Off, Pittsburgh, PA USA.
[Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
RP Burkitt, KH (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,Bldg 2,Room A3004N 151C-H, Pittsburgh, PA 15206 USA.
EM Kelly.Burkitt@va.gov
FU Office of Research and Development, Department of Veterans Affairs; VA
Pittsburgh Healthcare System
FX This material is based on work supported in part by the Office of
Research and Development, Department of Veterans Affairs, and the VA
Pittsburgh Healthcare System. None of the authors has any conflict of
interest or financial interest associated with this study. The findings
and conclusions reported in this article are those of the authors and do
not necessarily represent the views of the Centers for Disease Control
and Prevention, the Department of Veterans Affairs, or the United States
Government.
NR 23
TC 5
Z9 5
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD MAY
PY 2010
VL 38
IS 4
BP 274
EP 282
DI 10.1016/j.ajic.2009.08.019
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 587GZ
UT WOS:000276979600004
PM 20137828
ER
PT J
AU Sox, HC
Helfand, M
Grimshaw, J
Dickersin, K
Tovey, D
Knottnerus, JA
Tugwell, P
AF Sox, Harold C.
Helfand, Mark
Grimshaw, Jeremy
Dickersin, Kay
Tovey, David
Knottnerus, J. Andre
Tugwell, Peter
CA PLoS Med Editors
TI Comparative Effectiveness Research: Challenges for Medical Journals
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Editorial Material
C1 [Helfand, Mark] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
[Sox, Harold C.] Dartmouth Med Sch, Dartmouth Inst, Hanover, NH USA.
[Helfand, Mark] Portland VA Med Ctr, Portland, OR USA.
[Grimshaw, Jeremy] Ottawa Hosp, Clin Epidemiol Program, Res Inst, Ottawa, ON, Canada.
[Dickersin, Kay] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Tovey, David; PLoS Med Editors] Cochrane Lib, London, England.
[Knottnerus, J. Andre] Univ Maastricht, Dept Gen Practice, Maastricht, Netherlands.
[Tugwell, Peter] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
[Tugwell, Peter] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada.
RP Helfand, M (reprint author), Oregon Hlth & Sci Univ, Dept Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM helfand@ohsu.edu
RI Knottnerus, Johannes/A-3829-2009
NR 7
TC 3
Z9 3
U1 0
U2 1
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD MAY
PY 2010
VL 16
IS 5
BP E131
EP E133
PG 3
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 602GF
UT WOS:000278125800013
PM 20455639
ER
PT J
AU Zeliadt, SB
Moinpour, CM
Blough, DK
Penson, DF
Hall, IJ
Smith, JL
Ekwueme, DU
Thompson, IM
Keane, TE
Ramsey, SD
AF Zeliadt, Steven B.
Moinpour, Carol M.
Blough, David K.
Penson, David F.
Hall, Ingrid J.
Smith, Judith Lee
Ekwueme, Donatus U.
Thompson, Ian M.
Keane, Thomas E.
Ramsey, Scott D.
TI Preliminary Treatment Considerations Among Men With Newly Diagnosed
Prostate Cancer
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID QUALITY-OF-LIFE; TREATMENT DECISION-MAKING; OUTCOMES; CARCINOMA;
INFORMATION; VALIDATION; CAPSURE; SCALE
AB Objective: To assess factors that may influence men's preference for surgery versus nonsurgical options among newly diagnosed patients considering treatments for local-stage prostate cancer.
Study Design: Prostate cancer patients were approached at urology clinics after diagnosis but prior to starting treatment in California, South Carolina, and Texas. Using a survey about the treatment decision-making process, patients were asked about their likes and dislikes of 5 common treatment options: surgery (prostatectomy), brachytherapy, external beam radiation therapy, hormone therapy, and watchful waiting.
Methods: Logistic regression identified associations between treatment characteristics and choice of prostatectomy compared with nonsurgical options, controlling for demographic, clinical, and psychological covariates.
Results: Of the 198 eligible men who returned the baseline survey, 59% indicated they only considered surgery and 41% considered at least 1 nonsurgical option. In multivariate analysis, patients who thought treatment efficacy was a primary concern were significantly more likely to prefer surgery only (odds ratio [OR] = 6.20, 95% confidence interval [95% CI] = 1.74, 22.10); those indicating concern about personal burden were significantly more likely to prefer nonsurgical options (OR = 0.07, 95% CI = 0.02, 0.22). Advice of friends and relatives and concerns over side effects were not significantly associated with preference for surgery versus other treatments.
Conclusions: Men's perceptions about treatment efficacy and the personal burden of treatment dominated preferences for surgery versus nonsurgical options. Interventions to aid treatment decision making should account for these elements to minimize the impact of physician biases and patient misperceptions on men's decisions as how best to manage their prostate cancer. (Am J Manag Care. 2010; 16(5): e121-e130)
C1 [Zeliadt, Steven B.; Moinpour, Carol M.; Ramsey, Scott D.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
[Zeliadt, Steven B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA.
[Blough, David K.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA.
[Penson, David F.] Univ So Calif, Dept Urol, Los Angeles, CA USA.
[Hall, Ingrid J.; Smith, Judith Lee; Ekwueme, Donatus U.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA.
[Thompson, Ian M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA.
[Keane, Thomas E.] Med Univ S Carolina, Div Urol Serv, Charleston, SC 29425 USA.
RP Ramsey, SD (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,M3-B232, Seattle, WA 98109 USA.
EM sramsey@fhcrc.org
FU Centers for Disease Control and Prevention [1-U48-DP-000050]
FX This publication was supported by Cooperative Agreement 1-U48-DP-000050
from the Centers for Disease Control and Prevention, Prevention Research
Centers Program, through the University of Washington Health Promotion
Research Center. The findings and conclusions in this report are those
of the authors and do not necessarily represent the official position of
the Centers for Disease Control and Prevention.
NR 36
TC 19
Z9 19
U1 2
U2 4
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD MAY
PY 2010
VL 16
IS 5
BP E121
EP E130
PG 10
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 602GF
UT WOS:000278125800012
PM 20455638
ER
PT J
AU Grady, D
Cauley, JA
Stock, JL
Cox, DA
Mitlak, BH
Song, JL
Cummings, SR
AF Grady, Deborah
Cauley, Jane A.
Stock, John L.
Cox, David A.
Mitlak, Bruce H.
Song, Jingli
Cummings, Steven R.
TI Effect of Raloxifene on All-cause Mortality
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article; Proceedings Paper
CT 8th International Symposium on Osteoporosis - Translating Research into
Clinical Practice
CY APR 01-09, 2009
CL Washington, DC
DE CORE; MORE; Mortality; Raloxifene, RUTH
ID RANDOMIZED CLINICAL-TRIAL; VERTEBRAL FRACTURE RISK; POSTMENOPAUSAL
WOMEN; BREAST-CANCER; REDUCTION; OSTEOPOROSIS; OUTCOMES
AB OBJECTIVE: Raloxifene, a selective estrogen receptor modulator, reduces osteoporosis and invasive breast cancer risk but increases risk for venous thromboembolism and fatal stroke in women with or at high risk for coronary heart disease. To assess the risk/benefit of raloxifene as a preventative treatment, we analyzed treatment effects on overall and cause-specific mortality.
METHODS: A pooled analysis of mortality data was performed from large clinical trials of raloxifene (60 mg/day) versus placebo, including the Multiple Outcomes of Raloxifene Evaluation/Continuing Outcomes Relevant to Evista studies (7705 postmenopausal osteoporotic women followed for 4 years and a subset of 4011 participants followed for an additional 4 years; 110 deaths) and the Raloxifene Use for the Heart trial (10,101 postmenopausal women with coronary disease or multiple risk factors for coronary disease followed for 5.6 years; 1 149 deaths). Cause of death was assessed by blinded adjudicators. Cox proportional hazards regression models compared mortality by treatment assignment in a pooled analysis of trial data from the Multiple Outcomes of Raloxifene Evaluation/Continuing Outcomes Relevant to Evista and Raloxifene Use for the Heart trials.
RESULTS: All-cause mortality was 10% lower among women assigned to raloxifene 60 mg/day versus placebo (relative hazard 0.90; 95% confidence interval, 0.80-1.00; P =.05). Lower overall mortality was primarily due to lower rates of noncardiovascular deaths, especially a lower rate of noncardiovascular, noncancer deaths.
CONCLUSIONS: All-cause mortality was 10% lower in pooled analyses among older postmenopausal women receiving raloxifene 60 mg/day compared with placebo, due primarily to a reduction in noncardiovascular, noncancer deaths. The mechanism whereby raloxifene might reduce the risk of noncardiovascular death is unclear. (c) 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine (2010) 123, 469.e1-469.e7
C1 [Grady, Deborah; Cummings, Steven R.] Univ Calif San Francisco, San Francisco, CA 94115 USA.
[Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA.
[Cauley, Jane A.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Stock, John L.; Cox, David A.; Mitlak, Bruce H.; Song, Jingli] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA.
[Cummings, Steven R.] Calif Pacific Med Ctr, Res Inst, San Francisco Coordinating Ctr, San Francisco, CA USA.
RP Grady, D (reprint author), Univ Calif San Francisco, 1635 Divisadero St, San Francisco, CA 94115 USA.
EM deborah.grady@ucsf.edu
OI Cauley, Jane A/0000-0003-0752-4408
NR 14
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD MAY
PY 2010
VL 123
IS 5
AR 469.e1
DI 10.1016/j.amjmed.2009.12.018
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 591HD
UT WOS:000277289900018
PM 20399327
ER
PT J
AU Block, K
Gorin, Y
New, DD
Eid, A
Chelmicki, T
Reed, A
Choudhury, GG
Parekh, DJ
Abboud, HE
AF Block, Karen
Gorin, Yves
New, David D.
Eid, Assaad
Chelmicki, Tomasz
Reed, Amanda
Choudhury, Goutam Ghosh
Parekh, Dipen J.
Abboud, Hanna E.
TI The NADPH Oxidase Subunit p22(phox) Inhibits the Function of the Tumor
Suppressor Protein Tuberin
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID RENAL-CELL CARCINOMA; PHOSPHOINOSITIDE 3-KINASE/AKT PATHWAY;
HYPOXIA-INDUCIBLE FACTOR-2-ALPHA; MATRIX-METALLOPROTEINASE; AKT
ACTIVATION; UP-REGULATION; NOX FAMILY; TARGET; CANCER; IDENTIFICATION
AB Mutations in the von Hippel-Lindau (VHL) gene give rise to renal cell carcinoma. Reactive oxygen species, generated by Nox oxidases, are involved in tumorigenesis. We have previously demonstrated that in VHL-deficient cells, p22(phox)-dependent Nox1 and Nox4 oxidases maintain hypoxia inducible factor-2 alpha (HIF-2 alpha) protein expression through an Akt-dependent translational pathway. Phosphorylation of tuberin, by Akt, results in its inactivation. Here we show that diphenyleneiodonium chloride, an inhibitor of Nox oxidases, and small-interfering RNA-mediated down-regulation of p22(phox) inhibit Akt-dependent phosphorylation of tuberin and stabilizes tuberin protein levels in VHL-deficient renal carcinoma cells. p22(phox)-mediated inactivation of tuberin is associated with an increase in ribosomal protein S6 kinase 1 and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1) phosphorylation as well as HIF-2 alpha stabilization. Importantly, we find that marked up-regulation of p22(phox) in human renal cell carcinoma correlates with increased tuberin phosphorylation, decreased tuberin protein levels, and increased phosphorylation of 4E-BP1. Our data provide the first evidence that p22(phox)-based Nox oxidases maintain HIF-2a protein expression through inactivation of tulberin and downstream activation of ribosomal protein S6 kinase 1/4E-BP1 pathway. (Am J Pathol 2010, 176:2447-2455; DOI: 10.2353/ajpath.2010.090606)
C1 [Block, Karen; Gorin, Yves; New, David D.; Eid, Assaad; Chelmicki, Tomasz; Choudhury, Goutam Ghosh; Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Reed, Amanda; Parekh, Dipen J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA.
[Block, Karen; Choudhury, Goutam Ghosh; Abboud, Hanna E.] S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX USA.
RP Block, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med MC 7882, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM block@uthscsa.edu
RI Bell, Tiffany/F-4403-2010
OI Gorin, Yves/0000-0003-4048-6925
FU National Institutes of Health [CA131272, DK078971, DK50190]; Veterans
Administration Research Service; University of Texas Health Science
Center at San Antonio Institute for Integration of Medicine and Science;
Veterans Administration
FX Supported by the National Institutes of Health (CA131272 to K.B.,
DK078971 to H.E.A., and DK50190 to G.G.C.), the Veterans Administration
Research Service (K.B., G.G.C., and H.E.A.), and the University of Texas
Health Science Center at San Antonio Institute for Integration of
Medicine and Science mentored career development award (D.J.P. and
K.B.). G.G.C. and K.B. are recipients of Veterans Administration
Research Career Scientific Awards.
NR 38
TC 21
Z9 21
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD MAY
PY 2010
VL 176
IS 5
BP 2447
EP 2455
DI 10.2353/ajpath.2010.090606
PG 9
WC Pathology
SC Pathology
GA 627XV
UT WOS:000280078600039
PM 20304964
ER
PT J
AU Rajan, S
McNeely, MJ
Hammond, M
Goldstein, B
Weaver, F
AF Rajan, Suparna
McNeely, Marguerite J.
Hammond, Margaret
Goldstein, Barry
Weaver, Frances
TI Association Between Obesity and Diabetes Mellitus in Veterans With
Spinal Cord Injuries and Disorders
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Spinal Cord Injury; Body Mass Index; Obesity; Diabetes Mellitus
ID BODY-MASS INDEX; DISEASE BURDEN; RISK-FACTORS; HEALTH; OVERWEIGHT; MEN;
PARAPLEGIA; MORTALITY; ADULTS; US
AB Objectives: To examine the association between body mass index (BMI) and clinically diagnosed diabetes in veterans with spinal cord injuries and disorders. We also sought to determine whether there is evidence to support a 10% reduction in BMI cut points, which would lower the upper limit of normal BMI from 24.99 to 22.49 kg/m(2), for persons with spinal cord injuries and disorders.
Design: Cross-sectional analysis using clinical data on 1938 male veterans. Prevalence ratios (95% confidence intervals) were calculated using a generalized linear model and adjusted for age, race, tobacco use, and paraplegia/tetraplegia status.
Results: Compared with the National Heart Lung Blood Institute normal BMI category (18.5-24.99 kg/m(2)), the prevalence of diabetes was 50% higher (adjusted prevalence ratio: 1.50, 95% CI: 1.11-2.01) in the overweight category (25-29.99 kg/m(2)) and similar to 3-fold higher (for obese classes 1-3, adjusted prevalence ratio: 2.74-3.03) in the obese category (BMI >= 30 kg/m(2)). Compared with the World Health Organization low-normal category (BMI, 18.5-22.99 kg/m(2)), there was no significant difference in the prevalence of diabetes for those in the high normal weight (BMI, 23-24.99 kg/m(2)) or low overweight (BMI, 25-27.49 kg/m(2)) categories. However, the prevalence of diabetes was 2-fold higher among those in the high overweight category (BMI, 27.5-29.99 kg/m(2); adjusted prevalence ratio: 2.00, 95% CI: 1.33-2.99).
Conclusions: BMI >= 25 kg/m(2) was associated with significantly higher diabetes prevalence in male veterans with spinal cord injuries and disorders, and this risk was especially pronounced at BMI >= 27.5 kg/m(2). These findings do not support the need to create spinal cord injuries and disorder-specific BMI definitions of overweight for purposes of determining diabetes risk.
C1 [Rajan, Suparna] VA Puget Sound Hlth Care Syst, Spinal Cord Injury Qual Enhancement Res Initiat, Seattle, WA 98108 USA.
[McNeely, Marguerite J.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA.
[Hammond, Margaret; Goldstein, Barry] Univ Washington, Dept Rehabil Med, Dept Vet Affairs, Spinal Cord Injury Disorders Serv, Seattle, WA 98195 USA.
[Weaver, Frances] Northwestern Univ, Dept Vet Affairs, Edward Hines Jr VA Med Ctr, Chicago, IL 60611 USA.
RP Rajan, S (reprint author), VA Puget Sound Hlth Care Syst, Spinal Cord Injury Qual Enhancement Res Initiat, 1660 S Columbian Way,128 NAT, Seattle, WA 98108 USA.
FU Department of Veterans Affairs
FX This article is based on a work supported by Office of Research and
Development, Health Services Research and Development Service, Quality
Enhancement Research Initiative of the Department of Veterans Affairs.
The views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs. Financial disclosure statements have been obtained, and no
conflicts of interest have been reported by the authors or by any
individuals in control of the content of this article.
NR 40
TC 8
Z9 9
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD MAY
PY 2010
VL 89
IS 5
BP 353
EP 361
DI 10.1097/PHM.0b013e3181d896b9
PG 9
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 592OJ
UT WOS:000277388600001
PM 20407300
ER
PT J
AU Collinger, JL
Fullerton, B
Impink, BG
Koontz, AM
Boninger, ML
AF Collinger, Jennifer L.
Fullerton, Bradley
Impink, Bradley G.
Koontz, Alicia M.
Boninger, Michael L.
TI Validation of Grayscale-Based Quantitative Ultrasound in Manual
Wheelchair Users Relationship to Established Clinical Measures of
Shoulder Pathology
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Ultrasound; Grayscale; Tendinopathy; Shoulder
ID SPINAL-CORD-INJURY; CHRONIC ACHILLES TENDINOPATHY; MUSCLE
ULTRASONOGRAPHY; PAIN; SONOGRAPHY; BIOMECHANICS; DISEASE; IMAGES
AB Objective: The primary aim of this study is to establish the validity of grayscale-based quantitative ultrasound (QUS) measures of the biceps and supraspinatus tendons.
Design: Nine QUS measures of the biceps and supraspinatus tendons were computed from ultrasound images collected from 67 manual wheelchair users. Shoulder pathology was measured using questionnaires, physical examination maneuvers, and a clinical ultrasound grading scale.
Results: Increased age, duration of wheelchair use, and body mass correlated with a darker and more homogenous tendon appearance. Subjects with pain during physical examination tests for biceps tenderness and acromioclavicular joint tenderness exhibited significantly different supraspinatus QUS values. Even when controlling for tendon depth, QUS measures of the biceps tendon differed significantly between subjects with healthy tendons, mild tendinosis, and severe tendinosis. Clinical grading of supraspinatus tendon health was correlated with QUS measures of the supraspinatus tendon.
Conclusions: QUS is valid method to quantify tendinopathy and may allow for early detection of tendinosis. Manual wheelchair users are at a high risk for developing shoulder tendon pathology and may benefit from QUS-based research that focuses on identifying interventions designed to reduce this risk.
C1 [Collinger, Jennifer L.; Impink, Bradley G.; Koontz, Alicia M.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Pittsburgh, PA 15206 USA.
[Collinger, Jennifer L.; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
[Collinger, Jennifer L.; Impink, Bradley G.; Koontz, Alicia M.; Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA.
[Fullerton, Bradley] Patient Phys Partnership & Dell Childrens Med Ctr, Austin, TX USA.
[Koontz, Alicia M.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
RP Boninger, ML (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, 7180 Highland Dr,Bldg 4,151R-1, Pittsburgh, PA 15206 USA.
OI Boninger, Michael/0000-0001-6966-919X
FU Office of Research and Development, Rehabilitation Research and
Development Service, Department of Veterans Affairs [B3142C]; National
Institute of Health [R21HD054529]; National Institute on Disability and
Rehabilitation Research (NIDRR) [H133E070024]; NSF
FX This article is based on work supported by the Office of Research and
Development, Rehabilitation Research and Development Service, Department
of Veterans Affairs, grant B3142C, the National Institute of Health,
grant R21HD054529, the National Institute on Disability and
Rehabilitation Research (NIDRR) Rehabilitation Engineering Research
Center on Spinal Cord Injury, grant H133E070024, and an NSF graduate
research fellowship. Financial disclosure statements have been obtained,
and no conflicts of interest have been reported by the authors or by any
individuals in control of the content of this article.
NR 23
TC 15
Z9 15
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD MAY
PY 2010
VL 89
IS 5
BP 390
EP 400
DI 10.1097/PHM.0b013e3181d8a238
PG 11
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 592OJ
UT WOS:000277388600006
PM 20407304
ER
PT J
AU Bhargava, P
Oliveira, G
Vaidya, S
Yeh, M
Dighe, M
AF Bhargava, P.
Oliveira, G.
Vaidya, S.
Yeh, M.
Dighe, M.
TI Unusual Presentations of Hepatocellular Carcinoma-A Review
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Meeting Abstract
CT 110th Annual Meeting of the American-Roentgen-Ray-Society
CY MAY 02-07, 2010
CL San Diego, CA
SP Amer Roentgen Ray Soc
C1 [Bhargava, P.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
EM bhargp@u.washington.edu
RI Bhargava, Puneet /F-1330-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2010
VL 194
IS 5
SU S
MA E275
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 586RV
UT WOS:000276931000518
ER
PT J
AU Choi, E
Choi, K
Masih, S
AF Choi, E.
Choi, K.
Masih, S.
TI Handy Imaging Guide to Musculoskeletal Hand Pathology
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Meeting Abstract
CT 110th Annual Meeting of the American-Roentgen-Ray-Society
CY MAY 02-07, 2010
CL San Diego, CA
SP Amer Roentgen Ray Soc
C1 [Choi, E.; Choi, K.; Masih, S.] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA.
[Choi, K.; Masih, S.] W Los Angeles Vet Adm, Los Angeles, CA USA.
EM eugenechoi@mednet.ucla.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2010
VL 194
IS 5
SU S
MA E429
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 586RV
UT WOS:000276931000671
ER
PT J
AU Chow, K
Lal, M
Modarresi, S
Masih, S
AF Chow, K.
Lal, M.
Modarresi, S.
Masih, S.
TI Imaging of Sacroiliac Joint Pathology
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Meeting Abstract
CT 110th Annual Meeting of the American-Roentgen-Ray-Society
CY MAY 02-07, 2010
CL San Diego, CA
SP Amer Roentgen Ray Soc
C1 [Chow, K.; Lal, M.; Modarresi, S.; Masih, S.] Vet Adm Greater Los Angeles, Los Angeles, CA USA.
EM kirachow@yahoo.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2010
VL 194
IS 5
SU S
MA E460
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 586RV
UT WOS:000276931000702
ER
PT J
AU Dighe, M
Bhargava, P
Fligner, C
Mitsumori, L
AF Dighe, M.
Bhargava, P.
Fligner, C.
Mitsumori, L.
TI Elevated Alpha Feto Protein Level in Pregnancy-Etiology and Imaging
Appearances
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Meeting Abstract
CT 110th Annual Meeting of the American-Roentgen-Ray-Society
CY MAY 02-07, 2010
CL San Diego, CA
SP Amer Roentgen Ray Soc
C1 [Dighe, M.; Bhargava, P.; Fligner, C.; Mitsumori, L.] Univ Washington, Seattle, WA 98195 USA.
[Bhargava, P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
EM bhargp@u.washington.edu
RI Bhargava, Puneet /F-1330-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2010
VL 194
IS 5
SU S
MA E389
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 586RV
UT WOS:000276931000631
ER
PT J
AU Dighe, M
Bhargava, P
Oliveira, G
Bush, W
Vaidya, S
AF Dighe, M.
Bhargava, P.
Oliveira, G.
Bush, W.
Vaidya, S.
TI Imaging of Adrenal Masses: A pictorial Review
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Meeting Abstract
CT 110th Annual Meeting of the American-Roentgen-Ray-Society
CY MAY 02-07, 2010
CL San Diego, CA
SP Amer Roentgen Ray Soc
C1 [Dighe, M.; Bhargava, P.; Oliveira, G.; Bush, W.; Vaidya, S.] Univ Washington, Seattle, WA 98195 USA.
[Bhargava, P.; Vaidya, S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
EM bhargp@u.washington.edu
RI Bhargava, Puneet /F-1330-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2010
VL 194
IS 5
SU S
MA E317
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 586RV
UT WOS:000276931000560
ER
PT J
AU Munir, R
Aslam, R
Yeh, B
AF Munir, R.
Aslam, R.
Yeh, B.
TI Prevalence and Significance of Periceliac Stranding on Multidetector CT
in Asymptomatic Patients
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Meeting Abstract
CT 110th Annual Meeting of the American-Roentgen-Ray-Society
CY MAY 02-07, 2010
CL San Diego, CA
SP Amer Roentgen Ray Soc
C1 [Munir, R.; Aslam, R.; Yeh, B.] San Francisco VA Med Ctr, San Francisco, CA USA.
EM reema.munir@radiology.ucsf.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2010
VL 194
IS 5
SU S
MA 201
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 586RV
UT WOS:000276931000201
ER
PT J
AU Tran, D
Wang, Z
Benedetti, N
Prevrhal, S
Yeh, B
AF Tran, D.
Wang, Z.
Benedetti, N.
Prevrhal, S.
Yeh, B.
TI Gallstone Detection In Vitro at Dual-Energy Compared With Conventional
CT
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Meeting Abstract
CT 110th Annual Meeting of the American-Roentgen-Ray-Society
CY MAY 02-07, 2010
CL San Diego, CA
SP Amer Roentgen Ray Soc
C1 [Tran, D.; Wang, Z.; Benedetti, N.; Prevrhal, S.] UCSF, San Francisco, CA USA.
[Yeh, B.] San Francisco VA Med Ctr, San Francisco, CA USA.
EM ben.yeh@radiology.ucsf.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2010
VL 194
IS 5
SU S
MA 198
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 586RV
UT WOS:000276931000198
ER
PT J
AU Parker, ED
Widome, R
Nettleton, JA
Pereira, MA
AF Parker, Emily D.
Widome, Rachel
Nettleton, Jennifer A.
Pereira, Mark A.
TI Food Security and Metabolic Syndrome in US Adults and Adolescents:
Findings From the National Health and Nutrition Examination Survey,
1999-2006
SO ANNALS OF EPIDEMIOLOGY
LA English
DT Article; Proceedings Paper
CT 41st Annual Meeting of the Society-for-Epidemiologic-Research
CY JUN 24-27, 2008
CL Chicago, IL
SP Soc Epidemiol Res
DE Cross-Sectional Studies; Food Security; NHANES; Metabolic Syndrome
ID DIETARY ENERGY DENSITY; TREATMENT-PANEL-III; OBESITY PARADOX;
INSECURITY; CHILDREN; OVERWEIGHT; DISEASE; WOMEN; RISK; DYSLIPIDEMIA
AB PURPOSE: We sought to examine the association of food security and metabolic syndrome in a representative sample of U.S. adults and adolescents We hypothesized that compared with those in food-secure households, adolescents and adults living in food-insecure households would have increased odds of (MetS)
METHODS: Data from the National Health and Nutrition Examination Surveys from 1999 to 2006 were combined and analyzed cross-sectionally Logistic regression was used to compute odds ratios and 95% confidence intervals (95% CI) in the association of household food security (fully food secure, marginal, low, and very low food security) and MetS.
RESULTS: Compared with those who were food secure, adults in households with marginal food security had 1.80-fold increased odds of MetS (95% CI, 1 30-2.49), and those with very low food security had a 1.65-fold increased odds of MetS (95% CI 1 12-2 42) There was no association with low food security The association of marginal household food security and MetS was not significant: in adolescents In adults and adolescents, very low was food security not associated with increased odds of MetS compared with those who were food secure
CONCLUSIONS: Members of households with marginal and very low food security are at increased risk of MetS A mechanism may be that foods that are inexpensive and easily accessible tend to be energy dense and nutrient poor Ann Epidemiol 2010, 20 364-370 (C) 2010 Elsevier Inc All rights reserved
C1 [Parker, Emily D.] HealthPartners, HealthPartners Res Fdn, Minneapolis, MN 55440 USA.
[Widome, Rachel] US Dept Vet Affairs, CCDOR, Minneapolis, MN USA.
[Widome, Rachel] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Nettleton, Jennifer A.] Univ Texas Houston, Sch Publ Hlth, Div Epidemiol, Houston, TX USA.
[Pereira, Mark A.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
RP Parker, ED (reprint author), HealthPartners, HealthPartners Res Fdn, Mail Stop 21111R,8170 33rd Ave S,POB 1524, Minneapolis, MN 55440 USA.
FU NCI NIH HHS [U54CA116849]
NR 36
TC 28
Z9 30
U1 1
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1047-2797
J9 ANN EPIDEMIOL
JI Ann. Epidemiol.
PD MAY
PY 2010
VL 20
IS 5
BP 364
EP 370
DI 10.1016/j.annepidem.2010.02.009
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 588UX
UT WOS:000277101000006
PM 20382337
ER
PT J
AU Raza, S
Siddiqui, UA
Megna, JL
Schwartz, TL
Batki, SL
AF Raza, Shafi
Siddiqui, Umar A.
Megna, James L.
Schwartz, Thomas L.
Batki, Steven L.
TI Pregabalin Treatment of Anxiety in Patients with Substance Use Disorders
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Letter
C1 [Raza, Shafi; Siddiqui, Umar A.; Megna, James L.; Schwartz, Thomas L.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA.
[Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, SUNY Upstate Med Univ, San Francisco Vet Adm Med Ctr, San Francisco, CA 94143 USA.
RP Raza, S (reprint author), SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA.
EM schwartt@upstate.edu
NR 3
TC 4
Z9 4
U1 0
U2 1
PU HARVEY WHITNEY BOOKS CO
PI CINCINNATI
PA PO BOX 42696, CINCINNATI, OH 45242 USA
SN 1060-0280
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD MAY
PY 2010
VL 44
IS 5
BP 937
EP 938
DI 10.1345/aph.1M656
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 591JD
UT WOS:000277295600022
PM 20388860
ER
PT J
AU Reust, DL
Reeves, ST
Abernathy, JH
Dixon, JA
Gaillard, WF
Mukherjee, R
Koval, CN
Stroud, RE
Spinale, FG
AF Reust, Daryl L.
Reeves, Scott T.
Abernathy, James H., III
Dixon, Jennifer A.
Gaillard, William F., Jr.
Mukherjee, Rupak
Koval, Christine N.
Stroud, Robert E.
Spinale, Francis G.
TI Interstitial Plasmin Activity With Epsilon Aminocaproic Acid: Temporal
and Regional Heterogeneity
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID PERIOPERATIVE BLOOD-TRANSFUSION; CARDIAC-SURGERY; RENAL-FAILURE;
FIBRINOLYSIS; APROTININ; INHIBITOR; PHARMACOKINETICS; THROMBOSIS;
THERAPY; BYPASS
AB Background. Epsilon aminocaproic acid (EACA) is used in cardiac surgery to modulate plasmin activity (PLact). The present study developed a fluorogenic-microdialysis system to measure in vivo region specific temporal changes in PLact after EACA administration.
Methods. Pigs (25 to 35 kg) received EACA (75 mg/kg, n = 7) or saline in which microdialysis probes were placed in the liver, myocardium, kidney, and quadricep muscle. The microdialysate contained a plasmin-specific fluorogenic peptide and fluorescence emission, which directly reflected PLact, determined at baseline, 30, 60, 90, and 120 minutes after EACA/vehicle infusion.
Results. Epsilon aminocaproic acid caused significant decreases in liver and quadricep PLact at 60, 90, 120 minutes, and at 30, 60, and 120 minutes, respectively (p < 0.05). In contrast, EACA induced significant biphasic changes in heart and kidney PLact profiles with initial increases followed by decreases at 90 and 120 minutes (p < 0.05). The peak EACA interstitial concentrations for all compartments occurred at 30 minutes after infusion, and were fivefold higher in the renal compartment and fourfold higher in the myocardium, when compared with the liver or muscle (p < 0.05).
Conclusions. Using a large animal model and in vivo microdialysis measurements of plasmin activity, the unique findings from this study were twofold. First, EACA induced temporally distinct plasmin activity profiles within the plasma and interstitial compartments. Second, EACA caused region-specific changes in plasmin activity profiles. These temporal and regional heterogeneic effects of EACA may have important therapeutic considerations when managing fibrinolysis in the perioperative period. (Ann Thorac Surg 2010; 89: 1538-45) (C) 2010 by The Society of Thoracic Surgeons
C1 [Spinale, Francis G.] Med Univ S Carolina, Dept Anesthesiol & Perioperat Med, Charleston, SC 29403 USA.
Med Univ S Carolina, Dept Cardiothorac Surg, Charleston, SC 29425 USA.
Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA.
RP Spinale, FG (reprint author), Med Univ S Carolina, Dept Anesthesiol & Perioperat Med, Strom Thurmond Res Bldg,114 Doughty St,Room 625, Charleston, SC 29403 USA.
EM wilburnm@musc.edu
FU NIH [HL059165, HL078650]; Veterans Affairs Health Administration
FX This study was supported in part by NIH grants HL059165, HL078650 and a
Merit Award from the Veterans Affairs Health Administration. The authors
gratefully acknowledge the assistance of Danyelle M. Townsend, PhD, and
Joachim de Klerk Uys, PhD, of the Medical University of South Carolina
Hollings Cancer Center, Drug Metabolism and Clinical Pharmacology Core
Facility, in the measurement of plasma and interstitial EACA
concentrations.
NR 34
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAY
PY 2010
VL 89
IS 5
BP 1538
EP 1545
DI 10.1016/j.athoracsur.2010.01.051
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 587KO
UT WOS:000276991200028
PM 20417774
ER
PT J
AU Wenk, JF
Zhang, ZH
Cheng, GM
Malhotra, D
Acevedo-Bolton, G
Burger, M
Suzuki, T
Saloner, DA
Wallace, AW
Guccione, JM
Ratcliffe, MB
AF Wenk, Jonathan F.
Zhang, Zhihong
Cheng, Guangming
Malhotra, Deepak
Acevedo-Bolton, Gabriel
Burger, Mike
Suzuki, Takamaro
Saloner, David A.
Wallace, Arthur W.
Guccione, Julius M.
Ratcliffe, Mark B.
TI First Finite Element Model of the Left Ventricle With Mitral Valve:
Insights Into Ischemic Mitral Regurgitation
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID 3-DIMENSIONAL STRAIN; CHORDAE TENDINEAE; ANEURYSM; ANNULOPLASTY;
PATHOGENESIS; REPLACEMENT; REDUCTION; SURGERY; STRESS; MUSCLE
AB Background. Left ventricular remodeling after posterobasal myocardial infarction can lead to ischemic mitral regurgitation. This occurs as a consequence of leaflet tethering due to posterior papillary muscle displacement.
Methods. A finite element model of the left ventricle, mitral apparatus, and chordae tendineae was created from magnetic resonance images from a sheep that developed moderate mitral regurgitation after posterobasal myocardial infarction. Each region of the model was characterized by a specific constitutive law that captured the material response when subjected to physiologic pressure loading.
Results. The model simulation produced a gap between the posterior and anterior leaflets, just above the infarcted posterior papillary muscle, which is indicative of mitral regurgitation. When the stiffness of the infarct region was reduced, this caused the wall to distend and the gap area between the leaflets to increase by 33%. Additionally, the stress in the leaflets increased around the chordal connection points near the gap.
Conclusions. The methodology outlined in this work will allow a finite element model of both the left ventricle and mitral valve to be generated using noninvasive techniques. (Ann Thorac Surg 2010; 89: 1546-54) (C) 2010 by The Society of Thoracic Surgeons
C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA.
Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA.
Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA.
Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.
Livermore Software Technol Corp, Livermore, CA USA.
RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA.
EM mark.ratcliffe@va.gov
FU National Institutes of Health [R01-HL-84431, R01-HL-63348, R01-HL-77921,
R01-HL-86400]
FX This study was supported by National Institutes of Health grants
R01-HL-84431 (Dr Ratcliffe), R01-HL-63348 (Dr Ratcliffe), R01-HL-77921
(Dr Guccione), and R01-HL-86400 (Dr Guccione). This support is
gratefully acknowledged.
NR 46
TC 57
Z9 57
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAY
PY 2010
VL 89
IS 5
BP 1546
EP 1554
DI 10.1016/j.athoracsur.2010.02.036
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 587KO
UT WOS:000276991200029
PM 20417775
ER
PT J
AU Gopaldas, RR
Bakaeen, FG
Dao, TK
Walsh, GL
Swisher, SG
Chu, D
AF Gopaldas, Raja R.
Bakaeen, Faisal G.
Dao, Tam K.
Walsh, Garrett L.
Swisher, Stephen G.
Chu, Danny
TI Video-Assisted Thoracoscopic Versus Open Thoracotomy Lobectomy in a
Cohort of 13,619 Patients
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Proceedings Paper
CT 56th Annual Meeting of the Southern-Thoracic-Surgical-Association
CY NOV 04-07, 2009
CL Marco Isl, FL
SP So Thorac Surg Assoc
ID THORACIC-SURGERY LOBECTOMY; LUNG-CANCER; RESECTION; DATABASE
AB Background. Video-assisted thoracoscopic surgery (VATS) is becoming increasingly popular for lung resection in some centers. However, the issue of whether VATS or open thoracotomy is better remains controversial. We compared outcomes of open and VATS lobectomy in a national database.
Methods. Using the 2004 and 2006 Nationwide Inpatient Sample database, we identified 13,619 discharge records of patients who underwent pulmonary lobectomy by means of thoracotomy (n = 12,860) or VATS (n = 759). Student's t and chi(2) tests were used to compare the two groups. Multivariable analysis was used to identify independent predictors of outcome measures.
Results. The two groups of patients had similar demo-graphics and preoperative comorbidities. They also had similar in-hospital mortality rates (3.1% versus 3.4%; p = 0.67); lengths of stay (9.3 +/- 0.1 versus 9.2 +/- 0.4 days; p = 0.84); hospitalization costs ($23,862 +/- $206 versus $25,125 +/- $ 1,093; p = 0.16); and rates of wound infection (0.8% versus 1.3%; p = 0.15), pulmonary complications (32.2% versus 31.2%; p = 0.55), and cardiovascular complications (3.4% versus 3.9%; p = 0.43). However, multivariable analysis showed that the VATS group had a significantly higher incidence of intraoperative complications than the thoracotomy group (odds ratio, 1.6; 95% confidence interval, 1.0 to 2.4; p = 0.04). A higher percentage of patients with annual income greater than $59,000 underwent VATS lobectomy than patients with income less than $59,000 (35.7% versus 25.4%; p < 0.0001).
Conclusions. Patients who underwent VATS lobectomy were 1.6 times more likely to have intraoperative complications than patients who underwent open lobectomy. However, short-term mortality, lengths of stay, and hospitalization costs were similar between the two groups of patients. There seems to be a socioeconomic disparity between VATS and open thoracotomy patients. (Ann Thorac Surg 2010; 89: 1563-70) (C) 2010 by The Society of Thoracic Surgeons
C1 [Chu, Danny] Univ Houston, Texas Heart Inst,St Lukes Episcopal Hosp, Div Cardiothorac Surg,Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr,Dept Surg, Houston, TX 77030 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
RP Chu, D (reprint author), Univ Houston, Texas Heart Inst,St Lukes Episcopal Hosp, Div Cardiothorac Surg,Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr,Dept Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
EM dchumd@gmail.com
NR 23
TC 68
Z9 74
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAY
PY 2010
VL 89
IS 5
BP 1563
EP 1570
DI 10.1016/j.athoracsur.2010.02.026
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 587KO
UT WOS:000276991200031
PM 20417778
ER
PT J
AU Ishaque, BM
Ge, PS
Rigberg, D
de Virgilio, C
AF Ishaque, Brandon M.
Ge, Phillip S.
Rigberg, David
de Virgilio, Christian
TI Acute Thrombosis of an Abdominal Aortic Aneurysm followed by Delayed
Rupture Associated with Bacterial Infection
SO ANNALS OF VASCULAR SURGERY
LA English
DT Article
ID ACUTE OCCLUSION; LIGATION
AB Sudden thrombosis of an abdominal aortic aneurysm (AAA) is distinctly rare and is associated with up to 50% mortality. Almost equally rare is infection of a preexisting AAA. We report an extremely unusual case of an AAA that thrombosed leading to acute limb ischemia. This was followed several months later by a delayed rupture of the thrombosed AAA associated with an Escherichia coli infection. We suspect the aortic thrombus was hematogenously seeded by a urinary tract infection. A review of the literature revealed that bacterial infection of a previously thrombosed AAA, leading to a delayed rupture, has not been previously reported.
C1 [Ishaque, Brandon M.; Ge, Phillip S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Rigberg, David; de Virgilio, Christian] W Los Angeles VA Med Ctr, Div Vasc Surg, Los Angeles, CA USA.
RP de Virgilio, C (reprint author), Harbor UCLA Med Ctr, Dept Surg, 1000 W Carson St Torrance, Torrance, CA 90309 USA.
EM cdevirgilio@labiomed.org
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0890-5096
EI 1615-5947
J9 ANN VASC SURG
JI Ann. Vasc. Surg.
PD MAY
PY 2010
VL 24
IS 4
AR 524.e1
DI 10.1016/j.avsg.2009.07.029
PG 4
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 592SQ
UT WOS:000277400700014
PM 20036505
ER
PT J
AU Byers, AL
Yaffe, K
Covinsky, KE
Friedman, MB
Bruce, ML
AF Byers, Amy L.
Yaffe, Kristine
Covinsky, Kenneth E.
Friedman, Michael B.
Bruce, Martha L.
TI High Occurrence of Mood and Anxiety Disorders Among Older Adults The
National Comorbidity Survey Replication
SO ARCHIVES OF GENERAL PSYCHIATRY
LA English
DT Article
ID WORLD-HEALTH-ORGANIZATION; DSM-IV DISORDERS; LATE-LIFE;
MENTAL-DISORDERS; NCS-R; 12-MONTH PREVALENCE; DEPRESSION SCALE;
FUTURE-RESEARCH; EPIDEMIOLOGY; SYMPTOMS
AB Context: Little is known about prevalence rates of DSM-IV disorders across age strata of older adults, including common conditions such as individual and coexisting mood and anxiety disorders.
Objective: To determine nationally representative estimates of 12-month prevalence rates of mood, anxiety, and comorbid mood-anxiety disorders across young-old, mid-old, old-old, and oldest-old community-dwelling adults.
Design: The National Comorbidity Survey Replication (NCS-R) is a population-based probability sample of 9282 participants 18 years and older, conducted between February 2001 and April 2003. The NCS-R survey used the fully structured World Health Organization World Mental Health Survey version of the Composite International Diagnostic Interview.
Setting: Continental United States.
Participants: We studied the 2575 participants 55 years and older who were part of NCS-R (43%, 55-64 years; 32%, 65-74 years; 20%, 75-84 years; 5%, >= 85 years). This included only noninstitutionalized adults, as all NCS-R participants resided in households within the community.
Main Outcome Measures: Twelve-month prevalence of mood disorders (major depressive disorder, dysthymia, bipolar disorder), anxiety disorders (panic disorder, agoraphobia, specific phobia, social phobia, generalized anxiety disorder, posttraumatic stress disorder), and coexisting mood-anxiety disorder were assessed using DSM-IV criteria. Prevalence rates were weighted to adjust for the complex design to infer generalizability to the US population.
Results: The likelihood of having a mood, anxiety, or combined mood-anxiety disorder generally showed a pattern of decline with age (P<.05). Twelve-month disorders showed higher rates in women compared with men, a statistically significant trend with age. In addition, anxiety disorders were as high if not higher than mood disorders across age groups (overall 12-month rates: mood, 5% and anxiety, 12%). No differences were found between race/ethnicity groups.
Conclusion: Prevalence rates of DSM-IV mood and anxiety disorders in late life tend to decline with age, but remain very common, especially in women. These results highlight the need for intervention and prevention strategies.
C1 [Byers, Amy L.] Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA.
[Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94121 USA.
[Friedman, Michael B.] Geriatr Mental Hlth Alliance, New York, NY USA.
[Bruce, Martha L.] Weill Cornell Med Coll, Weill Cornell Inst Geriatr Psychiat, Dept Psychiat, White Plains, NY USA.
RP Byers, AL (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, 4150 Clement St,116H, San Francisco, CA 94121 USA.
EM amy.byers@ucsf.edu
FU National Institute of Mental Health [MH079093, U01-MH60220]; National
Institute on Aging [AG031155]; National Institute of Drug Abuse, the
Substance Abuse and Mental Health Services Administration; Robert Wood
Johnson Foundation [044708]; John W. Alden Trust
FX Dr Byers is supported by K01 Career Development Award MH079093 from the
National Institute of Mental Health. Dr Yaffe is supported, in part, by
K24 Midcareer Investigator Award AG031155 from the National Institute on
Aging. The NCS-R was supported by National Institute of Mental Health
grant U01-MH60220, with supplemental support from the National Institute
of Drug Abuse, the Substance Abuse and Mental Health Services
Administration, the Robert Wood Johnson Foundation grant 044708, and the
John W. Alden Trust.
NR 45
TC 182
Z9 187
U1 1
U2 23
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-990X
J9 ARCH GEN PSYCHIAT
JI Arch. Gen. Psychiatry
PD MAY
PY 2010
VL 67
IS 5
BP 489
EP 496
PG 8
WC Psychiatry
SC Psychiatry
GA 590XH
UT WOS:000277261200007
PM 20439830
ER
PT J
AU Skelton, F
Kunik, ME
Regev, T
Naik, AD
AF Skelton, Felicia
Kunik, Mark E.
Regev, Tziona
Naik, Aanand D.
TI Determining if an older adult can make and execute decisions to live
safely at home: A capacity assessment and intervention model
SO ARCHIVES OF GERONTOLOGY AND GERIATRICS
LA English
DT Article
DE Older adults; Capacity; Decision making; Independent Living; Assessment
ID GUARDIANSHIP; CLINICIAN; COMMUNITY
AB Determining an older adult's capacity to live safely and independently in the community presents a serious and complicated challenge to the health care system. Evaluating one's ability to make and execute decisions regarding safe and independent living incorporates clinical assessments, bioethical considerations, and often legal declarations of capacity. Capacity assessments usually result in life changes for patients and their families, including a caregiver managing some everyday tasks, placement outside of the home, and even legal guardianship. The process of determining capacity and recommending intervention is often inefficient and highly variable in most cases. Physicians are rarely trained to conduct capacity assessments and assessment methods are heterogeneous. An interdisciplinary team (IDT) of clinicians developed the capacity assessment and intervention (CAI) model at a community outpatient geriatrics clinic to address these critical gaps. This report follows one patient through the entire CAI model, describing processes for a typical case. It then examines two additional case reports that highlight common challenges in capacity assessment. The CAI model uses assessment methods common to geriatrics clinical practice and conducts assessments and interventions in a standardized fashion. Reliance on common, validated measures increases generalizability of the model across geriatrics practice settings and patient populations. Published by Elsevier Ireland Ltd.
C1 [Kunik, Mark E.; Naik, Aanand D.] Michael E DeBakey VA Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77021 USA.
[Skelton, Felicia; Kunik, Mark E.; Naik, Aanand D.] Baylor Coll Med, Alkek Dept Internal Med, Houston, TX 77030 USA.
[Kunik, Mark E.; Naik, Aanand D.] Michael E DeBakey VA Med Ctr, S Cent Mental Illness Res Educ & Clin Ctr, Houston, TX 77030 USA.
[Kunik, Mark E.] Baylor Coll Med, Menninger Dept Psychiat, Houston, TX 77030 USA.
[Regev, Tziona; Naik, Aanand D.] Harris Cty Hosp Dist, Geriatr Program, Quentin Mease Community Hosp, Houston, TX 77004 USA.
RP Naik, AD (reprint author), Michael E DeBakey VA Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, 2450 Holcombe Blvd, Houston, TX 77021 USA.
EM anaik@bcm.tmc.edu
FU Greenwall Foundation (Naik, PI); Hartford Foundation; Atlantic
Philanthropies; Harris County Hospital District; Houston VA HSR&D Center
of Excellence [HFP90-020]; NIA K23 [5K23AG027144]; American Foundation
on Aging Research
FX This study was supported by a bioethics project grant from the Greenwall
Foundation (Naik, PI), the Practice Change Fellows Program (Regev)
supported by the Hartford Foundation and Atlantic Philanthropies. The
capacity assessment and intervention model receives ongoing support from
the Harris County Hospital District and the Houston VA HSR&D Center of
Excellence (HFP90-020). Dr. Naik is also supported by an NIA K23 grant
(5K23AG027144). Felicia Skelton was supported by a medical student
training in aging research (MSTAR) grant from the American Foundation on
Aging Research. None of the funding agencies played a role in the design
and conduct of the study, analysis and interpretation of the data, or
the preparation and approval of the manuscript.
NR 16
TC 11
Z9 11
U1 1
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-4943
J9 ARCH GERONTOL GERIAT
JI Arch. Gerontol. Geriatr.
PD MAY-JUN
PY 2010
VL 50
IS 3
BP 300
EP 305
DI 10.1016/j.archger.2009.04.016
PG 6
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 580NB
UT WOS:000276454900011
PM 19481271
ER
PT J
AU Weintraub, D
Koester, J
Potenza, MN
Siderowf, AD
Stacy, M
Voon, V
Whetteckey, J
Wunderlich, GR
Lang, AE
AF Weintraub, Daniel
Koester, Juergen
Potenza, Marc N.
Siderowf, Andrew D.
Stacy, Mark
Voon, Valerie
Whetteckey, Jacqueline
Wunderlich, Glen R.
Lang, Anthony E.
TI Impulse Control Disorders in Parkinson Disease A Cross-Sectional Study
of 3090 Patients
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID BINGE-EATING DISORDER; DOPAMINE AGONISTS; UNITED-STATES; PREVALENCE;
BEHAVIORS; DYSREGULATION; EPIDEMIOLOGY; ASSOCIATION; COMORBIDITY;
ADDICTIONS
AB Context: Anassociation between dopamine-replacement therapies and impulse control disorders (ICDs) in Parkinson disease(PD) has been suggested in preliminary studies.
Objectives: To ascertain point prevalence estimates of 4 ICDs in PD and examine their associations with dopamine-replacement therapies and other clinical characteristics.
Design: Cross-sectional study using an a priori established sampling procedure for subject recruitment and raters blinded to PD medication status.
Patients: Three thousand ninety patients with treated idiopathic PD receiving routine clinical care at 46 movement disorder centers in the United States and Canada.
Main Outcome Measures: The Massachusetts Gambling Screen score for current problem/pathological gambling, the Minnesota Impulsive Disorders Interview score for compulsive sexual behavior and buying, and Diagnostic and Statistical Manual of Mental Disorders research criteria for binge-eating disorder.
Results: An ICD was identified in 13.6% of patients (gambling in 5.0%, compulsive sexual behavior in 3.5%, compulsive buying in 5.7%, and binge-eating disorder in 4.3%), and 3.9% had 2 or more ICDs. Impulse control disorders were more common in patients treated with a dopamine agonist than in patients not taking a dopamine agonist (17.1% vs 6.9%; odds ratio [OR], 2.72; 95% confidence interval [CI], 2.08-3.54; P<.001). Impulse control disorder frequency was similar for pramipexole and ropinirole (17.7% vs 15.5%; OR, 1.22; 95% CI, 0.94-1.57; P=.14). Additional variables independently associated with ICDs were levodopa use, living in the United States, younger age, being unmarried, current cigarette smoking, and a family history of gambling problems.
Conclusions: Dopamine agonist treatment in PD is associated with 2-to 3.5-fold increased odds of having an ICD. This association represents a drug class relationship across ICDs. The association of other demographic and clinical variables with ICDs suggests a complex relationship that requires additional investigation to optimize prevention and treatment strategies.
C1 [Weintraub, Daniel; Siderowf, Andrew D.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Potenza, Marc N.] Yale Univ, Sch Med, New Haven, CT USA.
[Stacy, Mark] Duke Univ, Med Ctr, Durham, NC USA.
[Voon, Valerie; Lang, Anthony E.] Univ Toronto, Toronto, ON, Canada.
[Whetteckey, Jacqueline] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA.
[Wunderlich, Glen R.] Boehringer Ingelheim Canada Ltd, Burlington, ON, Canada.
[Koester, Juergen] Boehringer Ingelheim pharm GmbH & Co KG, Ingelheim, Germany.
RP Weintraub, D (reprint author), Univ Penn, Sch Med, 3615 Chestnut St,Room 330, Philadelphia, PA 19104 USA.
EM daniel.weintraub@uphs.upenn.edu
FU Boehringer Ingelheim; BrainCells; Merck Serono; Novartis; Ovation;
Wyeth; Somaxon; Mohegan Sun Casino; Forest Laboratories pharmaceuticals;
National Center for Responsible Gaming and its affiliate; Institute for
Research on Gambling Disorders; Teva; Allergan; Osmotica; Biogen;
General Electric; Kyowa; Neurologix; Synosia; Ceregene; Eisai;
Medtronic; Prestwick; Solvay; Taro
FX Dr Weintraub has received consulting fees, honoraria, or grant support
from Boehringer Ingelheim, BrainCells, Merck Serono, Novartis, Ovation,
and Wyeth. Dr Potenza has received consulting fees or honoraria from
Boehringer Ingelheim, has consulted for and has financial interests in
Somaxon, has received research support from Mohegan Sun Casino and
Forest Laboratories pharmaceuticals, and has consulted for law offices
and the federal public defender's office on issues related to ICDs. He
has also received support from the National Center for Responsible
Gaming and its affiliate, the Institute for Research on Gambling
Disorders. Dr Siderowf has received consulting fees or honoraria from
Boehringer Ingelheim, Merck Serono, and Teva. Dr Stacy has received
consulting fees or honoraria from Allergan, Boehringer Ingelheim,
Osmotica, Biogen, General Electric, Kyowa, Neurologix, Novartis,
Synosia, and Teva. Dr Lang has received consulting fees or honoraria
from Boehringer Ingelheim, Ceregene, Eisai, Medtronic, Novartis,
Prestwick, Merck Serono, Solvay, Taro, and Teva.
NR 35
TC 488
Z9 497
U1 5
U2 41
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD MAY
PY 2010
VL 67
IS 5
BP 589
EP 595
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 593OF
UT WOS:000277467000011
PM 20457959
ER
PT J
AU Yu, CE
Marchani, E
Nikisch, G
Muller, U
Nolte, D
Hertel, A
Wijsman, EM
Bird, TD
AF Yu, Chang-En
Marchani, Elizabeth
Nikisch, Georg
Mueller, Ulrich
Nolte, Dagmar
Hertel, Andreas
Wijsman, Ellen M.
Bird, Thomas D.
TI The N141I Mutation in PSEN2 Implications for the Quintessential Case of
Alzheimer Disease
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID AUGUSTE D; CHROMOSOME-1; PATIENT; LOCUS
AB Objective: To connect a new family with early-onset Alzheimer disease (EOAD) in Germany to the American Volga German pedigrees.
Design: Pedigree molecular genetic analysis.
Setting: University Medical Centers in Fulda and Giessen, Germany, and in Seattle, Washington.
Results: The families from Fulda, Germany, and the American Volga German families with EOAD share the same N141I PSEN2 mutation on an identical haplotypic background. This establishes that the N141I mutation occurred prior to emigration of the families from the Hesse region to Russia in the 1760s, and documents that relatives of the original immigrant families are presently living in Germany with the mutation and the disease.
Conclusion: A family with the N141I mutation in PSEN2 that presently lives in Germany has been connected to the haplotype that carries the same mutation in pedigrees descended from the Volga Germans. This raises the possibility that the original patient with Alzheimer disease (Auguste D.), who had EOAD and lived in this same region of Germany, may also have had the PSEN2 N141I mutation.
C1 [Yu, Chang-En; Bird, Thomas D.] Univ Washington, Geriatr Res Educ & Clin Ctr, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Bird, Thomas D.] Univ Washington, Dept Neurol, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Marchani, Elizabeth; Wijsman, Ellen M.; Bird, Thomas D.] Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Nikisch, Georg] Klinikum Fulda GAG, Dept Psychiat & Psychotherapy, Fulda, Germany.
[Hertel, Andreas] Klinikum Fulda GAG, Dept Nucl Med, Fulda, Germany.
[Mueller, Ulrich; Nolte, Dagmar] Univ Giessen, Inst Humangenet, Giessen, Germany.
RP Bird, TD (reprint author), Univ Washington, Geriatr Res Educ & Clin Ctr, Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-182 GRECC, Seattle, WA 98108 USA.
EM tomnroz@u.washington.edu
FU Veterans Affairs Research funds; National Institutes of Health/National
Institute on Aging [AG005136-24]
FX This study was supported by Veterans Affairs Research funds and National
Institutes of Health/National Institute on Aging grant AG005136-24.
NR 9
TC 9
Z9 10
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD MAY
PY 2010
VL 67
IS 5
BP 631
EP 633
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 593OF
UT WOS:000277467000017
PM 20457965
ER
PT J
AU Koontz, AM
Brindle, ED
Kankipati, P
Feathers, D
Cooper, RA
AF Koontz, Alicia M.
Brindle, Eric D.
Kankipati, Padmaja
Feathers, David
Cooper, Rory A.
TI Design Features That Affect the Maneuverability of Wheelchairs and
Scooters
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Architectural accessibility; Rehabilitation; Wheelchairs
ID USERS; PARTICIPATION; PROPULSION; POSITION; RECLINE; TILT
AB Objective: To determine the minimum space required for wheeled mobility device users to perform 4 maneuverability tasks and to investigate the impact of selected design attributes on space.
Design: Case series.
Setting: University laboratory, Veterans Affairs research facility, vocational training center, and a national wheelchair sport event.
Participants: The sample of convenience included manual wheelchair (MWC; n=109), power wheelchair (PWC; n=100), and scooter users (n=14).
Intervention: A mock environment was constructed to create passageways to form an L-turn, 360 degrees-turn in place, and a U-turn with and without a barrier. Passageway openings were increased in 5-cm increments until the user could successfully perform each task without hitting the walls. Structural dimensions of the device and user were collected using an electromechanical probe. Mobility devices were grouped into categories based on design features and compared using I-way analysis of variance and post hoc pairwise Bonferroni-corrected tests.
Main Outcome Measure: Minimum passageway widths for the 4 maneuverability tasks.
Results: Ultra light MWCs with rear axles posterior to the shoulder had the shortest lengths and required the least amount of space compared with all other types of MWCs (P<.05). Mid-wheel-drive PWCs required the least space for the 360 degrees-turn in place compared with front-wheel-drive and rear-wheel-drive PWCs (P<.01) but performed equally as well as front-wheel-drive models on all other turning tasks. PWCs with seat functions required more space to perform the tasks.
Conclusions: Between 10% and 100% of users would not be able to maneuver in spaces that meet current Accessibility Guidelines for Buildings and Facilities specifications. This study provides data that can be used to support wheelchair prescription and home modifications and to update standards to improve the accessibility of public areas.
C1 [Koontz, Alicia M.; Brindle, Eric D.; Kankipati, Padmaja; Cooper, Rory A.] Vet Affairs Pittsburgh HealthCare Syst, Human Engn Res Labs, Pittsburgh, PA USA.
[Koontz, Alicia M.; Brindle, Eric D.; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA.
[Koontz, Alicia M.; Kankipati, Padmaja; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
[Feathers, David] Cornell Univ, Dept Design & Environm Analy, Ithaca, NY USA.
RP Koontz, AM (reprint author), VA Pittsburgh Hlth Care Syst, Human Engn Res Labs 151R1H, 7180 Highland Dr,151R1-H, Pittsburgh, PA 15206 USA.
EM akoontz@pitt.edu
FU United States Access Board [070213]; Department of Veterans Affairs
Rehabilitation Research & Development Service [B3142C]; National Science
Foundation [EEC 0552351]
FX Supported by the United States Access Board (project no. 070213).
Department of Veterans Affairs Rehabilitation Research & Development
Service (project no. B3142C), and the National Science Foundation (grant
no. EEC 0552351).
NR 14
TC 10
Z9 10
U1 3
U2 14
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD MAY
PY 2010
VL 91
IS 5
BP 759
EP 764
DI 10.1016/j.apmr.2010.01.009
PG 6
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 594LK
UT WOS:000277539000013
PM 20434614
ER
PT J
AU Chang, A
Hochberg, M
Song, J
Dunlop, D
Chmiel, JS
Nevitt, M
Hayes, K
Eaton, C
Bathon, J
Jackson, R
Kwoh, CK
Sharma, L
AF Chang, Alison
Hochberg, Marc
Song, Jing
Dunlop, Dorothy
Chmiel, Joan S.
Nevitt, Michael
Hayes, Karen
Eaton, Charles
Bathon, Joan
Jackson, Rebecca
Kwoh, C. Kent
Sharma, Leena
TI Frequency of Varus and Valgus Thrust and Factors Associated With Thrust
Presence in Persons With or at Higher Risk of Developing Knee
Osteoarthritis
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID MAXIMAL ISOMETRIC STRENGTH; AFRICAN-AMERICANS; MUSCLE STRENGTH; WEDGED
INSOLES; WOMEN; MEN; CAUCASIANS; ALIGNMENT; HEALTHY; PROJECT
AB Objective. Varus thrust observed during gait has been shown to be associated with a 4-fold increase in the risk of medial knee osteoarthritis (OA) progression. Valgus thrust is believed to be less common than varus thrust; the prevalence of each is uncertain. Racial differences in risk factors may help explain variations in the natural history of knee OA. We undertook this study to determine the frequency of varus and valgus thrust in African Americans and Caucasians and to identify factors associated with thrust presence.
Methods. The Osteoarthritis Initiative cohort includes men and women who have knee OA or are at increased risk of developing it. Trained examiners assessed thrust presence by gait observation. Logistic regression with generalized estimating equations was used to identify factors associated with thrust presence, and odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated.
Results. Compared with Caucasians, African Americans had lower odds of varus thrust, controlling for age, sex, body mass index (BMI), injury, surgery, disease severity, strength, pain, and alignment in persons without knee OA (adjusted OR 0.50 [95% CI 0.36, 0.72]) and in those with knee OA (adjusted OR 0.46 [95% CI 0.34, 0.61]). Also independently associated with varus thrust were age, sex, BMI, disease severity, strength, and alignment. The odds of valgus thrust were greater for African Americans than for Caucasians in persons without knee OA (adjusted OR 1.69 [95% CI 1.02, 2.80]) and in those with knee OA (adjusted OR 1.98 [95% CI 1.35, 2.91]). Also independently associated with valgus thrust were disease severity and malalignment.
Conclusion. Compared with Caucasians, African Americans had lower odds of varus thrust and greater odds of valgus thrust. These findings may help explain the difference between these groups in the pattern of OA involvement at the knee.
C1 [Sharma, Leena] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA.
[Hochberg, Marc] Univ Maryland, Baltimore, MD 21201 USA.
[Nevitt, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Eaton, Charles] Brown Univ, Pawtucket, RI USA.
[Bathon, Joan] Johns Hopkins Univ, Baltimore, MD USA.
[Jackson, Rebecca] Ohio State Univ, Columbus, OH 43210 USA.
[Kwoh, C. Kent] Univ Pittsburgh, Pittsburgh, PA USA.
[Kwoh, C. Kent] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Sharma, L (reprint author), Northwestern Univ, Feinberg Sch Med, Div Rheumatol, 240 E Huron St,Suite M300, Chicago, IL 60611 USA.
EM L-Sharma@northwestern.edu
RI Chang, Alison/D-8203-2011
OI Chang, Alison/0000-0001-7309-9687
FU NIH (National Institute of Arthritis and Musculoskeletal and Skin
Diseases [NIAMS]) [R01-AR-52918]; OAI; NIH [N01-AR-2-2258,
N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262]; Merck
Research Laboratories; Novartis Pharmaceuticals Corporation;
GlaxoSmithKline; Pfizer, Inc.; Roche; Crescendo Biosciences
FX Supported by the NIH (National Institute of Arthritis and
Musculoskeletal and Skin Diseases [NIAMS] grant R01-AR-52918) and the
OAI. The OAI is a public-private partnership comprising five contracts
(N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, and
N01-AR-2-2262) funded by the NIH and conducted by the OAI Study
Investigators. Private funding partners include Merck Research
Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and
Pfizer, Inc. Private sector funding for the OAI is managed by the
Foundation for the NIH. This article was prepared using an OAI public
use data set in addition to data obtained within an NIH/NIAMS-funded
ancillary grant.; Dr. Hayes receives royalties for the Manual for
Physical Agents, 5th edition, Prentice Hall, 2000. Dr. Bathon has
received consulting fees, speaking fees, and/or honoraria from Roche
(less than $10,000) and Crescendo Biosciences (more than $10,000).
NR 23
TC 22
Z9 23
U1 0
U2 5
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD MAY
PY 2010
VL 62
IS 5
BP 1403
EP 1411
DI 10.1002/art.27377
PG 9
WC Rheumatology
SC Rheumatology
GA 619LT
UT WOS:000279432400023
PM 20213800
ER
PT J
AU Chu, CR
Williams, A
Tolliver, D
Kwoh, CK
Bruno, S
Irrgang, JJ
AF Chu, Constance R.
Williams, Ashley
Tolliver, David
Kwoh, C. Kent
Bruno, Stephen, III
Irrgang, James J.
TI Clinical Optical Coherence Tomography of Early Articular Cartilage
Degeneration in Patients With Degenerative Meniscal Tears
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID ANTERIOR CRUCIATE LIGAMENT; KNEE OSTEOARTHRITIS; MRI; T2; DEGRADATION;
RUPTURE; DISEASE; IMPACT; REPAIR; T-2
AB Objective. Quantitative and nondestructive methods for clinical diagnosis and staging of articular cartilage degeneration are important to the evaluation of potential disease-modifying treatments in osteoarthritis (OA). Optical coherence tomography (OCT) is a novel imaging technology that can generate microscopic-resolution cross-sectional images of articular cartilage in near real-time. This study tested the hypotheses that OCT can be used clinically to identify early cartilage degeneration and that OCT findings correlate with magnetic resonance imaging (MRI) T2 values and arthroscopy results.
Methods. Patients undergoing arthroscopy for degenerative meniscal tears were recruited under Institutional Review Board-approved protocols. Thirty consecutive subjects completing preoperative 3.0T MRI, arthroscopy, and intraoperative OCT comprised the study group. Qualitative and quantitative OCT results and MRI T2 values were compared with modified Outerbridge cartilage degeneration scores (0-4 scale) assigned at arthroscopy.
Results. Arthroscopic grades showed cartilage abnormality in 23 of the 30 patients. OCT grades were abnormal in 28 of the 30 patients. Both qualitative and quantitative OCT strongly correlated with the arthroscopy results (P = 0.004 and P = 0.0002, respectively, by Kruskal-Wallis test). Neither the superficial nor the deep cartilage T2 values correlated with the arthroscopy results. The quantitative OCT results correlated with the T2 values in the superficial cartilage (Pearson's r = 0.39, P = 0.03).
Conclusion. These data show that OCT can be used clinically to provide qualitative and quantitative assessments of early articular cartilage degeneration that strongly correlate with arthroscopy results. The correlation between the quantitative OCT values and T2 values for the superficial cartilage further supports the utility of OCT as a clinical research tool, providing quantifiable microscopic resolution data on the articular cartilage structure. New technologies for nondestructive quantitative assessment of human articular cartilage degeneration may facilitate the development of strategies to delay or prevent the onset of OA.
C1 [Chu, Constance R.] Univ Pittsburgh, Cartilage Restorat Ctr, Pittsburgh, PA 15213 USA.
[Tolliver, David] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
[Kwoh, C. Kent] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Chu, CR (reprint author), Univ Pittsburgh, Cartilage Restorat Ctr, 3471 5th Ave,Suite 911, Pittsburgh, PA 15213 USA.
EM chucr@upmc.edu
FU NIH [1-R01-AR-052784-CRC]
FX Supported by the NIH (grant 1-R01-AR-052784-CRC).
NR 35
TC 37
Z9 39
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD MAY
PY 2010
VL 62
IS 5
BP 1412
EP 1420
DI 10.1002/art.27378
PG 9
WC Rheumatology
SC Rheumatology
GA 619LT
UT WOS:000279432400024
PM 20213801
ER
PT J
AU Cavusoglu, E
Ruwende, C
Chopra, V
Poludasu, S
Yanamadala, S
Frishman, WH
Eng, C
Pinsky, DJ
Marmur, JD
AF Cavusoglu, Erdal
Ruwende, Cyril
Chopra, Vineet
Poludasu, Shyam
Yanamadala, Sunitha
Frishman, William H.
Eng, Calvin
Pinsky, David J.
Marmur, Jonathan D.
TI Relation of baseline plasma ADMA levels to cardiovascular morbidity and
mortality at two years in men with diabetes mellitus referred for
coronary angiography
SO ATHEROSCLEROSIS
LA English
DT Article
DE Biomarker; Nitric oxide; ADMA; Diabetes mellitus; Myocardial infarction;
Prognosis
ID ASYMMETRIC DIMETHYLARGININE ADMA; NITRIC-OXIDE SYNTHASE; ENDOTHELIAL
DYSFUNCTION; ENDOGENOUS INHIBITOR; OXIDATIVE STRESS; ARTERY-DISEASE;
EVENTS; RISK; NEPHROPATHY; DEATH
AB Background: Patients with diabetes mellitus (DM) have been shown to have higher levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide (NO) synthase. Higher plasma levels of ADMA have been implicated in the pathogenesis of endothelial dysfunction and atherosclerosis by lowering NO levels. High baseline plasma levels of ADMA in patients with DM have been shown to predict diabetes related complications. However, there are limited data on the prognostic significance of baseline ADMA levels in patients with established DM.
Methods: The present study investigated the long-term prognostic significance of baseline plasma ADMA levels in a well-characterized cohort of 170 high-risk diabetic men with known or suspected coronary artery disease who were referred for coronary angiography. All patients were followed prospectively for the development of vascular outcomes, including all-cause mortality.
Results: After controlling for a variety of baseline variables (including established biomarkers such as hs-CRP and fibrinogen), plasma ADMA levels (analyzed as the upper tertile of baseline values compared with the lower two tertiles) were a strong and independent predictor of all-cause mortality (HR 2.63, 95% CI 1.13-6.11, p = 0.0247) when using a Cox proportional hazards model. In addition, baseline ADMA values were also an independent predictor of the composite outcome of all-cause mortality or MI (fatal or non-fatal) (HR 2.44, 95% CI 1.26-4.72, p = 0.0079), as well as the composite outcome of all-cause mortality, MI (fatal or nonfatal), or stroke (HR 2.00, 95% CI 1.10-3.62, p = 0.0232).
Conclusion: These data demonstrate that elevated baseline levels of ADMA are a strong and independent predictor of cardiovascular outcomes (including all-cause mortality) in patients with DM. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Cavusoglu, Erdal; Poludasu, Shyam; Marmur, Jonathan D.] Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA.
[Cavusoglu, Erdal; Chopra, Vineet; Eng, Calvin] Bronx Vet Affairs Med Ctr, Dept Med, Div Cardiol, Bronx, NY USA.
[Ruwende, Cyril; Yanamadala, Sunitha; Pinsky, David J.] Univ Michigan, Dept Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA.
[Frishman, William H.] New York Med Coll, Dept Med, Westchester Med Ctr, Valhalla, NY 10595 USA.
RP Cavusoglu, E (reprint author), Suny Downstate Med Ctr, Dept Med, Div Cardiol, 450 Clarkson Ave,Box 1199, Brooklyn, NY 11203 USA.
EM ECavusoglu@aol.com
NR 31
TC 37
Z9 38
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2010
VL 210
IS 1
BP 226
EP 231
DI 10.1016/j.atherosclerosis.2009.10.034
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 588PR
UT WOS:000277085300037
PM 19944421
ER
PT J
AU Turner, AP
Jakupcak, M
AF Turner, Aaron P.
Jakupcak, Matthew
TI Behavioral Activation for Treatment of PTSD and Depression in an Iraqi
Combat Veteran with Multiple Physical Injuries
SO BEHAVIOURAL AND COGNITIVE PSYCHOTHERAPY
LA English
DT Article
DE Behavioral activation; PTSD; depression; rehabilitation; veteran
ID POSTTRAUMATIC-STRESS-DISORDER; AFGHANISTAN; THERAPY; WAR
AB Background: Physical injury and psychological trauma associated with combat in the wars in Iraq and Afghanistan frequently lead to a constellation of symptoms including pain, post traumatic stress disorder (PTSD), and depression. Method: This single case study describes the application of a behaviorally-based psychotherapy known as behavioral activation for the treatment of post traumatic stress disorder (PTSD) and depressive symptoms in a recent combat veteran with multiple physical injuries sustained from a blast injury. Treatment was provided concurrently with other rehabilitation services and consisted of weekly individual sessions for 4 months, followed by monthly sessions for 4 months. Results: Clinically significant reductions in PTSD and depressive symptoms were noted between baseline and 1 year follow-up. Conclusion: Preliminary evidence from this case suggests that behavioral activation may be a promising treatment for PTSD and depression, and can be readily tailored to individuals with physical limitations such as pain and mobility restriction. Treatment can be provided in the context of concurrent interdisciplinary medical and rehabilitation care.
C1 [Turner, Aaron P.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA.
Univ Washington, Seattle, WA 98195 USA.
RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117-RCS,1660 S Columbian Way, Seattle, WA 98108 USA.
EM aaron.turner@va.gov
OI Turner, Aaron/0000-0001-6897-8003
NR 17
TC 8
Z9 9
U1 0
U2 5
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1352-4658
J9 BEHAV COGN PSYCHOTH
JI Behav. Cognit. Psychther.
PD MAY
PY 2010
VL 38
IS 3
BP 355
EP 361
DI 10.1017/S1352465810000081
PG 7
WC Psychology, Clinical
SC Psychology
GA 603LC
UT WOS:000278209100007
PM 20374670
ER
PT J
AU Koenigsberg, HW
Fan, J
Liu, X
Guise, K
Ochsner, KN
Guerreri, S
New, AS
Goodman, M
Siever, LJ
AF Koenigsberg, Harold W.
Fan, Jin
Liu, Xun
Guise, Kevin
Ochsner, Kevin N.
Guerreri, Stephanie
New, Antonia S.
Goodman, Marianne
Siever, Larry J.
TI Sensitization and Habituation of Neural Networks in Response to Aversive
Social Cues in Borderline and Avoidant Personality Disorder Patients
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 65th Annual Convention of the Society-of-Biological-Psychiatry
CY MAY 20-22, 2010
CL New Orleans, LA
SP Soc Biol Psychiat
C1 [Koenigsberg, Harold W.; Fan, Jin; Liu, Xun; Guise, Kevin; Guerreri, Stephanie; New, Antonia S.; Goodman, Marianne; Siever, Larry J.] Mt Sinai Sch Med, New York, NY USA.
[Koenigsberg, Harold W.; New, Antonia S.; Goodman, Marianne; Siever, Larry J.] James J Peters VA Med Ctr, New York, NY USA.
[Ochsner, Kevin N.] Columbia Univ, Dept Psychol, New York, NY 10027 USA.
RI Liu, Xun/C-2400-2009
OI Liu, Xun/0000-0003-1366-8926
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2010
VL 67
IS 9
SU S
MA 59
BP 19S
EP 19S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 588IX
UT WOS:000277064200059
ER
PT J
AU Shiovitz, RN
Mitsis, EM
Weiner, DM
Bang, C
Elder, GA
Tang, CY
Hazlett, EA
AF Shiovitz, Rachel N.
Mitsis, Effie M.
Weiner, Daniel M.
Bang, Charlene
Elder, Gregory A.
Tang, Cheuk Y.
Hazlett, Erin A.
TI Relationship between DTI White Matter Abnormalities and Impulsivity in
OIF/OEF Combat Veterans with Blast-Related Mild TBI
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 65th Annual Convention of the Society-of-Biological-Psychiatry
CY MAY 20-22, 2010
CL New Orleans, LA
SP Soc Biol Psychiat
C1 [Shiovitz, Rachel N.; Mitsis, Effie M.; Bang, Charlene; Tang, Cheuk Y.; Hazlett, Erin A.] Mt Sinai Sch Med, New York, NY USA.
[Hazlett, Erin A.] James J Peters VAMC, MIRECC, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2010
VL 67
IS 9
SU S
MA 154
BP 48S
EP 48S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 588IX
UT WOS:000277064200154
ER
PT J
AU Mitsis, EM
Shiovitz, R
Nikolskaya, G
Elder, G
Bang, C
Cristian, A
Hazlett, E
Buchsbaum, MS
AF Mitsis, Effie M.
Shiovitz, Rachel
Nikolskaya, Galina
Elder, Gregory
Bang, Charlene
Cristian, Adrian
Hazlett, Erin
Buchsbaum, Monte S.
TI FDG-PET Regional Glucose Abnormalities in White Matter in Civilian
Impact and Military Blast-Related Mild Traumatic Brain Injury
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 65th Annual Convention of the Society-of-Biological-Psychiatry
CY MAY 20-22, 2010
CL New Orleans, LA
SP Soc Biol Psychiat
C1 [Mitsis, Effie M.; Shiovitz, Rachel; Elder, Gregory; Bang, Charlene; Cristian, Adrian; Hazlett, Erin] Mt Sinai Sch Med, New York, NY USA.
[Mitsis, Effie M.; Elder, Gregory; Bang, Charlene; Cristian, Adrian] James J Peters VAMC, Bronx, NY USA.
[Nikolskaya, Galina; Buchsbaum, Monte S.] Univ Calif San Diego, San Diego, CA 92103 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2010
VL 67
IS 9
SU S
MA 521
BP 150S
EP 150S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 588IX
UT WOS:000277064200477
ER
PT J
AU Rosell, DR
Thompson, JL
Slifstein, M
Xu, XY
Frankle, WG
New, AS
Goodman, M
Weinstein, SC
Laruelle, M
Abi-Dargham, A
Siever, LJ
AF Rosell, Daniel R.
Thompson, Judy L.
Slifstein, Mark
Xu, Xiaoyan
Frankle, W. Gordon
New, Antonia S.
Goodman, Marianne
Weinstein, Shauna C.
Laruelle, Marc
Abi-Dargham, Anissa
Siever, Larry J.
TI Evidence Increased 5-HT2A Receptor Availability in the Orbitofrontal
Cortex is Associated with Impulsive Physical Aggression in a State
Dependent Manner
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 65th Annual Convention of the Society-of-Biological-Psychiatry
CY MAY 20-22, 2010
CL New Orleans, LA
SP Soc Biol Psychiat
C1 [Rosell, Daniel R.; New, Antonia S.; Goodman, Marianne; Weinstein, Shauna C.; Siever, Larry J.] James J Peters VA Med Ctr, Bronx, NY USA.
[Thompson, Judy L.; Slifstein, Mark; Xu, Xiaoyan; Abi-Dargham, Anissa] Columbia Univ, Med Ctr, New York, NY USA.
[Thompson, Judy L.; Slifstein, Mark; Xu, Xiaoyan; Abi-Dargham, Anissa] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Frankle, W. Gordon] Univ Pittsburgh, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA.
[Laruelle, Marc] Imperial Coll London, London, England.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2010
VL 67
IS 9
SU S
MA 848
BP 246S
EP 246S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 588IX
UT WOS:000277064200778
ER
PT J
AU Pence, SG
Gard, DE
Cooper, S
Grotewold, S
Mahayni, A
Woo, J
Fisher, M
Vinogradov, S
AF Pence, Sunny G.
Gard, David E.
Cooper, Shanna
Grotewold, Susan
Mahayni, Ali
Woo, Jessica
Fisher, Melissa
Vinogradov, Sophia
TI Reducing Cognitive Demand in Ecological Momentary Assessment in
Schizophrenia: A Feasibility Study Using Cellular Telephones
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 65th Annual Convention of the Society-of-Biological-Psychiatry
CY MAY 20-22, 2010
CL New Orleans, LA
SP Soc Biol Psychiat
C1 [Pence, Sunny G.; Gard, David E.; Cooper, Shanna; Grotewold, Susan; Mahayni, Ali; Woo, Jessica; Fisher, Melissa] San Francisco State Univ, San Francisco, CA 94132 USA.
[Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2010
VL 67
IS 9
SU S
MA 896
BP 262S
EP 262S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 588IX
UT WOS:000277064200826
ER
PT J
AU Sakurai, T
Ramoz, N
Barreto, M
Gazdoiu, M
Takahashi, N
Gertner, M
Dorr, N
Sosa, MAG
De Gasperi, R
Perez, G
Schmeidler, J
Mitropoulou, V
Le, HC
Lupu, M
Hof, PR
Elder, GA
Buxbaum, JD
AF Sakurai, Takeshi
Ramoz, Nicolas
Barreto, Marta
Gazdoiu, Mihaela
Takahashi, Nagahide
Gertner, Michael
Dorr, Nathan
Sosa, Miguel A. Gama
De Gasperi, Rita
Perez, Gissel
Schmeidler, James
Mitropoulou, Vivian
Le, H. Carl
Lupu, Mihaela
Hof, Patrick R.
Elder, Gregory A.
Buxbaum, Joseph D.
TI Slc25a12 Disruption Alters Myelination and Neurofilaments: A Model for a
Hypomyelination Syndrome and Childhood Neurodevelopmental Disorders
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Malate/aspartate shuttle; mitochondria; N-acetylaspartate (NAA);
neuron-oligodendrocyte interactions; pyruvate
ID MAGNETIC-RESONANCE-SPECTROSCOPY; AUTISM SPECTRUM DISORDERS;
ASPARTATE-GLUTAMATE; BRAIN-METABOLITES; WHITE-MATTER; CARRIER; GENE;
ASSOCIATION; CHILDREN; MITOCHONDRIA
AB Background: SLC25A12, a susceptibility gene for autism spectrum disorders that is mutated in a neurodevelopmental syndrome, encodes a mitochondrial aspartate-glutamate carrier (aspartate-glutamate carrier isoform 1 [AGC1]). AGC1 is an important component of the malate/aspartate shuttle, a crucial system supporting oxidative phosphorylation and adenosine triphosphate production.
Methods: We characterized mice with a disruption of the Slc25a12 gene, followed by confirmatory in vitro studies.
Results: Slc25a12-knockout mice, which showed no AGC1 by immunoblotting, were born normally but displayed delayed development and died around 3 weeks after birth. In postnatal day 13 to 14 knockout brains, the brains were smaller with no obvious alteration in gross structure. However, we found a reduction in myelin basic protein (MBP)-positive fibers, consistent with a previous report. Furthermore, the neocortex of knockout mice contained abnormal neurofilamentous accumulations in neurons, suggesting defective axonal transport and/or neurodegeneration. Slice cultures prepared from knockout mice also showed a myelination defect, and reduction of Slc25a12 in rat primary oligodendrocytes led to a cell-autonomous reduction in MBP expression. Myelin deficits in slice cultures from knockout mice could be reversed by administration of pyruvate, indicating that reduction in AGC1 activity leads to reduced production of aspartate/N-acetylaspartate and/or alterations in the dihydronicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide(+) ratio, resulting in myelin defects.
Conclusions: Our data implicate AGC1 activity in myelination and in neuronal structure and indicate that while loss of AGC1 leads to hypomyelination and neuronal changes, subtle alterations in AGC1 expression could affect brain development, contributing to increased autism susceptibility.
C1 [Sakurai, Takeshi; Ramoz, Nicolas; Barreto, Marta; Gazdoiu, Mihaela; Takahashi, Nagahide; Gertner, Michael; Dorr, Nathan; Sosa, Miguel A. Gama; De Gasperi, Rita; Perez, Gissel; Schmeidler, James; Mitropoulou, Vivian; Elder, Gregory A.; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Sakurai, Takeshi; Ramoz, Nicolas; Buxbaum, Joseph D.] Mt Sinai Sch Med, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA.
[Sakurai, Takeshi] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
[Sakurai, Takeshi] Mt Sinai Sch Med, Black Family Stem Cell Inst, New York, NY 10029 USA.
[Hof, Patrick R.; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA.
[Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA.
[Le, H. Carl; Lupu, Mihaela] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA.
[Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY USA.
RP Buxbaum, JD (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1668, New York, NY 10029 USA.
EM joseph.buxbaum@mssm.edu
RI Le, Hongbiao /H-4735-2011; Barreto, Marta/F-5591-2012; ramoz,
nicolas/K-3316-2015
OI Barreto, Marta/0000-0001-6464-548X; Buxbaum, Joseph/0000-0001-8898-8313
FU New York State Spinal Cord Injury [C020935]; Stanley Medical Research
Institute [06R-1427]; Seaver Foundation; National Institute of Mental
Health [MH066673]; National Institutes of Health (NIH) [R24CA83084,
P30CA08748]
FX TS is a Seaver Fellow and supported in part by New York State Spinal
Cord Injury contract (C020935) and Stanley Medical Research Institute
research grant (06R-1427). This research was supported by the Seaver
Foundation (TS and JDB) and the National Institute of Mental Health
(MH066673, JDB). Technical services at the Memorial Sloan-Kettering
Cancer Center Small-Animal Imaging Core Facility were supported in part
by National Institutes of Health (NIH) Small-Animal Imaging Research
Program Grant R24CA83084 and NIH Center Grant P30CA08748.
NR 31
TC 23
Z9 25
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2010
VL 67
IS 9
BP 887
EP 894
DI 10.1016/j.biopsych.2009.08.042
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 588IW
UT WOS:000277064100013
PM 20015484
ER
PT J
AU Kilpatrick, LA
Ornitz, E
Ibrahimovic, H
Treanor, M
Craske, M
Nazarian, M
Labus, JS
Mayer, EA
Naliboff, BD
AF Kilpatrick, L. A.
Ornitz, E.
Ibrahimovic, H.
Treanor, M.
Craske, M.
Nazarian, M.
Labus, J. S.
Mayer, E. A.
Naliboff, B. D.
TI Sex-related differences in prepulse inhibition of startle in irritable
bowel syndrome (IBS)
SO BIOLOGICAL PSYCHOLOGY
LA English
DT Article
DE Irritable bowel syndrome; Functional bowel disorders; Acoustic startle
response; Prepulse inhibition of startle; Sex differences;
Hypervigilence
ID REGIONAL BRAIN RESPONSE; ACOUSTIC STARTLE; MENSTRUAL-CYCLE;
GASTROINTESTINAL-DISEASE; SCHIZOPHRENIA-PATIENTS; VISCERAL STIMULI;
SENSORIMOTOR; DISORDER; DEFICITS; MODULATION
AB Alterations in central networks involved in the regulation of arousal, attention, and cognition may be critical for irritable bowel syndrome (IBS) symptom maintenance and exacerbation. Differential sensitivities in these networks may underlie sex differences noted in IBS. The current study examined prepulse inhibition (PPI), a measure of sensorimotor gating, in male and female IBS patients. Relationships between PPI and symptom severity were examined, as well as potential menstrual status effects. Compared to healthy controls, male IBS patients had significantly reduced PPI; whereas female IBS patients (particularly naturally cycling women) had significantly enhanced PPI suggesting hypervigilance. Considering previously demonstrated sex-related differences in perceptual and brain imaging findings in IBS patients, the current findings suggest that different neurobiological mechanisms underlie symptom presentation in male and female IBS patients. Compromised filtering of information in male IBS patients may be due to compromised top down (prefrontal, midcingulate) control mechanisms while increased attention to threat due to increased limbic and paralimbic circuits may be characteristic of female IBS patients. Published by Elsevier B.V.
C1 [Kilpatrick, L. A.; Ornitz, E.; Ibrahimovic, H.; Labus, J. S.; Mayer, E. A.; Naliboff, B. D.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Los Angeles, CA 90073 USA.
[Ornitz, E.; Mayer, E. A.; Naliboff, B. D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90073 USA.
[Kilpatrick, L. A.; Mayer, E. A.] Univ Calif Los Angeles, Dept Physiol & Med, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90073 USA.
[Ornitz, E.; Labus, J. S.; Mayer, E. A.] Univ Calif Los Angeles, Brain Res Inst, David Geffen Sch Med, Los Angeles, CA 90073 USA.
[Treanor, M.; Craske, M.; Nazarian, M.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90073 USA.
[Naliboff, B. D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Naliboff, BD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, CURE Bld 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM naliboff@ucla.edu
RI Kilpatrick, Lisa/E-6995-2015
FU NIH [NR007768, P50 DK64539, R24 AT002681]; VA Medical Research
FX Supported in part by NIH grants NR007768 (BN), P50 DK64539 (EM), R24
AT002681 (EM), VA Medical Research (BN), and a gift from the Virginia
Friedhofer Charitable Trust (EO).
NR 59
TC 16
Z9 16
U1 2
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-0511
J9 BIOL PSYCHOL
JI Biol. Psychol.
PD MAY
PY 2010
VL 84
IS 2
BP 272
EP 278
DI 10.1016/j.biopsycho.2010.02.012
PG 7
WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology,
Experimental
SC Psychology; Behavioral Sciences
GA 616GQ
UT WOS:000279197500013
PM 20193731
ER
PT J
AU Saless, N
Franco, GEL
Litscher, S
Kattappuram, RS
Houlihan, MJ
Vanderby, R
Demant, P
Blank, RD
AF Saless, Neema
Franco, Gloria E. Lopez
Litscher, Suzanne
Kattappuram, Robbie S.
Houlihan, Meghan J.
Vanderby, Ray
Demant, Peter
Blank, Robert D.
TI Linkage mapping of femoral material properties in a reciprocal
intercross of HcB-8 and HcB-23 recombinant mouse strains
SO BONE
LA English
DT Article
DE Recombinant congenic mice; Biomechanics; Linkage mapping; Systems
biology; Bone quality
ID QUANTITATIVE TRAIT LOCI; CONGENIC MICE; MECHANICAL-PROPERTIES; GENETIC
DISSECTION; SKELETAL TRAITS; UTAH PARADIGM; BONE STRENGTH; RISK-FACTORS;
POPULATION; GEOMETRY
AB Skeletal fragility is an important health problem with a large genetic component. We performed a 603 animal F2 reciprocal intercross of the recombinant congenic strains HcB-8 and HcB-23 to genetically map quantitative trait loci (QTLs) for tissue-level femoral biomechanical performance. These included elastic and post-yield strain, Young's modulus, elastic and maximum stress, and toughness and were calculated from 3-point bend testing of femora by the application of standard beam equations. We mapped these with R/qtl and QTL Cartographer and established significance levels empirically by permutation testing. Significant QTLs for at least one trait are present on chromosomes 1, 6, and 10 in the full F2 population, with additional QTLs evident in subpopulations defined by sex and cross direction. On chromosome 10, we find a QTL for post-yield strain and toughness, phenotypes that have not been mapped previously. Notably, the HcB-8 allele at this QTL increases post-yield strain and toughness, but decreases bone mineral density (BMD), while the material property QTLs on chromosomes 1, 6, and at a second chromosome 10 QTL are independent of BMD. We find significant sex x QTL and cross direction x QTL interactions. A robust, pleiotropic chromosome 4 QTL that we previously reported at the whole-bone level showed no evidence of linkage at the tissue-level, supporting our interpretation that modeling capacity is its primary phenotype. Our data demonstrate an inverse relationship between femoral perimeter and Young's modulus, with R(2) = 0.27, supporting the view that geometric and material bone properties are subject to an integrated set of regulatory mechanisms. Mapping QTLs for tissue-level biomechanical performance advances understanding of the genetic basis of bone quality. Published by Elsevier Inc.
C1 [Saless, Neema; Franco, Gloria E. Lopez; Litscher, Suzanne; Kattappuram, Robbie S.; Houlihan, Meghan J.; Vanderby, Ray; Blank, Robert D.] Univ Wisconsin, Madison, WI USA.
[Saless, Neema; Franco, Gloria E. Lopez; Litscher, Suzanne; Blank, Robert D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Demant, Peter] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
RP Blank, RD (reprint author), H4-556 CSC 5148,600 Highland Ave, Madison, WI 53792 USA.
EM rdb@medicine.wisc.edu
OI Blank, Robert Daniel/0000-0003-2950-1944
FU Office of Research and Development; Biomedical Laboratory RD Service;
Department of Veterans Affairs; NIH [AR54753]
FX This material is based upon work supported by the Office of Research and
Development, Biomedical Laboratory R&D Service, Department of Veterans
Affairs (RDB) and performed in the Geriatrics Research, Education, and
Clinical Center at the William S. Middleton Memorial Veterans Hospital.
This report is Madison GRECC manuscript 2009-11. This work is also
supported in part by NIH grant AR54753 (RDB).
NR 45
TC 12
Z9 12
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD MAY
PY 2010
VL 46
IS 5
BP 1251
EP 1259
DI 10.1016/j.bone.2010.01.375
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 586VC
UT WOS:000276941000005
PM 20102754
ER
PT J
AU Watson, GS
Leverenz, JB
AF Watson, G. Stennis
Leverenz, James B.
TI Profile of Cognitive Impairment in Parkinson's Disease
SO BRAIN PATHOLOGY
LA English
DT Article
DE Parkinson's disease; dementia; cognitive impairment; neuropsychology
ID LEWY BODIES; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; WORKING-MEMORY;
DEMENTIA; INCIDENT; DEFICITS; NEUROPATHOLOGY; METAANALYSIS; PERFORMANCE
AB Cognitive impairment (CI) is a common nonmotor complication of Parkinson's disease (PD), and is associated with significant disability for patients and burden for caregivers. Similar to motor symptoms, the characteristics of CI in PD can be quite variable, both in terms of what cognitive domains are impaired, and the timing of onset and rate of progression. This review will examine the profile of cognitive domain impairments observed in PD, with a focus on early CI (without dementia). We will also discuss possible relationships between specific cognitive domain impairments in PD and pathological processes such as Lewy-related pathology and Alzheimer's disease. It is our hypothesis that the specific characteristics of CI observed in individual PD patients provide clues to the underlying pathological processes, and that understanding the biological basis of this clinical phenomenon will assist in directing disease-specific treatments. Given the high lifetime risk for CI in PD, it is imperative that we improve our understanding and treatments for this common and disabling problem in PD.
C1 [Leverenz, James B.] VA Puget Sound Hlth Care Syst, MIRECC 116MIRECC, Seattle Div, Mental Illness Ctr, Seattle, WA 98108 USA.
[Leverenz, James B.] VA Puget Sound Hlth Care Syst, MIRECC 116MIRECC, Seattle Div, Parkinsons Dis Ctr, Seattle, WA 98108 USA.
[Watson, G. Stennis] VA Puget Sound Hlth Care Syst, MIRECC 116MIRECC, Seattle Div, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA.
[Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Watson, G. Stennis; Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Leverenz, JB (reprint author), VA Puget Sound Hlth Care Syst, MIRECC 116MIRECC, Seattle Div, Mental Illness Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM leverenz@u.washington.edu
FU NIA NIH HHS [K01 AG023640, K01 AG023640-05]; NINDS NIH HHS [P50
NS062684, P50 NS062684-01A1, P50 NS062684-01A16220]; PHS HHS
[P50MS062684-01A1]
NR 58
TC 25
Z9 27
U1 4
U2 13
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1015-6305
J9 BRAIN PATHOL
JI Brain Pathol.
PD MAY
PY 2010
VL 20
IS 3
BP 640
EP 645
DI 10.1111/j.1750-3639.2010.00373.x
PG 6
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 582MQ
UT WOS:000276602100013
PM 20522089
ER
PT J
AU Liao, SL
Elmariah, S
van der Zee, S
Sealove, BA
Fuster, V
AF Liao, Steve L.
Elmariah, Sammy
van der Zee, Sarina
Sealove, Brett A.
Fuster, Valentin
TI Does Medical Therapy for Thoracic Aortic Aneurysms Really Work? Are
beta-Blockers Truly Indicated? CON
SO CARDIOLOGY CLINICS
LA English
DT Article
DE Aortic aneurysm; Medical therapy; beta-Dockers
ID ANGIOTENSIN-II BLOCKADE; SMOOTH-MUSCLE-CELLS; MARFAN-SYNDROME; MATRIX
METALLOPROTEINASES; ADRENERGIC-BLOCKADE; EXPANSION RATE; SIMVASTATIN
SUPPRESSES; EXTRACELLULAR-MATRIX; ROOT DILATION; DOUBLE-BLIND
AB Thoracic aortic aneurysms (TAA) often represent the final manifestation of hereditary or degenerative disease processes. TAA are primarily caused by age-related degenerative changes. In this article, the authors highlight the most common pathophysiologic mechanisms responsible for TAA formation and review the paucity of evidence supporting the spectrum of medical therapies for TAA other than renin-angiotensin inhibition. More clinical trials on TAA are required before medical therapies such as beta-blockers, statins, and macrolide antibiotics can be recommended.
C1 [Liao, Steve L.; Elmariah, Sammy; van der Zee, Sarina; Sealove, Brett A.; Fuster, Valentin] Mt Sinai Sch Med, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA.
[Liao, Steve L.] James J Peters Vet Affairs Med Ctr, Dept Med, Div Cardiovasc, Bronx, NY USA.
[Fuster, Valentin] Ctr Nacl Invest Cardiovasc, Madrid, Spain.
RP Fuster, V (reprint author), Mt Sinai Sch Med, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, Zena & Michael A Wiener Cardiovasc Inst, 1 Gustave L Levy Pl,Box 1030, New York, NY 10029 USA.
EM valentin.fuster@mssm.edu
RI Fuster, Valentin/H-4319-2015
OI Fuster, Valentin/0000-0002-9043-9986
NR 75
TC 3
Z9 3
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8651
J9 CARDIOL CLIN
JI Cardiol. Clin.
PD MAY
PY 2010
VL 28
IS 2
BP 261
EP +
DI 10.1016/j.cc1.2010.01.002
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 604UT
UT WOS:000278304700016
PM 20452539
ER
PT J
AU Ghosh-Choudhury, N
Mandal, CC
Ghosh-Choudhury, N
Choudhury, GG
AF Ghosh-Choudhury, Nayana
Mandal, Chandi Charan
Ghosh-Choudhury, Nandini
Choudhury, Goutam Ghosh
TI Simvastatin induces derepression of PTEN expression via NF kappa B to
inhibit breast cancer cell growth
SO CELLULAR SIGNALLING
LA English
DT Article
DE Statin; Breast tumor; Bcl(XL); Akt kinase
ID HMG-COA REDUCTASE; TUMOR-SUPPRESSOR PTEN; PROTEIN-KINASE; IN-VITRO;
COLORECTAL-CANCER; SIGNALING PATHWAY; INDUCED APOPTOSIS; PI3K PATHWAY;
COLON CARCINOGENESIS; AKT/MAMMALIAN TARGET
AB Sustained activation of Akt kinase acts as a focal regulator to increase cell growth and survival, which causes tumorigenesis including breast cancer. Statins, potent inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, display anticancer activity. The molecular mechanisms by which statins block cancer cell growth are poorly understood. We demonstrate that in the tumors derived from MDA-MB-231 human breast cancer cell xenografts, simvastatin significantly inhibited phosphorylation of Akt with concomitant attenuation of the expression of the anti-apoptotic protein Bcl(XL). In many cancer cells, Bcl(XL) is a target of NF kappa B. Simvastatin inhibited the DNA binding and transcriptional activities of NF kappa B resulting in marked reduction in transcription of Bcl(XL). Signals transmitted by anti-neoplastic mechanism implanted in the cancer cells serve to obstruct the initial outgrowth of tumors. One such mechanism represents the action of the tumor suppressor protein PTEN, which negatively regulates Akt kinase activity. We provide the first evidence for significantly increased levels of PTEN in the tumors of simvastatin-administered mice. Importantly, simvastatin markedly prevented binding of NF kappa B to the two canonical recognition elements, NFRE-1 and NFRE-2 present in the PTEN promoter. Contrary to the transcriptional suppression of Bcl(XL), simmastatin significantly increased the transcription of PTEN. Furthermore, expression of NF kappa B p65 subunit inhibited transcription of PTEN, resulting in reduced protein expression, which leads to enhanced phosphorylation of Akt. Taken together, our data present a novel bifaceted mechanism where simmastatin acts on a nodal transcription factor NF kappa B, which attenuates the expression of anti-apoptotic Bcl(XL) and simultaneously derepresses the expression of anti-proliferative/proapoptotic tumor suppressor PTEN to prevent breast cancer cell growth. Published by Elsevier Inc.
C1 [Ghosh-Choudhury, Nayana; Mandal, Chandi Charan; Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Nandini; Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, VA Res, San Antonio, TX USA.
[Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Geriatr Res, Educ & Clin Res, San Antonio, TX USA.
[Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
RP Ghosh-Choudhury, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
EM choudhury@uthscsa.edu
FU NIH [RO1 AR52425, RO1 DK50190]; VA Research Service Merit Review;
Department of Veterans Affairs; Juvenile Diabetes Research Foundation
[1-2008-185]
FX The authors thank Patricia St Clair for excellent technical assistance.
We thank Brent Wagner, M.D., for critically reading the manuscript. This
work was supported by NIH RO1 AR52425 and VA Research Service Merit
Review grants (NGC). GGC is a recipient of a Senior Research Career
Scientist Award from the Department of Veterans Affairs. GGC is
supported by NIH RO1 DK50190, VA Research Service Merit Review and
Juvenile Diabetes Research Foundation 1-2008-185 grants.
NR 116
TC 71
Z9 71
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
J9 CELL SIGNAL
JI Cell. Signal.
PD MAY
PY 2010
VL 22
IS 5
BP 749
EP 758
DI 10.1016/j.cellsig.2009.12.010
PG 10
WC Cell Biology
SC Cell Biology
GA 574JG
UT WOS:000275984600005
PM 20060890
ER
PT J
AU Afessa, B
Shorr, A
Anzueto, AR
Craven, DE
Schinner, R
Kollef, MH
AF Afessa, Bakele
Shorr, Andrew
Anzueto, Antonio R.
Craven, Donald E.
Schinner, Regina
Kollef, Marin H.
TI Association Between a Silver-Coated Endotracheal Tube and Reduced
Mortality in Patients With Ventilator-Associated Pneumonia
SO CHEST
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; MECHANICAL VENTILATION;
STAPHYLOCOCCUS-AUREUS; SUBGLOTTIC SECRETIONS; CONTINUOUS ASPIRATION;
NOSOCOMIAL PNEUMONIA; DOUBLE-BLIND; DECONTAMINATION; COLONIZATION;
INFECTION
AB Background: A silver-coated endotracheal tube (ETT) reduced the incidence of ventilator-associated pneumonia (VAP) compared with an uncoated ETT in the North American Silver-Coated Endotracheal Tube (NASCENT) study.
Methods: To evaluate the effect of an ETT and risk factors on mortality, we performed a retrospective cohort analysis in patients who developed VAP in the NASCENT study. We determined causes of death and VAP due to potentially multidrug-resistant bacteria (eg, Pseudomonas, Acinetobacter) and performed stepwise multivariate logistic regression with the following predefined variables: treatment group, Acute Physiology and Chronic Health Evaluation (APACHE) 11 score, continuous sedation, coma, COPD, emergency surgery/trauma, immunodeficiency, potentially multidrug-resistant bacteria, and inappropriate initial antibiotics.
Results: The silver-coated ETT was associated with reduced mortality in patients with VAP (silver vs control, 5/37 [14%] vs 20/56 [36%], P = .03), but not in those without VAP (228/729 [31%] vs 178/687 [26%], P = .03). The only between-group difference in leading causes of death was respiratory failure (silver vs control, 45/233 [19%] vs 22/198 [11%], P = .02). Of the VAP-related deaths, one in the silver group was caused by Acinetobacter sepsis. In the control group, six deaths were caused by sepsis and three by pneumonia; six of nine pathogens were potentially multidrug resistant. In multivariate analysis, the treatment group was a predictor of mortality (odds ratio, silver vs control, 0.28; 95% CI, 0.09-0.89; P = .03). APACHE II >= 20 and inappropriate antibiotics also remained in the model (P < .1).
Conclusions: These findings suggest that a silver-coated ETT was associated with reduced mortality in patients who developed VAP in the NASCENT study. Studies are needed to confirm these exploratory findings. CHEST 2010; 137(5):1015-1021
C1 [Afessa, Bakele] Mayo Clin, Div Pulm & Crit Care Med, Coll Med, Rochester, MN 55905 USA.
[Shorr, Andrew] Washington Hosp Ctr, Washington, DC 20010 USA.
[Anzueto, Antonio R.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
[Anzueto, Antonio R.] Univ Hosp, San Antonio, TX USA.
[Anzueto, Antonio R.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Craven, Donald E.] Lahey Clin Med Ctr, Burlington, MA 01803 USA.
[Craven, Donald E.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Schinner, Regina] FGK Clin Res GmbH, Munich, Germany.
[Kollef, Marin H.] Washington Univ, Sch Med, St Louis, MO USA.
RP Afessa, B (reprint author), Mayo Clin, Div Pulm & Crit Care Med, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.
EM Afessa.bekele@mayo.edu
FU C. R. Bard, Inc.; Johnson Johnson; Astellas; Pfizer; Bayer-Schering
Pharma; GlaxoSmithKline; Boehringer Ingelheim; Schering-Plough; KCI;
sanofi-aventis; Bard; Covidien; Merck; Ortho-McNeil; Wyeth; Arpida;
Bayer-Nektar; Cubist; Elan
FX Funding/Support: This study, including statistical analysis and
manuscript preparation, was supported by a pint from C. R. Bard, Inc.;
Financial/nonfinancial disclosures: The authors have reported to CHEST
the following conflicts of interest: Dr Shorr reported receiving grant
support from Johnson & Johnson and Pfizer; consulting fees from
Astellas, Johnson & Johnson, and Pfizer; and lecture fees from Johnson &
Johnson, Merck, and Pfizer Dr Anzueto reported receiving grant support
from Bayer-Schering Pharma and GlaxoSmithKline and consulting and
lecture fees from Bayer-Schering Pharma, Boehringer Ingelheim,
GlaxoSmithKline, Schering-Plough, Pfizer, KCI (lecturing only), and
sanofi-aventis (consulting only). Dr Craven reported receiving grant
support from Bard; lecture fees from Covidien, Merck, Ortho-McNeil,
Pfizer, and Wyeth; and consulting fees from Arpida, Bayer-Nektar,
Cubist, Johnson & Johnson, and Wyeth. Dr Kollef reported receiving
consulting fee from Kimberly Clark and lecture fees and grant support
from Bard, Elan, Merck, Ortho-McNeil (lecture fees only), and Pfizer. Dr
Afessa and Ms Schirmer have reported that no potential conflicts of
interest exist with any companies/organizations whose products or
services may be discussed in this article.
NR 22
TC 23
Z9 25
U1 0
U2 6
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD MAY
PY 2010
VL 137
IS 5
BP 1015
EP 1021
DI 10.1378/chest.09-0391
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 594MR
UT WOS:000277542300004
PM 20038737
ER
PT J
AU Ho, PM
Tsai, TT
Maddox, TM
Powers, JD
Carroll, NM
Jackevicius, C
Go, AS
Margolis, KL
DeFor, TA
Rumsfeld, JS
Magid, DJ
AF Ho, P. Michael
Tsai, Thomas T.
Maddox, Thomas M.
Powers, J. David
Carroll, Nikki M.
Jackevicius, Cynthia
Go, Alan S.
Margolis, Karen L.
DeFor, Terese A.
Rumsfeld, John S.
Magid, David J.
TI Delays in Filling Clopidogrel Prescription After Hospital Discharge and
Adverse Outcomes After Drug-Eluting Stent Implantation Implications for
Transitions of Care
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE stents; drugs; epidemiology
ID MYOCARDIAL-INFARCTION; THROMBOSIS; PREVALENCE; PREDICTORS;
DISCONTINUATION; INTERVENTION; MORTALITY; REGISTRY; THERAPY; EVENTS
AB Background-Adjuvant clopidogrel therapy is essential after drug-eluting stent (DES) implantation. The frequency with which patients delay filling a clopidogrel prescription after DES implantation and the association of this delay with adverse outcomes is unknown.
Methods and Results-This was a retrospective cohort study of patients discharged after DES implantation from 3 large integrated health care systems. Filling a clopidogrel prescription was based on pharmacy dispensing data. The primary end point was all-cause mortality or myocardial infarction (MI). Of 7402 patients discharged after DES implantation, 16% (n = 1210) did not fill a clopidogrel prescription on day of discharge and the median time delay was 3 days (interquartile range, 1 to 23 days). Compared with patients filling clopidogrel on day of discharge, patients with any delay in filling clopidogrel had higher death/MI rates during follow-up (14.2% versus 7.9%; P<0.001). In multivariable analysis, patients with any delay had increased risk of death/MI (hazard ratio, 1.53; 95% confidence interval, 1.25 to 1.87). Patients with any delay remained at increased risk of adverse outcomes when the delay cutoff was changed to >1, >3, or >5 days after discharge. Factors associated with delay included older age, prior MI, diabetes, renal failure, prior revascularization, cardiogenic shock, in-hospital bleeding, and clopidogrel use within 24 hours of admission.
Conclusions-One in 6 patients delay filling their index clopidogrel prescription after hospital discharge after DES implantation. This delay was associated with increased risk of adverse outcomes and highlights the importance of the transition period from hospital discharge to outpatient setting as a potential opportunity to improve care delivery and patient outcomes. (Circ Cardiovasc Qual Outcomes. 2010; 3: 261-266.)
C1 [Ho, P. Michael; Tsai, Thomas T.; Maddox, Thomas M.; Powers, J. David; Carroll, Nikki M.; Rumsfeld, John S.; Magid, David J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA.
[Ho, P. Michael; Tsai, Thomas T.; Maddox, Thomas M.; Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
[Ho, P. Michael; Tsai, Thomas T.; Maddox, Thomas M.; Rumsfeld, John S.; Magid, David J.] Univ Colorado Denver, Denver, CO USA.
[Jackevicius, Cynthia] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
[Jackevicius, Cynthia] Univ Toronto, Toronto, ON, Canada.
[Jackevicius, Cynthia] Inst Clin Evaluat Sci, Toronto, ON, Canada.
[Jackevicius, Cynthia] Western Univ, Pomona, CA USA.
[Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Margolis, Karen L.; DeFor, Terese A.] HealthPartners Res Fdn, Minneapolis, MN USA.
RP Ho, PM (reprint author), 1055 Clermont St 111B, Denver, CO 80220 USA.
EM Michael.ho@coloradooutcomes.org
FU Agency for Healthcare Research and Quality (AHRQ) [1U18HS016955]; NHLBI
[U19HL091179]; AHA Pharmaceutical Roundtable Outcomes Research Center
[AHA 0875162N]; VA Research and Development Career Development Award
[05-026-2]
FX This study was supported by a grant to The HMO Research Network Center
for Education and Research on Therapeutics (CERTs) (1U18HS016955) from
the Agency for Healthcare Research and Quality (AHRQ). The Effective
Health Care Cardiovascular Consortium by DEcIDE contributed to the
development of the stent database used in the study. Drs Magid and Go
are supported by the Cardiovascular Research Network (CVRN), which is
funded by NHLBI (U19HL091179). Dr Go is also supported by an AHA
Pharmaceutical Roundtable Outcomes Research Center (AHA No. 0875162N).
Dr Ho is supported by a VA Research and Development Career Development
Award (05-026-2) and serves as a consultant for Wellpoint, Inc.
NR 16
TC 35
Z9 36
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2010
VL 3
IS 3
BP 261
EP 266
DI 10.1161/CIRCOUTCOMES.109.902031
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 597RN
UT WOS:000277778400008
PM 20407117
ER
PT J
AU Ho, PM
Tsai, TT
Wang, TY
Shetterly, SM
Clarke, CL
Go, AS
Sedrakyan, A
Rumsfeld, JS
Peterson, ED
Magid, DJ
AF Ho, P. Michael
Tsai, Thomas T.
Wang, Tracy Y.
Shetterly, Susan M.
Clarke, Christina L.
Go, Alan S.
Sedrakyan, Art
Rumsfeld, John S.
Peterson, Eric D.
Magid, David J.
TI Adverse Events After Stopping Clopidogrel in Post-Acute Coronary
Syndrome Patients Insights From a Large Integrated Healthcare Delivery
System
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE drugs; epidemiology; myocardial infarction
ID POSTTREATMENT PLATELET REACTIVITY; MYOCARDIAL-INFARCTION; ANTIPLATELET
THERAPY; ARTERY-DISEASE; INCREASED RISK; MEDICATION; OUTCOMES; DEATH
AB Background-A prior study from the Veterans Health Administration found a clustering of cardiovascular events after clopidogrel cessation. We sought to confirm and expand these findings.
Methods and Results-This was a retrospective cohort study of 2017 patients with acute coronary syndrome discharged on clopidogrel from an integrated health care delivery system. Rates of all-cause mortality or acute myocardial infarction (MI) within 1 year after stopping clopidogrel were assessed among patients who did not have an event before stopping clopidogrel. Death/MI occurred in 4.3% (n = 71) of patients. The rates of death/MI were 3.07, 1.62, 0.70, and 0.95 per 10 000 patient-days for the time intervals of 0 to 90, 91 to 180, 181 to 270, and 271 to 360 days after stopping clopidogrel. In multivariable analysis, the 0- to 90-day interval after stopping clopidogrel was associated with higher risk of death/MI (incidence rate ratio, 2.74; 95% confidence interval, 1.69 to 4.44) compared with 91- to 360-day interval. There was a similar trend of increased events after stopping clopidogrel for various subgroups (women versus men, medical therapy versus percutaneous coronary intervention, stent type, and >= 6 months or <6 months of clopidogrel treatment). Among patients taking clopidogrel but stopping ACE inhibitor medications, the event rates were similar in the 0- to 90-day versus the 91- to 360-day interval (2.67 versus 2.91 per 10 000 patient-days; P=0.91).
Conclusions-We observed a clustering of adverse events in the 0 to 90 days after stopping clopidogrel. This clustering of events was not present among patients stopping ACE inhibitors. These findings are consistent with a possible rebound platelet hyper-reactivity after stopping clopidogrel and additional platelet studies are needed to confirm this effect. (Circ Cardiovasc Qual Outcomes. 2010; 3:303-308.)
C1 [Ho, P. Michael; Tsai, Thomas T.; Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
[Ho, P. Michael; Tsai, Thomas T.; Shetterly, Susan M.; Clarke, Christina L.; Rumsfeld, John S.; Magid, David J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA.
[Ho, P. Michael; Tsai, Thomas T.; Rumsfeld, John S.; Magid, David J.] Univ Colorado Denver, Denver, CO USA.
[Wang, Tracy Y.; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA.
[Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Ho, PM (reprint author), 1055 Clermont St 111B, Denver, CO 80220 USA.
EM michael.ho@coloradooutcomes.org
FU Agency for Healthcare Research and Quality; US Department of Health and
Human Services; Developing Evidence to Inform Decisions about
Effectiveness (DEcIDE)
FX This project was funded under Contract No. 290-05-0033 from the Agency
for Healthcare Research and Quality, US Department of Health and Human
Services, as part of the Developing Evidence to Inform Decisions about
Effectiveness (DEcIDE) program. The authors of this report are
responsible for its content. Statements in the report should not be
construed as endorsement by the Agency for Healthcare Research and
Quality or the US Department of Health and Human Services.
NR 18
TC 27
Z9 31
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2010
VL 3
IS 3
BP 303
EP 308
DI 10.1161/CIRCOUTCOMES.109.890707
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 597RN
UT WOS:000277778400013
PM 20354221
ER
PT J
AU Peterson, PN
Rumsfeld, JS
Liang, L
Hernandez, AF
Peterson, ED
Fonarow, GC
Masoudi, FA
AF Peterson, Pamela N.
Rumsfeld, John S.
Liang, Li
Hernandez, Adrian F.
Peterson, Eric D.
Fonarow, Gregg C.
Masoudi, Frederick A.
CA Amer Heart Assoc
TI Treatment and Risk in Heart Failure Gaps in Evidence or Quality?
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE heart failure; pharmacotherapy; health policy and outcomes research
ID CONVERTING ENZYME-INHIBITORS; VENTRICULAR EJECTION FRACTIONS; ACUTE
CORONARY SYNDROMES; MORBIDITY PROGRAM; MORTALITY; SURVIVAL; ENALAPRIL;
STRATIFICATION; ASSOCIATION; CANDESARTAN
AB Background-Although the absolute benefits of an intervention are proportional to patients' underlying risk, studies in heart failure have noted a paradoxical inverse relationship between treatment and risk. The extent to which this reflects higher rates of contraindications in patients with higher risk or larger gaps in care quality has not been explored.
Methods and Results-We studied 18 307 patients with left ventricular systolic dysfunction surviving hospitalization between January 2005 and June 2007 from 194 hospitals participating in Get With The Guidelines (GWTG)-Heart Failure. Patients were categorized according to their estimated risk for in-hospital mortality using a validated risk score. The proportions of patients with documented contraindications to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers as well as the use of these medications among patients without contraindications at hospital discharge was determined across levels of risk. For each therapy, the proportion of patients with contraindications was significantly higher with increasing patient risk (P<0.001 for each). Even after excluding those with contraindications, the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers was significantly lower with increasing risk (P<0.001 for each).
Conclusions-The use of evidence-based therapies is lower in patients with heart failure at higher risk of mortality both because of higher rates of contraindications to therapy and lower rates of use among eligible patients. Optimizing heart failure outcomes will require both the expansion of the evidence base for treating the highest-risk patients as well as the development of effective strategies to assure that eligible high-risk patients receive all appropriate therapies. (Circ Cardiovasc Qual Outcomes. 2010; 3:309-315.)
C1 [Peterson, Pamela N.; Masoudi, Frederick A.] Denver Hlth Med Ctr, Denver, CO USA.
[Peterson, Pamela N.; Rumsfeld, John S.; Masoudi, Frederick A.] Univ Colorado Denver, Denver, CO USA.
[Peterson, Pamela N.; Rumsfeld, John S.; Masoudi, Frederick A.] Kaiser Permanente, Inst Hlth Res, Denver, CO USA.
[Liang, Li; Hernandez, Adrian F.; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
RP Peterson, PN (reprint author), Div Cardiol, Mail Code 0960,777 Bannock St, Denver, CO 80204 USA.
EM Pamela.Peterson@ucdenver.edu
RI Hernandez, Adrian F./A-7818-2016
OI Hernandez, Adrian F./0000-0003-3387-9616
FU American Heart Association; GlaxoSmithKline; Medtronic; American Heart
Association Pharmaceutical Roundtable [067001N, 0675060N]; American
Heart Association Young Investigator Database Research Seed
FX Get With The Guidelines Heart Failure is a program of the American Heart
Association and was supported in part by unrestricted educational grants
from GlaxoSmithKline and Medtronic. Dr P. N. Peterson is supported by an
American Heart Association Pharmaceutical Roundtable grant 067001N and
an American Heart Association Young Investigator Database Research Seed
grant. Dr Hernandez is supported by an American Heart Association
Pharmaceutical Roundtable grant 0675060N. None of the funders had any
role in the design and conduct of the study; collection, management,
analysis, and interpretation of the data; or preparation, review, or
approval of the manuscript.
NR 28
TC 26
Z9 28
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2010
VL 3
IS 3
BP 309
EP 315
DI 10.1161/CIRCOUTCOMES.109.879478
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 597RN
UT WOS:000277778400014
PM 20388872
ER
PT J
AU Ross, JS
Krumholz, HM
AF Ross, Joseph S.
Krumholz, Harlan M.
TI Response to Letter Regarding Article, "Recent National Trends in
Readmission Rates After Heart Failure Hospitalization"
SO CIRCULATION-HEART FAILURE
LA English
DT Letter
ID CLINICAL-OUTCOMES
C1 [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA.
[Ross, Joseph S.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Ross, Joseph S.] James J Peters Vet Adm Med Ctr, HSR&D Res Enhancement Award Program, Bronx, NY USA.
[Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med,Dept Epidemiol & Publ Hlth, Dept Med,Sect Hlth Policy & Adm, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA.
[Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA.
RP Ross, JS (reprint author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA.
NR 5
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3289
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD MAY
PY 2010
VL 3
IS 3
BP E17
EP E17
DI 10.1161/CIRCHEARTFAILURE.110.952895
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 598HK
UT WOS:000277825800026
ER
PT J
AU Molano, I
Mathenia, J
Ruiz, P
Gilkeson, GS
Zhang, XK
AF Molano, I.
Mathenia, J.
Ruiz, P.
Gilkeson, G. S.
Zhang, X. K.
TI Decreased expression of Fli-1 in bone marrow-derived haematopoietic
cells significantly affects disease development in Murphy Roths
Large/lymphoproliferation (MRL/lpr) mice
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE bone marrow transplantation; Fli-1 transcription factor; hematopoietic
cells; lupus
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; TRANSCRIPTION FACTOR; MARGINAL ZONE;
RENAL-DISEASE; ETS FAMILY; B-CELLS; PATHOGENESIS; MEMBER; GENE;
GLOMERULONEPHRITIS
AB P>The transcription factor Fli-1 is implicated in the pathogenesis of both murine and human lupus. Decreased expression of Fli-1 in heterozygous (Fli-1+/-) Murphy Roths Large (MRL)/lpr mice resulted in significantly lower kidney pathological scores and markedly increased survival. In this study, bone marrow (BM) transplantation was used to investigate the role of decreased expression of Fli-1 in haematopoietic versus non-haematopoietic cell lineages in autoimmune disease development. Wild-type (WT) MRL/lpr that received BM from Fli-1+/- MRL/lpr mice had statistically significantly lower autoantibodies, less proteinuria, reduced renal disease and prolonged survival compared to WT MRL/lpr mice that received BM from WT MRL/lpr mice. Although not statistically significant, Fli-1+/- MRL/lpr mice that received BM from WT MRL/lpr mice also had lower autoantibodies and improved survival compared to WT MRL/lpr mice that received BM from WT MRL/lpr mice. Our data indicate that expression of Fli-1 in haematopoietic cell lineages has a significant effect on disease development in MRL/lpr mice.
C1 [Molano, I.; Gilkeson, G. S.; Zhang, X. K.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
[Mathenia, J.; Gilkeson, G. S.; Zhang, X. K.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC USA.
[Ruiz, P.] Univ Miami, Sch Med, Miami, FL USA.
RP Zhang, XK (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Suite 912,96 Jonathan Lucas St MSC637, Charleston, SC 29425 USA.
EM zhangjo@musc.edu
FU National Institutes of Health [AR054546]; Medical Research Service,
Department of Veterans Affairs
FX This study was supported by National Institutes of Health grants
(AR054546 to X. K. Z.) and the Medical Research Service, Department of
Veterans Affairs (to X. Z. and G. G.).
NR 25
TC 9
Z9 10
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD MAY
PY 2010
VL 160
IS 2
BP 275
EP 282
DI 10.1111/j.1365-2249.2009.04080.x
PG 8
WC Immunology
SC Immunology
GA 581CT
UT WOS:000276499400016
PM 20015093
ER
PT J
AU Reese, PP
Tehrani, T
Lim, MA
Asch, DA
Blumberg, EA
Simon, MK
Bloom, RD
Halpern, SD
AF Reese, Peter P.
Tehrani, Tara
Lim, Mary Ann
Asch, David A.
Blumberg, Emily A.
Simon, Maureen K.
Bloom, Roy D.
Halpern, Scott D.
TI Determinants of the Decision to Accept a Kidney from a Donor at
Increased Risk for Blood-Borne Viral Infection
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID INFORMING CANDIDATES; CONJOINT-ANALYSIS; TRANSPLANTATION; RECIPIENT;
DISEASE
AB Background and objectives: The use of kidneys from donors at increased risk for viral infections (DIRVI) such as HIV could increase the number of transplants and decrease waiting times. This study aimed to identify the proportion of kidney transplant candidates that would accept a kidney from a DIRVI and the factors that influenced this decision.
Design, setting, participants, & measurements: Conjoint analysis was used to assess the conditions in which renal transplant candidates would accept a DIRVI kidney. Candidates completed 12 scenarios in which the waiting time for a kidney, the donor age as a surrogate for kidney quality, and the risk of contracting HIV were systematically varied.
Results: Among 175 respondents, 42 (24.0%) rejected DIRVI kidneys under all conditions, 103 (58.9%) accepted DIRVI kidneys under some conditions, and 31 (17.7%) always accepted DIRVI kidneys. In multivariable logistic regression, patients were more likely to accept a DIRVI kidney when waiting time was longer, the donor was younger, and HIV risk was lower (P < 0.01 for each variable). Patients on dialysis (P < 0.01) and older patients (P = 0.04) more commonly accepted DIRVI kidneys, but self-rated sense of health was not associated with DIRVI kidney acceptance.
Conclusions: Most renal transplant candidates would accept a DIRVI kidney under some circumstances. These findings suggest that recipients can be allowed to make prospective choices regarding DIRVI kidney acceptance without hindering placement of these organs. Clin J Am Soc Nephrol 5: 917-923, 2010. doi: 10.2215/CJN.08251109
C1 [Reese, Peter P.] Univ Penn, Dept Med, Div Renal, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Reese, Peter P.; Asch, David A.; Halpern, Scott D.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Reese, Peter P.; Simon, Maureen K.; Bloom, Roy D.] Univ Penn, Penn Transplant Inst, Philadelphia, PA 19104 USA.
[Blumberg, Emily A.] Univ Penn, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA.
[Halpern, Scott D.] Univ Penn, Div Pulm, Dept Med, Philadelphia, PA 19104 USA.
[Asch, David A.] Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Reese, PP (reprint author), Univ Penn, Dept Med, Div Renal, Ctr Clin Epidemiol & Biostat, 908 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM peter.reese@uphs.upenn.edu
OI Asch, David/0000-0002-7970-286X
FU National Institutes of Health Career Development [K23-DK078688-01];
Greenwall Foundation
FX Dr. Reese is supported by a National Institutes of Health Career
Development Award, K23-DK078688-01. Dr. Halpern is supported by a
Greenwall Foundation Faculty Scholar Award in Bioethics. Preliminary 10.
data from this study were presented at the May 30 through June 3, 2009
American Transplant Congress in Boston, Massachusetts.
NR 21
TC 16
Z9 16
U1 0
U2 3
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD MAY
PY 2010
VL 5
IS 5
BP 917
EP 923
DI 10.2215/CJN.08251109
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 593TJ
UT WOS:000277483300027
PM 20338966
ER
PT J
AU Lipsky, BA
Berendt, AR
AF Lipsky, Benjamin A.
Berendt, Anthony R.
TI Hyperbaric Oxygen Therapy for Diabetic Foot Wounds Has hope hurdled
hype?
SO DIABETES CARE
LA English
DT Editorial Material
ID ULCERS
C1 [Lipsky, Benjamin A.] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA.
[Berendt, Anthony R.] Nuffield Orthopaed Ctr NHS Trust, Bone Infect Unit, Oxford, England.
RP Lipsky, BA (reprint author), Univ Washington, VA Puget Sound, Seattle, WA 98195 USA.
EM dblipsky@hotmail.com
OI Lipsky, Benjamin A./0000-0001-9886-5114
NR 18
TC 17
Z9 19
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2010
VL 33
IS 5
BP 1143
EP 1145
DI 10.2337/dc10-0393
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 595RV
UT WOS:000277631200039
PM 20427686
ER
PT J
AU Boyko, EJ
AF Boyko, Edward J.
TI ACCORD Glycemia Results Continue to Puzzle
SO DIABETES CARE
LA English
DT Editorial Material
ID EPIDEMIOLOGIC ANALYSIS; SEVERE HYPOGLYCEMIA
C1 [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Boyko, Edward J.] Univ Washington, Seattle, WA 98195 USA.
RP Boyko, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA.
EM eboyko@uw.edu
OI Boyko, Edward/0000-0002-3695-192X
FU NIDDK NIH HHS [P30 DK017047]
NR 4
TC 3
Z9 3
U1 0
U2 0
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2010
VL 33
IS 5
BP 1149
EP 1150
DI 10.2337/dc10-0432
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 595RV
UT WOS:000277631200041
PM 20427688
ER
PT J
AU Boyko, EJ
AF Boyko, Edward J.
TI Utility of Homeostasis Model Assessment of beta-Cell Function in
Predicting Diabetes in 12,924 Healthy Koreans Response
SO DIABETES CARE
LA English
DT Letter
C1 [Boyko, Edward J.] Seattle Epidemiol Res & Informat Ctr ERIC, VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA USA.
RP Boyko, EJ (reprint author), Seattle Epidemiol Res & Informat Ctr ERIC, VA Puget Sound Hlth Care Syst, Seattle, WA USA.
EM eboyko@u.washington.edu
OI Boyko, Edward/0000-0002-3695-192X
NR 5
TC 1
Z9 1
U1 0
U2 1
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2010
VL 33
IS 5
BP E71
EP E71
DI 10.2337/dc10-0196
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V26BN
UT WOS:000208521200007
PM 20427680
ER
PT J
AU Lipsky, BA
Tabak, YP
Johannes, RS
Vo, L
Hyde, L
Weigelt, JA
AF Lipsky, B. A.
Tabak, Y. P.
Johannes, R. S.
Vo, L.
Hyde, L.
Weigelt, J. A.
TI Skin and soft tissue infections in hospitalised patients with diabetes:
culture isolates and risk factors associated with mortality, length of
stay and cost
SO DIABETOLOGIA
LA English
DT Article
DE Diabetes; Foot infections; Hospitalised patients; Length of stay;
Mortality; MRSA; Skin and soft tissue infection
ID RESISTANT STAPHYLOCOCCUS-AUREUS; LARGE US DATABASE; COMPLICATED SKIN;
FOOT INFECTIONS; SURGICAL SITE; DOUBLE-BLIND; ECONOMIC OUTCOMES;
UNITED-STATES; EPIDEMIOLOGY; PATHOGENS
AB Skin and soft tissue infections (SSTIs) cause substantial morbidity in persons with diabetes. There are few data on pathogens or risk factors associated with important outcomes in diabetic patients hospitalised with SSTIs.
Using a clinical research database from CareFusion, we identified 3,030 hospitalised diabetic patients with positive culture isolates and a diagnosis of SSTI in 97 US hospitals between 2003 and 2007. We classified the culture isolates and analysed their association with the anatomic location of infection, mortality, length of stay and hospital costs.
The only culture isolate with a significantly increased prevalence was methicillin-resistant Staphylococcus aureus (MRSA); prevalence for infection of the foot was increased from 11.6 to 21.9% (p < 0.0001) and for non-foot locations from 14.0% to 24.6% (p = 0.006). Patients with non-foot (vs foot) infections were more severely ill at presentation and had higher mortality rates (2.2% vs 1.0%, p < 0.05). Significant independent risk factors associated with higher mortality rates included having a polymicrobial culture with Pseudomonas aeruginosa (OR 3.1), a monomicrobial culture with other gram-negatives (OR 8.9), greater illness severity (OR 1.9) and being transferred from another hospital (OR 5.1). These factors and need for major surgery were also independently associated with longer length of stay and higher costs.
Among diabetic patients hospitalised with SSTI from 2003 to 2007, only MRSA increased in prevalence. Patients with non-foot (vs foot) infections were more severely ill. Independent risk factors for increased mortality rates, length of stay and costs included more severe illness, transfer from another hospital and wound cultures with Pseudomonas or other gram-negatives.
C1 [Lipsky, B. A.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Tabak, Y. P.; Johannes, R. S.; Hyde, L.] CareFusion, Clin Res, Marlborough, MA USA.
[Johannes, R. S.] Harvard Univ, Sch Med, Div Gastroenterol, Boston, MA USA.
[Vo, L.] Ortho McNeil Janssen Sci Affairs LLC, Raritan, NJ USA.
[Weigelt, J. A.] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA.
RP Lipsky, BA (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98195 USA.
EM balipsky@uw.edu
OI Lipsky, Benjamin A./0000-0001-9886-5114
FU Ortho-McNeil Janssen Scientific Affairs, LLC
FX B. A. Lipsky and J. A. Weigelt served as consultants for Ortho-McNeil
Janssen Scientific Affairs, LLC, Raritan, NJ, USA. Y. P. Tabak, R. S.
Johannes and L. Hyde are employees of CareFusion, Marlborough, MA, USA.
L. Vo is an employee of Ortho-McNeil Janssen Scientific Affairs. This
study was supported by Ortho-McNeil Janssen Scientific Affairs, LLC.
NR 44
TC 47
Z9 51
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD MAY
PY 2010
VL 53
IS 5
BP 914
EP 923
DI 10.1007/s00125-010-1672-5
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 580CK
UT WOS:000276424300015
PM 20146051
ER
PT J
AU Brau, N
AF Brau, Norbert
TI In Memoriam: Edmund J. Bini, MD, MPH (1967-2010)
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Biographical-Item
C1 [Brau, Norbert] Bronx Vet Affairs Med Ctr, New York, NY USA.
[Brau, Norbert] Mt Sinai Sch Med, New York, NY USA.
RP Brau, N (reprint author), Bronx Vet Affairs Med Ctr, New York, NY USA.
EM Norbert.Brau@va.gov
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD MAY
PY 2010
VL 55
IS 5
BP 1193
EP 1193
DI 10.1007/s10620-010-1224-3
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 591EZ
UT WOS:000277283500001
PM 20383583
ER
PT J
AU Kovacs, TO
Freston, JW
Haber, MM
Atkinson, S
Hunt, B
Peura, DA
AF Kovacs, Thomas O.
Freston, James W.
Haber, Marian M.
Atkinson, Stuart
Hunt, Barbara
Peura, David A.
TI Long-Term Quality of Life Improvement in Subjects with Healed Erosive
Esophagitis: Treatment with Lansoprazole
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Quality of life; Lansoprazole; Erosive esophagitis; Gastroesophageal
reflux disease; Long-term maintenance therapy
ID GASTROESOPHAGEAL-REFLUX DISEASE; GERD PATIENTS; PRIMARY-CARE; SURVEY
SF-36; RANITIDINE; OMEPRAZOLE; QUESTIONNAIRE; SYMPTOMS; RELIEF
AB Gastroesophageal reflux disease (GERD) is a chronic symptomatic condition and may be associated with erosive esophagitis (EE). Considerable data on the long-term maintenance of healing of EE are available, but data on long-term GERD symptom prevention and patient quality of life (QOL) are limited.
To investigate QOL in subjects with healed EE who received 12 months of double-blind maintenance treatment with lansoprazole or ranitidine, followed by long-term open-label lansoprazole therapy to prevent recurrence of EE.
Subjects with healed EE received 12 months of double-blind maintenance treatment with lansoprazole 15 mg once daily or ranitidine 150 mg twice daily, followed by dose-titrated, open-label lansoprazole therapy for up to 82 months.
During double-blind treatment (n = 206), lansoprazole-treated patients showed significantly (P a parts per thousand currency sign 0.05) greater improvements than ranitidine-treated patients in the frequency, severity, and 'bothersomeness' of heartburn, the symptom index, problems of activity limitation, eating and drinking problems, symptom problems, health distress, and social functioning. During dose-titrated, open-label treatment (n = 195), all disease-specific QOL scales except sleep improved significantly (P < 0.001) from open-label baseline at each time-point.
Maintenance treatment with lansoprazole for 12 months in healed EE subjects produced significantly greater improvements in QOL indicators than ranitidine. These improvements were sustained during dose-titrated, open-label lansoprazole treatment.
C1 [Kovacs, Thomas O.] VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA.
[Freston, James W.] Univ Connecticut, Ctr Hlth, Farmington, CT USA.
[Haber, Marian M.] Drexel Univ, Coll Med, Dept Pathol, Philadelphia, PA 19104 USA.
[Atkinson, Stuart] Takeda Global Res & Dev Ctr Inc, Dept Clin Sci, Deerfield, IL USA.
[Hunt, Barbara] Takeda Global Res & Dev Ctr Inc, Dept Stat, Deerfield, IL USA.
[Peura, David A.] Univ Virginia Hlth Syst, Div Gastroenterol & Hepatol, Charlottesville, VA USA.
RP Kovacs, TO (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA.
EM TKovacs@mednet.ucla.edu
NR 27
TC 4
Z9 4
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD MAY
PY 2010
VL 55
IS 5
BP 1325
EP 1336
DI 10.1007/s10620-009-0871-8
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 591EZ
UT WOS:000277283500019
PM 19582579
ER
PT J
AU Bridges, TM
LeBois, EP
Hopkins, CR
Wood, MR
Jones, CK
Conn, PJ
Lindsley, CW
AF Bridges, Thomas M.
LeBois, Evan P.
Hopkins, Corey R.
Wood, Michael R.
Jones, Carrie K.
Conn, P. Jeffrey
Lindsley, Craig W.
TI THE ANTIPSYCHOTIC POTENTIAL OF MUSCARINIC ALLOSTERIC MODULATION
SO DRUG NEWS & PERSPECTIVES
LA English
DT Article
ID RECEPTOR AGONIST XANOMELINE; PROTEIN-COUPLED RECEPTORS;
CENTRAL-NERVOUS-SYSTEM; ACETYLCHOLINE-RECEPTOR; IN-VIVO;
N-DESMETHYLCLOZAPINE; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; RAT-BRAIN;
DOPAMINERGIC TRANSMISSION
AB The cholinergic hypothesis of schizophrenia emerged over 50 years ago based on clinical observations with both anticholinergics and pan-muscarinic agonists. Not until the 1990s did the cholinergic hypothesis of schizophrenia receive renewed enthusiasm based on clinical data with xanometine, a muscarinic acetylcholine receptor M(1)/M(4)-preferring orthosteric agonist. In a clinical trial with Alzheimer's patients, xanometine not only improved cognitive performance, but also reduced psychotic behaviors. This encouraging data spurred a second clinical trial in schizophrenic patients, wherein xanomeline significantly improved the positive, negative and cognitive symptom clusters. However, the question remained: Was the antipsychotic efficacy due to activation of M(1), M(4) or both M(1)/M(4)? Classical orthosteric ligands lacked the muscarinic receptor subtype selectivity required to address this key question. More recently, functional assays have allowed for the discovery of ligands that bind at allosteric sites, binding sites distinct from the orthosteric (acetylcholine) site, which are structurally less conserved and thereby afford high levels of receptor subtype selectivity. Recently, allosteric ligands, with unprecedented selectivity for either M(1) or M(4), have been discovered and have demonstrated comparable efficacy to xanometine in preclinical antipsychotic and cognition models. These data suggest that selective allosteric activation of either M(1) or M(4) has antipsychotic potential through distinct, yet complimentary mechanisms.
C1 [Hopkins, Corey R.; Wood, Michael R.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Vanderbilt Program Drug Discovery, Nashville, TN 37232 USA.
[Hopkins, Corey R.; Wood, Michael R.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.] Vanderbilt Univ, Med Ctr, Vanderbilt Specialized Chem Ctr MLPCN, Nashville, TN 37232 USA.
[Lindsley, Craig W.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA.
[Jones, Carrie K.] US Dept Vet Affairs, TVHS, Nashville, TN USA.
RP Lindsley, CW (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Vanderbilt Program Drug Discovery, 12415-D MRBIV Langford, Nashville, TN 37232 USA.
EM craig.lindsley@vanderbilt.edu
RI Conn, Peter/D-7848-2012
FU Merck Co.; Johnson Johnson; Hoffman-La Roche; GlaxoSmithKline; Lundbeck
Research USA; Epix Pharmaceuticals; Invitrogen Life Technologies; Evotec
Inc.; Addex Pharmaceuticals; Michael J. Fox Foundation; Seaside
Therapeutics; Cephalon Inc.; AstraZeneca USA; NeurOp Inc.; Forest
Research Institute; LEK Consulting; The Frankel Group; Prestwick
Chemical Co.; Millipore Corp.; Genentech; IMS Health; Primary Insight;
Otsuka; University of Toronto; American Society for Bone and Mineral
Research; University of Alabama Birmingham; University of Michigan;
Southern Research Inst.; Harvard Medical School; University of North
Carolina; NIH; Vanderbilt University; NIH/NIMH [R01 MH086601-01]
FX T.M. Bridges, E.P. LeBois, C.R. Hopkins, M.R. Wood and C.W. Lindsley
state that they have no potential conflicts of interest to disclose.
P.J. Conn has received compensation over the past 2 years as a
consultant from Merck & Co., Johnson & Johnson, Hoffman-La Roche,
GlaxoSmithKline, Lundbeck Research USA, Epix Pharmaceuticals, Invitrogen
Life Technologies, Evotec Inc., Addex Pharmaceuticals, Michael J. Fox
Foundation, Seaside Therapeutics, Cephalon Inc., AstraZeneca USA, NeurOp
Inc., Forest Research Institute, LEK Consulting, The Frankel Group,
Prestwick Chemical Co., Millipore Corp., Genentech, IMS Health, Primary
Insight and Otsuka. Dr. Conn has also received honoraria as a speaker
from University of Toronto, American Society for Bone and Mineral
Research, University of Alabama Birmingham, University of Michigan,
Southern Research Inst., Harvard Medical School and the University of
North Carolina. Dr. Conn receives research support that includes salary
support from NIH, Michael J. Fox Foundation, Seaside Therapeutics, and
Vanderbilt University. C.K. Jones is the recipient of Research Grant R01
MH086601-01 (PI, Jones) NIH/NIMH, M, positive allosteric modulators for
the treatment of schizophrenia.
NR 106
TC 28
Z9 28
U1 1
U2 4
PU PROUS SCIENCE, SA-THOMSON REUTERS
PI BARCELONA
PA PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN
SN 0214-0934
J9 DRUG NEWS PERSPECT
JI Drug News Perspect.
PD MAY
PY 2010
VL 23
IS 4
BP 229
EP 240
DI 10.1358/dnp.2010.23.4.1416977
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 620SL
UT WOS:000279519900002
PM 20520852
ER
PT J
AU Watkins, N
Cole, F
Weidemann, S
AF Watkins, Nicholas
Cole, Frances
Weidemann, Sue
TI The War Memorial as Healing Environment: The Psychological Effect of the
Vietnam Veterans Memorial on Vietnam War Combat Veterans' Posttraumatic
Stress Disorder Symptoms
SO ENVIRONMENT AND BEHAVIOR
LA English
DT Article
DE posttraumatic stress disorder; Vietnam Veterans Memorial; place
attachment; mourning; transitional phenomena
ID BUILT ENVIRONMENT
AB It has been hypothesized that experiences with memorials might reduce trauma-related symptoms. Magazines and scholarly work suggest that the Vietnam Veterans Memorial in Washington, DC, helps Vietnam War veterans overcome combat-related losses. This study tested the memorial's effect on veterans' trauma-related symptoms and identified features of the memorial that impacted symptoms. The longitudinal, quasi-experiment was conducted using standardized measures of posttraumatic stress disorder (PTSD) symptom severity. The study included 62 male Vietnam War combat veterans diagnosed with PTSD. The measures were administered before and after the trip to the memorial. The results showed that the severity of a veteran's symptoms varied by how many times he had visited the memorial before the study. There were distinct links between the memorial's design features and a veteran's experiences of the memorial. The study's results indicated that architects can create effective memorial designs by understanding how memorials facilitate the mourning processes.
C1 [Watkins, Nicholas] HOK, New York, NY 10011 USA.
[Cole, Frances] US Dept Vet Affairs, Philadelphia, PA USA.
[Weidemann, Sue] Workpl Anal Consulting, Buffalo, NY USA.
RP Watkins, N (reprint author), HOK, 620 Ave Amer,6th Floor, New York, NY 10011 USA.
EM nick.watkins@hok.com
NR 46
TC 6
Z9 6
U1 2
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0013-9165
J9 ENVIRON BEHAV
JI Environ. Behav.
PD MAY
PY 2010
VL 42
IS 3
BP 351
EP 375
DI 10.1177/0013916510361873
PG 25
WC Environmental Studies; Psychology, Multidisciplinary
SC Environmental Sciences & Ecology; Psychology
GA 579VE
UT WOS:000276403500005
ER
PT J
AU Fisher, R
Salanova, V
Witt, T
Worth, R
Henry, T
Gross, R
Oommen, K
Osorio, I
Nazzaro, J
Labar, D
Kaplitt, M
Sperling, M
Sandok, E
Neal, J
Handforth, A
Stern, J
DeSalles, A
Chung, S
Shetter, A
Bergen, D
Bakay, R
Henderson, J
French, J
Baltuch, G
Rosenfeld, W
Youkilis, A
Marks, W
Garcia, P
Barbaro, N
Fountain, N
Bazil, C
Goodman, R
McKhann, G
Krishnamurthy, KB
Papavassiliou, S
Epstein, C
Pollard, J
Tonder, L
Grebin, J
Coffey, R
Graves, N
AF Fisher, Robert
Salanova, Vicenta
Witt, Thomas
Worth, Robert
Henry, Thomas
Gross, Robert
Oommen, Kalarickal
Osorio, Ivan
Nazzaro, Jules
Labar, Douglas
Kaplitt, Michael
Sperling, Michael
Sandok, Evan
Neal, John
Handforth, Adrian
Stern, John
DeSalles, Antonio
Chung, Steve
Shetter, Andrew
Bergen, Donna
Bakay, Roy
Henderson, Jaimie
French, Jacqueline
Baltuch, Gordon
Rosenfeld, William
Youkilis, Andrew
Marks, William
Garcia, Paul
Barbaro, Nicolas
Fountain, Nathan
Bazil, Carl
Goodman, Robert
McKhann, Guy
Krishnamurthy, K. Babu
Papavassiliou, Steven
Epstein, Charles
Pollard, John
Tonder, Lisa
Grebin, Joan
Coffey, Robert
Graves, Nina
CA SANTE Study Grp
TI Electrical stimulation of the anterior nucleus of thalamus for treatment
of refractory epilepsy
SO EPILEPSIA
LA English
DT Article
DE Epilepsy; Seizures; Deep brain stimulation; Epilepsy surgery; Thalamus
ID DEEP-BRAIN-STIMULATION; INTRACTABLE EPILEPSY; PARKINSONS-DISEASE;
SURGERY
AB P>Purpose:
We report a multicenter, double-blind, randomized trial of bilateral stimulation of the anterior nuclei of the thalamus for localization-related epilepsy.
Methods:
Participants were adults with medically refractory partial seizures, including secondarily generalized seizures. Half received stimulation and half no stimulation during a 3-month blinded phase; then all received unblinded stimulation.
Results:
One hundred ten participants were randomized. Baseline monthly median seizure frequency was 19.5. In the last month of the blinded phase the stimulated group had a 29% greater reduction in seizures compared with the control group, as estimated by a generalized estimating equations (GEE) model (p = 0.002). Unadjusted median declines at the end of the blinded phase were 14.5% in the control group and 40.4% in the stimulated group. Complex partial and "most severe" seizures were significantly reduced by stimulation. By 2 years, there was a 56% median percent reduction in seizure frequency; 54% of patients had a seizure reduction of at least 50%, and 14 patients were seizure-free for at least 6 months. Five deaths occurred and none were from implantation or stimulation. No participant had symptomatic hemorrhage or brain infection. Two participants had acute, transient stimulation-associated seizures. Cognition and mood showed no group differences, but participants in the stimulated group were more likely to report depression or memory problems as adverse events.
Discussion:
Bilateral stimulation of the anterior nuclei of the thalamus reduces seizures. Benefit persisted for 2 years of study. Complication rates were modest. Deep brain stimulation of the anterior thalamus is useful for some people with medically refractory partial and secondarily generalized seizures.
C1 [Fisher, Robert] Stanford Univ, Dept Neurol, Sch Med, Stanford, CA 94305 USA.
[Salanova, Vicenta; Witt, Thomas; Worth, Robert] Indiana Univ, Indianapolis, IN 46204 USA.
[Henry, Thomas; Gross, Robert; Epstein, Charles] Emory Univ, Atlanta, GA 30322 USA.
[Oommen, Kalarickal] Univ Oklahoma, Oklahoma City, OK USA.
[Osorio, Ivan; Nazzaro, Jules] Univ Kansas, Kansas City, KS USA.
[Labar, Douglas; Kaplitt, Michael] Weill Cornell, New York, NY USA.
[Sperling, Michael] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
[Sandok, Evan; Neal, John] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA.
[Handforth, Adrian; DeSalles, Antonio] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Stern, John] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Chung, Steve; Shetter, Andrew] Barrow Neurol Inst, Phoenix, AZ 85013 USA.
[Bergen, Donna; Bakay, Roy] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA.
[French, Jacqueline; Baltuch, Gordon; Pollard, John] Univ Penn, Philadelphia, PA 19104 USA.
[Marks, William; Garcia, Paul; Barbaro, Nicolas] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Fountain, Nathan] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
[Bazil, Carl; Goodman, Robert; McKhann, Guy] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
[Krishnamurthy, K. Babu; Papavassiliou, Steven] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Tonder, Lisa; Grebin, Joan; Coffey, Robert; Graves, Nina] Medtronic, Minneapolis, MN USA.
RP Fisher, R (reprint author), Stanford Univ, Dept Neurol, Sch Med, Room A343,300 Pasteur Dr, Stanford, CA 94305 USA.
EM robert.fisher@stanford.edu
RI ; Graves, Nicholas/A-3052-2011; French, Jacqueline/G-6795-2013
OI Henderson, Jaimie/0000-0002-3276-2267; French,
Jacqueline/0000-0003-2242-8027; Henry, Thomas/0000-0002-5708-903X;
Herman, Susan/0000-0002-6556-083X
FU Medtronic, Inc. (Minneapolis, MN); NIH [R01 NS39344-01]
FX The study was supported by Medtronic, Inc. (Minneapolis, MN) and an NIH
grant R01 NS39344-01 to RSF to assist with planning of the study. Dr.
Fisher, who primarily wrote the article, receives no personal financial
support from Medtronic and does not own Medtronic equities. Dr. Fisher
is supported by the Maslah Saul MD Chair, James and Carrie Anderson
Epilepsy Research Laboratory, and the Susan Horngren Fund.
NR 27
TC 471
Z9 491
U1 12
U2 68
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD MAY
PY 2010
VL 51
IS 5
BP 899
EP 908
DI 10.1111/j.1528-1167.2010.02536.x
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 587OA
UT WOS:000277000900024
PM 20331461
ER
PT J
AU Metra, M
Cleland, JG
Weatherley, BD
Dittrich, HC
Givertz, MM
Massie, BM
O'Connor, CM
Ponikowski, P
Teerlink, JR
Voors, AA
Cotter, G
AF Metra, Marco
Cleland, John G.
Weatherley, Beth Davison
Dittrich, Howard C.
Givertz, Michael M.
Massie, Barry M.
O'Connor, Christopher M.
Ponikowski, Piotr
Teerlink, John R.
Voors, Adriaan A.
Cotter, Gad
TI Dyspnoea in patients with acute heart failure: an analysis of its
clinical course, determinants, and relationship to 60-day outcomes in
the PROTECT pilot study
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Acute heart failure; Dyspnoea; Prognosis; Rolofylline; Adenosine
antagonists
ID WORSENING RENAL-FUNCTION; IN-HOSPITAL MORTALITY; RANDOMIZED CONTROLLED
TRIAL; A(1) RECEPTOR ANTAGONIST; EUROPEAN-SOCIETY; OF-CARDIOLOGY;
TASK-FORCE; ASSOCIATION; IMPAIRMENT; ADMISSION
AB Dyspnoea is the most common symptom leading to hospitalization for acute heart failure (AHF). Its early and persistent relief is an important goal of therapy, but little is known about its course, determinants, and prognostic significance.
In a post hoc analysis, we studied changes in dyspnoea and in-hospital course in 303 subjects with AHF enrolled in the PROTECT pilot trial. Changes in dyspnoea were assessed by patient self-report using a seven-point Likert scale daily to discharge and at Days 7 and 14. We defined dyspnoea relief as a moderate to marked improvement of dyspnoea at both 24 and 48 h, and treatment success as dyspnoea relief without worsening HF or renal function or death during the first 7 days. Dyspnoea relief occurred in 54% of the patients, while treatment success was achieved in 44% of the patients. By Day 14, only 75% of patients reported a moderate or marked improvement in dyspnoea. Both dyspnoea relief and treatment success were associated with greater improvement in signs of congestion, shorter hospitalization duration, and a lower 60-day mortality rate. Treatment success, but not dyspnoea relief, was also associated with a lower incidence of 60-day death or re-hospitalization for HF or renal failure.
Half of patients admitted for AHF do not have substantial improvement in dyspnoea at 24 h and 25% do not have substantial improvement at 7 and 14 days from admission. Dyspnoea relief and treatment success are associated with shorter length of stay and lower 60-day mortality. These analyses should be confirmed in larger studies.
C1 [Metra, Marco] Univ Brescia, I-25100 Brescia, Italy.
[Cleland, John G.] Univ Hull, Kingston Upon Hull, Yorks, England.
[Weatherley, Beth Davison; Cotter, Gad] Momentum Res Inc, Durham, NC USA.
[Dittrich, Howard C.] NovaCardia Inc, San Diego, CA USA.
[Givertz, Michael M.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
[Massie, Barry M.; Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Massie, Barry M.; Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA.
[O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA.
[Ponikowski, Piotr] Kardiol Klin, Wroclaw, Poland.
[Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.
RP Metra, M (reprint author), Univ Brescia, I-25100 Brescia, Italy.
EM metramarco@libero.it
RI Teerlink, John/D-2986-2012; Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064; Cleland,
John/0000-0002-1471-7016; Metra, Marco/0000-0001-6691-8568
FU NovaCardia, Inc
FX This study was funded by NovaCardia, Inc. As of September 2007,
NovaCardia is a wholly owned subsidiary of Merck & Co, Inc.
NR 35
TC 27
Z9 28
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1388-9842
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD MAY
PY 2010
VL 12
IS 5
BP 499
EP 507
DI 10.1093/eurjhf/hfq021
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 587MW
UT WOS:000276997600012
PM 20228387
ER
PT J
AU Simms, LJ
Zelazny, K
Yam, WH
Gros, DF
AF Simms, Leonard J.
Zelazny, Kerry
Yam, Wern How
Gros, Daniel F.
TI Self-informant Agreement for Personality and Evaluative Person
Descriptors: Comparing Methods for Creating Informant Measures
SO EUROPEAN JOURNAL OF PERSONALITY
LA English
DT Article
DE self-informant agreement, Big Five; Big Seven; evaluative traits,
informant measures
ID CROSS-CULTURAL GENERALITY; BIG-7 FACTOR MODEL; 5-FACTOR MODEL; REPORTED
PERSONALITY; PSYCHIATRIC-PATIENT; MENTAL-HEALTH; TRAITS; BEHAVIOR;
ACQUAINTANCESHIP; PERSPECTIVE
AB Little attention typically is paid to the way self-report measures are translated for use in self-informant agreement studies. We studied two possible methods for creating informant measures (a) the traditional method in which self-report items were translated from the first- to the third-person and (14 an alternative meta-perceptual method in which informants were directed to rate their perception of the targets' self perception. We hypothesized that the latter method would yield stronger self-informant agreement for evaluative personality dimensions measured by indirect item markers We studied these methods in a sample of 303 undergraduate friendship dyads. Results revealed mean-level differences between methods, similar self-informant agreement across methods. stronger agreement for Big Five dimensions than for evaluative dimensions, and incremental validity for meta-perceptual informant rating methods Limited power reduced the interpretability of several sparse acquaintanceship effects. We conclude that traditional informant methods are appropriate for most personality traits. but meta-perceptual methods may be more appropriate when personality questionnaire items reflect indirect indicators of the trait being measured, which is particularly likely for evaluative traits Copyright (C) 2010 John Wiley & Sons, Ltd
C1 [Simms, Leonard J.] SUNY Buffalo, Dept Psychol, Buffalo, NY 14260 USA.
[Gros, Daniel F.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
[Gros, Daniel F.] Med Univ S Carolina, Charleston, SC USA.
RP Simms, LJ (reprint author), SUNY Buffalo, Dept Psychol, Pk Hall 218, Buffalo, NY 14260 USA.
FU NIMH NIH HHS [R01 MH080086, R01 MH080086-03]
NR 49
TC 10
Z9 10
U1 0
U2 8
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0890-2070
J9 EUR J PERSONALITY
JI Eur. J. Personal.
PD MAY
PY 2010
VL 24
IS 3
SI SI
BP 207
EP 221
DI 10.1002/per.763
PG 15
WC Psychology, Social
SC Psychology
GA 599IW
UT WOS:000277905900004
PM 21541262
ER
PT J
AU Yadav, V
Shinto, L
Bourdette, D
AF Yadav, Vijayshree
Shinto, Lynne
Bourdette, Dennis
TI Complementary and alternative medicine for the treatment of multiple
sclerosis
SO EXPERT REVIEW OF CLINICAL IMMUNOLOGY
LA English
DT Article
DE antioxidants; complementary and alternative medicine; dietary
supplements; essential fatty acids; lipoic acid; low-fat diet; multiple
sclerosis
ID ALPHA-LIPOIC ACID; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; RANDOMIZED
CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; TUMOR-NECROSIS-FACTOR;
SYMPTOMATIC DIABETIC POLYNEUROPATHY; POLYUNSATURATED FATTY-ACIDS;
STIMULATES CAMP PRODUCTION; PLANT CANNABIS EXTRACTS;
CENTRAL-NERVOUS-SYSTEM
AB Multiple sclerosis (MS) is a chronic disabling disease of the CNS that affects people during early adulthood. Despite several US FDA-approved medications, the treatment options in MS are limited. Many people with MS explore complementary and alternative medicine (CAM) treatments to help control their MS and treat their symptoms. Surveys suggest that up to 70% of people with MS have tried one or more CAM treatment for their MS. People with MS using CAM generally report deriving some benefit from the therapies. The CAM therapies most frequently used include diet, omega-3 fatty acids and antioxidants. There is very limited research evaluating the safety and effectiveness of CAM in MS. The most promising among CAM therapies that warrant further investigation are a low-fat diet, omega-3 fatty acids, lipoic acid and vitamin D supplementation as potential anti-inflammatory and neuroprotective agents in both relapsing and progressive forms of MS. There is very limited research evaluating the safety and effectiveness of CAM in MS. However, in recent years, the NIH and the National MS Society have been actively supporting the research in this very important area.
C1 [Yadav, Vijayshree; Shinto, Lynne; Bourdette, Dennis] Oregon Hlth & Sci Univ, Dept Neurol L226, Portland, OR 97239 USA.
[Bourdette, Dennis] Portland VA Med Ctr, Portland, OR USA.
RP Yadav, V (reprint author), Oregon Hlth & Sci Univ, Dept Neurol L226, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM yadavv@ohsu.edu
FU National MS Society [PP0921, CA 1055-A-3]; NIH [P50AT00066-01];
Department of Veterans Affairs; Nancy Davis Center Without Walls
FX Vijayshree Yadav has received personal compensation for activities with
Biogen Idec as a speaker. Dennis Bourdette has received personal
compensation for activities with Biogen Idec, EMD Serono, Pfizer Inc.
and Teva Neurosciences as a speaker or faculty member. This study was
supported by the National MS Society (PP0921 and CA 1055-A-3), the NIH
(P50AT00066-01), the Department of Veterans Affairs and the Nancy Davis
Center Without Walls. The authors have no other relevant affiliations or
financial involvement with any organization or entity with a financial
interest in or financial conflict with the subject matter or materials
discussed in the manuscript apart from those disclosed.
NR 168
TC 24
Z9 25
U1 1
U2 12
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1744-666X
J9 EXPERT REV CLIN IMMU
JI Expert Rev. Clin. Immunol.
PD MAY
PY 2010
VL 6
IS 3
BP 381
EP 395
DI 10.1586/ECI.10.12
PG 15
WC Immunology
SC Immunology
GA 602VI
UT WOS:000278166600014
PM 20441425
ER
PT J
AU Jang, YC
Lustgarten, MS
Liu, YH
Muller, FL
Bhattacharya, A
Liang, HY
Salmon, AB
Brooks, SV
Larkin, L
Hayworth, CR
Richardson, A
Van Remmen, H
AF Jang, Youngmok C.
Lustgarten, Michael S.
Liu, Yuhong
Muller, Florian L.
Bhattacharya, Arunabh
Liang, Hanyu
Salmon, Adam B.
Brooks, Susan V.
Larkin, Lisa
Hayworth, Christopher R.
Richardson, Arlan
Van Remmen, Holly
TI Increased superoxide in vivo accelerates age-associated muscle atrophy
through mitochondrial dysfunction and neuromuscular junction
degeneration
SO FASEB JOURNAL
LA English
DT Article
DE apoptosis; oxidative stress; sarcopenia
ID SKELETAL-MUSCLE; OXIDATIVE STRESS; MOTOR-NEURONS; MYONUCLEAR NUMBER;
MOUSE HINDLIMB; FIBER TYPES; CELL-DEATH; DENERVATION; APOPTOSIS; MICE
AB Oxidative stress has been implicated in the etiology of age-related muscle loss (sarcopenia). However, the underlying mechanisms by which oxidative stress contributes to sarcopenia have not been thoroughly investigated. To directly examine the role of chronic oxidative stress in vivo, we used a mouse model that lacks the antioxidant enzyme CuZnSOD (Sod1). Sod1(-/-) mice are characterized by high levels of oxidative damage and an acceleration of sarcopenia. In the present study, we demonstrate that muscle atrophy in Sod1(-/-) mice is accompanied by a progressive decline in mitochondrial bioenergetic function and an elevation of mitochondrial generation of reactive oxygen species. In addition, Sod1(-/-) muscle exhibits a more rapid induction of mitochondrial-mediated apoptosis and loss of myonuclei. Furthermore, aged Sod1(-/-) mice show a striking increase in muscle mitochondrial content near the neuromuscular junctions (NMJs). Despite the increase in content, the function of mitochondria is significantly impaired, with increased denervated NMJs and fragmentation of acetylcholine receptors. As a consequence, contractile force in aged Sod1(-/-) muscles is greatly diminished. Collectively, we show that Sod1(-/-) mice display characteristics of normal aging muscle in an accelerated manner and propose that the superoxide-induced NMJ degeneration and mitochondrial dysfunction are potential mechanisms of sarcopenia.-Jang, Y. C., Lustgarten, M. S., Liu, Y., Muller, F. L., Bhattacharya, A., Liang, H., Salmon, A. B., Brooks, S. V., Larkin, L., Hayworth, C. R., Richardson, A., and Van Remmen, H. Increased superoxide in vivo accelerates age-associated muscle atrophy through mitochondrial dysfunction and neuromuscular junction degeneration. FASEB J. 24, 1376-1390 (2010). www.fasebj.org
C1 [Jang, Youngmok C.; Liu, Yuhong; Muller, Florian L.; Bhattacharya, Arunabh; Liang, Hanyu; Salmon, Adam B.; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA.
[Lustgarten, Michael S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA.
[Jang, Youngmok C.; Lustgarten, Michael S.; Liu, Yuhong; Muller, Florian L.; Bhattacharya, Arunabh; Liang, Hanyu; Salmon, Adam B.; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Brooks, Susan V.; Larkin, Lisa] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
[Hayworth, Christopher R.] Univ Texas Austin, Neurobiol Sect, Austin, TX 78712 USA.
[Hayworth, Christopher R.] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA.
[Richardson, Arlan; Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM vanremmen@uthscsa.edu
FU American Federation for Aging Research [P01AG020591]
FX The authors thank Drs. Charles Epstein (University of California, San
Francisco, CA, USA) and Ting Ting Huang (Stanford University, Palo Alto,
CA, USA) for providing Sod1-null breeders, Corinne Price for
proofreading our manuscript, and Drs. Asish Chaudhuri, Anson Pierce,
James Lechleiter, Walter Ward, and Victoria Frohlich for their input and
technical assistance. This work was supported by P01AG020591 (to H. V.
R., A. R., S. V. B., L. L.), and a Julie Martin Mid-Career grant from
the American Federation for Aging Research (to H. V. R.).
NR 58
TC 98
Z9 100
U1 0
U2 6
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD MAY
PY 2010
VL 24
IS 5
BP 1376
EP 1390
DI 10.1096/fj.09-146308
PG 15
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 589OD
UT WOS:000277158900011
PM 20040516
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI How many polyps are there?
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID COLONOSCOPY
AB Background: Frequently, there is disagreement between consecutive endoscopies about the true number of mucosal lesions.
Objective: To develop a simple means to estimate the total number of mucosal lesions and the number of lesions missed during consecutive endoscopies.
Design: Probability modeling of endoscopic outcomes.
Patients: Subjects undergoing 2 consecutive endoscopies.
Main Outcome Measurements: Total number of mucosal lesions and number of missed lesions.
Results: If a represents the number of lesions seen by the first endoscopist, b the number of lesions seen by the second endoscopist, and c the number of identical lesions seen by both, then the total number of lesions is given by T = ab/c, and the number of lesions missed by both is given by M = (a - c)(b - c)/c. The estimated numbers for all lesions and for missed lesions increase as the number of identical lesions seen by both endoscopists decreases. If the number of identical lesions seen by both endoscopists matches the number of lesions found by any one endoscopist, the numbers of estimated and found polyps are identical and the number of missed polyps equals zero.
Limitations: The analysis assumes that both endoscopists work independently of each other and are equally qualified. The formulas also fail to account for varying characteristics of similar lesions.
Conclusion: The analysis presents a simple, unbiased means to estimate the total number of mucosal lesions if 2 consecutive endoscopies yield slightly conflicting results. (Gastrointest Endosc 2010;71:1009-12.)
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
NR 5
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD MAY
PY 2010
VL 71
IS 6
BP 1009
EP 1012
DI 10.1016/j.gie.2009.11.050
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 596QQ
UT WOS:000277700500019
PM 20231022
ER
PT J
AU Okada, T
Suehiro, Y
Ueno, K
Mitomori, S
Kaneko, S
Nishioka, M
Okayama, N
Sakai, K
Higaki, S
Hazama, S
Hirata, H
Sakaida, I
Oka, M
Hinoda, Y
AF Okada, Toshiyuki
Suehiro, Yutaka
Ueno, Koji
Mitomori, Shoko
Kaneko, Sayaka
Nishioka, Mitsuaki
Okayama, Naoko
Sakai, Kouhei
Higaki, Shingo
Hazama, Shoichi
Hirata, Hiroshi
Sakaida, Isao
Oka, Masaaki
Hinoda, Yuji
TI TWIST1 Hypermethylation Is Observed Frequently in Colorectal Tumors and
its Overexpression Is Associated with Unfavorable Outcomes in Patients
with Colorectal Cancer
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID METHYLATION-SPECIFIC PCR; BREAST-CANCER; MESENCHYMAL TRANSITION;
PANCREATIC-CANCER; REGULATORS SNAIL; DNA METHYLATION; MULTIPLE GENES;
UP-REGULATION; METASTASIS; EXPRESSION
AB Although growing evidence demonstrates that TWIST1 is an interesting tumor biomarker, little is known about the clinical significance of TWIST1 expression and TWIST1 methylation in human primary colorectal cancer. In this study, we examined the association of TWIST1 expression and TWIST1 methylation with clinicopathologic features in human primary colorectal tumors. Primary colorectal cancer (CRC) specimens from 319 patients, corresponding normal colorectal nontumorous mucosa from 251 patients with cancer, and colorectal adenomas from 189 patients were used. Methylation and expression levels of TWIST1 were compared with clinicopathologic features. The TWIST1 methylation level was higher in colorectal adenoma and cancer than in normal colorectal mucosa. Elevated TWIST1 mRNA expression in normal colorectal mucosa in patients with CRC as well as in primary CRC specimens was associated with unfavorable outcomes. There was no correlation between TWIST1 methylation and TWIST1 expression. Our results suggest that TWIST1 methylation may be a useful biomarker for screening colorectal tumors. In addition, TWIST1 mRNA expression is a possible molecular marker for predicting the outcome in patients with CRC. Confirmatory studies using independent data sets are needed to confirm our findings. (C) 2010 Wiley-Liss, Inc.
C1 [Okada, Toshiyuki; Suehiro, Yutaka; Ueno, Koji; Mitomori, Shoko; Kaneko, Sayaka; Nishioka, Mitsuaki; Okayama, Naoko; Sakai, Kouhei; Hinoda, Yuji] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Yamaguchi 7558505, Japan.
[Higaki, Shingo; Sakaida, Isao] Yamaguchi Univ, Grad Sch Med, Dept Mol Sci & Appl Med Gastroenterol & Hepatol, Yamaguchi 7558505, Japan.
[Hazama, Shoichi; Oka, Masaaki] Yamaguchi Univ, Grad Sch Med, Dept Digest Surg & Surg Oncol Surg 2, Yamaguchi 7558505, Japan.
[Hirata, Hiroshi] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hirata, Hiroshi] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA.
RP Suehiro, Y (reprint author), Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.
EM ysuehiro@yamaguchi-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
[21590626]
FX Ministry of Education, Culture, Sports, Science and Technology, Japan,
Grant number: 21590626.
NR 45
TC 30
Z9 33
U1 0
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1045-2257
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD MAY
PY 2010
VL 49
IS 5
BP 452
EP 462
DI 10.1002/gcc.20755
PG 11
WC Oncology; Genetics & Heredity
SC Oncology; Genetics & Heredity
GA 575BH
UT WOS:000276037900005
PM 20140954
ER
PT J
AU Restrepo, MI
Anzueto, A
Arroliga, AC
Afessa, B
Atkinson, MJ
Ho, NJ
Schinner, R
Bracken, RL
Kollef, MH
AF Restrepo, Marcos I.
Anzueto, Antonio
Arroliga, Alejandro C.
Afessa, Bekele
Atkinson, Mark J.
Ho, Ngoc J.
Schinner, Regina
Bracken, Ronald L.
Kollef, Marin H.
TI Economic Burden of Ventilator-Associated Pneumonia Based on Total
Resource Utilization
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID EVIDENCE-BASED GUIDELINES; COST; PREVENTION; PROGRAM; PAYMENT; SYSTEM;
IMPACT
AB OBJECTIVES. To characterize the current economic burden of ventilator-associated pneumonia (VAP) and to determine which services increase the cost of VAP in North American hospitals.
DESIGN AND SETTING. We performed a retrospective, matched cohort analysis of mechanically ventilated patients enrolled in the North American Silver-Coated Endotracheal Tube ( NASCENT) study, a prospective, randomized study conducted from 2002 to 2006 in 54 medical centers, including 45 teaching institutions (83.3%).
METHODS. Case patients with microbiologically confirmed VAP (n = 30) were identified from 542 study participants with claims data and were matched by use of a primary diagnostic code, and subsequently by the Acute Physiology and Chronic Health Evaluation II score, to control patients without VAP (n = 90). Costs were estimated by applying hospital-specific cost-to-charge ratios based on all-payer inpatient costs associated with VAP diagnosis-related groups.
RESULTS. Median total charges per patient were $ 198,200 for case patients and $ 96,540 for matched control patients (P < .001); corresponding median hospital costs were $ 76,730 for case patients and $ 41,250 for control patients (P = .001). After adjusting for diagnosis-related group payments, median losses to hospitals were $ 32,140 for case patients and $ 19,360 for control patients (P = .151). The median duration of intubation was longer for case patients than for control patients (10.1 days vs 4.7 days; P < .001), as were the median duration of intensive care unit stay (18.5 days vs 8.0 days; P < .001) and the median duration of hospitalization (26.5 days vs 14.0 days; P < .001). Examples of services likely to be directly related to VAP and having higher median costs for case patients were hospital care (P < .05) and respiratory therapy (P < .05).
CONCLUSIONS. VAP was associated with increased hospital costs, longer duration of hospital stay, and a higher number of hospital services being affected, which underscores the need for bundled measures to prevent VAP. trial registration. NASCENT study ClinicalTrials. gov Identifier: NCT00148642. Infect Control Hosp Epidemiol 2010; 31(5):509-515
C1 [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, Dept Med, San Antonio, TX 78229 USA.
[Restrepo, Marcos I.] Vet Evidence Based Res Disseminat Implementat Ctr, San Antonio, TX USA.
[Restrepo, Marcos I.; Anzueto, Antonio] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
[Anzueto, Antonio] Univ Hosp, San Antonio, TX USA.
[Arroliga, Alejandro C.] Scott & White & Texas A&M Hlth Sci Ctr Coll Med, Temple, TX USA.
[Afessa, Bekele] Mayo Clin, Coll Med, Rochester, MN USA.
[Atkinson, Mark J.] Univ Calif San Diego, Hlth Serv Res Ctr, San Diego, CA USA.
[Ho, Ngoc J.] Kaiser Permanente, Dept Res & Evaluat, Pasadena, CA USA.
[Bracken, Ronald L.] CR Bard, Covington, GA USA.
[Kollef, Marin H.] Washington Univ, Sch Med, St Louis, MO USA.
[Schinner, Regina] FGK Clin Res GmbH, Munich, Germany.
RP Restrepo, MI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, Dept Med, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78229 USA.
EM restrepom@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
FU Bard
FX This study, including the statistical analysis and manuscript
preparation, was supported by a research grant from Bard. The Aequitas
Group and Hamilton House received compensation from Bard for their
contributions.
NR 25
TC 40
Z9 44
U1 1
U2 5
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD MAY
PY 2010
VL 31
IS 5
BP 509
EP 515
DI 10.1086/651669
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 577WR
UT WOS:000276255200010
PM 20302428
ER
PT J
AU Gonzalez, M
Arroliga, AC
Frutos-Vivar, F
Raymondos, K
Esteban, A
Putensen, C
Apezteguia, C
Hurtado, J
Desmery, P
Tomicic, V
Elizalde, J
Abroug, F
Arabi, Y
Moreno, R
Anzueto, A
Ferguson, ND
AF Gonzalez, Marco
Arroliga, Alejandro C.
Frutos-Vivar, Fernando
Raymondos, Konstantinos
Esteban, Andres
Putensen, Christian
Apezteguia, Carlos
Hurtado, Javier
Desmery, Pablo
Tomicic, Vinko
Elizalde, Jose
Abroug, Fekri
Arabi, Yaseen
Moreno, Rui
Anzueto, Antonio
Ferguson, Niall D.
TI Airway pressure release ventilation versus assist-control ventilation: a
comparative propensity score and international cohort study
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Mechanical ventilation; Airway pressure release ventilation;
Assist-control ventilation; Mortality; Epidemiology; Propensity score
ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; SUPPORT
AB To compare characteristics and clinical outcomes of patients receiving airway pressure release ventilation (APRV) or biphasic positive airway pressure (BIPAP) to assist-control ventilation (A/C) as their primary mode of ventilatory support. The objective was to estimate if patients ventilated with APRV/BIPAP have a lower mortality.
Secondary analysis of an observational study in 349 intensive care units from 23 countries. A total of 234 patients were included who were ventilated only with APRV/BIPAP and 1,228 patients who were ventilated only with A/C. A case-matched analysis according to a propensity score was used to make comparisons between groups.
In logistic regression analysis, the most important factor associated with the use of APRV/BIPAP was the country (196 of 234 patients were from German units). Patients with coma or congestive heart failure as the reason to start mechanical ventilation, pH < 7.15 prior to mechanical ventilation, and patients who developed respiratory failure (SOFA score > 2) after intubation with or without criteria of acute respiratory distress syndrome were less likely to be ventilated with APRV/BIPAP. In the case-matched analysis there were no differences in outcomes, including mortality in the intensive care unit, days of mechanical ventilation or weaning, rate of reintubation, length of stay in the intensive care unit or hospital, and mortality in the hospital.
In this study, the APRV/BIPAP ventilation mode is being used widely across many causes of respiratory failure, but only in selected geographic areas. In our patient population we could not demonstrate any improvement in outcomes with APRV/BIPAP compared with assist-control ventilation.
C1 [Frutos-Vivar, Fernando; Esteban, Andres] Hosp Univ Getafe, Intens Care Unit, Madrid 28905, Spain.
[Gonzalez, Marco] Clin Medellin, Medellin, Colombia.
[Gonzalez, Marco] Univ Pontificia Bolivariana, Medellin, Colombia.
[Arroliga, Alejandro C.] Scott & White Mem Hosp & Clin, Temple, TX USA.
[Arroliga, Alejandro C.] Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA.
[Frutos-Vivar, Fernando; Esteban, Andres] CIBER Enfermedades Resp, Madrid, Spain.
[Raymondos, Konstantinos] Hannover Med Sch, D-30623 Hannover, Germany.
[Putensen, Christian] Univ Bonn, Dept Anesthesiol & Intens Care Med, D-5300 Bonn, Germany.
[Apezteguia, Carlos] Hosp Prof A Posadas, Buenos Aires, DF, Argentina.
[Hurtado, Javier] Hosp Clin Montevideo, Montevideo, Uruguay.
[Desmery, Pablo] Sanatorio Mitre, Buenos Aires, DF, Argentina.
[Tomicic, Vinko] Clin Alemana Santiago, Santiago, Chile.
[Elizalde, Jose] Hosp ABC, Mexico City, DF, Mexico.
[Abroug, Fekri] Fattouma Bourguiba Monastir, Monastir, Tunisia.
[Arabi, Yaseen] King Abdul Aziz Med City, Riyadh, Saudi Arabia.
[Moreno, Rui] Hosp Santo Antonio dos Capuchos, Lisbon, Portugal.
[Anzueto, Antonio] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Ferguson, Niall D.] Univ Toronto, Dept Med, Interdept Div Crit Care Med, Div Respirol,Univ Hlth Network, Toronto, ON, Canada.
[Ferguson, Niall D.] Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
RP Esteban, A (reprint author), Hosp Univ Getafe, Intens Care Unit, Carretera Toledo,Km 12-500, Madrid 28905, Spain.
EM aesteban@ucigetafe.com
OI Frutos-Vivar, Fernando/0000-0002-4648-9636; Ferguson,
Niall/0000-0002-6213-5264
FU Canadian Institutes of Health Research (Ottawa, Canada)
FX Dr. Ferguson is supported by a New Investigator Award from the Canadian
Institutes of Health Research (Ottawa, Canada).
NR 13
TC 28
Z9 31
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD MAY
PY 2010
VL 36
IS 5
BP 817
EP 827
DI 10.1007/s00134-010-1837-1
PG 11
WC Critical Care Medicine
SC General & Internal Medicine
GA 580EE
UT WOS:000276429200012
PM 20229042
ER
PT J
AU Jubran, A
Lawm, G
Kelly, J
Duffner, LA
Gungor, G
Collins, EG
Lanuza, DM
Hoffman, LA
Tobin, MJ
AF Jubran, Amal
Lawm, Gerald
Kelly, Joanne
Duffner, Lisa A.
Gungor, Gokay
Collins, Eileen G.
Lanuza, Dorothy M.
Hoffman, Leslie A.
Tobin, Martin J.
TI Depressive disorders during weaning from prolonged mechanical
ventilation
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Mechanical ventilation; Weaning; Depressive disorders
ID INTENSIVE-CARE-UNIT; QUALITY-OF-LIFE; CRITICALLY-ILL PATIENTS; DELIRIUM
SCREENING CHECKLIST; CONTROLLED-TRIAL; TERM; OUTCOMES; ILLNESS; ICU;
INTERVENTION
AB Patients who require mechanical ventilation are at risk of emotional stress because of total dependence on a machine for breathing. The stress may negatively impact ventilator weaning and survival. The purpose of this study was to determine whether depressive disorders in patients being weaned from prolonged mechanical ventilation are linked to weaning failure and decreased survival.
A prospective study of 478 consecutive patients transferred to a long-term acute care hospital for weaning from prolonged ventilation was undertaken. A clinical psychologist conducted a psychiatric interview to assess for the presence of depressive disorders.
Of the 478 patients, 142 had persistent coma or delirium and were unable to be evaluated for depressive disorders. Of the remaining 336 patients, 142 (42%) were diagnosed with depressive disorders. In multivariate analysis, co-morbidity score [odds ratio (OR), 1.23; P = 0.007], functional dependence before the acute illness (OR, 1.70, P = 0.03) and history of psychiatric disorders (OR, 3.04, P = 0.0001) were independent predictors of depressive disorders. The rate of weaning failure was higher in patients with depressive disorders than in those without such disorders (61 vs. 33%, P = 0.0001), as was mortality (24 vs. 10%, P = 0.0008). The presence of depressive disorders was independently associated with mortality (OR, 4.3; P = 0.0002); age (OR, 1.06; P = 0.001) and co-morbidity score (OR, 1.24; P = 0.02) also predicted mortality.
Depressive disorders were diagnosed in 42% of patients who were being weaned from prolonged ventilation. Patients with depressive disorders were more likely to experience weaning failure and death.
C1 [Jubran, Amal; Gungor, Gokay; Tobin, Martin J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA.
[Jubran, Amal; Gungor, Gokay; Tobin, Martin J.] Loyola Univ, Chicago Stritch Sch Med, Maywood, IL 60153 USA.
[Lawm, Gerald; Kelly, Joanne; Duffner, Lisa A.] RML Specialty Hosp, Hinsdale, IL USA.
[Collins, Eileen G.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA.
[Collins, Eileen G.] Univ Illinois, Coll Nursing, Chicago, IL USA.
[Lanuza, Dorothy M.] Univ Wisconsin, Sch Nursing, Madison, WI USA.
[Hoffman, Leslie A.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA.
RP Jubran, A (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA.
EM ajubran@lumc.edu; mtobin2@lumc.edu
OI Gungor, Gokay/0000-0003-2294-489X
FU National Institute of Health [RO1 NR008782]; Veterans Administration
Research Service
FX This paper was supported by funding from the National Institute of
Health (RO1 NR008782) and a Merit Review grant from the Veterans
Administration Research Service
NR 39
TC 60
Z9 62
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD MAY
PY 2010
VL 36
IS 5
BP 828
EP 835
DI 10.1007/s00134-010-1842-4
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 580EE
UT WOS:000276429200013
PM 20232042
ER
PT J
AU Katon, WJ
Russo, JE
Heckbert, SR
Lin, EHB
Ciechanowski, P
Ludman, E
Young, B
Von Korff, M
AF Katon, Wayne J.
Russo, Joan E.
Heckbert, Susan R.
Lin, Elizabeth H. B.
Ciechanowski, Paul
Ludman, Evette
Young, Bessie
Von Korff, Michael
TI The relationship between changes in depression symptoms and changes in
health risk behaviors in patients with diabetes
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE depression; behavior; health risk; symptom
ID SELF-CARE; CARDIOVASCULAR EVENTS; PHYSICAL-ACTIVITY; OUTCOMES;
MORTALITY; ADJUDICATION; POPULATION; ADHERENCE; SMOKING; COHORT
AB Background: This longitudinal study of patients with diabetes examined the relationship between changes in depressive symptoms and changes in diabetes self-care behaviors over 5 years.
Design, Patients and Measurements: A total of 2759 patients with diabetes enrolled in a large HMO were followed over a 5-year period. Patients filled out a baseline mail survey and participated in a telephone interview 5 years later. Depression was measured with the Patient Health Questionnaire (PHQ-9) and diabetes self-care was measured with the Summary of Diabetes Self-Care Activities (SDSCA) questionnaire. Baseline and longitudinal evidence of diabetes and medical disease severity and complications were measured using ICD-9 and CPT codes and verified by chart review.
Results: At the 5-year follow-up, patients with diabetes with either persistent or worsening depressive symptoms compared to those in the no depression group had significantly fewer days per week of following a healthy diet or participating in >= 30 mm of exercise. At 5-year follow-up, patients with clinical improvement in depression symptoms showed no differences compared to the no depression group on number of days per week of adherence to diet but showed deterioration in adherence to exercise on some, but not all, measures.
Conclusions: Patients with diabetes with persistent or worsening depressive symptoms over 5 years had significantly worse adherence to dietary and exercise regimens than patients in the no depression group. These results emphasize the need to further develop and test interventions to improve both quality of care for depression and self-care in diabetes patients. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Katon, Wayne J.; Russo, Joan E.; Ciechanowski, Paul] Univ Washington, Dept Psychiat, Sch Med, Seattle, WA 98195 USA.
[Heckbert, Susan R.; Lin, Elizabeth H. B.; Ludman, Evette; Von Korff, Michael] Grp Hlth, Ctr Hlth Studies, Seattle, WA USA.
[Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Sch Med, Seattle, WA 98195 USA.
[Young, Bessie] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Young, Bessie] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA.
RP Katon, WJ (reprint author), Univ Washington, Dept Psychiat, Sch Med, Seattle, WA 98195 USA.
EM wkaton@u.washington.edu
FU National Institute of Mental Health [K24 MH067587, MH 073686]
FX This study was supported by grants from the National Institute of Mental
Health to Dr Katon (K24 MH067587) and Dr Von Korff (MH 073686).
NR 27
TC 40
Z9 40
U1 2
U2 8
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0885-6230
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD MAY
PY 2010
VL 25
IS 5
BP 466
EP 475
DI 10.1002/gps.2363
PG 10
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 591XN
UT WOS:000277338900005
PM 19711303
ER
PT J
AU Mitsis, EM
Jacobs, D
Luo, XD
Andrews, H
Andrews, K
Sano, M
AF Mitsis, Effie M.
Jacobs, Diane
Luo, Xiaodong
Andrews, Howard
Andrews, Karen
Sano, Mary
TI Evaluating cognition in an elderly cohort via telephone assessment
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE telephone assessment; aging; cognition
ID IMPAIRMENT; VALIDATION; DEMENTIA; BATTERY; POPULATION; DISEASE; MEMORY
AB Objective: Longitudinal neuropsychological assessment provides the opportunity to observe the earliest transition to cognitive impairment in healthy, elderly individuals. We examined the feasibility, and its comparability to in-person assessment, of a telephone administered battery of established neuropsychological measures of cognitive functioning in healthy, elderly women.
Methods: Fifty-four women (age = 79+/-7.7; education = 15.4+/-3.3) who were in self-reported good health were recruited from senior centers and other community sources. A two-way cross-over design was used in which participants were randomly assigned to receive either (1) in-person neuropsychological assessment followed by telephone assessment and (2) telephone assessment followed by in-person assessment, separated by approximately 4 weeks. Linear regression models were used to determine whether there were performance differences by method (in-person vs. telephone), and equivalence testing assessed comparability of the two methods.
Results: There were no statistically significant differences in performance between in-person and telephone assessments on most neuropsychological tests, with the exception of digit span backward, Oral Trail Making Test Part A, and delayed recall on the SRT, the latter likely related to non-comparable exposure (6-trials in-person vs. 3-trials telephone). Equivalence testing differences fell in the pre-specified clinical equivalence zones, providing evidence of comparability of the two methods.
Conclusions: These pilot data support telephone administration of a neuropsychological battery that yields comparable performance to in-person assessment with respect to most instruments. Significant differences in scores on some measures suggest care should be taken in selecting specific measures used in a neuropsychological battery administered by telephone. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Mitsis, Effie M.; Luo, Xiaodong; Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, Alzheimers Dis Res Ctr, New York, NY 10029 USA.
[Mitsis, Effie M.; Luo, Xiaodong; Sano, Mary] James J Peters VA Med Ctr, Bronx, NY USA.
[Andrews, Howard; Andrews, Karen] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
RP Mitsis, EM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Alzheimers Dis Res Ctr, New York, NY 10029 USA.
EM effie.mitsis@mssm.edu
FU [R01 AG15922]
FX The authors wish to thank the directors of the community centers in the
New York metropolitan area who provided us with the opportunity to
recruit within their midst. This study was supported by R01 AG15922 (Dr.
Sano).
NR 19
TC 5
Z9 5
U1 0
U2 9
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0885-6230
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD MAY
PY 2010
VL 25
IS 5
BP 531
EP 539
DI 10.1002/gps.2373
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 591XN
UT WOS:000277338900014
PM 19697298
ER
PT J
AU Osawa, R
Singh, N
AF Osawa, Ryosuke
Singh, Nina
TI Colitis as a manifestation of infliximab-associated disseminated
cryptococcosis
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Cryptococcosis; Cryptococcus; Gastrointestinal diseases; Crohn's
disease; Tumor necrosis factor-alpha inhibitors
ID TUMOR-NECROSIS-FACTOR; ORGAN TRANSPLANT RECIPIENTS; INFECTION JOBS
SYNDROME; HIV-NEGATIVE PATIENT; IMMUNE RECONSTITUTION; GASTROINTESTINAL
CRYPTOCOCCOSIS; ESOPHAGEAL CRYPTOCOCCOSIS; ANTIRETROVIRAL THERAPY;
RHEUMATOID-ARTHRITIS; NEOFORMANS INFECTION
AB The ability of tumor necrosis factor (TNF)-alpha inhibitors to impair pivotal pro-inflammatory host defenses may facilitate the development of disseminated cryptococcosis. Gastrointestinal (GI) tract disease is an unusual presentation of this yeast infection. We describe a unique case of disseminated cryptococcosis presenting as colitis that mimicked an exacerbation of Crohn's disease in a TNF-alpha inhibitor recipient. Review of existing literature shows that in immunocompromised patients, GI cryptococcosis invariably coexists with disseminated cryptococcosis, often lacks prominent GI symptomatology, and is primarily diagnosed postmortem. In cases with opportunistic infections, discontinuation of TNF-alpha inhibitors is a common practice, however rapid rebound of inflammatory responses may incur the risk of immune reconstitution syndrome. (C) 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Singh, Nina] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA.
Univ Pittsburgh, Pittsburgh, PA 15240 USA.
RP Singh, N (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA.
EM nis5@pitt.edu
FU Pfizer; Schering-Plough; Enzon Inc.
FX Conflict of interest: Dr Singh has received research support from
Pfizer, Schering-Plough, and Enzon Inc. Dr Osawa has no interests to
declare. There was no source of support for this study.
NR 52
TC 11
Z9 11
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAY
PY 2010
VL 14
IS 5
BP E436
EP E440
DI 10.1016/j.ijid.2009.05.019
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 587IG
UT WOS:000276983400015
PM 19660974
ER
PT J
AU Vaid, M
Katiyar, SK
AF Vaid, Mudit
Katiyar, Santosh K.
TI Molecular mechanisms of inhibition of photocarcinogenesis by silymarin,
a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review)
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Review
DE antioxidant; oxidative stress; inflammation; silymarin;
photocarcinogenesis; interleukins; ultraviolet radiation; contact
hypersensitivity
ID TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE; RANDOMIZED
CONTROLLED-TRIAL; INDUCED OXIDATIVE STRESS; NONMELANOMA SKIN-CANCER;
ULTRAVIOLET-RADIATION; CONTACT HYPERSENSITIVITY; MOUSE SKIN; IMMUNE
SUPPRESSION; DNA-REPAIR; IN-VIVO
AB Changes in life style over the past several decades including much of the time spent outdoors and the use of tanning devices for cosmetic purposes by individuals have led to an increase in the incidence of solar ultraviolet (UV) radiation-induced skin diseases including the risk of skin cancers. Solar UV radiations are considered as the most prevalent environmental carcinogens, and chronic exposure of the skin to UV leads to squamous and basal cell carcinoma and melanoma in human population A wide variety of phytochemicals have been reported to have substantial anti-carcinogenic activity because of their antioxidant and anti-inflammatory properties Silymarin is one of them and extensively studied for its skin photoprotective capabilities. Silymarin. a flavanolignan, is extracted from the fruits and seeds of milk thistle (Silybum marianum L Gaertn), and has been shown to have chemopreventive effects against photocarcinogenesis in mouse tumor models. Topical treatment of silymarin inhibited photocarcinogenesis in mice in terms of tumor incidence, tumor multiplicity and growth of the tumors Wide range of in vivo mechanistic studies conducted in a variety of mouse models indicated that silymarin has anti-oxidant, anti-inflammatory and immunomodulatory properties which led to the prevention of photocarcinogenesis in mice. This review summarizes and updates the photo protective potential of silymarin with the particular emphasis on its in vivo mechanism of actions It is suggested that silymarin may favorably supplement sunscreen protection, and may be useful for skin diseases associated with solar UV radiation-induced inflammation, oxidative stress and immunomodulatory effects.
C1 [Vaid, Mudit; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU USPHS [CA 105368]; Veterans Administration Merit Review Award
FX The original work reported from Dr Katiyar's laboratory was supported
from the funds from USPHS Grant, CA 105368 (S.K.K.) and Veterans
Administration Merit Review Award (S.K.K.).
NR 91
TC 31
Z9 31
U1 3
U2 18
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAY
PY 2010
VL 36
IS 5
BP 1053
EP 1060
DI 10.3892/ijo_00000586
PG 8
WC Oncology
SC Oncology
GA 589EQ
UT WOS:000277129600002
PM 20372777
ER
PT J
AU Friedlander, AH
AF Friedlander, Arthur H.
TI Amoxicillin prophylaxis is not associated with anaphylaxis
SO INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Letter
ID ENDOCARDITIS
C1 [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Ronald Reagan Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA.
RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM arthur.friedlander@med.va.gov
NR 5
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0901-5027
J9 INT J ORAL MAX SURG
JI Int. J. Oral Maxillofac. Surg.
PD MAY
PY 2010
VL 39
IS 5
BP 520
EP 520
DI 10.1016/j.ijom.2010.01.020
PG 1
WC Dentistry, Oral Surgery & Medicine; Surgery
SC Dentistry, Oral Surgery & Medicine; Surgery
GA 608LA
UT WOS:000278584400022
PM 20189771
ER
PT J
AU Tong, J
Liu, CX
Summanen, PH
Xu, HX
Finegold, SM
AF Tong, Jia
Liu, Chengxu
Summanen, Paula H.
Xu, Huaxi
Finegold, Sydney M.
TI Corynebacterium pyruviciproducens sp nov., a pyruvic acid producer
SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY
LA English
DT Article
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; DEOXYRIBONUCLEIC-ACID; CORYNEFORM
BACTERIA; CLINICAL MATERIAL; IDENTIFICATION; SEQUENCE; STRAINS;
INFECTIONS; GENE; HYBRIDIZATION
AB A coryneform strain, 06-1773O(T) (=WAL 19168(T)), derived from a groin abscess sample was characterized using phenotypic and molecular taxonomic methods. Comparative analyses revealed more than 3% divergence of the 16S rRNA gene sequence and about 10% divergence of the partial rpoB gene sequence from the type strain of Corynebacterium glucuronolyticum. The strain could also be differentiated from C. glucuronolyticum by a set of phenotypic properties. A DNA-DNA relatedness study between strain WAL 19168(T) and C. glucuronolyticum CCUG 35055(T) showed a relatedness value of 13.3% (13.7% on repeat analysis). The genotypic and phenotypic data show that the strain merits classification within a novel species of Corynebacterium. We propose the name Corynebacterium pyruviciproducens sp. nov. for the novel species. The type strain is 06-1773O(T) (=WAL 19168(T) =CCUG 57046(T) =ATCC BAA-1742(T)).
C1 [Tong, Jia; Finegold, Sydney M.] Univ Calif Los Angeles, Dept Med, Los Angeles Sch Med, Los Angeles, CA 90024 USA.
[Tong, Jia; Liu, Chengxu; Summanen, Paula H.] W Los Angeles Vet Affairs Med Ctr, Res Serv, Los Angeles, CA 90073 USA.
[Tong, Jia; Xu, Huaxi] Jiangsu Univ, Sch Food Sci & Engn, Zhenjiang, Peoples R China.
[Tong, Jia; Xu, Huaxi] Jiangsu Univ, Sch Med Technol, Zhenjiang, Peoples R China.
[Finegold, Sydney M.] Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles Sch Med, Los Angeles, CA USA.
[Finegold, Sydney M.] W Los Angeles Vet Affairs Med Ctr, Infect Dis Sect, Los Angeles, CA 90073 USA.
RP Finegold, SM (reprint author), Univ Calif Los Angeles, Dept Med, Los Angeles Sch Med, Los Angeles, CA 90024 USA.
EM sidfinegol@aol.com
FU DOD [W81XWH-0510134]; VA
FX This work has been supported in part by DOD grant # W81XWH-0510134 and
VA Merit Review funds.
NR 30
TC 6
Z9 9
U1 0
U2 2
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
BERKS, ENGLAND
SN 1466-5026
J9 INT J SYST EVOL MICR
JI Int. J. Syst. Evol. Microbiol.
PD MAY
PY 2010
VL 60
BP 1135
EP 1140
DI 10.1099/ijs.0.011783-0
PN 5
PG 6
WC Microbiology
SC Microbiology
GA 603UK
UT WOS:000278233400022
PM 19666798
ER
PT J
AU Dougherty, RH
Sidhu, SS
Raman, K
Solon, M
Solberg, OD
Caughey, GH
Woodruff, PG
Fahy, JV
AF Dougherty, Ryan H.
Sidhu, Sukhvinder S.
Raman, Kavita
Solon, Margaret
Solberg, Owen D.
Caughey, George H.
Woodruff, Prescott G.
Fahy, John V.
TI Accumulation of intraepithelial mast cells with a unique protease
phenotype in T(H)2-high asthma
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Asthma; mast cells; tryptase; chymase; carboxypeptidase A3; stem cell
factor
ID EPITHELIAL-CELLS; CARBOXYPEPTIDASE-A; ATOPIC ASTHMATICS; ANGIOTENSIN-II;
HUMAN AIRWAY; EXPRESSION; CHYMASE; INFLAMMATION; BASOPHILS; ADHESION
AB Background: Previously, we found that mast cell tryptases and carboxypeptidase A3 (CPA3) are differentially expressed in the airway epithelium in asthmatic subjects. We also found that asthmatic subjects can be divided into 2 subgroups ("T(H)2 high" and "T(H)2 low" asthma) based on epithelial cell gene signatures for the activity of T(H)2 cytokines.
Objectives: We sought to characterize intraepithelial mast cells (IEMCs) in asthma.
Methods: We performed gene expression profiling in epithelial brushings and stereology-based quantification of mast cell numbers in endobronchial biopsy specimens from healthy control and asthmatic subjects before and after treatment with inhaled corticosteroids (ICSs). We also performed gene expression and protein quantification studies in cultured airway epithelial cells and mast cells.
Results: By means of unsupervised clustering, mast cell gene expression in the airway epithelium related closely to the expression of IL-13 signature genes. The levels of expression of mast cell genes correlate positively with lung function improvements with ICSs. IEMC density was 2-fold higher than normal in subjects with T(H)2-high asthma compared with that seen in subjects with T(H)2-low asthma or healthy control subjects (P = .015 for both comparisons), and these cells were characterized by expression of tryptases and CPA3 but not chymase. IL-13 induced expression of stem cell factor in cultured airway epithelial cells, and mast cells exposed to conditioned media from IL-13 activated epithelial cells showed downregulation of chymase but no change in tryptase or CPA3 expression.
Conclusion: IEMC numbers are increased in subjects with T(H)2-high asthma, have an unusual protease phenotype (tryptase and CPA3 high and chymase low), and predict responsiveness to ICSs. IL-13 stimulated production of stem cell factor by epithelial cells potentially explains mast cell accumulation in TH2-high asthmatic epithelium. (J Allergy Clin Immunol 2010;125:1046-53.)
C1 [Dougherty, Ryan H.; Sidhu, Sukhvinder S.; Solon, Margaret; Solberg, Owen D.; Caughey, George H.; Woodruff, Prescott G.; Fahy, John V.] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA.
[Dougherty, Ryan H.; Solon, Margaret; Solberg, Owen D.; Caughey, George H.; Woodruff, Prescott G.; Fahy, John V.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.
[Dougherty, Ryan H.] Calif Pacific Med Ctr, San Francisco Crit Care Med Grp, San Francisco, CA USA.
[Raman, Kavita; Caughey, George H.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Fahy, JV (reprint author), 513 Parnassus Ave,Box 0130, San Francisco, CA 94143 USA.
EM john.fahy@ucsf.edu
FU National Institutes of Health [F32HL093999-01, A1077439-025, R01
HL080414, R01 HL095372, P01 HL024136]
FX Supported by the National Institutes of Health National Research Service
Award F32HL093999-01 (R.H.D.), A1077439-025 and R01 HL080414 (J.V.F.),
R01 HL095372 (P.G.W.), and P01 HL024136 (G.H.C.).
NR 43
TC 95
Z9 96
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD MAY
PY 2010
VL 125
IS 5
BP 1046
EP 1053
DI 10.1016/j.jaci.2010.03.003
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA 596LO
UT WOS:000277686700013
PM 20451039
ER
PT J
AU Tomer, Y
AF Tomer, Yaron
TI Hepatitis C and interferon induced thyroiditis
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article; Proceedings Paper
CT 7th International Congress on Autoimmunity
CY MAY 05-09, 2010
CL Ljubljana, SLOVENIA
DE Interferon; Thyroiditis; Autoimmunity
ID AUTOIMMUNE ENDOCRINE DISEASE; HUMAN THYROCYTE CULTURES; CHRONIC
VIRAL-HEPATITIS; HIV ENVELOPE PROTEINS; HCV CHRONIC HEPATITIS;
GRAVES-DISEASE; ALPHA THERAPY; VIRUS-INFECTION; YERSINIA-ENTEROCOLITICA;
GENETIC SUSCEPTIBILITY
AB Autoimmune thyroid diseases (AITDs) are complex diseases that develop as a result of interactions between genetic, epigenetic, and environmental factors. Significant progress has been made in our understanding of the genetic and environmental triggers contributing to AITD. The major environmental triggers of AITD include iodine, smoking, medications, pregnancy, and possibly stress. In this review we will focus on two well-documented environmental triggers of AITD, hepatitis C virus (HCV) infection and interferon alpha (IFNa) therapy. Chronic HCV infection has been shown to be associated with increased incidence of clinical and subclinical autoimmune thyroiditis (i.e. the presence of thyroid antibodies in euthyroid subjects). Moreover, IFNa therapy of chronic HCV infection is associated with subclinical or clinical thyroiditis in up to 40% of cases which can be autoimmune, or non-autoimmune thyroiditis. In some cases interferon induced thyroiditis (IIT) in chronic HCV patients may result in severe symptomatology necessitating discontinuation of therapy. While the epidemiology and clinical presentation of HCV and interferon induced thyroiditis have been well characterized, the mechanisms causing these conditions are still poorly understood. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Tomer, Yaron] Mt Sinai Med Ctr, Dept Med, Div Endocrinol, New York, NY 10029 USA.
[Tomer, Yaron] James J Peters VA Med Ctr, New York, NY USA.
RP Tomer, Y (reprint author), Mt Sinai Med Ctr, Dept Med, Div Endocrinol, Box 1118,1 Gustave L Levy Pl, New York, NY 10029 USA.
EM Yaron.Tomer@mssm.edu
FU NIDDK NIH HHS [DK61659, R01 DK061659, R01 DK061659-08]
NR 82
TC 59
Z9 61
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
EI 1095-9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD MAY
PY 2010
VL 34
IS 3
SI SI
BP J322
EP J326
DI 10.1016/j.jaut.2009.11.008
PG 5
WC Immunology
SC Immunology
GA 585IJ
UT WOS:000276818300016
PM 20022216
ER
PT J
AU Roodman, GD
AF Roodman, G. David
TI Targeting the bone microenvironment in multiple myeloma
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Review
DE Multiple myeloma; Bone microenvironment; Bisphosphonates; Osteoclast;
Cytokines
ID HIGH-DOSE PAMIDRONATE; MARROW STROMAL CELLS; B LIGAND RANKL; OSTEOBLAST
DIFFERENTIATION; RECEPTOR ACTIVATOR; PLASMA-CELLS; OSTEOCLAST FORMATION;
OSTEOLYTIC LESIONS; TUMOR PROGRESSION; POTENTIAL ROLE
AB Multiple myeloma (MM) is a plasma cell malignancy characterized by the frequent development of osteolytic lesions, osteopenia, pathological fractures, and/or severe bone pain. In the past few years several potential factors involved in this process have been identified and, with the increased knowledge of the signaling pathways involved in the regulation of normal osteoblast and osteoclast function, have provided us with a better understanding of the contributions of the marrow microenvironment to MM bone disease. These studies have identified several potential novel targets for treating MM bone disease in addition to the current standard treatment of bisphosphonates. In this article, we discuss several potential targets for treating MM bone disease as well as novel therapies that are in clinical trials for these patients.
C1 Univ Pittsburgh, Dept Med Hematol Oncol, Vet Affairs Pittsburgh Healthcare Syst, Sch Med, Pittsburgh, PA 15240 USA.
RP Roodman, GD (reprint author), Univ Pittsburgh, Dept Med Hematol Oncol, Vet Affairs Pittsburgh Healthcare Syst, Sch Med, Res & Dev 151-U Univ Dr C,Rm 2E113, Pittsburgh, PA 15240 USA.
EM Roodmangd@upmc.edu
NR 55
TC 20
Z9 21
U1 0
U2 4
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0914-8779
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAY
PY 2010
VL 28
IS 3
BP 244
EP 250
DI 10.1007/s00774-009-0154-7
PG 7
WC Endocrinology & Metabolism; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 593OU
UT WOS:000277469200002
PM 20127498
ER
PT J
AU Bonewald, LF
Roodman, GD
Boyce, BF
Gutierrez, GE
Yoneda, T
Guise, TA
Martin, TJ
AF Bonewald, Lynda F.
Roodman, G. David
Boyce, Brendan F.
Gutierrez, Gloria E.
Yoneda, Toshiyuki
Guise, Theresa A.
Martin, T. John
TI Gregory Robert Mundy 1942-2010 IN MEMORIAM
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Biographical-Item
C1 [Bonewald, Lynda F.] Univ Missouri, Kansas City, MO 64110 USA.
[Roodman, G. David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Boyce, Brendan F.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
[Gutierrez, Gloria E.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Yoneda, Toshiyuki] Osaka Univ, Grad Sch Dent, Suita, Osaka, Japan.
[Guise, Theresa A.] Indiana Univ, Sch Med, Indianapolis, IN USA.
[Martin, T. John] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia.
RP Bonewald, LF (reprint author), Univ Missouri, Kansas City, MO 64110 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2010
VL 25
IS 5
BP 931
EP 933
DI 10.1002/jbmr.109
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 604PX
UT WOS:000278292100001
ER
PT J
AU Li, YC
Samuvel, DJ
Sundararaj, KP
Lopes-Virella, MF
Huang, Y
AF Li, Yanchun
Samuvel, Devadoss J.
Sundararaj, Kamala P.
Lopes-Virella, Maria F.
Huang, Yan
TI IL-6 and High Glucose Synergistically Upregulate MMP-1 Expression by
U937 Mononuclear Phagocytes via ERK1/2 and JNK Pathways and c-Jun
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE MATRIX METALLOPROTEINASES; INTERLEUKIN 6; DIABETES; MITOGEN-ACTIVATED
PROTEIN KINASES
ID FACTOR-KAPPA-B; MATRIX METALLOPROTEINASES; GENE-EXPRESSION;
CELL-DIFFERENTIATION; BACTERIAL-MENINGITIS; INFLAMMATORY MARKERS;
PERIODONTAL-DISEASE; REACTIVE PROTEIN; INTERLEUKIN-6; RECEPTOR
AB Matrix metalloproteinases (MMPs) play a pivotal role in tissue remodeling and destruction in inflammation-associated diseases such as cardiovascular disease and periodontal disease. Although it is known that interleukin (IL)-6 is a key proinflamatory cytokine, it remains unclear how IL-6 regulates MMP expression by mononuclear phagocytes. Furthermore, it remains undetermined how IL-6 in combination with hyperglycemia affects MMP expression. In the present study, we investigated the regulatory effect of IL-6 alone or in combination with high glucose on MMP-1 expression by U937 mononuclear phagocytes. We found that IL-6 is a powerful stimulator for MMP-1 expression and high glucose further augmented IL-6-stimulated MMP-1 expression. We also found that high glucose, IL-6, and lipopolysaccharide act in concert to stimulate MMP-1 expression. In the studies to elucidate underlying mechanisms, the extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) pathways were found to be required for stimulation of MMP-1 by IL-6 and high glucose. We also observed that IL-6 and high glucose stimulated the expression of c-Jun, a key subunit of AP-1 known to be essential for MMP-1 transcription. The role of c-Jun in MMP-1 expression was confirmed by the finding that suppression of c-Jun expression by RNA interference significantly inhibited MMP-1 expression. Finally, we demonstrated that similarly to U937 mononuclear phagocytes, IL-6 and high glucose also stimulated MMP-1 secretion from human primary monocytes. In conclusion, this study demonstrated that IL-6 anti high glucose synergistically stimulated MMP-1 expression in mononuclear phagocytes via ERK and JNK cascades and c-Jun upregulation. J. Cell. Biochem. 110: 248-259, 2010. (C) 2010 Wiley-Liss, Inc.
C1 [Lopes-Virella, Maria F.; Huang, Yan] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Li, Yanchun; Samuvel, Devadoss J.; Sundararaj, Kamala P.; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Coll Med, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA.
RP Huang, Y (reprint author), Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA.
EM huangyan@muse.edu
FU Department of Veterans Affairs; NIH [DE16353]
FX Grant sponsor: Department of Veterans Affairs; Grant sponsor: NIH; Grant
number: DE16353.
NR 50
TC 26
Z9 28
U1 0
U2 7
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAY 1
PY 2010
VL 110
IS 1
BP 248
EP 259
DI 10.1002/jcb.22532
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 593CO
UT WOS:000277429700027
PM 20225236
ER
PT J
AU Helfand, M
AF Helfand, Mark
TI AHRQ Series Editorial: Public involvement improves methods development
in comparative effectiveness reviews
SO JOURNAL OF CLINICAL EPIDEMIOLOGY
LA English
DT Editorial Material
ID STRENGTH; QUALITY; TRIALS; WORLD
C1 Portland VA Med Ctr, Oregon Evidence Based Practice Ctr Hosp & Special, Portland, OR 97219 USA.
RP Helfand, M (reprint author), Portland VA Med Ctr, Oregon Evidence Based Practice Ctr Hosp & Special, P3MED, Portland, OR 97219 USA.
EM helfand@ohsu.edu
NR 17
TC 4
Z9 4
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-4356
J9 J CLIN EPIDEMIOL
JI J. Clin. Epidemiol.
PD MAY
PY 2010
VL 63
IS 5
BP 471
EP 473
DI 10.1016/j.jclinepi.2009.11.018
PG 3
WC Health Care Sciences & Services; Public, Environmental & Occupational
Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 581OY
UT WOS:000276534800001
PM 20346860
ER
PT J
AU Helfand, M
Balshem, H
AF Helfand, Mark
Balshem, Howard
TI AHRQ Series Paper 2: Principles for developing guidance: AHRQ and the
Effective Health-Care Program
SO JOURNAL OF CLINICAL EPIDEMIOLOGY
LA English
DT Article
DE Comparative effectiveness reviews; Stakeholders; Hierarchy of evidence;
Patient-centered care; Avoiding bias; Evidence-based medicine
ID PRACTICAL CLINICAL-TRIALS; SERVICES-TASK-FORCE; SYSTEMATIC REVIEWS;
DECISION-MAKING; CHALLENGES; INTERVENTIONS; METAANALYSES; HIERARCHY;
MEDICINE; DELIVERY
AB Objective: This article describes some of the fundamental principles that have been developed to guide the work of producing comparative effectiveness reviews (CERs).
Study Design and Setting: We briefly describe the role stakeholders play in providing important insights that inform the evidence-gathering process, and discuss the critical role of analytic frameworks in illuminating the relationship between surrogate measures and health outcomes, providing an understanding of the context in which clinical decisions are made and the uncertainties that underlie clinical controversies.
Results: We describe the Effective Health Care program conceptual model for considering different types of evidence that emphasizes minimizing the risk of bias, but places high-quality, highly applicable evidence about effectiveness at the top of the hierarchy. Finally; we briefly describe areas of future methodological research.
Conclusion: CERs have become a foundation for decision-making in clinical practice and health policy. To be useful, CERs must approach the evidence from a patient-centered perspective; explore the clinical logic underlying the rationale for a service; cast a broad net with respect to types of evidence, placing a high value on effectiveness and applicability, in addition to internal validity; and, present benefits and harms for treatments and tests in a consistent way. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Helfand, Mark; Balshem, Howard] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Oregon Evidence Based Practice Ctr, Portland, OR 97239 USA.
[Helfand, Mark] Portland VA Med Ctr, Dept Hosp & Specialty Med, Portland, OR 97239 USA.
RP Balshem, H (reprint author), Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Oregon Evidence Based Practice Ctr, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM balshemh@ohsu.edu
NR 47
TC 28
Z9 28
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-4356
J9 J CLIN EPIDEMIOL
JI J. Clin. Epidemiol.
PD MAY
PY 2010
VL 63
IS 5
BP 484
EP 490
DI 10.1016/j.jclinepi.2009.05.005
PG 7
WC Health Care Sciences & Services; Public, Environmental & Occupational
Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 581OY
UT WOS:000276534800006
PM 19716268
ER
PT J
AU Whitlock, EP
Lopez, SA
Chang, S
Helfand, M
Eder, M
Floyd, N
AF Whitlock, Evelyn P.
Lopez, Sarah A.
Chang, Stephanie
Helfand, Mark
Eder, Michelle
Floyd, Nicole
TI AHRQ Series Paper 3: Identifying, selecting, and refining topics for
comparative effectiveness systematic reviews: AHRQ and the Effective
Health-Care program
SO JOURNAL OF CLINICAL EPIDEMIOLOGY
LA English
DT Article
DE Comparative effectiveness; Evidence-based practice; Systematic review;
Priority setting; Methods; Decision making
ID CLINICAL-PRACTICE GUIDELINES; SETTING PRIORITIES; CHALLENGES
AB Objective: This article discusses the identification, selection, and refinement of topics for comparative effectiveness systematic reviews within the Agency for Healthcare Research and Quality's Effective Health Care (EHC) program.
Study Design and Setting: The EHC program seeks to align its research topic selection with the overall goals of the program, impartially and consistently apply predefined criteria to potential topics, involve stakeholders to identify high-priority topics, be transparent and accountable, and continually evaluate and improve processes.
Results: A topic prioritization group representing stakeholder and scientific perspectives evaluates topic nominations that fit within the EHC program (are "appropriate") to determine how "important" topics are as considered against seven criteria. The group then judges whether a new comparative effectiveness systematic review would be a duplication of existing research syntheses, and if not duplicative, if there is adequate type and volume of research to conduct a new systematic review. Finally, the group considers the "potential value and impact" of a comparative effectiveness systematic review.
Conclusion: As the EHC program develops, ongoing challenges include ensuring the program addresses truly unmet needs for synthesized research because national and international efforts in this arena are uncoordinated, as well as engaging a range of stakeholders in program decisions while also achieving efficiency and timeliness. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Whitlock, Evelyn P.; Helfand, Mark; Eder, Michelle; Floyd, Nicole] Oregon Evidence Based Practice Ctr, Portland, OR 97227 USA.
[Whitlock, Evelyn P.; Eder, Michelle] Kaiser Permanente Ctr Hlth Res, Portland, OR 97227 USA.
[Lopez, Sarah A.; Floyd, Nicole] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Chang, Stephanie] Agcy Healthcare Res & Qual, Dept Hlth & Human Serv, Rockville, MD 20850 USA.
[Helfand, Mark] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Whitlock, EP (reprint author), Oregon Evidence Based Practice Ctr, Portland, OR 97227 USA.
EM evelyn.whitlock@kpchr.org
NR 23
TC 45
Z9 46
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-4356
J9 J CLIN EPIDEMIOL
JI J. Clin. Epidemiol.
PD MAY
PY 2010
VL 63
IS 5
BP 491
EP 501
DI 10.1016/j.jclinepi.2009.03.008
PG 11
WC Health Care Sciences & Services; Public, Environmental & Occupational
Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 581OY
UT WOS:000276534800007
PM 19540721
ER
PT J
AU Owens, DK
Lohr, KN
Atkins, D
Treadwell, JR
Reston, JT
Bass, EB
Chang, S
Helfand, M
AF Owens, Douglas K.
Lohr, Kathleen N.
Atkins, David
Treadwell, Jonathan R.
Reston, James T.
Bass, Eric B.
Chang, Stephanie
Helfand, Mark
TI AHRQ Series Paper 5: Grading the strength of a body of evidence when
comparing medical interventions-Agency for Healthcare Research and
Quality and the Effective Health-Care Program
SO JOURNAL OF CLINICAL EPIDEMIOLOGY
LA English
DT Article
DE Comparative effectiveness; Evidence-based medicine; Methods; Strength of
evidence; Systematic reviews
ID RECOMMENDATIONS
AB Objective: To establish guidance on grading strength of evidence for the Evidence-based Practice Center (EPC) program of the U.S. Agency for Healthcare Research and Quality.
Study Design and Setting: Authors reviewed authoritative systems for grading strength of evidence, identified domains and methods that should be considered when grading bodies of evidence in systematic reviews, considered public comments on an earlier draft, and discussed the approach with representatives of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group.
Results: The EPC approach is conceptually similar to the GRADE system of evidence rating; it requires assessment of four domains: risk of bias, consistency, directness, and precision. Additional domains to be used when appropriate include dose response association, presence of confounders that would diminish an observed effect, strength of association, and publication bias. Strength of evidence receives a single grade: high, moderate, low, or insufficient. We give definitions, examples, mechanisms for scoring domains, and an approach for assigning strength of evidence.
Conclusion: EPCs should grade strength of evidence separately for each major outcome and, for comparative effectiveness reviews, all major comparisons. We will collaborate with the GRADE group to address ongoing challenges in assessing the strength of evidence. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Owens, Douglas K.] Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford UCSF Evidence Based Practice Ctr, Stanford, CA 94305 USA.
[Owens, Douglas K.] VA Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA.
[Owens, Douglas K.] Stanford Univ, Ctr Primary Care & Outcomes Res, Palo Alto, CA 94304 USA.
[Lohr, Kathleen N.] RTI Int, Res Triangle Pk, NC 27709 USA.
[Atkins, David] Dept Vet Affairs, Hlth Serv Res & Dev Serv, Qual Enhancement Res Initiat, Washington, DC 20420 USA.
[Treadwell, Jonathan R.; Reston, James T.] ECRI Inst, Evidence Based Practice Ctr, Plymouth Meeting, PA 19462 USA.
[Bass, Eric B.] Johns Hopkins Univ, Evidence Based Practice Ctr, Baltimore, MD 21287 USA.
[Chang, Stephanie] Agcy Healthcare Res & Qual, Ctr Outcomes & Evidence, Rockville, MD 20850 USA.
[Helfand, Mark] Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, Portland, OR 97207 USA.
[Helfand, Mark] Portland VA Med Ctr, Portland, OR 97207 USA.
RP Owens, DK (reprint author), Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford UCSF Evidence Based Practice Ctr, 117 Encina Commons, Stanford, CA 94305 USA.
EM owens@stanford.edu
FU AHRQ
FX This research was funded through contracts from the AHRQ to the
following EPCs: ECRI Institute (290-02-0019); Johns Hopkins University
(290-02-0018), Oregon Health & Science University (290-02-0009); RTI
International (290-02-0016); and Stanford University (290-02-0017). The
opinions expressed here are those of the authors and do not necessarily
represent the views of the AHRQ, the Department of Health and Human
Services, or the Department of Veterans Affairs. The authors thank
Valerie King, MD, MPH, of the John M. Eisenberg Center at Oregon Health
& Science University for her insightful comments on an earlier draft;
and Loraine Monroe, of RTI International, for superior assistance with
manuscript preparation. We thank Gordon Guyatt, Holger Schunemann, and
the members of the GRADE working group for their work on rating quality
of evidence, for very helpful discussions about our approach, and for
comments on the manuscript.
NR 15
TC 234
Z9 237
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-4356
J9 J CLIN EPIDEMIOL
JI J. Clin. Epidemiol.
PD MAY
PY 2010
VL 63
IS 5
BP 513
EP 523
DI 10.1016/j.jclinepi.2009.03.009
PG 11
WC Health Care Sciences & Services; Public, Environmental & Occupational
Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 581OY
UT WOS:000276534800009
PM 19595577
ER
PT J
AU Leykum, L
Mortensen, E
AF Leykum, Luci
Mortensen, Eric
TI Exploring the Potential Causes of the Emergence of Hospitalists: Chicken
vs. Egg
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
ID UNITED-STATES; CARE; MOVEMENT; GROWTH
C1 [Leykum, Luci; Mortensen, Eric] Univ Texas Hlth Sci Ctr San Antonio, VERDICT S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Leykum, Luci] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hosp Med, San Antonio, TX 78229 USA.
RP Mortensen, E (reprint author), Univ Texas Hlth Sci Ctr San Antonio, VERDICT S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
EM mortensene@uthscsa.edu
NR 10
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2010
VL 25
IS 5
BP 378
EP 379
DI 10.1007/s11606-010-1320-2
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 584AH
UT WOS:000276721900002
PM 20309739
ER
PT J
AU Katon, WJ
Lin, EHB
Williams, LH
Ciechanowski, P
Heckbert, SR
Ludman, E
Rutter, C
Crane, PK
Oliver, M
Von Korff, M
AF Katon, Wayne J.
Lin, Elizabeth H. B.
Williams, Lisa H.
Ciechanowski, Paul
Heckbert, Susan R.
Ludman, Evette
Rutter, Carolyn
Crane, Paul K.
Oliver, Malia
Von Korff, Michael
TI Comorbid Depression Is Associated with an Increased Risk of Dementia
Diagnosis in Patients with Diabetes: A Prospective Cohort Study
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE depression; dementia; diabetes
ID ALZHEIMERS-DISEASE; MAJOR DEPRESSION; HIPPOCAMPAL VOLUME; COGNITIVE
DECLINE; EPSILON-4 ALLELE; OLDER-ADULTS; SELF-CARE; SYMPTOMS; HEALTH;
WOMEN
AB Both depression and diabetes have been found to be risk factors for dementia. This study examined whether comorbid depression in patients with diabetes increases the risk for dementia compared to those with diabetes alone.
We conducted a prospective cohort study of 3,837 primary care patients with diabetes (mean age 63.2 +/- 13.2 years) enrolled in an HMO in Washington State. The Patient Health Questionnaire (PHQ-9) was used to assess depression at baseline, and ICD-9 diagnoses for dementia were used to identify cases of dementia. Cohort members with no previous ICD-9 diagnosis of dementia prior to baseline were followed for a 5-year period. The risk of dementia for patients with both major depression and diabetes at baseline relative to patients with diabetes alone was estimated using cause-specific Cox proportional hazard regression models that adjusted for age, gender, education, race/ethnicity, diabetes duration, treatment with insulin, diabetes complications, nondiabetes-related medical comorbidity, hypertension, BMI, physical inactivity, smoking, HbA(1c), and number of primary care visits per month.
Over the 5-year period, 36 of 455 (7.9%) patients with major depression and diabetes (incidence rate of 21.5 per 1,000 person-years) versus 163 of 3,382 (4.8%) patients with diabetes alone (incidence rate of 11.8 per 1,000 person-years) had one or more ICD-9 diagnoses of dementia. Patients with comorbid major depression had an increased risk of dementia (fully adjusted hazard ratio 2.69, 95% CI 1.77, 4.07).
Patients with major depression and diabetes had an increased risk of development of dementia compared to those with diabetes alone. These data add to recent findings showing that depression was associated with an increased risk of macrovascular and microvascular complications in patients with diabetes.
C1 [Katon, Wayne J.; Ciechanowski, Paul] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Lin, Elizabeth H. B.; Ludman, Evette; Rutter, Carolyn; Oliver, Malia; Von Korff, Michael] Grp Hlth Res Inst, Seattle, WA USA.
[Williams, Lisa H.; Crane, Paul K.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Williams, Lisa H.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Heckbert, Susan R.] Univ Washington, Sch Med, Dept Epidemiol, Seattle, WA USA.
RP Katon, WJ (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, 1959 NE Pacific St,Box 356560, Seattle, WA 98195 USA.
EM wkaton@u.washington.edu
RI Crane, Paul/C-8623-2014
OI Crane, Paul/0000-0003-4278-7465
FU NIMH [R01 MH073686, K24 MH069741]
FX This study was supported by NIMH R01 MH073686 (Von Korff) and NIMH K24
MH069741 (Katon). The authors would like to acknowledge Jurgen Unutzer,
MD, MPH, for providing critiques for this manuscript.
NR 55
TC 52
Z9 53
U1 2
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2010
VL 25
IS 5
BP 423
EP 429
DI 10.1007/s11606-009-1248-6
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 584AH
UT WOS:000276721900012
PM 20108126
ER
PT J
AU Jacobs, EA
Beach, MC
Saha, S
AF Jacobs, Elizabeth A.
Beach, Mary Catherine
Saha, Somnath
TI What Matters in Health Disparities Education-Changing Hearts or Minds?
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
ID ATTITUDES
C1 [Jacobs, Elizabeth A.] John H Stroger Jr Hosp Cook Cty, Div Gen Med, Chicago, IL 60612 USA.
[Jacobs, Elizabeth A.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Beach, Mary Catherine] Johns Hopkins Univ, Div Gen Internal Med, Chicago, IL USA.
[Saha, Somnath] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR USA.
RP Jacobs, EA (reprint author), John H Stroger Jr Hosp Cook Cty, Div Gen Med, 1900 W Polk St,16th Floor, Chicago, IL 60612 USA.
EM ejacobs@rush.edu
NR 14
TC 2
Z9 2
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2010
VL 25
SU 2
BP S198
EP S199
DI 10.1007/s11606-010-1297-x
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 591AQ
UT WOS:000277270300025
PM 20352521
ER
PT J
AU Jung, SR
Hille, B
Nguyen, TD
Koh, DS
AF Jung, Seung-Ryoung
Hille, Bertil
Nguyen, Toan D.
Koh, Duk-Su
TI Cyclic AMP potentiates Ca2+-dependent exocytosis in pancreatic duct
epithelial cells
SO JOURNAL OF GENERAL PHYSIOLOGY
LA English
DT Article
ID PAROTID ACINAR-CELLS; PROTEIN-KINASE-A; REGULATED EXOCYTOSIS; CHROMAFFIN
CELLS; ACTIVATED RECEPTOR-2; TRANSMITTER RELEASE; SECRETORY GRANULES;
VESICLE DYNAMICS; ION CHANNELS; SYNAPSIN-I
AB Exocytosis is evoked by intracellular signals, including Ca2+ and protein kinases. We determined how such signals interact to promote exocytosis in exocrine pancreatic duct epithelial cells (PDECs). Exocytosis, detected using carbon-fiber microamperometry, was stimulated by [Ca2+](i) increases induced either through Ca2+ influx using ionomycin or by activation of P2Y2 or protease-activated receptor 2 receptors. In each case, the exocytosis was strongly potentiated when cyclic AMP (cAMP) was elevated either by activating adenylyl cyclase with forskolin or by activating the endogenous vasoactive intestinal peptide receptor. This potentiation was completely inhibited by H-89 and partially blocked by Rp-8-Br-cAMPS, inhibitors of protein kinase A. Optical monitoring of fluorescently labeled secretory granules showed slow migration toward the plasma membrane during Ca2+ elevations. Neither this Ca2+-dependent granule movement nor the number of granules found near the plasma membrane were detectably changed by raising cAMP, suggesting that cAMP potentiates Ca2+-dependent exocytosis at a later stage. A kinetic model was made of the exocytosis stimulated by UTP, trypsin, and Ca2+ ionophores with and without cAMP increase. In the model, without a cAMP rise, receptor activation stimulates exocytosis both by Ca2+ elevation and by the action of another messenger(s). With cAMP elevation the docking/priming step for secretory granules was accelerated, augmenting the releasable granule pool size, and the Ca2+ sensitivity of the final fusion step was increased, augmenting the rate of exocytosis. Presumably both cAMP actions require cAMP-dependent phosphorylation of target proteins. cAMP-dependent potentiation of Ca2+-induced exocytosis has physiological implications for mucin secretion and, possibly, for membrane protein insertion in the pancreatic duct. In addition, mechanisms underlying this potentiation of slow exocytosis may also exist in other cell systems.
C1 [Jung, Seung-Ryoung; Hille, Bertil; Koh, Duk-Su] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.
[Nguyen, Toan D.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Nguyen, Toan D.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Jung, Seung-Ryoung; Koh, Duk-Su] POSTECH, Dept Phys, Pohang 790784, Kyungbuk, South Korea.
RP Koh, DS (reprint author), Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.
EM koh@u.washington.edu
FU Korea Science and Engineering Foundation [M7-2004-000-10106-0]; R&D
Program of Advanced Technologies; National Institutes of Health
[GM083913]; Department of Veterans Affairs
FX This work was supported by the International Research Internship Program
of the Korea Science and Engineering Foundation (to S.-R. Jung,
M7-2004-000-10106-0), grants from R&D Program of Advanced Technologies
(to D.-S. Koh), the National Institutes of Health (GM083913 to B.
Hille), and the Department of Veterans Affairs (Merit Review to T. D.
Nguyen).
NR 54
TC 8
Z9 8
U1 0
U2 0
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1295
J9 J GEN PHYSIOL
JI J. Gen. Physiol.
PD MAY
PY 2010
VL 135
IS 5
BP 527
EP 543
DI 10.1085/jgp.200910355
PG 17
WC Physiology
SC Physiology
GA 587ZM
UT WOS:000277035500011
PM 20421376
ER
PT J
AU Chren, MM
AF Chren, Mary-Margaret
TI Interpretation of Quality-of-Life Scores
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Editorial Material
AB Patients' reports of their experience with illness are a key health outcome, but scores that measure these reports can be difficult to interpret. Skindex-29 measures skin-related quality of life reliably and validly. In this issue, Prinsen and colleagues compare patients' responses to "anchor" questions with their Skindex scores to derive clinically meaningful scores for the subscales of Skindex-29. The cutoff scores identify patients whose skin diseases severely affect their quality of life.
C1 [Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94121 USA.
[Chren, Mary-Margaret] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA.
RP Chren, MM (reprint author), Univ Calif San Francisco, Dept Dermatol, San Francisco VAMC 151R,4150 Clement St, San Francisco, CA 94121 USA.
EM chrenm@derm.ucsf.edu
FU NIAMS NIH HHS [K24 AR052667-07, K24 AR052667]
NR 12
TC 8
Z9 9
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2010
VL 130
IS 5
BP 1207
EP 1209
DI 10.1038/jid.2010.51
PG 4
WC Dermatology
SC Dermatology
GA 587EL
UT WOS:000276972300005
PM 20393476
ER
PT J
AU Asgari, MM
Tang, J
Warton, ME
Chren, MM
Quesenberry, CP
Bikle, D
Horst, RL
Orentreich, N
Vogelman, JH
Friedman, GD
AF Asgari, Maryam M.
Tang, Jean
Warton, Margaret E.
Chren, Mary-Margaret
Quesenberry, Charles P., Jr.
Bikle, Dan
Horst, Ronald L.
Orentreich, Norman
Vogelman, Joseph H.
Friedman, Gary D.
TI Association of Prediagnostic Serum Vitamin D Levels with the Development
of Basal Cell Carcinoma
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID SKIN-CANCER; PROSTATE-CANCER; UNITED-STATES; SUN EXPOSURE; D SYSTEM;
POPULATION; RISK; RECEPTOR; MEN
AB We investigated the association between serum 25-hydroxyvitamin D (25(OH) D) levels and basal cell carcinoma (BCC) risk in a nested case-control study at Kaiser Permanente Northern California (KPNC). A total of 220 case patients with BCC diagnosed after serum collection were matched to 220 control subjects. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) using conditional logistic regression. Fully adjusted models included body mass index (BMI), smoking, education, sun-exposure variables, X-ray exposure, and personal history of cancer. For each measure of serum 25(OH) D (continuous, clinically relevant tertiles, quintiles), we found an increased risk of BCC in unadjusted models (OR = 1.03, 95% CI 1.00-1.05, P<0.05; OR = 3.98, 95% CI: 1.31-12.31, deficient vs. sufficient, test for trend P-value <0.01; OR = 2.32, 95% CI: 1.20-4.50, 1st vs. 5th quintile, test for trend P-value 0.03). In fully adjusted models, the values attenuated slightly (OR = 1.02, 95% CI 1.00-1.05, P<0.05; OR = 3.61, 95% CI: 1.00-13.10, deficient vs. sufficient, t-trend P = 0.03; OR = 2.09 1st vs. 5th quintile, 95% CI: 0.95-4.58, t-trend P = 0.11). Our findings suggest that higher prediagnostic serum 25(OH) D levels may be associated with increased risk of subsequent BCC. Further studies to evaluate the effect of sun exposure on BCC and serum 25(OH) D levels may be warranted.
C1 [Asgari, Maryam M.] Kaiser Permanente No Calif, Kaiser Permanente, Div Res, Oakland, CA 94612 USA.
[Asgari, Maryam M.; Chren, Mary-Margaret; Bikle, Dan] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Tang, Jean] Stanford Univ, Dept Dermatol, Sch Med, Stanford, CA 94305 USA.
[Chren, Mary-Margaret] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program REAP, San Francisco, CA USA.
[Horst, Ronald L.] Heartland Assays, Ames, IA USA.
[Orentreich, Norman; Vogelman, Joseph H.] Orentreich Fdn Adv Sci Inc, Cold Spring On Hudson, NY USA.
[Friedman, Gary D.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA.
RP Asgari, MM (reprint author), Kaiser Permanente No Calif, Kaiser Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM Maryam.m.asgari@kp.org
RI Asgari, Maryam/O-4947-2016
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
[K23 AR 051037, RO1AR05003, K24 AR05266]; Kaiser Foundation Research
Institute [9601]; American Institute of Cancer Research [07A140];
Veterans Administration
FX We thank Nancy P Durr of OFAS for editorial assistance. This research
was supported by the National Institute of Arthritis and Musculoskeletal
and Skin Diseases (K23 AR 051037, MA; RO1AR05003, DB; K24 AR05266, MC),
Kaiser Foundation Research Institute (Community Benefits Grant 9601,
MA), American Institute of Cancer Research (07A140, DB), and Veterans
Administration Merit Review (DB).
NR 32
TC 33
Z9 35
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2010
VL 130
IS 5
BP 1438
EP 1443
DI 10.1038/jid.2009.402
PG 6
WC Dermatology
SC Dermatology
GA 587EL
UT WOS:000276972300031
PM 20043012
ER
PT J
AU Li, WJ
Wu, SS
Ahmad, M
Jiang, JF
Liu, H
Nagayama, T
Rose, ME
Tyurin, VA
Tyurina, YY
Borisenko, GG
Belikova, N
Chen, J
Kagan, VE
Graham, SH
AF Li, Wenjin
Wu, Shasha
Ahmad, Muzamil
Jiang, Jianfei
Liu, Hao
Nagayama, Tetsuya
Rose, Marie E.
Tyurin, Vladimir A.
Tyurina, Yulia Y.
Borisenko, Grigory G.
Belikova, Natalia
Chen, Jun
Kagan, Valerian E.
Graham, Steven H.
TI The cyclooxygenase site, but not the peroxidase site of cyclooxygenase-2
is required for neurotoxicity in hypoxic and ischemic injury
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE cell death; cyclooxygenase-2; hypoxia; ischemia; prostaglandin
ID PROSTAGLANDIN-H-SYNTHASE; TRAUMATIC BRAIN-INJURY; CEREBRAL-ISCHEMIA;
ASCORBIC-ACID; CELL-DEATH; ENDOPEROXIDE SYNTHASE; REACTION-MECHANISM;
SUPEROXIDE ANION; GENE-EXPRESSION; MOUSE MODEL
AB P>Cyclooxygenase-2 (COX-2) activity has been implicated in the pathogenesis of ischemic injury, but the exact mechanisms responsible for its toxicity remain unclear. Infection of primary neurons with an adenovirus expressing wild type (WT) COX-2 increased the susceptibility of neurons to hypoxia. Infection with an adenoviral vector expressing COX-2 with a mutation at the cyclooxygenase site did not increase susceptibility to hypoxia, whereas over-expression of COX-2 with a mutation in the peroxidase site produced similar susceptibility to hypoxia as WT COX-2. Primary neuronal cultures obtained from transgenic mice bearing a mutation in the COX-2 cylooxygenase site were protected from hypoxia. Mice with a mutation in the cyclooxygenase site had smaller infarctions 24 h after 70 min of middle cerebral artery occlusion than WT control mice. COX-2 activity had no effect on the formation of protein carbonyls. Ascorbate radicals were detected by electron paramagnetic resonance as a product of recombinant COX-2 activity and were blocked by COX-2 inhibitors. Similarly, formation of ascorbate radicals was inhibited in the presence of COX-2 inhibitors and in homogenates obtained from COX-2 null mice. Taken together, these results indicate that the cyclooxygenase activity of COX-2 is necessary to exacerbate neuronal hypoxia/ischemia injury rather than the peroxidase activity of the enzyme.
C1 [Li, Wenjin; Wu, Shasha; Ahmad, Muzamil; Liu, Hao; Nagayama, Tetsuya; Rose, Marie E.; Chen, Jun; Graham, Steven H.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Li, Wenjin; Wu, Shasha; Ahmad, Muzamil; Liu, Hao; Nagayama, Tetsuya; Rose, Marie E.; Chen, Jun; Graham, Steven H.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Jiang, Jianfei; Tyurin, Vladimir A.; Tyurina, Yulia Y.; Borisenko, Grigory G.; Belikova, Natalia; Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA.
RP Graham, SH (reprint author), VA Pittsburgh Healthcare, Geriatr Res Educ & Clin Ctr 00GRH, Highland Dr, Pittsburgh, PA 15205 USA.
EM sgra@pitt.edu
OI Tyurin, Vladimir/0000-0002-3474-1697
FU NIH [NS37549, HL70755, R03TW007320]; VA Merit Review program (SHG);
Pennsylvania Department of Health [SAP 4100027294]
FX The authors thank Pat Strickler for secretarial support. The Y371F mouse
model was provided by Dr. Colin Funk of Queen's University, Kingston,
Ontario. WT COX-2, H374Y COX-2 and Y371F COX-2 cDNAs were a gift of Dr.
L.J. Marnett (Vanderbilt University, Nashville, TN). SC58125 and
recombinant COX-2 were a gift of Peter Isakson (Monsanto-Searle, Saint
Louis, MO.). This work was supported by NIH NS37549 and the VA Merit
Review program (SHG), and by NIH Grants HL70755, R03TW007320 and the
Pennsylvania Department of Health SAP 4100027294 (VEK). The authors
declare no conflict of interest.
NR 52
TC 7
Z9 7
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2010
VL 113
IS 4
BP 965
EP 977
DI 10.1111/j.1471-4159.2010.06674.x
PG 13
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 583EM
UT WOS:000276656100015
PM 20236388
ER
PT J
AU Offner, H
Vandenbark, AA
AF Offner, Halina
Vandenbark, Arthur A.
TI RTL therapy for multiple sclerosis Phase 1 clinical study
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Meeting Abstract
CT 2nd International Conference on Advances in Clinical Neuroimmunology
CY MAY 31-JUN 01, 2010
CL Gdansk, POLAND
C1 [Offner, Halina; Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD MAY
PY 2010
VL 222
IS 1-2
BP 2
EP 3
PG 2
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 603WR
UT WOS:000278239300004
ER
PT J
AU Slee, SJ
Higgs, MH
Fairhall, AL
Spain, WJ
AF Slee, Sean J.
Higgs, Matthew H.
Fairhall, Adrienne L.
Spain, William J.
TI Tonotopic Tuning in a Sound Localization Circuit
SO JOURNAL OF NEUROPHYSIOLOGY
LA English
DT Article
ID INTERAURAL TIME DIFFERENCE; IMPROVES COINCIDENCE DETECTION; SUPERIOR
OLIVARY NUCLEUS; STEM AUDITORY NUCLEI; BRAIN-STEM; COCHLEAR NUCLEUS;
SYNAPTIC TRANSMISSION; CENTRAL NEURONS; LAMINARIS; CHICKEN
AB Slee SJ, Higgs MH, Fairhall AL, Spain WJ. Tonotopic tuning in a sound localization circuit. J Neurophysiol 103: 2857-2875, 2010. First published March 10, 2010; doi: 10.1152/jn.00678.2009. Nucleus laminaris (NL) neurons encode interaural time difference (ITD), the cue used to localize low-frequency sounds. A physiologically based model of NL input suggests that ITD information is contained in narrow frequency bands around harmonics of the sound frequency. This suggested a theory, which predicts that, for each tone frequency, there is an optimal time course for synaptic inputs to NL that will elicit the largest modulation of NL firing rate as a function of ITD. The theory also suggested that neurons in different tonotopic regions of NL require specialized tuning to take advantage of the input gradient. Tonotopic tuning in NL was investigated in brain slices by separating the nucleus into three regions based on its anatomical tonotopic map. Patch-clamp recordings in each region were used to measure both the synaptic and the intrinsic electrical properties. The data revealed a tonotopic gradient of synaptic time course that closely matched the theoretical predictions. We also found postsynaptic band-pass filtering. Analysis of the combined synaptic and postsynaptic filters revealed a frequency-dependent gradient of gain for the transformation of tone amplitude to NL firing rate modulation. Models constructed from the experimental data for each tonotopic region demonstrate that the tonotopic tuning measured in NL can improve ITD encoding across sound frequencies.
C1 [Slee, Sean J.; Higgs, Matthew H.; Fairhall, Adrienne L.; Spain, William J.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.
[Spain, William J.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Spain, William J.] VA Puget Sound Hlth Care Syst, Neurol Sect, Seattle, WA USA.
RP Spain, WJ (reprint author), Neurol 127,1660 S Columbian Way, Seattle, WA 98108 USA.
EM spain@u.washington.edu
FU Veterans Administration; National Institutes of Health;
Burroughs-Welcome Careers at the Scientific Interface award; Sloan
Research Fellowship
FX This work was supported by a Veterans Administration Merit Review to W.
J. Spain, a National Institutes of Health training grant to S. J. Slee,
and a Burroughs-Welcome Careers at the Scientific Interface award and
Sloan Research Fellowship to A. L. Fairhall.
NR 49
TC 17
Z9 17
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3077
J9 J NEUROPHYSIOL
JI J. Neurophysiol.
PD MAY
PY 2010
VL 103
IS 5
BP 2857
EP 2875
DI 10.1152/jn.00678.2009
PG 19
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 594UN
UT WOS:000277564500048
PM 20220079
ER
PT J
AU Dixon, JA
Spinale, FG
AF Dixon, Jennifer A.
Spinale, Francis G.
TI Pathophysiology of Myocardial Injury and Remodeling: Implications for
Molecular Imaging
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE basic cardiology; technical cardiology; clinical cardiology; MRI;
cardiac MRI; infarct expansion; myocardial remodeling
ID CARDIOVASCULAR MAGNETIC-RESONANCE; MESENCHYMAL STEM-CELLS; COLLAGEN
DEPOSITION; INFARCTION; TRANSPLANTATION; INHIBITION; METABOLISM; MODEL;
RAT
AB Despite advances in reperfusion therapy, acute coronary syndromes can still result in myocardial injury and subsequent myocardial infarction (MI). Molecular, cellular, and interstitial events antecedent to the acute MI culminate in deleterious changes in the size, shape, and function of the left ventricle (LV), collectively termed LV remodeling. Three distinct anatomic and physiologic LV regions can be described after MI: the infarct, border zone, and remote regions. Given the complexity of post-MI remodeling, imaging modalities must be equally diverse to elucidate this process. The focus of this review will first be on cardiovascular MRI of the anatomic and pathophysiologic LV regions of greatest interest with regard to the natural history of the post-MI remodeling process. This review will then examine imaging modalities that provide translational and molecular insight into burgeoning treatment fields for the attenuation of post-MI remodeling, such as cardiac restraint devices and stem cell therapy.
C1 Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA.
Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Spinale, FG (reprint author), Strom Thurmond Res Ctr, 114 Doughty St,Suite 625, Charleston, SC 29425 USA.
EM wilburnm@musc.edu
FU NHLBI NIH HHS [R01 HL059165-12, R01 HL059165]
NR 38
TC 4
Z9 5
U1 0
U2 1
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
J9 J NUCL MED
JI J. Nucl. Med.
PD MAY
PY 2010
VL 51
SU 1
BP 102S
EP 106S
DI 10.2967/jnumed.109.068213
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 592XG
UT WOS:000277414600010
PM 20395340
ER
PT J
AU McKlveen, JM
Wilson, JM
Rubin, RT
Rhodes, ME
AF McKlveen, Jessica M.
Wilson, Jared M.
Rubin, Robert T.
Rhodes, Michael E.
TI Sexually diergic, dose-dependent hypothalamic-pituitary-adrenal axis
responses to nicotine in a dynamic in vitro perfusion system
SO JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
LA English
DT Article
DE ACTH; AVP; Cholinergic; CORT; CRH; Hormones; HPA Axis; Methods;
Nicotine; Rat
ID CORTICOTROPIN-RELEASING HORMONE; ESTROUS-CYCLE INFLUENCES; HPA AXIS;
ARGININE-VASOPRESSIN; FEMALE RATS; CHOLINERGIC STIMULATION;
PARAVENTRICULAR NUCLEUS; ANTERIOR-PITUITARY; STRESS-RESPONSE;
SEX-DIFFERENCES
AB Introduction: The hypothalamic-pituitary-adrenal cortical (HPA) axis modulates physiological responses to stress. We previously reported sexually diergic, dose-dependent HPA responses in vivo following nicotine administration: Male rats had greater arginine vasopressin (AVP) responses than females, and female rats had greater adrenocorticotropic hormone (ACTH) and corticosterone (CORT) responses than males. The goal of the present study was to further investigate sexually diergic, dose-dependent HPA responses following nicotine addition to an in vitro model of the HPA axis, so that hormone output could be determined at each level of the axis. Methods: Hypothalami, pituitaries, and adrenal glands were harvested from male and female rats. One-half hypothalamus, one-half pituitary, and one adrenal gland were placed individually into three jacketed tissue baths connected by tubing and perfused in series with physiological medium. Sampling ports between tissue baths were used to collect buffer before and after addition of various doses of nicotine, for measurement of AVP and corticotropin-releasing hormone (CRH) from the hypothalamus bath, ACTH from the pituitary bath, and CORT from the adrenal bath. Hormones were measured by highly specific immunoassays. Results: Stable temperatures, flow rates, pH, and hormone baselines were achieved in the in vitro system. Consistent with our in vivo and earlier in vitro studies, nicotine added to the hypothalamus tissue bath significantly increased HPA responses in a sex- and dose-dependent manner: Males had greater AVP responses than did females, and females had greater CRH responses than did males. Sexually diergic ACTH and CORT responses were less apparent and were higher in females. Discussion: Our in vitro system accurately models in vivo HPA responses to nicotine in both sexes and thus represents a reliable method for investigating the effects of nicotine on components of the HPA axis. These studies may be pertinent to understanding the biological differences to nicotine between men and women smokers. (C) 2010 Elsevier Inc. All rights reserved.
C1 [McKlveen, Jessica M.; Wilson, Jared M.; Rhodes, Michael E.] St Vincent Coll, Dept Biol, Latrobe, PA 15650 USA.
[Rubin, Robert T.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA.
RP Rhodes, ME (reprint author), St Vincent Coll, Dept Biol, 300 Fraser Purchase Rd, Latrobe, PA 15650 USA.
EM michael.rhodes@email.stvincent.edu
FU NIH [MH28380-28]; Saint Vincent College
FX The technical assistance of Anna N. Taylor, Ph.D. and Delia L Tio, for
their contributions to the AVP, ACTH and CORT assays, is gratefully
acknowledged. This work was supported by NIH grant MH28380-28 to RTR and
a Saint Vincent College Faculty Research Grant to MER.
NR 58
TC 4
Z9 4
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8719
J9 J PHARMACOL TOX MET
JI J. Pharmacol. Toxicol. Methods
PD MAY-JUN
PY 2010
VL 61
IS 3
BP 311
EP 318
DI 10.1016/j.vascn.2010.01.009
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 660FE
UT WOS:000282624700011
PM 20117222
ER
PT J
AU Zhang, XY
Xiu, MH
Chen, DC
Zhu, FY
Wu, GY
Haile, CN
Lu, L
Kosten, TA
Kosten, TR
AF Zhang, Xiang Yang
Xiu, Mei Hong
Chen, Da Chun
Zhu, Feng Yan
Wu, Gui Ying
Haile, Colin N.
Lu, Lin
Kosten, Therese A.
Kosten, Thomas R.
TI Increased S100B serum levels in schizophrenic patients with tardive
dyskinesia: Association with dyskinetic movements
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Tardive dyskinesia; Schizophrenia; S100B; Antipsychotic treatment
ID S-100B PROTEIN; ANTIPSYCHOTICS; CLOZAPINE; SYMPTOMS; BRAIN; BLOOD
AB Several studies show that calcium-binding protein S100B is increased in schizophrenia and may be involved in the pathogenesis of tardive dyskinesia (TD). We therefore compared serum S100B levels in normal controls (n = 60), schizophrenic patients with (n = 32) and without TD (n = 50). Assessments included the abnormal involuntary movement scale (AIMS) and the positive and negative syndrome scale (PANSS). Serum S100B levels were measured by enzyme-linked immunosorbent assay (ELISA). The results indicated that patients with TD had higher serum S100B levels than normals and those without TD. Serum S100B levels were positively correlated with AIMS scores in patients with TD. These data suggest that increased S100B levels may be related to neuro-degeneration, associated with TO pathophysiology. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Zhang, Xiang Yang; Wu, Gui Ying; Haile, Colin N.; Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Zhang, Xiang Yang; Xiu, Mei Hong; Chen, Da Chun; Zhu, Feng Yan] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing, Peoples R China.
[Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100871, Peoples R China.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu; kosten@bcm.edu
OI Haile, Colin/0000-0001-8293-7291
FU Beijing Municipal Natural Science Foundation [7072035]; Stanley Medical
Research Institute [03T-459, 05T-726]; Department of Veterans Affairs;
VISN 16; Mental Illness Research, Education and Clinical Center
(MIRECC); United States National Institute of Health [K05-DA0454,
P50-DA18827, U01-MH79639]
FX The authors would like to thank Drs. Yun Long Tan, Wu Fang Zhang, Zhi
Ren Wang, Bao Hua Zhang, and Gui Gang Yang for all of their hard work
and significant contributions toward the study.; This study was funded
by the Beijing Municipal Natural Science Foundation (ID: 7072035), the
Stanley Medical Research Institute (03T-459 and 05T-726), and the
Department of Veterans Affairs, VISN 16, Mental Illness Research,
Education and Clinical Center (MIRECC), United States National Institute
of Health K05-DA0454, P50-DA18827 and U01-MH79639.
NR 33
TC 11
Z9 12
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD MAY
PY 2010
VL 44
IS 7
BP 429
EP 433
DI 10.1016/j.jpsychires.2009.10.012
PG 5
WC Psychiatry
SC Psychiatry
GA 603XA
UT WOS:000278240200003
PM 19932492
ER
PT J
AU Buccheri, R
Trygstad, L
Buffum, MD
Gerlock, AA
AF Buccheri, Robin
Trygstad, Louise
Buffum, Martha D.
Gerlock, April A.
TI Developing an Evidence-Based Practice for Psychiatric Nursing
SO JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES
LA English
DT Editorial Material
ID BEHAVIORAL-MANAGEMENT; HALLUCINATIONS
C1 [Buccheri, Robin; Trygstad, Louise] Univ San Francisco, Sch Nursing, San Francisco, CA 94117 USA.
[Buffum, Martha D.] VA Med Ctr, San Francisco, CA USA.
[Gerlock, April A.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA.
[Gerlock, April A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Buccheri, R (reprint author), Univ San Francisco, Sch Nursing, San Francisco, CA 94117 USA.
NR 11
TC 3
Z9 3
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0279-3695
J9 J PSYCHOSOC NURS MEN
JI J. Psychosoc. Nurs. Ment. Health Serv.
PD MAY
PY 2010
VL 48
IS 5
BP 3
EP 5
DI 10.3928/02793695-20100331-01
PG 3
WC Nursing
SC Nursing
GA 595BU
UT WOS:000277586500001
PM 20645442
ER
PT J
AU Gerlock, AA
Buccheri, R
Buffum, MD
Trygstad, L
Dowling, GA
AF Gerlock, April A.
Buccheri, Robin
Buffum, Martha D.
Trygstad, Louise
Dowling, Glenna A.
TI Responding to Command Hallucinations to Harm The Unpleasant Voices Scale
and Harm Command Safety Protocol
SO JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES
LA English
DT Article
ID AUDITORY HALLUCINATIONS; BEHAVIORAL-MANAGEMENT; SCHIZOPHRENIA;
DANGEROUSNESS
AB Command hallucinations are relatively common in voice hearers and are taken seriously because of the potential threat to self and others. Many variables mediate the relationship between hearing commands and acting on them. This article describes the implementation of the Harm Command Safety Protocol and the Unpleasant Voices Scale to respond to command hallucinations to harm in the context of the dissemination of a multisite, evidence-based behavioral management course for patients with auditory hallucinations.
C1 [Gerlock, April A.] VA Puget Sound Hlth Care Syst, Amer Lake Div, Tacoma, WA 98493 USA.
[Gerlock, April A.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA.
[Trygstad, Louise] Univ San Francisco, Sch Nursing, San Francisco, CA 94117 USA.
[Dowling, Glenna A.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94143 USA.
RP Gerlock, AA (reprint author), VA Puget Sound Hlth Care Syst, Amer Lake Div, 5000 Vet Dr, Tacoma, WA 98493 USA.
EM April.Gerlock@va.gov
NR 25
TC 5
Z9 5
U1 2
U2 6
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0279-3695
J9 J PSYCHOSOC NURS MEN
JI J. Psychosoc. Nurs. Ment. Health Serv.
PD MAY
PY 2010
VL 48
IS 5
BP 26
EP 33
DI 10.3928/02793695-20100304-03
PG 8
WC Nursing
SC Nursing
GA 595BU
UT WOS:000277586500008
PM 20349886
ER
PT J
AU Hirsh, JM
Boyle, DJ
Collier, DH
Oxenfeld, AJ
Caplan, L
AF Hirsh, Joel M.
Boyle, Dennis J.
Collier, David H.
Oxenfeld, Abbey J.
Caplan, Liron
TI Health Literacy Predicts the Discrepancy Between Patient and Provider
Global Assessments of Rheumatoid Arthritis Activity at a Public Urban
Rheumatology Clinic
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE RHEUMATOID ARTHRITIS; LITERACY; PATIENT OUTCOME ASSESSMENT; EDUCATION
STATUS
ID DISEASE-ACTIVITY; OLDER-ADULTS; ASSESSMENT QUESTIONNAIRE; PHYSICIAN;
CARE; ASSOCIATION; DISPARITIES; PERCEPTION; SCORES; SCALE
AB Objective. Numerous studies report that significant discordance exists between patient and provider [physician] measures of rheumatoid arthritis (RA). We examined whether health literacy explains this discordance.
Methods. We recruited English-speaking adult patients with RA for this cross-sectional study. Subjects completed 2 versions of patient global assessments of disease activity (PTGA), using standard terminology from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and the 28-joint count Disease Activity Score 28 (DAS28). The provider global assessment (MDGA) was also obtained. The discrepancy between PTGA and MDGA was calculated as the absolute difference between these assessments. We used validated instruments l:Short Test of Functional Health Literacy in Adults (S-TOFHLA) and Rapid Estimate of Adult Literacy in Medicine (REALM)] and linear regression to determine whether health literacy predicts disease measure discrepancy.
Results. The study included 110 subjects. Limited health literacy was a common finding by both the REALM and S-TOFHLA. PTGA and MDGA showed fair to good correlation (r = 0.66-0.68), although both versions of the PTGA were significantly higher than MDGA by the t-test (p < 0.001). The S-TOFHLA and REALM both were associated with the absolute difference between the MDGA and PTGA by linear regression, and results remained statistically significant in multivariate analysis.
Conclusion. Health literacy was independently associated with the extent of discrepancy between PTGA and MDGA in English-speaking patients with RA at an urban clinic. This finding should influence our interpretation of disease measures. (First Release March 15 2010; J Rheumatol 2010;37:961-6; doi:10.3899/jrheum.090964)
C1 [Hirsh, Joel M.; Oxenfeld, Abbey J.] Denver Hlth Med Ctr, Dept Med, Div Rheumatol, Denver, CO 80204 USA.
[Collier, David H.; Caplan, Liron] Univ Colorado, Dept Med, Denver Sch Med, Div Rheumatol, Denver, CO USA.
[Caplan, Liron] Denver VA Med Ctr, Dept Med, Denver, CO USA.
RP Hirsh, JM (reprint author), Denver Hlth Med Ctr, Dept Med, Div Rheumatol, 777 Bannock St,Mail Code 4000, Denver, CO 80204 USA.
EM joel.hirshMD@dhha.org
FU Denver Health Department of Medicine; VA Health Service Research and
Development Career Development Award [07-221]
FX Supported by the Denver Health Department of Medicine. Dr. Caplan is
supported by a VA Health Service Research and Development Career
Development Award (07-221). The views expressed in this article are
those Of the authors and do not necessarily reflect the position or
policy of the US Department of Veterans Affairs.
NR 44
TC 19
Z9 20
U1 1
U2 1
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
EI 1499-2752
J9 J RHEUMATOL
JI J. Rheumatol.
PD MAY
PY 2010
VL 37
IS 5
BP 961
EP 966
DI 10.3899/jrheum.090964
PG 6
WC Rheumatology
SC Rheumatology
GA 596PH
UT WOS:000277696700015
PM 20231210
ER
PT J
AU Konrad-Martin, D
James, KE
Gordon, JS
Reavis, KM
Phillips, DS
Bratt, GW
Fausti, SA
AF Konrad-Martin, Dawn
James, Kenneth E.
Gordon, Jane S.
Reavis, Kelly M.
Phillips, David S.
Bratt, Gene W.
Fausti, Stephen A.
TI Evaluation of Audiometric Threshold Shift Criteria for Ototoxicity
Monitoring
SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY
LA English
DT Article
DE Audiologic monitoring/testing; distortion-product otoacoustic emissions;
hearing loss; high-frequency audiometry; ototoxicity monitoring;
tinnitus; veteran
ID HIGH-FREQUENCY AUDIOMETRY; PURE-TONE THRESHOLDS;
CIS-DIAMMINEDICHLOROPLATINUM; HEARING-LOSS; AMINOGLYCOSIDE OTOTOXICITY;
CISPLATIN OTOTOXICITY; OTOACOUSTIC EMISSIONS; SENNHEISER HDA-200; DOSE
CISPLATIN; RISK-FACTORS
AB Background: There is disagreement about ototoxicity monitoring methods. Controversy exists about what audiometric threshold shift criteria should be used, which frequencies should be tested, and with what step size. An evaluation of the test performance achieved using various criteria and methods for ototoxicity monitoring may help resolve these issues.
Purpose: (1) Evaluate test performance achieved using various significant threshold shift (STS) definitions for ototoxicity monitoring in a predominately veteran population; and (2) determine whether testing in 1/6- or 1/3-octave steps improves test performance compared to 1/2-octave steps.
Research Design: A prospective, observational study design was used in which STSs were evaluated at frequencies within an octave of each subject's high-frequency hearing limit at two time points, an early monitoring test and the final monitoring test.
Study Sample: Data were analyzed from 78 ears of 41 patients receiving cisplatin and from 53 ears of 28 hospitalized patients receiving nonototoxic antibiotics. Cisplatin-treated subjects received a cumulative dosage >= 350 mg by the final monitoring test. Testing schedule, age, and pre-exposure hearing characteristics were similar between the subject groups.
Data Collection and Analysis: Threshold shifts relative to baseline were examined to determine whether they met criteria based on magnitudes of positive STS (shifts of >= 5, 10, 15, or 20 dB) and numbers of frequencies affected (shifts at >= 1, 2, or 3 adjacent frequencies) for data collected using approximately 16-, 1/3-, or 1/2-octave steps. Thresholds were confirmed during monitoring sessions in which shifts were identified. Test performance was evaluated with receiver operating characteristic (ROC) curves developed using a surrogate "gold standard"; true positive (TP) rates were derived from the cisplatin-exposed group and false positive (FP) rates from the nonexposed, control group. Best STS definitions were identified that achieved the greatest areas under ROC curves or resulted in the highest TP rates for a fixed FP rate near 5%, chosen to minimize the number of patients incorrectly diagnosed with ototoxic hearing loss.
Results: At the early monitoring test, average threshold shifts differed only slightly across groups. Test-frequency step size did not affect performance, and changes at one or more frequencies yielded the best test performance. At the final monitoring test, average threshold shifts were +10.5 dB for the cisplatin group, compared with -0.2 dB for the control group. Compared with the 1/2-octave step size used clinically, use of smaller frequency steps improved test performance for threshold shifts at >= 2 or >= 3 adjacent frequencies. Best overall test performance was achieved using a criterion cutoff of >= 10 dB threshold shift at >= 2 adjacent frequencies tested in 1/6-octave steps. Best test performance for the 1/2-octave step size was achieved for shifts >= 15 dB at one or more frequencies.
Conclusions: An ototoxicity monitoring protocol that uses an individualized, one-octave range of frequencies tested in 1/6-octave steps is quick to administer and has an acceptable FP rate. Similar test performance can be achieved using 1/3-octave test frequencies, which further reduces monitoring test time.
C1 [Konrad-Martin, Dawn; James, Kenneth E.; Gordon, Jane S.; Reavis, Kelly M.; Phillips, David S.; Fausti, Stephen A.] Oregon Hlth & Sci Univ, Sch Med, Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res, Nashville, TN USA.
[Konrad-Martin, Dawn; Fausti, Stephen A.] Oregon Hlth & Sci Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Nashville, TN USA.
[Bratt, Gene W.] Oregon Hlth & Sci Univ, Sch Med, Dept Publ Hlth & Prevent Med, Nashville, TN USA.
[Bratt, Gene W.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Audiol Serv, Nashville, TN USA.
[Bratt, Gene W.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Speech Pathol Serv, Nashville, TN USA.
[James, Kenneth E.; Phillips, David S.] Vanderbilt Univ, Dept Hearing & Speech Sci, Nashville, TN USA.
RP Konrad-Martin, D (reprint author), 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM dawn.martin@va.gov
OI Reavis, Kelly/0000-0002-4906-1010
FU United States Department of Veterans Affairs (VA), Veterans Health
Administration, Office of Research and Development Rehabilitation
Research and Development (RRD) Service [C4447K, C4183R, C2346R]
FX Work supported by the United States Department of Veterans Affairs (VA),
Veterans Health Administration, Office of Research and Development
Rehabilitation Research and Development (RR&D) Service grants C4447K,
C4183R, and C2346R. The authors appreciate significant contributions to
this work by Douglas Noffsinger, Oregon Health and Science University;
Amy Britt, Jennifer Dillard, Mia Rosenfeld, Kirsti Raleigh, Dawn
Bradley, VA Tennessee Valley Health Care System; Stephanie Girvan, Karen
Sugiura, VA Greater Los Angeles Health Care System; and Daniel
McDermott, Carolyn Landsverk, VA RR&D National Center for Rehabilitative
Auditory Research. Portions of this paper were presented at the 2007
American Auditory Society Meeting in Scottsdale, AZ, and the 2007
American Speech-Language-Hearing Association Convention in Boston, MA.
NR 47
TC 8
Z9 8
U1 3
U2 11
PU AMER ACAD AUDIOLOGY
PI RESTON
PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA
SN 1050-0545
J9 J AM ACAD AUDIOL
JI J. Am. Acad. Audiol.
PD MAY
PY 2010
VL 21
IS 5
BP 301
EP 314
DI 10.3766/jaaa.21.5.3
PG 14
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 615MH
UT WOS:000279138900003
PM 20569665
ER
PT J
AU Strickland, PAO
Hudson, SV
Piasecki, A
Hahn, K
Cohen, D
Orzano, AJ
Parchman, ML
Crabtree, BF
AF Strickland, Pamela A. Ohman
Hudson, Shawna V.
Piasecki, Alicja
Hahn, Karissa
Cohen, Deborah
Orzano, A. John
Parchman, Michael L.
Crabtree, Benjamin F.
TI Features of the Chronic Care Model (CCM) Associated with Behavioral
Counseling and Diabetes Care in Community Primary Care
SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE
LA English
DT Article
DE Primary Health Care; Chronic Disease; Diabetes; Chronic Care Model
ID QUALITY IMPROVEMENT; HEALTH-CARE; CHRONIC ILLNESS; DIETARY INTERVENTION;
RANDOMIZED-TRIAL; SELF-MANAGEMENT; FAMILY MEDICINE; CHRONIC DISEASE;
OBESE-PATIENTS; RISK-FACTORS
AB Background: The Chronic Care Model (CCM) was developed to improve chronic disease care, but it may also inform delivery of other types of preventive care. Using hierarchical analyses of service delivery to patients, we explored associations of CCM implementation with diabetes care and counseling for diet or weight loss and physical activity in community-based primary care offices.
Methods: Secondary analysis focused on baseline data from 25 practices (with an average of 4 physicians per practice) participating in an intervention trial targeting improved colorectal cancer screening rates. This intervention made no reference to the CCM. CCM implementation was measured through staff and clinical management surveys and was associated with patient care indicators (chart audits and patient questionnaires).
Results: Overall, practices had low levels of CCM implementation. However, higher levels of CCM implementation were associated with better diabetes assessment and treatment of patients (P = .009 and .015, respectively), particularly among practices open to "innovation." Physical activity counseling for obese and, particularly, overweight patients was strongly associated with CCM implementation (P = .0017), particularly among practices open to "innovation"; however, this association did not hold for overweight and obese patients with diabetes.
Conclusions: Very modest levels of CCM implementation in unsupported primary care practices are associated with improved care for patients with diabetes and higher rates of behavioral counseling. Incremental incorporation of CCM components is an option, especially for community practices with stretched resources and with cultures of "innovativeness." (J Am Board Fam Med 2010;23:295-305.)
C1 [Strickland, Pamela A. Ohman] Univ Med & Dent New Jersey, Sch Publ Hlth, Dept Biostat, Piscataway, NJ 08854 USA.
[Crabtree, Benjamin F.] Univ Med & Dent New Jersey, Sch Publ Hlth, Dept Epidemiol, Piscataway, NJ 08854 USA.
[Strickland, Pamela A. Ohman; Hudson, Shawna V.; Piasecki, Alicja; Hahn, Karissa; Cohen, Deborah; Crabtree, Benjamin F.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Family Med, New Brunswick, NJ USA.
[Strickland, Pamela A. Ohman; Hudson, Shawna V.; Crabtree, Benjamin F.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA.
[Orzano, A. John] Dept Family Med, Concord, NH USA.
[Crabtree, Benjamin F.] Ctr Res Family Practice & Primary Care, Cleveland, OH USA.
[Parchman, Michael L.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Strickland, PAO (reprint author), Univ Med & Dent New Jersey, Sch Publ Hlth, Dept Biostat, 683 Hoes Lane W,Room 218,POB 9, Piscataway, NJ 08854 USA.
EM ohmanpa@umdnj.edu
OI Parchman, Michael/0000-0001-7129-2889
FU National Cancer Institute [R01 CA11287]; American Academy of Family
Physicians' Research Center; Cancer Institute of New Jersey's Primary
Care Research shared resource
FX Research was supported by the National Cancer Institute (R01 CA11287),
an American Academy of Family Physicians' Research Center grant, and the
Cancer Institute of New Jersey's Primary Care Research shared resource.
NR 59
TC 19
Z9 19
U1 2
U2 16
PU AMER BOARD FAMILY MEDICINE
PI LEXINGTON
PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA
SN 1557-2625
J9 J AM BOARD FAM MED
JI J. Am. Board Fam. Med.
PD MAY-JUN
PY 2010
VL 23
IS 3
BP 295
EP 305
DI 10.3122/jabfm.2010.03.090141
PG 11
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 592OZ
UT WOS:000277390200004
PM 20453175
ER
PT J
AU Semla, TP
Ouslander, JG
AF Semla, Todd P.
Ouslander, Joseph G.
TI The American Geriatrics Society Transitions to New Leadership
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Editorial Material
C1 [Semla, Todd P.] US Dept Vet Affairs, Chicago, IL USA.
[Semla, Todd P.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA.
[Semla, Todd P.] Northwestern Univ, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.
[Ouslander, Joseph G.] Florida Atlantic Univ, Geriatr Programs, Charles E Schmidt Coll Biomed Sci, Boca Raton, FL 33431 USA.
RP Semla, TP (reprint author), US Dept Vet Affairs, Chicago, IL USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2010
VL 58
IS 5
BP 820
EP 821
DI 10.1111/j.1532-5415.2010.02846.x
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 592XE
UT WOS:000277414400003
PM 20722818
ER
PT J
AU Martin, JL
Fiorentino, L
Jouldjian, S
Josephson, KR
Alessi, CA
AF Martin, Jennifer L.
Fiorentino, Lavinia
Jouldjian, Stella
Josephson, Karen R.
Alessi, Cathy A.
TI Sleep Quality in Residents of Assisted Living Facilities: Effect on
Quality of Life, Functional Status, and Depression
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE sleep; assisted living facilities; depression; quality of life;
functional status
ID FORM HEALTH SURVEY; OLDER-ADULTS; OSTEOPOROTIC FRACTURES; COGNITIVE
IMPAIRMENT; DAYTIME SLEEPINESS; NURSING FACILITY; SELF-REPORT;
COMORBIDITY; PEOPLE; WOMEN
AB OBJECTIVES
To describe sleep patterns in older adults living in assisted living facilities (ALFs) and to explore the relationship between sleep disturbance and quality of life, functional status, and depression over 6 months of follow-up.
DESIGN
Prospective, observational cohort study.
SETTING
Eighteen ALFs in the Los Angeles area.
PARTICIPANTS
One hundred twenty-one ALF residents aged 65 and older (mean age 85.3, 86% female, 88% non-Hispanic white).
MEASUREMENTS
Data were collected at baseline and 3 and 6 months after enrollment. Data collected were demographics, physical and cognitive functioning, depression, quality of life, comorbidities, medications, and subjective (i.e., questionnaires) and objective (i.e., 3 days and nights of wrist actigraphy) measures of sleep.
RESULTS
Sixty-five percent of participants reported clinically significant sleep disturbance on the Pittsburgh Sleep Quality Index, and objective wrist actigraphy confirmed poor sleep quality. In regression analyses including sleep variables and other predictors, more self-reported sleep disturbance at baseline was associated with worse health-related quality of life (Medical Outcomes Study 12-item Short Form Survey Mental Component Summary score) and worse depressive symptoms five-item Geriatric Depression Scale at follow-up. Worse nighttime sleep (according to actigraphy) at baseline was associated with worse activities of daily living functioning and more depressive symptoms at follow-up.
CONCLUSIONS
Sleep disturbance is common in older ALF residents, and poor sleep is associated with declining functional status and quality of life and greater depression over 6 months of follow-up. Studies are needed to determine whether improving sleep in ALF residents will result in improvements in these outcomes. Well-established treatments should be adapted for use in ALFs and systematically evaluated in future research.
C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Univ Calif Los Angeles, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA 90095 USA.
Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Martin, JL (reprint author), VAGLAHS GRECC 11E, 16111 Plummer St, North Hills, CA 91343 USA.
EM Jennifer.martin@va.gov
FU Sepracor Inc., Marlborough, Massachusetts; National Institutes of Health
(NIH), National Institute on Aging [K23 AG028452]; National Institute of
Mental Health [T32 MH 019925-11]; University of California at Los
Angeles (UCLA) Academic Senate Council on Research; Veterans Affairs
(VA) Greater Los Angeles Healthcare System, Geriatric Research,
Education and Clinical Center; VA Health Services Research and
Development [IIR 04-321-2]; UCLA Cousins Center for
Psychoneuroimmunology
FX The authors thank the participating facilities, the residents who took
part in the study, and the research staff who made this study possible.
In particular, we wish to thank Terry Vandenberg, MA, and Rebecca Saia,
who served as project coordinators for this study.; Conflicts of
Interest: Funding for this project was provided to Dr. Alessi from
Sepracor Inc., Marlborough, Massachusetts. The authors have no other
potential conflicts of interest to disclose. This study was supported by
National Institutes of Health (NIH), National Institute on Aging Grant
K23 AG028452 and National Institute of Mental Health Grant T32 MH
019925-11; the University of California at Los Angeles (UCLA) Academic
Senate Council on Research; the Veterans Affairs (VA) Greater Los
Angeles Healthcare System, Geriatric Research, Education and Clinical
Center; VA Health Services Research and Development (IIR 04-321-2); and
the UCLA Cousins Center for Psychoneuroimmunology.; Author
Contributions: Dr. Martin: study design, analysis and interpretation of
data, and preparation of the manuscript. Dr. Fiorentino, Ms. Jouldjian,
and Ms. Josephson: analysis and interpretation of data and preparation
of the manuscript. Dr. Alessi: study concept and design, analysis and
interpretation of data, and preparation of the manuscript.; Sponsor's
Role: The study sponsors had no input into the design, implementation,
analysis, or interpretation of this study.
NR 47
TC 17
Z9 17
U1 4
U2 15
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2010
VL 58
IS 5
BP 829
EP 836
DI 10.1111/j.1532-5415.2010.02815.x
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 592XE
UT WOS:000277414400005
PM 20722819
ER
PT J
AU Burgio, KL
Johnson, TM
Goode, PS
Markland, AD
Richter, HE
Roth, DL
Sawyer, P
Allman, RM
AF Burgio, Kathryn L.
Johnson, Theodore M., II
Goode, Patricia S.
Markland, Alayne D.
Richter, Holly E.
Roth, David L.
Sawyer, Patricia
Allman, Richard M.
TI Prevalence and Correlates of Nocturia in Community-Dwelling Older Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE nocturia; urination; epidemiology; prevalence; risk factors
ID URINARY-TRACT SYMPTOMS; DANISH POPULATION; BACH SURVEY; RISK-FACTOR;
WOMEN; SLEEP; MEN; ASSOCIATION; FINLAND; DISEASE
AB OBJECTIVES
To determine the prevalence and correlates of nocturia in community-dwelling older adults.
DESIGN
Planned secondary analysis of cross-sectional data from the University of Alabama at Birmingham Study of Aging population-based survey.
SETTING
Participants' homes.
PARTICIPANTS
One thousand older adults (aged 65-106) recruited from Medicare beneficiary lists between 1999 and 2001. The sample was selected to include 25% each African-American women, African-American men, white women, and white men.
MEASUREMENTS
In-person interviews included sociodemographic information, medical history, Mini-Mental State Examination (MMSE) score, and measurement of body mass index (BMI). Nocturia was defined in the main analyses as rising two or more times per night to void.
RESULTS
Nocturia was more common in men than women (63.2% vs 53.8%, odds ratio (OR)=1.48, 95% confidence interval (CI)=1.15-1.91, P=.003) and more common in African Americans than whites (66.3% vs 50.9%, OR=1.89, 95% CI=1.46-2.45, P <.001). In multiple backward elimination regression analysis in men, nocturia was significantly associated with African-American race (OR=1.54) and BMI (OR=1.22 per 5 kg/m2). Higher MMSE score was protective (OR=0.96). In women, nocturia was associated with older age (OR=1.21 per 5 years), African-American race (OR=1.64), history of any urine leakage (OR=2.17), swelling in feet and legs (OR=1.67), and hypertension (OR=1.62). Higher education was protective (OR=0.92).
CONCLUSION
Nocturia in community-dwelling older adults is a common symptom associated with male sex, African-American race, and some medical conditions. Given the significant morbidity associated with nocturia, any evaluation of lower urinary tract symptoms should include assessment for the presence of nocturia.
C1 [Burgio, Kathryn L.; Johnson, Theodore M., II; Goode, Patricia S.; Markland, Alayne D.; Roth, David L.; Allman, Richard M.] Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, Birmingham, AL USA.
[Burgio, Kathryn L.; Goode, Patricia S.; Markland, Alayne D.; Sawyer, Patricia; Allman, Richard M.] Univ Alabama, Sch Med, Dept Med, Birmingham, AL USA.
[Richter, Holly E.] Univ Alabama, Sch Med, Dept Surg, Birmingham, AL USA.
[Burgio, Kathryn L.; Goode, Patricia S.; Markland, Alayne D.; Richter, Holly E.; Roth, David L.; Sawyer, Patricia; Allman, Richard M.] Univ Alabama, Ctr Aging, Sch Publ Hlth, Birmingham, AL USA.
[Roth, David L.] Univ Alabama, Dept Biostat, Sch Publ Hlth, Birmingham, AL USA.
[Johnson, Theodore M., II; Roth, David L.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA.
RP Burgio, KL (reprint author), Birmingham VA Med Ctr, GRECC 11G,700 S 19th St, Birmingham, AL 35294 USA.
EM kburgio@uab.edu
OI Markland, Alayne/0000-0002-6567-6744
FU National Institute on Aging; Birmingham/Atlanta Geriatric Research,
Education and Clinical Center, Department of Veterans Affairs,
Birmingham, Alabama
FX Conflict of Interest: Because the present manuscript describes an
epidemiological study, we do not believe that any of the financial
relationships listed here represent a conflict of interest.; This
project was funded by grants from the National Institute on Aging,
including the Resource Center on Minority Aging Research and the
Birmingham/Atlanta Geriatric Research, Education and Clinical Center,
Department of Veterans Affairs, Birmingham, Alabama.; Kathryn L. Burgio:
Pfizer (consultant and co-investigator on a behavioral trial, research
grant), Astellas (Pelvic Floor Advisory Board), Johnson & Johnson
(consultant). Theodore M. Johnson: Johnson & Johnson (consultant),
Pfizer (consultant, research grant), Ferring (consultant), Astellas
(adviser to a mentee with an investigator-initiated grant). Patricia S.
Goode: Pfizer (research grant). Holly E. Richter: Astellas (research
grant), Pfizer (research grant).; Author Contributions: All individuals
who contributed significantly are listed as authors. All authors
approved the final version for submission. Kathryn L. Burgio, Theodore
M. Johnson, Patricia S. Goode, and Alayne D. Markland: conception and
design, analysis and interpretation of data, drafting article. Holly E.
Richter and David L. Roth: Conception and design, analysis and
interpretation of data, critical revision. Patricia Sawyer and Richard
M. Allman: Acquisition of data, analysis and interpretation of data,
critical revision.; Sponsor's Role: The sponsor was not involved in the
design, methods, subject recruitment, data collection, data analysis, or
preparation of the manuscript.
NR 35
TC 33
Z9 36
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2010
VL 58
IS 5
BP 861
EP 866
DI 10.1111/j.1532-5415.2010.02822.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 592XE
UT WOS:000277414400009
PM 20406317
ER
PT J
AU Yaffe, K
Lindquist, K
Vittinghoff, E
Barnes, D
Simonsick, EM
Newman, A
Satterfield, S
Rosano, C
Rubin, SM
Ayonayon, HN
Harris, T
AF Yaffe, Kristine
Lindquist, Karla
Vittinghoff, Eric
Barnes, Deborah
Simonsick, Eleanor M.
Newman, Anne
Satterfield, Suzanne
Rosano, Caterina
Rubin, Susan M.
Ayonayon, Hilsa N.
Harris, Tamara
CA Hlth Aging & Body Compsition Study
TI The Effect of Maintaining Cognition on Risk of Disability and Death
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE cognition; cognitive maintenance; mortality; disability
ID INDIVIDUAL-DIFFERENCES; OLDER-ADULTS; DECLINE; IMPAIRMENT; AGE;
DEMENTIA; TRAJECTORIES; PERFORMANCE; MORTALITY; RATS
AB OBJECTIVES
To determine whether long-term maintenance of cognition is associated with health advantages such as lower mortality or incident disability in older adults.
DESIGN
Longitudinal cohort study.
SETTING
Community clinics at two sites.
PARTICIPANTS
Two thousand seven hundred thirty-three adults with a mean age of 74 at baseline and 80 at follow-up.
MEASUREMENTS
Cognitive function was assessed using the Modified Mini-Mental State Examination (3MS), a test of global cognition, at least two times. Three cognitive groups were defined based on 4-year participant-specific slopes (maintainers, slopes of >= 0; minor decliners, slopes < 0 but no more than 1 standard deviation (SD) below the mean; major decliners, slopes > 1 SD below the mean). Whether the cognitive groups differed in mortality and incident disability during the subsequent 3 years was determined.
RESULTS
Nine hundred eighty-four (36%) participants were maintainers, 1,314 (48%) were minor decliners, and 435 (16%) were major decliners. Maintainers had lower mortality (7% vs 14%, hazard ratio (HR)=0.48, 95% confidence interval (CI)=0.36-0.63) and incident disability (22% vs 29%, HR=0.74, 95% CI=0.62-0.89) than minor decliners. After adjustment for age, race, sex, education, apolipoprotein E epsilon 4, depression, body mass index, stroke, hypertension, and diabetes mellitus, these differences remained. As expected, major decliners had greater mortality (20%) and incident disability (40%) than minor decliners.
CONCLUSION
A substantial proportion of older adults maintain cognitive function in their eighth and ninth decades of life. These older adults demonstrate lower risk of death and functional decline than those with minor cognitive decline, supporting the concept of "successful" cognitive aging.
C1 [Yaffe, Kristine; Barnes, Deborah] Univ Calif San Francisco, Dept Psychiat, Sch Med, San Francisco, CA 94121 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, Sch Med, San Francisco, CA 94121 USA.
[Yaffe, Kristine; Vittinghoff, Eric; Rubin, Susan M.; Ayonayon, Hilsa N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Sch Med, San Francisco, CA 94121 USA.
[Lindquist, Karla] Univ Calif San Francisco, Dept Med, Sch Med, San Francisco, CA 94121 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA.
[Newman, Anne; Rosano, Caterina] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA.
[Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA.
[Harris, Tamara] NIA, Dept Epidemiol, Demog & Biometry Program, Bethesda, MD 20892 USA.
RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, Sch Med, Box 181,4150 Clement St, San Francisco, CA 94121 USA.
EM kristine.yaffe@ucsf.edu
RI Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150
FU National Institutes of Health, National Institute on Aging;
[AG-6-2101]; [AG-6-2103]; [AG-6-2106]; [AG021918]; [AG031155]
FX Conflict of Interest: The editor in chief has reviewed the conflict of
interest checklist provided by the authors and has determined that the
authors have no financial or any other kind of personal conflicts with
this paper.; Funded by Grants AG-6-2101, AG-6-2103, AG-6-2106, and
AG021918. This research was supported in part by the Intramural Research
Program of the National Institutes of Health, National Institute on
Aging. Dr. Yaffe was supported in part by AG031155 and an anonymous
foundation.; Author Contributions: Study concept and design: KY, KL, EV,
DB. Acquisition of subjects and data: ES, AN, SS, SR, HA, TH. Analysis
and interpretation of data: KY, KL, EV, DB, ES, AN, SS, CR, SR, HA, TH.
Preparation of manuscript: KY, KL, EV, DB, ES, AN, SS, CR, SR, HA, TH).;
Sponsor's Role: The National Institute on Aging played a role in
overseeing study performance and data collection.
NR 24
TC 33
Z9 33
U1 1
U2 5
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2010
VL 58
IS 5
BP 889
EP 894
DI 10.1111/j.1532-5415.2010.02818.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 592XE
UT WOS:000277414400013
PM 20406308
ER
PT J
AU Norton, MC
Smith, KR
Ostbye, T
Tschanz, JT
Corcoran, C
Schwartz, S
Piercy, KW
Rabins, PV
Steffens, DC
Skoog, I
Breitner, JCS
Welsh-Bohmer, KA
AF Norton, Maria C.
Smith, Ken R.
Ostbye, Truls
Tschanz, JoAnn T.
Corcoran, Chris
Schwartz, Sarah
Piercy, Kathleen W.
Rabins, Peter V.
Steffens, David C.
Skoog, Ingmar
Breitner, John C. S.
Welsh-Bohmer, Kathleen A.
CA Cache Cty Investigators
TI Greater Risk of Dementia When Spouse Has Dementia? The Cache County
Study
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE dementia; caregiving; stress
ID COGNITIVE DECLINE; PHYSICAL HEALTH; CAREGIVERS; STRESS; QUESTIONNAIRE;
METAANALYSIS; PREVALENCE; DEPRESSION; IMPACT
AB OBJECTIVES
To examine the effects of caring for a spouse with dementia on the caregiver's risk for incident dementia.
DESIGN
Population-based study of incident dementia in spouses of persons with dementia.
SETTING
Rural county in northern Utah.
PARTICIPANTS
Two thousand four hundred forty-two subjects (1,221 married couples) aged 65 and older.
MEASUREMENTS
Incident dementia was diagnosed in 255 subjects, with onset defined as age when subject met Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised, criteria for dementia. Cox proportional hazards regression tested the effect of time-dependent exposure to dementia in one's spouse, adjusted for potential confounders.
RESULTS
A subject whose spouse experienced incident dementia onset had a six times greater risk for incident dementia as subjects whose spouses were dementia free (hazard rate ratio (HRR)=6.0, 95% confidence interval (CI)=2.2-16.2, P <.001). In sex-specific analyses, husbands had higher risks (HRR=11.9, 95% CI=1.7-85.5, P=.01) than wives (HRR=3.7, 95% CI=1.2-11.6, P=.03).
CONCLUSION
The chronic and often severe stress associated with dementia caregiving may exert substantial risk for the development of dementia in spouse caregivers. Additional (not mutually exclusive) explanations for findings are discussed.
C1 [Norton, Maria C.; Piercy, Kathleen W.] Univ Utah, Dept Family Consumer & Human Dev, Salt Lake City, UT USA.
[Norton, Maria C.; Tschanz, JoAnn T.] Univ Utah, Dept Psychol, Salt Lake City, UT USA.
[Norton, Maria C.; Tschanz, JoAnn T.; Corcoran, Chris; Schwartz, Sarah; Piercy, Kathleen W.] Univ Utah, Ctr Epidemiol Studies, Salt Lake City, UT USA.
[Smith, Ken R.] Univ Utah, Dept Family & Consumer Studies, Salt Lake City, UT USA.
[Smith, Ken R.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
[Ostbye, Truls] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA.
[Ostbye, Truls; Welsh-Bohmer, Kathleen A.] Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC 27710 USA.
[Ostbye, Truls] Duke NUS Grad Med Sch, Singapore, Singapore.
[Corcoran, Chris; Schwartz, Sarah] Utah State Univ, Dept Math & Stat, Logan, UT 84322 USA.
[Rabins, Peter V.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.
[Steffens, David C.] Univ Gothenburg, Dept Psychiat & Behav Sci, Gothenburg, Sweden.
[Skoog, Ingmar] Univ Gothenburg, Inst Neurosci & Physiol, Sect Psychiat & Neurochem, Unit Neuropsychiat Epidemiol, Gothenburg, Sweden.
[Breitner, John C. S.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Breitner, John C. S.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Norton, MC (reprint author), Utah State Univ, Cache Cty Memory Study, 4440 Old Main Hill, Logan, UT 84322 USA.
EM maria.norton@usu.edu
RI Corcoran, Chris/F-2155-2010; piercy, kathleen/F-4808-2010; Tschanz,
JoAnn/E-5986-2010; Norton, Maria/E-6994-2013; Schwartz,
Sarah/E-2050-2016
OI Schwartz, Sarah/0000-0001-9980-7493
FU National Institutes of Health [AG-031272, AG-011380, AG-021136]
FX Dr. Welsh-Bohmer and Dr. Breitner developed the neuropsychological
testing and clinical assessment procedures. Dr. Tschanz provided
training and oversight of all field staff and reviewed all individual
neuropsychological test results to render professional diagnoses. The
board-certified or board-eligible geriatric psychiatrists or
neurologists who examined the study members included Drs. Steinberg,
Breitner, Steffens, Lyketsos, Gagliardi, Raj, Christopher, and Green.
Dr. Williams also examined several subjects and provided expert
neurologic consultation. Dr. Townsend conducted autopsy examinations.
Ms. Leslie coordinated the autopsy enrollment program. Diagnosticians at
the expert consensus conferences included Drs. Breitner, Burke,
Lyketsos, Plassman, Steffens, Steinberg, Toohill, Tschanz, and
Welsh-Bohmer. We acknowledge the additional contributions of the
following individuals whose activities have helped to ensure the success
of the project: Cara Brewer, BA, Tony Calvert, BSC, Carol Leslie, MS,
Georgiann Sanborn, MS, Michelle McCart, Heidi Wengreen, PhD, RD, James
Wyatt, and Peter P. Zandi, PhD, MPH, Roxane Pfister, MS, Nancy Sassano,
PhD.; Conflict of Interest: None of the authors has any financial or
personal conflicts of interest, or relationships and affiliations
relevant to the subject of this manuscript. This work was supported by
National Institutes of Health Grants AG-031272, AG-011380, and
AG-021136.; Author Contributions: Dr. Norton had full access to all the
data and takes responsibility for data integrity and accuracy of the
data analysis. Dr. Norton and Dr. Tschanz: obtaining funding; conception
and design; acquisition, analysis, and interpretation of data;
preparation of manuscript. Dr. Smith, Dr. circle divide stbye, and Dr.
Corcoran: conception and design, analysis and interpretation of data,
preparation of manuscript. Ms. Schwartz: data file creation and
statistical analysis, preparation of manuscript. Dr. Piercy, Dr. Rabins,
Dr. Skoog: conception and design, preparation of manuscript. Dr.
Steffens: conception and design, acquisition of data, preparation of
manuscript. Dr. Breitner and Dr. Welsh-Bohmer: obtaining funding,
acquisition of the data, preparation of manuscript.; Sponsor's Role:
Provision of funding to support data collection, analysis,
interpretation, and manuscript preparation.
NR 30
TC 34
Z9 34
U1 0
U2 11
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2010
VL 58
IS 5
BP 895
EP 900
DI 10.1111/j.1532-5415.2010.02806.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 592XE
UT WOS:000277414400014
PM 20722820
ER
PT J
AU Dzierzewski, JM
Williams, JM
Roditi, D
Marsiske, M
Mccoy, K
McNamara, J
Dautovich, N
Robinson, ME
McCrae, CS
AF Dzierzewski, Joseph M.
Williams, Jacob M.
Roditi, Daniela
Marsiske, Michael
McCoy, Karin
McNamara, Joseph
Dautovich, Natalie
Robinson, Michael E.
McCrae, Christina S.
TI Daily Variations in Objective Nighttime Sleep and Subjective Morning
Pain in Older Adults with Insomnia: Evidence of Covariation over Time
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE sleep; pain; older adults; multilevel modeling; daily associations
ID MINI-MENTAL-STATE; DEPRESSION; HEALTH; METAANALYSIS; COMPLAINTS;
INTENSITY; THERAPY; TRIALS
AB OBJECTIVES
To examine the relationship between objectively measured nocturnal sleep and subjective report of morning pain in older adults with insomnia; to examine not only the difference between persons in the association between sleep and pain (mean level over 14 days), but also the within-person, day-to-day association.
DESIGN
Cross-sectional.
SETTING
North-central Florida.
PARTICIPANTS
Fifty community-dwelling older adults (mean age +/- standard deviation 69.1 +/- 7.0, range 60-90) with insomnia.
MEASUREMENTS
Daily home-based assessment using nightly actigraphic measurement of sleep and daily self-report of pain over 14 consecutive days.
RESULTS
Between persons, average sleep over 14 days was not associated with average levels of rated pain, but after a night in which an older adult with insomnia experienced above-average total sleep time he or she subsequently reported below-average pain ratings. The model explained approximately 24% of the within-person and 8% of the between-person variance in pain ratings.
CONCLUSIONS
Sleep and pain show day-to-day associations (i.e., covary over time) in older adults with insomnia. Such associations may suggest that common physiological systems underlie the experience of insomnia and pain. Future research should examine the crossover effects of sleep treatment on pain and of pain treatment on sleep.
C1 [Dzierzewski, Joseph M.; Williams, Jacob M.; Roditi, Daniela; Marsiske, Michael; Robinson, Michael E.; McCrae, Christina S.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA.
[McNamara, Joseph] Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA.
[Dautovich, Natalie] Univ Florida, Dept Psychol, Gainesville, FL 32610 USA.
[McCoy, Karin] Univ Texas Hlth Sci Ctr San Antonio, Psychol Serv, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[McCoy, Karin] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, San Antonio, TX 78229 USA.
RP McCrae, CS (reprint author), Univ Florida, Dept Clin & Hlth Psychol, POB 100165 HSC,101 S Newell Dr, Gainesville, FL 32610 USA.
EM csmccrae@phhp.ufl.edu
OI Marsiske, Michael/0000-0001-5973-2116; McCrae,
Christina/0000-0003-4313-6867
FU National Institutes of Health, National Institute on Aging [AG0244591];
National Institute on Aging [F31-AG-032802, T32-AG-020499]
FX Conflict of Interest: The editor in chief has reviewed the conflict of
interest checklist provided by the authors and has determined that the
authors have no financial or any other kind of personal conflicts with
this paper.; This study was supported by the National Institutes of
Health, National Institute on Aging (AG0244591; McCrae-PI). Joseph M.
Dzierzewski was supported by an Institutional Training Grant
(T32-AG-020499) awarded to the University of Florida and by an
Individual Training Grant (F31-AG-032802), both awarded by the National
Institute on Aging.; Author Contributions: Joseph M. Dzierzewski:
conceptualization, acquisition of subjects and data, analysis and
interpretation of data, and preparation of manuscript. Jacob M. Williams
and Daniela Roditi: conceptualization, interpretation of data, and
preparation of manuscript. Michael Marsiske: study design, acquisition
of subjects, critical review and feedback, and interpretation of data.
Karin McCoy: study design, critical review and feedback. Joseph McNamara
and Natalie Dautovich: acquisition of subjects and data, critical review
and feedback. Michael E. Robinson: interpretation of data, critical
review and feedback. Christina S. McCrae: study design, acquisition of
subjects and data, interpretation of data, critical review and
feedback.; Sponsor's Role: The content is solely the responsibility of
the authors and does not necessarily represent the official views of the
National Institute on Aging or the National Institutes of Health, nor
was either funding institution responsible for the design, methods,
subject recruitment, data collection, analysis, or preparation of
manuscript.
NR 30
TC 12
Z9 12
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2010
VL 58
IS 5
BP 925
EP 930
DI 10.1111/j.1532-5415.2010.02803.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 592XE
UT WOS:000277414400019
PM 20406316
ER
PT J
AU Shah, F
Burack, O
Boockvar, KS
AF Shah, Faraaz
Burack, Orah
Boockvar, Kenneth S.
TI Perceived Barriers to Communication Between Hospital and Nursing Home at
Time of Patient Transfer
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Communication barriers; nursing homes; hospitals; patient transfer
ID TRANSITIONAL CARE; SAFETY CULTURE; QUALITY; RESIDENTS; EMERGENCY;
OUTCOMES
AB Objectives: To identify perceived barriers to communication between hospital and nursing home at the time of patient transfer and examine associations between perceived barriers and hospital and nursing home characteristics.
Design: Mailed survey.
Setting: Medicare- or Medicaid-certified nursing homes in New York State.
Participants: Nursing home administrators, with input from other nursing home staff.
Measurements: Respondents rated the importance as a barrier to hospital-nursing home communication of (1) hospital providers' attitude, time, effort, training, payment, and familiarity with nursing home patients; (2) unplanned and off-hours transfers; (3) HIPAA privacy regulations; and (4) lost or failed information transmission. Associations were determined between barriers and the following organizational characteristics: (1) hospital-nursing home affiliations, pharmacy or laboratory agreements, cross-site staff visits, and cross-site physician care; (2) hospital size, teaching status, and frequency of geriatrics specialty care; (3) nursing home size, location, type, staffing, and Medicare quality indicators; and (4) hospital-to-nursing home communication, consistency of hospital care with health care goals, and communication quality improvement efforts.
Results: Of 647 questionnaires sent, 229 were returned (35.4%). The most frequently reported perceived barriers to communication were sudden or unplanned transfers (44.4%), transfers that occur at night or on the weekend (41.4%), and hospital providers' lack of effort (51.0%), lack of familiarity with patients (45.0%), and lack of time (43.5%). Increased hospital size, teaching hospitals, and urban nursing home location were associated with greater perceived importance of these barriers, and cross-site staff visits and hospital provision of laboratory and pharmacy services to the nursing home were associated with lower perceived importance of these barriers.
Conclusions: Hospital and nursing home characteristics and interorganizational relationships were associated with nursing home administrators' perceptions of barriers to hospital-nursing home communication. These findings may inform design and targeting of interventions to improve intersite communication processes. (J Am Med Dir Assoc 2010; 11: 239-245)
C1 [Boockvar, Kenneth S.] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Shah, Faraaz] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Burack, Orah; Boockvar, Kenneth S.] Jewish Home Lifecare, New York, NY USA.
[Boockvar, Kenneth S.] Mt Sinai Sch Med, New York, NY USA.
RP Boockvar, KS (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM kenneth.boockvar@mssm.edu
OI Boockvar, Kenneth/0000-0003-1165-5558
FU Mount Sinai School of Medicine; Pfizer/Foundation for Health in Aging;
New York State Department of Health; VA Health Services Research and
Development Service
FX Financial support was provided by a Mount Sinai School of Medicine
Summer Research Fellowship (F.S.), a Pfizer/Foundation for Health in
Aging Junior Faculty Scholarship for Research on Health Outcomes in
Geriatrics (K.S.B.), and the New York State Department of Health. K.S.B.
is currently a Research Career Development Awardee from the VA Health
Services Research and Development Service.
NR 21
TC 13
Z9 13
U1 2
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD MAY
PY 2010
VL 11
IS 4
BP 239
EP 245
DI 10.1016/j.jamda.2009.08.006
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 600ZX
UT WOS:000278028800004
PM 20439042
ER
PT J
AU Almendral, JL
Shick, V
Rosendorff, C
Atlas, SA
AF Almendral, Jesus L.
Shick, Vladislav
Rosendorff, Clive
Atlas, Steven A.
TI Association between transforming growth factor-beta(1) and left
ventricular mass and diameter in hypertensive patients
SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION
LA English
DT Article
DE Echocardiography; growth factors; left ventricular hypertrophy;
renin-angiotensin-aldosterone system
ID FACTOR-BETA; ANGIOTENSIN-II; BLOOD-PRESSURE; CARDIAC FIBROSIS;
HYPERTROPHY; EXPRESSION; HEART; TGF-BETA-1; CARDIOMYOCYTES; MECHANISMS
AB Angiotensin II influences development of left ventricular hypertrophy (LVH) by stimulating cardiomyocyte hypertrophy, fibroblast proliferation, and collagen synthesis. Because pro-fibrotic actions of angiotensin may be mediated by increased production of transforming growth factor-beta(1) (TGF-beta(1)), we assessed whether serum TGF-beta(1) levels might reflect involvement in LVH development. We analyzed relationships between left ventricular mass and levels of renin, aldosterone, and TGF-beta(1) in 67 hypertensive subjects (mean age 64 +/- 11.3 years) with electrocardiographic evidence of LVH. Levels were obtained after a 2-week washout of antihypertensive medications; two-dimensional echocardiography was subsequently performed. Linear regression analysis showed a correlation between TGF-beta(1) and LV mass (r = 0.36, P = .002). This was apparently explained by the correlation between TGF-beta(1), and left ventricular diastolic internal diameter (r = 0.42, P < .001), because no correlation between TGF-beta(1) levels and LV wall thickness was found. In multivariate analysis, the correlation between TGF-beta(1) and internal diameter remained significant (r = 0.39, P = .0014). There were no racial differences in levels of TGF-beta(1), or left ventricular geometry, and no correlations between age, blood pressure, renin, aldosterone, and left ventricular mass or dimensions. These findings indicate that serum TGF-beta(1) levels are related to left ventricular structure in hypertensive subjects, suggesting its possible involvement in the process of hypertensive left ventricular remodeling. J Am Soc Hypertens 2010;4(3):135-141. Published by Elsevier Inc on behalf of American Society of Hypertension.
C1 James J Peters Dept Vet Affairs Med Ctr, Bronx, NY USA.
Mt Sinai Sch Med, New York, NY USA.
RP Atlas, SA (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Steven.Atlas@va.gov
FU Sankyo Pharma, Inc.; Department of Veterans Affairs
FX Supported by a grant from Sankyo Pharma, Inc., and by general research
support from the Department of Veterans Affairs.
NR 30
TC 12
Z9 16
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1933-1711
J9 J AM SOC HYPERTENS
JI J. Am. Soc. Hypertens.
PD MAY-JUN
PY 2010
VL 4
IS 3
BP 135
EP 141
DI 10.1016/j.jash.2010.02.007
PG 7
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 602CG
UT WOS:000278115200005
PM 20470998
ER
PT J
AU Cannuscio, CC
Weiss, EE
Asch, DA
AF Cannuscio, Carolyn C.
Weiss, Eve E.
Asch, David A.
TI The Contribution of Urban Foodways to Health Disparities
SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE
LA English
DT Article
DE Food environment; Foodways; Food deserts; Nutrition; Health disparities;
Violence; Segregation; Alcohol; Mental health; Youth; Corner stores;
Fast food; Economic exclusion
ID NEIGHBORHOOD ALCOHOL ENVIRONMENT; PHYSICAL-ACTIVITY; VEGETABLE
CONSUMPTION; BUILT ENVIRONMENT; RETAIL ACCESS; OBESITY; DESERTS; FRUIT;
ASSOCIATIONS; STORES
AB How do urban food environments produce health disparities? The literature currently emphasizes the etiologic relevance of urban food deserts and their nutritional shortcomings. This paper instead examines the health relevance of foodways-the social dynamics surrounding the production, purchase, and consumption of food. We report on data from 32 photo-elicitation interviews conducted with adult residents of Philadelphia, examining distinct foodways and health concerns that play out in the most commonly discussed retail establishments: corner stores, "Stop and Go's" (delis that also sell beer), and Chinese takeout restaurants. Corner store visits, described as a routinized element of children's school day, were implicated in early life patterning of unsound nutritional choices. Stop and Go's were described as a health threat because of their alcohol sales and tacit promotion of public drunkenness, coupled with accessibility to youth. Stop and Go's and Chinese takeouts both were perceived as generators of violence in part because of on-site sales of alcohol, drug paraphernalia, and illicit drugs. Chinese takeouts also were described as symbolic reminders of African Americans' economic exclusion and as places infused with race/ethnic tension and hostile merchant-customer interactions. Instead of viewing the food environment simply as a source of calories and nutrients, participants discussed the complex social dynamics that play out therein, raising a range of important considerations for (especially disadvantaged) urban residents' safety, physical well-being, and mental health.
C1 [Cannuscio, Carolyn C.] Univ Penn, Sch Med, Sect Publ Hlth, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn C.; Asch, David A.] Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn C.; Weiss, Eve E.] Univ Penn, Sch Med, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA.
[Asch, David A.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Asch, David A.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Asch, David A.] Univ Penn, Wharton Sch, Hlth Care Management Dept, Philadelphia, PA 19104 USA.
RP Cannuscio, CC (reprint author), Univ Penn, Sch Med, Sect Publ Hlth, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
EM carolyncannu@gmail.com
OI Asch, David/0000-0002-7970-286X
FU Robert Wood Johnson Foundation
FX This project was supported by a grant from the Robert Wood Johnson
Foundation Health & Society Scholars Program at the University of
Pennsylvania. We thank the project's participants and the following
staff photographers and research assistants: Nora Becker, Elias
Friedman, Hannah Fruchtman, Rachel X. Han, Michelle Holshue, Jeremy
Kaplan, Amina Massey, Jeannette Schroeder, Liz Sullivan, Aaron Walker,
Ahmed Whitt, and Janet Weiner. We also thank the reviewers for their
insightful comments.
NR 63
TC 38
Z9 38
U1 3
U2 45
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1099-3460
J9 J URBAN HEALTH
JI J. Urban Health
PD MAY
PY 2010
VL 87
IS 3
BP 381
EP 393
DI 10.1007/s11524-010-9441-9
PG 13
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 596WK
UT WOS:000277716000004
PM 20354910
ER
PT J
AU Bergman, J
Gore, JL
Singer, JS
Anger, JT
Litwin, MS
AF Bergman, Jonathan
Gore, John L.
Singer, Jennifer S.
Anger, Jennifer T.
Litwin, Mark S.
TI Readability of Health Related Quality of Life Instruments in Urology
SO JOURNAL OF UROLOGY
LA English
DT Article
DE urology; reading; comprehension; quality of life; questionnaires
ID BENIGN PROSTATIC HYPERPLASIA; URINARY-INCONTINENCE; QUESTIONNAIRE;
INFORMATION; VALIDATION; INTERNET; DISEASES; IMPACT; CANCER; MEN
AB Purpose: The average American adult reads at a fifth to eighth-grade level, with wide variability, presenting challenges for the assessment of self-reported health related quality of life. We identified the health related quality of life instruments used in patients with urological diseases and evaluated their readability.
Materials and Methods: We focused on the most burdensome urological diseases, based on total expenditures in the United States. We then identified disease specific instruments by systematically searching PubMed (R), the Cochrane Database of Systematic Reviews, Googlel (TM), Google Scholar (TM), the Patient Reported Outcome and Quality of Life Instruments Database (Mapi Research Institute, Lyon, France) and Yahoo!(R) for health related quality of life studies in patients with these urological conditions. Where disease specific instruments were lacking, we noted the general health related quality of life measures most commonly used. For each instrument, we calculated the median Flesch-Kincaid grade level, the proportion of questionnaire items below an eighth-grade reading level, the mean Flesch Reading Ease, and the mean number of words per sentence and characters per word, all of which are validated measures of readability.
Results: The average +/-SD of the median Flesh-Kincaid reading levels was 6.5 +/- 2.1 (range 1.0 to 12.0). Of the 76 instruments 61 (80%) were at or below an eighth-grade reading level. The mean reading ease was greater than 30 for each of the 76 questionnaires and greater than 60 for 66 (87%). Urinary tract infection, the costliest urological disease, has only 1 disease specific health related quality of life measure. Urolithiasis, the second costliest, has none.
Conclusions: The reading level of health related quality of life questionnaires in urology is appropriate for the reading ability of most adults in the United States. However, the most burdensome urological diseases lack disease specific health related quality of life instruments.
C1 [Bergman, Jonathan; Gore, John L.; Singer, Jennifer S.; Anger, Jennifer T.; Litwin, Mark S.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA.
[Litwin, Mark S.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA 90095 USA.
[Litwin, Mark S.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Gore, John L.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90095 USA.
[Gore, John L.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Bergman, J (reprint author), Univ Calif Los Angeles, Dept Urol, Box 951738, Los Angeles, CA 90095 USA.
EM jbergman@mednet.ucla.edu
OI Gore, John/0000-0002-2847-5062
NR 21
TC 17
Z9 17
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD MAY
PY 2010
VL 183
IS 5
BP 1977
EP 1981
DI 10.1016/j.juro.2009.12.107
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 584JJ
UT WOS:000276747600131
PM 20303519
ER
PT J
AU Sonnenberg, A
Naugler, WE
AF Sonnenberg, Amnon
Naugler, Willscott E.
TI Models of influence in chronic liver disease
SO LIVER INTERNATIONAL
LA English
DT Article
DE autoimmune hepatitis; Child A and Child C cirrhosis; decision analysis;
hepatitis C virus infection; Markov chain; stochastic modelling
ID CHRONIC HEPATITIS-C; HEPATOCELLULAR-CARCINOMA; COST-EFFECTIVENESS;
CIRRHOSIS; MANAGEMENT; RIBAVIRIN
AB Background & Aims: Liver disease is often characterized by an intricate network of multiple, simultaneously interacting factors with organ-specific, as well as systemic effects. The aim of the present study is to introduce a new mathematical model on how to weigh a variety of factors contributing to chronic liver disease by the relevance of their influence on the overall disease processes. Methods: Liver disease is modelled as the interaction of multiple internal and external factors. Each factor can potentially interact with any of the other factors in the model. The strength of interactions is expressed as per cent. The sum of all interactions contributing to each individual factor adds up to 100%. This model corresponds mathematically to a transposed Markov matrix. The analysis uses the two examples of hepatitis C virus (HCV) and autoimmune hepatitis (AIH). Results: Impaired liver function is the most influential factor and increases in relevance as the degree of hepatic fibrosis increases. The relative importance of treating the primary disease process (HCV or AIH) diminishes as fibrosis develops. Similarly, psychosocial factors become less important with disease progression. Liver transplant is most important for Child's C cirrhosis. It is relatively influential for the early phase of AIH but not HCV, reflecting the fact that some cases of non-cirrhotic AIH can progress rapidly to acute liver failure. Conclusion: In a disease process characterized by a large array of multiple interacting factors, the decision tool of a transposed Markov chain helps to sort the contributing factors by the magnitude of their influence.
C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Portland VA Med Ctr, Portland, OR USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 18
TC 3
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1478-3223
J9 LIVER INT
JI Liver Int.
PD MAY
PY 2010
VL 30
IS 5
BP 718
EP 724
DI 10.1111/j.1478-3231.2009.02196.x
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 581DU
UT WOS:000276502500010
PM 20040051
ER
PT J
AU Zarkin, GA
Bray, JW
Aldridge, A
Mills, M
Cisler, RA
Couper, D
Mckay, JR
O'Malley, S
AF Zarkin, Gary A.
Bray, Jeremy W.
Aldridge, Arnie
Mills, Michael
Cisler, Ron A.
Couper, David
McKay, James R.
O'Malley, Stephanie
TI The Effect of Alcohol Treatment on Social Costs of Alcohol Dependence
Results From the COMBINE Study
SO MEDICAL CARE
LA English
DT Article
DE alcohol treatment; social costs; cost offsets
ID HEALTH-CARE UTILIZATION; UNITED-STATES; ABUSE; TRIAL
AB Background: The COMBINE (combined pharmacotherapies and behavioral intervention) clinical trial recently evaluated the efficacy of pharmacotherapies, behavioral therapies, and their combinations for the treatment of alcohol dependence. Previously, the cost and cost-effectiveness of COMBINE have been studied. Policy makers, patients, and nonalcohol-dependent individuals may be concerned not only with alcohol treatment costs but also with the effect of alcohol interventions on broader social costs and outcomes.
Objectives: To estimate the sum of treatment costs plus the costs of health care utilization, arrests, and motor vehicle accidents for the 9 treatments in COMBINE 3 years postrandomization.
Research Design: A cost study based on a randomized controlled clinical trial.
Subjects: The study involved 786 participants 3 years postrandomization.
Results: Multivariate results show no significant differences in mean costs between any of the treatment arms as compared with medical management (MM) + placebo for the 3-year postrandomization sample. The median costs of MM + acamprosate, MM + naltrexone, MM + acamprosate + naltrexone, and MM + acamprosate + combined behavioral intervention were significantly lower than the median cost for MM + placebo.
Conclusions: The results show that social cost savings are generated relative to MM + placebo by 3 years postrandomization, and the magnitude of these cost savings is greater than the costs of the COMBINE treatment received 3 years prior. Our study suggests that several alcohol treatments may indeed lead to reduced median social costs associated with health care, arrests, and motor vehicle accidents.
C1 [Zarkin, Gary A.; Bray, Jeremy W.; Aldridge, Arnie; Mills, Michael] RTI Int, Res Triangle Pk, NC 27709 USA.
[Cisler, Ron A.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Urban Populat Hlth, Milwaukee, WI 53201 USA.
[Cisler, Ron A.] Aurora Hlth Care Inc, Milwaukee, WI USA.
[Couper, David] Univ N Carolina, Chapel Hill, NC USA.
[McKay, James R.] Univ Penn, Philadelphia, PA 19104 USA.
[McKay, James R.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[O'Malley, Stephanie] Yale Univ, New Haven, CT USA.
RP Zarkin, GA (reprint author), RTI Int, 3040 Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA.
EM gaz@rti.org
FU NIAAA [1-R01-AA12788, K05014715]
FX Supported by NIAAA grant 1-R01-AA12788 and K05014715.
NR 21
TC 15
Z9 15
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD MAY
PY 2010
VL 48
IS 5
BP 396
EP 401
DI 10.1097/MLR.0b013e3181d68859
PG 6
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 591YW
UT WOS:000277342500002
PM 20393362
ER
PT J
AU Srinivas, SK
Epstein, AJ
Nicholson, S
Herrin, J
Asch, DA
AF Srinivas, Sindhu K.
Epstein, Andrew J.
Nicholson, Sean
Herrin, Jeph
Asch, David A.
TI Improvements in US Maternal Obstetrical Outcomes From 1992 to 2006
SO MEDICAL CARE
LA English
DT Article
DE obstetrics; maternal outcomes; trends; complications after delivery
ID PRIMARY CESAREAN DELIVERY; IDENTIFY INDICATIONS; UNITED-STATES; TRENDS;
RISK; RATES; EPISIOTOMY; HEMORRHAGE
AB Background: Over 4 million women give birth annually in the United States, making delivery one of the most common reasons for hospital care.
Objective: We examined 15-year trends in risk-adjusted maternal complications following childbirth.
Research Design: We examined maternal obstetrical outcomes from 1992-2006 among women undergoing cesarean delivery (CD) and vaginal delivery (VD). A composite measure of major maternal complications including infection, hemorrhage, laceration, and other major operative and thrombotic complications was evaluated.
Subjects: Population-based sample of over 6 million women from Florida and New York hospital discharge data.
Measures: Obstetric procedures and maternal complications post-delivery.
Results: During the 15-year time period, the CD rate decreased from 24.7% in 1992 to 23% in 1996 and increased to 34.7% in 2006. The risk-adjusted rate of any major complication declined from 14.7% in 1992 to 10.7% in 2006 for all deliveries; from 14.4% to 11.6% for VD; and from 15.7% to 8.5% for CD. During 1992 to 2006, the average number of comorbidities increased from 0.65 to 0.93 for patients overall, from 0.43 to 0.58 for VD patients, and 1.34 to 1.59 for CD patients.
Conclusion: As evidenced by New York and Florida, the US has seen large reductions in major maternal complications over the past 15 years. Concurrently, the average number of comorbidities increased. These results reflect substantial improvements in maternal delivery outcomes.
C1 [Srinivas, Sindhu K.] Univ Penn, Dept OB GYN, Philadelphia, PA 19104 USA.
[Srinivas, Sindhu K.; Epstein, Andrew J.; Nicholson, Sean; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Epstein, Andrew J.; Herrin, Jeph] Yale Univ, New Haven, CT USA.
[Nicholson, Sean] Cornell Univ, New York, NY 10021 USA.
[Asch, David A.] Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Srinivas, SK (reprint author), Univ Penn, Dept OB GYN, 421 Curie Blvd,BRB 2-3 1353, Philadelphia, PA 19104 USA.
EM ssrinivas@obgyn.upenn.edu
OI Asch, David/0000-0002-7970-286X
FU Stemmler Fund of the National Board of Medical Examiners
FX Supported by the Stemmler Fund of the National Board of Medical
Examiners. This research has been performed independent of the funding
source.
NR 26
TC 26
Z9 26
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD MAY
PY 2010
VL 48
IS 5
BP 487
EP 493
DI 10.1097/MLR.0b013e3181d68840
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 591YW
UT WOS:000277342500015
PM 20393363
ER
PT J
AU Sox, HC
Helfand, M
Grimshaw, J
Dickersin, K
Tovey, D
Knottnerus, JA
Tugwell, P
AF Sox, Harold C.
Helfand, Mark
Grimshaw, Jeremy
Dickersin, Kay
Tovey, David
Knottnerus, J. Andre
Tugwell, Peter
TI Comparative Effectiveness Research: Challenges for Medical Journals
SO MEDICAL DECISION MAKING
LA English
DT Editorial Material
C1 [Helfand, Mark] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA.
[Sox, Harold C.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dartmouth Inst, Hanover, NH 03756 USA.
[Helfand, Mark] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
[Grimshaw, Jeremy] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
[Dickersin, Kay] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Tovey, David] Cochrane Lib, London, England.
[Knottnerus, J. Andre] Univ Maastricht, Dept Gen Practice, Maastricht, Netherlands.
[Tugwell, Peter] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
[Tugwell, Peter] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada.
RP Helfand, M (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM helfand@ohsu.edu
RI Grimshaw, Jeremy/D-8726-2013; Knottnerus, Andre/F-4866-2013; Knottnerus,
Johannes/A-3829-2009
NR 7
TC 3
Z9 3
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0272-989X
J9 MED DECIS MAKING
JI Med. Decis. Mak.
PD MAY-JUN
PY 2010
VL 30
IS 3
BP 301
EP 303
DI 10.1177/0272989X10370815
PG 3
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA 599EH
UT WOS:000277892800004
PM 20424174
ER
PT J
AU Nierenberg, NE
Thompson, GR
Lewis, JS
Hogan, BK
Patterson, TF
AF Nierenberg, Natalie E.
Thompson, George R., III
Lewis, James S., II
Hogan, Brian K.
Patterson, Thomas F.
TI Voriconazole use and pharmacokinetics in combination with
interferon-gamma for refractory cryptococcal meningitis in a patient
receiving low-dose ritonavir
SO MEDICAL MYCOLOGY
LA English
DT Article
DE cryptococcus; voriconazole; salvage; therapeutic drug monitoring
ID FUNGAL-INFECTIONS; ANTIFUNGAL CHEMOTHERAPY; ADVERSE EVENTS; SAFETY;
POSACONAZOLE; NEOFORMANS; EFFICACY
AB We present a case of relapsing cryptococcal meningitis unresponsive to standard therapy. Voriconazole induction, including the utilization of voriconazole therapeutic drug monitoring in both serum and CSF, with transition to voriconazole plus interferon-gamma (IFN-gamma) was successfully used in a patient receiving antiretroviral therapy with abacavir/lamivudine and lopinavir/ritonavir. Initial voriconazole levels at standard doses of 4 mg/kg twice daily intravenously were low when co-administered with lopinavir/ritonavir but increased to recommended therapeutic levels with an increase of the voriconazole dose to 7 mg/kg twice daily. This case highlights the utility of voriconazole therapeutic drug monitoring when prescribed concurrently with a ritonavir boosted protease inhibitor and the potential role of combination therapy with IFN-gamma for refractory cryptococcal meningitis.
C1 [Nierenberg, Natalie E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Gen Med, San Antonio, TX 78229 USA.
[Thompson, George R., III; Lewis, James S., II; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, San Antonio, TX 78229 USA.
[Lewis, James S., II] Univ Texas Hlth Sci Ctr San Antonio, Pharm Serv Univ Hlth Syst, San Antonio, TX 78229 USA.
[Hogan, Brian K.] Brooke Army Med Ctr, San Antonio, TX USA.
[Thompson, George R., III; Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Nierenberg, NE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Gen Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM nierenberg@uthscsa.edu
FU Basilea; Merck; Pfizer; Schering-Plough
FX Declaration of interest: G. R. T. has served as a consultant for
Basilea. T. F. P. has received research support from Basilea, Merck,
Pfizer, and Schering-Plough and has received honoraria or served as a
consultant for Basilea, Merck, and Pfizer. All other authors have no
potential conflicts to disclose.
NR 19
TC 10
Z9 11
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1369-3786
J9 MED MYCOL
JI Med. Mycol.
PD MAY
PY 2010
VL 48
IS 3
BP 532
EP 536
DI 10.3109/13693780903325282
PG 5
WC Infectious Diseases; Mycology; Veterinary Sciences
SC Infectious Diseases; Mycology; Veterinary Sciences
GA 579IV
UT WOS:000276363900014
PM 19835489
ER
PT J
AU Westbrook, SD
Wiederhold, NP
Vallor, AC
Kotara, S
Bernardo, S
Lee, SA
Kirkpatrick, WR
Toro, JJ
Freytes, C
Patterson, TF
Redding, SW
AF Westbrook, Steven D.
Wiederhold, Nathan P.
Vallor, Ana C.
Kotara, Susann
Bernardo, Stella
Lee, Samuel A.
Kirkpatrick, William R.
Toro, Juan J.
Freytes, Cesaro
Patterson, Thomas F.
Redding, Spencer W.
TI Loss of in vitro resistance in Candida glabrata following
discontinuation of fluconazole prophylaxis in a hematopoietic stem cell
transplantation patient
SO MEDICAL MYCOLOGY
LA English
DT Article
DE hematopoietic stem cell transplantation; Candida glabrata; fluconazole
resistance
ID CHROMOGENIC AGAR; ALBICANS; PCR
AB We report a case of fluconazole-resistant oropharyngeal colonization caused by a strain of Candida glabrata that rapidly regained susceptibility once prophylaxis with this agent was discontinued and echinocandin therapy was initiated. Isolates collected before and after discontinuation of fluconazole were confirmed to be isogenic by RAPD analysis. Transcription analysis demonstrated constitutive expression of genes encoding efflux pumps in the isolate recovered on fluconazole prophylaxis and transient expression in those isolates collected after fluconazole was discontinued.
C1 [Westbrook, Steven D.; Redding, Spencer W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA.
[Wiederhold, Nathan P.; Vallor, Ana C.; Kotara, Susann; Bernardo, Stella; Lee, Samuel A.; Kirkpatrick, William R.; Toro, Juan J.; Freytes, Cesaro; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Westbrook, Steven D.; Vallor, Ana C.; Bernardo, Stella; Lee, Samuel A.; Kirkpatrick, William R.; Toro, Juan J.; Freytes, Cesaro; Patterson, Thomas F.; Redding, Spencer W.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Wiederhold, Nathan P.] Univ Texas Austin, Coll Pharm, Div Pharmacotherapy, Austin, TX 78712 USA.
RP Westbrook, SD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Dent Diagnost Sci, 7703 Floyd Curl Dr,Mail Code 7919, San Antonio, TX 78229 USA.
EM westbrooks@uthscsa.edu
OI Wiederhold, Nathan/0000-0002-2225-5122
FU National Institute of Dental and Craniofacial Research [DE-18096];
Pfizer; Schering-Plough; CyDex Pharmaceuticals; Merck; Nektar
Therapeutics
FX This work was supported in part by Public Health Service Grant DE-18096
from the National Institute of Dental and Craniofacial Research. The
authors gratefully acknowledge Jon Maust and Marcos Olivo for their
technical assistance with yeast identification and isolation.; Conflict
of interest: SDW, ACV, SK, SB, SAL, WRK, JJT, COF: None to declare.
N.P.W. has received research support from Pfizer, Schering-Plough, and
CyDex Pharmaceuticals. T. F. P. has received research support from
Merck, Pfizer, Schering-Plough, and Nektar Therapeutics, has served on
the speakers bureau for Merck and Pfizer, and as a consultant for
Basilea, Merck, Nektar, Pfizer, and
NR 9
TC 2
Z9 2
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1369-3786
J9 MED MYCOL
JI Med. Mycol.
PD MAY
PY 2010
VL 48
IS 3
BP 557
EP U24
DI 10.3109/13693780903213504
PG 4
WC Infectious Diseases; Mycology; Veterinary Sciences
SC Infectious Diseases; Mycology; Veterinary Sciences
GA 579IV
UT WOS:000276363900018
PM 20370365
ER
PT J
AU Emmons, RR
Cirnigliaro, CM
Kirshblum, SC
Galea, MD
Spungen, AM
Bauman, WA
AF Emmons, Racine R.
Cirnigliaro, Christopher M.
Kirshblum, Steven C.
Galea, Marinella D.
Spungen, Ann M.
Bauman, William A.
TI Abdominal Adiposity and Insulin Level Influence Lipoprotein Particle
Size and Concentration in Spinal Cord Injury
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the American-College-Sports-Medicine/Inaugural
World Congress on Exercise is Medicine
CY JUN 05, 2010
CL Baltimore, MD
SP Amer Coll Sports Med
C1 [Emmons, Racine R.; Cirnigliaro, Christopher M.; Galea, Marinella D.; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Bronx, NY USA.
[Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA.
EM racine.emmons@va.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2010
VL 42
IS 5
SU 1
MA 2168
BP 532
EP 532
PG 1
WC Sport Sciences
SC Sport Sciences
GA 759FO
UT WOS:000290226301821
ER
PT J
AU Levitt, JM
Yamashita, H
Jian, WG
Lerner, SP
Sonpavde, G
AF Levitt, Jonathan M.
Yamashita, Hideyuki
Jian, Weiguo
Lerner, Seth P.
Sonpavde, Guru
TI Dasatinib Is Preclinically Active against Src-Overexpressing Human
Transitional Cell Carcinoma of the Urothelium with Activated Src
Signaling
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID FAMILY KINASE INHIBITOR; OVARIAN-CANCER CELLS; NUDE-MOUSE MODEL;
TYROSINE KINASE; ADENOCARCINOMA CELLS; PROSTATE-CANCER; BLADDER-CANCER;
CYCLE ARREST; EXPRESSION; APOPTOSIS
AB Dasatinib is an orally administered multitargeted kinase inhibitor that targets Src family tyrosine kinases, Abl, c-Kit, and PDGFR. A preclinical study was conducted to evaluate dasatinib alone or combined with cisplatin for human transitional cell carcinoma (TCC). Expression of Src in a human TCC tissue microarray was evaluated by immunohistochemistry. The activity of dasatinib and/or cisplatin was evaluated in six human TCC cell lines. Western blot was done to assess Src and phosphorylated-Src (p-Src) expression. The activity of dasatinib alone and in combination with cisplatin was determined in murine subcutaneous xenografts. Sixty-two percent to 75% of human TCC expressed Src. Dasatinib displayed significant antiproliferative activity at nanomolar concentrations against two human TCC cell lines (RT4 and Hu456) that exhibited high Src and p-Src expression and were cisplatin-resistant. RT4 cells were the most sensitive and displayed the highest level of Src pathway activation (p-Src/Src ratio). Dasatinib downregulated p-Src in either sensitive or resistant cells. TCC cells that were sensitive to cisplatin (5637 and TCC-SUP) were highly resistant to dasatinib and exhibited low Src expression. Dasatinib showed antitumor activity in RT4 murine xenografts, and the combination of dasatinib and cisplatin was significantly more active than placebo. Combination dasatinib plus cisplatin significantly inhibited proliferation and promoted apoptosis in vivo. In conclusion, dasatinib displayed significant preclinical antitumor activity against Src-overexpressing human TCC with active Src signaling and was highly active in combination with cisplatin in vivo. Further clinical development might be warranted in selected human subjects. Mol Cancer Ther; 9(5); 1128-35. (C) 2010 AACR.
C1 [Levitt, Jonathan M.; Yamashita, Hideyuki; Jian, Weiguo; Lerner, Seth P.; Sonpavde, Guru] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.
[Levitt, Jonathan M.] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA.
[Sonpavde, Guru] Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Sonpavde, G (reprint author), 501 Med Ctr Blvd, Webster, TX 77598 USA.
EM gurus@bcm.edu
FU Bristol-Myers Squibb
FX G. Sonpavde and S. P. Lerner: research funding, Bristol-Myers Squibb. No
other potential conflicts of interest were disclosed.
NR 34
TC 18
Z9 18
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD MAY
PY 2010
VL 9
IS 5
BP 1128
EP 1135
DI 10.1158/1535-7163.MCT-10-0096
PG 8
WC Oncology
SC Oncology
GA 607GQ
UT WOS:000278487500007
PM 20406945
ER
PT J
AU Jackson, PL
Xu, X
Wilson, L
Weathington, NM
Clancy, JP
Blalock, JE
Gaggar, A
AF Jackson, Patricia L.
Xu, Xin
Wilson, Landon
Weathington, Nathaniel M.
Clancy, John Paul
Blalock, James Edwin
Gaggar, Amit
TI Human Neutrophil Elastase-Mediated Cleavage Sites of MMP-9 and TIMP-1:
Implications to Cystic Fibrosis Proteolytic Dysfunction
SO MOLECULAR MEDICINE
LA English
DT Article
ID MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; ACTIVATION; LUNG;
MATRIX-METALLOPROTEINASE-9; INFLAMMATION; GELATINASE; EXPRESSION;
MULTIPLE; DISEASE
AB Cystic fibrosis (CF) is a lethal genetic disorder characterized by airway remodeling and inflammation, leading to premature death. Recent evidence suggests the importance of protease activity in CF pathogenesis. One prominent protease, matrix metalloprotease (MMP)-9, demonstrates increased activity in CF individuals undergoing acute pulmonary exacerbation. This is thought to be mediated by both direct MMP-9 activation and the degradation of its natural inhibitor, tissue inhibitor of metalloprotease-1 (TIMP-1). To examine if this relationship exists in nonexacerbating CF individuals, we examined protease activity in sputum from these individuals compared with nondisease controls. We demonstrated increased gelatinolytic activity in CF sputum. These samples had elevated human neutrophil elastase (HNE) levels which correlated with an increased MMP-9/TIMP-1 ratio. To determine if HNE could discretely cleave and activate MMP-9, these enzymes were coincubated and two specific cleavage sites, between Valine(38) and Alanine(39), and between Alanine(39) and glutamic acid(40) were observed. These sites corresponded with appropriate molecular weight for the activated MMP-9 isoform in CF sputum. Using N-terminal sequencing of cleavage fragments obtained with TIMP-1 incubation with HNE, we confirmed the TIMP-1 cleavage site for HNE is at Valine(69)-Cysteine(70). We also show for the first time that human neutrophils were capable of degrading TIMP-1 ex vivo and that a 16 kDa TIMP-1 fragment was identified in CF sputum, consistent with the expected cleavage of TIMP-1 by HNE. These results demonstrate increased MMP-9 activity in stable CF lung disease, and the presence of specific protease products in CF sputum highlights that HNE-mediated activity plays a role in this dysregulation. (C) 2010 The Feinstein Institute for Medical Research, www.feinsteininstitute.org
C1 [Jackson, Patricia L.; Xu, Xin; Weathington, Nathaniel M.; Blalock, James Edwin; Gaggar, Amit] Univ Alabama, Dept Med, Birmingham, AL 35294 USA.
[Jackson, Patricia L.; Xu, Xin; Blalock, James Edwin; Gaggar, Amit] Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA.
[Wilson, Landon] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
[Clancy, John Paul] Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA.
[Clancy, John Paul; Blalock, James Edwin; Gaggar, Amit] Univ Alabama, Gregory Fleming James Cyst Fibrosis Ctr, Birmingham, AL 35294 USA.
[Gaggar, Amit] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Gaggar, A (reprint author), 1918 Univ Blvd,MCLM 898, Birmingham, AL 35294 USA.
EM plj@uab.edu; agaggar@uab.edu
OI Blalock, J. Edwin/0000-0001-5303-8123
FU UAB Comprehensive Cancer Center [P30 CA13148]; NHLBI; NIDDK; [S10
RR16849]
FX The authors would like to thank Marion Kirk for his efforts in
sequencing TIMP-1 fragments. We also would like to thank Uros Djekic for
his contribution to this manuscript. We would like to thank cessing of
proteomics samples were provided by NCRR Shared Instrumentation grant
S10 RR16849 (HK). Funds for the operation of the Mass Spectrometry
Shared Facility came in part from the UAB Comprehensive Cancer Center
Core Support Grant (P30 CA13148).; This project was supported in part by
grants from the NHLBI and NIDDK. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the NIH.
NR 32
TC 35
Z9 37
U1 1
U2 8
PU FEINSTEIN INST MED RES
PI MANHASSET
PA 350 COMMUNITY DR, MANHASSET, NY 11030 USA
SN 1076-1551
J9 MOL MED
JI Mol. Med.
PD MAY-JUN
PY 2010
VL 16
IS 5-6
BP 159
EP 166
DI 10.2119/molmed.2009.00109
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA 593VF
UT WOS:000277489000002
PM 20111696
ER
PT J
AU Kraut, JA
Madias, NE
AF Kraut, Jeffrey A.
Madias, Nicolaos E.
TI Metabolic acidosis: pathophysiology, diagnosis and management
SO NATURE REVIEWS NEPHROLOGY
LA English
DT Review
ID RENAL TUBULAR-ACIDOSIS; SERUM ANION GAP; CHRONIC KIDNEY-DISEASE;
5-OXOPROLINE PYROGLUTAMIC ACID; HYPOVOLEMIC CIRCULATORY SHOCK;
CRITICALLY-ILL PATIENTS; LACTIC-ACIDOSIS; SODIUM-BICARBONATE;
DIABETIC-KETOACIDOSIS; POTASSIUM BICARBONATE
AB Metabolic acidosis is characterized by a primary reduction in serum bicarbonate (HCO3-) concentration, a secondary decrease in the arterial partial pressure of carbon dioxide (PaCO2) of similar to 1 mmHg for every 1 mmol/l fall in serum HCO3- concentration, and a reduction in blood pH. Acute forms (lasting minutes to several days) and chronic forms (lasting weeks to years) of the disorder can occur, for which the underlying cause/s and resulting adverse effects may differ. Acute forms of metabolic acidosis most frequently result from the overproduction of organic acids such as ketoacids or lactic acid; by contrast, chronic metabolic acidosis often reflects bicarbonate wasting and/or impaired renal acidification. The calculation of the serum anion gap, calculated as [Na+]-([HCO3 ]+[Cl ]), aids diagnosis by classifying the disorders into categories of normal (hyperchloremic) anion gap or elevated anion gap. These categories can overlap, however. Adverse effects of acute metabolic acidosis primarily include decreased cardiac output, arterial dilatation with hypotension, altered oxygen delivery, decreased ATP production, predisposition to arrhythmias, and impairment of the immune response. The main adverse effects of chronic metabolic acidosis are increased muscle degradation and abnormal bone metabolism. Using base to treat acute metabolic acidosis is controversial because of a lack of definitive benefit and because of potential complications. By contrast, the administration of base for the treatment of chronic metabolic acidosis is associated with improved cellular function and few complications.
C1 [Madias, Nicolaos E.] St Elizabeths Med Ctr, Dept Med, Div Nephrol, Brighton, MA 02135 USA.
[Kraut, Jeffrey A.] Vet Adm Greater Los Angeles VHAGLA Healthcare Sys, Div Nephrol, Los Angeles, CA 90073 USA.
RP Madias, NE (reprint author), St Elizabeths Med Ctr, Dept Med, Div Nephrol, 736 Cambridge St, Brighton, MA 02135 USA.
EM nicolaos.madias@caritaschristi.org
FU Veterans Administration
FX J. A. Kraut's work is supported in part by research funds from the
Veterans Administration. C. P. Vega, University of California, Irvine,
CA, is the author of and is solely responsible for the content of the
learning objectives, questions and answers of the MedscapeCME-accredited
continuing medical education activity associated with this article.
NR 124
TC 75
Z9 81
U1 8
U2 88
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5061
EI 1759-507X
J9 NAT REV NEPHROL
JI Nat. Rev. Nephrol.
PD MAY
PY 2010
VL 6
IS 5
BP 274
EP 285
DI 10.1038/nrneph.2010.33
PG 12
WC Urology & Nephrology
SC Urology & Nephrology
GA 589NZ
UT WOS:000277158400009
PM 20308999
ER
PT J
AU Schwartz, DL
Mitchell, AD
Lahna, DL
Luber, HS
Huckans, MS
Mitchell, SH
Hoffman, WF
AF Schwartz, Daniel L.
Mitchell, Alex D.
Lahna, David L.
Luber, Hannah S.
Huckans, Marilyn S.
Mitchell, Suzanne H.
Hoffman, William F.
TI Global and local morphometric differences in recently abstinent
methamphetamine-dependent individuals
SO NEUROIMAGE
LA English
DT Article
ID VOXEL-BASED MORPHOMETRY; DELAY DISCOUNTING TASK; DECISION-MAKING;
OXIDATIVE STRESS; STRUCTURAL ABNORMALITIES; MICROGLIAL ACTIVATION;
INTERTEMPORAL CHOICE; CIGARETTE-SMOKING; AMYGDALA VOLUME; IMPULSE
CONTROL
AB Methamphetamine (MA) is associated with behavioral and cognitive deficits that may be related to macrostructural abnormalities. Quantitative anatomical comparisons between controls and methamphetamine-dependent individuals have produced conflicting results. We examined local and global differences in brain structure in 61 abstinent methamphetamine-dependent individuals and 44 controls with voxel-based morphometry and tissue segmentation. We related regional differences in gray matter density and whole brain segmentation volumes to performance on a behavioral measure of impulsivity and group membership using multiple linear regression. Within the MA group, we related cortical and subcortical gray matter density to length of abstinence. Controls had greater density relative to MA in bilateral insula and left middle frontal gyros. Impulsivity was higher in the MA group and, within all subjects, impulsivity was positively correlated with gray matter density in posterior cingulate cortex and ventral striatum and negatively correlated in left superior frontal gyrus. Length of abstinence from MA was associated with greater amygdalar density. Earlier age of first use of MA (in subjects who initiated use before age 2D was associated with smaller intracranial volume. The findings are consistent with multiple possible mechanisms including neuroadaptations due to addictive behavior, neuroinflammation as well as dopaminergic and serotonergic neurotoxicity. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Schwartz, Daniel L.; Mitchell, Alex D.; Lahna, David L.; Luber, Hannah S.; Huckans, Marilyn S.; Hoffman, William F.] Portland VA Med Ctr, Res Serv, Portland, OR USA.
[Mitchell, Alex D.; Huckans, Marilyn S.; Hoffman, William F.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA.
[Schwartz, Daniel L.; Lahna, David L.; Luber, Hannah S.; Huckans, Marilyn S.; Mitchell, Suzanne H.; Hoffman, William F.] Portland VA Med Ctr, Methamphetamine Abuse Res Ctr, Portland, OR USA.
[Schwartz, Daniel L.; Lahna, David L.; Luber, Hannah S.; Huckans, Marilyn S.; Mitchell, Suzanne H.; Hoffman, William F.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Mitchell, Suzanne H.; Hoffman, William F.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA.
RP Schwartz, DL (reprint author), Portland VA Med Ctr, Res Serv, Portland, OR USA.
EM schwartd@ohsu.edu
OI Mitchell, Suzanne/0000-0002-0225-7200
FU Department of Veterans Affairs Merit Review Program; Stanley Medical
Research Institute; Department of Veterans Affairs Career Development
Program; NM [P50DA018165, DA015543]
FX Supported by the Department of Veterans Affairs Merit Review Program
(WFH), Stanley Medical Research Institute and Department of Veterans
Affairs Career Development Program (MSH), NM grants P50DA018165 (WFH,
SHM, BHM), and DA015543 (SHM).
NR 74
TC 58
Z9 63
U1 3
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD MAY 1
PY 2010
VL 50
IS 4
BP 1392
EP 1401
DI 10.1016/j.neuroimage.2010.01.056
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 574VY
UT WOS:000276023500006
PM 20096794
ER
PT J
AU Koenigsberg, HW
Fan, J
Ochsner, KN
Liu, X
Guise, K
Pizzarello, S
Dorantes, C
Tecuta, L
Guerreri, S
Goodman, M
New, A
Flory, J
Siever, LJ
AF Koenigsberg, Harold W.
Fan, Jin
Ochsner, Kevin N.
Liu, Xun
Guise, Kevin
Pizzarello, Scott
Dorantes, Christine
Tecuta, Lucia
Guerreri, Stephanie
Goodman, Marianne
New, Antonia
Flory, Janine
Siever, Larry J.
TI Neural correlates of using distancing to regulate emotional responses to
social situations
SO NEUROPSYCHOLOGIA
LA English
DT Article
DE Emotion; Cognitive reappraisal; Social cognitive neuroscience; Emotional
distancing; Emotion regulation; fMRI
ID EVENT-RELATED FMRI; BORDERLINE PERSONALITY-DISORDER; ANTERIOR CINGULATE
CORTEX; PREFRONTAL CORTEX; NEGATIVE AFFECT; VOLUNTARY SUPPRESSION;
ATTENTIONAL CONTROL; SELF; BRAIN; ACTIVATION
AB Cognitive reappraisal is a commonly used and highly adaptive strategy for emotion regulation that has been studied in healthy volunteers. Most studies to date have focused on forms of reappraisal that involve reinterpreting the meaning of stimuli and have intermixed social and non-social emotional stimuli. Here we examined the neural correlates of the regulation of negative emotion elicited by social situations using a less studied form of reappraisal known as distancing. Whole brain fMRI data were obtained as participants viewed aversive and neutral social scenes with instructions to either simply look at and respond naturally to the images or to downregulate their emotional responses by distancing. Three key findings were obtained accompanied with the reduced aversive response behaviorally. First, across both instruction types, aversive social images activated the amygdala. Second, across both image types, distancing activated the precuneus and posterior cingulate cortex (PCC), intraparietal sulci (IPS), and middle/superior temporal gyrus (M/STG). Third, when distancing one's self from aversive images, activity increased in dorsal anterior cingulate (dACC), medial prefrontal cortex (mPFC), lateral prefrontal cortex, precuneus and PCC, IPS, and M/STG, meanwhile, and decreased in the amygdala. These findings demonstrate that distancing from aversive social cues modulates amygdala activity via engagement of networks implicated in social perception, perspective-taking, and attentional allocation. Published by Elsevier Ltd.
C1 [Koenigsberg, Harold W.] James J Peters VA Med Ctr, Mt Sinai Sch Med, Bronx, NY 10468 USA.
[Koenigsberg, Harold W.; Fan, Jin; Liu, Xun; Guise, Kevin; Dorantes, Christine; Tecuta, Lucia; Guerreri, Stephanie; Goodman, Marianne; New, Antonia; Flory, Janine; Siever, Larry J.] Mt Sinai Sch Med, New York, NY USA.
[Ochsner, Kevin N.] Columbia Univ, Dept Psychol, New York, NY 10027 USA.
[Pizzarello, Scott] Univ Florida, Tallahassee, FL USA.
RP Koenigsberg, HW (reprint author), James J Peters VA Med Ctr, Mt Sinai Sch Med, 130 W Kingsbridge Rd,116A, Bronx, NY 10468 USA.
EM HWarrenK@nyc.rr.com
RI Fan, Jin/A-6716-2009; Liu, Xun/C-2400-2009
OI Fan, Jin/0000-0001-9630-8330; Liu, Xun/0000-0003-1366-8926; TECUTA,
LUCIA/0000-0002-7984-3064
FU National Institute of Mental Health [RO1 MH077813, MH076137]; National
Center for Research Resources, National Institutes of Health [5MO1
RR00071]
FX Completion of this work was supported in part by grants from the
National Institute of Mental Health (RO1 MH077813, PI: H.W.K.; MH076137,
PI: K.N.O.) and from the National Center for Research Resources,
National Institutes of Health for the Mount Sinai General Clinical
Research Center (5MO1 RR00071).
NR 67
TC 71
Z9 72
U1 7
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3932
J9 NEUROPSYCHOLOGIA
JI Neuropsychologia
PD MAY
PY 2010
VL 48
IS 6
BP 1813
EP 1822
DI 10.1016/j.neuropsychologia.2010.03.002
PG 10
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 604FE
UT WOS:000278261900033
PM 20226799
ER
PT J
AU McClure, MM
Harvey, PD
Goodman, M
Triebwasser, J
New, A
Koenigsberg, HW
Sprung, LJ
Flory, JD
Siever, LJ
AF McClure, Margaret M.
Harvey, Philip D.
Goodman, Marianne
Triebwasser, Joseph
New, Antonia
Koenigsberg, Harold W.
Sprung, Larry J.
Flory, Janine D.
Siever, Larry J.
TI Pergolide Treatment of Cognitive Deficits Associated with Schizotypal
Personality Disorder: Continued Evidence of the Importance of the
Dopamine System in the Schizophrenia Spectrum
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE schizotypal personality; schizotypy; schizophrenia spectrum; cognition;
pergolide; dopamine
ID VISUOSPATIAL WORKING-MEMORY; PREFRONTAL CORTEX; PARKINSONS-DISEASE;
NEUROPSYCHOLOGICAL PERFORMANCE; RECEPTOR STIMULATION; AGED MONKEYS;
FOLLOW-UP; TASK; DYSFUNCTION; IMPAIRMENT
AB Cognitive deficits observed in schizophrenia are also frequently found in individuals with other schizophrenia spectrum disorders, such as schizotypal personality disorder (SPD). Dopamine appears to be a particularly important modulator of cognitive processes such as those impaired in schizophrenia spectrum disorders. In a double-blind, placebo-controlled clinical trial, we administered pergolide, a dopamine agonist targeting D(1) and D(2) receptors, to 25 participants with SPD and assessed the effect of pergolide treatment, as compared with placebo, on neuropsychological performance. We found that the pergolide group showed improvements in visual-spatial working memory, executive functioning, and verbal learning and memory. These results suggest that dopamine agonists may provide benefit for the cognitive abnormalities of schizophrenia spectrum disorders. Neuropsychopharmacology (2010) 35, 1356-1362; doi: 10.1038/npp.2010.5; published online 3 February 2010
C1 [McClure, Margaret M.] Mt Sinai Sch Med, VA VISN MIRECC 3, Bronx, NY 10468 USA.
[Harvey, Philip D.] Emory Univ, Sch Med, Atlanta, GA USA.
[Goodman, Marianne; Triebwasser, Joseph; Koenigsberg, Harold W.; Flory, Janine D.; Siever, Larry J.] James J Peters VA Med Ctr, Bronx, NY USA.
[Flory, Janine D.] Queens Coll, Queens, NY USA.
RP McClure, MM (reprint author), Mt Sinai Sch Med, VA VISN MIRECC 3, 130 W Kingsbridge Rd,00MH, Bronx, NY 10468 USA.
EM Margaret.McNamara@mssm.edu
FU Veterans Affairs [7609-028]; Veterans Affairs VISN3 Mental Illness
Research, Education, and Clinical Center; National Center for Research
Resources (NCRR), National Institutes of Health (NIH) [MO1-RR-00071]
FX This work was supported by a Veterans Affairs Merit Review Grant
(7609-028) to Dr Larry J Siever and by the Veterans Affairs VISN3 Mental
Illness Research, Education, and Clinical Center. This work was also
supported in part by Grant Number MO1-RR-00071 from the National Center
for Research Resources (NCRR), a component of the National Institutes of
Health (NIH). Its contents are solely the responsibility of the authors
and do not necessarily represent the official views of NCRR or NIH.
NR 60
TC 27
Z9 27
U1 2
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD MAY
PY 2010
VL 35
IS 6
BP 1356
EP 1362
DI 10.1038/npp.2010.5
PG 7
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 586KJ
UT WOS:000276906500012
PM 20130535
ER
PT J
AU Santos, CF
Kurhanewicz, J
Tabatabai, ZL
Simko, JP
Keshari, KR
Gbegnon, A
DeLos Santos, R
Federman, S
Shinohara, K
Carroll, PR
Haqq, CM
Swanson, MG
AF Santos, Carissa F.
Kurhanewicz, John
Tabatabai, Z. Laura
Simko, Jeffry P.
Keshari, Kayvan R.
Gbegnon, Akpene
DeLos Santos, Romelyn
Federman, Scot
Shinohara, Katsuto
Carroll, Peter R.
Haqq, Christopher M.
Swanson, Mark G.
TI Metabolic, pathologic, and genetic analysis of prostate tissues:
quantitative evaluation of histopathologic and mRNA integrity after
HR-MAS spectroscopy
SO NMR IN BIOMEDICINE
LA English
DT Article
DE cDNA microarray; gene expression; high resolution magic angle spinning
(HR-MAS) spectroscopy; prostate cancer; radical prostatectomy; RNA
integrity number (RIN); significance analysis of microarrays (SAM);
transrectal ultrasound (TRUS) guided biopsy
ID POLYMERASE CHAIN-REACTION; MAGNETIC-RESONANCE SPECTROSCOPY; SPINNING
H-1-NMR SPECTROSCOPY; EXPRESSION ANALYSIS; PROTON NMR; RADICAL
PROSTATECTOMY; CANCER TISSUE; FATTY-ACIDS; IN-VIVO; RESOLUTION
AB The impact of high-resolution magic angle spinning (HR-MAS) spectroscopy on the histopathologic and mRNA integrity of human prostate tissues was evaluated. Forty prostate tissues were harvested at transrectal ultrasound (TRUS) guided biopsy (n = 20) or radical prostatectomy surgery (n = 20), snap-frozen on dry ice, and stored at 80 C until use. Twenty-one samples (n = 11 biopsy, n = 10 surgical) underwent HR-MAS spectroscopy prior to histopathologic and cDNA microarray analysis, while 19 control samples (n = 9 biopsy, n = 10 surgical) underwent only histopathologic and microarray analysis. Frozen tissues were sectioned at 14-mu m intervals and placed on individual histopathology slides. Every 8th slide was stained with hematoxylin and eosin (H&E) and used to target areas of predominantly epithelial tissue on the remaining slides for mRNA integrity and cDNA microarray analysis. Histopathologic integrity was graded from 1 (best) to 5 (worst) by two 'blinded' pathologists. Histopathologic integrity scores were not significantly different for post-surgical tissues (HR-MAS vs controls); however, one pathologist's scores were significantly lower for biopsy tissues following HR-MAS while the other pathologist's scores were not. mRNA integrity assays were performed using an Agilent 2100 Bioanalyzer and the electrophoretic traces were scored with an RNA integrity number (RIN) from 1 (degraded) to 10 (intact). RIN scores were not significantly different for surgical tissues, but were significantly lower for biopsy tissues following HR-MAS spectroscopy. The isolated mRNA then underwent two rounds of amplification, conversion to cDNA, coupling to Cy3 and Cy5 dyes, microarray hybridization, imaging, and analysis. Significance analysis of microarrays (SAM) identified no significantly over- or under-expressed genes, including 14 housekeeping genes, between HR-MAS and control samples of surgical and biopsy tissues (5% false discovery rate). This study demonstrates that histopathologic and genetic microarray analysis can be successfully performed on prostate surgical and biopsy tissues following HR-MAS analysis; however, biopsy tissues are more fragile than surgical tissues. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Santos, Carissa F.; Kurhanewicz, John; Keshari, Kayvan R.; Gbegnon, Akpene; DeLos Santos, Romelyn; Swanson, Mark G.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94158 USA.
[Tabatabai, Z. Laura; Simko, Jeffry P.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94158 USA.
[Federman, Scot] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA.
[Shinohara, Katsuto; Carroll, Peter R.; Haqq, Christopher M.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94158 USA.
[Tabatabai, Z. Laura] San Francisco Vet Adm Med Ctr, San Francisco, CA USA.
[Haqq, Christopher M.] Cougar Biotechnol, Los Angeles, CA USA.
RP Kurhanewicz, J (reprint author), Univ Calif San Francisco, Dept Radiol, Byers Hall,Box 2520,1700 4th St,Room 203E, San Francisco, CA 94158 USA.
EM john.kurhanewicz@radiology.ucsf.edu
OI Keshari, Kayvan/0000-0002-5181-8035
FU National Institutes of Health [K01 CA096618, R01 CA/02751, R01
CA101042]; American Cancer Society [RSG-05-241-01-CCE]; University of
California Discovery [ITL-B1004-10148]
FX Contract/grant sponsor: National Institutes of Health; contract/grant
number: K01 CA096618, R01 CA/02751, R01 CA101042.; Contract/grant
sponsor: American Cancer Society; contract/grant number:
RSG-05-241-01-CCE.; Contract/grant sponsor: University of California
Discovery Grant; contract/ grant number: ITL-B1004-10148.
NR 55
TC 17
Z9 17
U1 0
U2 4
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0952-3480
J9 NMR BIOMED
JI NMR Biomed.
PD MAY
PY 2010
VL 23
IS 4
BP 391
EP 398
DI 10.1002/nbm.1474
PG 8
WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
GA 594HA
UT WOS:000277525800008
PM 20033906
ER
PT J
AU Livhits, M
Mercado, C
Yermilov, I
Parikh, JA
Dutson, E
Mehran, A
Ko, CY
Gibbons, MM
AF Livhits, Masha
Mercado, Cheryl
Yermilov, Irina
Parikh, Janak A.
Dutson, Erik
Mehran, Amir
Ko, Clifford Y.
Gibbons, Melinda Maggard
TI Exercise Following Bariatric Surgery: Systematic Review
SO OBESITY SURGERY
LA English
DT Review
DE Bariatric surgery; Weight loss; Exercise
ID PHYSICAL-ACTIVITY QUESTIONNAIRE; GASTRIC BYPASS-SURGERY; WEIGHT-LOSS;
CONTROLLED-TRIAL; OBESITY; OVERWEIGHT; BMI; MEN; ASSOCIATION;
RELIABILITY
AB The contribution of physical activity on the degree of weight loss following bariatric surgery is unclear. To determine impact of exercise on postoperative weight loss. Medline search (1988-2009) was completed using MeSH terms including bariatric procedures and a spectrum of patient factors with potential relationship to weight loss outcomes. Of the 934 screened articles, 14 reported on exercise and weight loss outcomes. The most commonly used instruments to measure activity level were the Baecke Physical Activity Questionnaire, the International Physical Activity Questionnaire, and a variety of self-made questionnaires. The definition of an active patient varied but generally required a minimum of 30 min of exercise at least 3 days per week. Thirteen articles reported on exercise and degree of postoperative weight loss (n = 4,108 patients). Eleven articles found a positive association of exercise on postoperative weight loss, and two did not. Meta-analysis of three studies revealed a significant increase in 1-year postoperative weight loss (mean difference = 4.2% total body mass index (BMI) loss, 95% confidence interval (CI; 0.26-8.11)) for patients who exercise postoperatively. Exercise following bariatric surgery appears to be associated with a greater weight loss of over 4% of BMI. While a causal relationship cannot be established with observational data, this finding supports the continued efforts to encourage and support patients' involvement in post-surgery exercise. Further research is necessary to determine the recommended activity guidelines for this patient population.
C1 [Livhits, Masha; Yermilov, Irina; Parikh, Janak A.; Ko, Clifford Y.; Gibbons, Melinda Maggard] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90073 USA.
[Gibbons, Melinda Maggard] Olive View UCLA, Dept Surg, Sylmar, CA 91342 USA.
[Livhits, Masha; Mercado, Cheryl; Yermilov, Irina; Parikh, Janak A.; Dutson, Erik; Mehran, Amir; Ko, Clifford Y.; Gibbons, Melinda Maggard] Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Livhits, M (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Surg, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mlivhits@mednet.ucla.edu
FU VA Department of Surgery, Robert Wood Johnson Physician Faculty
FX We would like to acknowledge the generous contribution of Paul G.
Shekelle to the design of our project and critical review of the
analysis. The VA Department of Surgery provided support for Dr. Livhits
and Dr. Maggard. Dr. Maggard's time was supported in part by a grant
from the Robert Wood Johnson Physician Faculty Scholars program.; VA
Department of Surgery, Robert Wood Johnson Physician Faculty Scholars
program
NR 33
TC 64
Z9 66
U1 6
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0960-8923
J9 OBES SURG
JI Obes. Surg.
PD MAY
PY 2010
VL 20
IS 5
BP 657
EP 665
DI 10.1007/s11695-010-0096-0
PG 9
WC Surgery
SC Surgery
GA 580SR
UT WOS:000276470700018
PM 20180039
ER
PT J
AU Martin, K
Rossi, V
Ferrucci, S
Pian, D
AF Martin, Krista
Rossi, Victoria
Ferrucci, Steven
Pian, Debi
TI Retinal astrocytic hamartoma
SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION
LA English
DT Article
DE Astrocytic hamartoma; Astrocytoma; Phakomatoses; Tuberous sclerosis
ID OPTICAL COHERENCE TOMOGRAPHY; TUBEROUS SCLEROSIS; SIMULATING
RETINOBLASTOMA; NEUROFIBROMATOSIS TYPE-1; SPONTANEOUS REGRESSION;
NEUROIMAGING FINDINGS; PIGMENT EPITHELIUM; TUMORS; PHAKOMATOSIS;
HYPERPLASIA
AB BACKGROUND: Retinal astrocytic hamartomas are glial tumors of the retinal nerve fiber layer that arise from retinal astrocytes. Classically they appear as a cream-white, well-circumscribed, elevated lesion that may present as multiple or solitary sites. A lesion is commonly seen with a multilobulated, "mulberry" appearance, but can also appear flat and semitranslucent. It is most frequently associated with tuberous sclerosis (TS) but may also be found rarely in patients with neurofibromatosis. Although the finding may point toward a systemic association, it can also be found incidentally on retinal examination as an isolated presentation.
CASE REPORTS: Two cases of solitary retinal astrocytic hamartomas without systemic complications discovered at routine examination are presented. Both patients were found to have a raised, multilobulated retinal lesion consistent with the appearance of a retinal astrocytic hamartoma. In both cases, the patients had no personal or family history of seizures or any signs of unusual dermatologic lesions. B-scan ultrasonography, fluorescein angiography, and magnetic resonance imaging (MRI) were performed as necessary.
CONCLUSION: A retinal astrocytic hamartoma is typically associated with TS but can also present as a spontaneous, idiopathic lesion. Prompt referral to rule out TS or other systemic associations, particularly in young children, is important. Neuroimaging, along with other diagnostic tests, may ensure the proper management and rule out need for further evaluation. Spontaneous lesions without systemic association can initially be monitored closely to rule out possible progression. Once stability has been established, annual follow-up with a primary care eye practitioner is appropriate. Optometry 2010;81:221-233
C1 [Martin, Krista] Vet Affairs Greater Los Angeles Healthcare Syst, Santa Maria Vet Affairs Community Based Outpatien, Santa Maria, CA USA.
[Rossi, Victoria; Ferrucci, Steven] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Vet Affairs Ambulatory Care Ctr Nursing, Sepulveda, CA USA.
[Ferrucci, Steven] So Calif Coll Optometry, Fullerton, CA USA.
[Pian, Debi] SUNY Coll Optometry, New York, NY 10010 USA.
RP Ferrucci, S (reprint author), Sepulveda VA Ambulatory Care Ctr, Dept Optometry, 16111 Plummer St,112E, Sepulveda, CA 91343 USA.
EM steven.ferrucci@va.gov
NR 48
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1529-1839
J9 OPTOMETRY
JI Optometry
PD MAY
PY 2010
VL 81
IS 5
BP 221
EP 233
DI 10.1016/j.optm.2009.12.009
PG 13
WC Ophthalmology
SC Ophthalmology
GA 800MD
UT WOS:000293364100003
PM 20435268
ER
PT J
AU Yumori, JW
Ilsen, P
Bright, DC
AF Yumori, Jasmine W.
Ilsen, Pauline
Bright, David C.
TI Conjunctival plasmacytoma
SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION
LA English
DT Article
DE Plasmacytoma; Solitary extramedullary plasmacytoma; Multiple myeloma;
Conjunctival tumor; Excisional biopsy
ID HEPATITIS-C VIRUS; EXTRAMEDULLARY PLASMACYTOMA; SOLITARY PLASMACYTOMA;
MULTIPLE-MYELOMA; LYMPHOMA; TUMORS; HEAD; NECK; MANIFESTATIONS;
INFECTION
AB BACKGROUND: Plasmacytomas are plasma cell tumors that may be a primary or secondary tumor focus, the latter of which are associated with multiple myeloma. We present a rare case of a solitary extramedullary plasmacytoma involving the conjunctiva.
CASE REPORT: A 33-year-old white man presented with the initial complaint of redness in both eyes, more in his right than left eye. A vascularized conjunctival lesion was noted in his right eye. The patient underwent excisional biopsy, which found a conjunctival plasmacytoma.
CONCLUSION: Although plasmacytomas of the eye and orbit are rare, it is important to be familiar with these tumors that may be associated with multiple myeloma. Definitive diagnosis is made by biopsy and histopathologic examination of the tissue. Plasmacytomas may be treated with external beam radiation, local excision, or radiotherapy after surgical excision. Long-term follow-up, including periodic systemic evaluation, is required to establish that orbital involvement is not an early manifestation of multiple myeloma. Optometry 2010;81:234-239
C1 [Yumori, Jasmine W.; Ilsen, Pauline; Bright, David C.] W Los Angeles Vet Affairs Hlth Ctr, Los Angeles, CA USA.
[Yumori, Jasmine W.] Western Univ Hlth Sci, Pomona, CA USA.
[Ilsen, Pauline; Bright, David C.] So Calif Coll Optometry, Fullerton, CA USA.
RP Yumori, JW (reprint author), 309 E 2nd St, Pomona, CA 91766 USA.
EM jyumori@westernu.edu
NR 43
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1529-1839
J9 OPTOMETRY
JI Optometry
PD MAY
PY 2010
VL 81
IS 5
BP 234
EP 239
DI 10.1016/j.optm.2009.11.006
PG 6
WC Ophthalmology
SC Ophthalmology
GA 800MD
UT WOS:000293364100004
PM 20435269
ER
PT J
AU Glynn, SM
AF Glynn, Shirley M.
TI The Psychosocial Characteristics and Needs of Patients Presenting with
Orofacial Injury
SO ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Sociodemographic; Socioeconomic; Orofacial injury; Trauma
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; FACIAL
INJURY; MANDIBULAR FRACTURES; MAXILLOFACIAL INJURY; SCREENING
INSTRUMENT; UNITED-STATES; TRAUMA CENTER; HEALTH-CARE; PREVALENCE
AB Individuals with orofacial injury presenting to urban trauma centers in the United States tend to be disproportionately socioeconomically disadvantaged, young, adult, ethnic minority men. Most injuries are assaultive in origin, suggesting poor impulse control and maladaptive social behaviors. Compared with matched control populations, patients with orofacial injuries are more likely to report higher levels of substance use behaviors and to manifest greater levels of hostility, anxiety, and depression. Although they have significantly greater current and lifetime need for mental health service and social service, actual use of social services is low. The underlying psychosocial characteristics of many patients with orofacial injury, along with unmet service needs, render them vulnerable for posttrauma psychological sequelae and may compromise functional outcomes and recovery.
C1 [Glynn, Shirley M.] VA Greater Los Angeles Healthcare Syst W Los Ange, Res Serv, Los Angeles, CA 90073 USA.
[Glynn, Shirley M.] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA.
RP Glynn, SM (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, B151J,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM sglynn@ucla.edu
FU National Institutes of Health/National Institute of Dental and
Craniofacial Research [P50/DE-10598]
FX This work was supported by Grant Number P50/DE-10598 from the National
Institutes of Health/National Institute of Dental and Craniofacial
Research.
NR 31
TC 2
Z9 2
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1042-3699
J9 ORAL MAXIL SURG CLIN
JI Oral Maxillofac. Surg. Clin. N. Am.
PD MAY
PY 2010
VL 22
IS 2
BP 209
EP +
DI 10.1016/j.coms.2010.01.003
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 864TV
UT WOS:000298263900002
PM 20403551
ER
PT J
AU Glynn, SM
Shetty, V
AF Glynn, Shirley M.
Shetty, Vivek
TI The Long-Term Psychological Sequelae of Orofacial Injury
SO ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Facial injury; Chronic sequela; Psychosocial; Screening
ID POSTTRAUMATIC-STRESS-DISORDER; RISK-FACTORS; ASSAULT VICTIMS; FACIAL
INJURY; TRAUMA CENTER; DEPRESSION; PTSD; INTERVENTIONS; PREVENTION;
SAMPLE
AB Significant subsets of patients who experience orofacial injury are at risk for developing adverse psychological sequelae such as posttraumatic stress disorder and depression. If undetected and untreated, the psychopathology can become recalcitrant and burden the social and vocational functioning of the patients and greatly diminish their quality of life. The hospital encounter and follow-up care visits provide the oral and maxillofacial surgeon with opportunities to screen for emerging psychological problems. Several screening instruments are available to assist the surgeon in identifying individuals who are at risk for subsequent mental health problems. Facilitated referrals to mental health services can be a practical approach for improving comprehensive medical care for vulnerable individuals and for reducing the potential morbidity of these covert, but disabling, sequelae.
C1 [Glynn, Shirley M.] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA.
[Shetty, Vivek] 23009 UCLA Sch Dent, Sect Oral & Maxillofacial Surg, Los Angeles, CA 90095 USA.
[Glynn, Shirley M.] VA Greater Angeles Healthcare Syst W Los Angeles, Res Serv, Los Angeles, CA 90073 USA.
RP Glynn, SM (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, B151J,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM sglynn@ucla.edu
FU National Institutes of Health/NIDCR [P50/DE-10598]
FX This work was supported by grant number P50/DE-10598 from the National
Institutes of Health/NIDCR.
NR 40
TC 4
Z9 4
U1 3
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1042-3699
J9 ORAL MAXIL SURG CLIN
JI Oral Maxillofac. Surg. Clin. N. Am.
PD MAY
PY 2010
VL 22
IS 2
BP 217
EP +
DI 10.1016/j.coms.2010.01.008
PG 9
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 864TV
UT WOS:000298263900003
PM 20403552
ER
PT J
AU Gironda, MW
Lui, A
AF Gironda, Melanie W.
Lui, Anna
TI Social Support and Resource Needs as Mediators of Recovery After Facial
Injury
SO ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Social support; Social network; Measures; Resource; Facial injury
ID SPINAL-CORD-INJURY; QUALITY-OF-LIFE; MULTIDIMENSIONAL SCALE; STRESS
RESISTANCE; BREAST-CANCER; HEALTH; IMPACT; ADOLESCENTS; DEPRESSION;
COMMUNITY
AB Although many trauma centers provide excellent surgical care, little attention is paid to psychosocial needs and problems of posttrauma adaptation. Social support and resource needs have been identified as significant mediators of recovery after injuries. This article presents an overview of various social and material resources instrumental to psychological adjustment and recovery. It also discusses the ways in which complex social networks can be both beneficial and damaging toward the recovery process and the implications for clinical care of patients with orofacial injury. Finally, appropriate social support resource measuring tools that may be used in clinical settings are presented.
C1 [Gironda, Melanie W.] Univ Calif Los Angeles, Div Publ Hlth & Community Dent, UCLA Sch Dent, Los Angeles, CA 90095 USA.
[Gironda, Melanie W.] Univ Calif Los Angeles, Sch Publ Affairs, Dept Social Welf, Los Angeles, CA 90095 USA.
[Lui, Anna] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA.
RP Gironda, MW (reprint author), Univ Calif Los Angeles, Div Publ Hlth & Community Dent, UCLA Sch Dent, Box 951668,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM mgironda@ucla.edu
NR 81
TC 3
Z9 3
U1 2
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1042-3699
J9 ORAL MAXIL SURG CLIN
JI Oral Maxillofac. Surg. Clin. N. Am.
PD MAY
PY 2010
VL 22
IS 2
BP 251
EP +
DI 10.1016/j.coms.2010.01.006
PG 10
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 864TV
UT WOS:000298263900008
PM 20403557
ER
PT J
AU Rosengren, BE
Nilsson, JA
Ohlsson, C
Mellstrom, D
Lorentzon, M
Ljunggren, O
Ribom, E
Mallmin, H
Stefanick, ML
Lapidus, JA
Leung, PC
Barrett-Connor, E
Orwoll, E
Karlsson, MK
AF Rosengren, B. E.
Nilsson, J. A.
Ohlsson, C.
Mellstrom, D.
Lorentzon, M.
Ljunggren, O.
Ribom, E.
Mallmin, H.
Stefanick, M. L.
Lapidus, J. A.
Leung, P. C.
Barrett-Connor, E.
Orwoll, E.
Karlsson, M. K.
CA MrOs Study Grp
TI EPIDEMIOLOGY OF FALLS AMONG 11009 ELDERLY MEN - THE MR OS STUDY
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Meeting Abstract
CT IOF World Congress on Osteoporosis/10th European Congress on Clinical
and Economic Aspects of Osteoporosis and Osteoarthritis
CY MAY 05-08, 2010
CL Florence, ITALY
C1 [Rosengren, B. E.; Nilsson, J. A.; Karlsson, M. K.] Lund Univ, Clin & Mol Osteoporosis Res Unit, Dept Orthoped Surg, Malmo, Sweden.
[Rosengren, B. E.; Nilsson, J. A.; Karlsson, M. K.] Lund Univ, Dept Clin Sci, Malmo Univ Hosp, Malmo, Sweden.
[Ohlsson, C.; Mellstrom, D.; Lorentzon, M.] Univ Gothenburg, Ctr Bone Res, Dept Internal Med & Geriatr, Sahlgrenska Acad, Gothenburg, Sweden.
[Ljunggren, O.] Uppsala Univ, Ctr Metab Bone Dis, Dept Med Sci, Uppsala, Sweden.
[Ribom, E.; Mallmin, H.] Uppsala Univ, Dept Orthoped Surg, Dept Surg Sci, Uppsala, Sweden.
[Stefanick, M. L.] Stanford Univ, Stanford Prevent Res Ctr, Dept Med, Palo Alto, CA 94304 USA.
[Lapidus, J. A.; Orwoll, E.] Oregon Hlth & Sci Univ, Bone & Mineral Res Unit, Portland, OR USA.
[Lapidus, J. A.] Portland VA Med Ctr, Portland, OR USA.
[Barrett-Connor, E.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA.
[Leung, P. C.] Chinese Univ Hong Kong, Inst Chinese Med, Hong Kong, Hong Kong, Peoples R China.
RI Rosengren, Bjorn/F-8345-2011
NR 0
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAY
PY 2010
VL 21
SU 1
BP 7
EP 8
DI 10.1007/s00198-010-1246-x
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 591KN
UT WOS:000277299400015
ER
PT J
AU Dohadwala, M
Wang, GY
Heinrich, E
Luo, J
Lau, O
Shih, H
Munaim, Q
Lee, G
Hong, LS
Lai, C
Abemayor, E
Fishbein, MC
Elashoff, DA
Dubinett, SM
John, MAS
AF Dohadwala, Mariam
Wang, Guanyu
Heinrich, Eileen
Luo, Jie
Lau, Ontario
Shih, Hubert
Munaim, Qahera
Lee, Gina
Hong, Longsheng
Lai, Chi
Abemayor, Elliot
Fishbein, Michael C.
Elashoff, David A.
Dubinett, Steven M.
John, Maie A. St.
TI The role of ZEB1 in the inflammation-induced promotion of EMT in HNSCC
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the
American-Academy-of-Otolaryngology-Head-and-Neck-Surgery-Foundation
CY OCT 04-07, 2009
CL San Diego, CA
SP Amer Acad Otolaryngol Head & Neck Surg Fdn
ID GROWTH-FACTOR RECEPTOR; CELL CARCINOMA LINES; E-CADHERIN; EXPRESSION;
CANCER; CYCLOOXYGENASE-2; HEAD; DIFFERENTIATION; PHENOTYPE; SNAIL
AB OBJECTIVES: To determine the role of ZEB1 in the inflammation-induced promotion of the epithelial-mesenchymal transition (EMT) in head and neck squamous cell carcinoma (HNSCC).
STUDY DESIGN: A molecular biology study. Real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR), Western blot analysis, and immunohistochemical staining of human HNSCC tissue sections were used to determine how inflammation affects the transcriptional repressor, ZEB1.
SETTING: An academic hospital laboratory.
SUBJECTS AND METHODS: Relative ZEB1 RNA levels were determined by RT-PCR, and protein expression was evaluated in situ by immunohistochemical staining of human HNSCC tissue sections.
RESULTS: IL-1 beta-treated HNSCC cell lines demonstrated a significant decrease in E-cadherin mRNA and an increase in the mRNA expression of the transcriptional repressor ZEB1. IL-1 beta exposure led to enhanced ZEB1 binding at the chromatin level, as determined by chromatin immunoprecipitation assays (ChIP). An inverse relationship between ZEB1 and E-cadherin was demonstrated in situ by immunohistochemical staining of human HNSCC tissue sections.
CONCLUSIONS: Our recent investigations indicate that inflammatory mediators are potent regulators of EMT in HNSCC. This is the first report indicating the role of ZEB1 in the inflammation-induced promotion of EMT in HNSCC. This newly defined pathway for transcriptional regulation of E-cadherin in HNSCC has important implications for targeted chemoprevention and therapy. (C) 2010 American Academy of Otolaryngology Head and Neck Surgery Foundation. All rights reserved.
C1 [Lau, Ontario; Shih, Hubert; Munaim, Qahera; Abemayor, Elliot; John, Maie A. St.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Head & Neck Surg, Los Angeles, CA 90095 USA.
[Dohadwala, Mariam; Wang, Guanyu; Heinrich, Eileen; Luo, Jie; Lee, Gina; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Lung Canc Res Program, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Dohadwala, Mariam; Wang, Guanyu; Heinrich, Eileen; Luo, Jie; Lee, Gina; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Dept Med, Los Angeles, CA 90095 USA.
[Heinrich, Eileen; Hong, Longsheng; Lai, Chi; Fishbein, Michael C.; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Abemayor, Elliot; Dubinett, Steven M.; John, Maie A. St.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Elashoff, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biostat, Los Angeles, CA 90095 USA.
[Dohadwala, Mariam; Lee, Gina; Dubinett, Steven M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP John, MAS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Head & Neck Surg, 37-131 CHS,10833 Conte Ave, Los Angeles, CA 90095 USA.
EM mstjohn@mednet.ucla.edu
FU NCI NIH HHS [R01 CA111851]
NR 18
TC 21
Z9 22
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0194-5998
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD MAY
PY 2010
VL 142
IS 5
BP 753
EP 759
DI 10.1016/j.otohns.2010.01.034
PG 7
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 591LT
UT WOS:000277302800021
PM 20416468
ER
PT J
AU Lau, MK
Davila, JA
Shaib, YH
AF Lau, Melvin K.
Davila, Jessica A.
Shaib, Yasser H.
TI Incidence and Survival of Pancreatic Head and Body and Tail Cancers A
Population-Based Study in the United States
SO PANCREAS
LA English
DT Article
DE pancreas; cancer; head; body; tail; incidence; survival; United States
ID ADENOCARCINOMA; EPIDEMIOLOGY; TRENDS
AB Objectives: Cancer of the body/tail of the pancreas is frequently separated from pancreatic head tumors. No studies have examined whether the demographics, disease characteristics, and patient survival with pancreatic body/tail cancers are different from pancreatic head tumors.
Methods: We used the Surveillance, Epidemiology, and End Results (SEER) registry to identify 43,946 cases of pancreatic cancer. The yearly incidence and survival rates were calculated. Cox proportional hazards model examined temporal trends in survival.
Results: The incidence rate for pancreatic head cancer has remained at 5.6% per 100,000, whereas the rate for pancreatic body/tail cancers has increased by 46% between 1973 and 2002. The 3-year survival rate has increased slightly for both groups. The Cox proportional hazards model analysis confirms this improvement. The 3-year survival rate for local-stage pancreatic body/tail cancer is 20.0% compared with 9% for local-stage pancreatic head cancer.
Conclusions: This study indicates that the incidence of pancreatic head cancer has remained stable, whereas the incidence of pancreatic body/tail cancers is rising. Despite higher survival rates among patients with pancreatic head cancer compared with those with pancreatic body/tail cancers in several variables, patients with local-stage pancreatic body/tail cancers had higher survival rates compared with local-stage pancreatic head cancer.
C1 Dept Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA.
Dept Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA.
Baylor Coll Med, Houston, TX 77030 USA.
RP Shaib, YH (reprint author), Michael E Debakey VA Med Ctr 111D, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM yshaib@bcm.tmc.edu
NR 9
TC 35
Z9 36
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAY
PY 2010
VL 39
IS 4
BP 458
EP 462
DI 10.1097/MPA.0b013e3181bd6489
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 587IP
UT WOS:000276984800006
PM 19924019
ER
PT J
AU Lara-Corrales, I
Arbuckle, A
Zarinehbaf, S
Pope, E
AF Lara-Corrales, Irene
Arbuckle, Alan
Zarinehbaf, Sanaz
Pope, Elena
TI Principles of Wound Care in Patients with Epidermolysis Bullosa
SO PEDIATRIC DERMATOLOGY
LA English
DT Review
ID AMNIOTIC MEMBRANE; GROWTH-FACTOR; SKIN WOUNDS; MANAGEMENT; ULCERS;
INFLAMMATION
AB Epidermolysis bullosa comprises a series of hereditary skin fragility disorders characterized by blister formation in response to minor friction or trauma. Acute and chronic wounds are part of the daily life of many epidermolysis bullosa patients. To offer proper care, health care providers need to understand the wound healing process, recognize the different types of wounds these patients may present, and be able to select among a wide variety of wound care products to optimize healing.
C1 [Lara-Corrales, Irene; Zarinehbaf, Sanaz; Pope, Elena] Hosp Sick Children, Dept Dermatol, Toronto, ON M5G 1X8, Canada.
[Arbuckle, Alan] Denver VA Med Ctr, Dept Dermatol, Denver, CO USA.
RP Pope, E (reprint author), Hosp Sick Children, Dept Dermatol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM elena.pope@sickkids.ca
NR 49
TC 10
Z9 11
U1 1
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0736-8046
J9 PEDIATR DERMATOL
JI Pediatr. Dermatol.
PD MAY-JUN
PY 2010
VL 27
IS 3
BP 229
EP 237
DI 10.1111/j.1525-1470.2010.01086.x
PG 9
WC Dermatology; Pediatrics
SC Dermatology; Pediatrics
GA 601DB
UT WOS:000278037100003
PM 20403117
ER
PT J
AU Miller, AL
Dassori, A
Lopez, L
Castillo, DA
Gonzalez, JM
Boone, C
Milam, C
Bond, GR
Velligan, DI
AF Miller, Alexander L.
Dassori, Albana
Lopez, Linda
Castillo, Desiree A.
Gonzalez, Jodi M.
Boone, Charles
Milam, Camis
Bond, Gary R.
Velligan, Dawn I.
TI Tools for Mental Health Agencies to Evaluate Research Protocols
SO PSYCHIATRIC SERVICES
LA English
DT Editorial Material
AB Research involving community mental health center clients, resources, or both can affect clinical care, administrative processes, and costs. To help agencies identify and quantify these effects, a stakeholder group examined and discussed a range of protocols and then developed questionnaires and rating scales for agency use. The purpose of these materials is to make explicit the risks, costs, and benefits of a research protocol so an agency can make informed decisions about protocol approval and implementation. The goal of this work was to promote the conduct of appropriate research in community mental health settings while reducing risks to the agency and its clientele. (Psychiatric Services 61:446-448, 2010)
C1 [Miller, Alexander L.; Dassori, Albana; Castillo, Desiree A.; Gonzalez, Jodi M.; Velligan, Dawn I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Dassori, Albana] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Lopez, Linda; Boone, Charles; Milam, Camis] Ctr Hlth Care Serv, San Antonio, TX USA.
[Bond, Gary R.] Dartmouth Med Sch, Dept Psychiat, Lebanon, NH USA.
RP Miller, AL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM millera@uthscsa.edu
FU NIMH NIH HHS [5R24-MH72830]
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD MAY
PY 2010
VL 61
IS 5
BP 446
EP 448
PG 3
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 590SX
UT WOS:000277249200004
PM 20439362
ER
PT J
AU Rodriguez, KL
Bayliss, N
Alexander, SC
Jeffreys, AS
Olsen, MK
Pollak, KI
Kennifer, SL
Tulsky, JA
Arnold, RM
AF Rodriguez, Keri L.
Bayliss, Nichole
Alexander, Stewart C.
Jeffreys, Amy S.
Olsen, Maren K.
Pollak, Kathryn I.
Kennifer, Sarah L.
Tulsky, James A.
Arnold, Robert M.
TI How oncologists and their patients with advanced cancer communicate
about health-related quality of life
SO PSYCHO-ONCOLOGY
LA English
DT Article
DE cancer; communication; oncology; patient provider relationship;
qualitative research; quality of life
ID CELL LUNG-CANCER; PHYSICIAN COMMUNICATION; CARE; CHEMOTHERAPY;
DEFINITION; AGREEMENT; OUTCOMES; SCORES; TRIAL
AB Objective: To describe the content and frequency of communication about health-related quality of life (HRQOL) during outpatient encounters between oncologists and their patients with advanced cancer.
Methods: We coded for HRQOL talk in a subset of audio-recorded conversations (each previously found to contain prognostic talk by the oncologist) from the Study of Communication in Oncologist-Patient Encounters Trial, a randomized controlled trial conducted from 2003 to 2008 in two large US academic medical centers and one Veterans Affairs Medical Center.
Results: Seventy-three encounters involved 70 patients and 37 oncologists. Patients were more likely to be female (53%), White (86%), married (78%), and possessing some college education (62%). Most oncologists were male (78%) and White (78%). Mean ages were 59 years for patients and 44 years for oncologists. Every encounter included some talk about HRQOL and HRQOL discussions made up, on average, 25% of the visit time. HRQOL segments described symptoms (50%), general HRQOL (27%), and the following concerns: physical (27%), functional (22%), psychological (9%), social (7%), spiritual (1%), and other (28%). Topics included treatment (56%), disease (14%), and testing (3%), and conversations focused on past (44%), present (68%), and future HRQOL (59%).
Conclusions: HRQOL discussions between oncologists and patients are common, but the emphasis is often on treatment (e.g. side effects) and symptoms (e.g. pain) even in patients with advanced disease. Given the often intense emotional experience of patients with advanced cancer, oncologists may need to pay more attention to psychological, social, and spiritual HRQOL concerns. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Rodriguez, Keri L.; Bayliss, Nichole] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Rodriguez, Keri L.; Arnold, Robert M.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Rodriguez, Keri L.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15206 USA.
[Alexander, Stewart C.; Jeffreys, Amy S.; Olsen, Maren K.; Tulsky, James A.] Durham VA Med Ctr, Hlth Serv Res & Dev, Durham, NC USA.
[Alexander, Stewart C.; Tulsky, James A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[Alexander, Stewart C.; Kennifer, Sarah L.; Tulsky, James A.] Duke Univ, Med Ctr, Ctr Palliat Care, Durham, NC 27710 USA.
[Olsen, Maren K.] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA.
[Pollak, Kathryn I.] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA.
[Pollak, Kathryn I.] Duke Univ, Med Ctr, Duke Comprehens Canc Ctr, Duke Canc Prevent Detect & Control Res Program, Durham, NC 27710 USA.
[Tulsky, James A.] Duke Univ, Med Ctr, Ctr Aging & Human Dev, Durham, NC 27710 USA.
[Arnold, Robert M.] Univ Pittsburgh, Sect Palliat Care & Med Eth, Pittsburgh, PA USA.
[Arnold, Robert M.] Univ Pittsburgh, Inst Enhance Palliat Care, Pittsburgh, PA USA.
RP Rodriguez, KL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,Bldg 2,Rm 4083E,151 CH, Pittsburgh, PA 15206 USA.
EM Keri.rodriguez@va.gov
FU VA HSRD Merit Review [MRP 04-410]; National Cancer Institute [3R01
CA-100387-03S1, R01 CA-100387]
FX Dr Rodriguez is supported by a VA HSR&D Merit Review Entry Program Award
(MRP 04-410) and a Minority Supplement Award from the National Cancer
Institute (3R01 CA-100387-03S1). This work was supported in part by a
grant awarded to Dr Tulsky by the National Cancer Institute (R01
CA-100387). The views expressed in this article are those of the authors
and do not necessarily reflect the position or policy of the Department
of Veterans Affairs. All manuscript authors declare that there are no
conflicts of interest (i.e. financial and personal relationships between
themselves and others that might bias their work).
NR 38
TC 25
Z9 25
U1 1
U2 7
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1057-9249
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD MAY
PY 2010
VL 19
IS 5
BP 490
EP 499
DI 10.1002/pon.1579
PG 10
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 591ZP
UT WOS:000277344400005
PM 19449348
ER
PT J
AU Gordon, AJ
Haas, GL
Luther, JF
Hilton, MT
Goldstein, G
AF Gordon, Adam J.
Haas, Gretchen L.
Luther, James F.
Hilton, Michael T.
Goldstein, Gerald
TI Personal, Medical, and Healthcare Utilization Among Homeless Veterans
Served by Metropolitan and Nonmetropolitan Veteran Facilities
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE homelessness; rural health; veterans; health services research
ID URBAN HOMELESS; MENTAL-ILLNESS; MOBILE CLINICS; HOUSED POOR; ADULTS;
SERVICES; PROGRAM; USERS
AB This study assessed differences in personal, medical, and health care utilization characteristics of homeless veterans living in metropolitan versus nonmetropolitan environments. Data were obtained from a Veterans Health Administration (VHA) network sample of homeless veterans. Chi-square tests were used to assess differences in demographics, military history, living situation, medical history, employment status, and health care utilization. Moderator analyses determined whether predictors of health care utilization varied by metropolitan status. Of 3,595 respondents, 60% were residing in metropolitan areas. Age, sex, and marital status were similar between metropolitan and nonmetropolitan homeless. Metropolitan homeless were less likely to receive public financial support or to be employed, to have at least one medical problem, one psychiatric problem, or current alcohol dependency, but more likely to be homeless longer. Of the 52% of the sample who used VHA care in the last 6 months, 53% were metropolitan versus 49% nonmetropolitan (p = .01). Metropolitan status predicted at least one VHA visit within the prior 6 months (OR: 1.3, CI: 1.1, 1.6). Significant differences occur in the personal, medical, and health care utilization characteristics of homeless veterans in metropolitan versus nonmetropolitan areas.
C1 [Gordon, Adam J.; Haas, Gretchen L.; Luther, James F.; Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA.
[Gordon, Adam J.; Haas, Gretchen L.; Hilton, Michael T.; Goldstein, Gerald] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
[Luther, James F.] Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, Pittsburgh, PA 15260 USA.
RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Mailcode 151-C-H,7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM adam.gordon@va.gov
FU NIMH NIH HHS [R25 MH054318, R25 MH054318-16]
NR 23
TC 10
Z9 10
U1 1
U2 2
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2010
VL 7
IS 2
BP 65
EP 74
DI 10.1037/a0018479
PG 10
WC Psychology, Clinical
SC Psychology
GA 789QF
UT WOS:000292529700002
PM 21152352
ER
PT J
AU Lysaker, PH
Glynn, SM
Wilkniss, SM
Silverstein, SM
AF Lysaker, Paul H.
Glynn, Shirley M.
Wilkniss, Sandra M.
Silverstein, Steven M.
TI Psychotherapy and Recovery From Schizophrenia: A Review of Potential
Applications and Need for Future Study
SO PSYCHOLOGICAL SERVICES
LA English
DT Review
DE schizophrenia; recovery; psychotherapy; metacognition; self
ID BORDERLINE PERSONALITY-DISORDER; COGNITIVE-BEHAVIORAL THERAPY;
RANDOMIZED CONTROLLED-TRIAL; SEVERE MENTAL-ILLNESS; SPECTRUM DISORDERS;
INDIVIDUAL PSYCHOTHERAPY; FOLLOW-UP; 1ST-EPISODE PSYCHOSIS; INTERNALIZED
STIGMA; SELF-EXPERIENCE
AB Recovery from schizophrenia has been conceptualized to involve not only symptom remission of symptoms and achievement of psychosocial milestones but also subjective changes in how persons appraise their lives and the extent to which they experience themselves as meaningful agents in the world. In this article we review the potential of individual psychotherapy to address these more subjective aspects of recovery. Literature on the effectiveness of psychotherapy for persons with schizophrenia is discussed, and two different paths by which psychotherapy might modify self-experience are described. First, we detail how psychotherapy could be conceptualized and tailored to help persons with schizophrenia to construct richer and fuller narrative accounts of their lives, including their strengths, challenges, losses, and hopes. Second, we explore how psychotherapy could target the capacity for metacognition or thinking about thinking, assisting persons with psychosis to become able to think about themselves and others in a generally more complex and flexible manner. The needs for future research are discussed along with a commentary on how current evidence- and skill-based treatments may contain key elements that could be considered psychotherapeutic.
C1 [Lysaker, Paul H.] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA.
[Lysaker, Paul H.] Indiana Univ Sch Med, Indianapolis, IN USA.
[Glynn, Shirley M.] Univ Calif Los Angeles, Ctr Med, Los Angeles, CA 90024 USA.
[Glynn, Shirley M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Wilkniss, Sandra M.] Thresholds Inst, Chicago, IL USA.
[Silverstein, Steven M.] Univ Med & Dent New Jersey, Univ Behav HealthCare, Piscataway, NJ 08854 USA.
[Silverstein, Steven M.] Robert Wood Johnson Med Sch, Piscataway, NJ USA.
RP Lysaker, PH (reprint author), Roudebush VA Med Ctr 116H, 1481 W 10th St, Indianapolis, IN 46202 USA.
EM plysaker@iupui.Ed
OI Lysaker, Paul/0000-0002-6617-9387
FU NIMH NIH HHS [R34 MH082161, R34 MH082161-03]
NR 123
TC 73
Z9 74
U1 4
U2 17
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2010
VL 7
IS 2
BP 75
EP 91
DI 10.1037/a0019115
PG 17
WC Psychology, Clinical
SC Psychology
GA 789QF
UT WOS:000292529700003
PM 20526422
ER
PT J
AU Ku, BS
Scott, KC
Kertesz, SG
Pitts, SR
AF Ku, Bon S.
Scott, Kevin C.
Kertesz, Stefan G.
Pitts, Stephen R.
TI Factors Associated with Use of Urban Emergency Departments by the US
Homeless Population
SO PUBLIC HEALTH REPORTS
LA English
DT Article
ID HEALTH-CARE UTILIZATION; NEW-YORK-CITY; FREQUENT USERS; SERVICE USE;
CASE-MANAGEMENT; LOS-ANGELES; ADULTS; PROGRAM; COHORT; COSTS
AB Objective. Homeless individuals frequently use emergency departments (EDs), but previous studies have investigated local rather than national ED utilization rates. This study sought to characterize homeless people who visited urban EDs across the U.S.
Methods. We analyzed the ED subset of the National Hospital Ambulatory Medical Care Survey (NHAMCS-ED), a nationally representative probability survey of ED visits, using methods appropriate for complex survey samples to compare demographic and clinical characteristics of visits by homeless vs. non-homeless people for survey years 2005 and 2006.
Results. Homeless individuals from all age groups made 550,000 ED visits annually (95% confidence interval [Cl] 419,000, 682,000), or 72 visits per 100 homeless people in the U.S. per year. Homeless people were older than others who used EDs (mean age of homeless people = 44 years compared with 36 years for others). ED visits by homeless people were independently associated with male gender, Medicaid coverage and lack of insurance, and Western geographic region. Additionally, homeless ED visitors were more likely to have arrived by ambulance, to be seen by a resident or intern, and to be diagnosed with either a psychiatric or substance abuse problem. Compared with others, ED visits by homeless people were four times more likely to occur within three days of a prior ED evaluation, and more than twice as likely to occur within a week of hospitalization.
Conclusions. Homeless people who seek care in urban EDs come by ambulance, lack medical insurance, and have psychiatric and substance abuse diagnoses more often than non-homeless people. The high incidence of repeat ED visits and frequent hospital use identifies a pressing need for policy remedies.
C1 [Ku, Bon S.] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA.
[Scott, Kevin C.] Thomas Jefferson Univ, Dept Family & Community Med, Philadelphia, PA 19107 USA.
[Kertesz, Stefan G.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA.
[Kertesz, Stefan G.] Univ Alabama, Sch Med, Birmingham, AL USA.
[Pitts, Stephen R.] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA USA.
RP Ku, BS (reprint author), Thomas Jefferson Univ, Dept Emergency Med, 1020 Sansom St,239 Thompson Bldg, Philadelphia, PA 19107 USA.
EM bon.ku@jefferson.edu
NR 44
TC 38
Z9 38
U1 2
U2 13
PU ASSOC SCHOOLS PUBLIC HEALTH
PI WASHINGTON
PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA
SN 0033-3549
J9 PUBLIC HEALTH REP
JI Public Health Rep.
PD MAY-JUN
PY 2010
VL 125
IS 3
BP 398
EP 405
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 581WD
UT WOS:000276555100008
PM 20433034
ER
PT J
AU Hoo, GWS
AF Hoo, Guy W. Soo
TI Chronic Obstructive Pulmonary Disease in the Veterans Affairs Hospitals:
Haven't We Seen This Before?
SO RESPIRATORY CARE
LA English
DT Editorial Material
ID COPD; DIAGNOSIS; SPIROMETRY; BURDEN; PREVALENCE; TRIAL
C1 [Hoo, Guy W. Soo] W Los Angeles Vet Affairs Healthcare Ctr, Pulm & Crit Care Sect, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Hoo, Guy W. Soo] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Hoo, GWS (reprint author), W Los Angeles Vet Affairs Healthcare Ctr, Pulm & Crit Care Sect, Vet Affairs Greater Los Angeles Healthcare Syst, 111Q,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM guy.soohoo@va.gov
NR 29
TC 0
Z9 0
U1 0
U2 0
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
J9 RESP CARE
JI Respir. Care
PD MAY
PY 2010
VL 55
IS 5
BP 643
EP 645
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 599TK
UT WOS:000277936100018
ER
PT J
AU Villarruel, AM
Zhou, Y
Gallegos, EC
Ronis, DL
AF Villarruel, Antonia M.
Zhou, Yan
Gallegos, Esther C.
Ronis, David L.
TI Examining long-term effects of Cuidate-a sexual risk reduction program
in Mexican youth
SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC
HEALTH
LA English
DT Article
DE Adolescent behavior; sexual behavior; adolescent health; risk reduction
behavior; follow-up studies; intervention studies; randomized controlled
trial; Mexico
ID RANDOMIZED CONTROLLED-TRIAL; SOCIAL-DESIRABILITY-SCALE; HIV PREVENTION
PROGRAM; LATINO YOUTH; INTERVENTION; ADOLESCENTS; BEHAVIORS
AB Objectives. To examine the effectiveness of a safer sex program (Cuidate) on sexual behavior, use of condoms, and use of other contraceptives among Mexican youth 48 months after the intervention.
Methods. A total of 708 or 85% of those who participated in the original randomized control study (n = 829) were assessed in the 48-month follow-up. Each participant completed a questionnaire on sexual behavior.
Results. Findings indicated that adolescents who participated in the Cuidate program were more likely to be older at first sex (odds ratio [OR], 1.27; 95% confidence interval [CI], 0.41-2.12; P < 0.05) and to use condoms at first sex (OR, 1.75; 95% CI, 1.14-2.69; P < 0.05) or some other type of contraception at first sex (OR, 1.53; 95% CI, 1.00-2.33; P < 0.05) than those in the control group. Effects of the intervention on consistent condom use, condom use at last sex, and number of sexual partners were not significant. Gender did not moderate any intervention effects. Social desirability moderated the effect of the intervention on age at first sex.
Conclusions. Results demonstrate the efficacy of Cuidate among Mexican adolescents. Future research, policy, and practice efforts should be directed at sustaining safe sex practices across adolescents' developmental and relationship trajectory.
C1 [Villarruel, Antonia M.; Ronis, David L.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48103 USA.
[Zhou, Yan] US FDA, Div Biometr 2, Off Biostat, Ctr Drug Evaluat & Res, Silver Spring, MD USA.
[Gallegos, Esther C.] Univ Autonoma Nuevo Leon, Escuela Enfermeria, Monterrey, NL, Mexico.
[Ronis, David L.] US Dept Vet Affairs, Ann Arbor, MI USA.
RP Villarruel, AM (reprint author), Univ Michigan, Sch Nursing, 400 North Ingalls, Ann Arbor, MI 48103 USA.
EM avillarr@umich.edu
FU NINR NIH HHS [R01 NR008059, NR04855]
NR 23
TC 13
Z9 13
U1 0
U2 8
PU PAN AMER HEALTH ORGANIZATION
PI WASHINGTON
PA 525 23RD ST NW, WASHINGTON, DC 20037 USA
SN 1020-4989
J9 REV PANAM SALUD PUBL
JI Rev. Panam. Salud Publica
PD MAY
PY 2010
VL 27
IS 5
BP 345
EP 351
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 620UT
UT WOS:000279526700004
PM 20602068
ER
PT J
AU Medalia, A
Thysen, J
AF Medalia, Alice
Thysen, Julie
TI A comparison of insight into clinical symptoms versus insight into
neuro-cognitive symptoms in schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Insight; Neuro-cognition; Schizophrenia; Awareness; Cognition
ID PSYCHOTIC-PATIENTS; PERFORMANCE; IMPAIRMENT; AWARENESS; DEFICITS; SCALE;
METAANALYSIS; UNAWARENESS; INTERVIEW; ILLNESS
AB Background: Schizophrenia is associated with neuropsychological deficits that have been linked to poor functional outcome. To address this problem, pharmacologic and behavioral treatments are being developed for cognitive impairments, but they will not be well utilized if people with schizophrenia do not perceive a need for treatment.
Aims: This study compared whether people with schizophrenia have a similar degree of insight into neuro-cognitive symptoms as clinical symptoms, and whether neuro-cognitive and clinical symptoms are similarly related to degree of insight into these two aspects of the illness.
Method: Seventy-one patients with schizophrenia were administered measures of clinical and neuro-cognitive status as well as clinician rated measures of insight into clinical and neuro-cognitive symptoms.
Results: Patients had significantly less insight into their neuro-cognitive symptoms than their clinical symptoms. On average, patients had good insight into clinical symptoms and partial insight into neuro-cognitive symptoms. Neuropsychological variables were related to insight into clinical symptoms, but not insight into neuro-cognition. Clinical variables were not significantly related to either type of insight.
Conclusions: Insight is not a unitary concept and the differences between awareness of neuro-cognition and awareness of clinical symptoms suggest that they have to be addressed separately in treatment. Specific education about cognitive symptoms may be necessary to improve awareness of this aspect of the schizophrenia. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Medalia, Alice] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA.
[Thysen, Julie] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Thysen, Julie] James J Peter VA Med Ctr, Bronx, NY USA.
RP Medalia, A (reprint author), 180 Ft Washington Ave,HP234, New York, NY 10032 USA.
EM am2938@columbia.edu
FU Eli Lilly, PI [F1D-US-X267]
FX This research was supported by an Eli Lilly Investigator Initiated
Trial, Grant # F1D-US-X267, PI: Alice Medalia, PhD. Eli Lilly had no
further role in the study design; in the collection, analysis and
interpretation of data; in the writing of the report; and in the
decision to submit the paper for publication.
NR 35
TC 29
Z9 30
U1 2
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD MAY
PY 2010
VL 118
IS 1-3
BP 134
EP 139
DI 10.1016/j.schres.2009.09.027
PG 6
WC Psychiatry
SC Psychiatry
GA 603NE
UT WOS:000278214500021
PM 19840898
ER
PT J
AU Delos Santos, RB
Gmurczyk, A
Obhrai, JS
Watnick, SG
AF Delos Santos, Rowena B.
Gmurczyk, Aleksandra
Obhrai, Jagdeep S.
Watnick, Suzanne G.
TI Cardiac Evaluation Prior to Kidney Transplantation
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; RENAL REPLACEMENT THERAPY;
ISCHEMIC-HEART-DISEASE; STRESS ECHOCARDIOGRAPHY; RISK SCORE; CANDIDATES;
FAILURE; ANGIOGRAPHY; RECIPIENTS; DIALYSIS
AB Kidney transplantation is the treatment of choice for most patients with stage 5 chronic kidney disease and end-stage renal disease (ESRD), offering improved quality of life and overall survival rates. However, the limited supply of available organs makes this a scarce resource. Cardiovascular complications continue to be the leading cause of mortality in the kidney transplant population, accounting for over 30% of deaths with a functioning allograft. Thus, preoperative cardiac risk assessment is critical to optimize patient selection and outcomes. Currently there is no consensus for cardiovascular evaluation in the chronic kidney disease and ESRD population prior to kidney transplantation; the recommendations of the American Society of Nephrology and American Society of Transplantation differ from those of the American Heart Association and the American College of Cardiology. Previously developed risk scores have also been used to risk stratify this population. In this review, we discuss two cases that illustrate the difficulties of interpreting the prognostic value of current testing strategies. We also discuss the importance of different tests for cardiovascular evaluation as well as previous nonkidney transplant specific risk scores used in the pre-kidney transplant population.
C1 [Watnick, Suzanne G.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Nephrol & Hypertens, Dept Internal Med, Portland, OR 97239 USA.
[Gmurczyk, Aleksandra] Northwestern Univ, Div Nephrol Hypertens, Dept Internal Med, Chicago, IL 60611 USA.
[Obhrai, Jagdeep S.] Oregon Hlth & Sci Univ, Transplant Med Sect, Div Nephrol & Hypertens, Dept Internal Med, Portland, OR 97239 USA.
RP Watnick, SG (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Nephrol & Hypertens, Dept Internal Med, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM watnicks@ohsu.edu
FU NIH/NIDDK [T32 DK067864]
FX This work was supported by NIH/NIDDK grant T32 DK067864.
NR 28
TC 2
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0894-0959
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD MAY-JUN
PY 2010
VL 23
IS 3
BP 324
EP 328
DI 10.1111/j.1525-139X.2010.00725.x
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 614TI
UT WOS:000279082300016
PM 20636926
ER
PT J
AU Epstein, MD
Bhargava, P
Medverd, JR
AF Epstein, Matthew D.
Bhargava, Puneet
Medverd, Jonathan R.
TI A 48-year-old man with chronic right shoulder pain and weakness after a
fall
SO SKELETAL RADIOLOGY
LA English
DT Editorial Material
C1 [Bhargava, Puneet; Medverd, Jonathan R.] Univ Washington, Dept Radiol, Seattle, WA 98108 USA.
[Bhargava, Puneet; Medverd, Jonathan R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Epstein, Matthew D.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, 1660 S Columbian Way,S-114 Radiol,Mail Stop 35828, Seattle, WA 98108 USA.
EM mde1@u.washington.edu; bhargp@u.washington.edu; jmed@u.washington.edu
RI Bhargava, Puneet /F-1330-2011
OI Bhargava, Puneet/0000-0002-3849-9666
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-2348
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD MAY
PY 2010
VL 39
IS 5
BP 489
EP 490
DI 10.1007/s00256-009-0846-z
PG 2
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA 573IZ
UT WOS:000275907900010
ER
PT J
AU Teodorescu, MC
Szklo-Coxe, M
AF Teodorescu, Mihai C.
Szklo-Coxe, Mariana
TI Sleep Well to Stay Safe: Ready for Primetime?
SO SLEEP
LA English
DT Editorial Material
ID OCCUPATIONAL INJURIES; WORKERS
C1 [Teodorescu, Mihai C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA.
[Szklo-Coxe, Mariana] Old Dominion Univ, Coll Hlth Sci, Sch Community & Environm Hlth, Norfolk, VA USA.
[Szklo-Coxe, Mariana] Eastern Virginia Med Sch, Dept Internal Med, Div Sleep Med, Norfolk, VA 23501 USA.
[Teodorescu, Mihai C.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
RP Teodorescu, MC (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,B5056, Madison, WI 53705 USA.
EM mct@medicine.wisc.edu
NR 15
TC 0
Z9 0
U1 0
U2 1
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD MAY 1
PY 2010
VL 33
IS 5
BP 577
EP 578
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 590NC
UT WOS:000277232200003
PM 20469798
ER
PT J
AU Iwai, M
Stetler, RA
Xing, J
Hu, XM
Gao, YQ
Zhang, WT
Chen, J
Cao, GD
AF Iwai, Masanori
Stetler, R. Anne
Xing, Juan
Hu, Xiaoming
Gao, Yanqin
Zhang, Wenting
Chen, Jun
Cao, Guodong
TI Enhanced Oligodendrogenesis and Recovery of Neurological Function by
Erythropoietin After Neonatal Hypoxic/Ischemic Brain Injury
SO STROKE
LA English
DT Article
DE erythropoietin; neonatal hypoxia/ischemia; neurogenesis;
oligodendrogenesis; white matter injury
ID HYPOXIA-ISCHEMIA; IN-VITRO; OLIGODENDROCYTES; RAT; HYPOXIA/ISCHEMIA;
PROLIFERATION; NEUROGENESIS; PROGENITORS; REPLACEMENT; THERAPY
AB Background and Purpose-Neuronal replacement has recently gained attention as a potential therapeutic target under ischemic conditions. However, the oligodendrogenic infrastructure is equally critical for restoration of brain function and is also sensitive to ischemic injury. Erythropoietin (EPO) is a neuroprotective molecule that stimulates neuronal replacement after neonatal hypoxia/ischemia (H/I) when delivered soon after the onset of reperfusion. Because EPO can improve recovery of neurological function in the absence of tissue protection, we hypothesize that EPO may improve neurological function via enhancement of white matter recovery after H/I. Thus, we sought to determine the effects of delayed administration of EPO on white matter injury and recovery of neurological function after neonatal H/I.
Methods-EPO (1000 U/kg) was injected intraperitoneally at multiple time points beginning 48 hours after H/I in postnatal day 7 rats. The effects of EPO on oligodendrogenesis, white matter injury, and neurogenesis were evaluated using bromodeoxyuridine incorporation and cell-specific immunohistochemistry. Neurological function was assessed by sensorimotor behavioral tests.
Results-Delayed administration of EPO was incapable of reducing brain volume loss but significantly increased oligodendrogenesis and maturation of oligodendrocytes and attenuated white matter injury after H/I. These effects occurred concurrently with enhanced neurogenesis. Delayed EPO treatment improved behavioral neurological outcomes 14 days after H/I injury.
Conclusions-Our study demonstrates that delayed administration of EPO promotes oligodendrogenesis and attenuates white matter injury concurrently with increased neurogenesis. These effects likely contribute to the observed improvement in neurological functional outcomes. (Stroke. 2010;41:1032-1037.)
C1 [Iwai, Masanori; Stetler, R. Anne; Xing, Juan; Hu, Xiaoming; Chen, Jun; Cao, Guodong] Univ Pittsburgh, Dept Neurol, Sch Med, Pittsburgh, PA 15260 USA.
[Iwai, Masanori; Stetler, R. Anne; Chen, Jun; Cao, Guodong] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Stetler, R. Anne; Gao, Yanqin; Zhang, Wenting; Chen, Jun; Cao, Guodong] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China.
RP Cao, GD (reprint author), Univ Pittsburgh, Dept Neurol, Sch Med, BST S505,3500 Terrace St, Pittsburgh, PA 15260 USA.
EM caog@upmc.edu
RI Gao, Yanqin/I-6790-2016
OI Gao, Yanqin/0000-0002-4915-9819
FU National Institutes of Health/NINDS [NS43802, NS45048, NS36736, NS56118,
NS053473]; VA Merit Review; AHA Scientist Development [06300064N]
FX This project was supported by National Institutes of Health/NINDS grants
NS43802, NS45048, NS36736, NS56118 (J.C.), and NS053473 (G. C.), VA
Merit Review grants (J.C. and G. C.), and AHA Scientist Development
grant 06300064N (G. C.).
NR 18
TC 86
Z9 94
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD MAY
PY 2010
VL 41
IS 5
BP 1032
EP 1037
DI 10.1161/STROKEAHA.109.570325
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 588IY
UT WOS:000277064300034
PM 20360553
ER
PT J
AU Ramsey, S
Zeliadt, SB
Blough, DK
Fedorenko, CR
Moinpour, CM
Hall, IJH
Smith, JL
Ekwueme, DU
Fairweather, ME
Thompson, IM
Keane, TE
Penson, D
AF Ramsey, S.
Zeliadt, S. B.
Blough, D. K.
Fedorenko, C. R.
Moinpour, C. M.
Hall, I. J. H.
Smith, Lee J.
Ekwueme, D. U.
Fairweather, M. E.
Thompson, Jr I. M.
Keane, T. E.
Penson, D.
TI A COMPARISON OF PHYSICIAN AND PATIENT DECISION MAKING FOR FIRST VERSUS
SECOND OPINIONS AMONG MEN WITH LOCAL STAGE PROSTATE CANCER
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Ramsey, S.; Fedorenko, C. R.; Moinpour, C. M.; Fairweather, M. E.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
[Zeliadt, S. B.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Hall, I. J. H.; Smith, Lee J.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Ekwueme, D. U.] Ctr Dis Control & Prevent, Snellville, GA USA.
[Thompson, Jr I. M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Keane, T. E.] Med Univ S Carolina, Med Ctr, Charleston, SC 29425 USA.
[Penson, D.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2010
VL 13
IS 3
BP A51
EP A51
DI 10.1016/S1098-3015(10)72233-6
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 589CJ
UT WOS:000277121900250
ER
PT J
AU Nguyen, HM
Rocha, MA
Chintalacharuvu, KR
Beenhouwer, DO
AF Nguyen, Hien M.
Rocha, Miguel A.
Chintalacharuvu, Koteswara R.
Beenhouwer, David O.
TI Detection and quantification of Panton-Valentine leukocidin in
Staphylococcus aureus cultures by ELISA and Western blotting:
Diethylpyrocarbonate inhibits binding of protein A to IgG
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE Staphylococcus aureus; Protein A; Panton-Valentine leukocidin;
Diethylpyrocarbonate; ELISA; Western Blot
ID ENTEROTOXIN-B; IMMUNOGLOBULIN; FC
AB Enzyme-linked immunosorbent assay (ELISA) and Western blotting are common techniques used to detect and quantify proteins in Staphylococcus aureus culture supernatants, such as Panton-Valentine leukocidin (PVL). However, protein A (Spa) secreted by most S. aureus strains may interfere with these assays by binding to the capturing and detecting antibodies. Here, we have shown that the addition of diethylpyrocarbonate (DEPC) inhibits the binding of Spa to rabbit anti-PVL used as the capturing antibody in ELISA. In Western blotting, the presence of DEPC prevented the binding of detecting antibody to Spa. These modified ELISA and Western blot techniques should prove useful for detecting and quantifying proteins in S. aureus culture supernatants. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Nguyen, Hien M.; Rocha, Miguel A.; Chintalacharuvu, Koteswara R.; Beenhouwer, David O.] Vet Affairs Greater Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA.
[Beenhouwer, David O.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
RP Beenhouwer, DO (reprint author), VA Greater Los Angeles, Div Infect Dis 111F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM dbeenhou@ucla.edu
FU National Institutes of Health [AI071025]
FX This work was supported by National Institutes of Health grant AI071025
to DOB.
NR 17
TC 11
Z9 11
U1 3
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD APR 30
PY 2010
VL 356
IS 1-2
BP 1
EP 5
DI 10.1016/j.jim.2010.03.005
PG 5
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 599OY
UT WOS:000277924200001
PM 20303971
ER
PT J
AU Leverenz, JB
Kim, HM
Samii, A
Gerton, B
Baca, M
Pate, J
Martinez, E
Thomas, S
Tsuang, DW
Zabetian, CP
AF Leverenz, J. B.
Kim, H. M.
Samii, A.
Gerton, B.
Baca, M.
Pate, J.
Martinez, E.
Thomas, S.
Tsuang, D. W.
Zabetian, C. P.
TI The Washington State Parkinson Disease Registry.
SO MOVEMENT DISORDERS
LA English
DT Meeting Abstract
CT 24th Annual Symposium on Etiology, Pathogenesis and Treatment of
Parkinson's Disease and Other Movement Disorders
CY MAY 15, 2010
CL Irving, TX
C1 [Leverenz, J. B.; Kim, H. M.; Samii, A.; Gerton, B.; Baca, M.; Pate, J.; Martinez, E.; Thomas, S.; Tsuang, D. W.; Zabetian, C. P.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Leverenz, J. B.; Samii, A.; Zabetian, C. P.] Univ Washington, Parkinson Dis Res Ctr, Seattle, WA 98195 USA.
[Leverenz, J. B.; Samii, A.; Zabetian, C. P.] Univ Washington, Educ Ctr, Seattle, WA 98195 USA.
[Leverenz, J. B.; Samii, A.; Zabetian, C. P.] Univ Washington, Ctr Clin, Seattle, WA 98195 USA.
[Leverenz, J. B.; Kim, H. M.; Samii, A.; Gerton, B.; Zabetian, C. P.] Univ Washington, Dept Neurol & Psychiat, Seattle, WA 98195 USA.
[Leverenz, J. B.; Tsuang, D. W.] Univ Washington, Dept Behav Sci, Seattle, WA 98195 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD APR 30
PY 2010
VL 25
IS 6
BP VI
EP VI
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 591OS
UT WOS:000277311500046
ER
PT J
AU Townsend, J
Bookheimer, SY
Foland-Ross, LC
Sugar, CA
Altshuler, LL
AF Townsend, Jennifer
Bookheimer, Susan Y.
Foland-Ross, Lara C.
Sugar, Catherine A.
Altshuler, Lori L.
TI fMRI abnormalities in dorsolateral prefrontal cortex during a working
memory task in manic, euthymic and depressed bipolar subjects
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article
DE Bipolar disorder; Dorsolateral prefrontal cortex; Parietal cortex;
Mania; Depression; Euthymia; Working memory
ID MOOD-REGULATING CIRCUIT; COGNITIVE IMPAIRMENT; FUNCTIONAL-MRI;
AFFECTIVE-DISORDERS; INCREASED AMYGDALA; BRAIN IMAGES; SCHIZOPHRENIA;
ACTIVATION; DYSFUNCTION; ROBUST
AB Neuropsychological studies of subjects with bipolar disorder suggest impairment of working memory not only in acute mood states, but also while subjects are euthymic. Using fMRI to probe working memory regions in bipolar subjects in different mood states, we sought to determine the functional neural basis for these impairments. Typical working memory areas in normal populations include dorsolateral prefrontal cortex (BA9/46) and the posterior parietal cortex (BA40). We evaluated the activation in these regions using an n-back task in 42 bipolar subjects (13 manic, 15 euthymic and 14 depressed subjects) and 14 control subjects. While both control and bipolar subjects performed similarly on the task, bipolar subjects in all three mood states showed a significant reduction in activation in right BA9/46 and right BA40. Patients with bipolar disorder exhibit significantly attenuated neural activation in working memory circuits, independent of mood state. The reduction of neural activation may suggest a trait-related deficit. Subjects with bipolar disorder activated other additional frontal and temporal regions, perhaps as a compensatory mechanism, but this remains to be further explored. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Townsend, Jennifer; Bookheimer, Susan Y.; Altshuler, Lori L.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Foland-Ross, Lara C.] Univ Calif Los Angeles, Sch Med, Dept Neurol, Lab NeuroImaging, Los Angeles, CA 90024 USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA USA.
[Altshuler, Lori L.] W Los Angeles Healthcare Ctr, Dept Psychiat, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Altshuler, LL (reprint author), 300 UCLA Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA.
EM laltshuler@mednet.ucla.edu
FU Stanley Medical Research Institute; NARSAD (National Association for
Research on Schizophrenia and Affective Disorders); National Institute
of Mental Health [K24 MH001848, R21 MH075944, 5F31MH078556]; Brain
Mapping Medical Research Organization; Brain Mapping Support Foundation;
Pierson-Lovelace Foundation; Ahmanson Foundation; William M. and Linda
R. Dietel Philanthropic Fund at the Northern Piedmont Community
Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital
Group Companies Charitable Foundation; Northstar Fund; National Center
for Research Resources (NCRR), a component of the National Institutes of
Health (NIH) [RR12169, RR13642, RR00865]
FX The authors gratefully acknowledge The Stanley Medical Research
Institute, NARSAD (National Association for Research on Schizophrenia
and Affective Disorders), and the National Institute of Mental Health
(K24 MH001848, R21 MH075944, 5F31MH078556) for their financial support
of this study. For generous support the authors also wish to thank the
Brain Mapping Medical Research Organization, Brain Mapping Support
Foundation, Pierson-Lovelace Foundation, The Ahmanson Foundation,
William M. and Linda R. Dietel Philanthropic Fund at the Northern
Piedmont Community Foundation, Tamkin Foundation, Jennifer Jones-Simon
Foundation, Capital Group Companies Charitable Foundation, Robson Family
and Northstar Fund. The project described was supported by Grant Numbers
RR12169, RR13642 and RR00865 from the National Center for Research
Resources (NCRR), a component of the National Institutes of Health
(NIH); its contents are solely the responsibility of the authors and do
not necessarily represent the official views of NCR or NIH.
NR 70
TC 56
Z9 61
U1 1
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0925-4927
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD APR 30
PY 2010
VL 182
IS 1
BP 22
EP 29
DI 10.1016/j.pscychresns.2009.11.010
PG 8
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 594KJ
UT WOS:000277536200004
PM 20227857
ER
PT J
AU Cushman, WC
Evans, GW
Byington, RP
Goff, DC
Grimm, RH
Cutler, JA
Simons-Morton, DG
Basile, JN
Corson, MA
Probstfield, JL
Katz, L
Peterson, KA
Friedewald, WT
Buse, JB
Bigger, JT
Gerstein, HC
Ismail-Beigi, F
AF Cushman, William C.
Evans, Gregory W.
Byington, Robert P.
Goff, David C., Jr.
Grimm, Richard H., Jr.
Cutler, Jeffrey A.
Simons-Morton, Denise G.
Basile, Jan N.
Corson, Marshall A.
Probstfield, Jeffrey L.
Katz, Lois
Peterson, Kevin A.
Friedewald, William T.
Buse, John B.
Bigger, J. Thomas
Gerstein, Hertzel C.
Ismail-Beigi, Faramarz
TI Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID MICROVASCULAR COMPLICATIONS; RISK; DISEASE; TRIAL; PREVENTION; HOT
AB BACKGROUND
There is no evidence from randomized trials to support a strategy of lowering systolic blood pressure below 135 to 140 mm Hg in persons with type 2 diabetes mellitus. We investigated whether therapy targeting normal systolic pressure (i.e., < 120 mm Hg) reduces major cardiovascular events in participants with type 2 diabetes at high risk for cardiovascular events.
METHODS
A total of 4733 participants with type 2 diabetes were randomly assigned to intensive therapy, targeting a systolic pressure of less than 120 mm Hg, or standard therapy, targeting a systolic pressure of less than 140 mm Hg. The primary composite outcome was nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The mean follow-up was 4.7 years.
RESULTS
After 1 year, the mean systolic blood pressure was 119.3 mm Hg in the intensive-therapy group and 133.5 mm Hg in the standard-therapy group. The annual rate of the primary outcome was 1.87% in the intensive-therapy group and 2.09% in the standard-therapy group (hazard ratio with intensive therapy, 0.88; 95% confidence interval [CI], 0.73 to 1.06; P = 0.20). The annual rates of death from any cause were 1.28% and 1.19% in the two groups, respectively (hazard ratio, 1.07; 95% CI, 0.85 to 1.35; P = 0.55). The annual rates of stroke, a prespecified secondary outcome, were 0.32% and 0.53% in the two groups, respectively (hazard ratio, 0.59; 95% CI, 0.39 to 0.89; P = 0.01). Serious adverse events attributed to antihypertensive treatment occurred in 77 of the 2362 participants in the intensive-therapy group (3.3%) and 30 of the 2371 participants in the standard-therapy group (1.3%) (P<0.001).
CONCLUSIONS
In patients with type 2 diabetes at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, did not reduce the rate of a composite outcome of fatal and nonfatal major cardiovascular events. (ClinicalTrials.gov number, NCT00000620.)
C1 [Cushman, William C.] Memphis Vet Affairs VA Med Ctr, Prevent Med Sect, Memphis, TN USA.
[Evans, Gregory W.; Byington, Robert P.; Goff, David C., Jr.] Wake Forest Univ, Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27109 USA.
[Grimm, Richard H., Jr.] Univ Minnesota, Berman Ctr Outcomes & Clin Res, Minneapolis, MN USA.
[Peterson, Kevin A.] Univ Minnesota, Dept Family Practice & Community Med, Minneapolis, MN USA.
[Cutler, Jeffrey A.; Simons-Morton, Denise G.] NHLBI, Bethesda, MD 20892 USA.
[Basile, Jan N.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Corson, Marshall A.; Probstfield, Jeffrey L.] Univ Washington, Dept Med, Seattle, WA USA.
[Buse, John B.] Univ N Carolina, Sch Med, Div Endocrinol, Chapel Hill, NC USA.
[Gerstein, Hertzel C.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
[Gerstein, Hertzel C.] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.
[Ismail-Beigi, Faramarz] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA.
[Ismail-Beigi, Faramarz] Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.
RP Cushman, WC (reprint author), Vet Affairs Med Ctr, Cushman Prevent Med Sect 111Q, 1030 Jefferson Ave, Memphis, TN 38104 USA.
EM william.cushman@va.gov
RI Friedewald, William/C-8034-2011
OI Peterson, Kevin/0000-0002-6914-8586
FU National Heart, Lung, and Blood Institute [N01-HC-95178, N01-HC-95179,
N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184,
IAA Y1-HC-9035, IAA Y1-HC-1010]; National Institutes of Health; National
Institute of Diabetes and Digestive and Kidney Diseases; National
Institute on Aging; National Eye Institute; Centers for Disease Control
and Prevention
FX Supported by contracts from the National Heart, Lung, and Blood
Institute (N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181,
N01-HC-95182, N01-HC-95183, N01-HC-95184, and IAA#Y1-HC-9035 and
IAA#Y1-HC-1010). Other components of the National Institutes of Health,
including the National Institute of Diabetes and Digestive and Kidney
Diseases, the National Institute on Aging, and the National Eye
Institute, contributed funding. The Centers for Disease Control and
Prevention funded substudies within ACCORD on cost-effectiveness and
health-related quality of life. General Clinical Research Centers
provide support at many sites. The following companies provided study
medications, equipment, or supplies: Abbott Laboratories, Amylin
Pharmaceutical, AstraZeneca Pharmaceuticals, Bayer HealthCare, Closer
Healthcare, GlaxoSmithKline Pharmaceuticals, King Pharmaceuticals,
Merck, Novartis Pharmaceuticals, Novo Nordisk, Omron Healthcare,
Sanofi-Aventis U.S., and Takeda.
NR 19
TC 1169
Z9 1207
U1 8
U2 60
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 29
PY 2010
VL 362
IS 17
BP 1575
EP 1585
DI 10.1056/NEJMoa1001286
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 589AX
UT WOS:000277117400006
ER
PT J
AU Sox, HC
Helfand, M
Grimshaw, J
Dickersin, K
Tovey, D
Knottnerus, JA
Tugwell, P
AF Sox, Harold C.
Helfand, Mark
Grimshaw, Jeremy
Dickersin, Kay
Tovey, David
Knottnerus, J. Andre
Tugwell, Peter
CA PLoS Med Editors
TI Comparative effectiveness research: Challenges for medical journals
SO TRIALS
LA English
DT Editorial Material
AB Editors from a number of medical journals lay out principles for journals considering publication of Comparative Effectiveness Research (CER). In order to encourage dissemination of this editorial, this article is freely available in PLoS Medicine and will be also published in Medical Decision Making, Croatian Medical Journal, The Cochrane Library, Trials, The American Journal of Managed Care, and Journal of Clinical Epidemiology.
C1 [Helfand, Mark] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
[Helfand, Mark] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Sox, Harold C.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dartmouth Inst, Hanover, NH 03756 USA.
[Grimshaw, Jeremy] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
[Dickersin, Kay] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Tovey, David; PLoS Med Editors] Cochrane Lib, London, England.
[Knottnerus, J. Andre] Univ Maastricht, Dept Gen Practice, Maastricht, Netherlands.
[Tugwell, Peter] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
[Tugwell, Peter] Univ Ottawa, Dept Epidemiol, Ottawa, ON, Canada.
[Tugwell, Peter] Univ Ottawa, Dept Community Med, Ottawa, ON, Canada.
RP Helfand, M (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
EM helfand@ohsu.edu
RI Knottnerus, Johannes/A-3829-2009
OI Grimshaw, Jeremy/0000-0001-8015-8243; Tugwell, Peter/0000-0001-5062-0556
NR 7
TC 3
Z9 3
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD APR 28
PY 2010
VL 11
AR 45
DI 10.1186/1745-6215-11-45
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 605FS
UT WOS:000278333700001
PM 20426805
ER
PT J
AU Sharma, S
Liao, SL
AF Sharma, Shikha
Liao, Steve L.
TI Chest pain? Bridging the gap in diagnosis
SO LANCET
LA English
DT Editorial Material
ID MYOCARDIAL BRIDGE
C1 [Sharma, Shikha; Liao, Steve L.] James J Peters VA Med Ctr, Dept Med, Cardiol Sect, Bronx, NY 10468 USA.
[Liao, Steve L.] Mt Sinai Sch Med, Ctr Cardiovasc Hlth, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA.
RP Liao, SL (reprint author), James J Peters VA Med Ctr, Dept Med, Cardiol Sect, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Steve.Liao@va.gov
NR 5
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 24
PY 2010
VL 375
IS 9724
BP 1494
EP 1494
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 590FL
UT WOS:000277210000036
PM 20417860
ER
PT J
AU Caccamo, A
Majumder, S
Richardson, A
Strong, R
Oddo, S
AF Caccamo, Antonella
Majumder, Smita
Richardson, Arlan
Strong, Randy
Oddo, Salvatore
TI Molecular Interplay between Mammalian Target of Rapamycin (mTOR),
Amyloid-beta, and Tau EFFECTS ON COGNITIVE IMPAIRMENTS
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PAIRED HELICAL FILAMENTS; TRIPLE-TRANSGENIC MODEL; P70 S6 KINASE;
ALZHEIMERS-DISEASE; A-BETA; LIFE-SPAN; SIGNALING PATHWAY; PROTEIN-TAU;
GLYCOPROTEIN COMPLEX; INDUCED APOPTOSIS
AB Accumulation of amyloid-beta (A beta) and Tau is an invariant feature of Alzheimer disease (AD). The upstream role of A beta accumulation in the disease pathogenesis is widely accepted, and there is strong evidence showing that A beta accumulation causes cognitive impairments. However, the molecular mechanisms linking A beta to cognitive decline remain to be elucidated. Here we show that the buildup of A beta increases the mammalian target of rapamycin (mTOR) signaling, whereas decreasing mTOR signaling reduces A beta levels, thereby highlighting an interrelation between mTOR signaling and A beta. The mTOR pathway plays a central role in controlling protein homeostasis and hence, neuronal functions; indeed mTOR signaling regulates different forms of learning and memory. Using an animal model of AD, we show that pharmacologically restoring mTOR signaling with rapamycin rescues cognitive deficits and ameliorates A beta and Tau pathology by increasing autophagy. Indeed, we further show that autophagy induction is necessary for the rapamycin mediated reduction in A beta levels. The results presented here provide a molecular basis for the A beta-induced cognitive deficits and, moreover, show that rapamycin, an FDA approved drug, improves learning and memory and reduces A beta and Tau pathology.
C1 [Caccamo, Antonella; Majumder, Smita; Oddo, Salvatore] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA.
[Caccamo, Antonella; Majumder, Smita; Richardson, Arlan; Strong, Randy; Oddo, Salvatore] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78245 USA.
[Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA.
[Richardson, Arlan; Strong, Randy] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
[Richardson, Arlan; Strong, Randy] S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX 78229 USA.
RP Oddo, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM oddo@uthscsa.edu
FU NIA [AG29729-4]; San Antonio Nathan Shock Aging Center [1P30-AG-13319];
Department of Veterans Affairs
FX This work was supported, in whole or in part, by National Institutes of
Health Grant AG29729-4 from the NIA (to S. O.), San Antonio Nathan Shock
Aging Center Grant 1P30-AG-13319, and a grant from the Department of
Veterans Affairs Enhancement Award Program.
NR 76
TC 305
Z9 325
U1 9
U2 45
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 23
PY 2010
VL 285
IS 17
BP 13107
EP 13120
DI 10.1074/jbc.M110.100420
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 584XO
UT WOS:000276787800067
PM 20178983
ER
PT J
AU Tsai, TT
Nallamothu, BK
Rumsfeld, JS
AF Tsai, Thomas T.
Nallamothu, Brahmajee K.
Rumsfeld, John S.
TI Contraindicated Medication Use in Dialysis Patients Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Tsai, Thomas T.; Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
[Nallamothu, Brahmajee K.] Ann Arbor VA Med Ctr, Ann Arbor, MI USA.
RP Tsai, TT (reprint author), Denver VA Med Ctr, Denver, CO USA.
EM thomas.tsai@va.gov
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 21
PY 2010
VL 303
IS 15
BP 1482
EP 1482
DI 10.1001/jama.2010.444
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 585SJ
UT WOS:000276849000022
ER
PT J
AU Nelson, HD
Naik, A
Humphrey, L
Tyne, K
AF Nelson, Heidi D.
Naik, Arpana
Humphrey, Linda
Tyne, Kari
TI The Background Review for the USPSTF Recommendation on Screening for
Breast Cancer Response
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Nelson, Heidi D.; Naik, Arpana] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Humphrey, Linda] Portland VA Med Ctr, Portland, OR 97239 USA.
[Tyne, Kari] HealthPartners, St Paul, MN 55114 USA.
RP Nelson, HD (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
NR 2
TC 1
Z9 1
U1 0
U2 0
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 20
PY 2010
VL 152
IS 8
BP 538
EP 539
DI 10.7326/0003-4819-152-8-201004200-00199
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 588FV
UT WOS:000277054400013
ER
PT J
AU Fiocco, AJ
Lindquist, K
Ferrell, R
Li, R
Simonsick, EM
Nalls, M
Harris, TB
Yaffe, K
AF Fiocco, A. J.
Lindquist, K.
Ferrell, R.
Li, R.
Simonsick, E. M.
Nalls, M.
Harris, T. B.
Yaffe, K.
CA Hlth ABC Study
TI COMT genotype and cognitive function An 8-year longitudinal study in
white and black elders
SO NEUROLOGY
LA English
DT Article
ID CATECHOL-O-METHYLTRANSFERASE; OLDER-ADULTS; PREFRONTAL FUNCTION;
ALZHEIMER-DISEASE; BODY-COMPOSITION; MESSENGER-RNA; POLYMORPHISM;
DOPAMINE; DEMENTIA; BRAIN
AB Objective: Catechol-O-methyltransferase (COMT), an enzyme that catalyzes the degradation of dopamine, is necessary for cognitive function. Few studies have examined the prospective association between COMT (val(158)met) genotype and cognition in older adults.
Methods: We assessed a biracial cohort of 2,858 elderly subjects without dementia who were followed for 8 years. The Modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST) were administered at baseline and years 3, 5, and 8. COMT by race, gender, and APOE status interactions were examined.
Results: Stratified by race and adjusted for covariates, repeated-measures mixed-effects models showed no association between COMT genotype and baseline cognitive function in black or white subjects. In white subjects, COMT was associated with change in 3MS (Met/Met: -2.3 [0.60], Met/Val: -1.7 [0.40], and Val/Val: -1.2 [0.50]) and DSST (Met/Met: -5.60 [1.00], Met/Val: -4.80 [0.70], Val/Val: -4.00 [0.90]). In black subjects, COMT was associated with change in the DSST (Met/Met: -4.10 [2.1], Met/Val: -4.80 [0.90], Val/Val -2.60 [1.00]).
Conclusion: These findings suggest that the Val allele has a protective impact on cognitive decline in late life. Neurology (R) 2010;74:1296-1302
C1 [Fiocco, A. J.; Yaffe, K.] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94121 USA.
[Yaffe, K.] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA.
[Yaffe, K.] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94121 USA.
[Lindquist, K.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94121 USA.
[Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Ferrell, R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
[Li, R.] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA.
[Simonsick, E. M.] NIA, Clin Res Branch, Baltimore, MD 21224 USA.
[Nalls, M.] NIA, Neurogenet Lab, Bethesda, MD 20892 USA.
[Harris, T. B.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA.
RP Fiocco, AJ (reprint author), Univ Calif San Francisco, Sch Med, Dept Psychiat, 4150 Clement St,Box 116H, San Francisco, CA 94121 USA.
EM afiocco@klaru-baycrest.on.ca
RI Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150; Kritchevsky,
Stephen/0000-0003-3336-6781
FU NIH, National Institute on Aging; Canadian Institute of Health;
[N01-AG-6-2101]; [N01-AG-6-2103]; [N01-AG-6-2106];
[1R21DK068608-01A2]; [AG031155]
FX Funded by N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106. The
measurement of F2-isoprostane was funded by 1R21DK068608-01A2. This
research was supported in part by the Intramural Research Program of the
NIH, National Institute on Aging. Dr. Fiocco is supported by the
Canadian Institute of Health Research Fellowship in the area of
Longitudinal Study on Aging. Dr. Yaffe was supported in part by AG031155
and an anonymous foundation.
NR 40
TC 13
Z9 13
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD APR 20
PY 2010
VL 74
IS 16
BP 1296
EP 1302
DI 10.1212/WNL.0b013e3181d9edba
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 585HQ
UT WOS:000276816200010
PM 20404311
ER
PT J
AU Yates, MA
Li, YX
Chlebeck, PJ
Offner, H
AF Yates, Melissa A.
Li, Yuexin
Chlebeck, Peter J.
Offner, Halina
TI GPR30, but not estrogen receptor-alpha, is crucial in the treatment of
experimental autoimmune encephalomyelitis by oral ethinyl estradiol
SO BMC IMMUNOLOGY
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; GLIAL-CELLS; EXPRESSION;
PREGNANCY; MICE; SUPPRESSES; CYTOKINE; THERAPY; PD-1
AB Background: Remission of multiple sclerosis during periods of high ovarian hormone secretion (such as pregnancy) has led to a great deal of interest in the potential for estrogens to treat autoimmune disease. Previous work has established that 17 beta-estradiol can inhibit onset of experimental autoimmune encephalomyelitis (EAE), while ethinyl estradiol (EE) can reduce the severity of established disease. In the current study, the influence of estrogen receptor-alpha (ER alpha) and the G-protein coupled estrogen receptor (GPR30 or GPER) on EE's ability to treat EAE was explored.
Results: EE reduced disease severity in wild-type and ERa knockout (ERKO) mice, but did not alter disease in the GPR30KO group. Production of anti-inflammatory IL-10 increased in EE-ERKO mice (which showed reduced disease) but not in EE-GPR30KO mice (who did not have improved disease).
Conclusions: Differential production of IL-10 following EE treatment in ERKO and GPR30KO animals may be responsible for the distinctly different effects on disease severity. Increased IL-10 in ERKO-EE compared to ERKO-Controls is likely to be an important factor in reducing established disease. The inability of EE to reduce disease in GPR30KO mice indicates an important but still undefined role for GPR30 in regulating immune reactivity.
C1 [Yates, Melissa A.; Li, Yuexin; Chlebeck, Peter J.; Offner, Halina] Portland VA Med Ctr, Portland, OR USA.
[Yates, Melissa A.; Li, Yuexin; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Yates, Melissa A.; Li, Yuexin; Chlebeck, Peter J.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
[Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA.
RP Offner, H (reprint author), Portland VA Med Ctr, Portland, OR USA.
EM offnerva@ohsu.edu
FU National Multiple Sclerosis Society [FG1832-A-1, RG3405-B-5]; NIH
[NS45445, NS49210]; Biomedical Laboratory R&D Service, Department of
Veterans Affairs
FX M.A.Y. was supported by a Postdoctoral Fellowship FG1832-A-1 from the
National Multiple Sclerosis Society, and this work was supported in part
by National Multiple Sclerosis Society grant RG3405-B-5; NIH grants
NS45445, and NS49210; and the Biomedical Laboratory R&D Service,
Department of Veterans Affairs. The authors would also like to thank Eva
Niehaus for her assistance in manuscript preparation.
NR 24
TC 29
Z9 31
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2172
J9 BMC IMMUNOL
JI BMC Immunol.
PD APR 19
PY 2010
VL 11
AR 20
DI 10.1186/1471-2172-11-20
PG 5
WC Immunology
SC Immunology
GA 591FU
UT WOS:000277286100001
PM 20403194
ER
PT J
AU Figlewicz, DP
Ioannou, G
Jay, JB
Kittleson, S
Savard, C
Roth, CL
AF Figlewicz, D. P.
Ioannou, G.
Jay, J. Bennett
Kittleson, S.
Savard, C.
Roth, C. L.
TI Effect of moderate intake of sweeteners on metabolic health in the rat
(vol 98, pg 618, 2009)
SO PHYSIOLOGY & BEHAVIOR
LA English
DT Correction
C1 [Figlewicz, D. P.; Jay, J. Bennett; Kittleson, S.] VA Puget Sound Hlth Care Syst, R&D 151, Seattle, WA 98108 USA.
[Figlewicz, D. P.; Jay, J. Bennett] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Ioannou, G.; Savard, C.] VA Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA 98108 USA.
[Roth, C. L.] Seattle Childrens Res Inst, Seattle, WA 98101 USA.
RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, R&D 151, Seattle, WA 98108 USA.
EM latte@u.washington.edu
NR 1
TC 1
Z9 1
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9384
J9 PHYSIOL BEHAV
JI Physiol. Behav.
PD APR 19
PY 2010
VL 99
IS 5
BP 691
EP 691
DI 10.1016/j.physbeh.2009.11.011
PG 1
WC Psychology, Biological; Behavioral Sciences
SC Psychology; Behavioral Sciences
GA 586FA
UT WOS:000276887100023
ER
PT J
AU Bagayoko, CO
Dufour, JC
Chaacho, S
Bouhaddou, O
Fieschi, M
AF Bagayoko, Cheick-Oumar
Dufour, Jean-Charles
Chaacho, Saad
Bouhaddou, Omar
Fieschi, Marius
TI Open source challenges for hospital information system (HIS) in
developing countries: a pilot project in Mali
SO BMC MEDICAL INFORMATICS AND DECISION MAKING
LA English
DT Article
AB Background: We are currently witnessing a significant increase in use of Open Source tools in the field of health. Our study aims to research the potential of these software packages for developing countries. Our experiment was conducted at the Centre Hospitalier Mere Enfant in Mali.
Methods: After reviewing several Open Source tools in the field of hospital information systems, Mediboard software was chosen for our study. To ensure the completeness of Mediboard in relation to the functionality required for a hospital information system, its features were compared to those of a well-defined comprehensive record management tool set up at the University Hospital "La Timone" of Marseilles in France. It was then installed on two Linux servers: a first server for testing and validation of different modules, and a second one for the deployed full implementation. After several months of use, we have evaluated the usability aspects of the system including feedback from end-users through a questionnaire.
Results: Initial results showed the potential of Open Source in the field of health IT for developing countries like Mali. Five main modules have been fully implemented: patient administrative and medical records management of hospital activities, tracking of practitioners' activities, infrastructure management and the billing system. This last component of the system has been fully developed by the local Mali team. The evaluation showed that the system is broadly accepted by all the users who participated in the study. 77% of the participants found the system useful; 85% found it easy; 100% of them believe the system increases the reliability of data. The same proportion encourages the continuation of the experiment and its expansion throughout the hospital.
Conclusions: In light of the results, we can conclude that the objective of our study was reached. However, it is important to take into account the recommendations and the challenges discussed here to avoid several potential pitfalls specific to the context of Africa. Our future work will target the full integration of the billing module in Mediboard and an expanded implementation throughout the hospital.
C1 [Bagayoko, Cheick-Oumar] Fac Med Pharm & Odontostomatol, DER Sante Publ, Bamako, Mali.
[Bagayoko, Cheick-Oumar; Dufour, Jean-Charles; Fieschi, Marius] Univ Aix Marseille 2, Fac Med, Lab Enseignement & Rech Traitement Informat Med, F-13385 Marseille 5, France.
[Chaacho, Saad] Ctr Hosp Ibn Sina de Rabat, Unite Veille Technol & Dev Logiciel, Rabat, Morocco.
[Bouhaddou, Omar] Hewlett Packard Enterprise Serv, San Diego, CA USA.
[Bouhaddou, Omar] US Dept Vet Affairs, San Diego, CA USA.
RP Bagayoko, CO (reprint author), Fac Med Pharm & Odontostomatol, DER Sante Publ, Bamako, Mali.
EM cob281@yahoo.fr
RI Dufour, Jean-Charles/E-2481-2013
OI Dufour, Jean-Charles/0000-0003-2392-1817
NR 13
TC 4
Z9 4
U1 1
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6947
J9 BMC MED INFORM DECIS
JI BMC Med. Inform. Decis. Mak.
PD APR 16
PY 2010
VL 10
AR 22
DI 10.1186/1472-6947-10-22
PG 13
WC Medical Informatics
SC Medical Informatics
GA 594DX
UT WOS:000277515200001
PM 20398366
ER
PT J
AU Siskind, LJ
Mullen, TD
Rosales, KR
Clarke, CJ
Hernandez-Corbacho, MJ
Edinger, AL
Obeid, LM
AF Siskind, Leah J.
Mullen, Thomas D.
Rosales, Kimberly Romero
Clarke, Christopher J.
Hernandez-Corbacho, Maria Jose
Edinger, Aimee L.
Obeid, Lina M.
TI The BCL-2 Protein BAK Is Required for Long-chain Ceramide Generation
during Apoptosis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CELL-DEATH; SPHINGOSINE KINASE-1; PROAPOPTOTIC BAX; MITOCHONDRIAL
APOPTOSIS; ACID SPHINGOMYELINASE; ENDOPLASMIC-RETICULUM; CANCER-CELLS;
ER STRESS; ACTIVATION; RESISTANCE
AB The BCL-2 family members BAK and BAX are required for apoptosis and trigger mitochondrial outer membrane permeabilization (MOMP). Here we identify a MOMP-independent function of BAK as a required factor for long-chain ceramide production in response to pro-apoptotic stress. UV-C irradiation of wild-type (WT) cells increased long-chain ceramides; blocking ceramide generation prevented caspase activation and cell death, demonstrating that long-chain ceramides play a key role in UV-C-induced apoptosis. In contrast, UV-C irradiation did not increase long-chain ceramides in BAK and BAX double knock-out cells. Notably, this was not specific to the cell type (baby mouse kidney cells, hematopoietic) nor the apoptotic stimulus employed (UV-C, cisplatin, and growth factor withdrawal). Importantly, long-chain ceramide generation was dependent on the presence of BAK, but not BAX. However, ceramide generation was independent of the known downstream actions of BAK in apoptosis(MOMP or caspase activation), suggesting a novel role for BAK in apoptosis. Finally, enzymatic assays identified ceramide synthase as the mechanism by which BAK regulates ceramide metabolism. There was no change in CerS expression at the message or protein level, indicating regulation at the post-translational level. Moreover, CerS activity in BAK KO microsomes can be reactivated upon addition of BAK-containing microsomes. The data presented indicate that ceramide-induced apoptosis is dependent upon BAK and identify a novel role for BAK during apoptosis. By establishing a unique role for BAK in long-chain ceramide metabolism, these studies further demonstrate that the seemingly redundant proteins BAK and BAX have distinct mechanisms of action during apoptosis induction.
C1 [Siskind, Leah J.; Mullen, Thomas D.; Hernandez-Corbacho, Maria Jose; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA.
[Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Rosales, Kimberly Romero; Edinger, Aimee L.] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.
[Clarke, Christopher J.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
RP Siskind, LJ (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med Geriatr, 114 Doughty St,MSC 779, Charleston, SC 29425 USA.
EM siskind@musc.edu
OI obeid, lina/0000-0002-0734-0847
FU NIEHS [1F30 ES016975-01]; NIA [F31 CA126494, K08 CA100526, R01
AG016583]; NCI [P01 CA097132]; Veterans Administration; American Cancer
Society [IRG-97-219-11]; Cancer Center Support Grant [P30 CA138313]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants 1F30 ES016975-01 (to T. D. M.) from NIEHS, F31 CA126494
(to K. R. R.), K08 CA100526 (to A. L. E.), and R01 AG016583 from NIA and
P01 CA097132 from NCI (to L. M. O.). This work was also supported by a
Veterans Administration Career Development Award-2 (to L. J. S.), pilot
project funding from a Veterans Administration REAP (to L. J. S. and L.
M. O.), and American Cancer Society Institutional Research Grant
IRG-97-219-11 (sub-award to L. J. S.). The shared resources of the
Hollings Cancer Center were supported in part by a Cancer Center Support
Grant (P30 CA138313).
NR 46
TC 60
Z9 65
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 16
PY 2010
VL 285
IS 16
BP 11818
EP 11826
DI 10.1074/jbc.M109.078121
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 584XI
UT WOS:000276787100009
PM 20172858
ER
PT J
AU Thukkani, N
Sonnenberg, A
AF Thukkani, N.
Sonnenberg, A.
TI The influence of environmental risk factors in hospitalization for
gastro-oesophageal reflux disease-related diagnoses in the United States
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID BARRETTS-ESOPHAGUS; HIATAL-HERNIA; EROSIVE ESOPHAGITIS; GERD SYMPTOMS;
PREVALENCE; POPULATION; FREQUENCY; SEVERITY; OBESITY; GENDER
AB P>Background
The impact of gastro-oesophageal reflux disease on hospitalization is unknown.
Aim
To describe the characteristics of patients hospitalized for diagnoses related to gastro-oesophageal reflux disease (GERD) and find potential environmental influences that affect their hospitalization.
Methods
Data from the Healthcare Cost and Utilization Project were used to study the demographic characteristics of hospitalizations associated with GERD during 2003-2006. Data from the Centers for Disease Control were used for information about the US prevalence of obesity.
Results
During 2003-2006, 0.5 million patients with a primary and 14.5 million patients with a secondary GERD-related diagnosis became hospitalized in the US. Oesophageal reflux and hiatal hernia were more common in female than in male inpatients, whereas Barrett's oesophagus and oesophageal adenocarcinoma were more common in male than in female inpatients. All GERD-related diagnoses were more common in white people than non-white people. Hospitalizations associated with oesophageal reflux, reflux oesophagitis and Barrett's oesophagus showed resembling geographical distributions among different US states. The prevalence of obesity and the hospitalization for hiatal hernia or reflux oesophagitis were also characterized by similar geographical distributions.
Conclusion
The large numbers of inpatients with a discharge diagnosis of GERD-related conditions attest to the frequent occurrence and relevance of GERD in contributing to hospitalization in the US.
C1 [Thukkani, N.; Sonnenberg, A.] Portland VA Med Ctr, Div Gastroenterol, Portland, OR USA.
[Thukkani, N.; Sonnenberg, A.] Oregon Hlth & Sci Univ, Div Gastroenterol, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, Div Gastroenterol, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 33
TC 5
Z9 5
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD APR 15
PY 2010
VL 31
IS 8
BP 852
EP 861
DI 10.1111/j.1365-2036.2010.04245.x
PG 10
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 571CC
UT WOS:000275726100008
PM 20102354
ER
PT J
AU Geng, H
Rademacher, BL
Pittsenbarger, J
Huang, CY
Harvey, CT
Lafortune, MC
Myrthue, A
Garzotto, M
Nelson, PS
Beer, TM
Qian, DZ
AF Geng, Hao
Rademacher, Brooks L.
Pittsenbarger, Janet
Huang, Chung-Ying
Harvey, Christopher T.
Lafortune, Marie C.
Myrthue, Anne
Garzotto, Mark
Nelson, Peter S.
Beer, Tomasz M.
Qian, David Z.
TI ID1 Enhances Docetaxel Cytotoxicity in Prostate Cancer Cells through
Inhibition of p21
SO CANCER RESEARCH
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; MITOXANTRONE PLUS PREDNISONE; ENDOTHELIAL
GROWTH-FACTOR; LOOP-HELIX PROTEINS; NEOADJUVANT DOCETAXEL; SIGNALING
PATHWAY; EPITHELIAL-CELLS; GENE-EXPRESSION; DNA-DAMAGE; IN-VIVO
AB To identify potential mechanisms underlying prostate cancer chemotherapy response and resistance, we compared the gene expression profiles in high-risk human prostate cancer specimens before and after neoadjuvant chemotherapy and radical prostatectomy. Among the molecular signatures associated with chemotherapy, transcripts encoding inhibitor of DNA binding 1 (ID1) were significantly upregulated. The patient biochemical relapse status was monitored in a long-term follow-up. Patients with ID1 upregulation were found to be associated with longer relapse-free survival than patients without ID1 increase. This in vivo clinical association was mechanistically investigated. The chemotherapy-induced ID1 upregulation was recapitulated in the prostate cancer cell line LNCaP. Docetaxel dose-dependently induced ID1 transcription, which was mediated by ID1 promoter E-box chromatin modification and c-Myc binding. Stable ID1 overexpression in LNCaP increased cell proliferation, promoted G(1) cell cycle progression, and enhanced docetaxel-induced cytotoxicity. These changes were accompanied by a decrease in cellular mitochondria content, an increase in BCL2 phosphorylation at serine 70, caspase-3 activation, and poly(ADP-ribose) polymerase cleavage. In contrast, ID1 siRNA in the LNCaP and C42B cell lines reduced cell proliferation and decreased docetaxel-induced cytotoxicity by inhibiting cell death. ID1-mediated chemosensitivity enhancement was in part due to ID1 suppression of p21. Overexpression of p21 in LNCaP-ID1-overexpressing cells restored the p21 level and reversed ID1-enhanced chemosensitivity. These molecular data provide a mechanistic rationale for the observed in vivo clinical association between ID1 upregulation and relapse-free survival. Taken together, it shows that ID1 expression has a novel therapeutic role in prostate cancer chemotherapy and prognosis. Cancer Res; 70(8); 3239-48. (C)2010 AACR.
C1 [Geng, Hao; Rademacher, Brooks L.; Pittsenbarger, Janet; Harvey, Christopher T.; Lafortune, Marie C.; Myrthue, Anne; Beer, Tomasz M.; Qian, David Z.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA.
[Garzotto, Mark] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97239 USA.
[Garzotto, Mark] Portland VA Med Ctr, Portland, OR USA.
[Huang, Chung-Ying; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA.
[Huang, Chung-Ying; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
[Nelson, Peter S.] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA.
RP Beer, TM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, 3303 SW Bond,CH14R, Portland, OR 97239 USA.
EM beert@ohsu.edu; qianzh@ohsu.edu
FU Aventis Pharmaceuticals [GIA US 16080]; Serono, Inc. [031.G0008]; NIH
[3M01RR00334-33S2, 1 R01 CA119125-01, U54CA126540]; PNW Prostate
Specialized Programs of Research Excellence [CA97186]
FX Grant GIA US 16080 from Aventis Pharmaceuticals; grant 031.G0008 from
Serono, Inc.; and NIH grants 3M01RR00334-33S2, 1 R01 CA119125-01,
U54CA126540, and PNW Prostate Specialized Programs of Research
Excellence grant CA97186.
NR 50
TC 19
Z9 19
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2010
VL 70
IS 8
BP 3239
EP 3248
DI 10.1158/0008-5472.CAN-09-3186
PG 10
WC Oncology
SC Oncology
GA 607GC
UT WOS:000278486100029
PM 20388787
ER
PT J
AU Pappas, PG
Alexander, BD
Andes, DR
Hadley, S
Kauffman, CA
Freifeld, A
Anaissie, EJ
Brumble, LM
Herwaldt, L
Ito, J
Kontoyiannis, DP
Lyon, GM
Marr, KA
Morrison, VA
Park, BJ
Patterson, TF
Perl, TM
Oster, RA
Schuster, MG
Walker, R
Walsh, TJ
Wannemuehler, KA
Chiller, TM
AF Pappas, Peter G.
Alexander, Barbara D.
Andes, David R.
Hadley, Susan
Kauffman, Carol A.
Freifeld, Alison
Anaissie, Elias J.
Brumble, Lisa M.
Herwaldt, Loreen
Ito, James
Kontoyiannis, Dimitrios P.
Lyon, G. Marshall
Marr, Kieren A.
Morrison, Vicki A.
Park, Benjamin J.
Patterson, Thomas F.
Perl, Trish M.
Oster, Robert A.
Schuster, Mindy G.
Walker, Randall
Walsh, Thomas J.
Wannemuehler, Kathleen A.
Chiller, Tom M.
TI Invasive Fungal Infections among Organ Transplant Recipients: Results of
the Transplant-Associated Infection Surveillance Network (TRANSNET)
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID SOLID-ORGAN; RISK-FACTORS; AMPHOTERICIN-B; ASPERGILLOSIS; KIDNEY;
PROPHYLAXIS; CANDIDIASIS; VORICONAZOLE; FLUCONAZOLE
AB Background. Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among organ transplant recipients. Multicenter prospective surveillance data to determine disease burden and secular trends are lacking.
Methods. The Transplant-Associated Infection Surveillance Network (TRANSNET) is a consortium of 23 US transplant centers, including 15 that contributed to the organ transplant recipient dataset. We prospectively identified IFIs among organ transplant recipients from March, 2001 through March, 2006 at these sites. To explore trends, we calculated the 12-month cumulative incidence among 9 sequential cohorts.
Results. During the surveillance period, 1208 IFIs were identified among 1063 organ transplant recipients. The most common IFIs were invasive candidiasis (53%), invasive aspergillosis (19%), cryptococcosis (8%), non-Aspergillus molds (8%), endemic fungi (5%), and zygomycosis (2%). Median time to onset of candidiasis, aspergillosis, and cryptococcosis was 103, 184, and 575 days, respectively. Among a cohort of 16,808 patients who underwent transplantation between March 2001 and September 2005 and were followed through March 2006, a total of 729 IFIs were reported among 633 persons. One-year cumulative incidences of the first IFI were 11.6%, 8.6%, 4.7%, 4.0%, 3.4%, and 1.3% for small bowel, lung, liver, heart, pancreas, and kidney transplant recipients, respectively. One-year incidence was highest for invasive candidiasis (1.95%) and aspergillosis (0.65%). Trend analysis showed a slight increase in cumulative incidence from 2002 to 2005.
Conclusions. We detected a slight increase in IFIs during the surveillance period. These data provide important insights into the timing and incidence of IFIs among organ transplant recipients, which can help to focus effective prevention and treatment strategies.
C1 [Pappas, Peter G.] Univ Alabama, Dept Med, Div Infect Dis, Med Ctr, Birmingham, AL 35294 USA.
[Oster, Robert A.] Univ Alabama, Dept Med, Div Prevent Med, Med Ctr, Birmingham, AL 35294 USA.
[Alexander, Barbara D.] Duke Univ, Med Ctr, Durham, NC USA.
[Andes, David R.] Univ Wisconsin, Madison, WI 53706 USA.
[Hadley, Susan] Tufts Med Ctr, Boston, MA USA.
[Kauffman, Carol A.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Kauffman, Carol A.] Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI USA.
[Freifeld, Alison] Univ Nebraska Med Ctr, Omaha, NE USA.
[Anaissie, Elias J.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
[Brumble, Lisa M.] Mayo Clin, Jacksonville, FL 32224 USA.
[Herwaldt, Loreen] Univ Iowa Hosp, Iowa City, IA USA.
[Ito, James] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Healthcare Syst, San Antonio, TX 78229 USA.
[Lyon, G. Marshall] Emory Univ, Sch Med, Atlanta, GA USA.
[Park, Benjamin J.; Wannemuehler, Kathleen A.; Chiller, Tom M.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA.
[Marr, Kieren A.; Perl, Trish M.] Johns Hopkins Univ, Med Ctr, Baltimore, MD 21218 USA.
[Marr, Kieren A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Morrison, Vicki A.] Univ Minnesota, Minneapolis, MN USA.
[Morrison, Vicki A.] Vet Affairs Med Ctr, Minneapolis, MN USA.
[Walker, Randall] Mayo Clin, Rochester, MN USA.
[Schuster, Mindy G.] Hosp Univ Penn, Philadelphia, PA 19104 USA.
[Walsh, Thomas J.] NCI, NIH, Bethesda, MD 20892 USA.
RP Pappas, PG (reprint author), Univ Alabama, Dept Med, Div Infect Dis, Med Ctr, 1900 Univ Blvd,229 THT, Birmingham, AL 35294 USA.
EM pappas@uab.edu
FU Merck; Pfizer; Schereing-Plough; Astellas; Nektar Therapeutics; Enzon
FX P. G. P. has received grant support from Merck, Pfizer,
Schereing-Plough, and Astellas and served as an adhoc advisor for
Novartis, Basilea, Merck, Pfizer, and Astellas. D. R. A. has received
grant support and served as an ad hoc advisor for Merck, Pfizer, and
Schering-Plough. T. F. P. has received research support and honoraria
from Merck, Pfizer, Schering-Plough, and Nektar Therapeutics and has
served as a consultant for Basilea, Merck, Nektar, and Pfizer. K. A. M.
has received grant support from Merck and Enzon and served as an ad hoc
advisor and/or consultant for Astellas, Basilea, Enzon, Merck, Pfizer,
and Schering-Plough. J.I.I. has received honoraria from Astellas, Enzon,
Pfizer, and Schering-Plough. VAM is on the speakers' bureau for Amgen,
Merck, Pfizer, Schering-Plough, and Celgene. All other authors: no
conflicts.
NR 40
TC 423
Z9 434
U1 2
U2 28
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD APR 15
PY 2010
VL 50
IS 8
BP 1101
EP 1111
DI 10.1086/651262
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 570BF
UT WOS:000275645900004
PM 20218876
ER
PT J
AU Yeh, CC
Li, HZ
Malhotra, D
Turcato, S
Nicholas, S
Tu, R
Zhu, BQ
Cha, J
Swigart, PM
Myagmar, BE
Baker, AJ
Simpson, PC
Mann, MJ
AF Yeh, Che-Chung
Li, Hongzhe
Malhotra, Deepak
Turcato, Sally
Nicholas, Susan
Tu, Richard
Zhu, Bo-Qing
Cha, John
Swigart, Philip M.
Myagmar, Bat-Erdene
Baker, Anthony J.
Simpson, Paul C.
Mann, Michael J.
TI Distinctive ERK and p38 Signaling in Remote and Infarcted Myocardium
During Post-MI Remodeling in the Mouse
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE MYOCARDIAL INFARCTION; MAP KINASE; REMODELING; APOPTOSIS
ID MITOGEN-ACTIVATED PROTEIN; CARDIAC-HYPERTROPHY; P38-ALPHA MAPK;
PRESSURE-OVERLOAD; HEART-FAILURE; APOPTOSIS; KINASE; INHIBITION;
CARDIOMYOPATHY; PATHWAY
AB Global activation of MAP kinases has been reported in both human and experimental heart failure. Chronic remodeling of the surviving ventricular wall after myocardial infarction (MI) involves both myocyte loss and fibrosis; we hypothesized that this cardiomyopathy involves differential shifts in pro- and anti-apoptotic MAP kinase signaling in cardiac myocyte (CM) and non-myocyte. Cardiomyopathy after coronary artery ligation in mice was characterized by echocardiography, ex vivo Langendorff preparation, histologic analysis and measurements of apoptosis. Phosphorylation (activation) of signaling molecules was analyzed by Western blot, ELISA and immunohistochemistry. Post-MI remodeling involved dramatic changes in the phosphorylation of both stress-activated MAP (SAP) kinase p38 as well as ERK, a known mediator of cell survival, but not of SAP kinase JNK or the anti-apoptotic mediator of PI3K, Akt. Phosphorylation of p38 rose early after MI in the infarct, whereas a more gradual rise in the remote myocardium accompanied a rise in apoptosis in that region. In both areas, ERK phosphorylation was lowest early after MI and rose steadily thereafter, though infarct phosphorylation was consistently higher. Immunostaining of p-ERK localized to fibrotic areas populated primarily by non-myocytes, whereas staining of p38 phosphorylation was stronger in areas of progressive CM apoptosis. Relative segregation of CMs and non-myocytes in different regions of the post-MI myocardium revealed signaling patterns that imply cell type-specific changes in pro- and anti-apoptotic MAP kinase signaling. Prevention of myocyte loss and of LV remodeling after MI may therefore require cell type-specific manipulation of p38 and ERK activation. J. Cell. Biochem. 109: 11851191, 2010. (C) 2010 Wiley-Liss, Inc.
C1 [Yeh, Che-Chung; Li, Hongzhe; Malhotra, Deepak; Nicholas, Susan; Tu, Richard; Cha, John; Mann, Michael J.] Univ Calif San Francisco, Div Cardiothorac Surg, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Zhu, Bo-Qing; Swigart, Philip M.; Myagmar, Bat-Erdene; Baker, Anthony J.; Simpson, Paul C.] Univ Calif San Francisco, Div Cardiol, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Turcato, Sally] Univ Calif San Francisco, Dept Radiol, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
RP Mann, MJ (reprint author), Univ Calif San Francisco, Div Cardiothorac Surg, San Francisco VA Med Ctr, 500 Parnassus Ave,Suite W420, San Francisco, CA 94143 USA.
EM michael.mann@ucsfmedctr.org
FU National Institutes of Health [1R01 HL083118, 1K08HL079239]; American
Heart Associstion [0465090Y]
FX Grant sponsor: National Institutes of Health; Grant numbers: 1R01
HL083118, 1K08HL079239; Grant sponsor: American Heart Associstion; Grant
number: 0465090Y.
NR 30
TC 22
Z9 24
U1 0
U2 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD APR 15
PY 2010
VL 109
IS 6
BP 1185
EP 1191
DI 10.1002/jcb.22498
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 587AI
UT WOS:000276958200014
PM 20186881
ER
PT J
AU Drummond, F
Doelken, P
Ahmed, QA
Gilbert, GE
Strange, C
Herpel, L
Frye, MD
AF Drummond, Fitzgerald
Doelken, Peter
Ahmed, Qanta A.
Gilbert, Gregory E.
Strange, Charlie
Herpel, Laura
Frye, Michael D.
TI Empiric Auto-Titrating CPAP in People with Suspected Obstructive Sleep
Apnea
SO JOURNAL OF CLINICAL SLEEP MEDICINE
LA English
DT Article
DE Auto-CPAP; OSAS; OSA; obstructive sleep apnea; Epworth sleepiness Scale;
Functional Outcomes of Sleep Questionnaire
ID POSITIVE AIRWAY PRESSURE; INDEPENDENT RISK-FACTOR; APNEA/HYPOPNEA
SYNDROME; PRACTICE PARAMETERS; DAYTIME SLEEPINESS; HYPOPNEA SYNDROME;
UNITED-STATES; OLDER-ADULTS; MORTALITY; TRIAL
AB Objective: Efficient diagnosis and treatment of obstructive sleep apnea (OSA) can be difficult because of time delays imposed by clinic visits and serial overnight polysomnography. In some cases, it may be desirable to initiate treatment for suspected OSA prior to polysomnography Our objective was to compare the improvement of daytime sleepiness and sleep-related quality of life of patients with high clinical likelihood of having OSA who were randomly assigned to receive empiric auto-titrating continuous positive airway pressure (CPAP) while awaiting polysomnogram versus current usual care.
Methods: Serial patients referred for overnight polysomnography who had high clinical likelihood of having OSA were randomly assigned to usual care or immediate initiation of auto-titrating CPAP. Epworth Sleepiness Scale (ESS) scores and the Functional Outcomes of Sleep Questionnaire (FOSQ) scores were obtained at baseline, 1 month after randomization, and again after initiation of fixed CPAP in control subjects and after the sleep study in auto-CPAP patients
Results: One hundred nine patients were randomized. Baseline demographics, daytime sleepiness, and sleep-related quality of life scores were similar between groups One-month ESS and FOSQ scores were improved in the group empirically treated with auto-titrating CPAP ESS scores improved in the first month by a mean of -3 2 (confidence interval -1 6 to -48, p < 0.001) and FOSQ scores improved by a mean of 1 5, (confidence interval 0 5 to 2 7, p = 0 02), whereas scores in the usual-care group did not change (p = NS) Following therapy directed by overnight polysomnography in the control group, there were no differences in ESS or FOSQ between the groups No adverse events were observed
Conclusion: Empiric auto-CPAP resulted in symptomatic improvement of daytime sleepiness and sleep-related quality of life in a cohort of patients awaiting polysomnography who had a high pretest probability of having OSA. Additional studies are needed to evaluate the applicability of empiric treatment to other populations
C1 [Frye, Michael D.] Ralph H Johnson VA Med Ctr, Pulm Sect, Med Specialties Serv, Div Pulm Crit Care Allergy & Sleep Med, Charleston, SC 29425 USA.
[Gilbert, Gregory E.] Med Univ S Carolina, Dept Biometry Bioinformat & Epidemiol, Charleston, SC 29425 USA.
RP Frye, MD (reprint author), Ralph H Johnson VA Med Ctr, Pulm Sect, Med Specialties Serv, Div Pulm Crit Care Allergy & Sleep Med, Charleston, SC 29425 USA.
RI Gilbert, Gregory/C-7735-2016
OI Gilbert, Gregory/0000-0003-0879-5496; Strange,
Charlie/0000-0002-8109-8067
NR 42
TC 7
Z9 7
U1 0
U2 2
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 1550-9389
J9 J CLIN SLEEP MED
JI J. Clin. Sleep Med.
PD APR 15
PY 2010
VL 6
IS 2
BP 140
EP 145
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 584XV
UT WOS:000276788500006
PM 20411690
ER
PT J
AU Hilsabeck, RC
Anstead, GM
Webb, AL
Hoyumpa, A
Ingmundson, P
Holliday, S
Zhang, Q
Casas, AM
Jovel, M
Stern, SL
AF Hilsabeck, Robin C.
Anstead, Gregory M.
Webb, Amy L.
Hoyumpa, Anastasio
Ingmundson, Paul
Holliday, Steve
Zhang, Qiong
Casas, Angela M.
Jovel, Marci
Stern, Stephen L.
TI Cognitive efficiency is associated with endogenous cytokine levels in
patients with chronic hepatitis C
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE Hepatitis C; Cytokines; Cognitive dysfunction; Interferon-alpha; Immune
system; ANAM
ID AICARDI-GOUTIERES-SYNDROME; SYSTEMIC-LUPUS-ERYTHEMATOSUS;
CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; AIDS DEMENTIA COMPLEX;
INTERFERON-ALPHA; VIRUS-INFECTION; INFLAMMATORY MARKERS;
QUANTITATIVE-EEG; IFN-ALPHA
AB The etiology of cognitive dysfunction in chronic hepatitis C (CHC) infection is unknown. Among the possibilities is cytokine activation, which has been associated with cognitive dysfunction in other chronic conditions. The purpose of this study was to investigate the relationship between endogenous IFN-alpha, IL-6, and INF-alpha and cognitive functioning in CHC patients. Seventy-eight veterans with CHC underwent cognitive testing and measurement of serum cytokines. In patients with detectable IFN-alpha, higher levels of IL-6 and INF-alpha were related to poorer cognitive functioning. Findings suggest CHC patients with immune responses characterized by elevated IFN-alpha may be at risk for cognitive difficulties. Published by Elsevier B.V.
C1 [Hilsabeck, Robin C.; Anstead, Gregory M.; Webb, Amy L.; Ingmundson, Paul; Holliday, Steve; Zhang, Qiong; Casas, Angela M.; Jovel, Marci; Stern, Stephen L.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Hilsabeck, Robin C.; Holliday, Steve; Stern, Stephen L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Anstead, Gregory M.; Webb, Amy L.; Hoyumpa, Anastasio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
RP Hilsabeck, RC (reprint author), S Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM Hilsabeck@uthscsa.edu
FU Research and Development Office; Frederic C. Bartter General Clinical
Research Center; Veterans Health Administration [VISN-17]; National
Institutes of Health [K23 NS051244]; National Center for Research
Resources [UL 1RR025767, M01-RR-01346]
FX Our deepest thanks go to the incredibly knowledgeable staff of the
Veterans Evidence Based Research Dissemination and Implementation Center
(VERDICT) at Audie L Murphy VA Hospital. In particular, we would like to
thank Polly Noel Hitchcock for help with study design, Chen-Pin Wang for
consultation about appropriate statistical analyses, and Judith
Patterson for database set-up. We gratefully acknowledge the support of
staff in the Research and Development Office and the Frederic C. Bartter
General Clinical Research Center, as well as the following colleagues
for help with data collection and management (in alphabetical order):
Olga Ali, Anna Dematatis, Stephanie Garcia, Geoffrey Hutchinson, Shawn
Johnson, Shuko Lee, Kenneth Major, Emma Mata-Galan, Isela Poy, and
Rebecca Stein. The authors would also like to thank Sunil Ahuja and his
research group for their very helpful insights in interpreting the
cytokine data and Robert A. Clark for helpful comments on the
manuscript. Our sincerest appreciation goes to the veterans who
volunteered to participate in this study.; This material is the result
of work supported with resources and the use of facilities at the South
Texas Veterans Health Care System and University of Texas Health
Sciences Center at San Antonio. The work was supported by grants from
VISN-17 of the Veterans Health Administration to SLS and National
Institutes of Health (K23 NS051244) to RCH. In addition, this project
was supported by Award Numbers UL 1RR025767 and M01-RR-01346 from the
National Center for Research Resources. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the Veterans Health Administration or the National
Institutes of Health.
NR 94
TC 15
Z9 15
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD APR 15
PY 2010
VL 221
IS 1-2
BP 53
EP 61
DI 10.1016/j.jneuroim.2010.01.017
PG 9
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 609JS
UT WOS:000278653100008
PM 20181398
ER
PT J
AU Chung, KA
Lobb, BM
Nutt, JG
McNames, J
Horak, F
AF Chung, Kathryn A.
Lobb, Brenna M.
Nutt, John G.
McNames, James
Horak, Fay
TI Objective Measurement of Dyskinesia in Parkinson's Disease using a Force
Plate
SO MOVEMENT DISORDERS
LA English
DT Article
DE dyskinesia; objective measurements; Parkinson's; force plate
ID LEVODOPA-INDUCED DYSKINESIAS; DEEP BRAIN-STIMULATION; RATING-SCALE;
MOTOR; RELIABILITY; TASKS; LIFE
AB Clinical investigation of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) is limited because of lack of objective measurements and no consensus on use of a standard measuring tool. Currently, clinical trials use subject-completed diaries of dyskinesia throughout the day or investigator-administered clinical rating scales. An objective and valid method of measuring LID would reduce bias, variability, and decrease the time and number needed in trials of potential anti-dyskinetic agents. We have investigated using a force plate under standing subjects, which records movement of the center of pressure (CoP) to quantify LID over a levodopa (L-dopa) cycle. Twenty-two PD subjects (15 with LID, 7 without LID) admitted to an inpatient research facility had their PD meds withheld overnight, followed by a 2 hours intravenous L-dopa infusion the next day. The root mean squared of the velocity in the anterior-posterior direction (RMSV) derived from an analysis of the CoP, and, the modified Abnormal Involuntary Movement Scale (mAIMS) were performed repeatedly for 6 hours, initially as subjects were OFF before the infusion, through infusion until OFF again. There was a high correlation between the area under the curve (AUC) of the mAIMS and the RMSV within and between subjects. As a measure of LID, RMSV had excellent validity and reliability between subjects, and using a force plate was feasible. Sensitivity to changes in LID was initially demonstrated but should be repeated. Thus. CoP recordings on a force plate can objectively quantify LID in PD and may be very useful in clinical trials or other investigations of dyskinesia. (C) 2010 Movement Disorder Society
C1 [Chung, Kathryn A.; Nutt, John G.; Horak, Fay] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Lobb, Brenna M.] Portland VA Med Ctr, Portland, OR USA.
[McNames, James] Portland State Univ, Dept Elect & Comp Engn, Portland, OR 97207 USA.
RP Chung, KA (reprint author), OP 32,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM chungka@ohsu.edu
FU US Public Health Service [ULIRR024140-02]; NIH [R01-NS21062]; National
Institutes on Aging [AG006457]; Intel Corporation; Schering-Plough;
Novartis Inc.
FX Supported by a Veteran's Administration Career Development Award, US
Public Health Service Grant ULIRR024140-02, NIH R01-NS21062, National
Institutes on Aging AG006457, and a grant from ,.; Dr. Nutt has received
grants/research from Schering-Plough, speaking fees from Novartis Inc.,
and has served as a consultant for XenoPort Inc., Impax Laboratories.
Neurogen Inc., and Synosia.
NR 21
TC 18
Z9 20
U1 1
U2 4
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD APR 15
PY 2010
VL 25
IS 5
BP 602
EP 608
DI 10.1002/mds.22856
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 590TJ
UT WOS:000277250600012
PM 20213818
ER
PT J
AU Bigler, ED
Abildskov, TJ
Wilde, EA
McCauley, SR
Li, XQ
Merkley, TL
Fearing, MA
Newsome, MR
Scheibel, RS
Hunter, JV
Chu, ZL
Levin, HS
AF Bigler, Erin D.
Abildskov, Tracy J.
Wilde, Elisabeth A.
McCauley, Stephen R.
Li, Xiaoqi
Merkley, Tricia L.
Fearing, Michael A.
Newsome, Mary R.
Scheibel, Randall S.
Hunter, Jill V.
Chu, Zili
Levin, Harvey S.
TI Diffuse damage in pediatric traumatic brain injury: A comparison of
automated versus operator-controlled quantification methods
SO NEUROIMAGE
LA English
DT Article
ID HUMAN CEREBRAL-CORTEX; MAGNETIC-RESONANCE IMAGES; CORTICAL SURFACE;
GEOMETRICALLY ACCURATE; LONGITUDINAL CHANGES; MRI FINDINGS;
SEGMENTATION; MODERATE; HIPPOCAMPAL; CHILDREN
AB This investigation had two main objectives: 1) to assess the comparability Of volumes determined by operator-controlled image quantification with automated image analysis in evaluating atrophic brain changes related to traumatic brain injury (TBI) in children, and 2) to assess the extent of diffuse structural changes throughout the brain as determined by reduced volume of a brain Structure or region of interest (ROI). Operator-control led methods used ANALYZE (R) software for segmentation and tracing routines of pre-defined brain structures and Rots. For automated image analyses, the open-access FreeSurfer program was used. Sixteen children with moderate-to-severe TBI were compared to individually matched, typically developing control children and the Volumes of 18 brain structures and/or ROIs were compared between the two methods. Both methods detected atrophic changes but differed in the magnitude of the atrophic effect with the best agreement in subcortical Structures. The volumes of all brain structures/ROIs were smaller in the TBI group regardless of method used; overall effect size differences were minimal for caudate and putamen but moderate to large for all other measures. This is reflective of the diffuse nature of TBI and its widespread impact on structural brain integrity, indicating that both FreeSurfer and operator-control led methods can reliably assess cross-sectional volumetric changes in pediatric TBI. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Bigler, Erin D.; Abildskov, Tracy J.; Merkley, Tricia L.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA.
[Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA.
[Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA.
[Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA.
[Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA.
[Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Wilde, Elisabeth A.; McCauley, Stephen R.; Li, Xiaoqi; Newsome, Mary R.; Scheibel, Randall S.; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA.
[McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA.
[Fearing, Michael A.] Hebrew SeniorLife, Dept Med Neuropyschol, Boston, MA USA.
[Hunter, Jill V.; Chu, Zili] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA.
[Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
[Wilde, Elisabeth A.; Newsome, Mary R.; Scheibel, Randall S.; Levin, Harvey S.] Michael E De Bakey Vet Affairs Med Ctr, Houston, TX USA.
RP Bigler, ED (reprint author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.
EM erin-bigler@byu.edu
FU National Institutes of Health [NS-21889]; TIRR Foundation. Erin D.
Bigler [1 R01 HD048946-01]
FX This research was supported by grant NS-21889 awarded to Harvey S. Levin
by the National Institutes of Health. We also acknowledge the generous
Support of Mission Connect of the TIRR Foundation. Erin D. Bigler was
partially supported by grant 1 R01 HD048946-01A.Z. We acknowledge the
contribution of Stacey K. Martin and Jo Ann Petrie for assistance in
manuscript preparation. We would also like to thank Paul Swank, PhD, for
his helpful advice regarding statistical methodology. Finally, we thank
the participants and their farnilies for their interest and involvement
in this study.
NR 56
TC 46
Z9 46
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD APR 15
PY 2010
VL 50
IS 3
BP 1017
EP 1026
DI 10.1016/j.neuroimage.2010.01.003
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 566YA
UT WOS:000275408200016
PM 20060915
ER
PT J
AU Greenstein, RJ
Brown, ST
AF Greenstein, Robert J.
Brown, Sheldon T.
TI Genomewide Association Study of Leprosy
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID CROHNS-DISEASE; MYCOBACTERIUM
C1 [Greenstein, Robert J.; Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA.
RP Greenstein, RJ (reprint author), James J Peters VA Med Ctr, Bronx, NY USA.
EM bgaxis@aol.com
NR 5
TC 3
Z9 3
U1 0
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 15
PY 2010
VL 362
IS 15
BP 1447
EP 1447
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 582XY
UT WOS:000276635300023
PM 20397291
ER
PT J
AU Smolderen, KG
Spertus, JA
Nallamothu, BK
Krumholz, HM
Tang, FM
Ross, JS
Ting, HH
Alexander, KP
Rathore, SS
Chan, PS
AF Smolderen, Kim G.
Spertus, John A.
Nallamothu, Brahmajee K.
Krumholz, Harlan M.
Tang, Fengming
Ross, Joseph S.
Ting, Henry H.
Alexander, Karen P.
Rathore, Saif S.
Chan, Paul S.
TI Health Care Insurance, Financial Concerns in Accessing Care, and Delays
to Hospital Presentation in Acute Myocardial Infarction
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID ACUTE CORONARY SYNDROME; PREHOSPITAL DELAY; PERCEIVED STRESS; UNINSURED
ADULTS; EMTALA PARADOX; HEART; TIME; THERAPY; DISEASE; TRENDS
AB Context Little is known about how health insurance status affects decisions to seek care during emergency medical conditions such as acute myocardial infarction (AMI).
Objective To examine the association between lack of health insurance and financial concerns about accessing care among those with health insurance, and the time from symptom onset to hospital presentation (prehospital delays) during AMI.
Design, Setting, and Patients Multicenter, prospective study using a registry of 3721 AMI patients enrolled between April 11, 2005, and December 31, 2008, at 24 US hospitals. Health insurance status was categorized as insured without financial concerns, insured but have financial concerns about accessing care, and uninsured. Insurance information was determined from medical records while financial concerns among those with health insurance were determined from structured interviews.
Main Outcome Measure Prehospital delay times (<= 2 hours, >2-6 hours, or >6 hours), adjusted for demographic, clinical, and social and psychological factors using hierarchical ordinal regression models.
Results Of 3721 patients, 2294 were insured without financial concerns (61.7%), 689 were insured but had financial concerns about accessing care (18.5%), and 738 were uninsured (19.8%). Uninsured and insured patients with financial concerns were more likely to delay seeking care during AMI and had prehospital delays of greater than 6 hours among 48.6% of uninsured patients and 44.6% of insured patients with financial concerns compared with only 39.3% of insured patients without financial concerns. Prehospital delays of less than 2 hours during AMI occurred among 36.6% of those insured without financial concerns compared with 33.5% of insured patients with financial concerns and 27.5% of uninsured patients (P < .001). After adjusting for potential confounders, prehospital delays were associated with insured patients with financial concerns (adjusted odds ratio, 1.21 [95% confidence interval, 1.05-1.41]; P=.01) and with uninsured patients (adjusted odds ratio, 1.38 [95% confidence interval, 1.17-1.63]; P < .001).
Conclusion Lack of health insurance and financial concerns about accessing care among those with health insurance were each associated with delays in seeking emergency care for AMI. JAMA. 2010; 303(14): 1392-1400
C1 [Smolderen, Kim G.] Tilburg Univ, Ctr Res Psychol Somat Dis, Dept Med Psychol & Neuropsychol, NL-5000 LE Tilburg, Netherlands.
[Spertus, John A.; Tang, Fengming; Chan, Paul S.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA.
[Spertus, John A.; Chan, Paul S.] Univ Missouri, Sch Med, Dept Internal Med, Kansas City, MO USA.
[Nallamothu, Brahmajee K.] Univ Michigan, Sch Med, VA Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA.
[Nallamothu, Brahmajee K.] Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48104 USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA.
[Krumholz, Harlan M.; Rathore, Saif S.] Yale Univ, Sch Med, MD PhD Program, New Haven, CT USA.
[Krumholz, Harlan M.] Yale New Haven Med Ctr, Sect Hlth Policy & Adm, Dept Epidemiol & Publ Hlth, New Haven, CT 06504 USA.
[Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA.
[Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA.
[Ross, Joseph S.] James J Peters VA Med Ctr, HSR&D Res Enhancement Award Program, Bronx, NY USA.
[Ross, Joseph S.] James J Peters VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA.
[Ting, Henry H.] Mayo Clin, Coll Med, Div Cardiovasc Dis, Rochester, MN USA.
[Alexander, Karen P.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
RP Chan, PS (reprint author), St Lukes Hosp, Mid Amer Heart Inst, 5th Floor,4401 Wornall Rd, Kansas City, MO 64111 USA.
EM pchan@cc-pc.com
RI Smolderen, Kim/B-8078-2015
FU National Heart, Lung, and Blood Institute Specialized Center of
Clinically Oriented Research in Cardiac Dysfunction and Disease [P50
HL077113]; National Institute on Aging [K08 AG032886]; American
Federation of Aging Research; National Institutes of Health's Center for
Research Resources [UL1 RR024139]; National Institute of General Medical
Sciences [5T32GM07205]; Agency for Healthcare Research and Quality
[1R36HS018283-01]
FX The Translational Research Investigating Underlying Disparities in Acute
Myocardial Infarction Patients' Health Status (TRIUMPH) study was
supported by grant P50 HL077113 from the National Heart, Lung, and Blood
Institute Specialized Center of Clinically Oriented Research in Cardiac
Dysfunction and Disease. Dr Ross is supported by grant K08 AG032886 from
the National Institute on Aging and by the American Federation of Aging
Research through the Paul B. Beeson Career Development Award Program. Mr
Rathore is supported, in part, by CTSA grant UL1 RR024139 from the
National Institutes of Health's Center for Research Resources, grant
5T32GM07205 from the National Institute of General Medical Sciences
Medical Scientist Training Program, and dissertation grant
1R36HS018283-01 from the Agency for Healthcare Research and Quality.
NR 38
TC 48
Z9 48
U1 1
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 14
PY 2010
VL 303
IS 14
BP 1392
EP 1400
DI 10.1001/jama.2010.409
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 582KX
UT WOS:000276597300024
PM 20388895
ER
PT J
AU Tokbtaeva, E
Munson, K
Sachs, G
Vagin, O
AF Tokbtaeva, Elmira
Munson, Keith
Sachs, George
Vagin, Olga
TI N-Glycan-Dependent Quality Control of the Na,K-ATPase beta 2 Subunit
SO BIOCHEMISTRY
LA English
DT Article
ID RETICULUM-ASSOCIATED DEGRADATION; NA+-K+-ATPASE; ENDOPLASMIC-RETICULUM;
GLYCOSYLATION SITES; XENOPUS-OOCYTES; ALPHA-SUBUNIT; PROTEIN; CALNEXIN;
CELLS; ER
AB Bulky hydrophilic N-glycans stabilize the proper tertiary structure of glycoproteins. In addition, N-glycans comprise the binding sites for the endoplasmic reticulum (ER)-resident lectins that assist correct folding of newly synthesized glycoproteins. To reveal the role of N-glycans in maturation of the Na,K-ATPase beta(2) subunit in the ER, the effects of preventing or modifying the beta(2) subunit N-glycosylation on trafficking of the subunit and its binding to the ER lectin chaperone, calnexin, were studied in M DCK cells. Preventing N-glycosylation abolishes binding of the beta(2) subunit to calnexin and results in the ER retention of the subunit. Furthermore, the fully N-glycosylated beta(2) subunit is retained in the ER when glycan calnexin interactions are prevented by castanospermine, showing that N-glycan-mediated calnexin binding is required for correct subunit folding. Calnexin binding persists for several hours after translation is stopped with cycloheximide, suggesting that the beta(2) subunit undergoes repeated post-translational calnexin-assisted folding attempts. Homology modeling of the beta(2) subunit using the crystal structure of the alpha(1)-beta(1) Na,K-ATPase shows the presence of a relatively hydrophobic amino acid cluster proximal to N-glycosylation sites 2 and 7. Combined, but not separate, removal of sites 2 and 7 dramatically impairs calnexin binding and prevents the export of the beta(2) subunit from the ER. Similarly, hydrophilic substitution of two hydrophobic amino acids in this cluster disrupts both beta(2)-calnexin binding and trafficking of the subunit to the Golgi. Therefore, the hydrophobic residues in the proximity of N-glycans 2 and 7 are required for post-translational calnexin binding to these N-glycans in incompletely folded conformers, which, in turn, is necessary for maturation of the Na,K-ATPase beta(2) subunit.
C1 [Vagin, Olga] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA.
Vet Adm Greater Los Angeles Hlth Care Syst, VAGLAHS W LA, Los Angeles, CA 90073 USA.
RP Vagin, O (reprint author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Bldg 113,Room 324,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM olgav@ucla.edu
FU National Institutes of Health [DK077149, DK058333]
FX Supported by National Institutes of Health Grants DK077149 and DK058333.
NR 49
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD APR 13
PY 2010
VL 49
IS 14
BP 3116
EP 3128
DI 10.1021/bi100115a
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 577YB
UT WOS:000276258800015
ER
PT J
AU Ettenhofer, ML
Foley, J
Castellon, SA
Hinkin, CH
AF Ettenhofer, Mark L.
Foley, Jessica
Castellon, Steven A.
Hinkin, Charles H.
TI Reciprocal prediction of medication adherence and neurocognition in
HIV/AIDS
SO NEUROLOGY
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED ADULTS; MEMORY;
METAANALYSIS; IMPAIRMENT; VALIDATION
AB Background: Antiretroviral medications have been shown to benefit neurocognition in HIV/AIDS, and neurocognitive deficits are a risk factor for poor adherence to these medications. However, little is known about the predictive pathways linking medication adherence with cognitive ability.
Methods: In the current 6-month cohort study, antiretroviral medication adherence was tracked prospectively among 91 HIV-positive adults using electronic monitoring. Comprehensive neuropsychological evaluations were performed at baseline and 6 months.
Results: Multivariate path analyses provided evidence that antiretroviral adherence and cognitive ability are reciprocally related, although the neurocognitive pathways of this relationship appear to vary by predictive direction. Executive function and learning/ memory were most strongly predictive of levels of medication adherence achieved, whereas higher levels of adherence were predictive of relative improvements in a wide range of frontostriatal brain functions including processing speed, attention, executive functions, and motor functioning.
Conclusions: These data provide evidence that cognition and adherence are reciprocally related in HIV/ AIDS. In particular, executive dysfunction may play a key role in this relationship. Interventions aimed at improving or preserving executive functions could hold promise for interrupting progressive declines in adherence and neurocognitive ability in HIV/ AIDS. Neurology (R) 2010;74:1217-1222
C1 [Ettenhofer, Mark L.; Foley, Jessica; Castellon, Steven A.; Hinkin, Charles H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Castellon, Steven A.; Hinkin, Charles H.] VA Greater Los Angeles Hlth Care Syst, Psychol Serv, Los Angeles, CA USA.
RP Ettenhofer, ML (reprint author), USUHS Dept Med & Clin Psychol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.
EM mark.ettenhofer@usuhs.mil
FU NIH [RO1 MH083553, T32 MH19535]; Veterans Administration; Breast Cancer
Research Foundation
FX Dr. Ettenhofer and Dr. Foley report no disclosures. Dr. Castellon
performs and bills for neuropsychological assessment in his clinical
practice ( 5% effort) and receives research support from the NIH (RO1
MH083553 [Co-I] and T32 MH19535 [Co-I]), the Veterans Administration (
Merit Review Grant), and the Breast Cancer Research Foundation. Dr.
Hinkin performs and bills for neuropsychological assessment in his
clinical practice (15% effort) and receives research support from the
NIH ( RO1 MH083553 [ PI] and T32 MH19535 [ PI]) and the Veterans
Administration ( Merit Review Grant).
NR 19
TC 40
Z9 40
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD APR 13
PY 2010
VL 74
IS 15
BP 1217
EP 1222
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 581NT
UT WOS:000276531400010
PM 20220123
ER
PT J
AU Koharudin, LMI
Liu, H
Di Maio, R
Kodali, RB
Graham, SH
Gronenborn, AM
AF Koharudin, Leonardus M. I.
Liu, Hao
Di Maio, Roberto
Kodali, Ravindra B.
Graham, Steven H.
Gronenborn, Angela M.
TI Cyclopentenone prostaglandin-induced unfolding and aggregation of the
Parkinson disease-associated UCH-L1
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE ubiquitin; NMR; neurodegeneration; protein modification; oxidative
damage
ID CARBOXYL-TERMINAL HYDROLASE; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2);
PROTEIN OXIDATION; UBIQUITIN; CYCLOOXYGENASE; PEROXIDATION; PRODUCTS;
INSIGHTS; BRAIN; GENE
AB Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) has been implicated in Parkinson's disease (PD) and is present in neurofibrillary tangles or Lewy bodies. However, the molecular basis for UCH-L1s involvement in proteinacious fibril formation is still elusive, especially in regard to the pathogenicity of the I93M mutation. Here we show that modification of UCH-L1 by cyclopentenone prostaglandins causes unfolding and aggregation. A single thiol group on Cys152 reacts with the alpha,beta-unsaturated carbonyl center in the cyclopentenone ring of prostaglandins, resulting in a covalent adduct. We also show that the PD-associated I93M mutant of UCH-L1 is well-folded, structurally similar to the wild-type protein, and aggregates upon conjugation by cyclopentenone prostaglandins. Our findings suggest a possible mechanistic link between UCH-L1 modification by cyclopentenone prostaglandins and the etiology of neurodegeneration.
C1 [Koharudin, Leonardus M. I.; Kodali, Ravindra B.; Gronenborn, Angela M.] Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA.
[Liu, Hao; Di Maio, Roberto; Graham, Steven H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA.
[Liu, Hao; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15240 USA.
RP Gronenborn, AM (reprint author), Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA.
EM amg100@pitt.edu
RI kodali, ravindra/D-1543-2010; Di Maio, Roberto/G-1788-2015
OI Gronenborn, Angela M/0000-0001-9072-3525
FU University of Pittsburgh School of Medicine; National Institutes of
Health [NS037459-10]; Fondazione Ri.MED (Sicily, Italy) fellowship
[NS037459-10]
FX We thank Guillermo Calero, Rieko Ishima, and In-Ja Byeon (Department of
Structural Biology, University of Pittsburgh School of Medicine,
Pittsburgh, PA 15260) for useful discussions and Mike Delk for NMR
technical support. This work was a collaboration between the
laboratories of S.G. and A.M.G. and was supported by startup funds from
the University of Pittsburgh School of Medicine to A.M.G. and by the
National Institutes of Health Grant (NS037459-10) to S.G.R.D.M. is
supported by a Fondazione Ri.MED (Sicily, Italy) fellowship.
NR 21
TC 35
Z9 37
U1 1
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 13
PY 2010
VL 107
IS 15
BP 6835
EP 6840
DI 10.1073/pnas.1002295107
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 583AC
UT WOS:000276642100051
PM 20231490
ER
PT J
AU Sweet, RA
Bennett, DA
Graff-Radford, NR
Mayeux, R
AF Sweet, Robert A.
Bennett, David A.
Graff-Radford, Neill R.
Mayeux, Richard
CA Natl Inst Aging
TI Assessment and familial aggregation of psychosis in Alzheimer's disease
from the National Institute on Aging Late Onset Alzheimer's Disease
Family Study
SO BRAIN
LA English
DT Article
DE Alzheimer's disease; family study; genetics; psychiatric comorbidity
ID GENOME-WIDE ASSOCIATION; NEUROPSYCHIATRIC INVENTORY; COGNITIVE
IMPAIRMENT; IDENTIFIES VARIANTS; SYMPTOMS; SORL1; RISK; DEMENTIA; GENE;
PHENOTYPE
AB Determining the genetic architecture of late onset Alzheimer's disease remains an important research objective. One approach to the identification of novel genetic variants contributing to the disease is the classification of biologically meaningful subgroups within the larger late-onset Alzheimer's disease phenotype. The occurrence of psychotic symptoms in patients with late-onset Alzheimer's disease may identify one such group. We attempted to establish methods for the reliable assessment of psychotic symptoms in a large, geographically dispersed collection of families, multiply affected with late onset Alzheimer's disease, who were participants in the larger National Institute on Aging Late Onset Alzheimer's Disease Family Study; and to characterize the correlates and familial aggregation of psychosis within this cohort. We found that reliable assessments of psychotic symptoms during in-person or phone interviews were readily implemented. The presence of psychosis in late onset Alzheimer's disease was significantly associated with degree of cognitive impairment, and significantly, albeit modestly, correlated with the severity of other behavioural symptoms. Psychosis significantly aggregated within late onset Alzheimer's disease families suggesting that it may identify a genetically determined subgroup. Future studies should examine the linkage and association of psychosis with genetic variation within these families.
C1 [Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA.
[Bennett, David A.] Rush Univ, Med Ctr, Dept Neurol, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA.
[Graff-Radford, Neill R.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
[Mayeux, Richard] Columbia Univ, Dept Neurol, New York, NY 10027 USA.
[Mayeux, Richard] Columbia Univ, Dept Psychiat, New York, NY 10027 USA.
[Mayeux, Richard] Columbia Univ, Dept Epidemiol, New York, NY 10027 USA.
RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA.
EM sweetra@upmc.edu
OI Farrer, Lindsay/0000-0001-5533-4225
FU NIA NIH HHS [R01 AG027342, P01AG02219, P01AG03991, P01AG05138, P30
AG013854, P30 AG013854-14, P30 AG013854-15, P30AG008017, P30AG010133,
P30AG028377, P30AG028383, P30AG10124, P30AG10161, P30AG12300,
P30AG13854, P50 AG005133, P50 AG005133-210020, P50 AG005136, P50
AG005136-28, P50AG005133, P50AG016579, P50AG016582, P50AG05134,
P50AG05136, P50AG05138, P50AG05142, P50AG05681, P50AG08702, P50AG165574,
R01 AG027224, R01 AG027224-04, R01AG027224, U24 AG021886, U24AG021886,
U24AG026395]
NR 35
TC 26
Z9 26
U1 2
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
J9 BRAIN
JI Brain
PD APR 10
PY 2010
VL 133
BP 1155
EP 1162
DI 10.1093/brain/awq001
PN 4
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 590KU
UT WOS:000277225600018
PM 20147454
ER
PT J
AU Rickards, LD
McGraw, SA
Araki, L
Casey, RJ
High, CW
Hombs, ME
Raysor, RS
AF Rickards, Lawrence D.
McGraw, Sarah A.
Araki, Lynnette
Casey, Roger J.
High, Cynthia W.
Hombs, Mary Ellen
Raysor, Robyn S.
TI Collaborative Initiative to Help End Chronic Homelessness: Introduction
SO JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH
LA English
DT Article
ID SEVERE MENTAL-ILLNESS; SUBSTANCE USE DISORDERS; NEW-YORK-CITY; DUAL
DIAGNOSIS; HEALTH-SERVICES; PSYCHIATRIC DISABILITIES;
COST-EFFECTIVENESS; HOUSING 1ST; CARE; INDIVIDUALS
AB The Collaborative Initiative to Help End Chronic Homelessness was a coordinated effort by the US Departments of Health and Human Services (HHS), Housing and Urban Development (HUD), and Veterans Affairs (VA), and the US Interagency Council on Homelessness to house and provide comprehensive supportive services to individuals with serious psychiatric, substance use, health, and related disabilities who were experiencing long-term chronic homelessness. Eleven communities received 3-year grants from HHS and VA (2003-2006) and up to 5-year grants from HUD (2003-2008) to implement the initiative. This article provides background on chronic homelessness, describes the federal collaboration to comprehensively address chronic homelessness, and introduces the seven articles in this special issue that describe the findings and lessons learned from the participating communities in addressing chronic homelessness. Collectively, these articles offer insight into the challenges and benefits of providing housing and services to individuals experiencing chronic homelessness.
C1 [McGraw, Sarah A.] New England Res Inst, Ctr Qualitat Res, Watertown, MA 02472 USA.
[Rickards, Lawrence D.] Subst Abuse & Mental Hlth Serv Adm, Homeless Programs Branch, Ctr Mental Hlth Serv, US Dept HHS, Rockville, MD 20420 USA.
[Araki, Lynnette] US Hlth Resources & Serv Adm, Off Planning Evaluat & Legislat, US Dept HHS, Rockville, MD 20857 USA.
[Casey, Roger J.] US Dept Vet Affairs, Homeless Grant Per Diem Program, Off Mental Hlth Serv 116E, Washington, DC 20420 USA.
[High, Cynthia W.] US Dept Housing & Urban Dev, Special Needs Assistance Program, Off Community Planning & Dev, Washington, DC 20036 USA.
[Hombs, Mary Ellen] US Interagcy Council Homelessness, Washington, DC USA.
[Raysor, Robyn S.] US Dept Housing & Urban Dev, Special Needs Assistance Program, Off Community Planning & Dev, Washington, DC 20041 USA.
RP McGraw, SA (reprint author), New England Res Inst, Ctr Qualitat Res, 9 Galen St, Watertown, MA 02472 USA.
EM LDRickards@msn.com; smcgraw@neriscience.com; laraki@hrsa.gov;
Roger.Casey@va.gov; Cynthia.W.High@HUD.gov; Maryellen.Hombs@USICH.gov;
Robyn.S.Raysor@HUD.gov
NR 62
TC 11
Z9 11
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1094-3412
J9 J BEHAV HEALTH SER R
JI J. Behav. Health Serv. Res.
PD APR 10
PY 2010
VL 37
IS 2
BP 149
EP 166
DI 10.1007/s11414-009-9175-1
PG 18
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 580HJ
UT WOS:000276438400003
PM 19337841
ER
PT J
AU Saxon, AJ
AF Saxon, Andrew J.
TI Morphine after Combat Injury and Post-Traumatic Stress Disorder
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Saxon, AJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
EM asaxon@uw.edu
NR 0
TC 0
Z9 0
U1 1
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 8
PY 2010
VL 362
IS 14
BP 1342
EP 1342
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 579SN
UT WOS:000276393700019
PM 20380026
ER
PT J
AU Chang, VW
Asch, DA
Werner, RM
AF Chang, Virginia W.
Asch, David A.
Werner, Rachel M.
TI Quality of Care Among Obese Patients
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID COLORECTAL-CANCER; MEDICARE BENEFICIARIES; PREVENTIVE SERVICES;
BODY-WEIGHT; HEALTH-CARE; CLAIMS DATA; SELF-REPORT; US ADULTS; WOMEN;
MAMMOGRAPHY
AB Context Clinicians often have negative attitudes toward obesity and express dissatisfaction in caring for obese patients. Moreover, obese patients often feel that clinicians are biased or disrespectful because of their weight. These observations raise the concern that obese patients may receive lower quality of care.
Objective To determine whether performance on common outpatient quality measures differs by patient weight status.
Design, Setting, and Participants Eight different performance measures were examined in 2 national-level patient populations: (1) Medicare beneficiaries (n=36 122) using data from the Medicare Beneficiary Survey (1994-2006); and (2) recipients of care from the Veterans Health Administration (VHA) (n=33 550) using data from an ongoing performance-evaluation program (2003-2004).
Main Outcome Measures Performance measures among eligible patients for diabetes care (eye examination, glycated hemoglobin [HbA(1c)] testing, and lipid screening), pneumococcal vaccination, influenza vaccination, screening mammography, colorectal cancer screening, and cervical cancer screening. Measures were based on a combination of administrative claims, survey, and chart review data.
Results We found no evidence that obese or overweight patients were less likely to receive recommended care relative to normal-weight patients. Moreover, success rates were marginally higher for obese and/or overweight patients on several measures. The most notable differentials were observed for recommended diabetes care among Medicare beneficiaries: comparing obese vs normal-weight patients with diabetes, obese patients were more likely to receive recommended care on lipid screening (72% vs 65%; odds ratio, 1.37 [95% confidence interval, 1.09-1.73]) and HbA(1c) testing (74% vs 62%; odds ratio, 1.73 [95% confidence interval, 1.41-2.11]). All analyses were adjusted for sociodemographic factors, health status, clinical complexity, and visit frequency.
Conclusions Among samples of patients from the Medicare and VHA populations, there was no evidence across 8 performance measures that obese or overweight patients received inferior care when compared with normal-weight patients. Being obese or overweight was associated with a marginally higher rate of recommended care on several measures. JAMA. 2010;303(13):1274-1281
C1 [Chang, Virginia W.; Asch, David A.; Werner, Rachel M.] Univ Penn, Sch Med, Dept Med, Ctr Hlth Equ Res & Promot,Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Chang, Virginia W.; Asch, David A.; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Chang, Virginia W.] Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA.
RP Chang, VW (reprint author), Univ Penn, Sch Med, Dept Med, Ctr Hlth Equ Res & Promot,Philadelphia VA Med Ctr, 1233 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM vwchang@mail.med.upenn.edu
OI Asch, David/0000-0002-7970-286X
FU Veterans Administration Health Services [IIR 06-096]; Robert Wood
Johnson Foundation
FX This work was supported by a Veterans Administration Health Services
Research and Development Merit Award (IIR 06-096); the Robert Wood
Johnson Foundation Physician Faculty Scholars Program; and a Veterans
Administration Health Services Research and Development Career
Development Award (to Dr Werner).
NR 40
TC 38
Z9 38
U1 2
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 7
PY 2010
VL 303
IS 13
BP 1274
EP 1281
DI 10.1001/jama.2010.339
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 579FM
UT WOS:000276353700027
PM 20371786
ER
PT J
AU Chou, R
Shekelle, P
AF Chou, Roger
Shekelle, Paul
TI Will This Patient Develop Persistent Disabling Low Back Pain?
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID PRIMARY-CARE; INCEPTION COHORT; PROGNOSTIC-FACTORS; CLINICAL-COURSE;
SCREENING QUESTIONNAIRE; GENERAL-PRACTICE; WORK DISABILITY; PREDICTORS;
RISK; FEAR
AB Context Low back pain is extremely common. Early identification of patients more likely to develop persistent disabling symptoms could help guide decisions regarding follow-up and management.
Objective To systematically review the usefulness of individual risk factors or risk prediction instruments for identifying patients more likely to develop persistent disabling low back pain.
Data Sources Electronic searches of MEDLINE (1966-January 2010) and EMBASE (1974-February 2010) and review of the bibliographies of retrieved articles.
Study Selection Prospective studies of patients with fewer than 8 weeks of low back pain from which likelihood ratios (LRs) were calculated for prediction of persistent disabling low back pain for findings attainable during the clinical evaluation.
Data Extraction Two authors independently assessed studies and extracted data to estimate LRs.
Data Synthesis A total of 20 studies evaluating 10 842 patients were identified. Presence of nonorganic signs (median [range] LR, 3.0 [1.7-4.6]), high levels of maladaptive pain coping behaviors (median [range] LR, 2.5 [2.2-2.8]), high baseline functional impairment (median [range] LR, 2.1 [1.2-2.7]), presence of psychiatric comorbidities (median [range] LR, 2.2 [1.9-2.3]), and low general health status (median [range] LR, 1.8 [1.1-2.0]) were the most useful predictors of worse outcomes at 1 year. Low levels of fear avoidance (median [range] LR, 0.39 [0.38-0.40]) and low baseline functional impairment (median [range] LR, 0.40 [0.10-0.52]) were the most useful items for predicting recovery at 1 year. Results were similar for outcomes at 3 to 6 months. Variables related to the work environment, baseline pain, and presence of radiculopathy were less useful for predicting worse outcomes (median LRs approximately 1.5), and a history of prior low back pain episodes and demographic variables were not useful (median LRs approximately 1.0). Several risk prediction instruments were useful for predicting outcomes, but none were extensively validated, and some validation studies showed LRs similar to estimates for individual risk factors.
Conclusion The most helpful components for predicting persistent disabling low back pain were maladaptive pain coping behaviors, nonorganic signs, functional impairment, general health status, and presence of psychiatric comorbidities. JAMA. 2010;303(13):1295-1302
C1 [Chou, Roger] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
[Chou, Roger] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA.
[Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Chou, R (reprint author), Oregon Hlth & Sci Univ, Dept Med, 3181 SW Sam Jackson Pk Rd,MC BICC, Portland, OR 97239 USA.
EM chour@ohsu.edu
NR 52
TC 200
Z9 202
U1 4
U2 25
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 7
PY 2010
VL 303
IS 13
BP 1295
EP 1302
DI 10.1001/jama.2010.344
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 579FM
UT WOS:000276353700030
PM 20371789
ER
PT J
AU Stolker, JM
McCullough, PA
Rao, S
Inzucchi, SE
Spertus, JA
Maddox, TM
Masoudi, FA
Xiao, L
Kosiborod, M
AF Stolker, Joshua M.
McCullough, Peter A.
Rao, Seshu
Inzucchi, Silvio E.
Spertus, John A.
Maddox, Thomas M.
Masoudi, Frederick A.
Xiao, Lan
Kosiborod, Mikhail
TI Pre-Procedural Glucose Levels and the Risk for Contrast-Induced Acute
Kidney Injury in Patients Undergoing Coronary Angiography
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE contrast nephropathy; acute kidney injury; glucose; diabetes; myocardial
infarction; coronary angiography
ID ACUTE MYOCARDIAL-INFARCTION; CRITICALLY-ILL PATIENTS;
ACUTE-RENAL-FAILURE; INTENSIVE INSULIN THERAPY; INDUCED NEPHROPATHY;
ACUTE HYPERGLYCEMIA; DIABETES-MELLITUS; BLOOD-GLUCOSE; NITRIC-OXIDE;
PRIMARY ANGIOPLASTY
AB Objectives
We sought to evaluate whether pre-procedural glucose levels are associated with contrast-induced acute kidney injury (CI-AKI) after coronary angiography.
Background
Although diabetes is a known risk factor for CI-AKI in patients undergoing coronary angiography, whether elevated pre-procedural glucose levels (regardless of pre-existing diabetes) are associated with higher risk for CI-AKI is unknown.
Methods
We evaluated 6,358 patients with acute myocardial infarctions undergoing coronary angiography. Patients were stratified into 5 pre-procedural glucose groups: <110 mg/dl, 110 to <140 mg/dl, 140 to <170 mg/dl, 170 to <200 mg/dl, and >= 200 mg/dl. Logistic regression models were used to evaluate the relationship between glucose levels and risk for CI-AKI, first in the entire cohort and then in patients with and without established diabetes. The primary outcome was CI-AKI (>= 0.3 mg/dl absolute or >= 50% relative serum creatinine increase during 48 h after the procedure).
Results
The relationship between pre-procedural glucose and CI-AKI varied markedly in patients with and without diabetes. There was a strong association between glucose and CI-AKI risk in patients without diabetes (CI-AKI rates across the 5 glucose groups from lowest to highest: 8.2%, 9.9%, 12.4%, 14.9%, and 24.3%; p < 0.001), but not in patients with diabetes (20.9%, 16.1%, 16.3%, 14.8%, and 19.2%, respectively; p = 0.24; p for glucose X diabetes interaction <0.001). After adjusting for confounders (including baseline glomerular filtration rate), the relationship between higher glucose and greater CI-AKI risk persisted in patients without diabetes (odds ratios [95% confidence intervals] for glucose groups of 110 to <140 mg/dl, 140 to <170, mg/dl 170 to <200 mg/dl, and >= 200 mg/dl: 1.31 [1.00 to 1.71], 1.51 [1.11 to 2.10], 1.58 [1.03 to 2.43], and 2.14 [1.46 to 3.14] vs. glucose <110 mg/dl, respectively), but this relationship was not seen in patients with established diabetes.
Conclusions
Elevated pre-procedural glucose is associated with greater risk for CI-AKI in patients without known diabetes who undergo coronary angiography in the setting of acute myocardial infarction. Measures used to prevent CI-AKI should be considered in these patients. (J Am Coll Cardiol 2010; 55: 1433-40) (C) 2010 by the American College of Cardiology Foundation
C1 [Stolker, Joshua M.; Rao, Seshu; Spertus, John A.; Xiao, Lan; Kosiborod, Mikhail] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA.
[Stolker, Joshua M.; Rao, Seshu; Spertus, John A.; Kosiborod, Mikhail] Univ Missouri, Kansas City, MO 64110 USA.
[McCullough, Peter A.] William Beaumont Hosp, Royal Oak, MI 48072 USA.
[Inzucchi, Silvio E.] Yale Univ, New Haven, CT USA.
[Inzucchi, Silvio E.] Yale New Haven Med Ctr, New Haven, CT 06504 USA.
[Maddox, Thomas M.] Denver VA Med Ctr, Denver, CO USA.
[Masoudi, Frederick A.] Denver Hlth Med Ctr, Denver, CO USA.
[Masoudi, Frederick A.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA.
RP Kosiborod, M (reprint author), St Lukes Hosp, Mid Amer Heart Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA.
EM mkosiborod@cc-pc.com
FU American Heart Association Career Development Award in Implementation
Research; AstraZeneca Pharmaceuticals; Pfizer Pharmaceuticals; Eli
Lilly; Sanofi-Aventis
FX The research for this analysis was supported by the American Heart
Association Career Development Award in Implementation Research, awarded
to Dr. Kosiborod. Dr. Stolker has received speaking honoraria from
AstraZeneca Pharmaceuticals and Pfizer Pharmaceuticals; has served as a
consultant to Novo Nordisk; and has served on the advisory board of
Educational Testing Consultants, LLC. Dr. Inzucchi has received research
grant support from Eli Lilly. Dr. Spertus has received research grant
support from Sanofi-Aventis and Eli Lilly. Dr. Masoudi was previously a
member of the advisory board of Takeda Pharmaceuticals. Dr. Kosiborod
has served on the advisory board of Sanofi-Aventis and has received
speaking honoraria from the Vascular Biology Working Group and DiaVed,
Inc. The Cerner Corporation collected deidentified clinical information
for the Health Facts database. The Cerner Corporation had no role in
study design, data analysis, interpretation of findings, or writing of
the manuscript. The American Heart Association had no role in the study.
NR 47
TC 35
Z9 37
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 6
PY 2010
VL 55
IS 14
BP 1433
EP 1440
DI 10.1016/j.jacc.2009.09.072
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 583AV
UT WOS:000276644500005
PM 20359592
ER
PT J
AU Jang, H
Arce, FT
Ramachandran, S
Capone, R
Azimova, R
Kagan, BL
Nussinov, R
Lal, R
AF Jang, Hyunbum
Arce, Fernando Teran
Ramachandran, Srinivasan
Capone, Ricardo
Azimova, Rushana
Kagan, Bruce L.
Nussinov, Ruth
Lal, Ratnesh
TI Truncated beta-amyloid peptide channels provide an alternative mechanism
for Alzheimer's Disease and Down syndrome
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE atomic force microscopy; molecular dynamics; cell calcium imaging;
neurite degeneration and cell death assays; single-channel conductance
ID PRION PROTEIN-FRAGMENT; HEPARIN-BINDING DOMAIN; ION CHANNELS;
ZN2+-SENSITIVE CHANNEL; COMMON MECHANISM; MOUSE MODELS; GRAMICIDIN-A; 3D
STRUCTURE; CONGO RED; IN-VITRO
AB Full-length amyloid beta peptides (A beta(1-40/42)) form neuritic amyloid plaques in Alzheimer's disease (AD) patients and are implicated in AD pathology. However, recent transgenic animal models cast doubt on their direct role in AD pathology. Nonamyloidogenic truncated amyloid-beta fragments (A beta(11-42) and A beta(17-42)) are also found in amyloid plaques of AD and in the preamyloid lesions of Down syndrome, a model system for early-onset AD study. Very little is known about the structure and activity of these smaller peptides, although they could be the primary AD and Down syndrome pathological agents. Using complementary techniques of molecular dynamics simulations, atomic force microscopy, channel conductance measurements, calcium imaging, neuritic degeneration, and cell death assays, we show that nonamyloidogenic A beta(9-42) and A beta(17-42) peptides form ion channels with loosely attached subunits and elicit single-channel conductances. The subunits appear mobile, suggesting insertion of small oligomers, followed by dynamic channel assembly and dissociation. These channels allow calcium uptake in amyloid precursor protein-deficient cells. The channel mediated calcium uptake induces neurite degeneration in human cortical neurons. Channel conductance, calcium uptake, and neurite degeneration are selectively inhibited by zinc, a blocker of amyloid ion channel activity. Thus, truncated A beta fragments could account for undefined roles played by full length A beta s and provide a unique mechanism of AD and Down syndrome pathologies. The toxicity of nonamyloidogenic peptides via an ion channel mechanism necessitates a reevaluation of the current therapeutic approaches targeting the nonamyloidogenic pathway as avenue for AD treatment.
C1 [Jang, Hyunbum; Nussinov, Ruth] Natl Canc Inst, SAIC Frederick Inc, Ctr Canc Res, Nanobiol Program, Frederick, MD 21702 USA.
[Arce, Fernando Teran; Ramachandran, Srinivasan; Capone, Ricardo; Lal, Ratnesh] Univ Chicago, Ctr Nanomed, Chicago, IL 60637 USA.
[Arce, Fernando Teran; Ramachandran, Srinivasan; Capone, Ricardo; Lal, Ratnesh] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
[Azimova, Rushana; Kagan, Bruce L.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Neuropsychiat Inst, Los Angeles, CA 90024 USA.
[Azimova, Rushana; Kagan, Bruce L.] Greater Los Angeles Vet Adm Hlth Syst, Los Angeles, CA 90024 USA.
[Nussinov, Ruth] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel.
RP Nussinov, R (reprint author), Natl Canc Inst, SAIC Frederick Inc, Ctr Canc Res, Nanobiol Program, Frederick, MD 21702 USA.
EM ruthnu@helix.nih.gov; rlal@ucsd.edu
RI Capone, Ricardo/D-1943-2010
OI Capone, Ricardo/0000-0002-7327-9837
FU National Institutes of Health [IIRG-05-14089]; National Cancer
Institute, National Institutes of Health [HHSN261200800001E]; National
Institutes of Health, National Cancer Institute, Center for Cancer
Research
FX We thank Dr. Robert Tycko for providing the A beta9-40
oligomer coordinates, Dr. Jeremy Marks for providing primary hippocampal
neurons, Dr Gopal Thinakaran for providing APP-null cells, and Drs.
Thinakaran and Sangram Sisodia for invaluable insights, as well as for
critical editing of the manuscript. This research was supported by the
National Institutes of Health (National Institute on Aging) extramural
program (R. L) and Alzheimer's Association Award IIRG-05-14089 (to
B.L.K.). This project has been funded in whole or in part with Federal
funds from the National Cancer Institute, National Institutes of Health,
under contract number HHSN261200800001E. The content of this publication
does not necessarily reflect the views or policies of the Department of
Health and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the U.S. Government.
This research was supported (in part) by the Intramural Research Program
of the National Institutes of Health, National Cancer Institute, Center
for Cancer Research.
NR 50
TC 106
Z9 108
U1 3
U2 40
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 6
PY 2010
VL 107
IS 14
BP 6538
EP 6543
DI 10.1073/pnas.0914251107
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 579MH
UT WOS:000276374400074
PM 20308552
ER
PT J
AU Landman, A
Meisel, ZF
AF Landman, Adam
Meisel, Zachary F.
TI The Robert Wood Johnson Foundation Clinical Scholars Program and
Emergency Medicine
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article
DE Robert Wood Johnson Foundation; Clinical Scholars Program; fellowship
training; research; health policy; leadership
ID PREDICT HOSPITAL ADMISSION; CARDIAC-ARREST; RESUSCITATION; VALIDATION;
RULE
AB P>Specialized research training for emergency physicians (EPs) may strengthen overall patient care through the development and improvement of clinical evidence in emergency care. One way an increasing number of emergency physicians have acquired these skills is through the Robert Wood Johnson Foundation Clinical Scholars Program (CSP), a 2-year fellowship that trains physicians to be leaders in improving health care. In addition to providing training in health policy and health services research, the CSP emphasizes the translation of research into action through leadership training, program development, and community-based participatory research. This article provides an in-depth look at the CSP and its impact on emergency medicine (EM). To date, 41 EPs have trained through the program, with increasing numbers in recent years. Graduates have gone on to become leaders in academia, public health, private industry, and foundations. Past and present EM-trained Clinical Scholars are working to find creative solutions for the challenges posed by the U.S. health care system and improve the delivery of emergency care. Emergency physicians who wish to conduct research or work with communities, organizations, practitioners, and policy-makers to address issues essential to the health and well-being of all Americans should consider the Robert Wood Johnson Foundation CSP.
C1 [Landman, Adam] Yale Univ, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA.
[Landman, Adam] Yale Univ, Dept Emergency Med, New Haven, CT USA.
[Landman, Adam] US Dept Vet Affairs, West Haven, CT USA.
[Meisel, Zachary F.] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA.
[Meisel, Zachary F.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA.
RP Landman, A (reprint author), Yale Univ, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06520 USA.
EM Adam.Landman@yale.edu
OI Landman, Adam/0000-0002-2166-0521
FU U.S. Department of Veterans Affairs; Robert Wood Johnson Foundation
FX Dr. Landman is a Robert Wood Johnson Clinical Scholar at Yale
University, supported by the U.S. Department of Veterans Affairs and the
Robert Wood Johnson Foundation. Dr. Meisel is a Robert Wood Johnson
Clinical Scholar at the University of Pennsylvania, supported by the
Robert Wood Johnson Foundation.; The Robert Wood Johnson Foundation and
U.S. Department of Veterans Affairs had no role in the preparation,
review, or approval of the manuscript.
NR 11
TC 5
Z9 5
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1069-6563
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD APR
PY 2010
VL 17
IS 4
BP E17
EP E22
DI 10.1111/j.1553-2712.2010.00692.x
PG 6
WC Emergency Medicine
SC Emergency Medicine
GA 577SR
UT WOS:000276244800001
PM 20148769
ER
PT J
AU Harper, GM
Lyss-Lerman, P
AF Harper, G. Michael
Lyss-Lerman, Pamela
TI Longitudinal Integrated Clerkships Reply
SO ACADEMIC MEDICINE
LA English
DT Letter
C1 [Harper, G. Michael] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA.
[Harper, G. Michael] San Francisco VA Med Ctr, San Francisco, CA USA.
[Lyss-Lerman, Pamela] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA.
RP Harper, GM (reprint author), Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA.
EM Michael.harper3@va.gov
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD APR
PY 2010
VL 85
IS 4
BP 569
EP 569
DI 10.1097/ACM.0b013e3181d308bb
PG 1
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 576GL
UT WOS:000276132300005
ER
PT J
AU Carnes, M
AF Carnes, Molly
TI Commentary: Deconstructing Gender Difference
SO ACADEMIC MEDICINE
LA English
DT Editorial Material
ID STEREOTYPES; PERFORMANCE; COMPETENCE; IDENTITY; THREAT; WOMEN; AIR
AB In Japan, as in the United States, a growing proportion of physicians are women. Hence, the different social roles that men and women occupy and the gendered norms for behavior are increasingly relevant in ensuring that male and female physicians have equal opportunity to participate and advance in all aspects of medicine. Elsewhere in this issue, Nomura and colleagues report on a large survey of primary care residents in Japan. They found that on average women's self-rated confidence on many clinical tasks was lower than men's. This is not surprising given similar gender differences in self-assessed competence in other research and the socialization of women in virtually all cultures to be modest. The actual differences in average scores were small suggesting considerable overlap in the distributions of responses from male and female residents. In addition, research from other countries finds no association between physicians' self-reported confidence in clinical tasks and objective measures of competence on which female physicians rate at or above the level of their male counterparts. Congruent with different social roles for men and women, Nomura and colleagues also found gender differences in the average responses about work-family priorities and aspirations toward leadership, but some women indicated a desire for research careers and some men were "life-oriented." The author of this commentary argues that to draw conclusions about all male or all female physicians from average differences of a large group of residents may reinforce gender stereotypes that continue to impede each individual female physician's career advancement and each individual male physician's struggle for work-life balance. Acad Med. 2010; 85: 575-577.
C1 [Carnes, Molly] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA.
[Carnes, Molly] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53715 USA.
[Carnes, Molly] Univ Wisconsin, Sch Med & Publ Hlth, Dept Psychiat, Madison, WI 53715 USA.
[Carnes, Molly] Univ Wisconsin, Coll Engn, Dept Ind & Syst Engn, Madison, WI 53715 USA.
[Carnes, Molly] Univ Wisconsin, Coll Engn, Women Sci & Engn Leadership Inst, Madison, WI 53715 USA.
[Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Women Vet Hlth Program, Madison, WI USA.
RP Carnes, M (reprint author), Univ Wisconsin, Ctr Womens Hlth Res, 700 Regent St,Suite 301, Madison, WI 53715 USA.
EM mlcarnes@wisc.edu
FU NIGMS NIH HHS [R01 GM088477, R01 GM088477-01]
NR 10
TC 12
Z9 12
U1 1
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD APR
PY 2010
VL 85
IS 4
BP 575
EP 577
DI 10.1097/ACM.0b013e3181d983de
PG 3
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 576GL
UT WOS:000276132300011
PM 20354367
ER
PT J
AU Kraemer, BC
Schuck, T
Wheeler, JM
Robinson, LC
Trojanowski, JQ
Lee, VMY
Schellenberg, GD
AF Kraemer, Brian C.
Schuck, Theresa
Wheeler, Jeanna M.
Robinson, Linda C.
Trojanowski, John Q.
Lee, Virginia M. Y.
Schellenberg, Gerard D.
TI Loss of murine TDP-43 disrupts motor function and plays an essential
role in embryogenesis
SO ACTA NEUROPATHOLOGICA
LA English
DT Article
ID AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; MOUSE
MODEL; TARDBP MUTATIONS; DEMENTIA FTDP-17; BINDING PROTEIN; STEM-CELLS;
DISEASE; GENE; TAU
AB Abnormal TDP-43 aggregation is a prominent feature in the neuropathology of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration. Mutations in TARDBP, the gene encoding TDP-43, cause some cases of ALS. The normal function of TDP-43 remains incompletely understood. To better understand TDP-43 biology, we generated mutant mice carrying a genetrap disruption of Tardbp. Mice homozygous for loss of TDP-43 are not viable. TDP-43 deficient embryos die about day 7.5 of embryonic development thereby demonstrating that TDP-43 protein is essential for normal prenatal development and survival. However, heterozygous Tardbp mutant mice exhibit signs of motor disturbance and muscle weakness. Compared with wild type control littermates, Tardbp (+/-) animals have significantly decreased forelimb grip strength and display deficits in a standard inverted grid test despite no evidence of pathologic changes in motor neurons. Thus, TDP-43 is essential for viability, and mild reduction in TDP-43 function is sufficient to cause motor deficits without degeneration of motor neurons.
C1 [Kraemer, Brian C.; Wheeler, Jeanna M.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA.
[Kraemer, Brian C.; Wheeler, Jeanna M.; Robinson, Linda C.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Schuck, Theresa; Trojanowski, John Q.; Lee, Virginia M. Y.; Schellenberg, Gerard D.] Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA.
[Schuck, Theresa; Trojanowski, John Q.; Lee, Virginia M. Y.; Schellenberg, Gerard D.] Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
RP Kraemer, BC (reprint author), Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA.
EM kraemerb@u.washington.edu
FU NIH [AG17586, NS064131]; Office of Research and Development Medical
Research Service, Department of Veterans Affairs
FX This work was supported by NIH grant AG17586 to GDS, VMYL, and JQT. This
work was also supported by grants to BCK from the Office of Research and
Development Medical Research Service, Department of Veterans Affairs and
NIH (NS064131). This work utilized facilities at the VA Puget Sound
Health Care System, Seattle, Washington. We thank Eddie Lee for
outstanding assistance examining neuropathology of Tardbp+/-
animals and Elaine Loomis, Leojean Anderson, and Harmony Danner for
excellent technical assistance. The lacZ monoclonal antibody was
obtained from the Developmental Studies Hybridoma Bank maintained by the
University of Iowa.
NR 52
TC 119
Z9 121
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0001-6322
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD APR
PY 2010
VL 119
IS 4
BP 409
EP 419
DI 10.1007/s00401-010-0659-0
PG 11
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 571LE
UT WOS:000275752500002
PM 20198480
ER
PT J
AU Stephens, DN
Duka, T
Crombag, HS
Cunningham, CL
Heilig, M
Crabbe, JC
AF Stephens, David N.
Duka, Theodora
Crombag, Hans S.
Cunningham, Christopher L.
Heilig, Markus
Crabbe, John C.
TI Reward sensitivity: issues of measurement, and achieving consilience
between human and animal phenotypes
SO ADDICTION BIOLOGY
LA English
DT Review
DE Animal models; conditioned place preference; craving; progressive ratio;
reward dysregulation; self administration
ID CONDITIONED PLACE PREFERENCE; PROGRESSIVE RATIO SCHEDULE; DRUG-SEEKING
BEHAVIOR; 5-HYDROXYINDOLEACETIC ACID CONCENTRATIONS;
INCENTIVE-SENSITIZATION THEORY; DIMINISHED SOCIAL COMPETENCE;
SELF-ADMINISTERED COCAINE; MEDIAL PREFRONTAL CORTEX; ADDICTION-LIKE
BEHAVIOR; NONHUMAN PRIMATE MODEL
AB Reward is a concept fundamental to discussions of drug abuse and addiction. The idea that altered sensitivity to either drug-reward, or to rewards in general, contributes to, or results from, drug-taking is a common theme in several theories of addiction. However, the concept of reward is problematic in that it is used to refer to apparently different behavioural phenomena, and even to diverse neurobiological processes (reward pathways). Whether these different phenomena are different behavioural expressions of a common underlying process is not established, and much research suggests that there may be only loose relationships among different aspects of reward. Measures of rewarding effects of drugs in humans often depend upon subjective reports. In animal studies, such insights are not available, and behavioural measures must be relied upon to infer rewarding effects of drugs or other events. In such animal studies, but also in many human methods established to objectify measures of reward, many other factors contribute to the behaviour being studied. For that reason, studying the biological (including genetic) bases of performance of tasks that ostensibly measure reward cannot provide unequivocal answers. The current overview outlines the strengths and weaknesses of current approaches that hinder the conciliation of cross-species studies of the genetics of reward sensitivity and the dysregulation of reward processes by drugs of abuse. Some suggestions are made as to how human and animal studies may be made to address more closely homologous behaviours, even if those processes are only partly able to isolate 'reward' from other factors contributing to behavioural output.
C1 [Stephens, David N.; Duka, Theodora; Crombag, Hans S.] Univ Sussex, Dept Psychol, Brighton BN1 9QG, E Sussex, England.
[Cunningham, Christopher L.; Crabbe, John C.] Oregon Hlth & Sci Univ, Sch Med, Dept Behav Neurosci, Portland, OR 97201 USA.
[Heilig, Markus] NIAAA, Lab Clin & Translat Studies, NIH, Bethesda, MD USA.
[Crabbe, John C.] Portland Alcohol Res Ctr, Portland, OR USA.
[Crabbe, John C.] Portland VA Med Ctr, Portland, OR USA.
RP Stephens, DN (reprint author), Univ Sussex, Dept Psychol, Brighton BN1 9QG, E Sussex, England.
EM d.stephens@sussex.ac.uk
RI Stephens, David/G-2384-2012
OI Heilig, Markus/0000-0003-2706-2482
FU Medical Research Council [G0802642, G0400568]
NR 195
TC 50
Z9 50
U1 5
U2 19
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1355-6215
J9 ADDICT BIOL
JI Addict. Biol.
PD APR
PY 2010
VL 15
IS 2
BP 145
EP 168
DI 10.1111/j.1369-1600.2009.00193.x
PG 24
WC Biochemistry & Molecular Biology; Substance Abuse
SC Biochemistry & Molecular Biology; Substance Abuse
GA 554AB
UT WOS:000274406800004
PM 20148777
ER
PT J
AU Ehlers, CL
Walter, NAR
Dick, DM
Buck, KJ
Crabbe, JC
AF Ehlers, Cindy L.
Walter, Nicole A. R.
Dick, Danielle M.
Buck, Kari J.
Crabbe, John C.
TI A comparison of selected quantitative trait loci associated with alcohol
use phenotypes in humans and mouse models
SO ADDICTION BIOLOGY
LA English
DT Review
DE Alcohol dependence; genetics; linkage analyses; mouse models of
alcoholism; phenotypes; QTL
ID RECOMBINANT INBRED MICE; GENOME-WIDE SEARCH; SOUTHWEST CALIFORNIA
INDIANS; IDENTIFY CANDIDATE GENES; LINKAGE ANALYSIS; ETHANOL WITHDRAWAL;
SUSCEPTIBILITY LOCI; PHYSICAL-DEPENDENCE; GABA(A) RECEPTOR; CONDUCT
DISORDER
AB Evidence for genetic linkage to alcohol and other substance dependence phenotypes in areas of the human and mouse genome have now been reported with some consistency across studies. However, the question remains as to whether the genes that underlie the alcohol-related behaviors seen in mice are the same as those that underlie the behaviors observed in human alcoholics. The aims of the current set of analyses were to identify a small set of alcohol-related phenotypes in human and in mouse by which to compare quantitative trait locus (QTL) data between the species using syntenic mapping. These analyses identified that QTLs for alcohol consumption and acute and chronic alcohol withdrawal on distal mouse chromosome 1 are syntenic to a region on human chromosome 1q where a number of studies have identified QTLs for alcohol-related phenotypes. Additionally, a QTL on human chromosome 15 for alcohol dependence severity/withdrawal identified in two human studies was found to be largely syntenic with a region on mouse chromosome 9, where two groups have found QTLs for alcohol preference. In both of these cases, while the QTLs were found to be syntenic, the exact phenotypes between humans and mice did not necessarily overlap. These studies demonstrate how this technique might be useful in the search for genes underlying alcohol-related phenotypes in multiple species. However, these findings also suggest that trying to match exact phenotypes in humans and mice may not be necessary or even optimal for determining whether similar genes influence a range of alcohol-related behaviors between the two species.
C1 [Ehlers, Cindy L.] Scripps Res Inst, Dept Mol & Integrat Neurosci, La Jolla, CA 92037 USA.
[Walter, Nicole A. R.; Buck, Kari J.; Crabbe, John C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Walter, Nicole A. R.; Buck, Kari J.; Crabbe, John C.] Portland VA Med Ctr, Dept Behav Neurosci, Portland Alcohol Res Ctr, Portland, OR USA.
[Dick, Danielle M.] Virginia Commonwealth Univ, Dept Psychiat, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA.
RP Ehlers, CL (reprint author), Scripps Res Inst, Dept Mol & Integrat Neurosci, 10550 N Torrey Pines Rd,SP30-1501, La Jolla, CA 92037 USA.
EM cindye@scripps.edu
FU National Institute on Alcohol Abuse and Alcoholism [AA 006059,
AA010201]; National Center on Minority Health and Health Disparities
(NCMHD) [U54 RR025204, AA010760, AA12714, AA011114, DA005228]
FX Supported in part by the National Institute on Alcohol Abuse and
Alcoholism Grants AA 006059, AA010201, the National Center on Minority
Health and Health Disparities (NCMHD), and U54 RR025204 to CLE,
AA010760, and AA12714 to JCC, AA011114 and DA005228 to KJB, and VA Merit
Review awards to KJB and JCC. DMD acknowledges support from a NARSAD
young investigator award. The authors thank Shirley Sanchez for editing
the manuscript.
NR 138
TC 35
Z9 36
U1 5
U2 5
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1355-6215
J9 ADDICT BIOL
JI Addict. Biol.
PD APR
PY 2010
VL 15
IS 2
BP 185
EP 199
DI 10.1111/j.1369-1600.2009.00195.x
PG 15
WC Biochemistry & Molecular Biology; Substance Abuse
SC Biochemistry & Molecular Biology; Substance Abuse
GA 554AB
UT WOS:000274406800006
PM 20148779
ER
PT J
AU Sueoka, K
Goulet, JL
Fiellin, DA
Rimland, D
Butt, AA
Gibert, C
Rodriguez-Barradas, MC
Bryant, K
Crystal, S
Justice, AC
AF Sueoka, Kristen
Goulet, Joseph L.
Fiellin, David A.
Rimland, David
Butt, Adeel A.
Gibert, Cynthia
Rodriguez-Barradas, Maria C.
Bryant, Kendall
Crystal, Stephen
Justice, Amy C.
TI Depression Symptoms and Treatment Among HIV Infected and Uninfected
Veterans
SO AIDS AND BEHAVIOR
LA English
DT Article
DE HIV-infection; Depression; Psychiatric status rating scales;
Anti-depressive agents
ID PRIMARY-CARE PATIENTS; PATIENT HEALTH QUESTIONNAIRE-9; DISORDERS;
VALIDITY; PHQ-9; PHYSICIANS; DIAGNOSIS; SEVERITY; DISEASES
AB Depression is one of the most common comorbid conditions affecting persons with HIV. We compared depressive symptoms and depression treatment using data from the Veterans Aging Cohort Study (VACS), a prospective cohort of HIV-infected and uninfected subjects. We identified subjects with a Patient Health Questionnaire score of 10 or greater. Treatment was defined as prescription of a selective serotonin reuptake inhibitor (SSRI) or mental health counseling. Overall, 16% of 4,480 subjects had depressive symptoms, and HIV-infected patients were more likely to have had depressive symptoms (OR = 1.38, 95% CI = 1.18, 1.62). Geographic site of care and having a mental health provider at the clinic was associated with treatment. In multivariable models restricted to 732 patients with depressive symptoms, receipt of depression treatment did not differ by HIV status (Adjusted OR = 1.11, 95% CI = 0.80, 1.54). Non-Hispanic whites were more likely to receive treatment (Adjusted OR = 2.09, 95% CI 1.04, 4.24). Primary care and HIV providers were equally unlikely to treat active depressive symptoms. Treatment variation by race, site, and availability of a mental health provider, suggests targets for intervention.
C1 [Goulet, Joseph L.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA.
[Sueoka, Kristen; Goulet, Joseph L.; Fiellin, David A.; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA.
[Rimland, David] VA Med Ctr, Atlanta, GA USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Butt, Adeel A.] Univ Pittsburgh, Pittsburgh, PA USA.
[Gibert, Cynthia] VA Med Ctr, Washington, DC USA.
[Gibert, Cynthia] George Washington Univ, Med Ctr, Washington, DC 20037 USA.
[Rodriguez-Barradas, Maria C.] Michael E De Bakey VAMC, Houston, TX USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA.
[Bryant, Kendall] NIAAA, NIH, Bethesda, MD USA.
[Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA.
RP Justice, AC (reprint author), VA Connecticut Healthcare Syst, 11ACSLG,Bldg 35A,Room 2-212,950 Campbell Ave, West Haven, CT 06516 USA.
EM amy.justice2@va.gov
OI Goulet, Joseph/0000-0002-0842-804X; Fiellin, David/0000-0002-4006-010X
FU NIA NIH HHS [K23 AG00826]; NIAAA NIH HHS [U01 AA 13566, U01 AA013566,
U10 AA 13566, U10 AA013566, U10 AA013566-08, U10 AA013566-09]
NR 25
TC 6
Z9 6
U1 2
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD APR
PY 2010
VL 14
IS 2
BP 272
EP 279
DI 10.1007/s10461-008-9428-7
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 567EB
UT WOS:000275424800005
PM 18648927
ER
PT J
AU Galvin, JE
Duda, JE
Kaufer, DI
Lippa, CF
Taylor, A
Zarit, SH
AF Galvin, James E.
Duda, John E.
Kaufer, Daniel I.
Lippa, Carol F.
Taylor, Angela
Zarit, Steven H.
TI Lewy Body Dementia Caregiver Burden and Unmet Needs
SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS
LA English
DT Article
DE Lewy body dementia; caregiver burden; stress
ID ALZHEIMERS-DISEASE; FAMILY CAREGIVERS; BODIES; IMPACT; INTERVENTION;
DEPRESSION; PREVALENCE; PREDICTORS; DIAGNOSIS; STRESS
AB Lewy body dementia (LBD) is a common cause of dementia but to date, little is known about caregiver burden. The Lewy Body Dementia Association (www.LBDA.org) conducted a web-based survey of 962 caregivers (mean age 56 y; 88% women). The most common initial symptoms were cognitive (48%), motor (39%), or both (13%). Caregivers expressed concerns about fear of future (77%), feeling stressed (54%), loss of social life (52%), and uncertainty about what to do next (50%). Caregivers reported moderate-to-severe burden; 80% felt the people around them did not understand their burden and 54% reported feelings of isolation with spousal caregivers reporting more burden than nonspousal caregivers. Only 29% hired in-home assistance, whereas less than 40% used respite or adult day care, geriatric case managers, or attended a support group meeting. Lack of service utilization occurred despite two-thirds of caregivers reporting medical crises requiring emergency services, psychiatric care, or law enforcement. Caregivers reported preferences for web-based information, directories of LBD expert providers, information on LBD research, and location of local support groups. These findings highlight significant unmet needs for LBD caregivers and provide targets for intervention to reduce caregiver burden. Community resources such as the Lewy Body Dementia Association may serve this end, while also providing practical information and support for caregivers.
C1 [Galvin, James E.] Washington Univ, Alzheimer Dis Res Ctr, Sch Med, Dept Neurol, St Louis, MO 63108 USA.
[Duda, John E.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Duda, John E.] Philadelphia VA Med Ctr, PADRECC, Philadelphia, PA USA.
[Lippa, Carol F.] Drexel Univ, Coll Med, Dept Neurol, Philadelphia, PA 19104 USA.
[Zarit, Steven H.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA.
[Kaufer, Daniel I.] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA.
[Taylor, Angela] Lewy Body Dementia Assoc, Atlanta, GA USA.
RP Galvin, JE (reprint author), Washington Univ, Alzheimer Dis Res Ctr, Sch Med, Dept Neurol, 4488 Forest Pk,Suite 130, St Louis, MO 63108 USA.
EM galvinj@neuro.wustl.edu
FU Lewy Body Dementia Association
FX The study was supported by the Lewy Body Dementia Association
(www.LBDA.org).
NR 26
TC 15
Z9 16
U1 2
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0893-0341
J9 ALZ DIS ASSOC DIS
JI Alzheimer Dis. Assoc. Dis.
PD APR-JUN
PY 2010
VL 24
IS 2
BP 177
EP 181
DI 10.1097/WAD.0b013e3181c72b5d
PG 5
WC Clinical Neurology; Pathology
SC Neurosciences & Neurology; Pathology
GA 607WJ
UT WOS:000278537700011
PM 20505434
ER
PT J
AU O'Brien, C
True, LD
Higano, CS
Rademacher, BLS
Garzotto, M
Beer, TM
AF O'Brien, Catherine
True, Lawrence D.
Higano, Celestia S.
Rademacher, Brooks L. S.
Garzotto, Mark
Beer, Tomasz M.
TI Histologic Changes Associated With Neoadjuvant Chemotherapy Are
Predictive of Nodal Metastases in Patients With High-Risk Prostate
Cancer
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE Neoadjuvant; Chemotherapy; Prostate; Carcinoma; Intraductal; Cribriform
ID ANDROGEN DEPRIVATION THERAPY; PHASE-II TRIAL; RADICAL PROSTATECTOMY;
HORMONAL-THERAPY; INTRADUCTAL CARCINOMA; INTRAEPITHELIAL NEOPLASIA;
PATHOLOGICAL-CHANGES; RANDOMIZED-TRIAL; FOLLOW-UP; ADENOCARCINOMA
AB Clinical trials are evaluating the effect of neoadjuvant chemotherapy on men with high-risk prostate cancer Little is known about the clinical significance of postchemotherapy tumor histopathologic features. We assessed the prognostic and predictive value of histologic features (intraductal carcinoma, vacuolated cell morphologic features, inconspicuous glands, cribriform architecture, and inconspicuous cancer cells) observed in 50 high-risk prostate cancers treated with preprostatectomy docetaxel and mitoxantrone At a median follow-up of 65 months, the overall relapse-free survival (RFS) rates at 2 and 5 years were 65% and 49% respectively. In univariate analyses (using the Kaplan-Meier method and log-rank tests), intraductal (P = 001) and cribriform (P = 014) histologic features were associated with shorter RFS In multivariate analyses, using the Cox proportioanl hazards regression, baseline prostate-specific antigen (P = 004), lymph node metastases (P < .007) were associated with shorter RFS In multivariable logistic regression analysis, only intraductal pattern (P = 007) predicted lymph node metastases Intraductal and cribriform histologic features apparently predict postchemotherapy outcome
C1 [Beer, Tomasz M.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA.
[Garzotto, Mark] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97239 USA.
[True, Lawrence D.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Higano, Celestia S.] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA.
[Garzotto, Mark] Portland VA Med Ctr, Portland, OR USA.
RP Beer, TM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, 3303 SW Bond,CH14R, Portland, OR 97239 USA.
FU NCI NIH HHS [R01 CA119125-01, R01 CA119125, 1 R01CA119125-01]; NCRR NIH
HHS [M01 RR000334-33S2, 3M01RR00334-33S2, M01 RR000334]
NR 38
TC 15
Z9 15
U1 0
U2 0
PU AMER SOC CLINICAL PATHOLOGY
PI CHICAGO
PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA
SN 0002-9173
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD APR
PY 2010
VL 133
IS 4
BP 654
EP 661
DI 10.1309/AJCP8EL5FTZSOBIH
PG 8
WC Pathology
SC Pathology
GA 572ID
UT WOS:000275821400017
PM 20231619
ER
PT J
AU Spiegel, BMR
Farid, M
Esrailian, E
Talley, J
Chang, L
AF Spiegel, Brennan M. R.
Farid, Mary
Esrailian, Eric
Talley, Jennifer
Chang, Lin
TI Is Irritable Bowel Syndrome a Diagnosis of Exclusion?: A Survey of
Primary Care Providers, Gastroenterologists, and IBS Experts
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID COMMUNITY GASTROENTEROLOGISTS; PAINFUL CONSTIPATION; QUALITY;
GUIDELINES; MANAGEMENT; DISORDERS; VIGNETTES; COLITIS
AB OBJECTIVES: Guidelines emphasize that irritable bowel syndrome (IBS) is not a diagnosis of exclusion and encourage clinicians to make a positive diagnosis using the Rome criteria alone. Yet many clinicians are concerned about overlooking alternative diagnoses. We measured beliefs about whether IBS is a diagnosis of exclusion, and measured testing proclivity between IBS experts and community providers.
METHODS: We developed a survey to measure decision-making in two standardized patients with Rome III-positive IBS, including IBS with diarrhea (D-IBS) and IBS with constipation (C-IBS). The survey elicited provider knowledge and beliefs about IBS, including testing proclivity and beliefs regarding IBS as a diagnosis of exclusion. We surveyed nurse practitioners, primary care physicians, community gastroenterologists, and IBS experts.
RESULTS: Experts were less likely than nonexperts to endorse IBS as a diagnosis of exclusion (8 vs. 72%; P < 0.0001). In the D-IBS vignette, experts were more likely to make a positive diagnosis of IBS (67 vs. 38%; P < 0.001), to perform fewer tests (2.0 vs. 4.1; P < 0.01), and to expend less money on testing (US$297 vs. $658; P < 0.01). Providers who believed IBS is a diagnosis of exclusion ordered 1.6 more tests and consumed $364 more than others (P < 0.0001). Experts only rated celiac sprue screening and complete blood count as appropriate in D-IBS; nonexperts rated most tests as appropriate. Parallel results were found in the C-IBS vignette.
CONCLUSIONS: Most community providers believe IBS is a diagnosis of exclusion; this belief is associated with increased resource use. Experts comply more closely with guidelines to diagnose IBS with minimal testing. This disconnect suggests that better implementation of guidelines is warranted to minimize variation and improve cost-effectiveness of care.
C1 [Spiegel, Brennan M. R.; Farid, Mary; Talley, Jennifer; Chang, Lin] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA 90073 USA.
[Spiegel, Brennan M. R.; Farid, Mary; Esrailian, Eric; Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90095 USA.
[Spiegel, Brennan M. R.] CURE Digest Dis Res Ctr, Los Angeles, CA USA.
[Spiegel, Brennan M. R.; Talley, Jennifer; Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Los Angeles, CA 90095 USA.
[Spiegel, Brennan M. R.; Chang, Lin] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA 90095 USA.
RP Spiegel, BMR (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ulca.edu
FU Veteran's Affairs Health Services Research and Development (HSR&D)
Career Development Transition Award [RCD 03-179-2]; NIH [P50 DK64539,
R01 AR46122, GCRC M01-RR00865]; [R24 AT002681]
FX Financial support : Spiegel was supported by a Veteran's Affairs Health
Services Research and Development (HSR&D) Career Development Transition
Award (RCD 03-179-2). Chang was supported by NIH Grants P50 DK64539, R01
AR46122, and GCRC M01-RR00865. Spiegel and Chang were supported by Grant
R24 AT002681.
NR 27
TC 74
Z9 76
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD APR
PY 2010
VL 105
IS 4
BP 848
EP 858
DI 10.1038/ajg.2010.47
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 582FQ
UT WOS:000276582300018
PM 20197761
ER
PT J
AU Weintraub, D
Rosenberg, PB
Drye, LT
Martin, BK
Frangakis, C
Mintzer, JE
Porsteinsson, AP
Schneider, LS
Rabins, PV
Munro, CA
Meinert, CL
Lyketsos, CG
AF Weintraub, Daniel
Rosenberg, Paul B.
Drye, Lea T.
Martin, Barbara K.
Frangakis, Constantine
Mintzer, Jacobo E.
Porsteinsson, Anton P.
Schneider, Lon S.
Rabins, Peter V.
Munro, Cynthia A.
Meinert, Curtis L.
Lyketsos, Constantine G.
CA Diads-2 Res Grp
TI Sertraline for the Treatment of Depression in Alzheimer Disease: Week-24
Outcomes
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Alzheimer disease; depression; sertraline
ID PROVISIONAL DIAGNOSTIC-CRITERIA; DOUBLE-BLIND; COGNITIVE IMPAIRMENT;
CACHE COUNTY; DEMENTIA; PLACEBO; ANTIDEPRESSANTS; EFFICACY; TRIAL;
DISTURBANCES
AB Background: Depression and antidepressant use are common in Alzheimer disease (AD), but the effect of antidepressant treatment for depression on longer term outcomes is unknown. The authors report the Week-24 outcomes of patients who participated in a 12-week efficacy study of sertraline for depression of AD. Methods: One hundred thirty-one participants (sertraline = 67, placebo = 64) with mild-moderate AD and depression participated in the study. Patients who showed improvement on the modified Alzheimer's Disease Cooperative Study Clinical Global Impression-Change (mADCS-CGIC) after 12 weeks of randomized treatment with sertraline or placebo continued double-blinded treatment for an additional 12 weeks. Depression response and remission at 24 weeks were based on mADCS-CGIC score and change in Cornell Scale for Depression in Dementia (CSDD) score. Secondary outcome measures included time to remission, nonmood neuropsychiatric symptoms, global cognition, function, and quality of life. Results: One hundred seventeen (89.3%) participants completed all study assessments and 74 (56.5%; sertraline = 38, placebo = 36) completed all 24 weeks on randomized treatment. By 24 weeks, there were no between-group differences in depression response (sertraline = 44.8%, placebo = 35.9%; odds ratio [95% CI] = 1.23 [0.64-2.35]), change in CSDD score (median difference = 0.6 [95% CI: -2.26 to 3.46], chi(2) [df = 2] = 1.03), remission rates (sertraline = 32.8%, placebo = 21.8%; odds ratio [95% CI] = 1.61 [0.70-3.68]), or secondary outcomes. Common selective serotonin reuptake inhibitor-associated adverse events, specifically diarrhea, dizziness, and dry mouth, and pulmonary serious adverse events were more frequent in sertraline-randomized patients than in placebo subjects. Conclusions: Sertraline treatment is not associated with delayed improvement between 12 and 24 weeks of treatment and may not be indicated for the treatment of depression of AD. (Am J Geriatr Psychiatry 2010; 18:332-340)
C1 [Rosenberg, Paul B.; Lyketsos, Constantine G.] Johns Hopkins Univ, Sch Med, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD 21218 USA.
[Rosenberg, Paul B.; Munro, Cynthia A.; Lyketsos, Constantine G.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21218 USA.
[Lyketsos, Constantine G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
[Martin, Barbara K.; Frangakis, Constantine; Meinert, Curtis L.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Clin Trials, Baltimore, MD USA.
[Munro, Cynthia A.] Johns Hopkins Univ, Sch Med, Div Med Psychol, Baltimore, MD 21218 USA.
[Mintzer, Jacobo E.] Med Univ S Carolina, Dept Neurosci, Div Translat Res, Charleston, SC 29425 USA.
[Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Weintraub, Daniel] Univ Penn, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA.
Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA.
[Porsteinsson, Anton P.] Univ Rochester, Sch Med & Dent, Dept Psychiat, AD CARE Program, Rochester, NY 14627 USA.
[Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Psychiat, Los Angeles, CA 90033 USA.
[Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA.
Univ So Calif, Leonard Davis Sch Gerontol, Los Angeles, CA 90089 USA.
Johns Hopkins Bayview, Baltimore, MD USA.
RP Weintraub, D (reprint author), 3615 Chestnut St,330, Philadelphia, PA 19104 USA.
EM daniel.weintraub@uphs.upenn.edu
OI Drye, Lea/0000-0002-2964-1878
FU NIA NIH HHS [K08 AG029157]; NIMH NIH HHS [1U01MH066177, 1U01MH066175,
U01 MH066136-05, 1U01MH066174, 1U01MH068014, U01 MH066136, 1U01MH066176,
U01 MH066176, 1U01MH066136, U01 MH066175-05, U01 MH066174, U01 MH068014,
U01 MH066177, U01 MH066175]
NR 34
TC 59
Z9 60
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD APR
PY 2010
VL 18
IS 4
BP 332
EP 340
DI 10.1097/JGP.0b013e3181cc0333
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 576RI
UT WOS:000276164700007
PM 20220589
ER
PT J
AU Zavala, J
Ramirez, M
Medina, R
Heard, P
Carter, E
Crandall, AL
Hale, D
Cody, J
Escamilla, M
AF Zavala, Juan
Ramirez, Mercedes
Medina, Rolando
Heard, Patricia
Carter, Erika
Crandall, Ana Lisa
Hale, Daniel
Cody, Jannine
Escamilla, Michael
TI Psychiatric Syndromes in Individuals With Chromosome 18 Abnormalities
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE 18p; 18q; deletions; tetrasomy; psychiatric disorders
ID LINKAGE DISEQUILIBRIUM ANALYSIS; SEVERE BIPOLAR DISORDER; IN-SITU
HYBRIDIZATION; INTERSTITIAL DELETION; MENTAL-RETARDATION; LONG ARM;
MOLECULAR CHARACTERIZATION; 18Q DELETIONS; SPEECH DELAY; FOLLOW-UP
AB Chromosome 18 abnormalities are associated with a range of physical abnormalities such as short stature and hearing impairments. Psychiatric manifestations have also been observed. This study focuses on the presentations of psychiatric syndromes as they relate to specific chromosomal abnormalities of chromosome 18. Twenty-five subjects (13 with an 18q deletion, 9 with 18p tetrasomy, and 3 with an 18p deletion), were interviewed by psychiatrists (blind to specific chromosomal abnormality) using the DIGS (subjects 18 and older) or KSADS-PL (subjects under 18). A consensus best estimation diagnostic process was employed to determine psychiatric syndromes. Oligonucleotide Array Comparative Genomic Hybridization (Agilent Technologies) was utilized to define specific regions of chromosome 18 that were deleted or duplicated. These data were further analyzed to determine critical regions of the chromosome as they relate to phenotypic manifestations in these subjects. 58.3% of the chromosome 18q- deletion subjects had depressive symptoms, 58.3% had anxiety symptoms, 25% had manic symptoms, and 25% had psychotic symptoms. 66.6% of the chromosome 18p- deletion subjects had anxiety symptoms, and none had depressive, manic, or psychotic symptoms. Fifty percent of the chromosome 18p tetrasomy subjects had anxiety symptoms, 12.5% had psychotic symptoms, and 12.5% had a mood disorder. All three chromosomal disorders were associated with high anxiety rates. Psychotic, manic and depressive disorders were seen mostly in 18q- subjects and this may be helpful in narrowing regions for candidate genes for these psychiatric conditions. (C) 2009 Wiley-Liss, Inc.
C1 [Escamilla, Michael] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, S Texas Psychiat Genet Res Ctr, San Antonio, TX 78205 USA.
[Medina, Rolando] S Texas Vet Hlth Care Syst, Audie L Murphy Div, Psychiat Serv, San Antonio, TX USA.
[Heard, Patricia; Carter, Erika; Crandall, Ana Lisa; Hale, Daniel; Cody, Jannine] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA.
[Escamilla, Michael] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Escamilla, Michael] Reg Acad Hlth Ctr, S Texas Med Genet Res Grp, Edinburg, TX USA.
RP Escamilla, M (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, S Texas Psychiat Genet Res Ctr, 454 Soledad,Suite 200, San Antonio, TX 78205 USA.
EM escamillam@uthscsa.edu
NR 59
TC 6
Z9 6
U1 3
U2 6
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1552-4841
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD APR
PY 2010
VL 153B
IS 3
BP 837
EP 845
DI 10.1002/ajmg.b.31047
PG 9
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA 582CX
UT WOS:000276574300014
PM 19927307
ER
PT J
AU Abangan, RS
Williams, CR
Mehrotra, M
Duncan, JD
LaRue, AC
AF Abangan, Romeo S., Jr.
Williams, Christopher R.
Mehrotra, Meenal
Duncan, James D.
LaRue, Amanda C.
TI MCP1 Directs Trafficking of Hematopoietic Stem Cell-Derived Fibroblast
Precursors in Solid Tumor
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID BONE-MARROW; IN-VITRO; FIBROCYTE DIFFERENTIATION; CIRCULATING
FIBROCYTES; MESENCHYMAL PROGENITOR; MONOLAYER CULTURES;
EPITHELIAL-CELLS; BREAST-CANCER; RECEPTOR; ORIGIN
AB Our previous studies have demonstrated that hematopoietic stem cells (HSCs) are a novel source of carcinoma-associated fibroblasts. However, the mechanisms regulating recruitment and homing of HSC-derived carcinoma-associated fibroblasts or their precursors to the tumor microenvironment are unknown. Herein, we demonstrate using a single cell transplantation model that circulating fibroblast precursors (CFPs) are of HSC origin. This population increased with tumor burden in vivo and functional in vitro studies showed that CFPs preferentially migrated and differentiated into fibroblasts in response to tumor, suggesting that HSC-derived CFPs serve as an intermediate between the bone marrow and tumor. Based on this chemotactic ability and our demonstration of a monocyte lineage origin for CFPs, we investigated the role of monocyte chemoattractant protein (MCP1) in mediating CFP recruitment/homing. Blocking tumor-produced MCP1 inhibited in vitro migration of CFPs in response to multiple tumor types, indicating broad biological significance for this CFP/chemokine interaction. In vivo, CCR2-expressing CFPs increased in circulation during the period of active tumor growth and stromal development. Inhibition of MCP1 during tumor development resulted in decreased tumor volume in tumor-bearing mice. Together these findings confirm an HSC origin for CFPs, demonstrate a role for MCP1 in regulating their contribution to the tumor microenvironment, and suggest a potential therapeutic target for limiting tumor growth. (An, J Pathol 2010,176:1914-1924. DOI: 10.2353/ajpath.2010.080839)
C1 [Abangan, Romeo S., Jr.; Williams, Christopher R.; Mehrotra, Meenal; Duncan, James D.; LaRue, Amanda C.] Med Univ S Carolina, Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA.
[Abangan, Romeo S., Jr.; Williams, Christopher R.; Mehrotra, Meenal; Duncan, James D.; LaRue, Amanda C.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Abangan, Romeo S., Jr.] Med Univ S Carolina, Coll Pharm, Charleston, SC 29425 USA.
[LaRue, Amanda C.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
RP LaRue, AC (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA.
EM laruerc@musc.edu
FU Research and Development, Medical Research Services, Department of
Veterans Affairs; American Cancer Society [IRG 97-219-08]
FX Supported by the office of Research and Development, Medical Research
Services, Department of Veterans Affairs to A.C.L. and the American
Cancer Society Institutional Research grant (IRG 97-219-08 to A.C.L.).
NR 47
TC 10
Z9 10
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD APR
PY 2010
VL 176
IS 4
BP 1914
EP 1926
DI 10.2353/ajpath.2010.080839
PG 13
WC Pathology
SC Pathology
GA 580SX
UT WOS:000276471500036
PM 20167869
ER
PT J
AU Recio, AC
Bohart, ZW
Havens, SR
Stiens, SA
AF Recio, Albert C.
Bohart, Zachary W.
Havens, Spencer R.
Stiens, Steven A.
TI Acute Spinal Cord Injury and Infection with Multidrug-Resistant
Acinetobacter calcoaceticus-baumannii Complex Among Returning Operation
Iraqi Freedom Soldiers Successful Innovations in Rehabilitation during
Isolation
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Isolation; Spinal Cord Injury (SCI); Rehabilitation; Acinetobacter
calcoaceticus-baumannii Complex
ID STAPHYLOCOCCUS-AUREUS; CLOSTRIDIUM-DIFFICILE; IMPACT; EPIDEMIOLOGY;
UNIT; SKIN
AB Recio AC, Bohart ZW, Havens SR, Stiens SA: Acute spinal cord injury and infection with multidrug-resistant Acinetobacter calcoaceticus-baumannii complex among returning Operation Iraqi Freedom soldiers: Successful innovations in rehabilitation during isolation. Am J Phys Med Rehabil 2009;89:331-335.
Concerns about drug-resistant infectious organisms are increasing in rehabilitation facilities. Resulting isolation protocols can potentially challenge the patients' access to medical care, psychological adaptation, mobility, and environmental interaction and therefore hinder the rehabilitation process. We report a systematic, retrospective case review of an active-duty Army sergeant who sustained a C5 American Spinal Cord Injury Association Impairment Scale A spinal cord injury while serving in Operation Iraqi Freedom. The patient's acute rehabilitation was complicated by an Acinetobacter calcoaceticus-baumannii complex infection, in the blood and urine, contracted while in Iraq. Isolation protocols were designed to enable regular hands-on contact for proprioceptive neuromuscular facilitation, transfers, wheelchair fitting, mobility training, and environmental control. After 1 mo of comprehensive acute interdisciplinary rehabilitation, delivered in a single room on the spinal cord injury unit, the patient acquired functional skills comparable with other complete C5 tetraplegics in our unit. If a patient with spinal cord injury must be placed in isolation, it is still feasible to conduct a comprehensive interdisciplinary rehabilitation program while strictly adhering to contact isolation protocols.
C1 [Recio, Albert C.] Johns Hopkins Sch Med, Hugo W Moser Res Inst Kennedy Krieger, Int Ctr Spinal Cord Injury, Baltimore, MD USA.
[Bohart, Zachary W.] Tufts Med Ctr, Dept Phys Med & Rehabil, Boston, MA USA.
[Havens, Spencer R.; Stiens, Steven A.] Univ Washington, VA Puget Sound Hlth Care Syst, Spinal Cord Injury Unit, Dept Rehabil Med, Seattle, WA 98195 USA.
RP Recio, AC (reprint author), Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.
NR 16
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD APR
PY 2010
VL 89
IS 4
BP 331
EP 335
DI 10.1097/PHM.0b013e3181c9d847
PG 5
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 584CA
UT WOS:000276726400008
PM 20068440
ER
PT J
AU Satterthwaite, TD
Wolf, DH
Loughead, J
Ruparel, K
Valdez, JN
Siegel, SJ
Kohler, CG
Gur, RE
Gur, RC
AF Satterthwaite, Theodore D.
Wolf, Daniel H.
Loughead, James
Ruparel, Kosha
Valdez, Jeffrey N.
Siegel, Steven J.
Kohler, Christian G.
Gur, Raquel E.
Gur, Ruben C.
TI Association of Enhanced Limbic Response to Threat With Decreased
Cortical Facial Recognition Memory Response in Schizophrenia
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID BRAIN SYSTEMS; EMOTION; ACTIVATION; RETRIEVAL; COGNITION; NETWORK; FMRI;
CONNECTIVITY; EXPRESSIONS; SPECIFICITY
AB Objective: Recognition memory of faces is impaired in patients with schizophrenia, as is the neural processing of threat-related signals, but how these deficits interact to produce symptoms is unclear. The authors used an affective face recognition paradigm to examine possible interactions between cognitive and affective neural systems in schizophrenia.
Method: Blood-oxygen-level-dependent response was examined by means of functional magnetic resonance imaging (3 Tesla) in healthy comparison subjects (N=21) and in patients with schizophrenia (N=12) or schizoaffective disorder, depressed type (N=4), during a two-choice recognition task that used images of human faces. Each target face, previously displayed with a threatening or nonthreatening affect, was displayed with neutral affect. Responses to successful recognition and responses to the effect of previously threatening versus nonthreatening affect were evaluated, and correlations with symptom severity (total Brief Psychiatric Rating Scale score) were examined. Functional connectivity analyses examined the relationship between activation in the amygdala and cortical regions involved in recognition memory.
Results: Patients performed the task more slowly than healthy comparison subjects. Comparison subjects recruited the expected cortical regions to a greater degree than patients, and patients with more severe symptoms demonstrated proportionally less recruitment. Increased symptoms were also correlated with augmented amygdala and orbitofrontal cortex response to threatening faces. Comparison subjects exhibited a negative correlation between activity in the amygdala and cortical regions involved in cognition, while patients showed weakening of this relationship.
Conclusions: Increased symptoms were related to an enhanced threat response in limbic regions and a diminished recognition memory response in cortical regions, supporting a link between these two brain systems that are often examined in isolation. This finding suggests that abnormal processing of threat-related signals in the environment may exacerbate cognitive impairment in schizophrenia.
C1 [Satterthwaite, Theodore D.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Satterthwaite, TD (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3535 Market St,2nd Floor, Philadelphia, PA 19104 USA.
EM Ted.Satterthwaite@uphs.upenn.edu
RI Wolf, Daniel/H-2581-2013
OI Siegel, Steven/0000-0001-8058-9713
FU AstraZeneca; Pfizer; NARSAD; NIMH [MH-19112, MH-060722-09]
FX Dr. Siegel has received grant support from AstraZeneca and is a
consultant for NuPathe. Drs. Raquel Gur and Ruben Gur have received
investigator-initiated grants from Pfizer and AstraZeneca. Drs.
Satterthwaite, Wolf, Loughead, and Kohler and Ms. Ruparel and Mr. Valdez
report no financial relationships with commercial interests.; Supported
by NARSAD (Dr. Wolf) and NIMH grants MH-19112 and MH-060722-09.
NR 40
TC 35
Z9 35
U1 1
U2 4
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD APR
PY 2010
VL 167
IS 4
BP 418
EP 426
DI 10.1176/appi.ajp.2009.09060808
PG 9
WC Psychiatry
SC Psychiatry
GA 577LE
UT WOS:000276223800012
PM 20194482
ER
PT J
AU Calkins, ME
Tepper, P
Gur, RC
Ragland, JD
Klei, L
Wiener, HW
Richard, J
Savage, RM
Allen, TB
O'Jile, J
Devlin, B
Kwentus, J
Aliyu, MH
Bradford, LD
Edwards, N
Lyons, PD
Nimgaonkar, VL
Santos, AB
Go, RCP
Gur, RE
AF Calkins, Monica E.
Tepper, Ping
Gur, Ruben C.
Ragland, J. Daniel
Klei, Lambertus
Wiener, Howard W.
Richard, Jan
Savage, Robert M.
Allen, Trina B.
O'Jile, Judith
Devlin, Bernie
Kwentus, Joseph
Aliyu, Muktar H.
Bradford, L. DiAnne
Edwards, Neil
Lyons, Paul D.
Nimgaonkar, Vishwajit L.
Santos, Alberto B.
Go, Rodney C. P.
Gur, Raquel E.
TI Project Among African-Americans to Explore Risks for Schizophrenia
(PAARTNERS): Evidence for Impairment and Heritability of Neurocognitive
Functioning in Families of Schizophrenia Patients
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID CEREBRAL BLOOD-FLOW; COGNITIVE DEFICITS; WORKING-MEMORY; 1ST-DEGREE
RELATIVES; RECOGNITION MEMORY; BIPOLAR DISORDER; ENDOPHENOTYPES;
PERFORMANCE; GENETICS; GENES
AB Objective: Neurocognitive impairments in schizophrenia are well replicated and widely regarded as candidate endophenotypes that may facilitate understanding of schizophrenia genetics and pathophysiology. The Project Among African-Americans to Explore Risks for Schizophrenia (PAARTNERS) aims to identify genes underlying liability to schizophrenia. The unprecedented size of its study group (N=1,872), made possible through use of a computerized neurocognitive battery, can help further investigation of the genetics of neurocognition. The current analysis evaluated two characteristics not fully addressed in prior research: 1) heritability of neurocognition in African American families and 2) relationship between neurocognition and psychopathology in families of African American probands with schizophrenia or schizoaffective disorder.
Method: Across eight data collection sites, patients with schizophrenia or schizoaffective disorder (N=610), their biological relatives (N=928), and community comparison subjects (N=334) completed a standardized diagnostic evaluation and the computerized neurocognitive battery. Performance accuracy and response time (speed) were measured separately for 10 neurocognitive domains.
Results: The patients with schizophrenia or schizoaffective disorder exhibited less accuracy and speed in most neurocognitive domains than their relatives both with and without other psychiatric disorders, who in turn were more impaired than comparison subjects in most domains. Estimated trait heritability after inclusion of the mean effect of diagnostic status, age, and sex revealed significant heritabilities for most neurocognitive domains, with the highest for accuracy of abstraction/flexibility, verbal memory, face memory, spatial processing, and emotion processing and for speed of attention.
Conclusions: Neurocognitive functions in African American families are heritable and associated with schizophrenia. They show potential for gene-mapping studies.
C1 [Calkins, Monica E.] Univ Penn, Schizophrenia Res Ctr, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
Univ Pittsburgh, Dept Epidemiol, Dept Psychiat, Pittsburgh, PA 15260 USA.
Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15260 USA.
Univ Calif Davis, Dept Psychiat & Behav Sci, Sacramento, CA 95817 USA.
Univ Alabama, Dept Epidemiol & Int Hlth, Birmingham, AL USA.
Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL USA.
Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27706 USA.
Durham VA Med Ctr, Dept Res, Durham, NC USA.
Univ Mississippi, Dept Psychiat & Human Behav, Med Ctr, Jackson, MS USA.
Vanderbilt Univ, Dept Prevent Med, Inst Global Hlth, Nashville, TN USA.
Morehouse Sch Med, Dept Psychiat, Atlanta, GA 30310 USA.
Univ Tennessee, Dept Psychiat, Coll Med, Memphis, TN USA.
Univ Virginia, Dept Neurol, Charlottesville, VA USA.
Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA.
Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Calkins, ME (reprint author), Univ Penn, Schizophrenia Res Ctr, Sch Med, Dept Psychiat, 9 Maloney,3600 Spruce St, Philadelphia, PA 19104 USA.
EM mcalkins@upenn.edu
FU University of Pennsylvania; AstraZeneca; Pfizer; Merck; Lundbeck; NIMH
[MH-66006, MH-66278, MH-066049, MH-66181, MH-66121, MH-066005, MH-66050,
MH-66263, MH-66004, K08-MH-79364]
FX Dr. Ruben Gur receives grant support through collaborations of the
University of Pennsylvania with AstraZeneca, Pfizer, and Merck and may
receive royalties from future commercial use of the Penn Computerized
Neurocognitive Battery. Dr. Ragland may receive royalties from future
commercial use of the Penn Computerized Neurocognitive Battery. Ms.
Richard may receive royalties from future commercial use of Penn
Computerized Neurocognitive Battery. Dr. Nimgaonkar received a research
grant from Lundbeck on an unrelated topic when this article was in
preparation. Dr. Raquel Gur receives grant support through
collaborations of the University of Pennsylvania with AstraZeneca and
Pfizer and may receive royalties from future commercial use of the Penn
Computerized Neurocognitive Battery. The remaining authors report no
financial relationships with commercial interests.; Supported by NIMH
RO1 grants MH-66006, MH-66278, MH-066049, MH-66181, MH-66121, MH-066005,
MH-66050, MH-66263, and MH-66004 and NIMH grant K08-MH-79364.
NR 42
TC 38
Z9 40
U1 1
U2 5
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD APR
PY 2010
VL 167
IS 4
BP 459
EP 472
DI 10.1176/appi.ajp.2009.08091351
PG 14
WC Psychiatry
SC Psychiatry
GA 577LE
UT WOS:000276223800017
PM 20194479
ER
PT J
AU Lucan, SC
Barg, FK
Long, JA
AF Lucan, Sean C.
Barg, Frances K.
Long, Judith A.
TI Promoters and Barriers to Fruit, Vegetable, and Fast-Food Consumption
Among Urban, Low-Income African Americans-A Qualitative Approach
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID UNITED-STATES; DIABETES-MELLITUS; PHYSICAL-ACTIVITY; NUTRITION; HEALTH;
RISK; CHOICES; ADULTS; DIET; US
AB To identify promoters of and barriers to fruit, vegetable, and fast-food consumption, we interviewed low-income African Americans in Philadelphia. Salient promoters and barriers were distinct from each other and differed by food type: taste was a promoter and cost a barrier to all foods; convenience, cravings, and preferences promoted consumption of fast foods; health concerns promoted consumption of fruits and vegetables and avoidance of fast foods. Promoters and barriers differed by gender and age. Strategies for dietary change should consider food type, gender, and age. (Am J Public Health. 2010;100:631-635. doi:10.2105/AJPH.2009.172692)
C1 [Lucan, Sean C.; Barg, Frances K.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
[Barg, Frances K.] Univ Penn, Dept Anthropol, Philadelphia, PA 19104 USA.
[Long, Judith A.] Vet Affairs Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Long, Judith A.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA.
RP Lucan, SC (reprint author), Albert Einstein Coll Med, Dept Family & Social Med, Montefiore Med Ctr, 1300 Morris Pk Ave,Mazer Bldg,4th Floor, Bronx, NY 10461 USA.
EM slucan@yahoo.com
RI Lucan, Sean/B-3815-2009
OI Lucan, Sean/0000-0002-4447-9709
FU Robert Wood Johnson Clinical Scholars Program; Pisacano Leadership
Foundation; National Institutes of Health; Robert Wood,Johnson Clinical
Scholars Program
FX Salary support and it research stipend for this project were provided by
the Robert Wood Johnson Clinical Scholars Program. The Pisacano
Leadership Foundation, the National Institutes of Health Local Repayment
Program for Health Disparities, and the Robert Wood,Johnson Clinical
Scholars Program provided financial support for S.C. Lucan's training.
NR 57
TC 48
Z9 48
U1 3
U2 14
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD APR
PY 2010
VL 100
IS 4
BP 631
EP 635
DI 10.2105/AJPH.2009.172692
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 573TG
UT WOS:000275937200013
PM 20167885
ER
PT J
AU Williams, BA
Baillargeon, JG
Lindquist, K
Walter, LC
Covinsky, KE
Whitson, HE
Steinman, MA
AF Williams, Brie A.
Baillargeon, Jacques G.
Lindquist, Karla
Walter, Louise C.
Covinsky, Kenneth E.
Whitson, Heather E.
Steinman, Michael A.
TI Medication Prescribing Practices for Older Prisoners in the Texas Prison
System
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID QUALITY-OF-CARE; INAPPROPRIATE MEDICATION; HEALTH-CARE; PHARMACOLOGICAL
CARE; DISEASE PROFILE; CRITERIA; INMATES; ADULTS
AB Objectives. We sought to assess appropriateness of medication prescribing for older Texas prisoners.
Methods. In this 12-month cross-sectional study of 13117 prisoners (aged >= 55 years), we assessed medication use with Zhan criteria and compared our results to prior studies of community prescribing. We assessed use of indicated medications with 6 Assessing Care of Vulnerable Elders indicators.
Results. Inappropriate medications were prescribed to a third of older prisoners; half of inappropriate use was attributable to over-the-counter antihistamines. When these antihistamines were excluded, inappropriate use dropped to 14% (>= 55 years) and 17% (>= 65 years), equivalent to rates in a Department of Veterans Affairs study (17%) and lower than rates in a health maintenance organization study (26%). Median rate of indicated medication use for the 6 indicators was 80% (range=12%-95%); gastrointestinal prophylaxis for patients on nonsteroidal anti-inflammatories at high risk for gastrointestinal bleed constituted the lowest rate.
Conclusions. Medication prescribing for older prisoners in Texas was similar to that for older community adults. However, overuse of antihistamines and underuse of gastrointestinal prophylaxis suggests a need for education of prison health care providers in appropriate prescribing practices for older adults. (Am J Public Health. 2010;100:756-761. doi:10.2105/AJPH.2008.154591)
C1 [Williams, Brie A.; Lindquist, Karla; Walter, Louise C.; Covinsky, Kenneth E.; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94121 USA.
[Williams, Brie A.; Walter, Louise C.; Covinsky, Kenneth E.; Steinman, Michael A.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA USA.
[Baillargeon, Jacques G.] Univ Texas Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77550 USA.
[Baillargeon, Jacques G.] Univ Texas Med Branch, Div Epidemiol, Galveston, TX 77550 USA.
[Whitson, Heather E.] Duke Univ, Dept Med, Div Geriatr, Durham, NC USA.
RP Williams, BA (reprint author), Univ Calif San Francisco, Div Geriatr, Dept Med, 4150 Clement St Box 181-G, San Francisco, CA 94121 USA.
EM brie.williams@ucsf.edu
FU Hartford Outcomes Research Scholars Award; Hellman Family Award;
Brookdale Leadership in Aging Fellowship; Veterans Affairs Health
Services Research and Development service [CDTA 01-013]; National
Institute on Aging; American Federation for Aging Research [K23
AG030999]
FX B.A. Williams was supported in part by the Hartford Outcomes Research
Scholars Award, the Hellman Family Award, and the Brookdale Leadership
in Aging Fellowship. M.A. Steinman was supported by grants from the
Veterans Affairs Health Services Research and Development service (CDTA
01-013) and the National Institute on Aging and the American Federation
for Aging Research (K23 AG030999).; We thank Leonard Pechacek for
providing copyediting support, Stephanie Zepeda for her knowledge of the
pharmacy system in the Texas Department of Criminal justice, and Neil
Nusbaum for his helpful insights.; The research described herein was
coordinated in part by the Texas Department of Criminal justice research
agreement (515-MR07).
NR 36
TC 11
Z9 11
U1 0
U2 4
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD APR
PY 2010
VL 100
IS 4
BP 756
EP 761
DI 10.2105/AJPH.2008.154591
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 573TG
UT WOS:000275937200031
PM 19762661
ER
PT J
AU Hsu, DJ
Stone, RA
Obrosky, DS
Yealy, DM
Meehan, TP
Fine, JM
Graff, LG
Fine, MJ
AF Hsu, Douglas J.
Stone, Roslyn A.
Obrosky, D. Scott
Yealy, Donald M.
Meehan, Thomas P.
Fine, Jonathan M.
Graff, Louis G.
Fine, Michael J.
TI Predictors of Timely Antibiotic Administration for Patients Hospitalized
With Community-Acquired Pneumonia From the Cluster-Randomized EDCAP
Trial
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE Pneumonia; Quality of care; Process of care
ID RESPIRATORY-TRACT INFECTIONS; ELDERLY PATIENTS; OF-CARE; QUALITY;
OUTCOMES; IMPROVE; INTERVENTION; GUIDELINES; MANAGEMENT; DELIVERY
AB Introduction: To identify factors associated with timely initiation of antibiotic therapy for patients hospitalized with pneumonia. Design: Secondary analysis of a cluster-randomized, controlled trial. Setting: Thirty-two emergency departments (EDs) in Pennsylvania and Connecticut. Subjects: Patients with a clinical and radiographic diagnosis of community-acquired pneumonia. Interventions: From January to December 2001, EDs were randomly allocated to guideline implementation strategies of low (n = 8), moderate (n = 12), and high intensity (n = 12) to improve the initial site of treatment and the performance of evidence-based processes of care. Our primary outcome was antibiotic initiation within 4 hours of presentation, which at that time was the recommended process of care for inpatients. Results: Of the 2076 inpatients enrolled, 1632 (78.6%) received antibiotic therapy within 4 hours of presentation. Antibiotic timeliness ranged from 55.6% to 100% (P < 0.001) by ED and from 77.0% to 79.7% (P = 0.2) across the 3 guideline implementation arms. In multivariable analysis, heart rate >= 125 per minute (OR = 1.6, 95% CI 1.1-2.3), respiratory rate >= 30 per minute (OR = 2.3, 95% CI 1.6-3.4), and aspiration pneumonia (OR = 3.7, 95% CI 1.1-12.7) were positively associated with timely initiation of antibiotic therapy, whereas a hematocrit <30% (OR = 0.6, 95% CI 0.4-1.0) was negatively associated with this outcome. Conclusions: Timely initiation of antibiotic therapy is associated primarily with patient-related factors that reflect severity of illness at presentation. Although this study demonstrates an opportunity to improve performance on this quality measure in nearly one quarter of inpatients with pneumonia, we failed to identify any modifiable patient, provider, or hospital level factors to target in such quality improvement efforts.
C1 [Hsu, Douglas J.; Stone, Roslyn A.; Obrosky, D. Scott; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Hsu, Douglas J.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Hsu, Douglas J.] Harvard Univ, Sch Med, Boston, MA USA.
[Meehan, Thomas P.] Qualidigm, Middletown, CT USA.
[Fine, Jonathan M.] Norwalk Hosp, Norwalk, CT 06856 USA.
[Graff, Louis G.] New Britain Gen Hosp, Dept Emergency Med, New Britain, CT USA.
[Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
[Yealy, Donald M.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15261 USA.
[Obrosky, D. Scott; Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA 15261 USA.
[Stone, Roslyn A.] Univ Pittsburgh, Ctr Res Hlth Care, Dept Med, Pittsburgh, PA 15261 USA.
RP Fine, MJ (reprint author), Vet Adm Pittsburgh Healthcare Syst 151 CH, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,Room 4059E, Pittsburgh, PA 15206 USA.
EM Michael.Fine@va.gov
FU Agency for Healthcare Research and Quality [RO1 HS10049]; National
Institute for Allergy and Infectious Diseases [K24 AI001769]
FX This study was supported by the Agency for Healthcare Research and
Quality grant RO1 HS10049 and in part by a career developmental award
from the National Institute for Allergy and Infectious Diseases grant
K24 AI001769 (to MJF).
NR 28
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-9629
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD APR
PY 2010
VL 339
IS 4
BP 307
EP 313
DI 10.1097/MAJ.0b013e3181d3cd63
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 582WA
UT WOS:000276629600002
PM 20224313
ER
PT J
AU Cadena, J
Thompson, GR
Patterson, JE
Nakashima, B
Owens, A
Echevarria, K
Mortensen, EM
AF Cadena, Jose
Thompson, George R., III
Patterson, Jan E.
Nakashima, Brandy
Owens, Aaron
Echevarria, Kelly
Mortensen, Eric M.
TI Clinical Predictors and Risk Factors for Relapsing Clostridium difficile
Infection
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE Relapse; Clostridium difficile; Antibiotic-associated diarrhea; CDI;
Mortality
ID PROTON-PUMP INHIBITORS; FLUOROQUINOLONE USE; DIARRHEA; DISEASE;
EPIDEMIC; COLITIS; QUEBEC; ASSOCIATION; STRAIN; VALIDATION
AB Background: Clostridium difficile infection (CDI) is a common cause of morbidity among hospitalized patients. Multiple factors have been associated with primary CDI, but risk factors for CDI relapses are less well described. Methods: This was a retrospective cohort study of patients with CDI over a 15-month period. We compared patients with relapsing and nonrelapsing CDI, including risk factors associated with primary CDI and other variables hypothesized to be associated with relapsing CDI and 90-day mortality. Multivariable logistic regression models were created to examine risk factors for relapse and 90-day mortality. Results: One hundred twenty-nine consecutive patients with CDI were included; 38 (29%) had relapsing CDI. Factors associated with relapsing CDI included fluoroquinolone use (71% versus 49%, P = 0.04) and incidence of stroke (29% versus 12%, P = 0.02). In a regression model, use of a fluoroquinolone was associated with relapsing CDI (OR = 2.52, 95% CI = 1.11-5.72). Factors associated with 90-day mortality included higher Charlson comorbidity index score (4.34 +/- 1.71 versus 3.42 +/- 2.08, P = 0.02), severe CDI (58% versus 32%, P = 0.01), and the use of piperacillin/tazobactam (45% versus 23%, P = 0.03) or meropenem (10% versus 1%, P = 0.04). In the regression analysis, 90-day mortality was associated with severe CDI (OR = 1.76; 95% CI = 1.19-2.59). Conclusion: Fluoroquinolone use and prior stroke are associated with an increased risk of relapsing CDI. Relapsing CDI and severe CDI are both associated with increased 90-day mortality.
C1 [Cadena, Jose; Thompson, George R., III; Patterson, Jan E.; Nakashima, Brandy; Echevarria, Kelly; Mortensen, Eric M.] S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78229 USA.
[Echevarria, Kelly] S Texas Vet Hlth Care Syst, Dept Pharm, San Antonio, TX 78229 USA.
[Nakashima, Brandy; Mortensen, Eric M.] S Texas Vet Hlth Care Syst, VERDICT Res Unit, San Antonio, TX 78229 USA.
[Cadena, Jose; Thompson, George R., III; Patterson, Jan E.; Owens, Aaron] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA.
[Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Div Gen Internal Med, San Antonio, TX 78229 USA.
[Owens, Aaron] Univ Texas Hlth Sci Ctr San Antonio, Hosp Med, San Antonio, TX 78229 USA.
[Echevarria, Kelly] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Resource Ctr, San Antonio, TX 78229 USA.
RP Cadena, J (reprint author), S Texas Vet Hlth Care Syst, Dept Med, MC 7881,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM josecadenaz@yahoo.com
OI Mortensen, Eric/0000-0002-3880-5563
NR 34
TC 24
Z9 26
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-9629
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD APR
PY 2010
VL 339
IS 4
BP 350
EP 355
DI 10.1097/MAJ.0b013e3181d3cdaa
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 582WA
UT WOS:000276629600009
PM 20224312
ER
PT J
AU Myaskovsky, L
McNulty, M
Dew, MA
Kormos, RL
AF Myaskovsky, Larissa
McNulty, Mary
Dew, Mary Amanda
Kormos, Robert L.
TI Predictors of Quality of Life in Caregivers to Cardiothoracic Transplant
Recipients.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 10th American Transplant Congress
CY MAY 01-05, 2010
CL San Diego, CA
SP Amer Soc Transplantat
C1 [Myaskovsky, Larissa; McNulty, Mary; Dew, Mary Amanda; Kormos, Robert L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2010
VL 10
SU 4
SI SI
BP 204
EP 204
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 573NX
UT WOS:000275921701564
ER
PT J
AU Myaskovsky, L
Almario, D
Dew, MA
Switzer, GE
Unruh, M
Ramkumar, M
Shapiro, R
AF Myaskovsky, Larissa
Almario, Donna
Dew, Mary Amanda
Switzer, Galen E.
Unruh, Mark
Ramkumar, Mohan
Shapiro, Ron
TI Racial Disparities in Kidney Transplant: Beyond Medical Factors.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 10th American Transplant Congress
CY MAY 01-05, 2010
CL San Diego, CA
SP Amer Soc Transplantat
C1 [Myaskovsky, Larissa; Almario, Donna; Switzer, Galen E.; Ramkumar, Mohan] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Myaskovsky, Larissa; Dew, Mary Amanda; Switzer, Galen E.; Unruh, Mark; Shapiro, Ron] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Almario, Donna] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2010
VL 10
SU 4
SI SI
BP 282
EP 282
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 573NX
UT WOS:000275921702253
ER
PT J
AU Cacciarelli, TV
Sun, HY
Singh, N
AF Cacciarelli, Thomas V.
Sun, H. Y.
Singh, Nina
TI Human Aging and Its Impact on Infections and Infectious Outcomes after
Orthotopic Liver Transplantation (OLTx).
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 10th American Transplant Congress
CY MAY 01-05, 2010
CL San Diego, CA
SP Amer Soc Transplantat
C1 [Cacciarelli, Thomas V.; Sun, H. Y.; Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Cacciarelli, Thomas V.; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA.
[Sun, H. Y.] NTUH, Taipei, Taiwan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2010
VL 10
SU 4
SI SI
BP 426
EP 426
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 573NX
UT WOS:000275921703045
ER
PT J
AU Myaskovsky, L
Dew, MA
Crowley-Matoka, M
Unruh, M
Dabbs, AD
Shapiro, R
Tan, H
AF Myaskovsky, Larissa
Dew, Mary Amanda
Crowley-Matoka, Megan
Unruh, Mark
Dabbs, Annette DeVito
Shapiro, Ron
Tan, Henkie
TI Is Donating a Kidney Associated with Changes in Health Habits?
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT 10th American Transplant Congress
CY MAY 01-05, 2010
CL San Diego, CA
SP Amer Soc Transplantat
C1 [Myaskovsky, Larissa; Dew, Mary Amanda; Crowley-Matoka, Megan; Unruh, Mark; Dabbs, Annette DeVito; Shapiro, Ron; Tan, Henkie] Univ Pittsburgh, Pittsburgh, PA USA.
[Myaskovsky, Larissa; Crowley-Matoka, Megan] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2010
VL 10
SU 4
SI SI
BP 536
EP 536
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 573NX
UT WOS:000275921703445
ER
PT J
AU Knight, SJ
Studts, JL
Latini, DM
Sands, LP
AF Knight, Sara J.
Studts, Jamie L.
Latini, David M.
Sands, Laura P.
TI UNDERSTANDING PATIENT PREFERENCES FOR PREVENTION AND TREATMENT
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Knight, Sara J.] San Francisco VA Med Ctr, Program Improve Care Vet Complex Comorbid Condit, San Francisco, CA 94121 USA.
[Knight, Sara J.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Studts, Jamie L.] Univ Kentucky, Coll Med, Dept Behav Sci, Lexington, KY 40536 USA.
[Latini, David M.] Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA.
[Latini, David M.] Baylor Coll Med, Houston, TX 77030 USA.
[Sands, Laura P.] Purdue Univ, Sch Nursing, W Lafayette, IN 47907 USA.
EM sara.knight@ucsf.edu
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2010
VL 39
SU 1
BP 2
EP 2
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 572OF
UT WOS:000275841700005
ER
PT J
AU Zeliadt, S
Penson, DF
Moinpour, AM
Blough, DK
Fedorenko, CR
Hall, IJ
Smith, JL
Ekwueme, D
Thompson, IM
Keane, TE
Ramsey, SD
AF Zeliadt, Steven
Penson, David F.
Moinpour, Arol M.
Blough, David K.
Fedorenko, Catherine R.
Hall, Ingrid J.
Smith, Judith Lee
Ekwueme, Donatus
Thompson, Ian M.
Keane, Thomas E.
Ramsey, Scott D.
TI PROVIDER INTERACTIONS WITH PARTNERS OF MEN NEWLY DIAGNOSED WITH PROSTATE
CANCER
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Zeliadt, Steven] VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA.
[Zeliadt, Steven; Penson, David F.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Moinpour, Arol M.; Fedorenko, Catherine R.; Ramsey, Scott D.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Blough, David K.] Univ Washington, Seattle, WA 98195 USA.
[Hall, Ingrid J.; Smith, Judith Lee; Ekwueme, Donatus] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Thompson, Ian M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Keane, Thomas E.] Med Univ S Carolina, Charleston, SC 29425 USA.
EM szeliadt@u.washington.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2010
VL 39
SU 1
BP 5
EP 5
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 572OF
UT WOS:000275841700017
ER
PT J
AU Myaskovsky, L
McNulty, M
Kormos, R
Dew, MA
AF Myaskovsky, Larissa
McNulty, Mary
Kormos, Robert
Dew, Mary Amanda
TI PREDICTORS OF QUALITY OF LIFE IN CAREGIVERS TO CARDIOTHORACIC TRANSPLANT
RECIPIENTS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Myaskovsky, Larissa; McNulty, Mary; Kormos, Robert; Dew, Mary Amanda] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15206 USA.
[Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
EM larissa.myaskovsky@va.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2010
VL 39
SU 1
BP 39
EP 39
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 572OF
UT WOS:000275841700152
ER
PT J
AU Littman, AJ
McDonell, M
Boyko, EJ
Fihn, SD
AF Littman, Alyson J.
McDonell, M.
Boyko, E. J.
Fihn, S. D.
TI IMPLEMENTATION OF A VA WEIGHT MANAGEMENT PROGRAM: WHO ENROLLS AND IS
THERE A BENEFIT?
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Littman, Alyson J.] Univ Washington, Seattle, WA 98101 USA.
[Littman, Alyson J.; McDonell, M.; Boyko, E. J.; Fihn, S. D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2010
VL 39
SU 1
BP 59
EP 59
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 572OF
UT WOS:000275841700226
ER
PT J
AU Littman, AJ
Forsberg, CW
Yancy, WS
Boyko, EJ
Koepsell, TD
AF Littman, Alyson J.
Forsberg, C. W.
Yancy, W. S.
Boyko, E. J.
Koepsell, T. D.
TI DO OBESE INDIVIDUALS GET LESS PREVENTIVE CARE?
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Littman, Alyson J.; Koepsell, T. D.] Univ Washington, Seattle, WA 98101 USA.
[Littman, Alyson J.; Forsberg, C. W.; Boyko, E. J.; Koepsell, T. D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Yancy, W. S.] Ctr Hlth Serv Res Primary Care, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2010
VL 39
SU 1
BP 89
EP 89
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 572OF
UT WOS:000275841700345
ER
PT J
AU Rees, C
Karter, AJ
Young, BA
Schillinger, D
Adler, N
AF Rees, Courtney
Karter, Andrew J.
Young, Bessie A.
Schillinger, Dean
Adler, Nancy
TI PREDICTORS OF SELF-REPORTED DISCRIMINATION IN THE DIABETES STUDY OF
NORTHERN CALIFORNIA
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Rees, Courtney; Karter, Andrew J.; Young, Bessie A.] Univ Washington, Seattle, WA 98195 USA.
[Karter, Andrew J.] Kaiser Permanente No Calif, Oakland, CA USA.
[Young, Bessie A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Schillinger, Dean; Adler, Nancy] UCSF, San Francisco, CA USA.
EM crees@u.washington.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2010
VL 39
SU 1
BP 137
EP 137
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 572OF
UT WOS:000275841700529
ER
PT J
AU Straits-Troster, K
Acheson, S
Beckham, J
Calhoun, P
Gierisch, JM
Hamlett-Berry, K
AF Straits-Troster, Kristy
Acheson, Shawn
Beckham, Jean
Calhoun, Patrick
Gierisch, Jennifer M.
Hamlett-Berry, Kim
TI TOBACCO USE AND CESSATION AMONG RETURNING COMBAT VETERANS: A MIXED
METHODS STUDY
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Straits-Troster, Kristy; Acheson, Shawn; Beckham, Jean; Calhoun, Patrick; Gierisch, Jennifer M.] Duke Univ, Durham, NC 27705 USA.
[Calhoun, Patrick; Gierisch, Jennifer M.] US Dept Vet Affairs, HSR&D, Durham, NC USA.
[Hamlett-Berry, Kim] US Dept Vet Affairs, Off Publ Hlth & Prevent, Durham, NC USA.
EM kristy.straits-troster2@va.gov
NR 0
TC 0
Z9 0
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2010
VL 39
SU 1
BP 158
EP 158
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 572OF
UT WOS:000275841700616
ER
PT J
AU Myaskovsky, L
Almario, D
Dew, MA
Switzer, G
Unruh, M
Ramkumar, M
Shapiro, R
AF Myaskovsky, Larissa
Almario, Donna
Dew, Mary Amanda
Switzer, Galen
Unruh, Mark
Ramkumar, Mohan
Shapiro, Ron
TI RACIAL DISPARITIES IN KIDNEY TRANSPLANT: BEYOND MEDICAL FACTORS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Myaskovsky, Larissa; Almario, Donna; Dew, Mary Amanda; Switzer, Galen; Unruh, Mark; Ramkumar, Mohan; Shapiro, Ron] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15206 USA.
[Myaskovsky, Larissa; Almario, Donna; Switzer, Galen; Ramkumar, Mohan] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
EM larissa.myaskovsky@va.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2010
VL 39
SU 1
BP 161
EP 161
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 572OF
UT WOS:000275841700628
ER
PT J
AU Cadmus, L
McTiernan, A
Ceballos, R
McGregor, B
Ramaprasad, J
Ulrich, C
Littman, A
AF Cadmus, Lisa
McTiernan, Anne
Ceballos, Rachael
McGregor, Bonnie
Ramaprasad, Jaya
Ulrich, Cornelia
Littman, Alyson
TI PREDICTORS OF ADHERENCE TO A SIX-MONTH YOGA INTERVENTION AMONG BREAST
CANCER SURVIVORS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Cadmus, Lisa] UCSD Moores Canc Ctr, San Diego, CA 92102 USA.
[McTiernan, Anne; Ceballos, Rachael; McGregor, Bonnie; Ulrich, Cornelia] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Ramaprasad, Jaya; Littman, Alyson] Univ Washington, Seattle, WA 98195 USA.
[Littman, Alyson] US Dept Vet Affairs, Seattle, WA USA.
EM lcadmus@ucsd.edu
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2010
VL 39
SU 1
BP 168
EP 168
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 572OF
UT WOS:000275841700652
ER
PT J
AU Preczewski, PJ
Bossarte, RM
He, H
Tu, X
AF Preczewski, Paul J.
Bossarte, Robert M.
He, Hua
Tu, Xin
TI BINGE DRINKING FREQUENCY PREDICTED BY VETERAN STATUS AND THE INTERACTIVE
RELATIONSHIP BETWEEN HISPANIC ETHNICITY AND VETERAN STATUS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Preczewski, Paul J.] Syracuse Univ, Syracuse, NY 13244 USA.
[Preczewski, Paul J.; Bossarte, Robert M.; He, Hua; Tu, Xin] US Dept Vet Affairs, Ctr Excellence, VMAC, Canandaigua, NY USA.
[Bossarte, Robert M.; He, Hua; Tu, Xin] Univ Rochester, Rochester, NY USA.
EM pjprecze@syr.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2010
VL 39
SU 1
BP 213
EP 213
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 572OF
UT WOS:000275841700831
ER
PT J
AU Martinez, R
Fierro, CA
Shireman, PK
Han, HC
AF Martinez, Ricky
Fierro, Cesar A.
Shireman, Paula K.
Han, Hai-Chao
TI Mechanical Buckling of Veins Under Internal Pressure
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE Critical buckling pressure; Mechanical stability; Tortuosity; Porcine
jugular veins
ID VARICOSE-VEINS; ELDERLY POPULATION; HYPERTENSION; TORTUOSITY; GRAFTS;
PREVALENCE; DISEASE; ABNORMALITIES; LEUKOARAIOSIS; ADAPTATION
AB Venous tortuosity is associated with multiple disease states and is often thought to be a consequence of venous hypertension and chronic venous disease. However, the underlying mechanisms of vein tortuosity are unclear. We hypothesized that increased pressure causes vein buckling that leads to a tortuous appearance. The specific aim of this study was to determine the critical buckling pressure of veins. We determined the buckling pressure of porcine jugular veins and measured the mechanical properties of these veins. Our results showed that the veins buckle when the transmural pressure exceeds a critical pressure that is strongly related to the axial stretch ratio in the veins. The critical pressures of the eight veins tested were 14.2 +/- A 5.4 and 26.4 +/- A 9.0 mmHg at axial stretch ratio 1.5 and 1.7, respectively. In conclusion, veins buckle into a tortuous shape at high lumen pressures or reduced axial stretch ratios. Our results are useful in understanding the development of venous tortuosity associated with varicose veins, venous valvular insufficiency, diabetic retinopathy, and vein grafts.
C1 [Martinez, Ricky; Fierro, Cesar A.; Han, Hai-Chao] Univ Texas San Antonio, Dept Mech Engn, San Antonio, TX 78249 USA.
[Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA.
[Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Shireman, Paula K.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Han, HC (reprint author), Univ Texas San Antonio, Dept Mech Engn, San Antonio, TX 78249 USA.
EM haichao.han@utsa.edu
RI Han, Hai-Chao/B-5003-2012
FU CAREER [0646646]; National Science Foundation [0602834]; Veterans
Administration; National Institute of Health [HL074236, HL095852]
FX This work was supported by a CAREER award # 0646646 and a REU supplement
from the National Science Foundation. It was also partially supported by
research grants from NSF (0602834), the Veterans Administration, and the
National Institute of Health (HL074236& HL095852). Wethank Dr. Yong-Ung
Lee and Miss Danika Hayman for their help in this study.
NR 44
TC 23
Z9 23
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0090-6964
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD APR
PY 2010
VL 38
IS 4
BP 1345
EP 1353
DI 10.1007/s10439-010-9929-1
PG 9
WC Engineering, Biomedical
SC Engineering
GA 575DL
UT WOS:000276046600007
PM 20094913
ER
PT J
AU Bilimoria, KY
Bentrem, DJ
Talamonti, MS
Stewart, AK
Winchester, DP
Ko, CY
AF Bilimoria, Karl Y.
Bentrem, David J.
Talamonti, Mark S.
Stewart, Andrew K.
Winchester, David P.
Ko, Clifford Y.
TI Risk-based Selective Referral for Cancer Surgery A Potential Strategy to
Improve Perioperative Outcomes
SO ANNALS OF SURGERY
LA English
DT Article
ID HIGH-VOLUME HOSPITALS; LONG-TERM SURVIVAL; UNITED-STATES; SURGICAL
OUTCOMES; OPERATIVE MORTALITY; HEALTH-CARE; QUALITY; REGIONALIZATION;
EXPERIENCE; COMORBIDITY
AB Background: Studies have demonstrated volume-outcome relationships for numerous operations, providing an impetus for regionalization; however, volume-based regionalization may not be feasible or necessary. Our objective was to determine if low-risk patients undergoing surgery at Community Hospitals have perioperative mortality rates comparable with Specialized Centers.
Methods: From the National Cancer Data Base, 940,718 patients from similar to 1430 hospitals were identified who underwent resection for 1 of 15 cancers (2003-2005). Patients were stratified by preoperative risk according to age and comorbidities. Separately for each cancer, regression modeling stratified by high-and low-risk groups was used to compare 60-day mortality at Specialized Centers (National Cancer Institute-designated and/or highest-volume quintile institutions), Other Academic Institutions (lower-volume, non-National Cancer Institute), and Community Hospitals.
Results: Low-risk patients had statistically similar perioperative mortality rates at Specialized Centers and Community Hospitals for 13 of 15 operations. High-risk patients had significantly lower perioperative mortality rates at Specialized Centers compared with Community Hospitals for 9 of 15 cancers. Regardless of risk group, perioperative mortality rates were significantly lower for pancreatectomy and esophagectomy at Specialized Centers. Risk-based referral compared with volume-based regionalization of most patients would require fewer patients to change to Specialized Centers.
Conclusions: Perioperative mortality for low-risk patients was comparable at Specialized Centers and Community Hospitals for all cancers except esophageal and pancreatic, thus questioning volume-based regionalization of all patients. Rather, only high-risk patients may need to change hospitals. Mortality rates could be reduced if factors at Specialized Centers resulting in better outcomes for high-risk patients can be identified and transferred to other hospitals.
C1 [Bilimoria, Karl Y.; Stewart, Andrew K.; Winchester, David P.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, Chicago, IL 60611 USA.
[Bilimoria, Karl Y.; Bentrem, David J.; Winchester, David P.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
[Talamonti, Mark S.; Winchester, David P.] NorthShore Univ Hlth Syst, Dept Surg, Evanston, IL USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Bilimoria, KY (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, Canc Programs, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA.
EM kbilimoria@facs.org
FU Northwestern University (KYB); American Cancer Society
FX Supported by the American College of Surgeons Clinical Scholars in
Residence Program and a Priority Grant from Northwestern University
(KYB). The NCDB is supported by the American College of Surgeons,
Commission on Cancer, and the American Cancer Society.
NR 51
TC 27
Z9 27
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-4932
J9 ANN SURG
JI Ann. Surg.
PD APR
PY 2010
VL 251
IS 4
BP 708
EP 716
DI 10.1097/SLA.0b013e3181c1bea2
PG 9
WC Surgery
SC Surgery
GA 580QS
UT WOS:000276464900020
PM 19898231
ER
PT J
AU Singhal, S
Ferraris, VA
Bridges, CR
Clough, ER
Mitchell, JD
Fernando, HC
Shrager, JB
AF Singhal, Sunil
Ferraris, Victor A.
Bridges, Charles R.
Clough, Ellen R.
Mitchell, John D.
Fernando, Hiran C.
Shrager, Joseph B.
TI Management of Alveolar Air Leaks After Pulmonary Resection
SO ANNALS OF THORACIC SURGERY
LA English
DT Review
ID AUTOLOGOUS BLOOD PATCH; CHEST TUBE MANAGEMENT; LUNG RESECTION; WATER
SEAL; SPONTANEOUS PNEUMOTHORAX; BRONCHOPLEURAL FISTULA; REDUCTION
SURGERY; RANDOMIZED-TRIAL; SPACE PROBLEMS; RISK-FACTORS
AB Air leaks are a common problem after pulmonary resection and can be a source of significant morbidity and mortality. Air leaks are associated with prolonged hospital stays, and infectious and cardiopulmonary complications, and they occasionally require reoperation. Despite reasonably robust literature on the topic, the optimal approaches to manage postoperative air leaks remain controversial. We used available literature and expert consensus to formulate suggestions regarding the preferred approaches to both routine and prolonged alveolar air leaks. This review summarizes our findings. (Ann Thorac Surg 2010;89:1327-35) (C) 2010 by The Society of Thoracic Surgeons
C1 Univ Penn, Sch Med, Div Thorac Surg, Philadelphia, PA 19104 USA.
Univ Penn, Sch Med, Div Cardiovasc Surg, Philadelphia, PA 19104 USA.
Univ Kentucky, Albert B Chandler Med Ctr, Div Cardiovasc & Thorac Surg, Lexington, KY 40536 USA.
Soc Thorac Surg, Chicago, IL USA.
Univ Colorado, Sch Med, Dept Surg, Div Cardiothorac Surg, Denver, CO USA.
Boston Med Ctr, Dept Cardiothorac Surg, Boston, MA USA.
Boston Univ, Sch Med, Boston, MA 02118 USA.
Stanford Univ, Sch Med, Dept Cardiothorac Surg, Div Thorac Surg, Stanford, CA 94305 USA.
Palo Alto Vet Affairs Hlth Care Syst, Palo Alto, CA USA.
Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Shrager, JB (reprint author), Falk Bldg,2nd Fl,300 Pasteur Dr, Stanford, CA 94305 USA.
EM shrager@stanford.edu
OI Fernando, Hiran/0000-0002-5330-7036
NR 65
TC 22
Z9 23
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD APR
PY 2010
VL 89
IS 4
BP 1327
EP 1335
DI 10.1016/j.athoracsur.2009.09.020
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 573CK
UT WOS:000275885800068
PM 20338378
ER
PT J
AU Asgari, MM
Chren, MM
Warton, EM
Friedman, GD
White, E
AF Asgari, Maryam M.
Chren, Mary-Margaret
Warton, E. Margaret
Friedman, Gary D.
White, Emily
TI Association Between Nonsteroidal Anti-inflammatory Drug Use and
Cutaneous Squamous Cell Carcinoma
SO ARCHIVES OF DERMATOLOGY
LA English
DT Article
ID NONMELANOMA SKIN-CANCER; HAIRLESS MICE; CYCLOOXYGENASE-2 INHIBITOR;
COLORECTAL ADENOMAS; LIFE-STYLE; COHORT; RISK; PHOTOCARCINOGENESIS;
INDOMETHACIN; METAANALYSIS
AB Objective: To examine the association between nonsteroidal anti-inflammatory drug (NSAID) use and cutaneous squamous cell carcinoma (SCC).
Design: Retrospective case-control study.
Setting: Kaiser Permanente Northern California(KPNC), a large population based-health maintenance organization.
Patients: Random sample of 415 KPNC members diagnosed as having a pathologically verified SCC in 2004 and 415 age-, sex-, and race-matched controls with no history of skin cancer.
Main Exposure Measure: Self-reported NSAID use in the 10 years prior to baseline. Use of NSAIDs was categorized based on type (any NSAIDs, aspirin, ibuprofen, and nonaspirin NSAIDs). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression to estimate the association of SCC with regular use, dose, and duration of exposure to the different NSAID types. Information on pharmacy-dispensed NSAIDs was also examined to assess its association with SCC risk. Models were adjusted for all ascertained SCC risk factors (fully adjusted model) and only those variables associated with both SCC risk and NSAID use (parsimonious model).
Results: Fully adjusted analyses showed no statistically significant reduction in SCC risk with self-reported regular use of any NSAID (OR, 1.32; 95% CI, 0.92-1.89), aspirin (OR, 1.38; 95% CI, 0.96-1.97), ibuprofen (OR, 0.74; 95% CI, 0.46-1.19), or nonaspirin NSAIDs (OR, 0.84; 95% CI, 0.56-1.26). Analyses examining duration, dose, and variables combining duration and dose of NSAID exposure did not appreciably change results. An analysis using the parsimonious model showed similar results. The data on pharmacy-dispensed NSAIDs also showed no association with SCC risk.
Conclusion: Neither self-reported nor pharmacy-dispensed NSAID exposure was associated with cutaneous SCC risk. Arch Dermatol. 2010; 146(4): 388-395
C1 [Asgari, Maryam M.; Warton, E. Margaret; Friedman, Gary D.] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA.
[Asgari, Maryam M.; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Friedman, Gary D.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA.
[White, Emily] Univ Washington, Dept Epidemiol, Med Ctr, Seattle, WA 98195 USA.
[White, Emily] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA.
[Chren, Mary-Margaret] San Francisco VA Med Ctr, Hlth Serv Res Enhancement Award Program, San Francisco, CA USA.
RP Asgari, MM (reprint author), Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM maryam.m.asgari@kp.org
RI Asgari, Maryam/O-4947-2016
FU National Institute of Arthritis Musculoskeletal and Skin Diseases [K23
AR 051037, K24 AR 052667]; National Cancer Institute [R01 CA 098838]
FX Funding/Support: This study was supported by grants from the National
Institute of Arthritis Musculoskeletal and Skin Diseases (K23 AR 051037
[Dr Asgari] and K24 AR 052667 [Dr Chren]) and from the National Cancer
Institute (R01 CA 098838 [Dr Friedman]).
NR 25
TC 18
Z9 19
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-987X
J9 ARCH DERMATOL
JI Arch. Dermatol.
PD APR
PY 2010
VL 146
IS 4
BP 388
EP 395
PG 8
WC Dermatology
SC Dermatology
GA 585GS
UT WOS:000276813500005
PM 20157019
ER
PT J
AU Diaz, LA
Llaurado, M
Rello, J
Restrepo, MI
AF Diaz, Luis Aurelio
Llaurado, Mireia
Rello, Jordi
Restrepo, Marcos I.
TI Non-Pharmacological Prevention of Ventilator Associated Pneumonia
SO ARCHIVOS DE BRONCONEUMOLOGIA
LA Spanish
DT Review
DE Ventilator-associated pneumonia; Artificial respiration; Cross
infection; Intensive care unit; Disease prevention
ID CRITICALLY-ILL PATIENTS; NOSOCOMIAL MAXILLARY SINUSITIS; RECEIVING
MECHANICAL VENTILATION; SUBGLOTTIC SECRETION DRAINAGE; EVIDENCE-BASED
GUIDELINES; POSITIVE-PRESSURE VENTILATION; RANDOMIZED CONTROLLED-TRIAL;
INTENSIVE-CARE-UNIT; NNIS SYSTEM REPORT; RISK-FACTORS
AB Ventilator-associated pneumonia (VAP) is the first cause of mortality clue to nosocomial infections in the intensive care unit Its incidence ranges nom 9% to 67% of patients on mechanical ventilation Risk factors are multiple and are associated with prolonged stays in hospital and intensive care units Additional costs for each episode of VAP range from 9,000 (sic) to 31,000 (sic)
Thus, its prevention should be considered as a priority This prevention could decrease associated morbidity, mortality, costs, and increase patient safety (C) 2009 SEPAR Published by Elsevier Espana, S L All rights reserved
C1 [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, S Texas Vet Hlth Care Syst Audie L Murphy Div, VERDICT, San Antonio, TX 78229 USA.
[Diaz, Luis Aurelio] Geisinger Hlth Syst, Danville, PA USA.
[Llaurado, Mireia; Rello, Jordi] Hosp Univ Joan XXIII, CIBER Enfermedades Resp CibeRes, Tarragona, Spain.
[Rello, Jordi] Univ Rovira & Virgili, IISPV, Tarragona, Spain.
RP Restrepo, MI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, S Texas Vet Hlth Care Syst Audie L Murphy Div, VERDICT, San Antonio, TX 78229 USA.
RI Restrepo, Marcos/H-4442-2014
OI LLAURADO-SERRA, MIREIA/0000-0002-5123-0581; Rello,
Jordi/0000-0003-0676-6210
NR 121
TC 8
Z9 12
U1 2
U2 8
PU EDICIONES DOYMA S A
PI BARCELONA
PA TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN
SN 0300-2896
J9 ARCH BRONCONEUMOL
JI Arch. Bronconeumol.
PD APR
PY 2010
VL 46
IS 4
BP 188
EP 195
DI 10.1016/j.arbres.2009.08.001
PG 8
WC Respiratory System
SC Respiratory System
GA 589AL
UT WOS:000277116000006
PM 19819060
ER
PT J
AU Schauer, IE
Knaub, LA
Lloyd, M
Watson, PA
Gliwa, C
Lewis, KE
Chait, A
Klemm, DJ
Gunter, JM
Bouchard, R
McDonald, TO
O'Brien, KD
Reusch, JEB
AF Schauer, Irene E.
Knaub, Leslie A.
Lloyd, Monique
Watson, Peter A.
Gliwa, Catherine
Lewis, Katherine E.
Chait, Alan
Klemm, Dwight J.
Gunter, Jody M.
Bouchard, Ron
McDonald, Thomas O.
O'Brien, Kevin D.
Reusch, Jane E. B.
TI CREB Downregulation in Vascular Disease A Common Response to
Cardiovascular Risk
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE atherosclerosis; insulin resistance; CREB; LDL; vascular smooth muscle
ID ELEMENT-BINDING-PROTEIN; MUSCLE-CELL-PROLIFERATION; SERUM AMYLOID-A;
GROWTH-FACTOR-I; TRANSCRIPTION FACTOR; GENE-EXPRESSION; MESSENGER-RNA;
PHOSPHATIDYLINOSITOL 3-KINASE; DILATED CARDIOMYOPATHY;
NEUROBLASTOMA-CELLS
AB Objective-To examine the impact of low-density lipoprotein (LDL), an established mediator of atherosclerosis, on the transcription factor cAMP-response element-binding protein (CREB), which is a regulator of vascular smooth muscle cell (VSMC) quiescence.
Methods and Results-VSMC CREB content is diminished in rodent models of diabetes and pulmonary hypertension. We examined aortic CREB content in rodent models of aging, hypertension, and insulin resistance, and we determined nuclear CREB protein in the medial VSMC of high-fat-fed LDL receptor-null mice. There was significant loss of CREB protein in all models. In vitro, primary culture rat aortic VSMC exposed to LDL and oxidized LDL exhibited a rapid, transient increase in CREB phosphorylation and transient phosphorylation/activation of Akt, ERK, JNK, ans p38 MAPK. Exposure to oxidized LDL, but not to LDL, for 24 to 48 hours decreased CREB protein in a dose-dependent fashion and led to nuclear exclusion of CREB. Pharmacological reactive oxygen species scavengers and inhibition of ERK activation blocked oxidized LDL-mediated CREB downregulation.
Conclusion-These data support a model wherein loss of VSMC CREB protein, which renders these cells more susceptible to activation and apoptosis, is a common pathological response to vascular injury and potentially contributes to plaque progression. (Arterioscler Thromb Vasc Biol. 2010; 30: 733-741.)
C1 [Schauer, Irene E.; Knaub, Leslie A.; Watson, Peter A.; Gliwa, Catherine; Gunter, Jody M.; Bouchard, Ron; Reusch, Jane E. B.] Denver VA Med Ctr, Denver, CO 80220 USA.
[Schauer, Irene E.; Knaub, Leslie A.; Lloyd, Monique; Watson, Peter A.; Gunter, Jody M.; Reusch, Jane E. B.] Univ Colorado, Dept Med, Div Endocrinol Diabet & Metab, Aurora, CO USA.
[Klemm, Dwight J.] Univ Colorado, Dept Med, Div Cardiovasc Pulm Res, Aurora, CO USA.
[Lewis, Katherine E.] ZymoGenetics Inc, Seattle, WA USA.
[McDonald, Thomas O.; O'Brien, Kevin D.] Univ Washington, Dept Med, Div Cardiol, Seattle, WA USA.
[Lewis, Katherine E.; Chait, Alan] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
RP Reusch, JEB (reprint author), Denver VA Med Ctr, ENDO 111-H,Room 9C120B,1055 Clermont St, Denver, CO 80220 USA.
EM jane.reusch@ucdenver.edu
FU VA Merit; Merck Investigator-initiated research support; BIRCWH K12;
[DK64741]; [HL56481]; [P30 DK035816]
FX VA Merit (to J.E.B.R.) and DK64741 (to J.E.B.R.), HL56481 (to D.J.K.),
Merck Investigator-initiated research support (to J.E.B.R., K.D.O.), P30
DK035816 (to A.C., T.O.M.,K.D.O.), and BIRCWH K12 (to I. E. S.).
NR 56
TC 40
Z9 40
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD APR
PY 2010
VL 30
IS 4
BP 733
EP U213
DI 10.1161/ATVBAHA.109.199133
PG 21
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 570XR
UT WOS:000275712500017
PM 20150559
ER
PT J
AU Rosenzweig, HL
Jann, MJ
Vance, EE
Planck, SR
Rosenbaum, JT
Davey, MP
AF Rosenzweig, Holly L.
Jann, Monica J.
Vance, Emily E.
Planck, Stephen R.
Rosenbaum, James T.
Davey, Michael P.
TI Nucleotide-Binding Oligomerization Domain 2 and Toll-like Receptor 2
Function Independently in a Murine Model of Arthritis Triggered by
Intraarticular Peptidoglycan
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID NOD-LIKE RECEPTORS; MURAMYL DIPEPTIDE; RHEUMATOID-ARTHRITIS; DENDRITIC
CELLS; ACTIVATION; AGONISTS; RESPONSES; INNATE; INFLAMMATION;
RECOGNITION
AB Objective. Blau syndrome is an autoinflammatory disease resulting from mutations in the NOD2 gene, wherein granulomatous arthritis, uveitis, and dermatitis develop. The mechanisms by which aberrant NOD2 causes joint inflammation are poorly understood. Indeed, very few studies have addressed the function of nucleotide-binding oligomerization domain 2 (NOD-2) in the joint. This study was undertaken to investigate NOD-2 function in an experimental model of arthritis and to explore the potential interplay between Toll-like receptor 2 (TLR-2) and NOD-2 in joint inflammation.
Methods. Mice deficient in TLR-2, myeloid differentiation factor 88 (MyD88), or NOD-2 and their wildtype controls were given an intraarticular injection of muramyl dipeptide (MDP), peptidoglycan (PG; a metabolite of which is MDP), or palmitoyl-3-cysteine-serine-lysine-4 (Pam(3)CSK(4)), a synthetic TLR-2 agonist. Joint inflammation was assessed by near-infrared fluorescence imaging and histologic analysis.
Results. Locally administered PG resulted in joint inflammation, which was markedly reduced in mice deficient in either TLR-2 or the TLR signaling mediator MyD88. In addition to TLR-2 signaling events, NOD-2 mediated joint inflammation, as evidenced by the fact that mice deficient in NOD-2 showed significantly reduced PG-induced arthritis. TLR-2 or MyD88 deficiency did not influence arthritis induced by the specific NOD-2 agonist MDP. In addition, NOD-2 deficiency did not alter the TLR-2-dependent joint inflammation elicited by the synthetic TLR-2 agonist Pam(3)CSK(4).
Conclusion. Whereas NOD-2 and TLR-2 are both critical for the development of PG-induced arthritis, they appear to elicit inflammation independently of each other. Our findings indicate that NOD-2 plays an inflammatory role in arthritis.
C1 [Rosenzweig, Holly L.; Vance, Emily E.; Planck, Stephen R.; Rosenbaum, James T.; Davey, Michael P.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Jann, Monica J.; Davey, Michael P.] Portland VA Med Ctr, Portland, OR USA.
RP Rosenzweig, HL (reprint author), Oregon Hlth & Sci Univ, Mail Stop L467 AD,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM rosenzwh@ohsu.edu
FU Stan and Madelle Rosenfeld Family Trust; Fund for Arthritis and
Infectious Disease Research; NIH (National Eye Institute)
[F32-EY-017254, EY-013093]; Research to Prevent Blindness Foundation;
American College of Rheumatology Research and Education Foundation;
Oregon Health & Science University; VA Merit Review
FX Supported by the Stan and Madelle Rosenfeld Family Trust and the Fund
for Arthritis and Infectious Disease Research. Dr. Rosenzweig's work was
supported by the NIH (National Eye Institute grant F32-EY-017254) and
the Research to Prevent Blindness Foundation; she is recipient of an
American College of Rheumatology Research and Education Foundation New
Investigator award and co-recipient of a Gerlinger award through the
Oregon Health & Science University. Dr. Rosenbaum's work was supported
by the NIH (National Eye Institute grant EY-013093). Dr. Davey's work
was supported by a VA Merit Review grant; he is co-recipient of a
Gerlinger award through the Oregon Health & Science University.
NR 31
TC 23
Z9 23
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD APR
PY 2010
VL 62
IS 4
BP 1051
EP 1059
DI 10.1002/art.27335
PG 9
WC Rheumatology
SC Rheumatology
GA 619LS
UT WOS:000279432300016
PM 20131263
ER
PT J
AU Gukovsky, I
Gukovskaya, AS
AF Gukovsky, Ilya
Gukovskaya, Anna S.
TI Impaired autophagy underlies key pathological responses of acute
pancreatitis
SO AUTOPHAGY
LA English
DT Editorial Material
DE pancreatitis; pancreatic acinar cell; trypsinogen activation; vacuole
formation; autophagic flux; protein degradation; cathepsin processing
AB The main function of the exocrine pancreas is to produce digestive enzymes, which normally are secreted as inactive zymogens and become activated after reaching the duodenum. Pancreatitis is a relatively common and potentially fatal inflammatory disease of the exocrine pancreas. Its mild forms are self-limited, but severe pancreatitis has 10%-30% mortality. The pathogenesis of pancreatitis remains obscure, and there are no specific treatments. The disease is believed to initiate in acinar cells, the main cell type of the exocrine pancreas. Hallmark responses of acute pancreatitis are the premature, intra-acinar cell activation of trypsinogen (i.e., its conversion from zymogen to active trypsin), vacuole accumulation, inflammation and death of acinar cells through both necrosis and apoptosis.
C1 [Gukovsky, Ilya] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
RP Gukovsky, I (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
EM igukovsk@ucla.edu
FU NIAAA NIH HHS [P50 AA011999]; NIDDK NIH HHS [R01 DK059936]
NR 0
TC 19
Z9 25
U1 0
U2 3
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
J9 AUTOPHAGY
JI Autophagy
PD APR 1
PY 2010
VL 6
IS 3
BP 428
EP 429
PG 2
WC Cell Biology
SC Cell Biology
GA 577CJ
UT WOS:000276198200020
PM 20215882
ER
PT J
AU Carson, JP
Kuprat, AP
Jiao, XM
Dyedov, V
del Pin, F
Guccione, JM
Ratcliffe, MB
Einstein, DR
AF Carson, James P.
Kuprat, Andrew P.
Jiao, Xiangmin
Dyedov, Volodymyr
del Pin, Facundo
Guccione, Julius M.
Ratcliffe, Mark B.
Einstein, Daniel R.
TI Adaptive generation of multimaterial grids from imaging data for
biomedical Lagrangian fluid-structure simulations
SO BIOMECHANICS AND MODELING IN MECHANOBIOLOGY
LA English
DT Article
DE Multimaterial grid generation; Micro MRI; Mouse heart; Fluid-structure
interaction; Volume-conserving smoothing
ID FINITE-ELEMENT-METHOD; SHEAR-STRESS; ENDOTHELIAL-CELLS; ISOGEOMETRIC
ANALYSIS; PARTICLE DEPOSITION; BLOOD-FLOW; CARDIOGENESIS; NURBS
AB Spatial discretization of complex imaging- derived fluid-solid geometries, such as the cardiac environment, is a critical but often overlooked challenge in biomechanical computations. This is particularly true in problems with Lagrangian interfaces, where the fluid and solid phases share a common interface geometrically. For simplicity and better accuracy, it is also highly desirable for the two phases to have a matching surface mesh at the interface between them. We outline a method for solving this problem, and illustrate the approach with a 3D fluid-solid mesh of the mouse heart. An MRI dataset of a perfusion-fixed mouse heart with 50 mu m isotropic resolution was semi-automatically segmented using a customized multimaterial connected-threshold approach that divided the volume into non-overlapping regions of blood, tissue, and background. Subsequently a multimaterial marching cubes algorithm was applied to the segmented data to produce two detailed, compatible isosurfaces, one for blood and one for tissue. Both isosurfaces were simultaneously smoothed with a multimaterial smoothing algorithm that exactly conserves the volume for each phase. Using these two isosurfaces, we developed and applied novel automated meshing algorithms to generate anisotropic hybrid meshes on arbitrary biological geometries with the number of layers and the desired element anisotropy for each phase as the only input parameters. Since our meshes adapt to the local feature sizes and include boundary layer prisms, they are more efficient and accurate than non-adaptive, isotropic meshes, and the fluid-structure interaction computations will tend to have relative error equilibrated over the whole mesh.
C1 [Carson, James P.; Kuprat, Andrew P.; Einstein, Daniel R.] Pacific NW Natl Lab, Richland, WA 99352 USA.
[Jiao, Xiangmin; Dyedov, Volodymyr] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA.
[del Pin, Facundo] Livermore Software Technol Corp, Livermore, CA USA.
[Guccione, Julius M.; Ratcliffe, Mark B.] San Francisco VA Med Ctr, UCSF Dept Surg, San Francisco, CA USA.
RP Carson, JP (reprint author), Pacific NW Natl Lab, Richland, WA 99352 USA.
EM james.carson@pnl.gov; andrew.kuprat@pnl.gov; jiao@ams.sunysb.edu;
vladimir@ams.sunysb.edu; fdelpin@lstc.com; julius.guccione@va.gov;
mark.ratcliffe@va.gov; daniel.einstein@pnl.gov
OI Kuprat, Andrew/0000-0003-4159-918X; Jiao, Xiangmin/0000-0002-7111-9813
FU NCRR/NCI [P41 RR05959/U24 CA092656]; National Heart Lung and Blood
Institute [1RO1HL073598-01A1, 1R01HL084431-01A1]; National Science
Foundation [DMS-0809285]; U.S Department of Energy [LDRD
DE-AC05-76RL01830]
FX MR data was supplied by Dr. G. Allan Johnson, Duke Center for In Vivo
Microscopy under support from NCRR/NCI (P41 RR05959/U24 CA092656). This
research was funded by the National Heart Lung and Blood Institute
Awards 1RO1HL073598-01A1 and 1R01HL084431-01A1, by the National Science
Foundation under award number DMS-0809285, and by the U.S Department of
Energy under LDRD DE-AC05-76RL01830.
NR 41
TC 9
Z9 9
U1 0
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1617-7959
J9 BIOMECH MODEL MECHAN
JI Biomech. Model. Mechanobiol.
PD APR
PY 2010
VL 9
IS 2
BP 187
EP 201
DI 10.1007/s10237-009-0170-5
PG 15
WC Biophysics; Engineering, Biomedical
SC Biophysics; Engineering
GA 568TM
UT WOS:000275545800006
PM 19727874
ER
PT J
AU Warden, SJ
Hassett, SM
Bond, JL
Rydberg, J
Grogg, JD
Hilles, EL
Bogenschutz, ED
Smith, HD
Fuchs, RK
Bliziotes, MM
Turner, CH
AF Warden, Stuart J.
Hassett, Sean M.
Bond, Julie L.
Rydberg, Johanna
Grogg, Jamie D.
Hilles, Erin L.
Bogenschutz, Elizabeth D.
Smith, Heather D.
Fuchs, Robyn K.
Bliziotes, M. Michael
Turner, Charles H.
TI Psychotropic drugs have contrasting skeletal effects that are
independent of their effects on physical activity levels
SO BONE
LA English
DT Article
DE Antidepressant; Depression; Fluoxetine; Osteoporosis; Prozac
ID SEROTONIN REUPTAKE INHIBITORS; BONE-MINERAL DENSITY; ANTIDEPRESSANT
DRUGS; CHRONIC FLUOXETINE; GROWING RATS; IN-VITRO; TRANSPORTER; RISK;
5-HYDROXYTRYPTAMINE; RECEPTOR
AB Popular psychotropic drugs, like the antidepressant selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), and the mood stabilizer lithium, may have skeletal effects. In particular, preclinical observations suggest a direct negative effect of SSRIs on the skeleton. A potential caveat in studies of the skeletal effects of psychotropic drugs is the hypoactive (skeletal unloading) phenotype they induce. The aim of this study was to investigate the contribution of physical inactivity to the skeletal effects of psychotropic drugs by studying bone changes in cage control and tail suspended mice treated with either vehicle, SSRI, TCA or lithium. Tail suspension was used to control for drug differences on physical activity levels by normalizing skeletal loading between groups. The psychotropic drugs were found to have contrasting skeletal effects which were independent of drug effects on animal physical activity levels. The latter was evident by an absence of statistical interactions between the activity and drug groups. Pharmacological inhibition of the 5-hydroxytryptamine (5-HT) transporter (5-HTT) using a SSRI reduced in vivo gains in lower extremity BMD, and negatively altered ex vivo measures of femoral and spinal bone density, architecture and mechanical properties. These effects were mediated by a decrease in bone formation without a change in bone resorption suggesting that the SSRI had anti-anabolic skeletal effects. In contrast, glycogen synthase kinase-3[beta] (GSK-3[beta]) inhibition using lithium had anabolic effects improving in vivo gains in BMD via an increase in bone formation, while TCA-mediated inhibition of the norepinephrine transporter had minimal skeletal effect. The observed negative skeletal effect of 5-HTT inhibition, combined with recent findings of direct and indirect effects of 5-HT on bone formation, are of interest given the frequent prescription of SSRIs for the treatment of depression and other affective disorders. Likewise, the anabolic effect of GSK-3[beta] inhibition using lithium reconfirms the importance of Wnt/beta-catenin signaling in the skeleton and it's targeting by recent drug discovery efforts. In conclusion, the current study demonstrates that different psychotropic drugs with differing underlying mechanisms of action have contrasting skeletal effects and that these effects do not result indirectly via the generation of animal physical inactivity. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Warden, Stuart J.; Hassett, Sean M.; Bond, Julie L.; Rydberg, Johanna; Grogg, Jamie D.; Hilles, Erin L.; Bogenschutz, Elizabeth D.; Smith, Heather D.; Fuchs, Robyn K.] Indiana Univ, Sch Hlth & Rehabil Sci, Dept Phys Therapy, Indianapolis, IN 46202 USA.
[Fuchs, Robyn K.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
[Warden, Stuart J.; Bliziotes, M. Michael] Portland VA Med Ctr, Portland, OR 97201 USA.
[Bliziotes, M. Michael] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Warden, Stuart J.; Turner, Charles H.] Indiana Univ Purdue Univ, Purdue Sch Engn & Technol, Dept Biomed Engn, Indianapolis, IN 46202 USA.
RP Warden, SJ (reprint author), Indiana Univ, Sch Hlth & Rehabil Sci, Dept Phys Therapy, 1140 W Michigan St,CF 326, Indianapolis, IN 46202 USA.
EM stwarden@iupui.edu
RI Warden, Stuart/C-5287-2012
OI Warden, Stuart/0000-0002-6415-4936
FU National Institutes of Health [R01 AR052018, S10 RR023710]
FX The authors thank Keith W. Condon for assistance with tissue processing.
This work was supported by the National Institutes of Health (R01
AR052018 and S10 RR023710).
NR 43
TC 21
Z9 24
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD APR
PY 2010
VL 46
IS 4
BP 985
EP 992
DI 10.1016/j.bone.2009.12.031
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 574RD
UT WOS:000276009400016
PM 20060080
ER
PT J
AU Dunlap, J
Le, C
Shukla, A
Patterson, J
Presnell, A
Heinrich, MC
Corless, CL
Troxell, ML
AF Dunlap, Jennifer
Le, Claudia
Shukla, Arielle
Patterson, Janice
Presnell, Ajia
Heinrich, Michael C.
Corless, Christopher L.
Troxell, Megan L.
TI Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast
carcinoma
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Phosphatidylinositol-3-kinase (PIK3CA); AKT1; Breast carcinoma;
Carcinoma in situ; Laser capture microdissection
ID CANCER-SPECIFIC MUTATIONS; MAMMARY EPITHELIAL-CELLS; PIK3CA
GENE-MUTATIONS; HIGH-FREQUENCY; ENDOMETRIAL CARCINOMA; 3'-KINASE
PATHWAY; PI3K/AKT PATHWAY; DRUG DISCOVERY; PTEN LOSS; 3-KINASE
AB Mutationally activated protein kinases are appealing therapeutic targets in breast carcinoma. Mutations in phosphatidylinositol-3-kinase (PI3KCA) have been described in 8-40% of invasive breast carcinomas, and AKT1 mutations have been characterized in 1-8% of breast carcinomas. However, there is little data on these mutations in breast precursor lesions. To further delineate the molecular evolution of breast tumorigenesis, samples of invasive breast carcinoma with an accompanying in situ component were macro dissected from formalin-fixed paraffin embedded tissue and screened for mutations in PIK3CA exons 7, 9, 20, and AKT1 exon 2. Laser capture micro dissection (LCM) was performed on mutation-positive carcinomas to directly compare the genotypes of separated invasive and in situ tumor cells. Among 81 cases of invasive carcinoma, there were eight mutations in PIK3CA exon 20 (7 H1047R, 1 H1047L) and four mutations in exon 9 (2 E545K, 1 E542K, 1 E545G), totaling 12/81 (14.8%). In 11 cases examined, paired LCM in situ tumor showed the identical PIK3CA mutation in invasive and in situ carcinoma. Likewise, 3 of 78 (3.8%) invasive carcinomas showed an AKT1 E17K mutation, and this mutation was identified in matching in situ carcinoma in both informative cases. Mutational status did not correlate with clinical parameters including hormone receptor status, grade, and lymph node status. The complete concordance of PIK3CA and AKT1 mutations in matched samples of invasive and in situ tumor indicates that these mutations occur early in breast cancer development and has implications with regard to therapeutics targeted to the PI3 kinase pathway.
C1 [Dunlap, Jennifer; Corless, Christopher L.; Troxell, Megan L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA.
[Le, Claudia; Shukla, Arielle; Patterson, Janice; Presnell, Ajia; Heinrich, Michael C.; Corless, Christopher L.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA.
[Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA.
[Heinrich, Michael C.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Dept Med, Portland, OR 97239 USA.
RP Troxell, ML (reprint author), Oregon Hlth & Sci Univ, Dept Pathol, L471,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM troxellm@ohsu.edu
OI Patterson, Janice/0000-0002-8969-2933
FU Department of Veterans Affairs; OHSU Medical Research Foundation
FX The authors wish to acknowledge expert technical assistance of Carolyn
Gendron, Rebecca Lewis, Judith Levine, Carol Beadling, and Andrea
Warrick. Dr. Terry Morgan provided assistance with the statistical
calculations. This work was supported in part by a VA Merit Review Grant
from the Department of Veterans Affairs (MCH) and by a grant from the
OHSU Medical Research Foundation.
NR 50
TC 66
Z9 66
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD APR
PY 2010
VL 120
IS 2
BP 409
EP 418
DI 10.1007/s10549-009-0406-1
PG 10
WC Oncology
SC Oncology
GA 569WK
UT WOS:000275633300014
PM 19418217
ER
PT J
AU Antonio, ALM
Crespi, CM
AF Antonio, Anna Liza M.
Crespi, Catherine M.
TI Predictors of interobserver agreement in breast imaging using the Breast
Imaging Reporting and Data System
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Review
DE Interobserver agreement; Kappa; Mammography; Breast cancer; BI-RADS
ID FIELD DIGITAL MAMMOGRAPHY; SCREEN-FILM MAMMOGRAPHY; BIOPSY
RECOMMENDATIONS; OBSERVER VARIABILITY; CANCER; MICROCALCIFICATIONS;
LESIONS; CLASSIFICATION; CONCORDANCE; ULTRASOUND
AB The Breast Imaging Reporting and Data System (BI-RADS) was introduced in 1993 to standardize the interpretation of mammograms. Though many studies have assessed the validity of the system, fewer have examined its reliability. Our objective is to identify predictors of reliability as measured by the kappa statistic. We identified studies conducted between 1993 and 2009 which reported kappa values for interpreting mammograms using any edition of BI-RADS. Bivariate and multivariate multilevel analyses were used to examine associations between potential predictors and kappa values. We identified ten eligible studies, which yielded 88 kappa values for the analysis. Potential predictors of kappa included: whether or not the study included negative cases, whether single- or two-view mammograms were used, whether or not mammograms were digital versus screen-film, whether or not the fourth edition of BI-RADS was utilized, the BI-RADS category being evaluated, whether or not readers were trained, whether or not there was an overlap in readers' professional activities, the number of cases in the study and the country in which the study was conducted. Our best multivariate model identified training, use of two-view mammograms and BI-RADS categories (masses, calcifications, and final assessments) as predictors of kappa. Training, use of two-view mammograms and focusing on mass description may be useful in increasing reliability in mammogram interpretation. Calcification and final assessment descriptors are areas for potential improvement. These findings are important for implementing policies in BI-RADS use before introducing the system in different settings and improving current implementations.
C1 [Antonio, Anna Liza M.; Crespi, Catherine M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA.
[Antonio, Anna Liza M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Crespi, Catherine M.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, Los Angeles, CA 90095 USA.
RP Antonio, ALM (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA.
EM aantonio@ucla.edu
OI Crespi, Catherine/0000-0002-6150-2181
FU NIH [CA 16042]
FX Crespi was supported by NIH CA 16042.
NR 41
TC 13
Z9 13
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD APR
PY 2010
VL 120
IS 3
BP 539
EP 546
DI 10.1007/s10549-010-0770-x
PG 8
WC Oncology
SC Oncology
GA 571LH
UT WOS:000275752800002
PM 20300960
ER
PT J
AU Litzenberger, JB
Kim, JB
Tummala, P
Jacobs, CR
AF Litzenberger, Julie B.
Kim, Jae-Beom
Tummala, Padmaja
Jacobs, Christopher R.
TI beta(1) Integrins Mediate Mechanosensitive Signaling Pathways in
Osteocytes
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Integrin; Mechanotransduction; Osteocyte; Fluid flow; Bone
ID OSCILLATORY FLUID-FLOW; BONE-FORMATION; SHEAR-STRESS; MC3T3-E1
OSTEOBLASTS; ADHESION KINASE; TRANSGENIC MICE; PROTEIN-KINASE; PGE(2)
RELEASE; ACTIVATION; CALCIUM
AB Integrins are cell-substrate adhesion proteins that initiate intracellular signaling and may serve as mechanosensors in bone. MLO-Y4 cells were stably transfected with a dominant negative form of the beta(1) integrin subunit (beta 1DN) containing the transmembrane domain and cytoplasmic tail of beta(1) integrin. Cells expressing beta 1DN had reduced vinculin localization to focal contacts but no change in intracellular actin organization. When exposed to oscillatory fluid flow, beta 1DN cells exhibited a significant reduction in the upregulation of cyclooxygenase-2 gene expression and prostaglandin E-2 release. Similarly, the ratio of receptor activator of NF-kappa B ligand mRNA to osteoprotegerin mRNA decreased significantly after exposure to fluid flow in control cells but not in beta 1DN cells. Interfering with integrin signaling did not affect mechanically induced intracellular calcium mobilization. These data suggest that integrins may initiate the cellular response of osteocytes to dynamic fluid flow and may serve as mechanosensitive molecules in bone.
C1 [Jacobs, Christopher R.] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.
[Litzenberger, Julie B.; Tummala, Padmaja] US Dept Vet Affairs, Bone & Joint Rehabil Ctr, Palo Alto, CA USA.
[Litzenberger, Julie B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.
[Kim, Jae-Beom] Univ Calif, Dept Stomatol, Stanford, CA USA.
[Kim, Jae-Beom] Caliper Life Sci, Alameda, CA USA.
[Tummala, Padmaja] MedImmune Vaccines, Mountain View, CA USA.
RP Jacobs, CR (reprint author), Columbia Univ, Dept Biomed Engn, 500 W 120th St,351 Engn Terrace, New York, NY 10027 USA.
EM Julitzy@gmail.com; christopher.jacobs@columbia.edu
FU NIAMS NIH HHS [R01 AR045989-10, AR45989, R01 AR045989, R21 AR054156, R21
AR054156-02]
NR 37
TC 37
Z9 38
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-967X
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD APR
PY 2010
VL 86
IS 4
BP 325
EP 332
DI 10.1007/s00223-010-9343-6
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 575DO
UT WOS:000276046900006
PM 20213106
ER
PT J
AU Rech, AJ
Mick, R
Kaplan, DE
Chang, KM
Domchek, SM
Vonderheide, RH
AF Rech, Andrew J.
Mick, Rosemarie
Kaplan, David E.
Chang, Kyong-Mi
Domchek, Susan M.
Vonderheide, Robert H.
TI Homeostasis of peripheral FoxP3(+) CD4(+) regulatory T cells in patients
with early and late stage breast cancer
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Article
DE Breast cancer; Regulatory T cell; Clinical trial
ID TUMOR-IMMUNITY; IN-VIVO; ANTITUMOR IMMUNITY; EXPRESSION; DEPLETION;
MELANOMA; INDUCTION; RESPONSES; BLOOD; RECRUITMENT
AB FoxP3 (+) CD4 (+) regulatory T cells (Tregs) are important mediators of peripheral immune tolerance, acting via multiple mechanisms to suppress cellular immunity including antitumor responses. Although therapeutic strategies have been proposed to deplete Tregs in patients with breast cancer and other malignancies, dynamic changes in the Treg compartment as a function of stage and treatment of breast cancer remain poorly understood. Here, we evaluated peripheral blood CD4(+) T cells and FoxP3(+) CD4(+) T cells from 45 patients with early or late stage breast cancer and compared percentages, absolute counts, and Treg function to those from healthy volunteers (HV) of comparable age. Patients having completed adjuvant chemotherapy and patients with metastatic cancer exhibited significantly lower absolute CD4 counts and significantly higher percentages of FoxP3(+) CD4(+) T cells. In contrast, the absolute counts of circulating FoxP3(+) CD4(+) T cells did not differ significantly among early stage patients, late stage patients, or HV. Functionally, FoxP3(+) CD4(+) T cells from all donor groups similarly expressed CTLA-4 and failed to secrete IFN-gamma in response to stimulation. Thus, although Tregs comprise an increased percentage of circulating CD4(+) T cells in patients with metastatic breast cancer and patients in remission after completing the adjuvant chemotherapy, the systemic Treg pool, as measured by absolute counts, appears relatively constant regardless of disease stage or treatment status. Total CD4(+) T cell counts are not constant, however, suggesting that homeostatic mechanisms, or susceptibility to cytotoxic or malignant insults, fundamentally differ for regulatory and non-regulatory CD4(+) T cells.
C1 [Rech, Andrew J.; Vonderheide, Robert H.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
[Mick, Rosemarie] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Kaplan, David E.; Chang, Kyong-Mi] Univ Penn, Sch Med, Div Gastroenterol, Dept Med, Philadelphia, PA 19104 USA.
[Kaplan, David E.; Chang, Kyong-Mi] Philadelphia Vet Affairs Med Ctr, Gastroenterol Sect, Philadelphia, PA USA.
[Domchek, Susan M.] Univ Penn, Sch Med, Abramson Canc Ctr, Div Hematol Oncol, Philadelphia, PA 19104 USA.
RP Vonderheide, RH (reprint author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, 551 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.
EM rhv@exchange.upenn.edu
OI Kaplan, David E./0000-0002-3839-336X
FU Breast Cancer Research Foundation; NCI [R01 CA111377]
FX We thank Theresa Colligon and Adrianna Recio, RN, and Drs. Daniel J.
Powell, Jr., Tatiana Golovina, and James Riley for helpful discussions.
This study was supported by grants from the Breast Cancer Research
Foundation and the NCI (R01 CA111377) and a gift from Mark and Paula
Solomon.
NR 44
TC 27
Z9 28
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-7004
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
PD APR
PY 2010
VL 59
IS 4
BP 599
EP 607
DI 10.1007/s00262-009-0780-x
PG 9
WC Oncology; Immunology
SC Oncology; Immunology
GA 549XH
UT WOS:000274087300010
PM 19855964
ER
PT J
AU Platt, AB
Localio, AR
Brensinger, CM
Cruess, DG
Christie, JD
Gross, R
Parker, CS
Price, M
Metlay, JP
Cohen, A
Newcomb, CW
Strom, BL
Laskin, MS
Kimmel, SE
AF Platt, Alec B.
Localio, A. Russell
Brensinger, Colleen M.
Cruess, Dean G.
Christie, Jason D.
Gross, Robert
Parker, Catherine S.
Price, Maureen
Metlay, Joshua P.
Cohen, Abigail
Newcomb, Craig W.
Strom, Brian L.
Laskin, Mitchell S.
Kimmel, Stephen E.
TI Can We Predict Daily Adherence to Warfarin? Results From the
International Normalized Ratio Adherence and Genetics (IN-RANGE) Study
SO CHEST
LA English
DT Article
ID ORAL ANTICOAGULANT TREATMENT; ATRIAL-FIBRILLATION; INCEPTION-COHORT;
RISK-FACTORS; MANAGEMENT; REGRESSION; THERAPY; RULES; NONADHERENCE;
OUTCOMES
AB Background: Warfarin is the primary therapy to prevent stroke and venous thromboembolism. Significant periods of nonadherence frequently go unreported by patients and undetected by providers. Currently, no comprehensive screening tool exists to help providers assess the risk of nonadherence at the time of initiation of warfarin therapy.
Methods: This article reports on a prospective cohort study of adults initiating warfarin therapy at two anticoagulation clinics (university- and Veterans Affairs-affiliated). Nonadherence, defined by failure to record a correct daily pill bottle opening, was measured daily by electronic pill cap monitoring. A multivariable logistic regression model was used to develop a point system to predict daily nonadherence to warfarin.
Results: We followed 114 subjects for a median of 141 days. Median nonadherence of the participants was 14.4% (interquartile range [IQR], 5.8-33.8). A point system, based on nine demographic, clinical, and psychosocial factors, distinguished those demonstrating low vs high levels of nonadherence: four points or fewer, median nonadherence 5.8% (IQR, 2.3-14.1); five points, 9.1% (IQR, 5.9-28.6); six points, 14.5% (IQR, 7.1-24.1); seven points, 14.7% (IQR, 7.0-34.7); and eight points or more, 29.3% (IQR, 15.5-41.9). The model produces a c-statistic of 0.66 (95% CI, 0.61-0.71), suggesting modest discriminating ability to predict day-level warfarin nonadherence.
Conclusions: Poor adherence to warfarin is common. A screening tool based on nine demographic, clinical, and psychosocial factors, if further validated in other patient populations, may help to identify groups of patients at lower risk for nonadherence so that intensified efforts at increased monitoring and intervention can be focused on higher-risk patients. CHEST 2010;137(4):883-889
C1 [Localio, A. Russell; Brensinger, Colleen M.; Christie, Jason D.; Gross, Robert; Price, Maureen; Metlay, Joshua P.; Cohen, Abigail; Newcomb, Craig W.; Strom, Brian L.; Kimmel, Stephen E.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Christie, Jason D.; Gross, Robert; Metlay, Joshua P.; Strom, Brian L.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Platt, Alec B.; Gross, Robert; Metlay, Joshua P.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA.
[Platt, Alec B.] Reading Hosp Med Ctr, Reading, PA USA.
[Localio, A. Russell; Gross, Robert; Metlay, Joshua P.; Strom, Brian L.] Univ Penn, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA.
[Cruess, Dean G.] Univ Connecticut, Dept Psychol, Storrs, CT USA.
[Parker, Catherine S.] Beth Israel Deaconess Med Ctr, Dept Internal Med, Boston, MA 02215 USA.
[Laskin, Mitchell S.] Hosp Univ Penn, Dept Pharm Serv, Philadelphia, PA 19104 USA.
RP Kimmel, SE (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, 707 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM stevek@mail.med.upenn.edu
RI Cohen, Abigail/K-9180-2013
OI Cohen, Abigail/0000-0002-7425-7218
FU National Institutes of Health [R01-HL66176]; Agency for Health Research
and Quality [P01-HS11530]; Pfizer; Merck; Novartis; GlaxoSmithKline;
Centocor; Bayer; National Institutes of Health; Agency for Health
Research and Quality; Aetna Foundation; Bristol-Myers Squibb;
[P20RR020741]; [K24HL070936]
FX The IN-RANGE study was supported by grants from the National Institutes
of Health [R01-HL66176] and the Agency for Health Research and Quality
[P01-HS11530]. Dr Kimmel was also supported by P20RR020741 and
K24HL070936.; The authors have reported to CHEST the following conflicts
of interest: Dr Kimmel has served as a consultant and/or received
research funding from several pharmaceutical companies, including
Pfizer, Merck, Novartis, GlaxoSmithKline, Centocor, and Bayer, all
unrelated to this lover. Dr Kimmel has received investigator-initiated
research funding from the National Institutes of Health, the Agency for
Health Research and Quality, and the Aetna Foundation for warfarin
research. Dr Gross has served as a consultant and/or received research
funding from GlaxoSmithKline and Bristol-Myers Squibb, and Dr Strom has
served as a consultant to Bristol-Myers Squibb and other pharmaceutical
companies, all unrelated to this paper. Drs Platt, Localio, Cruess,
Christie, Parker, Meday, and Cohen; Mss Brensinger and Price; and Messrs
Newcomb and Laskin have reported that no potential conflicts of interest
exist with any companies/organizations whose products or services may be
discussed in this article.; The National Institutes of Health and the
Agency for Health Research and Quality, which provided grants, had no
role in the design and conduct of the study; the collection, management,
analysis, and interpretation of the data; or the preparation, review,
and approval of the manuscript.
NR 34
TC 20
Z9 21
U1 0
U2 2
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD APR
PY 2010
VL 137
IS 4
BP 883
EP 889
DI 10.1378/chest.09-0039
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 582XA
UT WOS:000276632400021
PM 19903973
ER
PT J
AU Ko, DT
Yun, LS
Wijeysundera, HC
Jackevicius, CA
Rao, SV
Austin, PC
Marquis, JF
Tu, JV
AF Ko, Dennis T.
Yun, Lingsong
Wijeysundera, Harindra C.
Jackevicius, Cynthia A.
Rao, Sunil V.
Austin, Peter C.
Marquis, Jean-Francois
Tu, Jack V.
TI Incidence, Predictors, and Prognostic Implications of Hospitalization
for Late Bleeding After Percutaneous Coronary Intervention for Patients
Older Than 65 Years
SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE bleeding; percutaneous coronary intervention; mortality; oral
anticoagulants
ID EXPERT CONSENSUS DOCUMENT; ST-SEGMENT-ELEVATION; DRUG-ELUTING STENTS;
ANTIPLATELET THERAPY; ATRIAL-FIBRILLATION; MYOCARDIAL-INFARCTION;
BLOOD-TRANSFUSION; ADVERSE OUTCOMES; RISK; TRIAL
AB Background-Previous data on bleeding after percutaneous coronary intervention (PCI) have been obtained primarily from randomized trials that focused on in-hospital bleeding. The incidence of late bleeding after PCI, its independent predictors, and its prognostic importance in clinical practice has not been fully addressed.
Methods and Results-We evaluated 22 798 patients aged >65 years who underwent PCI from December 1, 2003, to March 31, 2007, in Ontario, Canada. Cox proportional hazard models were used to determine factors associated with late bleeding, which was defined as hospitalization for bleeding after discharge from the index PCI, and to estimate risk of death or myocardial infarction associated with late bleeding. We found that 2.5% of patients were hospitalized for bleeding in the year after PCI, with 56% of bleeding episodes due to gastrointestinal bleed. The most significant predictor of late bleeding was warfarin use after PCI (hazard ratio [HR], 3.12). Other significant predictors included age (HR, 1.41 per 10 years), male sex (HR, 1.24), cancer (HR, 1.80), previous bleeding (HR, 2.42), chronic kidney disease (HR, 1.93), and nonsteroidal antiinflammatory drug use (HR, 1.73). After adjusting for baseline covariates, hospitalization for a bleeding episode was associated with a significantly increased 1-year hazard of death or myocardial infarction (HR, 2.39; 95% CI, 1.93 to 2.97) and death (HR, 3.38; 95% CI, 2.60 to 4.40).
Conclusions-Hospitalization for late bleeding after PCI is associated with substantially increased risk of death and myocardial infarction. The use of triple therapy (ie, aspirin, thienopyridine, and warfarin) is associated with the highest risk of late bleeding. (Circ Cardiovasc Interv. 2010;3:140-147.)
C1 [Ko, Dennis T.; Wijeysundera, Harindra C.; Tu, Jack V.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Div Cardiol, Toronto, ON, Canada.
[Ko, Dennis T.; Jackevicius, Cynthia A.; Austin, Peter C.; Tu, Jack V.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada.
[Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Pomona, CA USA.
[Jackevicius, Cynthia A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Rao, Sunil V.] Duke Clin Res Inst, Durham, NC USA.
[Marquis, Jean-Francois] Univ Ottawa, Inst Heart, Ottawa, ON, Canada.
RP Ko, DT (reprint author), Inst Clin Evaluat Sci G1 06, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM dennis.ko@ices.on.ca
OI Ko, Dennis/0000-0001-6840-8051; Tu, Jack/0000-0003-0111-722X; Austin,
Peter/0000-0003-3337-233X
FU Ontario Health Technology Advisory Committee; Medical Advisory
Secretariat; Canadian Institutes of Health Research (CIHR) [82747];
Heart and Stroke Foundation of Ontario (HSFO); HSFO; Institute for
Clinical Evaluative Sciences; Cardiac Care Network of Ontario; Ministry
of Health and Long-Term Care
FX We acknowledge that the data used in this publication are from the
Cardiac Care Network of Ontario and its member hospitals. The Cardiac
Care Network of Ontario serves as an advisory body to the Ministry of
Health and Long-Term Care and is dedicated to improving the quality,
efficiency, access, and equity of adult cardiovascular services in
Ontario, Canada. We also acknowledge the support from the Ontario Health
Technology Advisory Committee and the Medical Advisory Secretariat.;
This study was funded by an operating grant from the Canadian Institutes
of Health Research (CIHR) (MOP 82747). Dr Ko was supported by a
Clinician-Scientist Award from the Heart and Stroke Foundation of
Ontario (HSFO) and a New Investigator award by CIHR. Dr Austin was
supported by a Career Investigator Award by the HSFO. Dr Tu was
supported by a Canada Research Chair in Health Services Research and a
Career Investigator Award from the HSFO. Dr Wijeysundera was supported
by a research fellowship award from the CIHR. The Institute for Clinical
Evaluative Sciences, Cardiac Care Network of Ontario, and Programs for
Assessment of Technology in Health Research Institute were funded by the
Ministry of Health and Long-Term Care.
NR 37
TC 33
Z9 34
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7640
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD APR
PY 2010
VL 3
IS 2
BP 140
EP U73
DI 10.1161/CIRCINTERVENTIONS.109.928721
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 586AP
UT WOS:000276873400009
PM 20332382
ER
PT J
AU Abraham, NS
Hartman, C
Hasche, J
AF Abraham, Neena S.
Hartman, Christine
Hasche, Jennifer
TI Reduced Hospitalization Cost for Upper Gastrointestinal Events That
Occur Among Elderly Veterans Who Are Gastroprotected
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Comparative Effectiveness; Administrative Database; Department of
Veterans Affairs; Gastrointestinal Hemorrhage; Health Resource Use
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; RESOURCE
UTILIZATION; ULCER COMPLICATIONS; NONSELECTIVE NSAIDS; MANAGED CARE;
DOUBLE-BLIND; RISK; PREVENTION; ASPIRIN
AB BACKGROUND & AIMS: Despite prescription of gastro-protection among elderly nonsteroidal anti-inflammatory drug (NSAID) users, residual bleeding can still occur. We sought to determine the effect of proton pump inhibitors (PPI) on hospitalization and resource use among veterans in whom an upper gastrointestinal event (UGIE) occurred. METHODS: We identified from national pharmacy records veterans >= 65 years prescribed an NSAID, cyclooxygenase-2 selective NSAID (coxib), or salicylate (>325 mg/day) at any Veterans Affairs (VA) facility (01/01/00-12/31/04). Prescription fill data were linked longitudinally to a Veterans Affairs-Medicare dataset of inpatient, outpatient, and death files, and demographic and provider data. Among veterans in whom a UGIE occurred, we assessed the effect of prescription strategy on hospitalization, using a multivariate logistic regression model. RESULTS: A total of 3566 UGIEs occurred among a cohort that was predominantly male (97.5%), white (77%), with a mean age of 73.5 (SD, 5.7). Hospitalization occurred in 47.5%, and gastroprotection was associated with a 30% reduction in hospitalization compared with no PPI. Five-year pharmacy costs associated with the PPI strategy exceeded the no-PPI strategy ($742,406 vs $184,282); however, a substantial reduction in medical costs was observed with PPI ($9,948,738 vs $18,686,081). CONCLUSIONS: Even if an NSAID-UGIE occurs in the PPI-protected older veteran, the reduction in need for hospitalization results in a cost saving to the Department of Veterans Affairs.
C1 [Abraham, Neena S.; Hartman, Christine; Hasche, Jennifer] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA.
[Abraham, Neena S.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
[Hartman, Christine] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
RP Abraham, NS (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd 152, Houston, TX 77030 USA.
EM nabraham@bcm.edu
FU American Gastroenterological Association Foundation; Department of
Veterans Affairs (VA) [IIR 115-05]; American Digestive Health Foundation
Outcomes Research Award; Astra Zeneca Pharmaceuticals; Houston Center
for Quality of Care & Utilization Studies, Houston Veterans Affairs
Medical Center [HFP90-020]
FX This study was funded in part by an American Gastroenterological
Association Foundation-Sucampo-ASP Designated Research Award in
Geriatric Gastroenterology, a Merit Review Award from the Department of
Veterans Affairs (VA) (IIR 115-05), an American Digestive Health
Foundation Outcomes Research Award, and an investigator-initiated
research grant from Astra Zeneca Pharmaceuticals. This material is the
result of work supported with resources and the use of facilities at the
Houston Center for Quality of Care & Utilization Studies, Houston
Veterans Affairs Medical Center (HFP90-020).
NR 38
TC 8
Z9 8
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD APR
PY 2010
VL 8
IS 4
BP 350
EP 356
DI 10.1016/j.cgh.2010.01.002
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 584WP
UT WOS:000276784700011
PM 20096378
ER
PT J
AU Parikh, M
Dolson, G
Ramanathan, V
Sangsiraprapha, W
AF Parikh, M.
Dolson, G.
Ramanathan, V.
Sangsiraprapha, W.
TI Novel H1N1-associated rhabdomyolysis leading to acute renal failure
SO CLINICAL MICROBIOLOGY AND INFECTION
LA English
DT Article
DE H1N1; influenza; myositis; renal failure; rhabdomyolysis
ID INFLUENZA-B VIRUS; A H1N1; INFECTION; MUSCLE; MYOSITIS
AB P>The WHO recently declared that the novel influenza H1N1 virus was responsible for the 2009 flu pandemic. As the virus continues to spread globally and affect more individuals, more complications of infection with this virus are being recognized. To our knowledge, we report the first case of H1N1-induced rhabdomyolysis leading to acute renal failure in an adult. This case highlights the importance of recognizing a significant extrapulmonary complication of H1N1 infection.
C1 [Parikh, M.] Baylor Coll Med, Dept Internal Med, Med Residency Off, Houston, TX 77030 USA.
[Dolson, G.; Ramanathan, V.; Sangsiraprapha, W.] Houston Vet Affairs Med Ctr, Nephrol Sect, Houston, TX USA.
RP Parikh, M (reprint author), Baylor Coll Med, Dept Internal Med, Med Residency Off, 1709 Dryden Suite 500, Houston, TX 77030 USA.
EM mrparikh@bcm.tmc.edu; dolson.georgem@med.va.gov
NR 13
TC 18
Z9 19
U1 1
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1198-743X
J9 CLIN MICROBIOL INFEC
JI Clin. Microbiol. Infect.
PD APR
PY 2010
VL 16
IS 4
BP 330
EP 332
DI 10.1111/j.1469-0691.2010.03185.x
PG 3
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 564AC
UT WOS:000275181700007
PM 20132248
ER
PT J
AU Pham, PCT
Dewar, K
Hashmi, S
Toscano, E
Pham, PMT
Pham, PAT
Pham, PTT
AF Pham, P. C. T.
Dewar, K.
Hashmi, S.
Toscano, E.
Pham, P. M. T.
Pham, P. A. T.
Pham, P. T. T.
TI Pain prevalence in patients with chronic kidney disease
SO CLINICAL NEPHROLOGY
LA English
DT Article
DE pain; chronic kidney disease
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE-2 INHIBITORS
AB Background: The prevalence of pain in patients with chronic kidney diseases (CKD) is not known. In the current study, we aim to determine the prevalence of pain in CKD patients and its associations with various medical and psychosocial factors. Methods: Consecutive CKD patients who were presented to the renal clinic at Olive View-UCLA Medical Center, a Los Angeles County tertiary referral center, over a 3-month period were interviewed on their medical and psychosocial histories and a history of pain including duration, severity and source. chi(2)-testing for independence and binary logistic regression performed for the presence of pain and CKD stages as well as other medical and psychosocial factors were determined. A separate survey for pain was also done for 100 consecutive non-CKD patients who were presented to our ambulatory medicine clinic for routine care. Results: 54.6% of 130 patients with known CKD interviewed were women. Any type of pain of at least a 2 week duration was reported in 72.9%. The most common source of pain was musculoskeletal. The presence of pain of less than a 2 week duration was associated with worse CKD stages (3 - 5 versus 1 - 2) and non-exercisers. Higher body mass index was associated with having pain lasting longer than a 2 week duration. Among patients who had pain, 33.8% used acetaminophen, 15.4% nonsteroidal anti-inflammatory drugs and 7.8% combination analgesics. In contrast to CKD patients, only 9% of non-CKD patients reported to have any type or duration of pain. Conclusions: Pain was much more prevalent among our CKD compared with non-CKD patients.
C1 [Pham, P. C. T.; Dewar, K.; Hashmi, S.; Toscano, E.] Olive View UCLA Med Ctr, Dept Med, Div Nephrol, Sylmar, CA 91342 USA.
[Pham, P. M. T.] Greater Los Angeles VA Med Ctr, Dept Med, Los Angeles, CA USA.
[Pham, P. A. T.] Mercy Gen Hosp, Sacramento, CA USA.
[Pham, P. T. T.] Univ Calif Los Angeles, David Geffen Sch Med, Kidney & Pancreas Transplant Program, Los Angeles, CA 90095 USA.
RP Pham, PCT (reprint author), Olive View UCLA Med Ctr, Dept Med, Div Nephrol, 14445 Olive View Dr,2B-182, Sylmar, CA 91342 USA.
EM pham.pc@ucla.edu
NR 9
TC 7
Z9 7
U1 0
U2 0
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0301-0430
J9 CLIN NEPHROL
JI Clin. Nephrol.
PD APR
PY 2010
VL 73
IS 4
BP 294
EP 299
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 577CB
UT WOS:000276197400006
PM 20353737
ER
PT J
AU Selby, EA
Anestis, MD
Bender, TW
Ribeiro, JD
Nock, MK
Rudd, MD
Bryan, CJ
Lim, IC
Baker, MT
Gutierrez, PM
Joiner, TE
AF Selby, Edward A.
Anestis, Michael D.
Bender, Theodore W.
Ribeiro, Jessica D.
Nock, Matthew K.
Rudd, M. David
Bryan, Craig J.
Lim, Ingrid C.
Baker, Monty T.
Gutierrez, Peter M.
Joiner, Thomas E., Jr.
TI Overcoming the fear of lethal injury: Evaluating suicidal behavior in
the military through the lens of the Interpersonal-Psychological Theory
of Suicide
SO CLINICAL PSYCHOLOGY REVIEW
LA English
DT Review
DE Military; Suicide; Combat; Posttraumatic stress disorder; Injury
ID POSTTRAUMATIC-STRESS-DISORDER; VIETNAM COMBAT VETERANS; MENTAL-HEALTH
PROBLEMS; RISK-FACTORS; WAR VETERANS; ARMED-FORCES; IRAQ WAR; PERCEIVED
BURDENSOMENESS; PSYCHIATRIC-DISORDERS; CHILDHOOD ADVERSITY
AB Suicide rates have been increasing in military personnel since the start of Operation Enduring Freedom and Operation Iraqi Freedom, and it is vital that efforts be made to advance suicide risk assessment techniques and treatment for members of the military who may be experiencing suicidal symptoms. One potential way to advance the understanding of suicide in the military is through the use of the Interpersonal-Psychological Theory of Suicide. This theory proposes that three necessary factors are needed to complete suicide: feelings that one does not belong with other people, feelings that one is a burden on others or society, and an acquired capability to overcome the fear and pain associated with suicide. This review analyzes the various ways that military service may influence suicidal behavior and integrates these findings into an overall framework with relevant practical implications. Findings suggest that although there are many important factors in military suicide, the acquired capability may be the most impacted by military experience because combat exposure and training may cause habituation to fear of painful experiences, including suicide. Future research directions, ways to enhance risk assessment, and treatment implications are also discussed. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Joiner, Thomas E., Jr.] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA.
[Nock, Matthew K.] Harvard Univ, Cambridge, MA 02138 USA.
[Rudd, M. David] Univ Utah, Salt Lake City, UT 84112 USA.
[Bryan, Craig J.] Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA.
[Baker, Monty T.] San Antonio Mil Med Ctr, Warrior Resiliency Program, San Antonio, TX USA.
[Gutierrez, Peter M.] Denver VA Med Ctr, Denver, CO USA.
[Gutierrez, Peter M.] Univ Colorado, Denver Sch Med, Boulder, CO 80309 USA.
RP Joiner, TE (reprint author), Florida State Univ, Dept Psychol, 1107 W Call St, Tallahassee, FL 32306 USA.
EM joiner@psy.fsu.edu
OI Bryan, Craig/0000-0002-9714-0733; Gutierrez, Peter/0000-0001-8981-8404
FU NIMH NIH HHS [F31 MH081396, F31 MH081396-01A2, F31 MH081396-02,
F31MH081396]
NR 106
TC 56
Z9 59
U1 2
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0272-7358
J9 CLIN PSYCHOL REV
JI Clin. Psychol. Rev.
PD APR
PY 2010
VL 30
IS 3
BP 298
EP 307
DI 10.1016/j.cpr.2009.12.004
PG 10
WC Psychology, Clinical
SC Psychology
GA 572BY
UT WOS:000275802700003
PM 20051309
ER
PT J
AU Gros, DF
Gros, KS
Simms, LJ
AF Gros, Daniel F.
Gros, Kirstin Stauffacher
Simms, Leonard J.
TI Relations Between Anxiety Symptoms and Relational Aggression and
Victimization in Emerging Adults
SO COGNITIVE THERAPY AND RESEARCH
LA English
DT Article
DE Social anxiety; Cognitive anxiety; Somatic anxiety; Relational
aggression; Relational victimization
ID SOCIAL-PSYCHOLOGICAL ADJUSTMENT; NATIONAL-COMORBIDITY-SURVEY;
STATE-TRAIT INVENTORY; QUALITY-OF-LIFE; PEER VICTIMIZATION; PHYSICAL
AGGRESSION; COLLEGE-STUDENTS; PSYCHOMETRIC PROPERTIES; SOMATIC
COMPLAINTS; COMMUNITY SAMPLE
AB Although it has been suggested that relational aggression (RA) and relational victimization (RV) are associated with elevated rates of social anxiety (SA), the nature of how these behaviors relate to the symptom development of SA has not yet been explored. In the present study, we investigated the relations between the symptoms of SA and general anxiety and RA and RV in a questionnaire study of 315 emerging adults. To identify the unique predictive power of RA/RV, a series of hierarchical regression analyses were conducted, controlling for gender, age, and physical aggression and victimization. All symptoms of anxiety were uniquely and positively predicted by RA; however, only symptoms of cognitive and somatic anxiety were predicted positively and uniquely by RV. These findings further elucidate the linkage between RA and anxiety in early adulthood, serving to highlight the importance of considering lifetime social history when investigating anxiety and aggression and victimization behaviors.
C1 [Gros, Daniel F.] Ralph H Johnson Vet Adm Med Ctr, Mental Hlth Serv, Charleston, SC 29410 USA.
[Gros, Daniel F.; Gros, Kirstin Stauffacher] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Simms, Leonard J.] SUNY Buffalo, Dept Psychol, Buffalo, NY 14260 USA.
RP Gros, DF (reprint author), Ralph H Johnson Vet Adm Med Ctr, Mental Hlth Serv, Charleston, SC 29410 USA.
EM grosd@musc.edu
NR 64
TC 9
Z9 9
U1 2
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0147-5916
J9 COGNITIVE THER RES
JI Cogn. Ther. Res.
PD APR
PY 2010
VL 34
IS 2
BP 134
EP 143
DI 10.1007/s10608-009-9236-z
PG 10
WC Psychology, Clinical
SC Psychology
GA 567ES
UT WOS:000275426600004
ER
PT J
AU Vernon, C
LeTourneau, JL
AF Vernon, Christopher
LeTourneau, Jennifer L.
TI Lactic Acidosis: Recognition, Kinetics, and Associated Prognosis
SO CRITICAL CARE CLINICS
LA English
DT Article
DE Lactic acidosis; Mitochondria; Prognosis; Critical care; Shock;
Metabolic diseases
ID PROPOFOL INFUSION SYNDROME; CONTROLLED CLINICAL-TRIAL; BLOOD LACTATE
LEVELS; SHORT-BOWEL SYNDROME; ACUTE LIVER-FAILURE; MITOCHONDRIAL
RESPIRATORY-CHAIN; PYRUVATE-CARBOXYLASE DEFICIENCY; PROPYLENE-GLYCOL
TOXICITY; CRITICALLY-ILL PATIENTS; HIV-INFECTED PATIENTS
AB Lactic acidosis is a common condition encountered by critical care providers. Elevated lactate and decreased lactate clearance are important for prognostication. Not all lactate in the intensive care unit is due to tissue hypoxia or ischemia and other sources should be evaluated. Lactate, in and of itself, is unlikely to be harmful and is a preferred fuel for many cells. Treatment of lactic acidosis continues to be aimed the underlying source.
C1 [LeTourneau, Jennifer L.] Portland VA Med Ctr, Pulm Dis Sect, Portland, OR 97239 USA.
[Vernon, Christopher] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97239 USA.
RP LeTourneau, JL (reprint author), Portland VA Med Ctr, Pulm Dis Sect, 3710 SW US Vet Hosp Rd,Mailcode P3PULM, Portland, OR 97239 USA.
EM Jennifer.Letourneau@va.gov
RI Andrade, Hugo/M-6631-2013
OI Andrade, Hugo/0000-0001-6781-6125
NR 219
TC 35
Z9 38
U1 0
U2 11
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0704
J9 CRIT CARE CLIN
JI Crit. Care Clin.
PD APR
PY 2010
VL 26
IS 2
BP 255
EP +
DI 10.1016/j.ccc.2009.12.007
PG 30
WC Critical Care Medicine
SC General & Internal Medicine
GA 590AB
UT WOS:000277194400003
PM 20381719
ER
PT J
AU Rello, J
Afessa, B
Anzueto, A
Arroliga, AC
Olson, ME
Restrepo, MI
Talsma, SS
Bracken, RL
Kollef, MH
AF Rello, Jordi
Afessa, Bekele
Anzueto, Antonio
Arroliga, Alejandro C.
Olson, Merle E.
Restrepo, Marcos I.
Talsma, Silke S.
Bracken, Ronald L.
Kollef, Marin H.
TI Activity of a silver-coated endotracheal tube in preclinical models of
ventilator-associated pneumonia and a study after extubation
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE biocompatible coated materials; endotracheal intubation; nosocomial
infections; ventilator-associated pneumonia; silver
ID IN-VITRO; PSEUDOMONAS-AERUGINOSA; BACTERIAL-COLONIZATION; BIOFILM
FORMATION; MICROBIAL COLONIZATION; ADHESION; BIOMATERIALS; CATHETERS;
ADHERENCE; SURFACES
AB Objective: To elucidate the mechanism of action of the silver-coated endotracheal tube in models of the early pathogenesis of ventilator-associated pneumonia.
Design: Open-labeled, prospective, controlled, sequentially conducted, preclinical studies, and in vitro assessment of tubes from patients.
Setting: Microbiology laboratory of a device manufacturer, animal research facility of a university, and a tertiary medical center.
Interventions: Endotracheal tubes were similar except for the silver coating. In the 21-day in vitro elution model, tube samples were incubated in saline solution at 37.8 degrees C. In the in vitro adherence model, coated and uncoated tubes were exposed to 21 respiratory isolates of radiolabeled microorganisms for 2-4 hrs. In the animal model, 12 healthy white rabbits were intubated for 16 hrs with noncuffed silver-coated or uncoated tubes and challenged with buccal administration of Pseudomonas aeruginosa. In the in vitro assessment, tubes from 16 patients underwent quantitative culture assessment and qualitative confocal laser scanning microscopy.
Measurements and Main Results: After in vitro incubation, the mean residual silver concentration was 2.6 mu g/cm(2), confirming that the coating was not entirely depleted. In vitro adherence to the silver-coated endotracheal tube was less than that of the uncoated tube for 12 of 21 isolates and equivalent for seven. For example, adherence to the silver-coated endotracheal tube was reduced >90% for all five isolates of P. aeruginosa (p < .05). In rabbits, P. aeruginosa colonization on the silver-coated endotracheal tube was reduced 99.9% compared with that on the uncoated tube (p < .0001); colonization in the tracheal and lung tissue was reduced >99% (p < .05). In the in vitro assessment, pathogens were detected on none of nine silver-coated tubes from patients and three of seven control tubes (p > .05).
Conclusions: The collective findings of this series of studies demonstrated that the silver-coated endotracheal tube was active in models designed to mimic the early pathogenesis of ventilator-associated pneumonia. (Crit Care Med 2010; 38: 1135-1140)
C1 [Rello, Jordi] Univ Rovira & Virgili, Joan XXIII Univ Hosp, CIBER Enfermedades Resp CIBERes, IISPV, Tarragona, Spain.
[Afessa, Bekele] Mayo Clin, Coll Med, Rochester, MN USA.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Univ Hosp, S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA.
[Arroliga, Alejandro C.] Scott & White Mem Hosp & Clin, Temple, TX USA.
[Arroliga, Alejandro C.] Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA.
[Olson, Merle E.] Innovotech Inc, Edmonton, AB, Canada.
[Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, VERDICT S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
[Talsma, Silke S.] Bard Med Div, Covington, GA USA.
[Bracken, Ronald L.] CR Bard Inc, Covington, GA USA.
[Kollef, Marin H.] Washington Univ, Sch Med, St Louis, MO USA.
RP Rello, J (reprint author), Univ Rovira & Virgili, Joan XXIII Univ Hosp, CIBER Enfermedades Resp CIBERes, IISPV, Tarragona, Spain.
EM jrello.hj23.ics@gencat.cat
RI Restrepo, Marcos/H-4442-2014
OI Olson, Merle/0000-0003-3654-7692; Rello, Jordi/0000-0003-0676-6210
FU C. R. Bard, Inc.; University of Calgary, Alberta, Canada; Mayo Clinic
College of Medicine, Rochester, MN
FX Supported by grants from C. R. Bard, Inc., and performed at the
University of Calgary, Alberta, Canada; C. R. Bard, Inc., Covington, GA;
and Mayo Clinic College of Medicine, Rochester, MN.
NR 31
TC 17
Z9 19
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD APR
PY 2010
VL 38
IS 4
BP 1135
EP 1140
DI 10.1097/CCM.0b013e3181cd12b8
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA 581CW
UT WOS:000276499700015
PM 20081533
ER
PT J
AU Arbuckle, HA
AF Arbuckle, H. Alan
TI Epidermolysis Bullosa Care in the United States
SO DERMATOLOGIC CLINICS
LA English
DT Article
DE Epidermolysis bullosa; EB centers; Interdisciplinary; Immunomapping
AB There is a wide range of health care delivery systems within the United States for patients with epidermolysis bullosa (EB). They range from nonexistent, primarily because of remote geographic locations, to 4 comprehensive interdisciplinary EB centers. This article lists the subspecialties available at each of the 4 centers.
C1 [Arbuckle, H. Alan] Denver VA Med Ctr, Dermatol Serv, Dept Dermatol, Denver, CO 80220 USA.
[Arbuckle, H. Alan] Childrens Hosp, Epidermolysis Bullosa Clin, Aurora, CO 80045 USA.
RP Arbuckle, HA (reprint author), Denver VA Med Ctr, Dermatol Serv, Dept Dermatol, 1055 Clermont St, Denver, CO 80220 USA.
EM Alan.Arbuckle@ucdenver.edu
NR 1
TC 5
Z9 6
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8635
J9 DERMATOL CLIN
JI Dermatol. Clin.
PD APR
PY 2010
VL 28
IS 2
BP 387
EP +
DI 10.1016/j.det.2010.02.012
PG 4
WC Dermatology
SC Dermatology
GA 604ME
UT WOS:000278282300029
PM 20447508
ER
PT J
AU Luo, NL
Liu, J
Chung, BH
Yang, QL
Klein, RL
Garvey, WT
Fu, YC
AF Luo, Nanlan
Liu, Jian
Chung, B. Hong
Yang, Qinglin
Klein, Richard L.
Garvey, W. Timothy
Fu, Yuchang
TI Macrophage Adiponectin Expression Improves Insulin Sensitivity and
Protects Against Inflammation and Atherosclerosis
SO DIABETES
LA English
DT Article
ID MONOCYTE-DERIVED MACROPHAGES; PIMA INDIAN POPULATION; ADIPOSE-TISSUE;
LIPID-ACCUMULATION; CARDIOVASCULAR-DISEASE; SKELETAL-MUSCLE; RESISTANCE;
OBESITY; HYPERINSULINEMIA; INFILTRATION
AB OBJECTIVE-Adiponectin is one of several important metabolically active cytokines secreted from adipose tissue. Epidemiologic studies have associated low-circulating levels of this adipokine with multiple metabolic disorders including obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. To investigate adiponectin-mediated changes in metabolism in vivo, we generated transgenic mice that specifically express the gene coding for human adiponectin in mouse macrophages using the human scavenger receptor A-I gene enhancer/promoter.
METHODS AND RESULTS-Using this transgenic mouse model, we found that adiponectin expression was associated with reduced whole-animal body and fat-pad weight and an improved lipid accumulation in macrophages when these transgenic mice were fed with a high-fat diet. Moreover, these macrophage Ad-TG mice exhibit enhanced whole-body glucose tolerance and insulin sensitivity with reduced proinflammatory cytokines, MCP-1 and TNF-a (both in the serum and in the metabolic active macrophage), adipose tissue, and skeletal muscle under the high-fat diet condition. Additional studies demonstrated that these macrophage adiponectin transgenic animals exhibit reduced macrophage foam cell formation in the arterial wall when these transgenic mice were crossed with an LDL receptor deficient mouse model and were fed a high-fat diet.
CONCLUSIONS-These results suggest that adiponectin expressed in macrophages can physiologically modulate metabolic activities in vivo by improving metabolism in distal tissues. The use of macrophages as carriers for adiponectin, a molecule with antidiabetes, anti-inflammatory, and antiatherogenic properties, provides a novel and unique strategy for studying the mechanisms of adiponectin-mediated alterations in body metabolism in vivo. Diabetes 59:791-799, 2010
C1 [Luo, Nanlan; Liu, Jian; Chung, B. Hong; Yang, Qinglin; Garvey, W. Timothy; Fu, Yuchang] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Klein, Richard L.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Fu, YC (reprint author), Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA.
EM yfu@uab.edu
RI 王, 强/F-4212-2011
FU UAB Diabetes Research and Training Center, NIH [1P60DK0797626-01,
PO1-HL55782, DK-38764]; Medical Research Service of the Department of
Veterans Affairs; American Diabetes Association [1-07-RA-49]
FX We are grateful to the UAB Diabetes Research and Training Center for
providing outstanding core services (supported by NIH 1P60DK0797626-01).
This work was supported by grants from the National Institutes of Health
(PO1-HL55782 and DK-38764), the Merit Review Program of the Medical
Research Service of the Department of Veterans Affairs to (W.T.G. and
R.L.K.), and the American Diabetes Association (1-07-RA-49) (to Y.F.).
NR 32
TC 57
Z9 62
U1 0
U2 4
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD APR
PY 2010
VL 59
IS 4
BP 791
EP 799
DI 10.2337/db09-1338
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 582MH
UT WOS:000276601200004
PM 20350970
ER
PT J
AU Egede, LE
Ellis, C
AF Egede, Leonard E.
Ellis, Charles
TI The Effects of Depression on Metabolic Control and Quality of Life in
Indigent Patients with Type 2 Diabetes
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID GLYCEMIC CONTROL; SOCIOECONOMIC-STATUS; AFRICAN-AMERICAN; HEALTH; CARE;
SYMPTOMS; MELLITUS; IMPACT; POPULATION; COSTS
AB Background: The objective of this study was to assess differences in metabolic control and health-related quality of life (QOL) among depressed and nondepressed adults in an indigent population with type 2 diabetes.
Research Design and Methods: Subjects completed validated surveys to assess depression and QOL. Depression was assessed with the Center for Epidemiological Studies-Depression Scale and defined as a score of >= 16. Metabolic control (hemoglobin A1C, total cholesterol, low-density lipoprotein [LDL] cholesterol, and high-density lipoprotein [HDL] cholesterol) measures were abstracted from medical records. We compared demographic characteristics, metabolic control, and QOL by depression status. Ordinary least squares regression was used to assess differences in QOL scores and metabolic control levels by depression status adjusting for covariates.
Results: In the study sample (n = 201), approximately 20% (n = 40) were depressed. In unadjusted analyses, subjects with depression had significantly lower SF-12 physical component summary (PCS) scores (30.4 +/- 7.3 vs. 39.6 +/- 11.8, P < 0.001) and mental component summary (MCS) scores (32.8 +/- 10.5 vs. 48.9 +/- 9.2, P <= 0.001) and significantly higher total cholesterol (209.3 +/- 72.1 vs. 186.6 +/- 50.9, P = 0.024) compared to those without depression. No significant differences were observed by depression status in hemoglobin A1C, LDL cholesterol, and HDL cholesterol. After adjustment for relevant covariates, depressed individuals continued to have lower SF-12 PCS (36.1 vs. 39.0, P <= 0.001) and MCS (41.6 vs. 46.8, P <= 0.001) scores, but the difference in total cholesterol levels was no longer significant.
Conclusions: In an indigent sample with type 2 diabetes, depression is significantly associated with decreased physical and mental components of QOL. This finding further reinforces the importance of addressing depression in all populations with type 2 diabetes.
C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA.
[Ellis, Charles] Med Univ S Carolina, Dept Hlth Profess, Charleston, SC 29425 USA.
[Egede, Leonard E.; Ellis, Charles] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU Agency for Health Care Research and Quality, Rockville, MD
[5K08HS11418]; Charleston, SC HSRD [REA 08-261]; Veterans Health
Administration Health Services Research and Development program [CDA
07-012-3]
FX This study was funded by grant 5K08HS11418 from the Agency for Health
Care Research and Quality, Rockville, MD. This work represents work
supported by the use of facilities at the Center for Disease Prevention
and Health Interventions for Diverse Populations funded by the
Charleston, SC HSR&D (REA 08-261). C. E. is supported by a career
development award (CDA 07-012-3) from the Veterans Health Administration
Health Services Research and Development program.
NR 36
TC 14
Z9 14
U1 2
U2 8
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD APR
PY 2010
VL 12
IS 4
BP 257
EP 262
DI 10.1089/dia.2009.0143
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 565NV
UT WOS:000275301700002
PM 20210563
ER
PT J
AU Conway, B
Miller, RG
Costacou, T
Fried, L
Kelsey, S
Evans, RW
Orchard, TJ
AF Conway, B.
Miller, R. G.
Costacou, T.
Fried, L.
Kelsey, S.
Evans, R. W.
Orchard, T. J.
TI Temporal patterns in overweight and obesity in Type 1 diabetes
SO DIABETIC MEDICINE
LA English
DT Article
DE intensive therapy; obesity; Type 1 diabetes
ID IMPROVED GLYCEMIC CONTROL; WEIGHT-GAIN; UNITED-STATES; BODY-WEIGHT;
BLOOD-PRESSURE; COMPLICATIONS; EPIDEMIOLOGY; ADULTS; ALCOHOL; TRENDS
AB P>Aims
Time trends in overweight and obesity in the general population have been well documented; however, temporal patterns in Type 1 diabetes (T1DM) have not been thoroughly investigated. We therefore assessed temporal patterns in overweight and obesity and predictors of weight change in 589 individuals from the Pittsburgh Epidemiology of Diabetes Complications Study, a cohort of childhood-onset T1DM.
Methods
Participants were first seen in 1986-1988, when mean age and diabetes duration were 29 and 20 years, respectively, and biennially thereafter for 18 years. Overweight was defined as 25.0 < body mass index (BMI) < 30.0 kg/m2. Obesity was defined as BMI >= 30.0 kg/m2.
Results
At baseline, the prevalence of overweight and obesity were 28.6% and 3.4%, respectively. After 18 years' follow-up, the prevalence of overweight increased by 47% while the prevalence of obesity increased sevenfold. Seven per cent were on intensive insulin therapy (>= 3 insulin injections per day or on insulin pump) at baseline; by 2004-2007, this was 82%. Predictors of weight change were a higher baseline HbA(1c), symptomatic autonomic neuropathy (inversely), overt nephropathy (inversely), and going onto intensive insulin therapy during follow-up.
Conclusions
These data demonstrate dramatic weight gain in T1DM and underscore the complexity of weight change in this disease.
C1 [Conway, B.; Miller, R. G.; Costacou, T.; Kelsey, S.; Evans, R. W.; Orchard, T. J.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15217 USA.
[Conway, B.] Vanderbilt Univ, Div Epidemiol, Nashville, TN USA.
[Fried, L.] VA Pittsburgh Healthcare Syst, Univ Dr Div, Pittsburgh, PA USA.
RP Orchard, TJ (reprint author), Univ Pittsburgh, Dept Epidemiol, 3512 5th Ave,2nd Fl, Pittsburgh, PA 15217 USA.
EM orchardt@edc.pitt.edu
OI orchard, trevor/0000-0001-9552-3215
FU National Institutes of Health [DK34818]
FX This work was supported by National Institutes of Health (grant number
DK34818). These data were presented in part at the 68th Annual American
Diabetes Association Scientific Sessions, June 2008. We would like to
think the participants of the Epidemiology of Diabetes Complications
study for their continued dedication and cooperation.
NR 21
TC 86
Z9 87
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0742-3071
J9 DIABETIC MED
JI Diabetic Med.
PD APR
PY 2010
VL 27
IS 4
BP 398
EP 404
DI 10.1111/j.1464-5491.2010.02956.x
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 580RH
UT WOS:000276466600005
PM 20536510
ER
PT J
AU Rubinsky, AD
Kivlahan, DR
Volk, RJ
Maynard, C
Bradley, KA
AF Rubinsky, Anna D.
Kivlahan, Daniel R.
Volk, Robert J.
Maynard, Charles
Bradley, Katharine A.
TI Estimating risk of alcohol dependence using alcohol screening scores
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Alcohol dependence; Alcohol screening; Stratum specific likelihood
ratio; Risk stratification; Assessment; Treatment
ID DISORDERS IDENTIFICATION TEST; BEHAVIORAL-COUNSELING INTERVENTIONS;
INTERVIEW SCHEDULE AUDADIS; PRIMARY-CARE VALIDATION; LIKELIHOOD RATIOS;
UNITED-STATES; PROBLEM DRINKING; DRUG MODULES; TEST AUDIT; QUESTION
AB Brief alcohol counseling interventions can reduce alcohol consumption and related morbidity among non-dependent risky drinkers, but more intensive alcohol treatment is recommended for persons with alcohol dependence. This study evaluated whether scores on common alcohol screening tests could identify patients likely to have current alcohol dependence so that more appropriate follow-up assessment and/or intervention could be offered. This cross-sectional study used secondary data from 392 male and 927 female adult family medicine outpatients (1993-1994). Likelihood ratios were used to empirically identify and evaluate ranges of scores of the AUDIT, the AUDIT-C, two single-item questions about frequency of binge drinking, and the CAGE questionnaire for detecting DSM-IV past-year alcohol dependence. Based on the prevalence of past-year alcohol dependence in this sample (men: 12.2%; women: 5.8%), zones of the AUDIT and AUDIT-C identified wide variability in the post-screening risk of alcohol dependence in men and women, even among those who screened positive for alcohol misuse. Among men, AUDIT zones 5-10, 11-14 and 15-40 were associated with post-screening probabilities of past-year alcohol dependence ranging from 18 to 87%, and AUDIT-C zones 5-6,7-9 and 10-12 were associated with probabilities ranging from 22 to 75%. Among women, AUDIT zones 3-4, 5-8, 9-12 and 13-40 were associated with post-screening probabilities of past-year alcohol dependence ranging from 6 to 94%, and AUDIT-C zones 3, 4-6, 7-9 and 10-12 were associated with probabilities ranging from 9 to 88%. AUDIT or AUDIT-C scores could be used to estimate the probability of past-year alcohol dependence among patients who screen positive for alcohol misuse and inform clinical decision-making. Published by Elsevier Ireland Ltd.
C1 [Rubinsky, Anna D.; Kivlahan, Daniel R.; Maynard, Charles; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, NW HSR&D Ctr Excellence, Seattle, WA 98101 USA.
[Rubinsky, Anna D.; Maynard, Charles; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Volk, Robert J.] Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med Ambulatory Treatment & Emer, Houston, TX 77230 USA.
RP Rubinsky, AD (reprint author), VA Puget Sound Hlth Care Syst, NW HSR&D Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM Anna.Rubinsky@va.gov
OI Maynard, Charles/0000-0002-1644-7814; Volk, Robert/0000-0001-8811-5854
FU Northwest Health Services Research and Development Center of Excellence,
VA Puget Sound Health Care System, Seattle, WA; National Institute on
Alcohol Abuse and Alcoholism [R21AA14672]
FX This material is the result of work supported by resources from the
Northwest Health Services Research and Development Center of Excellence,
VA Puget Sound Health Care System, Seattle, WA. The research reported in
this article was supported by National Institute on Alcohol Abuse and
Alcoholism R21AA14672.
NR 47
TC 60
Z9 61
U1 3
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD APR 1
PY 2010
VL 108
IS 1-2
BP 29
EP 36
DI 10.1016/j.drugalcdep.2009.11.009
PG 8
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 579NB
UT WOS:000276376600005
PM 20042299
ER
PT J
AU Souza, P
Gallun, F
AF Souza, Pamela
Gallun, Frederick
TI Amplification and Consonant Modulation Spectra
SO EAR AND HEARING
LA English
DT Article
ID SPEECH-INTELLIGIBILITY; HEARING; COMPRESSION; FREQUENCY; ACOUSTICS;
ENVELOPE; NOISE
AB Objective: In previous work, a simplified version of the modulation spectrum, the Spectral Correlation Index, was shown to be related to consonant error patterns. It is unknown what effect clinical amplification strategies will have on the modulation spectrum. Accordingly, the goals of this study were to examine the effect of clinical amplification strategies on the consonant modulation spectrum and to determine whether there was a relationship between the modulation spectrum and consonant errors for spectrally robust, amplified speech presented to listeners with hearing loss.
Design: Participants were 13 adults ( mean age, 67 yrs) with mild to moderate sensorineural hearing loss. Each listener was fit monaurally in the test ear with a 16- band, four-channel behind the ear hearing aid. One memory of the hearing aid was programmed with compression limiting amplification and one with fast-acting wide-dynamic range compression (WDRC) amplification. Twenty-two consonant-vowel syllables were presented to the listener and recorded at the output of the hearing aid using a probe microphone system. A modulation spectrum was obtained for each amplified and unamplified consonant-vowel. Consonant recognition was also measured for each listener.
Results: Results show that ( 1) WDRC increased heterogeneity of the modulation spectrum across consonants and ( 2) for spectrally robust speech processed with either compression limiting or WDRC amplification, two consonants with similar modulation spectra are more likely to be confused with one another than are the two consonants with dissimilar modulation spectra.
Conclusion: These data expand and confirm earlier results linking the modulation spectrum to specific consonant errors.
C1 [Souza, Pamela] Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL 60208 USA.
[Gallun, Frederick] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA.
RP Souza, P (reprint author), Northwestern Univ, Dept Commun Sci & Disorders, Frances Searle Bldg,2240 Campus Dr, Evanston, IL 60208 USA.
EM p-souza@northwestern.edu
OI Gallun, Frederick/0000-0002-4145-2199
FU [R01 DC 006014]; [P30 DC 04661]; [CD2 C4963W]
FX This work was supported by grants R01 DC 006014 and P30 DC 04661 (to
P.S.), and by grant VA RR&D CD2 C4963W (to F.G.).
NR 21
TC 8
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0196-0202
J9 EAR HEARING
JI Ear Hear.
PD APR
PY 2010
VL 31
IS 2
BP 268
EP 276
DI 10.1097/AUD.0b013e3181c9fb9c
PG 9
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 618PR
UT WOS:000279368600013
PM 20071993
ER
PT J
AU de Lissovoy, G
Fraeman, K
Teerlink, JR
Mullahy, J
Salon, J
Sterz, R
Durtschi, A
Padley, RJ
AF de Lissovoy, Greg
Fraeman, Kathy
Teerlink, John R.
Mullahy, John
Salon, Jeff
Sterz, Raimund
Durtschi, Amy
Padley, Robert J.
TI Hospital costs for treatment of acute heart failure: economic analysis
of the REVIVE II study
SO EUROPEAN JOURNAL OF HEALTH ECONOMICS
LA English
DT Article
DE Acute heart failure; Inotropes; Levosimendan; Dobutamine;
Cost-effectiveness; Pharmacoeconomics; Health care; Hospitalization
ID RISK STRATIFICATION; LEVOSIMENDAN; DOBUTAMINE; TRIAL; SURVIVAL;
EFFICACY; SAFETY; LIDO
AB Acute heart failure (AHF) is the leading cause of hospital admission among older Americans. The Randomized EValuation of Intravenous Levosimendan Efficacy (REVIVE II) trial compared patients randomly assigned to a single infusion of levosimendan (levo) or placebo (SOC), each in addition to local standard treatments for AHF. We report an economic analysis of REVIVE II from the hospital perspective.
REVIVE II enrolled patients (N = 600) hospitalized for treatment of acute decompensated heart failure (ADHF) who remained dyspneic at rest despite treatment with intravenous diuretics. Case report forms documented index hospital treatment (drug administration, procedures, days of treatment by care unit), as well as subsequent hospital and emergency department admissions during follow-up ending 90 days from date of randomization. These data were used to impute cost of admission based on an econometric cost function derived from > 100,000 ADHF hospital billing records selected per REVIVE II inclusion criteria.
Index admission mean length of stay (LOS) was shorter for the levo group compared with standard of care (SOC) (7.03 vs 8.96 days, P = 0.008) although intensive care unit (ICU)/cardiac care unit (CCU) days were similar (levo 2.88, SOC 3.22, P = 0.63). Excluding cost for levo, predicted mean (median) cost for the index admission was levo US $13,590 (9,458), SOC $19,021 (10,692) with a difference of $5,431 (1,234) favoring levo (P = 0.04). During follow-up through end of study day 90, no significant differences were observed in numbers of hospital admissions (P = 0.67), inpatient days (P = 0.81) or emergency department visits (P = 0.41). Cost-effectiveness was performed with a REVIVE-II sub-set conforming to current labeling, which excluded patients with low baseline blood pressure. Assuming an average price for levo in countries where currently approved, there was better than 50% likelihood that levo was both cost-saving and improved survival. Likelihood that levo would be cost-effective for willingness-to-pay below $50,000 per year of life gained was about 65%.
In the REVIVE II trial, patients treated with levo had shorter LOS and lower cost for the initial hospital admission relative to patients treated with SOC. Based on sub-group analysis of patients administered per the current label, levo appears cost-effective relative to SOC.
C1 [de Lissovoy, Greg; Fraeman, Kathy] United BioSource Corp, Bethesda, MD 20814 USA.
[Teerlink, John R.] Univ Calif San Francisco, Cardiol Sect, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Mullahy, John] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA.
[Salon, Jeff; Sterz, Raimund; Durtschi, Amy; Padley, Robert J.] Abbott Labs, Abbott Pk, IL 60064 USA.
RP de Lissovoy, G (reprint author), United BioSource Corp, 7101 Wisconsin Ave,Suite 600, Bethesda, MD 20814 USA.
EM greg.delissovoy@unitedbiosource.com
RI Teerlink, John/D-2986-2012
NR 17
TC 19
Z9 20
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1618-7598
J9 EUR J HEALTH ECON
JI Eur. J. Health Econ.
PD APR
PY 2010
VL 11
IS 2
BP 185
EP 193
DI 10.1007/s10198-009-0165-2
PG 9
WC Economics; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 567NI
UT WOS:000275453400008
PM 19582491
ER
PT J
AU Lee, H
Brecha, NC
AF Lee, Helen
Brecha, Nicholas C.
TI Immunocytochemical evidence for SNARE protein-dependent transmitter
release from guinea pig horizontal cells
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Review
DE mammalian visual system; retina; synaptic proteins; synaptic vesicle
ID GAMMA-AMINOBUTYRIC-ACID; TIGER SALAMANDER RETINA; VESICULAR GABA
TRANSPORTER; SYNAPTIC VESICLE PROTEINS; C-LIKE IMMUNOREACTIVITY; OUTER
PLEXIFORM LAYER; IN-SITU HYBRIDIZATION; MULLER GLIAL-CELLS; ROD BIPOLAR
CELLS; MOUSE RETINA
AB Horizontal cells are lateral interneurons that participate in visual processing in the outer retina but the cellular mechanisms underlying transmitter release from these cells are not fully understood. In non-mammalian horizontal cells, GABA release has been shown to occur by a non-vesicular mechanism. However, recent evidence in mammalian horizontal cells favors a vesicular mechanism as they lack plasmalemmal GABA transporters and some soluble NSF attachment protein receptor (SNARE) core proteins have been identified in rodent horizontal cells. Moreover, immunoreactivity for GABA and the molecular machinery to synthesize GABA have been found in guinea pig horizontal cells, suggesting that if components of the SNARE complex are expressed they could contribute to the vesicular release of GABA. In this study we investigated whether these vesicular and synaptic proteins are expressed by guinea pig horizontal cells using immunohistochemistry with well-characterized antibodies to evaluate their cellular distribution. Components of synaptic vesicles including vesicular GABA transporter, synapsin I and synaptic vesicle protein 2A were localized to horizontal cell processes and endings, along with the SNARE core complex proteins, syntaxin-1a, syntaxin-4 and synaptosomal-associated protein 25 (SNAP-25). Complexin I/II, a cytosolic protein that stabilizes the activated SNARE fusion core, strongly immunostained horizontal cell soma and processes. In addition, the vesicular Ca2+-sensor, synaptotagmin-2, which is essential for Ca2+-mediated vesicular release, was also localized to horizontal cell processes and somata. These morphological findings from guinea pig horizontal cells suggest that mammalian horizontal cells have the capacity to utilize a regulated Ca2+-dependent vesicular pathway to release neurotransmitter, and that this mechanism may be shared among many mammalian species.
C1 [Lee, Helen; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
[Lee, Helen; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA.
[Brecha, Nicholas C.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Lee, H (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM hlee@jsei.ucla.edu
FU NIH [EY 15573]; Jules Stein Eye Institute EyeSTAR program
FX We thank Drs Salvatore Stella Jr, Arlene Hirano, Chenying Guo, Iona
Raymond and Steve Barnes for their insightful comments on this
manuscript. Supported by NIH EY 15573 and the Jules Stein Eye Institute
EyeSTAR program. N.C.B. is a VA Senior Career Research Scientist.
NR 182
TC 17
Z9 17
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0953-816X
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD APR
PY 2010
VL 31
IS 8
BP 1388
EP 1401
DI 10.1111/j.1460-9568.2010.07181.x
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 585WD
UT WOS:000276860000007
PM 20384779
ER
PT J
AU Ohye, H
Sugawara, M
AF Ohye, Hidemi
Sugawara, Masahiro
TI Dual oxidase, hydrogen peroxide and thyroid diseases
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Review
DE dual oxidase; hydrogen peroxide; congenital hypothyroidism; Hashimoto's
thyroiditis; papillary thyroid cancer
ID AIRWAY EPITHELIAL-CELLS; CONGENITAL HYPOTHYROIDISM; NADPH-OXIDASE; H2O2
GENERATION; GENE-EXPRESSION; IODIDE ORGANIFICATION;
FUNCTIONAL-CHARACTERIZATION; H2O2-GENERATING ACTIVITY; MATURATION
FACTOR; THOX2 GENE
AB The thyroid gland is a unique endocrine organ that requires hydrogen peroxide (H2O2) for thyroid hormone formation. The molecule for H2O2 production in the thyroid gland has been known as dual oxidase 2 (DUOX2). Recently, NADPH oxidase 4 (NOX4), a homolog of the NOX family, was added as a new intracellular source of reactive oxygen species (ROS) in the human thyroid gland. This review focuses on the recent progress of the DUOX system and its possible contribution to human thyroid diseases. Also, we discuss human thyroid diseases related to abnormal H2O2 generation. The DUOX molecule contains peroxidase-like and NADPH oxidase-like domains. Human thyroid gland also contains DUOX1 that shares 83% similarity with the DUOX2 gene. However, thyroid DUOX1 protein appears to play a minor role in H2O2 production. DUOX proteins require DUOX maturation or activation factors (DUOXA1 or 2) for proper translocation of DUOX from the endoplasmic reticulum to the apical plasma membrane, where H2O2 production takes place. Thyroid cells contain antioxidants to protect cells from the H2O2-mediated oxidative damage. Loss of this balance may result in thyroid cell dysfunction and thyroid diseases. Mutation of either DUOX2 or DUOXA2 gene is a newly recognized cause of hypothyroidism due to insufficient H2O2 production. Papillary thyroid carcinoma, the most common thyroid cancer, is closely linked to the increased ROS production by NOX4. Hashimoto's thyroiditis, a common autoimmune thyroid disease in women, becomes conspicuous when iodide intake increases. This phenomenon may be explained by the abnormality of iodide-induced H2O2 or other ROS in susceptible individuals. Discovery of DUOX proteins and NOX4 provides us with valuable tools for a better understanding of pathophysiology of prevalent thyroid diseases.
C1 [Ohye, Hidemi; Sugawara, Masahiro] Greater Los Angeles Vet Affair Healthcare Syst, Endocrinol & Diabet Div, Los Angeles, CA USA.
[Ohye, Hidemi; Sugawara, Masahiro] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
RP Sugawara, M (reprint author), Greater Los Angeles VA Hlth Care Syst 111M, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM msugawar@ucla.edu
FU VA Merit Review
FX We thank Dr Jerome M Hershman for critical reading of the manuscript.
This work is supported by the VA Merit Review Research Grant.
NR 74
TC 39
Z9 41
U1 1
U2 8
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD APR
PY 2010
VL 235
IS 4
BP 424
EP 433
DI 10.1258/ebm.2009.009241
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 596NK
UT WOS:000277691700003
PM 20407074
ER
PT J
AU Sethi, S
AF Sethi, Sanjay
TI Antibiotics in acute exacerbations of chronic bronchitis
SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
LA English
DT Review
DE antimicrobial resistance; chronic bronchitis; COPD; exacerbation;
Haemophilus influenzae; Moraxella catarrhalis; Streptococcus pneumoniae
ID OBSTRUCTIVE PULMONARY-DISEASE; RESISTANT STREPTOCOCCUS-PNEUMONIAE;
RESPIRATORY-TRACT INFECTIONS; TRUST SURVEILLANCE PROGRAM; LONG-TERM
OUTCOMES; HAEMOPHILUS-INFLUENZAE; ANTIMICROBIAL RESISTANCE; ALEXANDER
PROJECT; UNITED-STATES; PROTEKT US
AB Acute exacerbations of chronic bronchitis (AECB) are a major contributor to morbidity and mortality in patients with chronic obstructive pulmonary disease, accounting for more than 16 million physician office visits and over 500,000 hospitalizations in the USA each year. Antimicrobials have been recognized by clinical guidelines as an important component in the management of AECB with a bacterial etiology. The challenge of identifying patients most likely to benefit from antimicrobial therapy is difficult in the clinical setting. However, appropriate risk stratification of patients, and the use of antimicrobials within the correct spectrum and for a suitable duration, can improve clinical outcomes while minimizing induction of antimicrobial resistance. With an improved design in pharmacologic and clinical studies, differences can be appreciated among the various antimicrobial agents available to treat AECB. Factors to be considered in antimicrobial agent selection include local tissue penetration, effects on bacteriological eradication, duration of therapy, speed of resolution and prevention or delay of recurrences.
C1 [Sethi, Sanjay] US Dept Vet Affairs, Western New York Healthcare Syst, VA Med Res 151, Buffalo, NY 14215 USA.
[Sethi, Sanjay] SUNY Buffalo, Dept Med, Div Pulm & Crit Care Med, Buffalo, NY 14260 USA.
RP Sethi, S (reprint author), US Dept Vet Affairs, Western New York Healthcare Syst, VA Med Res 151, 3495 Bailey Ave, Buffalo, NY 14215 USA.
EM ssethi@buffalo.edu
FU Bayer; Cornerstone; Glaxo Smith Kline; Mpex; Pfizer; Sanofi-Aventis;
Schering; Schering-Plough, Corporation
FX The author has received research support, honoraria or consulting fees
from Bayer, Cornerstone, Glaxo Smith Kline, Mpex, Pfizer, Sanofi-Aventis
and Schering. The author has no other relevant affiliations or financial
involvement with any organization or entity with a financial interest in
or financial conflict with the subject matter or materials discussed in
the manuscript apart from those disclosed.; The author would like to
acknowledge the editorial assistance of Shabber Abbas in the preparation
of this manuscript. Support for this assistance was provided by
Schering-Plough, Corporation. The author accepts full responsibility for
the construction and authorship of this manuscript. No other writing
assistance was utilized in the production of this manuscript.
NR 84
TC 5
Z9 6
U1 0
U2 1
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1478-7210
J9 EXPERT REV ANTI-INFE
JI Expert Rev. Anti-Infect. Ther.
PD APR
PY 2010
VL 8
IS 4
BP 405
EP 417
DI 10.1586/ERI.09.133
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 592KT
UT WOS:000277378500011
PM 20377336
ER
PT J
AU Acevedo-Torres, K
Torres-Ramos, CA
Walter, CA
Ayala-Torres, S
AF Acevedo-Torres, Karina
Torres-Ramos, Carlos A.
Walter, Christi A.
Ayala-Torres, Sylvette
TI Age-Dependent Accumulation of Mitochondrial DNA Damage in Brain Tissues
Derived from Apex1+/- Mice
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Acevedo-Torres, Karina] San Juan Bautista Sch Med, Dept Biochem, Caguas, PR USA.
[Torres-Ramos, Carlos A.] Univ Puerto Rico, Dept Physiol, San Juan, PR 00936 USA.
[Ayala-Torres, Sylvette] Univ Puerto Rico, Dept Pharmacol, San Juan, PR 00936 USA.
[Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Walter, Christi A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2010
VL 24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA V28IW
UT WOS:000208675506622
ER
PT J
AU Bunni, MA
Morinelli, TA
Bell, PD
Raymond, JR
Garnovskaya, MN
AF Bunni, Marlene A.
Morinelli, Thomas A.
Bell, Phillip D.
Raymond, John R.
Garnovskaya, Maria N.
TI Bradykinin B2 receptor activates extracellular signal regulated kinase
in renal cells from a mouse model of polycystic kidney disease
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Bunni, Marlene A.; Morinelli, Thomas A.; Bell, Phillip D.; Raymond, John R.; Garnovskaya, Maria N.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Bunni, Marlene A.; Morinelli, Thomas A.; Bell, Phillip D.; Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson VAMC, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2010
VL 24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA V28IW
UT WOS:000208675507264
ER
PT J
AU Chen, YX
Gelfond, J
McManus, LM
Shireman, PK
AF Chen, Yongxin
Gelfond, Jonathan
McManus, Linda M.
Shireman, Paula K.
TI MiRNA Expression Patterns during Skeletal Muscle Regeneration
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Chen, Yongxin; Gelfond, Jonathan; McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Chen, Yongxin; Shireman, Paula K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2010
VL 24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA V28IW
UT WOS:000208675500248
ER
PT J
AU Ferruzzi, MG
Ho, L
Pasinetti, GM
AF Ferruzzi, Mario G.
Ho, Lap
Pasinetti, Giulio M.
TI Carotenoid levels in ageing human brain with reduced cognitive function
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Ferruzzi, Mario G.] Purdue Univ, W Lafayette, IN 47907 USA.
[Ho, Lap] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA.
[Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Ho, Lap; Pasinetti, Giulio M.] James J Peters VA Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2010
VL 24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA V28IW
UT WOS:000208675504033
ER
PT J
AU Ho, L
Ferruzzi, MG
Janle, EM
Lobo, J
Chen, TY
Talcott, ST
Simon, J
Wu, QL
Wang, J
Cheng, A
Weaver, CM
Percival, SS
Pasinetti, GM
AF Ho, Lap
Ferruzzi, Mario G.
Janle, Elsa M.
Lobo, Jessica
Chen, Tzu-Ying
Talcott, Stephen T.
Simon, Jim
Wu, Qing Li
Wang, Jun
Cheng, Alice
Weaver, Connie M.
Percival, Susan S.
Pasinetti, Giulio Maria
TI Bioavailability of grape-derived polyphenolics and implications in
Alzheimer's disease prevention and therapy
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Ho, Lap; Wang, Jun; Cheng, Alice; Pasinetti, Giulio Maria] Mt Sinai Sch Med, New York, NY USA.
[Ho, Lap; Pasinetti, Giulio Maria] James J Peters VA Med Ctr, GRECC, Bronx, NY USA.
[Ferruzzi, Mario G.; Janle, Elsa M.; Lobo, Jessica; Chen, Tzu-Ying; Weaver, Connie M.] Purdue Univ, W Lafayette, IN 47907 USA.
[Talcott, Stephen T.] Texas A&M Univ, College Stn, TX USA.
[Simon, Jim; Wu, Qing Li] Rutgers State Univ, New Brunswick, NJ 08903 USA.
[Percival, Susan S.] Univ Florida, Gainesville, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2010
VL 24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA V28IW
UT WOS:000208675502736
ER
PT J
AU Pasinetti, GM
Chen, TY
Janle, EM
Cheng, A
AF Pasinetti, Giulio Maria
Chen, Tzu-Ying
Janle, Elsa M.
Cheng, Alice
TI Role of Grape-Derived Polyphenols in the Prevention of Alzheimer's
disease and the Promotion of Healthy Aging
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Pasinetti, Giulio Maria; Cheng, Alice] Mt Sinai Sch Med, New York, NY USA.
[Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Chen, Tzu-Ying; Janle, Elsa M.] Purdue Univ, W Lafayette, IN 47907 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2010
VL 24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA V28IW
UT WOS:000208675505640
ER
PT J
AU Sas, KM
Janech, MG
Amria, MY
Stenbit, AE
Bell, PD
AF Sas, Kelli Margot
Janech, Michael G.
Amria, May Y.
Stenbit, Antine E.
Bell, P. Darwin
TI Cilia movement represses mitogen-activated protein kinase signaling by
enhancing expression of the raf kinase inhibitor protein
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Sas, Kelli Margot; Janech, Michael G.; Amria, May Y.; Stenbit, Antine E.; Bell, P. Darwin] Med Univ S Carolina, Charleston, SC 29425 USA.
[Janech, Michael G.; Bell, P. Darwin] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2010
VL 24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA V28IW
UT WOS:000208675505371
ER
PT J
AU Soto-Pina, AE
Kadapakkam, S
Mehring, C
Hinojosa-Laborde, C
Strong, R
AF Soto-Pina, Alexandra Estela
Kadapakkam, Sheela
Mehring, Cynthia
Hinojosa-Laborde, Carmen
Strong, Randy
TI Sympathectomy does not inhibit dexamethasone-induced hypertension
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Soto-Pina, Alexandra Estela; Kadapakkam, Sheela; Mehring, Cynthia; Hinojosa-Laborde, Carmen; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Soto-Pina, Alexandra Estela; Kadapakkam, Sheela; Strong, Randy] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2010
VL 24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA V28IW
UT WOS:000208675501845
ER
PT J
AU Torres-Ramos, CA
Torres-Ortz, C
Walter, C
Ayala-Torres, S
AF Torres-Ramos, Carlos A.
Torres-Ortz, Ceidy
Walter, Christi
Ayala-Torres, Sylvette
TI Apex1 haploinsufficiency leads to age-dependent increases in mtDNA
lesions in liver
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Torres-Ramos, Carlos A.] Univ Puerto Rico, Dept Physiol, San Juan, PR 00936 USA.
[Torres-Ramos, Carlos A.; Torres-Ortz, Ceidy; Ayala-Torres, Sylvette] Univ Puerto Rico, Dept Biochem, San Juan, PR 00936 USA.
[Ayala-Torres, Sylvette] Univ Puerto Rico, Dept Pharmacol, San Juan, PR 00936 USA.
[Walter, Christi] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Walter, Christi] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2010
VL 24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA V28IW
UT WOS:000208675505663
ER
PT J
AU Wick, MJ
Miller, YE
Dempsey, EC
AF Wick, Marilee J.
Miller, York E.
Dempsey, Edward C.
TI Neprilysin Peptidase-Independent Complex Formation In Pulmonary Artery
Smooth Muscle Cells
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Wick, Marilee J.; Dempsey, Edward C.] Univ Colorado Denver, CVP Res, Med, Aurora, CO USA.
[Miller, York E.] Univ Colorado Denver, Div Pulm, Aurora, CO USA.
[Wick, Marilee J.; Miller, York E.; Dempsey, Edward C.] Denver VAMC, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2010
VL 24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA V28IW
UT WOS:000208675506363
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI Inflationary caution in GI endoscopy
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Editorial Material
ID COLONOSCOPY; TIME
C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
NR 8
TC 2
Z9 2
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD APR
PY 2010
VL 71
IS 4
BP 789
EP 791
DI 10.1016/j.gie.2009.12.044
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 580LE
UT WOS:000276449000021
PM 20363420
ER
PT J
AU Mercado, C
Zingmond, D
Karlan, BY
Sekaris, E
Gross, J
Maggard-Gibbons, M
Tomlinson, JS
Ko, CY
AF Mercado, Cheryl
Zingmond, David
Karlan, Beth Y.
Sekaris, Evan
Gross, Jenny
Maggard-Gibbons, Melinda
Tomlinson, James S.
Ko, Clifford Y.
TI Quality of care in advanced ovarian cancer: The importance of provider
specialty
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Ovarian cancer; Outcomes; Quality of life
ID ACHIEVING EXCELLENT OUTCOMES; HOSPITAL VOLUME; SURGEON VOLUME;
COLORECTAL RESECTION; EXPERIENCE; CARCINOMA; SURROGATE; INDEX; SERVE
AB Background. One of the cornerstones of ovarian cancer therapy is cytoreductive surgery, which can be performed by surgeons with different specialty training. We examined whether surgeon specialty impacts quality of life (as proxied by presence of ostomy) and overall survival for women with advanced ovarian cancer.
Methods. Stage IIIC/IV ovarian cancer patients were identified using 4 state cancer registries: California, Washington, New York, and Florida and linked records to the corresponding inpatient-hospital discharge file, AMA Masterfile, and 2000 U.S. Census SF4 File. Predictors of receipt of care by a general surgeon and creation of fecal ostomy were analyzed. Multivariate modeling was performed to assess the association of hospital volume (low volume (LV) [0-4 cases], middle volume (MV) [5-9], high volume (HV) [10-19], and very high volume (VHV) [20+]) and surgeon specialty training (gynecologic oncologists/gynecologists, general surgeons, and other specialty) on survival.
Results. We identified 31,897 Stage IIIC/IV patients; mean age was 64 years. Treatment of patients by a general surgeon was predicted by LV, rural patient residence, poverty, and high level of comorbidity. Patients had lower hazard of death when treated in higher volume hospitals as compared to LV [VHV hazard ratio (HR) = 0.79, P<.0001; HV HR = 0.89, P<0.001]. Patients treated by a general surgeon had higher likelihood of an ostomy (OR = 4.46, P<.0001) and hazard of death (HR = 1.63, P<.0001) compared to gynecologic oncologist/gynecologist.
Conclusions. Advanced stage ovarian cancer patients have better survival when treated by gynecologic oncology/gynecology trained surgeons. Data suggest that referral to these specialists may optimize surgical debulking and minimize the creation of a fecal ostomy. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Mercado, Cheryl; Zingmond, David; Sekaris, Evan; Maggard-Gibbons, Melinda; Tomlinson, James S.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Karlan, Beth Y.; Gross, Jenny] Cedars Sinai Med Ctr, Div Gynecol Oncol, Womens Canc Res Inst, Los Angeles, CA 90048 USA.
[Maggard-Gibbons, Melinda] Olive View UCLA, Dept Surg, Sylmar, CA 91342 USA.
[Tomlinson, James S.; Ko, Clifford Y.] VA Greater Angeles Los Healthcare Syst, Dept Surg, Los Angeles, CA 90073 USA.
RP Ko, CY (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 72-215 Ctr Hlth Sci,Box 956904, Los Angeles, CA 90095 USA.
EM cko@mednet.ucla.edu
RI Lester, Jenny/B-5933-2012
FU Centers for Disease Control; American Cancer Society
FX This work was supported by the Centers for Disease Control and the
American Cancer Society.
NR 24
TC 39
Z9 39
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD APR
PY 2010
VL 117
IS 1
BP 18
EP 22
DI 10.1016/j.ygyno.2009.12.033
PG 5
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 582JV
UT WOS:000276594200004
PM 20106512
ER
PT J
AU Selim, AJ
Berlowitz, D
Kazis, LE
Rogers, W
Wright, SM
Qian, SX
Rothendler, JA
Spiro, A
Miller, D
Selim, BJ
Fincke, BG
AF Selim, Alfredo J.
Berlowitz, Dan
Kazis, Lewis E.
Rogers, William
Wright, Steven M.
Qian, Shirley X.
Rothendler, James A.
Spiro, Avron, III
Miller, Donald
Selim, Bernardo J.
Fincke, Benjamin G.
TI Comparison of Health Outcomes for Male Seniors in the Veterans Health
Administration and Medicare Advantage Plans
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Health outcomes; system comparison; quality of care
ID QUALITY-OF-CARE; MANAGED CARE; MYOCARDIAL-INFARCTION; ILL PATIENTS;
MORTALITY; SERVICES; PROGRAM; SYSTEM; HOSPITALS; INDICATOR
AB Objectives
To compare the Veterans Health Administration (VHA) with the Medicare Advantage (MA) plans with regard to health outcomes.
Data Sources
The Medicare Health Outcome Survey, the 1999 Large Health Survey of Veteran Enrollees, and the Ambulatory Care Survey of Healthcare Experiences of Patients (Fiscal Years 2002 and 2003).
Study Design
A retrospective study.
Extraction Methods
Men 65+ receiving care in MA (N=198,421) or in VHA (N=360,316). We compared the risk-adjusted probability of being alive with the same or better physical (PCS) and mental (MCS) health at 2-years follow-up. We computed hazard ratio (HR) for 2-year mortality.
Principal Findings
Veterans had a higher adjusted probability of being alive with the same or better PCS compared with MA participants (VHA 69.2 versus MA 63.6 percent, p <.001). VHA patients had a higher adjusted probability than MA patients of being alive with the same or better MCS (76.1 versus 69.6 percent, p <.001). The HRs for mortality in the MA were higher than in the VHA (HR, 1.26 [95 percent CI 1.23-1.29]).
Conclusions
Our findings indicate that the VHA has better patient outcomes than the private managed care plans in Medicare. The VHA's performance offers encouragement that the public sector can both finance and provide exemplary health care.
C1 [Selim, Alfredo J.] Edith Nourse Rogers Mem Hosp 152, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA.
[Selim, Alfredo J.] Boston VA Hlth Care Syst, Emergency Serv, W Roxbury, MA USA.
[Selim, Alfredo J.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Fincke, Benjamin G.] Edith Nourse Rogers Mem Hosp, Ctr Hlth Qual Outcomes & Econ Res, Dept Vet Affairs Med Ctr, Patient Care Serv,Med Serv, Bedford, MA USA.
[Rothendler, James A.; Spiro, Avron, III; Miller, Donald] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Rogers, William] Tufts Univ New England Med Ctr, New England Med Ctr, Hlth Inst, Boston, MA USA.
[Wright, Steven M.] US Dept Vet Affairs, Off Qual & Performance, Washington, DC USA.
[Selim, Bernardo J.] Yale New Haven Med Ctr, New Haven, CT 06504 USA.
[Fincke, Benjamin G.] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Selim, AJ (reprint author), Edith Nourse Rogers Mem Hosp 152, Ctr Hlth Qual Outcomes & Econ Res, Bldg 70,200 Springs Rd, Bedford, MA 01730 USA.
EM alfredo.selim2@va.gov
OI Spiro III, Avron/0000-0003-4080-8621; Kazis, Lewis/0000-0003-1800-5849
FU Centers for Medicare and Medicaid Services; National Committee for
Quality Assurance (NCQA) [500-00-0055]; Office of Quality and
Performance (OQP) of the Department of Veterans Affairs; Center for
Health Quality, Outcomes and Economic Research (CHQOER); Department of
Veterans Affairs; Boston University School of Public Health
FX Disclosures: The research in this article was supported by the Centers
for Medicare and Medicaid Services and the National Committee for
Quality Assurance (NCQA) under contract numbers 500-00-0055 with NCQA,
Office of Quality and Performance (OQP) of the Department of Veterans
Affairs, The Center for Health Quality, Outcomes and Economic Research
(CHQOER), Department of Veterans Affairs and Boston University School of
Public Health.
NR 48
TC 11
Z9 11
U1 1
U2 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0017-9124
J9 HEALTH SERV RES
JI Health Serv. Res.
PD APR
PY 2010
VL 45
IS 2
BP 376
EP 396
DI 10.1111/j.1475-6773.2009.01068.x
PG 21
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 565YT
UT WOS:000275335900003
PM 20050934
ER
PT J
AU Kinnaird, AN
Anstead, GM
AF Kinnaird, A. N.
Anstead, G. M.
TI Hemorrhagic Cystitis and Possible Neurologic Disease from BK Virus
Infection in a Patient with AIDS
SO INFECTION
LA English
DT Article
ID PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ACTIVE ANTIRETROVIRAL
THERAPY; POLYOMAVIRUS INFECTION; RECIPIENTS; NEPHRITIS; CIDOFOVIR;
SURVIVAL; DNA
AB BK virus (BKV)-associated hemorrhagic cystitis occurs in bone marrow transplant recipients but is rare among other immunosuppressed patients. We present a rare case of BKV-associated hemorrhagic cystitis in a 48-year-old man with AIDS and previously diagnosed progressive multifocal leukoencephalopathy.
C1 [Anstead, G. M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, Off Educ Programs, San Antonio, TX 78229 USA.
[Anstead, G. M.] S Texas Vet Healthcare Syst, Div Infect Dis, Dept Med, San Antonio, TX USA.
RP Kinnaird, AN (reprint author), 4903 Edgemoor Ln,Apt 802, Bethesda, MD 20814 USA.
EM akinnairdmd@gmail.com
NR 27
TC 9
Z9 9
U1 0
U2 0
PU URBAN & VOGEL
PI MUNICH
PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY
SN 0300-8126
J9 INFECTION
JI Infection
PD APR
PY 2010
VL 38
IS 2
BP 124
EP 127
DI 10.1007/s15010-009-9201-5
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA 584VI
UT WOS:000276781100008
PM 20198406
ER
PT J
AU Joos, B
Rieder, P
Fischer, M
Kuster, H
Rusert, P
Trkola, A
Pillai, SK
Wong, JK
Weber, R
Gunthard, HF
AF Joos, Beda
Rieder, Philip
Fischer, Marek
Kuster, Herbert
Rusert, Peter
Trkola, Alexandra
Pillai, Satish K.
Wong, Joseph K.
Weber, Rainer
Guenthard, Huldrych F.
TI Association between specific HIV-1 Env traits and virologic control in
vivo
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article; Proceedings Paper
CT 14th International Bioinformatics Workshop on Virus Evolution and
Molecular Epidemiology
CY SEP 08-12, 2008
CL Cape Town, SOUTH AFRICA
DE HIV-1; Envelope gp120; Evolution; Machine learning
ID STRUCTURED TREATMENT INTERRUPTIONS; POTENT ANTIRETROVIRAL THERAPY; VIRUS
TYPE-1 ENV; CHRONIC INFECTION; SET-POINT; IMMUNITY; RNA; REPLICATION;
PREDICTION; RESPONSES
AB HIV RNA levels are influenced by genetic characteristics of both the host and the virus Here we applied machine learning techniques to determine if plasma-derived HIV-1 amino acid sequences can be used to predict spontaneous virologic control We studied the relationship between HIV-1 env genotype and viral load in 20 chronically infected patients undergoing treatment interruptions (SSITT, Swiss-Spanish Intermittent Treatment Trial) and in 104 primary HIV infected (PHI) patients before antiretroviral therapy (cART) and where applicable also after treatment stop Extensive longitudinal sampling during the interruptions was performed in nine SSITT patients Sequences obtained from these nine patients during the first virus rebound were used as a training data set and revealed a strong genetic signature (accuracy 98 6% in cross-validation) associated with control of viremia at levels below 5000 copies/mL of viral RNA maintained for at least 2 months after the final cART stop The simple sequence pattern at gp120 positions 268E/358T was confirmed to be predictive of control in the clonal sequences originating from these patients during all subsequent rebounds Sequences from the remaining 11 SSITT patients with less frequent sampling and from the PHI patients were used for external validation High sensitivities (71-100%) and negative predictive values (80-100%) but low positive predictive values (12-40%) were achieved in the patient-wise analysis which was based on presence of the genetic pattern in all clones. These results suggest that presence of virus lacking the amino acid pattern 268E/358T is associated with VL >5000 at baseline of PHI and with low probability of spontaneous virologic control after treatment stop Conversely, however, presence of 268E/358T does not predict control of viremia. These residues in HIV gp120 might affect in vivo HIV-1 fitness either at the level of Env function or influence susceptibility to adaptive or innate immune response (C) 2009 Elsevier B V All rights reserved
C1 [Joos, Beda; Rieder, Philip; Fischer, Marek; Kuster, Herbert; Weber, Rainer; Guenthard, Huldrych F.] Univ Zurich Hosp, Dept Med, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland.
[Rusert, Peter; Trkola, Alexandra] Univ Zurich, Inst Med Virol, CH-8006 Zurich, Switzerland.
[Pillai, Satish K.; Wong, Joseph K.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
RP Joos, B (reprint author), Univ Zurich Hosp, Dept Med, Div Infect Dis & Hosp Epidemiol, Ramistr 100, CH-8091 Zurich, Switzerland.
RI Joos, Beda/D-5547-2009; gunthard, huldrych/F-1724-2011; Kuster,
Herbert/A-3912-2013; Infektiologie, USZ/A-6921-2011; SHCS,
ch/G-4077-2011; SHCS, only/G-4080-2011; Weber, Rainer/D-5175-2012; SHCS,
all/G-4072-2011; Trkola, Alexandra/K-2115-2012
OI Joos, Beda/0000-0002-3082-8875; gunthard, huldrych/0000-0002-1142-6723;
Trkola, Alexandra/0000-0003-1013-876X
FU NIDA NIH HHS [K01 DA024654]
NR 29
TC 1
Z9 1
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD APR
PY 2010
VL 10
IS 3
SI SI
BP 365
EP 372
DI 10.1016/j.meegid.2009.06.002
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 586UB
UT WOS:000276937900003
PM 19524069
ER
PT J
AU Burns, SP
Kaufman, RP
Mack, CD
Bulger, E
AF Burns, Stephen P.
Kaufman, Robert P.
Mack, Christopher D.
Bulger, Eileen
TI Cost of spinal cord injuries caused by rollover automobile crashes
SO INJURY PREVENTION
LA English
DT Article
ID RISK
AB Objective To determine the reduction in direct cost for treatment of spinal cord injuries (SCI) in belted occupants involved in rollover automobile crashes in the USA that would result if severe roof intrusion were eliminated.
Methods Risk of SCI per rollover crash and by belted/unbelted status was calculated for roof intrusion magnitude categories using 1993-2006 National Automotive Sampling System Crashworthiness Data System (CDS) data. Direct costs of SCI based on neurological level and completeness of SCI were calculated using data from the National SCI Statistical Center.
Results A reduction in rate of SCI for belted occupants with >15 cm roof intrusion to the rate seen for belted occupants with 8-15 cm roof intrusion would reduce the direct cost of SCI by approximately $97 million annually.
Conclusion There would be substantial cost savings solely by a reduction in one uncommon type of injury, SCI, if severe roof intrusion were eliminated.
C1 [Burns, Stephen P.] Univ Washington, VA Puget Sound Hlth Care Syst, Spinal Cord Injury Serv 128, Seattle, WA 98108 USA.
[Burns, Stephen P.; Kaufman, Robert P.; Mack, Christopher D.; Bulger, Eileen] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98108 USA.
[Burns, Stephen P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98108 USA.
[Bulger, Eileen] Univ Washington, Dept Surg, Seattle, WA 98108 USA.
RP Burns, SP (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Spinal Cord Injury Serv 128, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM spburns@u.washington.edu
FU NHTSA [DTNH22-05-H-11001]; Centers for Disease Control and Prevention
(CDC) [R49 CCR002570-19]; National Institute on Disability and
Rehabilitation Research (NIDRR) [H133N060033]; Veterans Affairs (VA)
Puget Sound Health Care System
FX Work was performed for the Crash Injury Research and Engineering Network
(CIREN) project at the University of Washington/Harborview Injury
Prevention and Research Center in cooperation with the US Department of
Transportation/National Highway Traffic Safety Administration (NHTSA).
Funding has been provided by NHTSA under Cooperative Agreement Number
DTNH22-05-H-11001. Additional support has been provided by Grant No. R49
CCR002570-19 from the Centers for Disease Control and Prevention (CDC),
Grant No. H133N060033 from the National Institute on Disability and
Rehabilitation Research (NIDRR), and the Veterans Affairs (VA) Puget
Sound Health Care System. Views expressed are those of the authors and
do not necessarily represent the views of NHTSA, CDC, NIDRR or VA. Study
design, data acquisition, analysis and interpretation, manuscript
preparation and review were conducted independent of sponsoring
organisations.
NR 20
TC 4
Z9 4
U1 1
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1353-8047
J9 INJURY PREV
JI Inj. Prev.
PD APR
PY 2010
VL 16
IS 2
BP 74
EP 78
DI 10.1136/ip.2008.021097
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 577FW
UT WOS:000276208800002
PM 20363811
ER
PT J
AU Goetz, MB
Leduc, R
Wyman, N
Kostman, JR
Labriola, AM
Lie, Y
Weidler, J
Coakley, E
Bates, M
Luskin-Hawk, R
AF Goetz, Matthew Bidwell
Leduc, Robert
Wyman, Nicole
Kostman, Jay R.
Labriola, Ann M.
Lie, Yolanda
Weidler, Jodi
Coakley, Eoin
Bates, Michael
Luskin-Hawk, Roberta
CA Long Term Monitoring Study CPCRA0
TI HIV Replication Capacity Is an Independent Predictor of Disease
Progression in Persons With Untreated Chronic HIV Infection
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE disease progression; HIV infections; natural history; replication
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PHENOTYPIC DRUG SUSCEPTIBILITY;
INHIBITOR-RESISTANT HIV-1; LONG-TERM SURVIVORS; VIRAL FITNESS;
CORECEPTOR TROPISM; CELL COUNTS; PROTEASE; THERAPY; LOAD
AB Objective: To assess the effect of pol replication capacity (RC) on the hazard ratio of progression to a composite endpoint of time to progression to < 350 CD4(+) cells per microliter, initiation of therapy, or death.
Methods: pol RC assays were performed after study closure in baseline samples obtained from 316 enrollees in a prospectively monitored cohort of treatment-naive adults with >= 450 CD4(+) cells per microliter and >= 1000 HIV-1 RNA copies per milliliter.
Results: The median RC was 79%. Patients with a lower RC had a lower median viral load (4.0 vs 4.2 Log HIV-1 RNA copies/mL, P = 0.026) and a lower rate of protease inhibitor resistance 2% vs 8%, P = 0.03). Otherwise, baseline demographic and laboratory characteristics were similar. The hazard ratio of progression to the composite endpoint was 0.73 ( P = 0.041) for persons with lower RC, 2.07 per 1.0 log(10) higher viral load (P < 0.001), and 0.86 per 50 cells per microliter higher CD4(+) cell count (P < 0.001). The effect of lower RC was also significant in a separate analysis of time to initiation of therapy (P = 0.04).
Conclusions: These results show that untreated patients with lower vs higher RC had a slower rate of progression as assessed by a composite outcome of time to CD4(+) count <= 350 cells per microliter, treatment initiation, or death.
C1 [Goetz, Matthew Bidwell] Vet Affairs Greater Los Angeles Healthcare Syst, Infect Dis Sect 111 F, Dept Med, Los Angeles, CA 90073 USA.
[Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Leduc, Robert; Wyman, Nicole] Univ Minnesota, Div Biostat, Minneapolis, MN USA.
[Kostman, Jay R.] Univ Penn Hlth Syst, Presbyterian Med Ctr, Dept Med, Philadelphia, PA USA.
[Labriola, Ann M.] George Washington Univ, Med Ctr, Washington, DC 20037 USA.
[Labriola, Ann M.] Vet Affairs Med Ctr, Dept Med, Washington, DC 20422 USA.
[Lie, Yolanda; Weidler, Jodi; Coakley, Eoin; Bates, Michael] Monogram Biosci, San Francisco, CA USA.
[Luskin-Hawk, Roberta] St Joseph Hosp, Dept Med, Chicago, IL USA.
RP Goetz, MB (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Infect Dis Sect 111 F, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM matthew.goetz@va.gov
OI Goetz, Matthew/0000-0003-4542-992X
FU National Institute of Allergy and Infectious Diseases [U01 AI042170, U01
AI046362, U01 AI068641]; SBIR [R44AI050321]
FX Supported by National Institute of Allergy and Infectious Diseases
grants U01 AI042170, U01 AI046362, and U01 AI068641 to the Community
Programs for Clinical Research on AIDS and SBIR R44AI050321 to Monogram
Biosciences.
NR 40
TC 6
Z9 6
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 1
PY 2010
VL 53
IS 4
BP 472
EP 479
DI 10.1097/QAI.0b013e3181cae480
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 567YW
UT WOS:000275486600006
PM 20032783
ER
PT J
AU Kim, WK
Meliton, V
Tetradis, S
Weinmaster, G
Hahn, TJ
Carlson, M
Nelson, SF
Parhami, F
AF Kim, Woo-Kyun
Meliton, Vicente
Tetradis, Sotirios
Weinmaster, Gerry
Hahn, Theodore J.
Carlson, Marc
Nelson, Stanley F.
Parhami, Farhad
TI Osteogenic Oxysterol, 20(S)-Hydroxycholesterol, Induces Notch Target
Gene Expression in Bone Marrow Stromal Cells
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OXYSTEROL; MESENCHYMAL STEM CELLS; NOTCH; HEDGEHOG; OSTEOGENESIS
ID INDUCED OSTEOBLASTIC DIFFERENTIATION; VASCULAR DEVELOPMENT; SIGNALING
PATHWAYS; SONIC-HEDGEHOG; IN-VIVO; HES-1; FATE; HEY1; INTEGRATION;
ACTIVATION
AB We previously reported that specific oxysterols stimulate osteogenic differentiation of pluripotent bone marrow stromal cells (MSCs) through activation of hedgehog (Hh) signaling and may serve as potential future therapies for intervention in osteopenia and osteoporosis. In this study we report that the osteogenic oxysterol 20(S)-hydroxycholesterol (20S) induces the expression of genes associated with Notch signaling. Using M2-10B4 (M2) MSCs, we found that 20S significantly induced HES-1, HEY-1, and HEY-2 mRNA expression compared with untreated cells, with maximal induction after 48 hours, whereas the nonosteogenic oxysterols did not Similar observations were made when M2 cells were treated with sonic hedgehog (Shh), and the specific Hh pathway inhibitor cyclopamine blocked 20S-induced Notch target gene expression. 20S did not induce Notch target genes in Smo(-/-) mouse embryonic fibroblasts, further confirming the role of Hh signaling in 20S-induced expression of Notch target genes. Despite the inability of liver X-receptor (LXR) synthetic ligand TO901317 to induce Notch target genes in M2 cells, LXR knockdown studies using siRNA showed inhibition of 20S-induced HEY-1 but not HES-1 expression, suggesting the partial role of LXR signaling in MSC responses to 20S Moreover, 20S-induced Notch target gene expression was independent of canonical Notch signaling because neither 20S nor Shh induced CBF1 luaferase reporter activity or NICD protein accumulation in the nucleus, which are hallmarks of canonical Notch signaling activation Finally, HES-1 and HEY-1 siRNA transfection significantly inhibited 20S-induced osteogenic genes, suggesting that the pro-osteogenic effects of 20S are regulated in part by HES-1 and HEY-1. (C) 2010 American Society for Bone and Mineral Research.
C1 [Kim, Woo-Kyun; Meliton, Vicente; Parhami, Farhad] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Tetradis, Sotirios] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.
[Weinmaster, Gerry] Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.
[Hahn, Theodore J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Hahn, Theodore J.] Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA.
[Carlson, Marc; Nelson, Stanley F.] Univ Calif Los Angeles, Dept Human Genet, Sch Med, Los Angeles, CA 90095 USA.
RP Parhami, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci, A2-237 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
RI Nelson, Stanley/D-4771-2009
FU NIAMS, National Institutes of Health (NIH) [RO1 AR050426]; National
Institute of Aging [5P30AG028748]
FX This work was supported in part by NIAMS, National Institutes of Health
(NIH) Grant RO1 AR050426, and a Pilot Study Award from the UCLA Claude
Pepper Older American Independence Center funded by the National
Institute of Aging Grant 5P30AG028748 We thank Dr Philip Beachy
(Stanford University) for providing the Smo-/- MEFs We are
grateful to Brendan D'Souza (UCLA Department of Biological Chemistry)
for critical review of this manuscript and insightful discussions
NR 47
TC 15
Z9 15
U1 0
U2 5
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2010
VL 25
IS 4
BP 782
EP 795
DI 10.1359/jbmr.091024
PG 14
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 589YF
UT WOS:000277189400011
PM 19839776
ER
PT J
AU Costanzo, MR
Saltzberg, MT
Jessup, M
Teerlink, JR
Sobotka, PA
AF Costanzo, Maria Rosa
Saltzberg, Mitchell T.
Jessup, Mariell
Teerlink, John R.
Sobotka, Paul A.
CA Ultrafiltration Versus Intravenous
TI Ultrafiltration is Associated With Fewer Rehospitalizations than
Continuous Diuretic Infusion in Patients With Decompensated Heart
Failure: Results From UNLOAD
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Ultrafiltration; diuretics; heart failure
ID BODY-FLUID; FUROSEMIDE; RESISTANCE; OUTCOMES; REGISTRY; TRIAL; DEATH
AB Background: Compare outcomes of ultrafiltration (UF) versus standard intravenous (IV) diuretics by continuous infusion or bolus injection in volume overloaded heart failure (HF) patients. In the Ultrafiltration versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated heart Failure (UNLOAD) study, UF produced greater fluid reduction and fewer HF rehospitalizations than IV diuretics in 200 hospitalized HF patients. Outcomes may be due to greater fluid removal, but UF removes more sodium/unit volume than diuretics.
Methods and Results: Outcomes of 100 patients randomized to UF were compared with those of patients randomized to standard IV diuretic therapy with continuous infusion (32) or bolus injections (68). Choice of diuretic therapy was by the treating physician. Forty-eight hour weight loss (kg): 5.0 +/- 3.1 UF, 3.6 +/- 3.5 continuous infusion, and 2.9 +/- 3.5 bolus diuretics (P = .001 UF versus bolus diuretic; P > .05 for the other comparisons). Net fluid loss (L): 4.6 +/- 2.6 UF, 3.9 +/- 2.7 continuous infusion, and 3.1 +/- 2.6 bolus diuretics (P < .001 UF versus bolus diuretic; P > .05 for the other comparisons). At 90 days, rehospitalizations plus unscheduled visits for HF/patient (rehospitalization equivalents) were fewer in UF group (0.65 +/- 1.36) than in continuous infusion (2.29 +/- 3.23; P = .016 versus UF) and bolus diuretics (1.31 +/- 1.87; P = .050 versus UF) groups. No serum creatinine differences occurred between groups up to 90 days.
Conclusions: Despite similar fluid loss with UF and continuous diuretic infusion, fewer HF rehospitalizations equivalents occurred only with UF. Removal of isotonic fluid by UF compared with hypotonic urine by diuretics more effectively reduces total body sodium in congested HE patients. (J Cardiac Fail 2010;16:277-284)
C1 [Costanzo, Maria Rosa] Midwest Heart Fdn, Lombard, IL USA.
[Saltzberg, Mitchell T.] Univ Penn, Dept Med, Div Cardiol, Christiana Hosp, Philadelphia, PA 19104 USA.
[Teerlink, John R.] Univ Calif San Francisco, Cardiol Sect, San Francisco Vet Affairs Med Ctr, Sch Med, San Francisco, CA 94143 USA.
[Sobotka, Paul A.] Ohio State Univ, Affiliate Fac, Columbus, OH 43210 USA.
RP Costanzo, MR (reprint author), Midwest Heart Fdn, Edward Heart Hosp, 4th Floor,801 S Washington St,POB 3226, Naperville, IL 60506 USA.
EM mcostanzo@midwestheart.com
RI Teerlink, John/D-2986-2012
NR 20
TC 56
Z9 63
U1 0
U2 2
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD APR
PY 2010
VL 16
IS 4
BP 277
EP 284
DI 10.1016/j.cardfail.2009.12.009
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 588HR
UT WOS:000277060400001
PM 20350693
ER
PT J
AU Yarbrough, WM
Mukherjee, R
Stroud, RE
Meyer, EC
Escobar, GP
Sample, JA
Hendrick, JW
Mingoia, JT
Spinale, FG
AF Yarbrough, William M.
Mukherjee, Rupak
Stroud, Robert E.
Meyer, Evan C.
Escobar, G. Patricia
Sample, Jeffrey A.
Hendrick, Jennifer W.
Mingoia, Joseph T.
Spinale, Francis G.
TI Caspase Inhibition Modulates Left Ventricular Remodeling Following
Myocardial Infarction Through Cellular and Extracellular Mechanisms
SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
LA English
DT Article; Proceedings Paper
CT Annual Scientific Meeting of the
Institute-of-Cardiovascular-Science-and-Medicine
CY DEC 13, 2009
CL Hong Kong, PEOPLES R CHINA
SP Inst Cardiovasc Sci & Med
DE myocardial infarction; remodeling; caspase inhibition; left ventricular
ID MATRIX-METALLOPROTEINASE INHIBITION; HEART-FAILURE; DNA FRAGMENTATION;
RABBIT HEART; IN-VIVO; APOPTOSIS; ISCHEMIA; DEATH; SIZE; RECOVERY
AB Background: Myocyte death occurs by necrosis and caspase-mediated apoptosis in myocardial infarction (MI). In vitro studies suggest caspase activation causes myocardial contractile protein degradation without inducing apoptosis. Thus, caspase activation may evoke left ventricular (LV) remodeling through independent processes post-MI. The effects of caspase activation on LV geometry post-MI remain unclear. This project applied pharmacologic caspase inhibition (CASPI) to a porcine model of MI.
Methods and Results: Pigs (34 kg) were instrumented to induce 60 minutes of coronary artery occlusion followed by reperfusion and a 7-day follow-up period. Upon reperfusion, the pigs were randomized to saline (n = 12) or CASPI (n = 10, IDN6734, 6 mg/kg IV, then 6 mg/kg/h for 24 hours). Plasma troponin-I values were reduced with CASPI compared with saline at 24 hours post-MI (133 +/- 15 vs. 189 +/- 20 ng/mL, respectively, P < 0.05). LV end-diastolic area (echocardiography) and interregional length (sonomicrometry) increased from baseline in both groups but were attenuated with CASPI by 40% and 90%, respectively (P < 0.05). Myocyte length was reduced with CASPI compared with saline (128 +/- 3 vs. 141 +/- 4 mm, respectively, P < 0.05). Plasma-free pro-matrix metalloproteinase-2 values increased from baseline with CASPI (27% +/- 6%, P < 0.05) indicative of reduced conversion to active MMP-2. Separate in vitro studies demonstrated that activated caspase species cleaved pro-MMP-2 yielding active MMP-2 forms and that MMP activity was increased in the presence of activated caspase-3.
Conclusions: CASPI attenuated regional and global LV remodeling post-MI and altered viable myocyte geometry. Caspases increased MMP activity in vitro, whereas CASPI modified conversion of MMP-2 to the active form in vivo. Taken together, the results of the present study suggest that the elaboration of caspases post-MI likely contribute to LV remodeling through both cellular and extracellular mechanisms.
C1 [Yarbrough, William M.; Mukherjee, Rupak; Stroud, Robert E.; Meyer, Evan C.; Escobar, G. Patricia; Sample, Jeffrey A.; Hendrick, Jennifer W.; Mingoia, Joseph T.; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA.
[Yarbrough, William M.; Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Spinale, FG (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, 770 MUSC Complex,STRB,Suite 625, Charleston, SC 29425 USA.
EM wilburnm@musc.edu
FU NHLBI NIH HHS [R01 HL059165, T32 HL007260, HL-81692, R01 HL057952,
HL-07260, R01 HL059165-12, R01 HL057952-12, HL-87134]
NR 30
TC 11
Z9 11
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0160-2446
J9 J CARDIOVASC PHARM
JI J. Cardiovasc. Pharmacol.
PD APR
PY 2010
VL 55
IS 4
BP 408
EP 416
DI 10.1097/FJC.0b013e3181d4ca66
PG 9
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA 591NN
UT WOS:000277307900014
PM 20147844
ER
PT J
AU Mishra, SK
Singh, P
AF Mishra, Shri Kant
Singh, Parampreet
TI History of Neuroimaging: The Legacy of William Oldendorf
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE history of neurology; neuroimaging; CT scan; Nobel Prize; neuroradiology
ID BRAIN-BARRIER PERMEABILITY; KETONE-BODIES; STARVATION; PHYSIOLOGY;
TRANSPORT; HEXOSES
AB The field of neuroimaging witnessed remarkable progress in the post-World War II era, resulting in tremendous benefits for healthcare today. One such important milestone was the development of the computerized axial tomography (CAT) scan. This state of the art technique has paved the way for modern diagnostic imaging like magnetic resonance imaging (MRI). Dr William Oldendorf, the first designer of axial tomography, is regarded by some as the true father of neuroimaging. However, because of various reasons, he was unable to succeed with his concept and was also unfortunately denied his due entitlement of the Nobel Prize for Medicine and Physiology in 1979. This article discusses his contributions to the fields of neuroimaging and neurosciences, along with the politics that surrounded the awarding of the Nobel Prize of 1979. Another associated topic that is touched on in this article is the ever-growing dispute over the interpretations of neuroimaging between neurologists and neuroradiologists.
C1 [Mishra, Shri Kant] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Mishra, Shri Kant] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Mishra, Shri Kant] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Mishra, Shri Kant; Singh, Parampreet] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA.
RP Mishra, SK (reprint author), 16111 Plummer St, Sepulveda, CA 91343 USA.
EM smishra@usc.edu
NR 23
TC 1
Z9 1
U1 0
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
J9 J CHILD NEUROL
JI J. Child Neurol.
PD APR
PY 2010
VL 25
IS 4
BP 508
EP 517
DI 10.1177/0883073809359083
PG 10
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 579HU
UT WOS:000276360400019
PM 20382954
ER
PT J
AU Harrington, AT
Mahlen, SD
Clarridge, JE
AF Harrington, Amanda T.
Mahlen, Steven D.
Clarridge, Jill E., III
TI Significantly Larger Numbers of Methicillin-Resistant Staphylococcus
aureus Bacteria Are Recovered from Polymicrobial Respiratory and Wound
Sites by Use of Chromogenic Primary Media than by Use of Conventional
Culture
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID MRSA-SELECT; CHROMAGAR MRSA; NASAL CARRIAGE; SWABS; MRSASELECT; THROAT;
ASSAY; AGAR
AB Previous studies have validated the properties and documented the utility of chromogenic agar for surveillance of methicillin-resistant Staphylococcus aureus (MRSA). In this study, we used one of the chromagars, MRSASelect (Bio-Rad), as one of the primary isolation media for selected wound and respiratory clinical specimens which, in our institution, were typically polymicrobial. We examined a total of 638 specimens; 142 (22%) MRSA isolates were recovered. Twenty-six of these isolates were recovered only on the MRSASelect plate, representing a 28% (15/54) increase for endotracheal aspirates/sputa and a 15% increase for superficial wounds/ulcers (11/73) compared to the results with conventional culture. One isolate (1 CFU) was recovered by conventional medium alone. MRSASelect has generally been used for surveillance cultures; however, we document that an additional 21% of MRSA isolates would have gone unreported in these selected clinical specimens using only standard culture media. For 40% (6/15) of inpatients, MRSA isolated from the MRSASelect plate was the sole indicator of MRSA. Although these isolates can represent either colonization or infection, they are a potential reservoir of infection and nosocomial transmission. Our data support the focused use of chromogenic selective media for the increased detection of MRSA in polymicrobial wound and respiratory specimens, which could have an impact on both clinical treatment and infection control.
C1 [Harrington, Amanda T.; Clarridge, Jill E., III] Puget Sound Hlth Care Syst, Seattle, WA USA.
[Mahlen, Steven D.; Clarridge, Jill E., III] Univ Washington, Seattle, WA 98195 USA.
RP Clarridge, JE (reprint author), VA Puget Sound Hlth Care Syst, Dept Pathol & Lab Med, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM jill.clarridge@va.gov
FU VA Puget Sound Health Care System, Seattle, WA
FX This material is the result of work supported in part by resources from
the VA Puget Sound Health Care System, Seattle, WA.
NR 15
TC 9
Z9 10
U1 2
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD APR
PY 2010
VL 48
IS 4
BP 1350
EP 1353
DI 10.1128/JCM.01770-09
PG 4
WC Microbiology
SC Microbiology
GA 576OC
UT WOS:000276153200046
PM 20181901
ER
PT J
AU Neuwelt, EA
Brock, P
AF Neuwelt, Edward A.
Brock, Penelope
TI Critical Need for International Consensus on Ototoxicity Assessment
Criteria
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID INDUCED HEARING-LOSS; CISPLATIN-INDUCED OTOTOXICITY;
CHILDRENS-ONCOLOGY-GROUP; CHILDHOOD HEPATOBLASTOMA; SODIUM THIOSULFATE;
N-ACETYLCYSTEINE; AMIFOSTINE; PLATINUM; TUMORS; MEDULLOBLASTOMA
C1 [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA.
[Brock, Penelope] Great Ormond St Hosp Sick Children, London WC1N 3JH, England.
[Brock, Penelope] Inst Child Hlth, London, England.
RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 26
TC 22
Z9 22
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 1
PY 2010
VL 28
IS 10
BP 1630
EP 1632
DI 10.1200/JCO.2009.26.7872
PG 3
WC Oncology
SC Oncology
GA 576NS
UT WOS:000276152200004
PM 20194840
ER
PT J
AU Marder, SR
Sorsaburu, S
Dunayevich, E
Karagianis, JL
Dawe, IC
Falk, DM
Dellva, MA
Carlson, JL
Cavazzoni, PA
Baker, RW
AF Marder, Stephen R.
Sorsaburu, Sebastian
Dunayevich, Eduardo
Karagianis, Jamie L.
Dawe, Ian C.
Falk, Deborah M.
Dellva, Mary Anne
Carlson, Janice L.
Cavazzoni, Patrizia A.
Baker, Robert W.
TI Case Reports of Postmarketing Adverse Event Experiences With Olanzapine
Intramuscular Treatment in Patients With Agitation
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID DOUBLE-BLIND; SCHIZOPHRENIA; PLACEBO; HALOPERIDOL; LORAZEPAM; MORTALITY;
DEMENTIA; EFFICACY; PEOPLE
AB Objective: Agitation is a medical emergency with increased risk for poor outcome. Successful treatment often requires intramuscular (IM) psychotropics. Safety data from the first 21 months of olanzapine IM, approved in the United States for the treatment of agitation associated with schizophrenia and bipolar disorder, are presented.
Method: A Lilly-maintained safety database was searched for all spontaneous adverse events (AEs) reported in temporal association with olanzapine IM treatment.
Results: The estimated worldwide patient exposure to olanzapine IM from January 1, 2004, through September 30, 2005, was 539,000; 160 cases containing AEs were reported from patients with schizophrenia (30%), bipolar disorder (21%), unspecified psychosis (10%), dementia (8%), and depression (5%). Many reported concomitant treatment with benzodiazepines (39%) or other antipsychotics (54%). The most frequently reported events involved the following organ systems: central nervous (21%), cardiac (12%), respiratory (6%), vascular (6%), and psychiatric (5%). Eightythree cases were considered serious, including 29 fatalities. In these fatalities, concomitant benzodiazepines or other antipsychotics were reported in 66% and 76% of cases, respectively. The most frequently reported events in the fatal cases involved the following organ systems: cardiovascular (41%), respiratory (21%), general (17%), and central nervous (10%). The majority of fatal cases (76%) included comorbid conditions and potentially clinically significant risk factors for AEs.
Conclusions: Clinicians should use care when treating agitated patients, especially when they present with concurrent medical conditions and are treated with multiple medications, which may increase the risk of poor or even fatal outcomes. Clinicians should use caution when using olanzapine IM and parenteral benzodiazepines simultaneously. J Clin Psychiatry 2010;71(4):433-441 (C) Copyright 2010 Physicians Postgraduate Press, Inc.
C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Marder, Stephen R.] Los Angeles Vet Adm, Los Angeles, CA USA.
[Dunayevich, Eduardo] Orexigen Therapeut, La Jolla, CA USA.
[Sorsaburu, Sebastian; Falk, Deborah M.; Dellva, Mary Anne; Carlson, Janice L.; Cavazzoni, Patrizia A.; Baker, Robert W.] Lilly Corp Ctr, Eli Lilly, Lilly Res Labs, Indianapolis, IN USA.
[Karagianis, Jamie L.] Eli Lilly, Toronto, ON, Canada.
[Dawe, Ian C.] Univ Toronto, St Michaels Hosp, Dept Psychiat, Toronto, ON M5B 1W8, Canada.
RP Marder, SR (reprint author), W Los Angeles VA Healthcare Ctr, Bldg 210,Room 130,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM marder@UCLA.edu
NR 19
TC 12
Z9 12
U1 1
U2 4
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 240008, MEMPHIS, TN 38124 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD APR
PY 2010
VL 71
IS 4
BP 433
EP 441
DI 10.4088/JCP.08m04411gry
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 588HI
UT WOS:000277059300008
PM 20156413
ER
PT J
AU Webb, CA
DeRubeis, RJ
Barber, JP
AF Webb, Christian A.
DeRubeis, Robert J.
Barber, Jacques P.
TI Therapist Adherence/Competence and Treatment Outcome: A Meta-Analytic
Review
SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
LA English
DT Article
DE meta-analysis; therapist; adherence; competence
ID TERM INDIVIDUAL PSYCHOTHERAPY; COGNITIVE-BEHAVIORAL THERAPY; BRIEF
DYNAMIC THERAPY; TRANSFERENCE INTERPRETATIONS; TREATMENT ADHERENCE;
RATING-SCALE; COMPETENCE; ALLIANCE; DEPRESSION; PATIENT
AB Objective: The authors conducted a meta-analytic review of adherence-outcome and competence-outcome findings, and examined plausible moderators of these relations. Method: A computerized search of the PsycINFO database was conducted. In addition, the reference sections of all obtained studies were examined for any additional relevant articles or review chapters. The literature search identified 36 studies that met the inclusion criteria. Results: R-type effect size estimates were derived from 32 adherence outcome and 17 competence outcome findings. Neither the mean weighted adherence outcome (r = .02) nor competence outcome (r = .07) effect size estimates were found to be significantly different from zero. Significant heterogeneity was observed across both the adherence outcome and competence outcome effect size estimates, suggesting that the individual studies were not all drawn from the same population. Moderator analyses revealed that larger competence outcome effect size estimates were associated with studies that either targeted depression or did not control for the influence of the therapeutic alliance. Conclusions: One explanation for these results is that, among the treatment modalities represented in this review, therapist adherence and competence play little role in determining symptom change. However, given the significant heterogeneity observed across findings, mean effect sizes must be interpreted with caution. Factors that may account for the nonsignificant adherence outcome and competence outcome findings reported within many of the studies reviewed are addressed. Finally, the implication of these results and directions for future process research are discussed.
C1 [Webb, Christian A.; DeRubeis, Robert J.] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA.
[Barber, Jacques P.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Barber, Jacques P.] Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA.
RP Webb, CA (reprint author), Univ Penn, Dept Psychol, 3815 Walnut St, Philadelphia, PA 19104 USA.
EM webb@sas.upenn.edu
OI barber, jacques/0000-0002-8762-2595
FU NIMH NIH HHS [R01 MH060998, R01 MH061410, R01MH061410, R01MH60998]
NR 71
TC 173
Z9 174
U1 8
U2 43
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-006X
J9 J CONSULT CLIN PSYCH
JI J. Consult. Clin. Psychol.
PD APR
PY 2010
VL 78
IS 2
BP 200
EP 211
DI 10.1037/a0018912
PG 12
WC Psychology, Clinical
SC Psychology
GA 582CK
UT WOS:000276572800007
PM 20350031
ER
PT J
AU Lin, JC
Karno, MP
Tang, LQ
Barry, KL
Blow, FC
Davis, JW
Ramirez, KD
Welgreen, S
Hoffing, M
Moore, AA
AF Lin, James C.
Karno, Mitchell P.
Tang, Lingqi
Barry, Kristen L.
Blow, Frederic C.
Davis, James W.
Ramirez, Karina D.
Welgreen, Sandra
Hoffing, Marc
Moore, Alison A.
TI Do Health Educator Telephone Calls Reduce At-risk Drinking Among Older
Adults in Primary Care?
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE alcohol; telephone intervention; health educator; at-risk drinking
ID RANDOMIZED-CONTROLLED-TRIAL; BRIEF PHYSICIAN ADVICE; ALCOHOL-USE;
GENERAL-PRACTITIONERS; BRIEF INTERVENTION; PROBLEM DRINKERS;
CONSUMPTION; MANAGEMENT; PEOPLE; PREVALENCE
AB Alcohol screening and brief intervention for unhealthy alcohol use has not been consistently delivered in primary care as part of preventive healthcare.
To explore whether telephone-based intervention delivered by a health educator is efficacious in reducing at-risk drinking among older adults in primary care settings.
Secondary analyses of data from a randomized controlled trial.
Subjects randomized to the intervention arm of the trial (n = 310).
Personalized risk reports, advice from physicians, booklet about alcohol and aging, and up to three telephone calls from a health educator. All interventions were completed before the three-month follow-up.
Risk outcomes (at-risk or not at-risk) at 3 and 12 months after enrollment.
In univariate analyses, compared to those who remained at risk, those who achieved not at-risk outcome at 3 months were more likely to be women, Hispanic or non-white, have lower levels of education, consume less alcohol, drink less frequently, and have lower baseline number of risks. In mixed-effects logistic regression models, completing all three health educator calls increased the odds of achieving not at-risk outcome compared to not completing any calls at 3 months (OR 5.31; 95% CI 1.92-14.7; p = 0.001), but not at 12 months (OR 2.01; 95% CI 0.71-5.67; p = 0.18).
Telephone-based intervention delivered by a health educator was moderately efficacious in reducing at-risk drinking at 3 months after enrollment among older adults receiving a multi-faceted intervention in primary care settings; however, the effect was not sustained at 12 months.
C1 [Lin, James C.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Lin, James C.; Davis, James W.; Ramirez, Karina D.; Moore, Alison A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Lin, James C.] Cheng Ching Hosp, Dept Med, Taichung, Taiwan.
[Karno, Mitchell P.; Moore, Alison A.] Univ Calif Los Angeles, Integrated Subst Abuse Programs, Los Angeles, CA USA.
[Tang, Lingqi] Univ Calif Los Angeles, Hlth Serv Res Ctr, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA.
[Barry, Kristen L.; Blow, Frederic C.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
[Welgreen, Sandra] Kaiser Permanente, Panorama City, CA USA.
[Hoffing, Marc] Desert Oasis Healthcare, Palm Springs, CA USA.
[Moore, Alison A.] Div Geriatr Med, Los Angeles, CA USA.
RP Lin, JC (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Ave,Bldg 220,Room 302, Los Angeles, CA 90073 USA.
EM jlin1207@ucla.edu
FU Special Fellowship in Advanced Geriatrics; VA Greater Los Angeles
Healthcare System; National Institutes of Health, National Institute on
Alcoholism and Alcohol Abuse [AA013937, AA15957]
FX Funding sources: Special Fellowship in Advanced Geriatrics, VA Greater
Los Angeles Healthcare System, and the National Institutes of Health,
National Institute on Alcoholism and Alcohol Abuse (AA013937 and
AA15957)
NR 43
TC 17
Z9 17
U1 4
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD APR
PY 2010
VL 25
IS 4
BP 334
EP 339
DI 10.1007/s11606-009-1223-2
PG 6
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 571TS
UT WOS:000275779300011
PM 20101471
ER
PT J
AU Brown, CJ
Bradberry, C
Howze, SG
Hickman, L
Ray, H
Peel, C
AF Brown, Cynthia J.
Bradberry, Christy
Howze, Shalaney Green
Hickman, Lindsay
Ray, Heather
Peel, Claire
TI Defining Community Ambulation From the Perspective of the Older Adult
SO JOURNAL OF GERIATRIC PHYSICAL THERAPY
LA English
DT Article
DE aging; mobility; walking
AB Background: Little is known regarding destinations and distances necessary for independent community ambulation after enactment of the Americans with Disability Act.
Objective: To qualitatively describe community locations visited by older adults and to determine ambulation distance required to visit these locations.
Design: Descriptive study.
Methods: Nineteen subjects, 65 years or older and who were independent with transportation, ambulation, and basic activities of daily living, were recruited from 4 senior centers in urban areas of central Alabama. The study was divided into 2 phases. In part 1, using qualitative methodology, older adults were interviewed to determine locations they visited in the community. In part 2, we visited the types of locations identified in part 1 and measured distances required to conduct business at each location. Obstacles, if any, to reaching these locations were identified.
Results: Subjects had a mean age of 76.6 (5.8) years; 80% were women, and 50% lived alone in the community. Locations visited by subjects were identified and measured. Researchers categorized locations as essential, essential to some people, and nonessential. Essential locations included bank, doctor's office, and either a grocery store, pharmacy, and department store or a "superstore." A minimum of approximately 200 m was required for community ambulation to most locations, although this distance varied significantly among locations.
Limitations: Geographic location and urban setting may not reflect distances necessary for rural residents.
Conclusions: Physical therapists can use the 200-m distance as a starting point for goal-setting for older adults desiring a return to community independence.
C1 [Brown, Cynthia J.] Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL USA.
[Brown, Cynthia J.] Univ Alabama, Dept Med, Birmingham, AL USA.
[Bradberry, Christy; Howze, Shalaney Green; Hickman, Lindsay; Ray, Heather; Peel, Claire] Univ Alabama, Sch Hlth Profess, Birmingham, W Midlands, England.
RP Brown, CJ (reprint author), Birmingham VAMC, GRECC 11-G Room 8226,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM cbrownmd@uab.edu
FU VA Research Career Development Award [E6326W]
FX The authors thank the subjects who participated in this study. C.
Bradberry, S. Green, L. Hickman, and H. Ray completed this project in
partial fulfillment of the requirements of the doctoral degree (physical
therapy), University of Alabama at Birmingham. Dr Brown is a recipient
of a VA Research Career Development Award (E6326W) and the John A.
Hartford-sponsored Southeast Center of Excellence in Geriatric Medicine
Special Fellows award.
NR 18
TC 8
Z9 8
U1 2
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1539-8412
J9 J GERIATR PHYS THER
JI J. Geriatr. Phys. Ther.
PD APR-JUN
PY 2010
VL 33
IS 2
BP 56
EP 63
PG 8
WC Geriatrics & Gerontology; Rehabilitation
SC Geriatrics & Gerontology; Rehabilitation
GA V21PK
UT WOS:000208219300003
PM 20718384
ER
PT J
AU Barrett, TW
Newton, K
Koudelka, C
Mori, M
Radcliffe, L
AF Barrett, Thomas W.
Newton, Kathleen
Koudelka, Caroline
Mori, Motomi
Radcliffe, LeAnn
TI Impact of Combination Medical Therapy on Mortality in Vascular Surgery
Patients
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article; Proceedings Paper
CT 3rd Annual Perioperative Medicine Meeting
CY SEP 11, 2007
CL Cleveland, OH
DE mortality; perioperative medicine; vascular surgery; veterans
ID PERIOPERATIVE MYOCARDIAL-ISCHEMIA; LONG-TERM MORTALITY; CONVERTING
ENZYME-INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; MAJOR NONCARDIAC
SURGERY; HIGH-RISK PATIENTS; CARDIOVASCULAR EVENTS; SECONDARY
PREVENTION; ANESTHETIC INDUCTION; PROPENSITY SCORE
AB BACKGROUND: Th use of beta-blockers or statins has been associated with decreased mortality after noncardiac surgery. There are no prior perioperative studies of concurrent use of other cardioprotective drugs. OBJECTIVE: To ascertain whether combinations of aspirin, beta-blockers, statins, and/or angiotensin-converting enzyme (ACE) inhibitors were associated with decreased mortality 6 months after vascular surgery.
PATIENTS AND DESIGN: We performed a retrospective cohort study on the 3020 patients who underwent vascular surgery between January 1998 and March 2005 at 5 regional Veterans Affairs (VA) medical centers. The Cochran-Mantel-Haenszel test was used to assess associations with 6-month all-cause mortality for the combination drug exposures compared to no exposure while adjusting for propensity score.
RESULTS: Exposure to all 4 of the study drugs compared to none had a propensity-adjusted relative risk (aRR) of 0.52 (95% confidence interval [CI], 0.26-1.01; P = 0.052), number needed to treat (NNT) 19; 3 drugs vs. none, aRR 0.60 (95% Cl, 0.38-0.95; P = 0.030), NNT 38; 2 drugs vs. none, aRR 0.68 (95% CI, 0.46-0.99; P = 0.043), NNT 170; and 1 drug vs. none, aRR 0.88 (95% CI, 0.63-1.22; P = 0.445). ACE inhibitor exposure was common in all combinations.
CONCLUSIONS: Combination use of 2 to 3 study drugs, some of which included ACE inhibitors, was associated with decreased mortality after vascular surgery. Combination use of all 4 study drugs was not statistically significant due to the small number of events in this group. Further prospective studies of combination perioperative aspirin, beta-blockers, statins, and ACE inhibitors are warranted. Journal of Hospital Medicine 2010;5:218-225. (C) 2010 Society of Hospital Medicine.
C1 [Barrett, Thomas W.] Portland Vet Affairs VA Med Ctr, Sect Gen Med, Portland, OR USA.
[Barrett, Thomas W.] Oregon Hlth & Sci Univ, Div Hosp Med, Portland, OR 97201 USA.
[Newton, Kathleen; Mori, Motomi] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Div Biostat, Portland, OR 97201 USA.
[Koudelka, Caroline; Mori, Motomi] Oregon Hlth & Sci Univ, Ctr Biostat Comp & Informat Biol & Med, Portland, OR 97201 USA.
[Radcliffe, LeAnn] Portland VA Med Ctr, Portland VA Res Fdn, Portland, OR USA.
RP Barrett, TW (reprint author), Portland VAMC P3MED, 3710 SW US VA Hosp Rd, Portland, OR 97207 USA.
EM barretth@ohsu.edu
FU NCRR NIH HHS [UL1 RR024140]
NR 41
TC 1
Z9 1
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD APR
PY 2010
VL 5
IS 4
BP 218
EP 225
DI 10.1002/jhm.614
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 588FJ
UT WOS:000277053100005
PM 20394027
ER
PT J
AU Bai, XY
Kim, SH
Azam, T
McGibney, MT
Huang, H
Dinarello, CA
Chan, ED
AF Bai, Xiyuan
Kim, Soo-Hyun
Azam, Tania
McGibney, Mischa T.
Huang, Hua
Dinarello, Charles A.
Chan, Edward D.
TI IL-32 Is a Host Protective Cytokine against Mycobacterium tuberculosis
in Differentiated THP-1 Human Macrophages
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE SYNTHASE; CASPASE-INDEPENDENT
PATHWAY; PHAGOSOME-LYSOSOME FUSION; GROWTH-FACTOR-BETA; T-CELLS;
VIRUS-INFECTION; BALB/C MICE; TNF-ALPHA; PROINFLAMMATORY CYTOKINE
AB Macrophages provide a first line of defense against Mycobacterium tuberculosis. However, in instances where macrophage activation for killing is suboptimal, M. tuberculosis is capable of surviving intracellularly. IL-32 is a recently described cytokine induced by M. tuberculosis in a variety of cell types including human monocytes and macrophages. In this study, we investigated the biological significance of IL-32 in an in vitro model of M. tuberculosis infection in differentiated THP-1 human macrophages in which IL-32 expression was silenced using stable expression of short hairpin RNA (shRNA). Inhibition of endogenous IL-32 production in THP-1 cells that express one of three distinct shRNA-IL-32 constructs significantly decreased M. tuberculosis induction of TNF-alpha by similar to 60%, IL-10 by 30-60%, and IL-8 by 40-50% and concomitantly increased the number of cell-associated M. tuberculosis bacteria compared with THP-1 cells stably expressing a scrambled shRNA. In THP-1 cells infected with M. tuberculosis and stimulated with rIL-32, a greater level of apoptosis was observed compared with that with M. tuberculosis infection alone. Obversely, there was significant abrogation of apoptosis induced by M. tuberculosis and a concomitant decrease in caspase-3 activation in cells depleted of endogenous IL-32. rIL-32 gamma significantly reduced the number of viable intracellular M. tuberculosis bacteria, which was modestly but significantly abrogated with a caspase-3 inhibitor. We conclude that IL-32 plays a host defense role against M. tuberculosis in differentiated THP-1 human macrophages. The Journal of Immunology, 2010,184: 3830-3840.
C1 [Chan, Edward D.] Natl Jewish Hlth, Dept Med, Div Mycobacterial & Resp Infect, Denver, CO 80206 USA.
[Bai, Xiyuan; McGibney, Mischa T.; Chan, Edward D.] Univ Colorado, Anschutz Med Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80045 USA.
[Azam, Tania; Dinarello, Charles A.] Univ Colorado, Anschutz Med Ctr, Div Infect Dis, Denver, CO 80045 USA.
[Huang, Hua] Natl Jewish Hlth, Dept Immunol, Denver, CO 80206 USA.
[Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA.
[Kim, Soo-Hyun] Konkuk Univ, Inst Biomed Sci & Technol, Lab Cytokine Immunol, Seoul, South Korea.
RP Chan, ED (reprint author), Natl Jewish Hlth, Dept Med, Div Mycobacterial & Resp Infect, Neustadt Bldg D509,1400 Jackson St, Denver, CO 80206 USA.
EM chane@njhealth.org
FU Office of Research and Development, Veterans Health Administration,
Department of Veterans Affairs; National Institutes of Health [AI15614]
FX This work was supported in part by the Office of Research and
Development, Veterans Health Administration, Department of Veterans
Affairs (to E.D.C.) and National Institutes of Health Grant AI15614 (to
C.A.D.).
NR 85
TC 48
Z9 52
U1 1
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD APR 1
PY 2010
VL 184
IS 7
BP 3830
EP 3840
DI 10.4049/jimmunol.0901913
PG 11
WC Immunology
SC Immunology
GA 573PV
UT WOS:000275927600061
PM 20190143
ER
PT J
AU Benayides, A
Fernandez, E
Sharp, Z
Strong, R
Kraig, E
AF Benayides, Adriana
Fernandez, Elizabeth
Sharp, Z.
Strong, Randy
Kraig, Ellen
TI Treg and rapamycin effects on humoral immunity in young and old mice
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Benayides, Adriana; Fernandez, Elizabeth; Sharp, Z.; Strong, Randy; Kraig, Ellen] UTHSCSA, Micro & Immunol, San Antonio, TX USA.
[Fernandez, Elizabeth] Barshop Inst Longev & Aging Studies, San Antonio, TX USA.
[Strong, Randy] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD APR 1
PY 2010
VL 184
SU 1
MA 84.12
PG 1
WC Immunology
SC Immunology
GA V44OM
UT WOS:000209758301224
ER
PT J
AU Clark, AM
Young, MR
AF Clark, Anna-Maria
Young, M. Rita
TI Administration of a vaccine composed of dendritic cells pulsed with
premalignant oral lesion lysate results in an increase in CD4+and CD8+T
cells and a decrease in Foxp3+cells in tongues of mice bearing
carcinogen induced premalignant oral lesions.
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Clark, Anna-Maria; Young, M. Rita] Med Univ South Carolina, Microbiol & Immunol, Charleston, SC USA.
[Clark, Anna-Maria; Young, M. Rita] Ralph H Johnson VAMC, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD APR 1
PY 2010
VL 184
SU 1
MA 131.24
PG 1
WC Immunology
SC Immunology
GA V44OM
UT WOS:000209758303175
ER
EF